1	immunophenotype	B
1	molecular subtype	KMT2A
1	Protocol	T16
1	NCI risk	HR
1	Age at diagnosis	0.1
1	WBC at diagnosis	149.8
1	Sex	F
1	Genetically-defined race	White
1	Asparaginase (IU/ml)	20
1	Bortezomib (nM)	0
1	CHZ868 (nM)	0
1	Cytarabine (µM)	0.4426846
1	Dasatinib (nM)	0
1	Daunorubicin (µM)	0
1	Dexamethasone  (µM)	0.1368618
1	Ibrutinib (µM)	0
1	Mercaptopurine (µM)	5876
1	Nelarabine (µM)	0
1	Panobinostat (nM)	0
1	Prednisolone (µM)	0.1080458
1	Ruxolitinib (nM)	0
1	Thioguanine (µM)	57.43808
1	Trametinib (nM)	0
1	Venetoclax (nM)	0
1	Vincristine (µM)	0.025
1	Vorinostat (nM)	0
1	asparagise_normalized	1
1	cytarabine_normalized	0.3467
1	dexamethasone_normalized	0.5734
1	mercaptopurine_normalized	1
1	prednisolone_normalized	0.1895
1	thioguanine_normalized	0.5239
1	vincristine_normalized	0
2	immunophenotype	B
2	molecular subtype	ETV6-RUNX1
2	Protocol	T16
2	NCI risk	SR
2	Age at diagnosis	5.6
2	WBC at diagnosis	9.8
2	Sex	M
2	Genetically-defined race	White
2	Asparaginase (IU/ml)	0.0016
2	Bortezomib (nM)	0
2	CHZ868 (nM)	0
2	Cytarabine (µM)	1.454368
2	Dasatinib (nM)	0
2	Daunorubicin (µM)	0
2	Dexamethasone  (µM)	0.01537649
2	Ibrutinib (µM)	0
2	Mercaptopurine (µM)	952.1028
2	Nelarabine (µM)	0
2	Panobinostat (nM)	0
2	Prednisolone (µM)	0.0075
2	Ruxolitinib (nM)	0
2	Thioguanine (µM)	16.45085
2	Trametinib (nM)	0
2	Venetoclax (nM)	0
2	Vincristine (µM)	0.05802176
2	Vorinostat (nM)	0
2	asparagise_normalized	0
2	cytarabine_normalized	0.5182
2	dexamethasone_normalized	0.3634
2	mercaptopurine_normalized	0.6749
2	prednisolone_normalized	0
2	thioguanine_normalized	0.1631
2	vincristine_normalized	0.0213
3	immunophenotype	T
3	molecular subtype	T-ALL
3	Protocol	T16
3	NCI risk	HR
3	Age at diagnosis	14.2
3	WBC at diagnosis	3.7
3	Sex	F
3	Genetically-defined race	Asian/Other
3	Asparaginase (IU/ml)	0.0016
3	Bortezomib (nM)	0
3	CHZ868 (nM)	0
3	Cytarabine (µM)	2.000542
3	Dasatinib (nM)	0
3	Daunorubicin (µM)	0
3	Dexamethasone  (µM)	0.1363423
3	Ibrutinib (µM)	0
3	Mercaptopurine (µM)	819.4745305
3	Nelarabine (µM)	0
3	Panobinostat (nM)	0
3	Prednisolone (µM)	0.08926875
3	Ruxolitinib (nM)	0
3	Thioguanine (µM)	11.68989
3	Trametinib (nM)	0
3	Venetoclax (nM)	0
3	Vincristine (µM)	0.025
3	Vorinostat (nM)	0
3	asparagise_normalized	0
3	cytarabine_normalized	0.5641
3	dexamethasone_normalized	0.5731
3	mercaptopurine_normalized	0.6316
3	prednisolone_normalized	0.1712
3	thioguanine_normalized	0.0645
3	vincristine_normalized	0
4	immunophenotype	B
4	molecular subtype	Hyperdiploid
4	Protocol	T16
4	NCI risk	SR
4	Age at diagnosis	4.1
4	WBC at diagnosis	3.1
4	Sex	M
4	Genetically-defined race	White
4	Asparaginase (IU/ml)	0
4	Bortezomib (nM)	0
4	CHZ868 (nM)	0
4	Cytarabine (µM)	0
4	Dasatinib (nM)	0
4	Daunorubicin (µM)	0
4	Dexamethasone  (µM)	23.2
4	Ibrutinib (µM)	0
4	Mercaptopurine (µM)	452.2491
4	Nelarabine (µM)	0
4	Panobinostat (nM)	0
4	Prednisolone (µM)	0
4	Ruxolitinib (nM)	0
4	Thioguanine (µM)	73.29894238
4	Trametinib (nM)	0
4	Venetoclax (nM)	0
4	Vincristine (µM)	0
4	Vorinostat (nM)	0
4	dexamethasone_normalized	1
4	mercaptopurine_normalized	0.4601
4	thioguanine_normalized	0.5943
5	immunophenotype	B
5	molecular subtype	ETV6-RUNX1
5	Protocol	T16
5	NCI risk	SR
5	Age at diagnosis	6.8
5	WBC at diagnosis	4.1
5	Sex	F
5	Genetically-defined race	black
5	Asparaginase (IU/ml)	0.0016
5	Bortezomib (nM)	0
5	CHZ868 (nM)	0
5	Cytarabine (µM)	1.612847
5	Dasatinib (nM)	0
5	Daunorubicin (µM)	0
5	Dexamethasone  (µM)	0.04458349
5	Ibrutinib (µM)	0
5	Mercaptopurine (µM)	576.0045
5	Nelarabine (µM)	0
5	Panobinostat (nM)	0
5	Prednisolone (µM)	0.0726671
5	Ruxolitinib (nM)	0
5	Thioguanine (µM)	13.57506
5	Trametinib (nM)	0
5	Venetoclax (nM)	0
5	Vincristine (µM)	0.128956132
5	Vorinostat (nM)	0
5	asparagise_normalized	0
5	cytarabine_normalized	0.5331
5	dexamethasone_normalized	0.4657
5	mercaptopurine_normalized	0.5299
5	prednisolone_normalized	0.1514
5	thioguanine_normalized	0.1076
5	vincristine_normalized	0.1356
6	immunophenotype	B
6	molecular subtype	Hyperdiploid
6	Protocol	T16
6	NCI risk	SR
6	Age at diagnosis	6.2
6	WBC at diagnosis	11
6	Sex	M
6	Genetically-defined race	White
6	Asparaginase (IU/ml)	0.003489337
6	Bortezomib (nM)	0
6	CHZ868 (nM)	0
6	Cytarabine (µM)	0.7964616
6	Dasatinib (nM)	20000
6	Daunorubicin (µM)	0
6	Dexamethasone  (µM)	23.2
6	Ibrutinib (µM)	0
6	Mercaptopurine (µM)	469.0728
6	Nelarabine (µM)	0
6	Panobinostat (nM)	0
6	Prednisolone (µM)	1006
6	Ruxolitinib (nM)	0
6	Thioguanine (µM)	35.16138
6	Trametinib (nM)	0
6	Venetoclax (nM)	0
6	Vincristine (µM)	0.025
6	Vorinostat (nM)	0
6	asparagise_normalized	0.0108
6	cytarabine_normalized	0.4313
6	dasatinib_normalized	1
6	dexamethasone_normalized	1
6	mercaptopurine_normalized	0.4706
6	prednisolone_normalized	1
6	thioguanine_normalized	0.3823
6	vincristine_normalized	0
7	immunophenotype	B
7	molecular subtype	MEF2D
7	Protocol	T16
7	NCI risk	HR
7	Age at diagnosis	12.4
7	WBC at diagnosis	5.8
7	Sex	F
7	Genetically-defined race	White
7	Asparaginase (IU/ml)	0.6191714
7	Bortezomib (nM)	0
7	CHZ868 (nM)	0
7	Cytarabine (µM)	2.623488
7	Dasatinib (nM)	20000
7	Daunorubicin (µM)	0
7	Dexamethasone  (µM)	0.02181625
7	Ibrutinib (µM)	0
7	Mercaptopurine (µM)	2495.15
7	Nelarabine (µM)	0
7	Panobinostat (nM)	17.58707
7	Prednisolone (µM)	0.0075
7	Ruxolitinib (nM)	20000
7	Thioguanine (µM)	13.03744
7	Trametinib (nM)	0
7	Venetoclax (nM)	0
7	Vincristine (µM)	0.025
7	Vorinostat (nM)	0
7	asparagise_normalized	0.6543
7	cytarabine_normalized	0.6032
7	dasatinib_normalized	1
7	dexamethasone_normalized	0.397
7	mercaptopurine_normalized	0.9529
7	panobinostat_normalized	0.4168
7	prednisolone_normalized	0
7	ruxolitinib_normalized	1
7	thioguanine_normalized	0.0959
7	vincristine_normalized	0
8	immunophenotype	B
8	molecular subtype	BCR-ABL1
8	Protocol	T16
8	NCI risk	SR
8	Age at diagnosis	8.5
8	WBC at diagnosis	3.6
8	Sex	M
8	Genetically-defined race	White
8	Asparaginase (IU/ml)	0.2423316
8	Bortezomib (nM)	0
8	CHZ868 (nM)	0
8	Cytarabine (µM)	2.991751004
8	Dasatinib (nM)	0
8	Daunorubicin (µM)	0
8	Dexamethasone  (µM)	23.2
8	Ibrutinib (µM)	0
8	Mercaptopurine (µM)	357.4836
8	Nelarabine (µM)	0
8	Panobinostat (nM)	0
8	Prednisolone (µM)	27.66338
8	Ruxolitinib (nM)	0
8	Thioguanine (µM)	37.05423
8	Trametinib (nM)	0
8	Venetoclax (nM)	0
8	Vincristine (µM)	0.025
8	Vorinostat (nM)	0
8	asparagise_normalized	0.5377
8	cytarabine_normalized	0.6222
8	dexamethasone_normalized	1
8	mercaptopurine_normalized	0.3922
8	prednisolone_normalized	0.7217
8	thioguanine_normalized	0.3974
8	vincristine_normalized	0
9	immunophenotype	B
9	molecular subtype	B-other
9	Protocol	T16
9	NCI risk	SR
9	Age at diagnosis	2.5
9	WBC at diagnosis	7.7
9	Sex	M
9	Genetically-defined race	black
9	Asparaginase (IU/ml)	0.524029
9	Bortezomib (nM)	0
9	CHZ868 (nM)	0
9	Cytarabine (µM)	0
9	Dasatinib (nM)	0
9	Daunorubicin (µM)	0
9	Dexamethasone  (µM)	0.0243241
9	Ibrutinib (µM)	0
9	Mercaptopurine (µM)	250.4212
9	Nelarabine (µM)	0
9	Panobinostat (nM)	0
9	Prednisolone (µM)	0.0075
9	Ruxolitinib (nM)	0
9	Thioguanine (µM)	14.23280645
9	Trametinib (nM)	0
9	Venetoclax (nM)	0
9	Vincristine (µM)	12.9502
9	Vorinostat (nM)	0
9	asparagise_normalized	0.6336
9	dexamethasone_normalized	0.4075
9	mercaptopurine_normalized	0.2895
9	prednisolone_normalized	0
9	thioguanine_normalized	0.1213
9	vincristine_normalized	0.7952
10	immunophenotype	B
10	molecular subtype	Low hypodiploid
10	Protocol	T16
10	NCI risk	HR
10	Age at diagnosis	13.8
10	WBC at diagnosis	9
10	Sex	F
10	Genetically-defined race	White
10	Asparaginase (IU/ml)	0.0016
10	Bortezomib (nM)	0
10	CHZ868 (nM)	0
10	Cytarabine (µM)	1.700003
10	Dasatinib (nM)	0
10	Daunorubicin (µM)	0
10	Dexamethasone  (µM)	8.002525
10	Ibrutinib (µM)	0
10	Mercaptopurine (µM)	193.8786
10	Nelarabine (µM)	0
10	Panobinostat (nM)	0
10	Prednisolone (µM)	9.956158
10	Ruxolitinib (nM)	0
10	Thioguanine (µM)	0
10	Trametinib (nM)	0
10	Venetoclax (nM)	0
10	Vincristine (µM)	0.025
10	Vorinostat (nM)	0
10	asparagise_normalized	0
10	cytarabine_normalized	0.5407
10	dexamethasone_normalized	0.9643
10	mercaptopurine_normalized	0.2157
10	prednisolone_normalized	0.6236
10	vincristine_normalized	0
11	immunophenotype	B
11	molecular subtype	Hyperdiploid
11	Protocol	T16
11	NCI risk	HR
11	Age at diagnosis	17.5
11	WBC at diagnosis	2.1
11	Sex	M
11	Genetically-defined race	black
11	Asparaginase (IU/ml)	0
11	Bortezomib (nM)	0
11	CHZ868 (nM)	0
11	Cytarabine (µM)	0
11	Dasatinib (nM)	0
11	Daunorubicin (µM)	0
11	Dexamethasone  (µM)	23.2
11	Ibrutinib (µM)	0
11	Mercaptopurine (µM)	763.6858447
11	Nelarabine (µM)	0
11	Panobinostat (nM)	0
11	Prednisolone (µM)	0.5386558
11	Ruxolitinib (nM)	0
11	Thioguanine (µM)	15.08529
11	Trametinib (nM)	0
11	Venetoclax (nM)	0
11	Vincristine (µM)	0
11	Vorinostat (nM)	0
11	dexamethasone_normalized	1
11	mercaptopurine_normalized	0.6113
11	prednisolone_normalized	0.3437
11	thioguanine_normalized	0.138
12	immunophenotype	B
12	molecular subtype	Hyperdiploid
12	Protocol	T16
12	NCI risk	SR
12	Age at diagnosis	3.9
12	WBC at diagnosis	18.5
12	Sex	M
12	Genetically-defined race	White
12	Asparaginase (IU/ml)	0.20906
12	Bortezomib (nM)	0
12	CHZ868 (nM)	0
12	Cytarabine (µM)	0.8071146
12	Dasatinib (nM)	0
12	Daunorubicin (µM)	0
12	Dexamethasone  (µM)	0.2033849
12	Ibrutinib (µM)	0
12	Mercaptopurine (µM)	347.5806
12	Nelarabine (µM)	0
12	Panobinostat (nM)	0
12	Prednisolone (µM)	0.1158049
12	Ruxolitinib (nM)	0
12	Thioguanine (µM)	24.57708
12	Trametinib (nM)	0
12	Venetoclax (nM)	0
12	Vincristine (µM)	18.37930281
12	Vorinostat (nM)	0
12	asparagise_normalized	0.5194
12	cytarabine_normalized	0.4333
12	dexamethasone_normalized	0.6115
12	mercaptopurine_normalized	0.3841
12	prednisolone_normalized	0.1961
12	thioguanine_normalized	0.2789
12	vincristine_normalized	0.8453
13	immunophenotype	B
13	molecular subtype	DUX4
13	Protocol	T16
13	NCI risk	SR
13	Age at diagnosis	9
13	WBC at diagnosis	6.3
13	Sex	F
13	Genetically-defined race	White
13	Asparaginase (IU/ml)	0.0016
13	Bortezomib (nM)	0
13	CHZ868 (nM)	0
13	Cytarabine (µM)	7.46733
13	Dasatinib (nM)	20000
13	Daunorubicin (µM)	0
13	Dexamethasone  (µM)	0.2847176
13	Ibrutinib (µM)	10.14729
13	Mercaptopurine (µM)	1377.509
13	Nelarabine (µM)	0
13	Panobinostat (nM)	2000
13	Prednisolone (µM)	0.261965
13	Ruxolitinib (nM)	20000
13	Thioguanine (µM)	57.81367
13	Trametinib (nM)	2000
13	Venetoclax (nM)	0
13	Vincristine (µM)	0.05058798
13	Vorinostat (nM)	0
13	asparagise_normalized	0
13	cytarabine_normalized	0.7541
13	dasatinib_normalized	1
13	dexamethasone_normalized	0.6438
13	ibrutinib_normalized	0.5398
13	mercaptopurine_normalized	0.7815
13	panobinostat_normalized	1
13	prednisolone_normalized	0.2745
13	ruxolitinib_normalized	1
13	thioguanine_normalized	0.5258
13	trametinib_normalized	1
13	vincristine_normalized	0.0017
14	immunophenotype	T
14	molecular subtype	T-ALL
14	Protocol	T16
14	NCI risk	HR
14	Age at diagnosis	10.1
14	WBC at diagnosis	63
14	Sex	M
14	Genetically-defined race	White
14	Asparaginase (IU/ml)	2.50688
14	Bortezomib (nM)	0
14	CHZ868 (nM)	0
14	Cytarabine (µM)	2.759048
14	Dasatinib (nM)	0.05
14	Daunorubicin (µM)	0
14	Dexamethasone  (µM)	0.238431422
14	Ibrutinib (µM)	0
14	Mercaptopurine (µM)	161.2042683
14	Nelarabine (µM)	0
14	Panobinostat (nM)	0
14	Prednisolone (µM)	1.406793
14	Ruxolitinib (nM)	5523.352
14	Thioguanine (µM)	12.6477821
14	Trametinib (nM)	1.339801
14	Venetoclax (nM)	0
14	Vincristine (µM)	0
14	Vorinostat (nM)	0
14	asparagise_normalized	0.8281
14	cytarabine_normalized	0.6105
14	dasatinib_normalized	0
14	dexamethasone_normalized	0.6268
14	mercaptopurine_normalized	0.1625
14	prednisolone_normalized	0.4358
14	ruxolitinib_normalized	0.9484
14	thioguanine_normalized	0.0872
14	trametinib_normalized	0.4254
15	immunophenotype	T
15	molecular subtype	T-ALL
15	Protocol	T16
15	NCI risk	HR
15	Age at diagnosis	10.3
15	WBC at diagnosis	31.3
15	Sex	M
15	Genetically-defined race	White
15	Asparaginase (IU/ml)	1.300402
15	Bortezomib (nM)	0
15	CHZ868 (nM)	0
15	Cytarabine (µM)	6.472874
15	Dasatinib (nM)	0
15	Daunorubicin (µM)	0.3447843
15	Dexamethasone  (µM)	23.2
15	Ibrutinib (µM)	0
15	Mercaptopurine (µM)	580.3694
15	Nelarabine (µM)	0
15	Panobinostat (nM)	0
15	Prednisolone (µM)	337.2553
15	Ruxolitinib (nM)	0
15	Thioguanine (µM)	15.79701
15	Trametinib (nM)	0
15	Venetoclax (nM)	0
15	Vincristine (µM)	15.9126
15	Vorinostat (nM)	0
15	asparagise_normalized	0.7465
15	cytarabine_normalized	0.7335
15	daunorubicin_normalized	0.6705
15	dexamethasone_normalized	1
15	mercaptopurine_normalized	0.5321
15	prednisolone_normalized	0.9616
15	thioguanine_normalized	0.1514
15	vincristine_normalized	0.8247
16	immunophenotype	B
16	molecular subtype	DUX4
16	Protocol	T16
16	NCI risk	SR
16	Age at diagnosis	1.9
16	WBC at diagnosis	11.1
16	Sex	M
16	Genetically-defined race	Asian/Other
16	Asparaginase (IU/ml)	0.09478062
16	Bortezomib (nM)	0.49
16	CHZ868 (nM)	0
16	Cytarabine (µM)	0.182719921
16	Dasatinib (nM)	22.21961
16	Daunorubicin (µM)	0
16	Dexamethasone  (µM)	0.2271444
16	Ibrutinib (µM)	0.78125
16	Mercaptopurine (µM)	187.429
16	Nelarabine (µM)	0
16	Panobinostat (nM)	4.122033
16	Prednisolone (µM)	0.06738381
16	Ruxolitinib (nM)	8860.815
16	Thioguanine (µM)	4.675
16	Trametinib (nM)	0.01059293
16	Venetoclax (nM)	0
16	Vincristine (µM)	0.025
16	Vorinostat (nM)	0
16	asparagise_normalized	0.4211
16	bortezomib_normalized	0
16	cytarabine_normalized	0.219
16	dasatinib_normalized	0.4693
16	dexamethasone_normalized	0.6221
16	ibrutinib_normalized	0
16	mercaptopurine_normalized	0.2059
16	panobinostat_normalized	0.2074
16	prednisolone_normalized	0.1442
16	ruxolitinib_normalized	0.9895
16	thioguanine_normalized	0
16	trametinib_normalized	0.005
16	vincristine_normalized	0
17	immunophenotype	B
17	molecular subtype	ETV6-RUNX1
17	Protocol	T16
17	NCI risk	SR
17	Age at diagnosis	6.9
17	WBC at diagnosis	4
17	Sex	M
17	Genetically-defined race	White
17	Asparaginase (IU/ml)	0.0016
17	Bortezomib (nM)	4.296639
17	CHZ868 (nM)	0
17	Cytarabine (µM)	1.573603
17	Dasatinib (nM)	20000
17	Daunorubicin (µM)	0
17	Dexamethasone  (µM)	0.1196977
17	Ibrutinib (µM)	10.29806
17	Mercaptopurine (µM)	319.9315
17	Nelarabine (µM)	0
17	Panobinostat (nM)	11.93091
17	Prednisolone (µM)	0.2525232
17	Ruxolitinib (nM)	20000
17	Thioguanine (µM)	19.84648
17	Trametinib (nM)	2000
17	Venetoclax (nM)	0
17	Vincristine (µM)	0.349567788
17	Vorinostat (nM)	0
17	asparagise_normalized	0
17	bortezomib_normalized	0.2133
17	cytarabine_normalized	0.5295
17	dasatinib_normalized	1
17	dexamethasone_normalized	0.5606
17	ibrutinib_normalized	0.5441
17	mercaptopurine_normalized	0.3602
17	panobinostat_normalized	0.3608
17	prednisolone_normalized	0.271
17	ruxolitinib_normalized	1
17	thioguanine_normalized	0.2172
17	trametinib_normalized	1
17	vincristine_normalized	0.2783
18	immunophenotype	B
18	molecular subtype	iAMP21
18	Protocol	T16
18	NCI risk	HR
18	Age at diagnosis	12.5
18	WBC at diagnosis	0.7
18	Sex	F
18	Genetically-defined race	White
18	Asparaginase (IU/ml)	0
18	Bortezomib (nM)	0
18	CHZ868 (nM)	0
18	Cytarabine (µM)	0
18	Dasatinib (nM)	0
18	Daunorubicin (µM)	0
18	Dexamethasone  (µM)	23.2
18	Ibrutinib (µM)	0
18	Mercaptopurine (µM)	2493.617
18	Nelarabine (µM)	0
18	Panobinostat (nM)	0
18	Prednisolone (µM)	1006
18	Ruxolitinib (nM)	0
18	Thioguanine (µM)	45.57623
18	Trametinib (nM)	0
18	Venetoclax (nM)	0
18	Vincristine (µM)	0
18	Vorinostat (nM)	0
18	dexamethasone_normalized	1
18	mercaptopurine_normalized	0.9527
18	prednisolone_normalized	1
18	thioguanine_normalized	0.4571
19	immunophenotype	B
19	molecular subtype	ETV6-RUNX1
19	Protocol	T16
19	NCI risk	SR
19	Age at diagnosis	3
19	WBC at diagnosis	2.2
19	Sex	F
19	Genetically-defined race	black
19	Asparaginase (IU/ml)	0
19	Bortezomib (nM)	0
19	CHZ868 (nM)	0
19	Cytarabine (µM)	0
19	Dasatinib (nM)	0
19	Daunorubicin (µM)	0
19	Dexamethasone  (µM)	0
19	Ibrutinib (µM)	0
19	Mercaptopurine (µM)	421.4646
19	Nelarabine (µM)	0
19	Panobinostat (nM)	0
19	Prednisolone (µM)	0
19	Ruxolitinib (nM)	0
19	Thioguanine (µM)	4.675
19	Trametinib (nM)	0
19	Venetoclax (nM)	0
19	Vincristine (µM)	0
19	Vorinostat (nM)	0
19	mercaptopurine_normalized	0.4398
19	thioguanine_normalized	0
20	immunophenotype	B
20	molecular subtype	DUX4
20	Protocol	T16
20	NCI risk	SR
20	Age at diagnosis	7.6
20	WBC at diagnosis	10.2
20	Sex	F
20	Genetically-defined race	Asian/Other
20	Asparaginase (IU/ml)	0.7122353
20	Bortezomib (nM)	4.232658
20	CHZ868 (nM)	0
20	Cytarabine (µM)	0.5401271
20	Dasatinib (nM)	36.18641
20	Daunorubicin (µM)	0
20	Dexamethasone  (µM)	0.01763004
20	Ibrutinib (µM)	5.36693
20	Mercaptopurine (µM)	2134.847891
20	Nelarabine (µM)	0
20	Panobinostat (nM)	3.916065
20	Prednisolone (µM)	0.0075
20	Ruxolitinib (nM)	20000
20	Thioguanine (µM)	0
20	Trametinib (nM)	3.32159455
20	Venetoclax (nM)	0
20	Vincristine (µM)	0.025
20	Vorinostat (nM)	0
20	asparagise_normalized	0.6717
20	bortezomib_normalized	0.2112
20	cytarabine_normalized	0.3753
20	dasatinib_normalized	0.5117
20	dexamethasone_normalized	0.3766
20	ibrutinib_normalized	0.356
20	mercaptopurine_normalized	0.9079
20	panobinostat_normalized	0.2
20	prednisolone_normalized	0
20	ruxolitinib_normalized	1
20	trametinib_normalized	0.5043
20	vincristine_normalized	0
21	immunophenotype	B
21	molecular subtype	Hyperdiploid
21	Protocol	T16
21	NCI risk	HR
21	Age at diagnosis	2.9
21	WBC at diagnosis	52.9
21	Sex	M
21	Genetically-defined race	Asian/Other
21	Asparaginase (IU/ml)	0.0016
21	Bortezomib (nM)	4.901396
21	CHZ868 (nM)	0
21	Cytarabine (µM)	0.145867085
21	Dasatinib (nM)	576.4655679
21	Daunorubicin (µM)	0
21	Dexamethasone  (µM)	0.188215183
21	Ibrutinib (µM)	0
21	Mercaptopurine (µM)	578.2412
21	Nelarabine (µM)	0
21	Panobinostat (nM)	2.578477
21	Prednisolone (µM)	0.1089319
21	Ruxolitinib (nM)	20000
21	Thioguanine (µM)	4.675
21	Trametinib (nM)	18.3208
21	Venetoclax (nM)	0
21	Vincristine (µM)	0.025
21	Vorinostat (nM)	0
21	asparagise_normalized	0
21	bortezomib_normalized	0.2324
21	cytarabine_normalized	0.1866
21	dasatinib_normalized	0.7522
21	dexamethasone_normalized	0.6041
21	mercaptopurine_normalized	0.531
21	panobinostat_normalized	0.1396
21	prednisolone_normalized	0.1903
21	ruxolitinib_normalized	1
21	thioguanine_normalized	0
21	trametinib_normalized	0.6526
21	vincristine_normalized	0
22	immunophenotype	B
22	molecular subtype	Hyperdiploid
22	Protocol	T16
22	NCI risk	SR
22	Age at diagnosis	3.9
22	WBC at diagnosis	3.7
22	Sex	M
22	Genetically-defined race	White
22	Asparaginase (IU/ml)	4.82213
22	Bortezomib (nM)	8.416374388
22	CHZ868 (nM)	0
22	Cytarabine (µM)	2.863023
22	Dasatinib (nM)	20000
22	Daunorubicin (µM)	0
22	Dexamethasone  (µM)	0
22	Ibrutinib (µM)	9.443861
22	Mercaptopurine (µM)	1151.423053
22	Nelarabine (µM)	0
22	Panobinostat (nM)	15.92698
22	Prednisolone (µM)	230.7864
22	Ruxolitinib (nM)	20000
22	Thioguanine (µM)	0
22	Trametinib (nM)	1.318942781
22	Venetoclax (nM)	0
22	Vincristine (µM)	0.025
22	Vorinostat (nM)	0
22	asparagise_normalized	0.9094
22	bortezomib_normalized	0.3104
22	cytarabine_normalized	0.6158
22	dasatinib_normalized	1
22	ibrutinib_normalized	0.5191
22	mercaptopurine_normalized	0.7297
22	panobinostat_normalized	0.4025
22	prednisolone_normalized	0.9252
22	ruxolitinib_normalized	1
22	trametinib_normalized	0.424
22	vincristine_normalized	0
23	immunophenotype	B
23	molecular subtype	DUX4
23	Protocol	T16
23	NCI risk	SR
23	Age at diagnosis	4.8
23	WBC at diagnosis	2.8
23	Sex	F
23	Genetically-defined race	White
23	Asparaginase (IU/ml)	20
23	Bortezomib (nM)	4.880236
23	CHZ868 (nM)	0
23	Cytarabine (µM)	0
23	Dasatinib (nM)	0
23	Daunorubicin (µM)	7.1
23	Dexamethasone  (µM)	0
23	Ibrutinib (µM)	0
23	Mercaptopurine (µM)	5876
23	Nelarabine (µM)	0
23	Panobinostat (nM)	31.7957
23	Prednisolone (µM)	1006
23	Ruxolitinib (nM)	0
23	Thioguanine (µM)	0
23	Trametinib (nM)	0
23	Venetoclax (nM)	0
23	Vincristine (µM)	108.34
23	Vorinostat (nM)	0
23	asparagise_normalized	1
23	bortezomib_normalized	0.2317
23	daunorubicin_normalized	1
23	mercaptopurine_normalized	1
23	panobinostat_normalized	0.5022
23	prednisolone_normalized	1
23	vincristine_normalized	1
24	immunophenotype	T
24	molecular subtype	T-ALL
24	Protocol	T16
24	NCI risk	SR
24	Age at diagnosis	6.8
24	WBC at diagnosis	10.7
24	Sex	M
24	Genetically-defined race	black
24	Asparaginase (IU/ml)	0.0016
24	Bortezomib (nM)	10.81806
24	CHZ868 (nM)	0
24	Cytarabine (µM)	0
24	Dasatinib (nM)	0
24	Daunorubicin (µM)	0.2037234
24	Dexamethasone  (µM)	0
24	Ibrutinib (µM)	0
24	Mercaptopurine (µM)	853.1238678
24	Nelarabine (µM)	0
24	Panobinostat (nM)	15.72282
24	Prednisolone (µM)	12.70646
24	Ruxolitinib (nM)	0
24	Thioguanine (µM)	0
24	Trametinib (nM)	0
24	Venetoclax (nM)	0
24	Vincristine (µM)	0.99943411
24	Vorinostat (nM)	0
24	asparagise_normalized	0
24	bortezomib_normalized	0.3466
24	daunorubicin_normalized	0.5961
24	mercaptopurine_normalized	0.6432
24	panobinostat_normalized	0.4006
24	prednisolone_normalized	0.647
24	vincristine_normalized	0.4286
25	immunophenotype	B
25	molecular subtype	ETV6-RUNX1
25	Protocol	T16
25	NCI risk	SR
25	Age at diagnosis	9.5
25	WBC at diagnosis	3.5
25	Sex	M
25	Genetically-defined race	Asian/Other
25	Asparaginase (IU/ml)	0.0016
25	Bortezomib (nM)	3.501313
25	CHZ868 (nM)	0
25	Cytarabine (µM)	0
25	Dasatinib (nM)	20000
25	Daunorubicin (µM)	0.006990262
25	Dexamethasone  (µM)	0
25	Ibrutinib (µM)	7.557404
25	Mercaptopurine (µM)	125.6103
25	Nelarabine (µM)	0
25	Panobinostat (nM)	3.018336
25	Prednisolone (µM)	0.09070653
25	Ruxolitinib (nM)	20000
25	Thioguanine (µM)	0
25	Trametinib (nM)	27.59428
25	Venetoclax (nM)	0
25	Vincristine (µM)	0.025
25	Vorinostat (nM)	0
25	asparagise_normalized	0
25	bortezomib_normalized	0.1838
25	dasatinib_normalized	1
25	daunorubicin_normalized	0.1195
25	ibrutinib_normalized	0.4548
25	mercaptopurine_normalized	0.0905
25	panobinostat_normalized	0.1624
25	prednisolone_normalized	0.1727
25	ruxolitinib_normalized	1
25	trametinib_normalized	0.6882
25	vincristine_normalized	0
26	immunophenotype	T
26	molecular subtype	T-ALL
26	Protocol	T16
26	NCI risk	HR
26	Age at diagnosis	2.1
26	WBC at diagnosis	62.1
26	Sex	F
26	Genetically-defined race	White
26	Asparaginase (IU/ml)	20
26	Bortezomib (nM)	2.542393
26	CHZ868 (nM)	0
26	Cytarabine (µM)	0
26	Dasatinib (nM)	20000
26	Daunorubicin (µM)	0.159651643
26	Dexamethasone  (µM)	0
26	Ibrutinib (µM)	19.51688
26	Mercaptopurine (µM)	2462.553
26	Nelarabine (µM)	0
26	Panobinostat (nM)	13.44656
26	Prednisolone (µM)	1006
26	Ruxolitinib (nM)	20000
26	Thioguanine (µM)	0
26	Trametinib (nM)	2000
26	Venetoclax (nM)	0
26	Vincristine (µM)	0.2390031
26	Vorinostat (nM)	0
26	asparagise_normalized	1
26	bortezomib_normalized	0.1376
26	dasatinib_normalized	1
26	daunorubicin_normalized	0.5617
26	ibrutinib_normalized	0.7286
26	mercaptopurine_normalized	0.9491
26	panobinostat_normalized	0.378
26	prednisolone_normalized	1
26	ruxolitinib_normalized	1
26	trametinib_normalized	1
26	vincristine_normalized	0.2239
27	immunophenotype	B
27	molecular subtype	ETV6-RUNX1
27	Protocol	T16
27	NCI risk	SR
27	Age at diagnosis	3.2
27	WBC at diagnosis	5.9
27	Sex	M
27	Genetically-defined race	Hispanic
27	Asparaginase (IU/ml)	0.0016
27	Bortezomib (nM)	2.782738
27	CHZ868 (nM)	0
27	Cytarabine (µM)	0
27	Dasatinib (nM)	20000
27	Daunorubicin (µM)	0.01242903
27	Dexamethasone  (µM)	0
27	Ibrutinib (µM)	7.400424
27	Mercaptopurine (µM)	45.9
27	Nelarabine (µM)	0
27	Panobinostat (nM)	3.394038
27	Prednisolone (µM)	0.0075
27	Ruxolitinib (nM)	20000
27	Thioguanine (µM)	0
27	Trametinib (nM)	13.63271
27	Venetoclax (nM)	0
27	Vincristine (µM)	0.07881843
27	Vorinostat (nM)	0
27	asparagise_normalized	0
27	bortezomib_normalized	0.1506
27	dasatinib_normalized	1
27	daunorubicin_normalized	0.2009
27	ibrutinib_normalized	0.4488
27	mercaptopurine_normalized	0
27	panobinostat_normalized	0.1793
27	prednisolone_normalized	0
27	ruxolitinib_normalized	1
27	trametinib_normalized	0.6269
27	vincristine_normalized	0.0651
28	immunophenotype	B
28	molecular subtype	Hyperdiploid
28	Protocol	T16
28	NCI risk	SR
28	Age at diagnosis	6
28	WBC at diagnosis	6.4
28	Sex	F
28	Genetically-defined race	White
28	Asparaginase (IU/ml)	20
28	Bortezomib (nM)	0
28	CHZ868 (nM)	0
28	Cytarabine (µM)	0
28	Dasatinib (nM)	8499.76
28	Daunorubicin (µM)	0.262906519
28	Dexamethasone  (µM)	0
28	Ibrutinib (µM)	0.78125
28	Mercaptopurine (µM)	5876
28	Nelarabine (µM)	0
28	Panobinostat (nM)	0
28	Prednisolone (µM)	1006
28	Ruxolitinib (nM)	20000
28	Thioguanine (µM)	0
28	Trametinib (nM)	0.005
28	Venetoclax (nM)	0
28	Vincristine (µM)	14.1293
28	Vorinostat (nM)	0
28	asparagise_normalized	1
28	dasatinib_normalized	0.9859
28	daunorubicin_normalized	0.6322
28	ibrutinib_normalized	0
28	mercaptopurine_normalized	1
28	prednisolone_normalized	1
28	ruxolitinib_normalized	1
28	trametinib_normalized	0
28	vincristine_normalized	0.8077
29	immunophenotype	B
29	molecular subtype	Ph-like_non_CRLF2
29	Protocol	T16
29	NCI risk	HR
29	Age at diagnosis	12.5
29	WBC at diagnosis	2.2
29	Sex	M
29	Genetically-defined race	Hispanic
29	Asparaginase (IU/ml)	1.872938
29	Bortezomib (nM)	4.552513
29	CHZ868 (nM)	0
29	Cytarabine (µM)	0
29	Dasatinib (nM)	0
29	Daunorubicin (µM)	0.2345338
29	Dexamethasone  (µM)	0
29	Ibrutinib (µM)	0
29	Mercaptopurine (µM)	5876
29	Nelarabine (µM)	0
29	Panobinostat (nM)	8.853968
29	Prednisolone (µM)	1006
29	Ruxolitinib (nM)	0
29	Thioguanine (µM)	0
29	Trametinib (nM)	0
29	Venetoclax (nM)	0
29	Vincristine (µM)	0.025
29	Vorinostat (nM)	0
29	asparagise_normalized	0.7918
29	bortezomib_normalized	0.2217
29	daunorubicin_normalized	0.616
29	mercaptopurine_normalized	1
29	panobinostat_normalized	0.3177
29	prednisolone_normalized	1
29	vincristine_normalized	0
30	immunophenotype	B
30	molecular subtype	ETV6-RUNX1
30	Protocol	T16
30	NCI risk	SR
30	Age at diagnosis	4.9
30	WBC at diagnosis	4.9
30	Sex	F
30	Genetically-defined race	black
30	Asparaginase (IU/ml)	0.0016
30	Bortezomib (nM)	11.05868
30	CHZ868 (nM)	0
30	Cytarabine (µM)	0
30	Dasatinib (nM)	0
30	Daunorubicin (µM)	0.1532208
30	Dexamethasone  (µM)	0
30	Ibrutinib (µM)	0
30	Mercaptopurine (µM)	0
30	Nelarabine (µM)	0
30	Panobinostat (nM)	14.80777
30	Prednisolone (µM)	0.1203674
30	Ruxolitinib (nM)	0
30	Thioguanine (µM)	0
30	Trametinib (nM)	0
30	Venetoclax (nM)	0
30	Vincristine (µM)	0.267212379
30	Vorinostat (nM)	0
30	asparagise_normalized	0
30	bortezomib_normalized	0.3498
30	daunorubicin_normalized	0.5559
30	panobinostat_normalized	0.3919
30	prednisolone_normalized	0.1999
30	vincristine_normalized	0.2398
31	immunophenotype	B
31	molecular subtype	Ph-like_non_CRLF2
31	Protocol	T16
31	NCI risk	HR
31	Age at diagnosis	15.4
31	WBC at diagnosis	1.5
31	Sex	M
31	Genetically-defined race	White
31	Asparaginase (IU/ml)	20
31	Bortezomib (nM)	0
31	CHZ868 (nM)	0
31	Cytarabine (µM)	0
31	Dasatinib (nM)	20000
31	Daunorubicin (µM)	0
31	Dexamethasone  (µM)	0
31	Ibrutinib (µM)	0
31	Mercaptopurine (µM)	1838.489
31	Nelarabine (µM)	0
31	Panobinostat (nM)	0
31	Prednisolone (µM)	1006
31	Ruxolitinib (nM)	20000
31	Thioguanine (µM)	0
31	Trametinib (nM)	0
31	Venetoclax (nM)	0
31	Vincristine (µM)	0
31	Vorinostat (nM)	0
31	asparagise_normalized	1
31	dasatinib_normalized	1
31	mercaptopurine_normalized	0.8647
31	prednisolone_normalized	1
31	ruxolitinib_normalized	1
32	immunophenotype	B
32	molecular subtype	Hyperdiploid
32	Protocol	T16
32	NCI risk	SR
32	Age at diagnosis	1.4
32	WBC at diagnosis	7
32	Sex	F
32	Genetically-defined race	White
32	Asparaginase (IU/ml)	0.02253861
32	Bortezomib (nM)	0
32	CHZ868 (nM)	0
32	Cytarabine (µM)	0
32	Dasatinib (nM)	0
32	Daunorubicin (µM)	0
32	Dexamethasone  (µM)	0
32	Ibrutinib (µM)	0
32	Mercaptopurine (µM)	829.5235
32	Nelarabine (µM)	0
32	Panobinostat (nM)	0
32	Prednisolone (µM)	0.0075
32	Ruxolitinib (nM)	0
32	Thioguanine (µM)	0
32	Trametinib (nM)	0
32	Venetoclax (nM)	0
32	Vincristine (µM)	0
32	Vorinostat (nM)	0
32	asparagise_normalized	0.2426
32	mercaptopurine_normalized	0.6351
32	prednisolone_normalized	0
33	immunophenotype	T
33	molecular subtype	T-ALL
33	Protocol	T16
33	NCI risk	SR
33	Age at diagnosis	3.4
33	WBC at diagnosis	41.2
33	Sex	M
33	Genetically-defined race	White
33	Asparaginase (IU/ml)	20
33	Bortezomib (nM)	5.842042
33	CHZ868 (nM)	0
33	Cytarabine (µM)	0
33	Dasatinib (nM)	0.8490176
33	Daunorubicin (µM)	0.4614312
33	Dexamethasone  (µM)	0
33	Ibrutinib (µM)	2.383633
33	Mercaptopurine (µM)	0
33	Nelarabine (µM)	0
33	Panobinostat (nM)	5.105111
33	Prednisolone (µM)	1006
33	Ruxolitinib (nM)	20000
33	Thioguanine (µM)	0
33	Trametinib (nM)	0.081491801
33	Venetoclax (nM)	0
33	Vincristine (µM)	108.34
33	Vorinostat (nM)	0
33	asparagise_normalized	1
33	bortezomib_normalized	0.2577
33	dasatinib_normalized	0.1858
33	daunorubicin_normalized	0.7117
33	ibrutinib_normalized	0.1219
33	panobinostat_normalized	0.2382
33	prednisolone_normalized	1
33	ruxolitinib_normalized	1
33	trametinib_normalized	0.1822
33	vincristine_normalized	1
34	immunophenotype	T
34	molecular subtype	T-ALL
34	Protocol	T16
34	NCI risk	HR
34	Age at diagnosis	10
34	WBC at diagnosis	180.9
34	Sex	F
34	Genetically-defined race	black
34	Asparaginase (IU/ml)	8.733479
34	Bortezomib (nM)	11.07523
34	CHZ868 (nM)	0
34	Cytarabine (µM)	0
34	Dasatinib (nM)	0.05
34	Daunorubicin (µM)	0.08023901
34	Dexamethasone  (µM)	0
34	Ibrutinib (µM)	0.78125
34	Mercaptopurine (µM)	0
34	Nelarabine (µM)	0
34	Panobinostat (nM)	6.939538
34	Prednisolone (µM)	1006
34	Ruxolitinib (nM)	185.3098
34	Thioguanine (µM)	0
34	Trametinib (nM)	0.09655531
34	Venetoclax (nM)	0
34	Vincristine (µM)	15.43806
34	Vorinostat (nM)	0
34	asparagise_normalized	0.9832
34	bortezomib_normalized	0.35
34	dasatinib_normalized	0
34	daunorubicin_normalized	0.4644
34	ibrutinib_normalized	0
34	panobinostat_normalized	0.2825
34	prednisolone_normalized	1
34	ruxolitinib_normalized	0.6536
34	trametinib_normalized	0.197
34	vincristine_normalized	0.8204
35	immunophenotype	B
35	molecular subtype	PAX5alt
35	Protocol	T16
35	NCI risk	SR
35	Age at diagnosis	2.8
35	WBC at diagnosis	44.7
35	Sex	M
35	Genetically-defined race	Hispanic
35	Asparaginase (IU/ml)	0.272555
35	Bortezomib (nM)	14.31838
35	CHZ868 (nM)	0
35	Cytarabine (µM)	0
35	Dasatinib (nM)	10.26118
35	Daunorubicin (µM)	0.1248727
35	Dexamethasone  (µM)	0
35	Ibrutinib (µM)	6.553786
35	Mercaptopurine (µM)	5876
35	Nelarabine (µM)	0
35	Panobinostat (nM)	1.658965
35	Prednisolone (µM)	0
35	Ruxolitinib (nM)	20000
35	Thioguanine (µM)	0
35	Trametinib (nM)	0.005
35	Venetoclax (nM)	0
35	Vincristine (µM)	0.025
35	Vorinostat (nM)	0
35	asparagise_normalized	0.5523
35	bortezomib_normalized	0.3871
35	dasatinib_normalized	0.4022
35	daunorubicin_normalized	0.5269
35	ibrutinib_normalized	0.4137
35	mercaptopurine_normalized	1
35	panobinostat_normalized	0.076
35	ruxolitinib_normalized	1
35	trametinib_normalized	0
35	vincristine_normalized	0
36	immunophenotype	T
36	molecular subtype	T-ALL
36	Protocol	T16
36	NCI risk	HR
36	Age at diagnosis	9.8
36	WBC at diagnosis	58.6
36	Sex	F
36	Genetically-defined race	White
36	Asparaginase (IU/ml)	0
36	Bortezomib (nM)	107.3788
36	CHZ868 (nM)	0
36	Cytarabine (µM)	0
36	Dasatinib (nM)	0.05
36	Daunorubicin (µM)	0.6211444
36	Dexamethasone  (µM)	0
36	Ibrutinib (µM)	3.555434
36	Mercaptopurine (µM)	545.4453
36	Nelarabine (µM)	0
36	Panobinostat (nM)	7.518928
36	Prednisolone (µM)	0.01530575
36	Ruxolitinib (nM)	20000
36	Thioguanine (µM)	0
36	Trametinib (nM)	0
36	Venetoclax (nM)	0
36	Vincristine (µM)	0.1177707
36	Vorinostat (nM)	0
36	bortezomib_normalized	0.6779
36	dasatinib_normalized	0
36	daunorubicin_normalized	0.7537
36	ibrutinib_normalized	0.2372
36	mercaptopurine_normalized	0.5142
36	panobinostat_normalized	0.2941
36	prednisolone_normalized	0.0019
36	ruxolitinib_normalized	1
36	vincristine_normalized	0.1226
37	immunophenotype	B
37	molecular subtype	ETV6-RUNX1
37	Protocol	T16
37	NCI risk	SR
37	Age at diagnosis	2.8
37	WBC at diagnosis	9.1
37	Sex	M
37	Genetically-defined race	Hispanic
37	Asparaginase (IU/ml)	0
37	Bortezomib (nM)	25.77907554
37	CHZ868 (nM)	0
37	Cytarabine (µM)	0
37	Dasatinib (nM)	20000
37	Daunorubicin (µM)	0.1753766
37	Dexamethasone  (µM)	0
37	Ibrutinib (µM)	11.78234
37	Mercaptopurine (µM)	1234.375
37	Nelarabine (µM)	0
37	Panobinostat (nM)	8.615368
37	Prednisolone (µM)	0.0075
37	Ruxolitinib (nM)	20000
37	Thioguanine (µM)	0
37	Trametinib (nM)	0
37	Venetoclax (nM)	0
37	Vincristine (µM)	11.8786
37	Vorinostat (nM)	0
37	bortezomib_normalized	0.472
37	dasatinib_normalized	1
37	daunorubicin_normalized	0.5749
37	ibrutinib_normalized	0.5829
37	mercaptopurine_normalized	0.7498
37	panobinostat_normalized	0.3138
37	prednisolone_normalized	0
37	ruxolitinib_normalized	1
37	vincristine_normalized	0.7829
38	immunophenotype	B
38	molecular subtype	Ph-like_CRLF2
38	Protocol	T16
38	NCI risk	SR
38	Age at diagnosis	4.2
38	WBC at diagnosis	5.4
38	Sex	F
38	Genetically-defined race	Asian/Other
38	Asparaginase (IU/ml)	0.0016
38	Bortezomib (nM)	0
38	CHZ868 (nM)	0
38	Cytarabine (µM)	0
38	Dasatinib (nM)	0
38	Daunorubicin (µM)	0
38	Dexamethasone  (µM)	0
38	Ibrutinib (µM)	0
38	Mercaptopurine (µM)	274.4892
38	Nelarabine (µM)	0
38	Panobinostat (nM)	0
38	Prednisolone (µM)	0
38	Ruxolitinib (nM)	0
38	Thioguanine (µM)	0
38	Trametinib (nM)	0
38	Venetoclax (nM)	0
38	Vincristine (µM)	0.05623295
38	Vorinostat (nM)	0
38	asparagise_normalized	0
38	mercaptopurine_normalized	0.316
38	vincristine_normalized	0.0168
39	immunophenotype	T
39	molecular subtype	ETP
39	Protocol	T16
39	NCI risk	SR
39	Age at diagnosis	6.1
39	WBC at diagnosis	1.6
39	Sex	M
39	Genetically-defined race	White
39	Asparaginase (IU/ml)	0.1738741
39	Bortezomib (nM)	0
39	CHZ868 (nM)	0
39	Cytarabine (µM)	0
39	Dasatinib (nM)	0
39	Daunorubicin (µM)	0
39	Dexamethasone  (µM)	0
39	Ibrutinib (µM)	0
39	Mercaptopurine (µM)	413.8294
39	Nelarabine (µM)	0
39	Panobinostat (nM)	0
39	Prednisolone (µM)	0.1378864
39	Ruxolitinib (nM)	0
39	Thioguanine (µM)	0
39	Trametinib (nM)	0
39	Venetoclax (nM)	0
39	Vincristine (µM)	10.31691
39	Vorinostat (nM)	0
39	asparagise_normalized	0.4965
39	mercaptopurine_normalized	0.4345
39	prednisolone_normalized	0.2129
39	vincristine_normalized	0.7627
40	immunophenotype	B
40	molecular subtype	ETV6-RUNX1
40	Protocol	T16
40	NCI risk	SR
40	Age at diagnosis	6.1
40	WBC at diagnosis	5.9
40	Sex	F
40	Genetically-defined race	White
40	Asparaginase (IU/ml)	0.1333441
40	Bortezomib (nM)	0
40	CHZ868 (nM)	0
40	Cytarabine (µM)	0
40	Dasatinib (nM)	20000
40	Daunorubicin (µM)	0
40	Dexamethasone  (µM)	0
40	Ibrutinib (µM)	0
40	Mercaptopurine (µM)	2363.4
40	Nelarabine (µM)	0
40	Panobinostat (nM)	0
40	Prednisolone (µM)	0.0075
40	Ruxolitinib (nM)	20000
40	Thioguanine (µM)	0
40	Trametinib (nM)	0
40	Venetoclax (nM)	0
40	Vincristine (µM)	0.025
40	Vorinostat (nM)	0
40	asparagise_normalized	0.4635
40	dasatinib_normalized	1
40	mercaptopurine_normalized	0.9372
40	prednisolone_normalized	0
40	ruxolitinib_normalized	1
40	vincristine_normalized	0
41	immunophenotype	B
41	molecular subtype	TCF3-PBX1
41	Protocol	T16
41	NCI risk	HR
41	Age at diagnosis	11.8
41	WBC at diagnosis	5.6
41	Sex	M
41	Genetically-defined race	black
41	Asparaginase (IU/ml)	0.684333293
41	Bortezomib (nM)	48.18394
41	CHZ868 (nM)	0
41	Cytarabine (µM)	0
41	Dasatinib (nM)	82.28653
41	Daunorubicin (µM)	0.04850884
41	Dexamethasone  (µM)	0
41	Ibrutinib (µM)	4.952263
41	Mercaptopurine (µM)	205.4951
41	Nelarabine (µM)	0
41	Panobinostat (nM)	1.283365
41	Prednisolone (µM)	0
41	Ruxolitinib (nM)	20000
41	Thioguanine (µM)	0
41	Trametinib (nM)	0.005
41	Venetoclax (nM)	0
41	Vincristine (µM)	0.025
41	Vorinostat (nM)	0
41	asparagise_normalized	0.6667
41	bortezomib_normalized	0.5622
41	dasatinib_normalized	0.5831
41	daunorubicin_normalized	0.3933
41	ibrutinib_normalized	0.3328
41	mercaptopurine_normalized	0.2325
41	panobinostat_normalized	0.0389
41	ruxolitinib_normalized	1
41	trametinib_normalized	0
41	vincristine_normalized	0
42	immunophenotype	T
42	molecular subtype	T-ALL
42	Protocol	T16
42	NCI risk	HR
42	Age at diagnosis	12
42	WBC at diagnosis	1.9
42	Sex	M
42	Genetically-defined race	black
42	Asparaginase (IU/ml)	9.262615
42	Bortezomib (nM)	14.90514
42	CHZ868 (nM)	0
42	Cytarabine (µM)	0
42	Dasatinib (nM)	0
42	Daunorubicin (µM)	0.20419
42	Dexamethasone  (µM)	0
42	Ibrutinib (µM)	0
42	Mercaptopurine (µM)	1284.206223
42	Nelarabine (µM)	0
42	Panobinostat (nM)	16.18671389
42	Prednisolone (µM)	216.6972
42	Ruxolitinib (nM)	0
42	Thioguanine (µM)	0
42	Trametinib (nM)	0
42	Venetoclax (nM)	0
42	Vincristine (µM)	1.051577
42	Vorinostat (nM)	0
42	asparagise_normalized	0.9905
42	bortezomib_normalized	0.3929
42	daunorubicin_normalized	0.5964
42	mercaptopurine_normalized	0.7612
42	panobinostat_normalized	0.4048
42	prednisolone_normalized	0.9192
42	vincristine_normalized	0.4359
43	immunophenotype	B
43	molecular subtype	Hyperdiploid
43	Protocol	T16
43	NCI risk	SR
43	Age at diagnosis	3.4
43	WBC at diagnosis	5.2
43	Sex	F
43	Genetically-defined race	Hispanic
43	Asparaginase (IU/ml)	20
43	Bortezomib (nM)	2000
43	CHZ868 (nM)	0
43	Cytarabine (µM)	0
43	Dasatinib (nM)	0
43	Daunorubicin (µM)	7.1
43	Dexamethasone  (µM)	0
43	Ibrutinib (µM)	0
43	Mercaptopurine (µM)	148.6115
43	Nelarabine (µM)	0
43	Panobinostat (nM)	2000
43	Prednisolone (µM)	1006
43	Ruxolitinib (nM)	0
43	Thioguanine (µM)	0
43	Trametinib (nM)	0
43	Venetoclax (nM)	0
43	Vincristine (µM)	108.34
43	Vorinostat (nM)	0
43	asparagise_normalized	1
43	bortezomib_normalized	1
43	daunorubicin_normalized	1
43	mercaptopurine_normalized	0.139
43	panobinostat_normalized	1
43	prednisolone_normalized	1
43	vincristine_normalized	1
44	immunophenotype	B
44	molecular subtype	ETV6-RUNX1-like
44	Protocol	T16
44	NCI risk	HR
44	Age at diagnosis	18.8
44	WBC at diagnosis	22.3
44	Sex	F
44	Genetically-defined race	White
44	Asparaginase (IU/ml)	0.0016
44	Bortezomib (nM)	3.688811
44	CHZ868 (nM)	0
44	Cytarabine (µM)	0
44	Dasatinib (nM)	20000
44	Daunorubicin (µM)	0.05754525
44	Dexamethasone  (µM)	0
44	Ibrutinib (µM)	9.818878
44	Mercaptopurine (µM)	554.5387
44	Nelarabine (µM)	0
44	Panobinostat (nM)	16.5956
44	Prednisolone (µM)	0.03753745
44	Ruxolitinib (nM)	20000
44	Thioguanine (µM)	0
44	Trametinib (nM)	0.005
44	Venetoclax (nM)	0
44	Vincristine (µM)	0.17198276
44	Vorinostat (nM)	0
44	asparagise_normalized	0
44	bortezomib_normalized	0.1913
44	dasatinib_normalized	1
44	daunorubicin_normalized	0.4175
44	ibrutinib_normalized	0.5303
44	mercaptopurine_normalized	0.5189
44	panobinostat_normalized	0.4084
44	prednisolone_normalized	0.088
44	ruxolitinib_normalized	1
44	trametinib_normalized	0
44	vincristine_normalized	0.1768
45	immunophenotype	B
45	molecular subtype	PAX5alt
45	Protocol	T16
45	NCI risk	SR
45	Age at diagnosis	2.4
45	WBC at diagnosis	4.4
45	Sex	M
45	Genetically-defined race	White
45	Asparaginase (IU/ml)	0
45	Bortezomib (nM)	7.742604
45	CHZ868 (nM)	0
45	Cytarabine (µM)	0
45	Dasatinib (nM)	331.5316
45	Daunorubicin (µM)	0.02346263
45	Dexamethasone  (µM)	0
45	Ibrutinib (µM)	5.293314
45	Mercaptopurine (µM)	358.4981
45	Nelarabine (µM)	0
45	Panobinostat (nM)	4.544838665
45	Prednisolone (µM)	0
45	Ruxolitinib (nM)	20000
45	Thioguanine (µM)	0
45	Trametinib (nM)	0.005
45	Venetoclax (nM)	0
45	Vincristine (µM)	0.025
45	Vorinostat (nM)	0
45	bortezomib_normalized	0.2983
45	dasatinib_normalized	0.7041
45	daunorubicin_normalized	0.2907
45	ibrutinib_normalized	0.3521
45	mercaptopurine_normalized	0.3931
45	panobinostat_normalized	0.2214
45	ruxolitinib_normalized	1
45	trametinib_normalized	0
45	vincristine_normalized	0
46	immunophenotype	B
46	molecular subtype	Hyperdiploid
46	Protocol	T16
46	NCI risk	SR
46	Age at diagnosis	6.4
46	WBC at diagnosis	1.8
46	Sex	M
46	Genetically-defined race	White
46	Asparaginase (IU/ml)	0.0016
46	Bortezomib (nM)	0
46	CHZ868 (nM)	0
46	Cytarabine (µM)	0
46	Dasatinib (nM)	0
46	Daunorubicin (µM)	0
46	Dexamethasone  (µM)	0
46	Ibrutinib (µM)	0
46	Mercaptopurine (µM)	428.4918
46	Nelarabine (µM)	0
46	Panobinostat (nM)	0
46	Prednisolone (µM)	0.08000557
46	Ruxolitinib (nM)	0
46	Thioguanine (µM)	0
46	Trametinib (nM)	0
46	Venetoclax (nM)	0
46	Vincristine (µM)	0.471743254
46	Vorinostat (nM)	0
46	asparagise_normalized	0
46	mercaptopurine_normalized	0.4445
46	prednisolone_normalized	0.1607
46	vincristine_normalized	0.3212
47	immunophenotype	B
47	molecular subtype	MEF2D
47	Protocol	T16
47	NCI risk	HR
47	Age at diagnosis	10.1
47	WBC at diagnosis	2.1
47	Sex	F
47	Genetically-defined race	Hispanic
47	Asparaginase (IU/ml)	1.199175
47	Bortezomib (nM)	0
47	CHZ868 (nM)	0
47	Cytarabine (µM)	0
47	Dasatinib (nM)	0
47	Daunorubicin (µM)	0
47	Dexamethasone  (µM)	0
47	Ibrutinib (µM)	0
47	Mercaptopurine (µM)	5876
47	Nelarabine (µM)	0
47	Panobinostat (nM)	0
47	Prednisolone (µM)	0.069338135
47	Ruxolitinib (nM)	0
47	Thioguanine (µM)	0
47	Trametinib (nM)	0
47	Venetoclax (nM)	0
47	Vincristine (µM)	0.2349503
47	Vorinostat (nM)	0
47	asparagise_normalized	0.7364
47	mercaptopurine_normalized	1
47	prednisolone_normalized	0.1469
47	vincristine_normalized	0.2214
48	immunophenotype	B
48	molecular subtype	Hyperdiploid
48	Protocol	T16
48	NCI risk	SR
48	Age at diagnosis	4.8
48	WBC at diagnosis	4.3
48	Sex	M
48	Genetically-defined race	Hispanic
48	Asparaginase (IU/ml)	0.0016
48	Bortezomib (nM)	132.1984
48	CHZ868 (nM)	0
48	Cytarabine (µM)	0
48	Dasatinib (nM)	0
48	Daunorubicin (µM)	0.1729594
48	Dexamethasone  (µM)	0
48	Ibrutinib (µM)	0
48	Mercaptopurine (µM)	448.8607
48	Nelarabine (µM)	0
48	Panobinostat (nM)	4.398665
48	Prednisolone (µM)	0
48	Ruxolitinib (nM)	0
48	Thioguanine (µM)	0
48	Trametinib (nM)	0
48	Venetoclax (nM)	0
48	Vincristine (µM)	0.09745642
48	Vorinostat (nM)	0
48	asparagise_normalized	0
48	bortezomib_normalized	0.7079
48	daunorubicin_normalized	0.573
48	mercaptopurine_normalized	0.4579
48	panobinostat_normalized	0.2167
48	vincristine_normalized	0.0955
49	immunophenotype	B
49	molecular subtype	ETV6-RUNX1
49	Protocol	T16
49	NCI risk	SR
49	Age at diagnosis	4.2
49	WBC at diagnosis	7.9
49	Sex	F
49	Genetically-defined race	White
49	Asparaginase (IU/ml)	3.077299
49	Bortezomib (nM)	0
49	CHZ868 (nM)	0
49	Cytarabine (µM)	0
49	Dasatinib (nM)	0
49	Daunorubicin (µM)	0
49	Dexamethasone  (µM)	0
49	Ibrutinib (µM)	0
49	Mercaptopurine (µM)	5876
49	Nelarabine (µM)	0
49	Panobinostat (nM)	0
49	Prednisolone (µM)	0.4336852
49	Ruxolitinib (nM)	0
49	Thioguanine (µM)	0
49	Trametinib (nM)	0
49	Venetoclax (nM)	0
49	Vincristine (µM)	22.25428
49	Vorinostat (nM)	0
49	asparagise_normalized	0.8535
49	mercaptopurine_normalized	1
49	prednisolone_normalized	0.3229
49	vincristine_normalized	0.8727
50	immunophenotype	B
50	molecular subtype	Hyperdiploid
50	Protocol	T16
50	NCI risk	SR
50	Age at diagnosis	8.3
50	WBC at diagnosis	5.9
50	Sex	M
50	Genetically-defined race	White
50	Asparaginase (IU/ml)	0
50	Bortezomib (nM)	13.78165
50	CHZ868 (nM)	0
50	Cytarabine (µM)	0
50	Dasatinib (nM)	20000
50	Daunorubicin (µM)	0.07712276
50	Dexamethasone  (µM)	0
50	Ibrutinib (µM)	4.589521
50	Mercaptopurine (µM)	0
50	Nelarabine (µM)	0
50	Panobinostat (nM)	1.618649
50	Prednisolone (µM)	0.109833
50	Ruxolitinib (nM)	20000
50	Thioguanine (µM)	0
50	Trametinib (nM)	0.005
50	Venetoclax (nM)	0
50	Vincristine (µM)	0.025
50	Vorinostat (nM)	0
50	bortezomib_normalized	0.3816
50	dasatinib_normalized	1
50	daunorubicin_normalized	0.4588
50	ibrutinib_normalized	0.3109
50	panobinostat_normalized	0.0724
50	prednisolone_normalized	0.1911
50	ruxolitinib_normalized	1
50	trametinib_normalized	0
50	vincristine_normalized	0
51	immunophenotype	B
51	molecular subtype	Hyperdiploid
51	Protocol	T16
51	NCI risk	SR
51	Age at diagnosis	2.4
51	WBC at diagnosis	13.8
51	Sex	M
51	Genetically-defined race	Hispanic
51	Asparaginase (IU/ml)	0.0016
51	Bortezomib (nM)	16.2637
51	CHZ868 (nM)	0
51	Cytarabine (µM)	0
51	Dasatinib (nM)	1562.519
51	Daunorubicin (µM)	0.05933643
51	Dexamethasone  (µM)	0
51	Ibrutinib (µM)	6.271128
51	Mercaptopurine (µM)	579.8811
51	Nelarabine (µM)	0
51	Panobinostat (nM)	4.082303
51	Prednisolone (µM)	285.9132
51	Ruxolitinib (nM)	20000
51	Thioguanine (µM)	0
51	Trametinib (nM)	0.140212125
51	Venetoclax (nM)	0
51	Vincristine (µM)	0.025
51	Vorinostat (nM)	0
51	asparagise_normalized	0
51	bortezomib_normalized	0.4055
51	dasatinib_normalized	0.8388
51	daunorubicin_normalized	0.4218
51	ibrutinib_normalized	0.401
51	mercaptopurine_normalized	0.5318
51	panobinostat_normalized	0.206
51	prednisolone_normalized	0.9458
51	ruxolitinib_normalized	1
51	trametinib_normalized	0.2294
51	vincristine_normalized	0
52	immunophenotype	B
52	molecular subtype	Hyperdiploid
52	Protocol	T16
52	NCI risk	SR
52	Age at diagnosis	4.9
52	WBC at diagnosis	9.4
52	Sex	M
52	Genetically-defined race	White
52	Asparaginase (IU/ml)	0
52	Bortezomib (nM)	0
52	CHZ868 (nM)	0
52	Cytarabine (µM)	0
52	Dasatinib (nM)	0
52	Daunorubicin (µM)	0
52	Dexamethasone  (µM)	0
52	Ibrutinib (µM)	0
52	Mercaptopurine (µM)	506.7304
52	Nelarabine (µM)	0
52	Panobinostat (nM)	0
52	Prednisolone (µM)	1006
52	Ruxolitinib (nM)	0
52	Thioguanine (µM)	0
52	Trametinib (nM)	0
52	Venetoclax (nM)	0
52	Vincristine (µM)	0
52	Vorinostat (nM)	0
52	mercaptopurine_normalized	0.4929
52	prednisolone_normalized	1
53	immunophenotype	B
53	molecular subtype	PAX5alt
53	Protocol	T16
53	NCI risk	HR
53	Age at diagnosis	15.1
53	WBC at diagnosis	4
53	Sex	M
53	Genetically-defined race	White
53	Asparaginase (IU/ml)	1.520804
53	Bortezomib (nM)	2.899888
53	CHZ868 (nM)	0
53	Cytarabine (µM)	0
53	Dasatinib (nM)	20000
53	Daunorubicin (µM)	0.2188817
53	Dexamethasone  (µM)	0
53	Ibrutinib (µM)	20.64279
53	Mercaptopurine (µM)	5876
53	Nelarabine (µM)	0
53	Panobinostat (nM)	26.01244
53	Prednisolone (µM)	20.72206
53	Ruxolitinib (nM)	20000
53	Thioguanine (µM)	0
53	Trametinib (nM)	593.0663
53	Venetoclax (nM)	0
53	Vincristine (µM)	0.8670898
53	Vorinostat (nM)	0
53	asparagise_normalized	0.766
53	bortezomib_normalized	0.1566
53	dasatinib_normalized	1
53	daunorubicin_normalized	0.6063
53	ibrutinib_normalized	0.7447
53	mercaptopurine_normalized	1
53	panobinostat_normalized	0.4733
53	prednisolone_normalized	0.6939
53	ruxolitinib_normalized	1
53	trametinib_normalized	0.9546
53	vincristine_normalized	0.4083
54	immunophenotype	B
54	molecular subtype	Hyperdiploid
54	Protocol	T16
54	NCI risk	HR
54	Age at diagnosis	8
54	WBC at diagnosis	220.2
54	Sex	F
54	Genetically-defined race	Hispanic
54	Asparaginase (IU/ml)	0.09904832
54	Bortezomib (nM)	10.35835
54	CHZ868 (nM)	0
54	Cytarabine (µM)	0
54	Dasatinib (nM)	20000
54	Daunorubicin (µM)	0.06605881
54	Dexamethasone  (µM)	0
54	Ibrutinib (µM)	18.96853353
54	Mercaptopurine (µM)	387.0778
54	Nelarabine (µM)	0
54	Panobinostat (nM)	0.49
54	Prednisolone (µM)	0.0075
54	Ruxolitinib (nM)	20000
54	Thioguanine (µM)	0
54	Trametinib (nM)	79.93846
54	Venetoclax (nM)	0.4458053
54	Vincristine (µM)	108.34
54	Vorinostat (nM)	0
54	asparagise_normalized	0.4265
54	bortezomib_normalized	0.3404
54	dasatinib_normalized	1
54	daunorubicin_normalized	0.437
54	ibrutinib_normalized	0.7203
54	mercaptopurine_normalized	0.4152
54	panobinostat_normalized	0
54	prednisolone_normalized	0
54	ruxolitinib_normalized	1
54	trametinib_normalized	0.7806
54	venetoclax_normalized	0.5298
54	vincristine_normalized	1
55	immunophenotype	B
55	molecular subtype	ETV6-RUNX1
55	Protocol	T16
55	NCI risk	SR
55	Age at diagnosis	3.9
55	WBC at diagnosis	4.9
55	Sex	M
55	Genetically-defined race	Asian/Other
55	Asparaginase (IU/ml)	0.067355483
55	Bortezomib (nM)	25.63239
55	CHZ868 (nM)	0
55	Cytarabine (µM)	0
55	Dasatinib (nM)	20000
55	Daunorubicin (µM)	0.1647892
55	Dexamethasone  (µM)	0
55	Ibrutinib (µM)	9.75992
55	Mercaptopurine (µM)	499.4251
55	Nelarabine (µM)	0
55	Panobinostat (nM)	6.777779
55	Prednisolone (µM)	0.0075
55	Ruxolitinib (nM)	20000
55	Thioguanine (µM)	0
55	Trametinib (nM)	2000
55	Venetoclax (nM)	5.720707
55	Vincristine (µM)	0.1678483
55	Vorinostat (nM)	0
55	asparagise_normalized	0.3786
55	bortezomib_normalized	0.4711
55	dasatinib_normalized	1
55	daunorubicin_normalized	0.5661
55	ibrutinib_normalized	0.5286
55	mercaptopurine_normalized	0.4887
55	panobinostat_normalized	0.2791
55	prednisolone_normalized	0
55	ruxolitinib_normalized	1
55	trametinib_normalized	1
55	venetoclax_normalized	0.7515
55	vincristine_normalized	0.1733
56	immunophenotype	T
56	molecular subtype	T-ALL
56	Protocol	T16
56	NCI risk	SR
56	Age at diagnosis	8.4
56	WBC at diagnosis	43.5
56	Sex	M
56	Genetically-defined race	black
56	Asparaginase (IU/ml)	0.004479774
56	Bortezomib (nM)	48.85357848
56	CHZ868 (nM)	0
56	Cytarabine (µM)	0
56	Dasatinib (nM)	0
56	Daunorubicin (µM)	0.06878989
56	Dexamethasone  (µM)	0
56	Ibrutinib (µM)	0
56	Mercaptopurine (µM)	269.5614
56	Nelarabine (µM)	0
56	Panobinostat (nM)	6.591682
56	Prednisolone (µM)	0.1086621
56	Ruxolitinib (nM)	0
56	Thioguanine (µM)	0
56	Trametinib (nM)	0
56	Venetoclax (nM)	0
56	Vincristine (µM)	0.07229433
56	Vorinostat (nM)	0
56	asparagise_normalized	0.0418
56	bortezomib_normalized	0.5642
56	daunorubicin_normalized	0.4427
56	mercaptopurine_normalized	0.3108
56	panobinostat_normalized	0.2751
56	prednisolone_normalized	0.19
56	vincristine_normalized	0.0528
57	immunophenotype	B
57	molecular subtype	Hyperdiploid
57	Protocol	T16
57	NCI risk	SR
57	Age at diagnosis	3.3
57	WBC at diagnosis	3.7
57	Sex	M
57	Genetically-defined race	White
57	Asparaginase (IU/ml)	0.04658728
57	Bortezomib (nM)	62.03650915
57	CHZ868 (nM)	0
57	Cytarabine (µM)	0
57	Dasatinib (nM)	20000
57	Daunorubicin (µM)	0.06998547
57	Dexamethasone  (µM)	0
57	Ibrutinib (µM)	12.61033
57	Mercaptopurine (µM)	647.046
57	Nelarabine (µM)	0
57	Panobinostat (nM)	16.72572158
57	Prednisolone (µM)	363.6921
57	Ruxolitinib (nM)	20000
57	Thioguanine (µM)	0
57	Trametinib (nM)	64.49547
57	Venetoclax (nM)	0.0005
57	Vincristine (µM)	2.623899
57	Vorinostat (nM)	0
57	asparagise_normalized	0.3328
57	bortezomib_normalized	0.5987
57	dasatinib_normalized	1
57	daunorubicin_normalized	0.4451
57	ibrutinib_normalized	0.6025
57	mercaptopurine_normalized	0.5634
57	panobinostat_normalized	0.4095
57	prednisolone_normalized	0.9689
57	ruxolitinib_normalized	1
57	trametinib_normalized	0.7619
57	venetoclax_normalized	0
57	vincristine_normalized	0.5668
58	immunophenotype	T
58	molecular subtype	T-ALL
58	Protocol	T16
58	NCI risk	HR
58	Age at diagnosis	11.6
58	WBC at diagnosis	4.9
58	Sex	M
58	Genetically-defined race	black
58	Asparaginase (IU/ml)	0.0189456
58	Bortezomib (nM)	4.081446
58	CHZ868 (nM)	0
58	Cytarabine (µM)	0
58	Dasatinib (nM)	456.0739
58	Daunorubicin (µM)	0.02364316
58	Dexamethasone  (µM)	0
58	Ibrutinib (µM)	5.543418
58	Mercaptopurine (µM)	0
58	Nelarabine (µM)	0
58	Panobinostat (nM)	4.051245
58	Prednisolone (µM)	1006
58	Ruxolitinib (nM)	20000
58	Thioguanine (µM)	0
58	Trametinib (nM)	2000
58	Venetoclax (nM)	1.213235
58	Vincristine (µM)	0.170782468
58	Vorinostat (nM)	0
58	asparagise_normalized	0.221
58	bortezomib_normalized	0.2059
58	dasatinib_normalized	0.7318
58	daunorubicin_normalized	0.2918
58	ibrutinib_normalized	0.3654
58	panobinostat_normalized	0.2049
58	prednisolone_normalized	1
58	ruxolitinib_normalized	1
58	trametinib_normalized	1
58	venetoclax_normalized	0.6168
58	vincristine_normalized	0.1758
59	immunophenotype	B
59	molecular subtype	PAX5alt
59	Protocol	T16
59	NCI risk	HR
59	Age at diagnosis	18.1
59	WBC at diagnosis	4.4
59	Sex	M
59	Genetically-defined race	Asian/Other
59	Asparaginase (IU/ml)	20
59	Bortezomib (nM)	4.024028
59	CHZ868 (nM)	0
59	Cytarabine (µM)	0
59	Dasatinib (nM)	6852.236
59	Daunorubicin (µM)	0.3612599
59	Dexamethasone  (µM)	0
59	Ibrutinib (µM)	3.911108
59	Mercaptopurine (µM)	0
59	Nelarabine (µM)	0
59	Panobinostat (nM)	18.75401
59	Prednisolone (µM)	1006
59	Ruxolitinib (nM)	20000
59	Thioguanine (µM)	0
59	Trametinib (nM)	0.1282207
59	Venetoclax (nM)	0.0005
59	Vincristine (µM)	108.34
59	Vorinostat (nM)	0
59	asparagise_normalized	1
59	bortezomib_normalized	0.2039
59	dasatinib_normalized	0.9672
59	daunorubicin_normalized	0.6771
59	ibrutinib_normalized	0.2647
59	panobinostat_normalized	0.426
59	prednisolone_normalized	1
59	ruxolitinib_normalized	1
59	trametinib_normalized	0.2216
59	venetoclax_normalized	0
59	vincristine_normalized	1
60	immunophenotype	B
60	molecular subtype	Hyperdiploid
60	Protocol	T16
60	NCI risk	SR
60	Age at diagnosis	4.1
60	WBC at diagnosis	4.8
60	Sex	M
60	Genetically-defined race	White
60	Asparaginase (IU/ml)	0.05157547
60	Bortezomib (nM)	4.157735
60	CHZ868 (nM)	0
60	Cytarabine (µM)	0
60	Dasatinib (nM)	5201.408
60	Daunorubicin (µM)	0.03243597
60	Dexamethasone  (µM)	0
60	Ibrutinib (µM)	3.185948
60	Mercaptopurine (µM)	578.5146
60	Nelarabine (µM)	0
60	Panobinostat (nM)	4.941296
60	Prednisolone (µM)	0
60	Ruxolitinib (nM)	20000
60	Thioguanine (µM)	0
60	Trametinib (nM)	5.142842776
60	Venetoclax (nM)	0.0005
60	Vincristine (µM)	0.025
60	Vorinostat (nM)	0
60	asparagise_normalized	0.3454
60	bortezomib_normalized	0.2086
60	dasatinib_normalized	0.9432
60	daunorubicin_normalized	0.3364
60	ibrutinib_normalized	0.2056
60	mercaptopurine_normalized	0.5311
60	panobinostat_normalized	0.2335
60	ruxolitinib_normalized	1
60	trametinib_normalized	0.5422
60	venetoclax_normalized	0
60	vincristine_normalized	0
61	immunophenotype	B
61	molecular subtype	Hyperdiploid
61	Protocol	T16
61	NCI risk	HR
61	Age at diagnosis	10
61	WBC at diagnosis	6.4
61	Sex	F
61	Genetically-defined race	White
61	Asparaginase (IU/ml)	20
61	Bortezomib (nM)	3.905656
61	CHZ868 (nM)	0
61	Cytarabine (µM)	0
61	Dasatinib (nM)	20000
61	Daunorubicin (µM)	0.18944
61	Dexamethasone  (µM)	0
61	Ibrutinib (µM)	8.061243
61	Mercaptopurine (µM)	5876
61	Nelarabine (µM)	0
61	Panobinostat (nM)	3.130197
61	Prednisolone (µM)	0
61	Ruxolitinib (nM)	20000
61	Thioguanine (µM)	0
61	Trametinib (nM)	2000
61	Venetoclax (nM)	0.0005
61	Vincristine (µM)	108.34
61	Vorinostat (nM)	0
61	asparagise_normalized	1
61	bortezomib_normalized	0.1996
61	dasatinib_normalized	1
61	daunorubicin_normalized	0.5858
61	ibrutinib_normalized	0.4734
61	mercaptopurine_normalized	1
61	panobinostat_normalized	0.1676
61	ruxolitinib_normalized	1
61	trametinib_normalized	1
61	venetoclax_normalized	0
61	vincristine_normalized	1
62	immunophenotype	B
62	molecular subtype	ETV6-RUNX1
62	Protocol	T16
62	NCI risk	SR
62	Age at diagnosis	8.7
62	WBC at diagnosis	3.7
62	Sex	M
62	Genetically-defined race	White
62	Asparaginase (IU/ml)	0.0016
62	Bortezomib (nM)	0
62	CHZ868 (nM)	0
62	Cytarabine (µM)	0
62	Dasatinib (nM)	0
62	Daunorubicin (µM)	0
62	Dexamethasone  (µM)	0
62	Ibrutinib (µM)	0
62	Mercaptopurine (µM)	1216.124
62	Nelarabine (µM)	0
62	Panobinostat (nM)	0
62	Prednisolone (µM)	0.2056252
62	Ruxolitinib (nM)	0
62	Thioguanine (µM)	0
62	Trametinib (nM)	0
62	Venetoclax (nM)	0
62	Vincristine (µM)	1.294833
62	Vorinostat (nM)	0
62	asparagise_normalized	0
62	mercaptopurine_normalized	0.7455
62	prednisolone_normalized	0.2512
62	vincristine_normalized	0.4657
63	immunophenotype	B
63	molecular subtype	iAMP21
63	Protocol	T16
63	NCI risk	HR
63	Age at diagnosis	11
63	WBC at diagnosis	24.1
63	Sex	M
63	Genetically-defined race	White
63	Asparaginase (IU/ml)	20
63	Bortezomib (nM)	3.630353
63	CHZ868 (nM)	0
63	Cytarabine (µM)	0
63	Dasatinib (nM)	4923.533
63	Daunorubicin (µM)	0.0247361
63	Dexamethasone  (µM)	0
63	Ibrutinib (µM)	2.80976
63	Mercaptopurine (µM)	5876
63	Nelarabine (µM)	0
63	Panobinostat (nM)	3.541227
63	Prednisolone (µM)	1006
63	Ruxolitinib (nM)	20000
63	Thioguanine (µM)	0
63	Trametinib (nM)	2000
63	Venetoclax (nM)	19.31042
63	Vincristine (µM)	0.05765279
63	Vorinostat (nM)	0
63	asparagise_normalized	1
63	bortezomib_normalized	0.189
63	dasatinib_normalized	0.9385
63	daunorubicin_normalized	0.2981
63	ibrutinib_normalized	0.1693
63	mercaptopurine_normalized	1
63	panobinostat_normalized	0.1854
63	prednisolone_normalized	1
63	ruxolitinib_normalized	1
63	trametinib_normalized	1
63	venetoclax_normalized	0.8572
63	vincristine_normalized	0.0204
64	immunophenotype	B
64	molecular subtype	Hyperdiploid
64	Protocol	T16
64	NCI risk	SR
64	Age at diagnosis	5.4
64	WBC at diagnosis	3.6
64	Sex	M
64	Genetically-defined race	White
64	Asparaginase (IU/ml)	0.3267395
64	Bortezomib (nM)	0
64	CHZ868 (nM)	0
64	Cytarabine (µM)	0
64	Dasatinib (nM)	0
64	Daunorubicin (µM)	0
64	Dexamethasone  (µM)	0
64	Ibrutinib (µM)	0
64	Mercaptopurine (µM)	642.0516
64	Nelarabine (µM)	0
64	Panobinostat (nM)	0
64	Prednisolone (µM)	210.4491
64	Ruxolitinib (nM)	0
64	Thioguanine (µM)	0
64	Trametinib (nM)	0
64	Venetoclax (nM)	0
64	Vincristine (µM)	17.26166
64	Vorinostat (nM)	0
64	asparagise_normalized	0.5749
64	mercaptopurine_normalized	0.5612
64	prednisolone_normalized	0.9164
64	vincristine_normalized	0.8363
65	immunophenotype	B
65	molecular subtype	Hyperdiploid
65	Protocol	T16
65	NCI risk	SR
65	Age at diagnosis	3.3
65	WBC at diagnosis	12.8
65	Sex	M
65	Genetically-defined race	White
65	Asparaginase (IU/ml)	20
65	Bortezomib (nM)	3.860787
65	CHZ868 (nM)	0
65	Cytarabine (µM)	0
65	Dasatinib (nM)	0
65	Daunorubicin (µM)	0.006373579
65	Dexamethasone  (µM)	0
65	Ibrutinib (µM)	0
65	Mercaptopurine (µM)	235.9694
65	Nelarabine (µM)	0
65	Panobinostat (nM)	1.205608
65	Prednisolone (µM)	0.0075
65	Ruxolitinib (nM)	0
65	Thioguanine (µM)	0
65	Trametinib (nM)	0
65	Venetoclax (nM)	0
65	Vincristine (µM)	0.025
65	Vorinostat (nM)	0
65	asparagise_normalized	1
65	bortezomib_normalized	0.1979
65	daunorubicin_normalized	0.1065
65	mercaptopurine_normalized	0.2724
65	panobinostat_normalized	0.0299
65	prednisolone_normalized	0
65	vincristine_normalized	0
66	immunophenotype	B
66	molecular subtype	ETV6-RUNX1
66	Protocol	T16
66	NCI risk	SR
66	Age at diagnosis	5.7
66	WBC at diagnosis	3.9
66	Sex	F
66	Genetically-defined race	White
66	Asparaginase (IU/ml)	4.584107
66	Bortezomib (nM)	3.545903
66	CHZ868 (nM)	0
66	Cytarabine (µM)	0
66	Dasatinib (nM)	20000
66	Daunorubicin (µM)	0.034980926
66	Dexamethasone  (µM)	0
66	Ibrutinib (µM)	3.717072
66	Mercaptopurine (µM)	5876
66	Nelarabine (µM)	0
66	Panobinostat (nM)	3.529503
66	Prednisolone (µM)	1.315688
66	Ruxolitinib (nM)	20000
66	Thioguanine (µM)	0
66	Trametinib (nM)	4.733297
66	Venetoclax (nM)	0.0005
66	Vincristine (µM)	0.025
66	Vorinostat (nM)	0
66	asparagise_normalized	0.9031
66	bortezomib_normalized	0.1856
66	dasatinib_normalized	1
66	daunorubicin_normalized	0.3471
66	ibrutinib_normalized	0.2501
66	mercaptopurine_normalized	1
66	panobinostat_normalized	0.185
66	prednisolone_normalized	0.4294
66	ruxolitinib_normalized	1
66	trametinib_normalized	0.535
66	venetoclax_normalized	0
66	vincristine_normalized	0
67	immunophenotype	B
67	molecular subtype	ETV6-RUNX1
67	Protocol	T16
67	NCI risk	SR
67	Age at diagnosis	3.3
67	WBC at diagnosis	3.3
67	Sex	M
67	Genetically-defined race	White
67	Asparaginase (IU/ml)	0
67	Bortezomib (nM)	0
67	CHZ868 (nM)	0
67	Cytarabine (µM)	0
67	Dasatinib (nM)	0
67	Daunorubicin (µM)	0
67	Dexamethasone  (µM)	0
67	Ibrutinib (µM)	0
67	Mercaptopurine (µM)	749.3314
67	Nelarabine (µM)	0
67	Panobinostat (nM)	0
67	Prednisolone (µM)	0.3869308
67	Ruxolitinib (nM)	0
67	Thioguanine (µM)	0
67	Trametinib (nM)	0
67	Venetoclax (nM)	0
67	Vincristine (µM)	0
67	Vorinostat (nM)	0
67	mercaptopurine_normalized	0.6058
67	prednisolone_normalized	0.3119
68	immunophenotype	B
68	molecular subtype	KMT2A
68	Protocol	T16
68	NCI risk	SR
68	Age at diagnosis	2
68	WBC at diagnosis	11.4
68	Sex	M
68	Genetically-defined race	Asian/Other
68	Asparaginase (IU/ml)	0.02882965
68	Bortezomib (nM)	4.599131
68	CHZ868 (nM)	0
68	Cytarabine (µM)	0
68	Dasatinib (nM)	0
68	Daunorubicin (µM)	0.026203673
68	Dexamethasone  (µM)	0
68	Ibrutinib (µM)	0
68	Mercaptopurine (µM)	121.1924
68	Nelarabine (µM)	0
68	Panobinostat (nM)	3.263722561
68	Prednisolone (µM)	1006
68	Ruxolitinib (nM)	0
68	Thioguanine (µM)	0
68	Trametinib (nM)	0
68	Venetoclax (nM)	0
68	Vincristine (µM)	0
68	Vorinostat (nM)	0
68	asparagise_normalized	0.2732
68	bortezomib_normalized	0.2232
68	daunorubicin_normalized	0.3063
68	mercaptopurine_normalized	0.0801
68	panobinostat_normalized	0.1737
68	prednisolone_normalized	1
69	immunophenotype	B
69	molecular subtype	ETV6-RUNX1
69	Protocol	T16
69	NCI risk	SR
69	Age at diagnosis	5
69	WBC at diagnosis	2.1
69	Sex	M
69	Genetically-defined race	Asian/Other
69	Asparaginase (IU/ml)	5.461553
69	Bortezomib (nM)	0
69	CHZ868 (nM)	0
69	Cytarabine (µM)	0
69	Dasatinib (nM)	0
69	Daunorubicin (µM)	0
69	Dexamethasone  (µM)	0
69	Ibrutinib (µM)	0
69	Mercaptopurine (µM)	5876
69	Nelarabine (µM)	0
69	Panobinostat (nM)	0
69	Prednisolone (µM)	16.5108
69	Ruxolitinib (nM)	0
69	Thioguanine (µM)	0
69	Trametinib (nM)	0
69	Venetoclax (nM)	0
69	Vincristine (µM)	7.00167
69	Vorinostat (nM)	0
69	asparagise_normalized	0.9248
69	mercaptopurine_normalized	1
69	prednisolone_normalized	0.6721
69	vincristine_normalized	0.7072
70	immunophenotype	B
70	molecular subtype	Hyperdiploid
70	Protocol	T16
70	NCI risk	SR
70	Age at diagnosis	7.3
70	WBC at diagnosis	3.3
70	Sex	M
70	Genetically-defined race	White
70	Asparaginase (IU/ml)	0.0016
70	Bortezomib (nM)	7.848655
70	CHZ868 (nM)	0
70	Cytarabine (µM)	0
70	Dasatinib (nM)	0
70	Daunorubicin (µM)	0.03150996
70	Dexamethasone  (µM)	0
70	Ibrutinib (µM)	0
70	Mercaptopurine (µM)	0
70	Nelarabine (µM)	0
70	Panobinostat (nM)	7.429957
70	Prednisolone (µM)	1006
70	Ruxolitinib (nM)	0
70	Thioguanine (µM)	0
70	Trametinib (nM)	0
70	Venetoclax (nM)	0
70	Vincristine (µM)	2.624227095
70	Vorinostat (nM)	0
70	asparagise_normalized	0
70	bortezomib_normalized	0.3003
70	daunorubicin_normalized	0.3323
70	panobinostat_normalized	0.2924
70	prednisolone_normalized	1
70	vincristine_normalized	0.5668
71	immunophenotype	B
71	molecular subtype	Hyperdiploid
71	Protocol	T16
71	NCI risk	SR
71	Age at diagnosis	3.2
71	WBC at diagnosis	11
71	Sex	M
71	Genetically-defined race	White
71	Asparaginase (IU/ml)	20
71	Bortezomib (nM)	22.45137
71	CHZ868 (nM)	0
71	Cytarabine (µM)	0
71	Dasatinib (nM)	1130.51
71	Daunorubicin (µM)	0.05996347
71	Dexamethasone  (µM)	0
71	Ibrutinib (µM)	4.33087
71	Mercaptopurine (µM)	5876
71	Nelarabine (µM)	0
71	Panobinostat (nM)	0
71	Prednisolone (µM)	1006
71	Ruxolitinib (nM)	20000
71	Thioguanine (µM)	0
71	Trametinib (nM)	0.005
71	Venetoclax (nM)	0.0005
71	Vincristine (µM)	108.34
71	Vorinostat (nM)	0
71	asparagise_normalized	1
71	bortezomib_normalized	0.452
71	dasatinib_normalized	0.8107
71	daunorubicin_normalized	0.4233
71	ibrutinib_normalized	0.2942
71	mercaptopurine_normalized	1
71	prednisolone_normalized	1
71	ruxolitinib_normalized	1
71	trametinib_normalized	0
71	venetoclax_normalized	0
71	vincristine_normalized	1
72	immunophenotype	B
72	molecular subtype	TCF3-PBX1
72	Protocol	T16
72	NCI risk	HR
72	Age at diagnosis	4.1
72	WBC at diagnosis	153.3
72	Sex	M
72	Genetically-defined race	White
72	Asparaginase (IU/ml)	0.9270309
72	Bortezomib (nM)	2.35542
72	CHZ868 (nM)	0
72	Cytarabine (µM)	0
72	Dasatinib (nM)	0
72	Daunorubicin (µM)	0.009632897
72	Dexamethasone  (µM)	0
72	Ibrutinib (µM)	0
72	Mercaptopurine (µM)	1254.899
72	Nelarabine (µM)	0
72	Panobinostat (nM)	0.49
72	Prednisolone (µM)	0.0075
72	Ruxolitinib (nM)	0
72	Thioguanine (µM)	0
72	Trametinib (nM)	0
72	Venetoclax (nM)	0
72	Vincristine (µM)	0.025
72	Vorinostat (nM)	0
72	asparagise_normalized	0.7044
72	bortezomib_normalized	0.1266
72	daunorubicin_normalized	0.1649
72	mercaptopurine_normalized	0.7546
72	panobinostat_normalized	0
72	prednisolone_normalized	0
72	vincristine_normalized	0
73	immunophenotype	B
73	molecular subtype	Hyperdiploid
73	Protocol	T16
73	NCI risk	SR
73	Age at diagnosis	8.1
73	WBC at diagnosis	2.2
73	Sex	F
73	Genetically-defined race	White
73	Asparaginase (IU/ml)	0.0016
73	Bortezomib (nM)	3.531269
73	CHZ868 (nM)	0
73	Cytarabine (µM)	0
73	Dasatinib (nM)	20000
73	Daunorubicin (µM)	0.01969296
73	Dexamethasone  (µM)	0
73	Ibrutinib (µM)	14.98484
73	Mercaptopurine (µM)	366.2668
73	Nelarabine (µM)	0
73	Panobinostat (nM)	3.51424
73	Prednisolone (µM)	0
73	Ruxolitinib (nM)	20000
73	Thioguanine (µM)	0
73	Trametinib (nM)	2000
73	Venetoclax (nM)	10.94608
73	Vincristine (µM)	0.025
73	Vorinostat (nM)	0
73	asparagise_normalized	0
73	bortezomib_normalized	0.185
73	dasatinib_normalized	1
73	daunorubicin_normalized	0.2659
73	ibrutinib_normalized	0.6523
73	mercaptopurine_normalized	0.3993
73	panobinostat_normalized	0.1843
73	ruxolitinib_normalized	1
73	trametinib_normalized	1
73	venetoclax_normalized	0.8079
73	vincristine_normalized	0
74	immunophenotype	T
74	molecular subtype	T-ALL
74	Protocol	T16
74	NCI risk	HR
74	Age at diagnosis	14.1
74	WBC at diagnosis	198.5
74	Sex	F
74	Genetically-defined race	White
74	Asparaginase (IU/ml)	0.0016
74	Bortezomib (nM)	8.676288659
74	CHZ868 (nM)	0
74	Cytarabine (µM)	0
74	Dasatinib (nM)	0.05
74	Daunorubicin (µM)	0.03775965
74	Dexamethasone  (µM)	0
74	Ibrutinib (µM)	2.553062
74	Mercaptopurine (µM)	146.8684
74	Nelarabine (µM)	0
74	Panobinostat (nM)	2.557783
74	Prednisolone (µM)	0.05560802
74	Ruxolitinib (nM)	20000
74	Thioguanine (µM)	0
74	Trametinib (nM)	37.60543
74	Venetoclax (nM)	200
74	Vincristine (µM)	0.06353341
74	Vorinostat (nM)	200000
74	asparagise_normalized	0
74	bortezomib_normalized	0.3148
74	dasatinib_normalized	0
74	daunorubicin_normalized	0.3579
74	ibrutinib_normalized	0.1417
74	mercaptopurine_normalized	0.1356
74	panobinostat_normalized	0.1385
74	prednisolone_normalized	0.1257
74	ruxolitinib_normalized	1
74	trametinib_normalized	0.7151
74	venetoclax_normalized	1
74	vincristine_normalized	0.0343
74	vorinostat_normalized	1
75	immunophenotype	B
75	molecular subtype	BCR-ABL1
75	Protocol	T16
75	NCI risk	SR
75	Age at diagnosis	5.6
75	WBC at diagnosis	10
75	Sex	F
75	Genetically-defined race	White
75	Asparaginase (IU/ml)	0.7162257
75	Bortezomib (nM)	8.587395
75	CHZ868 (nM)	0
75	Cytarabine (µM)	0
75	Dasatinib (nM)	0.05
75	Daunorubicin (µM)	0.05491164
75	Dexamethasone  (µM)	0
75	Ibrutinib (µM)	4.126278
75	Mercaptopurine (µM)	5876
75	Nelarabine (µM)	0
75	Panobinostat (nM)	6.846714
75	Prednisolone (µM)	0.999936866
75	Ruxolitinib (nM)	20000
75	Thioguanine (µM)	0
75	Trametinib (nM)	83.29078276
75	Venetoclax (nM)	25.12908
75	Vincristine (µM)	0.06115427
75	Vorinostat (nM)	200000
75	asparagise_normalized	0.6724
75	bortezomib_normalized	0.3133
75	dasatinib_normalized	0
75	daunorubicin_normalized	0.4108
75	ibrutinib_normalized	0.2802
75	mercaptopurine_normalized	1
75	panobinostat_normalized	0.2806
75	prednisolone_normalized	0.403
75	ruxolitinib_normalized	1
75	trametinib_normalized	0.7841
75	venetoclax_normalized	0.88
75	vincristine_normalized	0.0288
75	vorinostat_normalized	1
76	immunophenotype	B
76	molecular subtype	Hyperdiploid
76	Protocol	T16
76	NCI risk	SR
76	Age at diagnosis	2.2
76	WBC at diagnosis	8.3
76	Sex	M
76	Genetically-defined race	White
76	Asparaginase (IU/ml)	20
76	Bortezomib (nM)	4.022996
76	CHZ868 (nM)	0
76	Cytarabine (µM)	0
76	Dasatinib (nM)	20000
76	Daunorubicin (µM)	0.011936227
76	Dexamethasone  (µM)	0
76	Ibrutinib (µM)	3.212867
76	Mercaptopurine (µM)	0
76	Nelarabine (µM)	0
76	Panobinostat (nM)	3.783313649
76	Prednisolone (µM)	1006
76	Ruxolitinib (nM)	20000
76	Thioguanine (µM)	0
76	Trametinib (nM)	0.005
76	Venetoclax (nM)	0.0005
76	Vincristine (µM)	0
76	Vorinostat (nM)	0
76	asparagise_normalized	1
76	bortezomib_normalized	0.2038
76	dasatinib_normalized	1
76	daunorubicin_normalized	0.1952
76	ibrutinib_normalized	0.208
76	panobinostat_normalized	0.195
76	prednisolone_normalized	1
76	ruxolitinib_normalized	1
76	trametinib_normalized	0
76	venetoclax_normalized	0
77	immunophenotype	B
77	molecular subtype	ETV6-RUNX1
77	Protocol	T16
77	NCI risk	HR
77	Age at diagnosis	1.8
77	WBC at diagnosis	131
77	Sex	F
77	Genetically-defined race	White
77	Asparaginase (IU/ml)	0.04834721
77	Bortezomib (nM)	4.371211
77	CHZ868 (nM)	0
77	Cytarabine (µM)	0
77	Dasatinib (nM)	20000
77	Daunorubicin (µM)	0.03116594
77	Dexamethasone  (µM)	0
77	Ibrutinib (µM)	12.56242
77	Mercaptopurine (µM)	5876
77	Nelarabine (µM)	0
77	Panobinostat (nM)	4.116609
77	Prednisolone (µM)	0.1340563
77	Ruxolitinib (nM)	20000
77	Thioguanine (µM)	0
77	Trametinib (nM)	876.4067
77	Venetoclax (nM)	2.125799
77	Vincristine (µM)	0.74671395
77	Vorinostat (nM)	200000
77	asparagise_normalized	0.3374
77	bortezomib_normalized	0.2158
77	dasatinib_normalized	1
77	daunorubicin_normalized	0.3308
77	ibrutinib_normalized	0.6014
77	mercaptopurine_normalized	1
77	panobinostat_normalized	0.2072
77	prednisolone_normalized	0.2102
77	ruxolitinib_normalized	1
77	trametinib_normalized	0.9885
77	venetoclax_normalized	0.6655
77	vincristine_normalized	0.3869
77	vorinostat_normalized	1
78	immunophenotype	B
78	molecular subtype	BCR-ABL1
78	Protocol	T16
78	NCI risk	HR
78	Age at diagnosis	14.2
78	WBC at diagnosis	3.2
78	Sex	M
78	Genetically-defined race	White
78	Asparaginase (IU/ml)	20
78	Bortezomib (nM)	0
78	CHZ868 (nM)	0
78	Cytarabine (µM)	0
78	Dasatinib (nM)	0
78	Daunorubicin (µM)	0
78	Dexamethasone  (µM)	0
78	Ibrutinib (µM)	0
78	Mercaptopurine (µM)	769.7451
78	Nelarabine (µM)	0
78	Panobinostat (nM)	0
78	Prednisolone (µM)	27.83624071
78	Ruxolitinib (nM)	0
78	Thioguanine (µM)	0
78	Trametinib (nM)	0
78	Venetoclax (nM)	0
78	Vincristine (µM)	0.1390673
78	Vorinostat (nM)	0
78	asparagise_normalized	1
78	mercaptopurine_normalized	0.6135
78	prednisolone_normalized	0.7222
78	vincristine_normalized	0.1464
79	immunophenotype	B
79	molecular subtype	ETV6-RUNX1
79	Protocol	T16
79	NCI risk	SR
79	Age at diagnosis	4.4
79	WBC at diagnosis	2.1
79	Sex	M
79	Genetically-defined race	White
79	Asparaginase (IU/ml)	0.0016
79	Bortezomib (nM)	6.250482
79	CHZ868 (nM)	0
79	Cytarabine (µM)	0
79	Dasatinib (nM)	20000
79	Daunorubicin (µM)	0.06742984
79	Dexamethasone  (µM)	0
79	Ibrutinib (µM)	9.104746
79	Mercaptopurine (µM)	320.1946
79	Nelarabine (µM)	0
79	Panobinostat (nM)	8.008742
79	Prednisolone (µM)	0.0075
79	Ruxolitinib (nM)	20000
79	Thioguanine (µM)	0
79	Trametinib (nM)	164.9292
79	Venetoclax (nM)	0.4573634
79	Vincristine (µM)	0.4556239
79	Vorinostat (nM)	180.2886
79	asparagise_normalized	0
79	bortezomib_normalized	0.2674
79	dasatinib_normalized	1
79	daunorubicin_normalized	0.4399
79	ibrutinib_normalized	0.5086
79	mercaptopurine_normalized	0.3605
79	panobinostat_normalized	0.3032
79	prednisolone_normalized	0
79	ruxolitinib_normalized	1
79	trametinib_normalized	0.8435
79	venetoclax_normalized	0.5321
79	vincristine_normalized	0.3162
79	vorinostat_normalized	0.4512
80	immunophenotype	B
80	molecular subtype	DUX4
80	Protocol	T16
80	NCI risk	HR
80	Age at diagnosis	11.9
80	WBC at diagnosis	34.9
80	Sex	F
80	Genetically-defined race	White
80	Asparaginase (IU/ml)	0.846912
80	Bortezomib (nM)	4.318771
80	CHZ868 (nM)	0
80	Cytarabine (µM)	0
80	Dasatinib (nM)	20000
80	Daunorubicin (µM)	0.01407273
80	Dexamethasone  (µM)	0
80	Ibrutinib (µM)	19.00791
80	Mercaptopurine (µM)	436.2176
80	Nelarabine (µM)	0
80	Panobinostat (nM)	4.045709
80	Prednisolone (µM)	1006
80	Ruxolitinib (nM)	20000
80	Thioguanine (µM)	0
80	Trametinib (nM)	0.9309722
80	Venetoclax (nM)	0.1338381
80	Vincristine (µM)	0
80	Vorinostat (nM)	676.4797
80	asparagise_normalized	0.6932
80	bortezomib_normalized	0.2141
80	dasatinib_normalized	1
80	daunorubicin_normalized	0.2184
80	ibrutinib_normalized	0.7209
80	mercaptopurine_normalized	0.4497
80	panobinostat_normalized	0.2047
80	prednisolone_normalized	1
80	ruxolitinib_normalized	1
80	trametinib_normalized	0.3938
80	venetoclax_normalized	0.4253
80	vorinostat_normalized	0.5661
81	immunophenotype	B
81	molecular subtype	Hyperdiploid
81	Protocol	T16
81	NCI risk	SR
81	Age at diagnosis	1.8
81	WBC at diagnosis	6.7
81	Sex	M
81	Genetically-defined race	White
81	Asparaginase (IU/ml)	7.47782
81	Bortezomib (nM)	0
81	CHZ868 (nM)	0
81	Cytarabine (µM)	0
81	Dasatinib (nM)	0
81	Daunorubicin (µM)	0
81	Dexamethasone  (µM)	0
81	Ibrutinib (µM)	0
81	Mercaptopurine (µM)	714.6993
81	Nelarabine (µM)	0
81	Panobinostat (nM)	0
81	Prednisolone (µM)	1006
81	Ruxolitinib (nM)	0
81	Thioguanine (µM)	0
81	Trametinib (nM)	0
81	Venetoclax (nM)	0
81	Vincristine (µM)	48.23069
81	Vorinostat (nM)	0
81	asparagise_normalized	0.9639
81	mercaptopurine_normalized	0.5921
81	prednisolone_normalized	1
81	vincristine_normalized	0.9834
82	immunophenotype	T
82	molecular subtype	T-ALL
82	Protocol	T17
82	NCI risk	HR
82	Age at diagnosis	13.8
82	WBC at diagnosis	52.7
82	Sex	F
82	Genetically-defined race	White
82	Asparaginase (IU/ml)	0.0016
82	Bortezomib (nM)	40.71347
82	CHZ868 (nM)	0
82	Cytarabine (µM)	0
82	Dasatinib (nM)	0
82	Daunorubicin (µM)	0
82	Dexamethasone  (µM)	0
82	Ibrutinib (µM)	0
82	Mercaptopurine (µM)	160.005
82	Nelarabine (µM)	0
82	Panobinostat (nM)	10.46703
82	Prednisolone (µM)	0.08763338
82	Ruxolitinib (nM)	0
82	Thioguanine (µM)	0
82	Trametinib (nM)	0
82	Venetoclax (nM)	0
82	Vincristine (µM)	0.025
82	Vorinostat (nM)	0
82	asparagise_normalized	0
82	bortezomib_normalized	0.5379
82	mercaptopurine_normalized	0.1603
82	panobinostat_normalized	0.3419
82	prednisolone_normalized	0.1694
82	vincristine_normalized	0
83	immunophenotype	B
83	molecular subtype	Ph-like_CRLF2
83	Protocol	T17
83	NCI risk	HR
83	Age at diagnosis	3.1
83	WBC at diagnosis	50.6
83	Sex	M
83	Genetically-defined race	White
83	Asparaginase (IU/ml)	0.5631736
83	Bortezomib (nM)	11.81975
83	CHZ868 (nM)	0
83	Cytarabine (µM)	0
83	Dasatinib (nM)	20000
83	Daunorubicin (µM)	0.01306439
83	Dexamethasone  (µM)	0
83	Ibrutinib (µM)	15.05026
83	Mercaptopurine (µM)	640.0717
83	Nelarabine (µM)	0
83	Panobinostat (nM)	1.378825
83	Prednisolone (µM)	0.01505326
83	Ruxolitinib (nM)	20000
83	Thioguanine (µM)	0
83	Trametinib (nM)	2000
83	Venetoclax (nM)	5.73875
83	Vincristine (µM)	0.08581375
83	Vorinostat (nM)	681.429
83	asparagise_normalized	0.6425
83	bortezomib_normalized	0.3594
83	dasatinib_normalized	1
83	daunorubicin_normalized	0.2079
83	ibrutinib_normalized	0.6536
83	mercaptopurine_normalized	0.5603
83	panobinostat_normalized	0.0493
83	prednisolone_normalized	0.0003
83	ruxolitinib_normalized	1
83	trametinib_normalized	1
83	venetoclax_normalized	0.7518
83	vincristine_normalized	0.0773
83	vorinostat_normalized	0.5667
84	immunophenotype	B
84	molecular subtype	Hyperdiploid
84	Protocol	T17
84	NCI risk	HR
84	Age at diagnosis	11
84	WBC at diagnosis	1.3
84	Sex	F
84	Genetically-defined race	White
84	Asparaginase (IU/ml)	0.0016
84	Bortezomib (nM)	18.97133
84	CHZ868 (nM)	0
84	Cytarabine (µM)	0
84	Dasatinib (nM)	20000
84	Daunorubicin (µM)	0.08793366
84	Dexamethasone  (µM)	0
84	Ibrutinib (µM)	7.662913154
84	Mercaptopurine (µM)	642.3613
84	Nelarabine (µM)	0
84	Panobinostat (nM)	4.556215
84	Prednisolone (µM)	0.4178999
84	Ruxolitinib (nM)	20000
84	Thioguanine (µM)	0
84	Trametinib (nM)	206.7957
84	Venetoclax (nM)	0.02973321
84	Vincristine (µM)	2.575211
84	Vorinostat (nM)	1317.262
84	asparagise_normalized	0
84	bortezomib_normalized	0.4277
84	dasatinib_normalized	1
84	daunorubicin_normalized	0.4774
84	ibrutinib_normalized	0.4588
84	mercaptopurine_normalized	0.5613
84	panobinostat_normalized	0.2218
84	prednisolone_normalized	0.3193
84	ruxolitinib_normalized	1
84	trametinib_normalized	0.8631
84	venetoclax_normalized	0.2946
84	vincristine_normalized	0.5641
84	vorinostat_normalized	0.6239
85	immunophenotype	B
85	molecular subtype	ETV6-RUNX1
85	Protocol	T17
85	NCI risk	HR
85	Age at diagnosis	2.6
85	WBC at diagnosis	61.2
85	Sex	M
85	Genetically-defined race	Asian/Other
85	Asparaginase (IU/ml)	0
85	Bortezomib (nM)	0
85	CHZ868 (nM)	0
85	Cytarabine (µM)	0
85	Dasatinib (nM)	20000
85	Daunorubicin (µM)	0
85	Dexamethasone  (µM)	0
85	Ibrutinib (µM)	19.29518
85	Mercaptopurine (µM)	0
85	Nelarabine (µM)	0
85	Panobinostat (nM)	0
85	Prednisolone (µM)	0.02006599
85	Ruxolitinib (nM)	20000
85	Thioguanine (µM)	0
85	Trametinib (nM)	2000
85	Venetoclax (nM)	6.335928
85	Vincristine (µM)	0
85	Vorinostat (nM)	0
85	dasatinib_normalized	1
85	ibrutinib_normalized	0.7253
85	prednisolone_normalized	0.0279
85	ruxolitinib_normalized	1
85	trametinib_normalized	1
85	venetoclax_normalized	0.7604
86	immunophenotype	T
86	molecular subtype	T-ALL
86	Protocol	T17
86	NCI risk	HR
86	Age at diagnosis	12.8
86	WBC at diagnosis	213
86	Sex	M
86	Genetically-defined race	Asian/Other
86	Asparaginase (IU/ml)	0.0016
86	Bortezomib (nM)	7.279857
86	CHZ868 (nM)	0
86	Cytarabine (µM)	0
86	Dasatinib (nM)	1.660459753
86	Daunorubicin (µM)	0.03308822
86	Dexamethasone  (µM)	0
86	Ibrutinib (µM)	2.308367
86	Mercaptopurine (µM)	403.7272
86	Nelarabine (µM)	0
86	Panobinostat (nM)	0.49
86	Prednisolone (µM)	0.0075
86	Ruxolitinib (nM)	20000
86	Thioguanine (µM)	0
86	Trametinib (nM)	6.952930273
86	Venetoclax (nM)	13.90002
86	Vincristine (µM)	0
86	Vorinostat (nM)	538.6044
86	asparagise_normalized	0
86	bortezomib_normalized	0.2895
86	dasatinib_normalized	0.244
86	daunorubicin_normalized	0.3393
86	ibrutinib_normalized	0.1126
86	mercaptopurine_normalized	0.4273
86	panobinostat_normalized	0
86	prednisolone_normalized	0
86	ruxolitinib_normalized	1
86	trametinib_normalized	0.5684
86	venetoclax_normalized	0.8286
86	vorinostat_normalized	0.5463
87	immunophenotype	B
87	molecular subtype	Ph-like_CRLF2
87	Protocol	T17
87	NCI risk	HR
87	Age at diagnosis	17.3
87	WBC at diagnosis	49.7
87	Sex	M
87	Genetically-defined race	White
87	Asparaginase (IU/ml)	0.077885629
87	Bortezomib (nM)	4.768498
87	CHZ868 (nM)	0
87	Cytarabine (µM)	0
87	Dasatinib (nM)	20000
87	Daunorubicin (µM)	0.04801386
87	Dexamethasone  (µM)	0
87	Ibrutinib (µM)	9.635443
87	Mercaptopurine (µM)	238.162
87	Nelarabine (µM)	0
87	Panobinostat (nM)	0
87	Prednisolone (µM)	0
87	Ruxolitinib (nM)	1060.478
87	Thioguanine (µM)	0
87	Trametinib (nM)	29.76026949
87	Venetoclax (nM)	0.7408313
87	Vincristine (µM)	0.025
87	Vorinostat (nM)	161.0869
87	asparagise_normalized	0.3967
87	bortezomib_normalized	0.2284
87	dasatinib_normalized	1
87	daunorubicin_normalized	0.3919
87	ibrutinib_normalized	0.5249
87	mercaptopurine_normalized	0.2751
87	ruxolitinib_normalized	0.8051
87	trametinib_normalized	0.6947
87	venetoclax_normalized	0.5739
87	vincristine_normalized	0
87	vorinostat_normalized	0.4414
88	immunophenotype	B
88	molecular subtype	DUX4
88	Protocol	T17
88	NCI risk	SR
88	Age at diagnosis	9.3
88	WBC at diagnosis	27
88	Sex	M
88	Genetically-defined race	black
88	Asparaginase (IU/ml)	1.635428
88	Bortezomib (nM)	4.718049708
88	CHZ868 (nM)	0
88	Cytarabine (µM)	0
88	Dasatinib (nM)	10.47275
88	Daunorubicin (µM)	0.01514746
88	Dexamethasone  (µM)	0
88	Ibrutinib (µM)	10.27615
88	Mercaptopurine (µM)	171.2267
88	Nelarabine (µM)	0
88	Panobinostat (nM)	6.991644
88	Prednisolone (µM)	0.07569672
88	Ruxolitinib (nM)	20000
88	Thioguanine (µM)	0
88	Trametinib (nM)	570.7826122
88	Venetoclax (nM)	200
88	Vincristine (µM)	0.025
88	Vorinostat (nM)	786.652
88	asparagise_normalized	0.775
88	bortezomib_normalized	0.2268
88	dasatinib_normalized	0.404
88	daunorubicin_normalized	0.2288
88	ibrutinib_normalized	0.5435
88	mercaptopurine_normalized	0.1799
88	panobinostat_normalized	0.2836
88	prednisolone_normalized	0.1553
88	ruxolitinib_normalized	1
88	trametinib_normalized	0.9513
88	venetoclax_normalized	1
88	vincristine_normalized	0
88	vorinostat_normalized	0.5792
89	immunophenotype	B
89	molecular subtype	Hyperdiploid
89	Protocol	T17
89	NCI risk	SR
89	Age at diagnosis	7.7
89	WBC at diagnosis	3.9
89	Sex	M
89	Genetically-defined race	White
89	Asparaginase (IU/ml)	0.0016
89	Bortezomib (nM)	47.94546
89	CHZ868 (nM)	0
89	Cytarabine (µM)	0
89	Dasatinib (nM)	20000
89	Daunorubicin (µM)	0.9418003
89	Dexamethasone  (µM)	0
89	Ibrutinib (µM)	8.818958
89	Mercaptopurine (µM)	964.2900952
89	Nelarabine (µM)	0
89	Panobinostat (nM)	19.58674505
89	Prednisolone (µM)	0.0075
89	Ruxolitinib (nM)	20000
89	Thioguanine (µM)	0
89	Trametinib (nM)	2000
89	Venetoclax (nM)	0.1460795
89	Vincristine (µM)	0.4561908
89	Vorinostat (nM)	709.6619
89	asparagise_normalized	0
89	bortezomib_normalized	0.5615
89	dasatinib_normalized	1
89	daunorubicin_normalized	0.8125
89	ibrutinib_normalized	0.4994
89	mercaptopurine_normalized	0.6786
89	panobinostat_normalized	0.4323
89	prednisolone_normalized	0
89	ruxolitinib_normalized	1
89	trametinib_normalized	1
89	venetoclax_normalized	0.4329
89	vincristine_normalized	0.3164
89	vorinostat_normalized	0.5702
90	immunophenotype	T
90	molecular subtype	T-ALL
90	Protocol	T17
90	NCI risk	HR
90	Age at diagnosis	11.3
90	WBC at diagnosis	34.4
90	Sex	M
90	Genetically-defined race	White
90	Asparaginase (IU/ml)	0.0016
90	Bortezomib (nM)	21.3331
90	CHZ868 (nM)	0
90	Cytarabine (µM)	0
90	Dasatinib (nM)	0
90	Daunorubicin (µM)	0.211814417
90	Dexamethasone  (µM)	0
90	Ibrutinib (µM)	0
90	Mercaptopurine (µM)	354.5571
90	Nelarabine (µM)	0
90	Panobinostat (nM)	16.27905
90	Prednisolone (µM)	1006
90	Ruxolitinib (nM)	0
90	Thioguanine (µM)	0
90	Trametinib (nM)	0
90	Venetoclax (nM)	0
90	Vincristine (µM)	0.1123224
90	Vorinostat (nM)	1232.343
90	asparagise_normalized	0
90	bortezomib_normalized	0.4446
90	daunorubicin_normalized	0.6016
90	mercaptopurine_normalized	0.3899
90	panobinostat_normalized	0.4056
90	prednisolone_normalized	1
90	vincristine_normalized	0.1158
90	vorinostat_normalized	0.6181
91	immunophenotype	B
91	molecular subtype	TCF3-HLF
91	Protocol	T17
91	NCI risk	SR
91	Age at diagnosis	7.6
91	WBC at diagnosis	9.1
91	Sex	F
91	Genetically-defined race	black
91	Asparaginase (IU/ml)	20
91	Bortezomib (nM)	51.14552483
91	CHZ868 (nM)	0
91	Cytarabine (µM)	0
91	Dasatinib (nM)	20000
91	Daunorubicin (µM)	0.2044962
91	Dexamethasone  (µM)	0
91	Ibrutinib (µM)	20.42972
91	Mercaptopurine (µM)	5876
91	Nelarabine (µM)	0
91	Panobinostat (nM)	24.72236
91	Prednisolone (µM)	1006
91	Ruxolitinib (nM)	20000
91	Thioguanine (µM)	0
91	Trametinib (nM)	99.06607
91	Venetoclax (nM)	0.1106676
91	Vincristine (µM)	0.1001061
91	Vorinostat (nM)	255.61
91	asparagise_normalized	1
91	bortezomib_normalized	0.5709
91	dasatinib_normalized	1
91	daunorubicin_normalized	0.5966
91	ibrutinib_normalized	0.7417
91	mercaptopurine_normalized	1
91	panobinostat_normalized	0.4659
91	prednisolone_normalized	1
91	ruxolitinib_normalized	1
91	trametinib_normalized	0.7992
91	venetoclax_normalized	0.4088
91	vincristine_normalized	0.0993
91	vorinostat_normalized	0.4815
92	immunophenotype	B
92	molecular subtype	Hyperdiploid
92	Protocol	T17
92	NCI risk	SR
92	Age at diagnosis	2.4
92	WBC at diagnosis	4.2
92	Sex	F
92	Genetically-defined race	White
92	Asparaginase (IU/ml)	0.6799662
92	Bortezomib (nM)	3.176838
92	CHZ868 (nM)	47.90395
92	Cytarabine (µM)	0
92	Dasatinib (nM)	1354.566
92	Daunorubicin (µM)	0.03084945
92	Dexamethasone  (µM)	0
92	Ibrutinib (µM)	10.55403
92	Mercaptopurine (µM)	886.5932
92	Nelarabine (µM)	0
92	Panobinostat (nM)	2.794338
92	Prednisolone (µM)	0.08357127
92	Ruxolitinib (nM)	20000
92	Thioguanine (µM)	0
92	Trametinib (nM)	0.0663771
92	Venetoclax (nM)	0.03307618
92	Vincristine (µM)	0.025
92	Vorinostat (nM)	1001.105
92	asparagise_normalized	0.6659
92	bortezomib_normalized	0.1698
92	CHZ868_normalized	0.5361
92	dasatinib_normalized	0.8264
92	daunorubicin_normalized	0.3293
92	ibrutinib_normalized	0.5512
92	mercaptopurine_normalized	0.6543
92	panobinostat_normalized	0.1512
92	prednisolone_normalized	0.1648
92	ruxolitinib_normalized	1
92	trametinib_normalized	0.1644
92	venetoclax_normalized	0.3039
92	vincristine_normalized	0
92	vorinostat_normalized	0.6001
93	immunophenotype	B
93	molecular subtype	BCR-ABL1
93	Protocol	T17
93	NCI risk	HR
93	Age at diagnosis	3.3
93	WBC at diagnosis	58.7
93	Sex	M
93	Genetically-defined race	Hispanic
93	Asparaginase (IU/ml)	0.3286689
93	Bortezomib (nM)	5.829942
93	CHZ868 (nM)	64.72481
93	Cytarabine (µM)	0
93	Dasatinib (nM)	0.05
93	Daunorubicin (µM)	0.09762979
93	Dexamethasone  (µM)	0
93	Ibrutinib (µM)	2.160465
93	Mercaptopurine (µM)	319.671
93	Nelarabine (µM)	0
93	Panobinostat (nM)	4.247194633
93	Prednisolone (µM)	0.0075
93	Ruxolitinib (nM)	20000
93	Thioguanine (µM)	0
93	Trametinib (nM)	2000
93	Venetoclax (nM)	200
93	Vincristine (µM)	0.025
93	Vorinostat (nM)	577.6538
93	asparagise_normalized	0.5756
93	bortezomib_normalized	0.2574
93	CHZ868_normalized	0.5622
93	dasatinib_normalized	0
93	daunorubicin_normalized	0.4922
93	ibrutinib_normalized	0.0935
93	mercaptopurine_normalized	0.36
93	panobinostat_normalized	0.2117
93	prednisolone_normalized	0
93	ruxolitinib_normalized	1
93	trametinib_normalized	1
93	venetoclax_normalized	1
93	vincristine_normalized	0
93	vorinostat_normalized	0.5523
94	immunophenotype	B
94	molecular subtype	iAMP21
94	Protocol	T17
94	NCI risk	HR
94	Age at diagnosis	13
94	WBC at diagnosis	9.4
94	Sex	F
94	Genetically-defined race	White
94	Asparaginase (IU/ml)	0.0016
94	Bortezomib (nM)	32.47094
94	CHZ868 (nM)	20000
94	Cytarabine (µM)	0
94	Dasatinib (nM)	20000
94	Daunorubicin (µM)	0.267443
94	Dexamethasone  (µM)	0
94	Ibrutinib (µM)	25.11898
94	Mercaptopurine (µM)	486.9225
94	Nelarabine (µM)	0
94	Panobinostat (nM)	4.233956689
94	Prednisolone (µM)	0.0075
94	Ruxolitinib (nM)	20000
94	Thioguanine (µM)	0
94	Trametinib (nM)	2000
94	Venetoclax (nM)	0.943054
94	Vincristine (µM)	0.073130221
94	Vorinostat (nM)	736.2595
94	asparagise_normalized	0
94	bortezomib_normalized	0.5053
94	CHZ868_normalized	1
94	dasatinib_normalized	1
94	daunorubicin_normalized	0.6346
94	ibrutinib_normalized	0.8014
94	mercaptopurine_normalized	0.4814
94	panobinostat_normalized	0.2112
94	prednisolone_normalized	0
94	ruxolitinib_normalized	1
94	trametinib_normalized	1
94	venetoclax_normalized	0.5949
94	vincristine_normalized	0.0544
94	vorinostat_normalized	0.5734
95	immunophenotype	B
95	molecular subtype	B-other
95	Protocol	T17
95	NCI risk	SR
95	Age at diagnosis	3.6
95	WBC at diagnosis	17.3
95	Sex	F
95	Genetically-defined race	White
95	Asparaginase (IU/ml)	0.0016
95	Bortezomib (nM)	11.55873
95	CHZ868 (nM)	0
95	Cytarabine (µM)	0
95	Dasatinib (nM)	20000
95	Daunorubicin (µM)	0.01035577
95	Dexamethasone  (µM)	0
95	Ibrutinib (µM)	17.75007
95	Mercaptopurine (µM)	45.9
95	Nelarabine (µM)	0
95	Panobinostat (nM)	1.836295
95	Prednisolone (µM)	0.04757444
95	Ruxolitinib (nM)	0
95	Thioguanine (µM)	0
95	Trametinib (nM)	2000
95	Venetoclax (nM)	0.2053325
95	Vincristine (µM)	0.025
95	Vorinostat (nM)	546.275
95	asparagise_normalized	0
95	bortezomib_normalized	0.3562
95	dasatinib_normalized	1
95	daunorubicin_normalized	0.1751
95	ibrutinib_normalized	0.7012
95	mercaptopurine_normalized	0
95	panobinostat_normalized	0.0906
95	prednisolone_normalized	0.1108
95	trametinib_normalized	1
95	venetoclax_normalized	0.4625
95	vincristine_normalized	0
95	vorinostat_normalized	0.5475
96	immunophenotype	B
96	molecular subtype	ETV6-RUNX1
96	Protocol	T17
96	NCI risk	SR
96	Age at diagnosis	3.8
96	WBC at diagnosis	7.4
96	Sex	F
96	Genetically-defined race	White
96	Asparaginase (IU/ml)	0.0016
96	Bortezomib (nM)	5.57735
96	CHZ868 (nM)	20000
96	Cytarabine (µM)	0
96	Dasatinib (nM)	1040.905474
96	Daunorubicin (µM)	0.05145029
96	Dexamethasone  (µM)	0
96	Ibrutinib (µM)	5.03668
96	Mercaptopurine (µM)	477.1998
96	Nelarabine (µM)	0
96	Panobinostat (nM)	3.041268
96	Prednisolone (µM)	0.0075
96	Ruxolitinib (nM)	20000
96	Thioguanine (µM)	0
96	Trametinib (nM)	2000
96	Venetoclax (nM)	0.752873275
96	Vincristine (µM)	0.025
96	Vorinostat (nM)	359.0741
96	asparagise_normalized	0
96	bortezomib_normalized	0.251
96	CHZ868_normalized	1
96	dasatinib_normalized	0.8035
96	daunorubicin_normalized	0.4016
96	ibrutinib_normalized	0.3377
96	mercaptopurine_normalized	0.4756
96	panobinostat_normalized	0.1635
96	prednisolone_normalized	0
96	ruxolitinib_normalized	1
96	trametinib_normalized	1
96	venetoclax_normalized	0.5753
96	vincristine_normalized	0
96	vorinostat_normalized	0.511
97	immunophenotype	B
97	molecular subtype	BCR-ABL1
97	Protocol	T17
97	NCI risk	HR
97	Age at diagnosis	15.4
97	WBC at diagnosis	65.2
97	Sex	F
97	Genetically-defined race	Asian/Other
97	Asparaginase (IU/ml)	0
97	Bortezomib (nM)	0
97	CHZ868 (nM)	1.434314
97	Cytarabine (µM)	0
97	Dasatinib (nM)	0.05
97	Daunorubicin (µM)	0
97	Dexamethasone  (µM)	0
97	Ibrutinib (µM)	1.729572
97	Mercaptopurine (µM)	0
97	Nelarabine (µM)	0
97	Panobinostat (nM)	0
97	Prednisolone (µM)	0
97	Ruxolitinib (nM)	20000
97	Thioguanine (µM)	0
97	Trametinib (nM)	2000
97	Venetoclax (nM)	0.1522961
97	Vincristine (µM)	0
97	Vorinostat (nM)	0
97	CHZ868_normalized	0.2313
97	dasatinib_normalized	0
97	ibrutinib_normalized	0.0293
97	ruxolitinib_normalized	1
97	trametinib_normalized	1
97	venetoclax_normalized	0.4365
98	immunophenotype	B
98	molecular subtype	Hyperdiploid
98	Protocol	T17
98	NCI risk	SR
98	Age at diagnosis	9.3
98	WBC at diagnosis	19
98	Sex	F
98	Genetically-defined race	White
98	Asparaginase (IU/ml)	0
98	Bortezomib (nM)	0
98	CHZ868 (nM)	0
98	Cytarabine (µM)	0
98	Dasatinib (nM)	0
98	Daunorubicin (µM)	0
98	Dexamethasone  (µM)	0
98	Ibrutinib (µM)	0
98	Mercaptopurine (µM)	435.1661
98	Nelarabine (µM)	0
98	Panobinostat (nM)	0
98	Prednisolone (µM)	0.1433952
98	Ruxolitinib (nM)	0
98	Thioguanine (µM)	0
98	Trametinib (nM)	0
98	Venetoclax (nM)	0
98	Vincristine (µM)	0
98	Vorinostat (nM)	0
98	mercaptopurine_normalized	0.449
98	prednisolone_normalized	0.2166
99	immunophenotype	T
99	molecular subtype	T-ALL
99	Protocol	T17
99	NCI risk	SR
99	Age at diagnosis	5.8
99	WBC at diagnosis	29.5
99	Sex	M
99	Genetically-defined race	Hispanic
99	Asparaginase (IU/ml)	20
99	Bortezomib (nM)	10.907
99	CHZ868 (nM)	20000
99	Cytarabine (µM)	0
99	Dasatinib (nM)	0.05
99	Daunorubicin (µM)	0.1390298
99	Dexamethasone  (µM)	0
99	Ibrutinib (µM)	2.63996521
99	Mercaptopurine (µM)	5876
99	Nelarabine (µM)	0
99	Panobinostat (nM)	3.830917
99	Prednisolone (µM)	0
99	Ruxolitinib (nM)	20000
99	Thioguanine (µM)	0
99	Trametinib (nM)	2.153845
99	Venetoclax (nM)	3.465217
99	Vincristine (µM)	0.482797188
99	Vorinostat (nM)	398.9972
99	asparagise_normalized	1
99	bortezomib_normalized	0.3478
99	CHZ868_normalized	1
99	dasatinib_normalized	0
99	daunorubicin_normalized	0.5421
99	ibrutinib_normalized	0.1513
99	mercaptopurine_normalized	1
99	panobinostat_normalized	0.1968
99	ruxolitinib_normalized	1
99	trametinib_normalized	0.4666
99	venetoclax_normalized	0.7079
99	vincristine_normalized	0.3245
99	vorinostat_normalized	0.5202
100	immunophenotype	T
100	molecular subtype	T-ALL
100	Protocol	T17
100	NCI risk	HR
100	Age at diagnosis	2.6
100	WBC at diagnosis	730
100	Sex	F
100	Genetically-defined race	White
100	Asparaginase (IU/ml)	20
100	Bortezomib (nM)	5.695935
100	CHZ868 (nM)	0
100	Cytarabine (µM)	0
100	Dasatinib (nM)	0
100	Daunorubicin (µM)	0.1003885
100	Dexamethasone  (µM)	0
100	Ibrutinib (µM)	0
100	Mercaptopurine (µM)	990.8595
100	Nelarabine (µM)	0
100	Panobinostat (nM)	4.015046
100	Prednisolone (µM)	6.407468
100	Ruxolitinib (nM)	0
100	Thioguanine (µM)	0
100	Trametinib (nM)	0
100	Venetoclax (nM)	0
100	Vincristine (µM)	16.61437
100	Vorinostat (nM)	0
100	asparagise_normalized	1
100	bortezomib_normalized	0.254
100	daunorubicin_normalized	0.4961
100	mercaptopurine_normalized	0.6864
100	panobinostat_normalized	0.2036
100	prednisolone_normalized	0.5813
100	vincristine_normalized	0.8309
101	immunophenotype	B
101	molecular subtype	ETV6-RUNX1
101	Protocol	T17
101	NCI risk	SR
101	Age at diagnosis	3.7
101	WBC at diagnosis	17.9
101	Sex	M
101	Genetically-defined race	White
101	Asparaginase (IU/ml)	0.0016
101	Bortezomib (nM)	11.21855
101	CHZ868 (nM)	4976.102
101	Cytarabine (µM)	0
101	Dasatinib (nM)	20000
101	Daunorubicin (µM)	0.04747619
101	Dexamethasone  (µM)	0
101	Ibrutinib (µM)	17.81671
101	Mercaptopurine (µM)	306.3514
101	Nelarabine (µM)	0
101	Panobinostat (nM)	8.645481
101	Prednisolone (µM)	0.05276369
101	Ruxolitinib (nM)	20000
101	Thioguanine (µM)	0
101	Trametinib (nM)	2000
101	Venetoclax (nM)	2.709194
101	Vincristine (µM)	0.252860004
101	Vorinostat (nM)	1557.639
101	asparagise_normalized	0
101	bortezomib_normalized	0.3519
101	CHZ868_normalized	0.9394
101	dasatinib_normalized	1
101	daunorubicin_normalized	0.3903
101	ibrutinib_normalized	0.7023
101	mercaptopurine_normalized	0.3477
101	panobinostat_normalized	0.3143
101	prednisolone_normalized	0.1207
101	ruxolitinib_normalized	1
101	trametinib_normalized	1
101	venetoclax_normalized	0.6866
101	vincristine_normalized	0.2319
101	vorinostat_normalized	0.6385
102	immunophenotype	B
102	molecular subtype	KMT2A
102	Protocol	T17
102	NCI risk	SR
102	Age at diagnosis	2.1
102	WBC at diagnosis	6.3
102	Sex	M
102	Genetically-defined race	Hispanic
102	Asparaginase (IU/ml)	20
102	Bortezomib (nM)	19.28768
102	CHZ868 (nM)	690.8158777
102	Cytarabine (µM)	0
102	Dasatinib (nM)	20000
102	Daunorubicin (µM)	0.2647476
102	Dexamethasone  (µM)	0
102	Ibrutinib (µM)	15.66475
102	Mercaptopurine (µM)	814.7685
102	Nelarabine (µM)	0
102	Panobinostat (nM)	55.25439
102	Prednisolone (µM)	219.124
102	Ruxolitinib (nM)	9324.914
102	Thioguanine (µM)	0
102	Trametinib (nM)	2000
102	Venetoclax (nM)	14.49985
102	Vincristine (µM)	0.54161
102	Vorinostat (nM)	2076.784
102	asparagise_normalized	1
102	bortezomib_normalized	0.4301
102	CHZ868_normalized	0.7679
102	dasatinib_normalized	1
102	daunorubicin_normalized	0.6331
102	ibrutinib_normalized	0.6651
102	mercaptopurine_normalized	0.6299
102	panobinostat_normalized	0.582
102	prednisolone_normalized	0.9203
102	ruxolitinib_normalized	0.9939
102	trametinib_normalized	1
102	venetoclax_normalized	0.8323
102	vincristine_normalized	0.341
102	vorinostat_normalized	0.6635
103	immunophenotype	T
103	molecular subtype	T-ALL
103	Protocol	T17
103	NCI risk	HR
103	Age at diagnosis	2.1
103	WBC at diagnosis	316.5
103	Sex	M
103	Genetically-defined race	White
103	Asparaginase (IU/ml)	0.7287947
103	Bortezomib (nM)	8.258897
103	CHZ868 (nM)	20000
103	Cytarabine (µM)	0
103	Dasatinib (nM)	2413.819362
103	Daunorubicin (µM)	0.06550654
103	Dexamethasone  (µM)	0
103	Ibrutinib (µM)	11.87683
103	Mercaptopurine (µM)	843.8305
103	Nelarabine (µM)	0
103	Panobinostat (nM)	3.469149
103	Prednisolone (µM)	0.04582775
103	Ruxolitinib (nM)	20000
103	Thioguanine (µM)	0
103	Trametinib (nM)	14.00386
103	Venetoclax (nM)	200
103	Vincristine (µM)	8.683134
103	Vorinostat (nM)	228.4611
103	asparagise_normalized	0.6746
103	bortezomib_normalized	0.3077
103	CHZ868_normalized	1
103	dasatinib_normalized	0.8765
103	daunorubicin_normalized	0.4358
103	ibrutinib_normalized	0.5852
103	mercaptopurine_normalized	0.6401
103	panobinostat_normalized	0.1825
103	prednisolone_normalized	0.1072
103	ruxolitinib_normalized	1
103	trametinib_normalized	0.6292
103	venetoclax_normalized	1
103	vincristine_normalized	0.738
103	vorinostat_normalized	0.4718
104	immunophenotype	B
104	molecular subtype	ETV6-RUNX1
104	Protocol	T17
104	NCI risk	HR
104	Age at diagnosis	8
104	WBC at diagnosis	167.9
104	Sex	F
104	Genetically-defined race	White
104	Asparaginase (IU/ml)	0.0016
104	Bortezomib (nM)	4.325796
104	CHZ868 (nM)	20000
104	Cytarabine (µM)	0
104	Dasatinib (nM)	20000
104	Daunorubicin (µM)	0.04912484
104	Dexamethasone  (µM)	0
104	Ibrutinib (µM)	22.62053
104	Mercaptopurine (µM)	1385.854
104	Nelarabine (µM)	0
104	Panobinostat (nM)	6.953473
104	Prednisolone (µM)	0.09626098
104	Ruxolitinib (nM)	20000
104	Thioguanine (µM)	0
104	Trametinib (nM)	801.4321
104	Venetoclax (nM)	200
104	Vincristine (µM)	0.2385593
104	Vorinostat (nM)	491.9204
104	asparagise_normalized	0
104	bortezomib_normalized	0.2143
104	CHZ868_normalized	1
104	dasatinib_normalized	1
104	daunorubicin_normalized	0.3951
104	ibrutinib_normalized	0.7711
104	mercaptopurine_normalized	0.7832
104	panobinostat_normalized	0.2828
104	prednisolone_normalized	0.1784
104	ruxolitinib_normalized	1
104	trametinib_normalized	0.9808
104	venetoclax_normalized	1
104	vincristine_normalized	0.2236
104	vorinostat_normalized	0.5384
105	immunophenotype	B
105	molecular subtype	KMT2A
105	Protocol	T17
105	NCI risk	SR
105	Age at diagnosis	1.8
105	WBC at diagnosis	25.5
105	Sex	F
105	Genetically-defined race	White
105	Asparaginase (IU/ml)	1.587379953
105	Bortezomib (nM)	212.1824
105	CHZ868 (nM)	0.05
105	Cytarabine (µM)	0
105	Dasatinib (nM)	39.18871
105	Daunorubicin (µM)	0.2518869
105	Dexamethasone  (µM)	0
105	Ibrutinib (µM)	4.986273
105	Mercaptopurine (µM)	166.4829
105	Nelarabine (µM)	0
105	Panobinostat (nM)	3.637005
105	Prednisolone (µM)	0.0075
105	Ruxolitinib (nM)	0
105	Thioguanine (µM)	0
105	Trametinib (nM)	719.196
105	Venetoclax (nM)	2.97601
105	Vincristine (µM)	0.656285812
105	Vorinostat (nM)	210.423
105	asparagise_normalized	0.7713
105	bortezomib_normalized	0.7762
105	CHZ868_normalized	0
105	dasatinib_normalized	0.5186
105	daunorubicin_normalized	0.6261
105	ibrutinib_normalized	0.3348
105	mercaptopurine_normalized	0.1718
105	panobinostat_normalized	0.1893
105	prednisolone_normalized	0
105	trametinib_normalized	0.9714
105	venetoclax_normalized	0.6947
105	vincristine_normalized	0.3684
105	vorinostat_normalized	0.4646
106	immunophenotype	B
106	molecular subtype	ETV6-RUNX1
106	Protocol	T17
106	NCI risk	SR
106	Age at diagnosis	2.6
106	WBC at diagnosis	6.2
106	Sex	F
106	Genetically-defined race	White
106	Asparaginase (IU/ml)	1.773144
106	Bortezomib (nM)	9.461172
106	CHZ868 (nM)	1784.996
106	Cytarabine (µM)	0
106	Dasatinib (nM)	1443.708
106	Daunorubicin (µM)	0.048636525
106	Dexamethasone  (µM)	0
106	Ibrutinib (µM)	7.109217
106	Mercaptopurine (µM)	1388.131
106	Nelarabine (µM)	0
106	Panobinostat (nM)	7.56864537
106	Prednisolone (µM)	0.01716585
106	Ruxolitinib (nM)	6800.094
106	Thioguanine (µM)	0
106	Trametinib (nM)	17.85725
106	Venetoclax (nM)	0.0005
106	Vincristine (µM)	0.1454542
106	Vorinostat (nM)	355.6189
106	asparagise_normalized	0.785
106	bortezomib_normalized	0.3273
106	CHZ868_normalized	0.8503
106	dasatinib_normalized	0.8319
106	daunorubicin_normalized	0.3937
106	ibrutinib_normalized	0.4372
106	mercaptopurine_normalized	0.7837
106	panobinostat_normalized	0.2951
106	prednisolone_normalized	0.0129
106	ruxolitinib_normalized	0.9665
106	trametinib_normalized	0.6504
106	venetoclax_normalized	0
106	vincristine_normalized	0.1528
106	vorinostat_normalized	0.5102
107	immunophenotype	B
107	molecular subtype	ETV6-RUNX1
107	Protocol	T17
107	NCI risk	SR
107	Age at diagnosis	8.6
107	WBC at diagnosis	3.1
107	Sex	F
107	Genetically-defined race	White
107	Asparaginase (IU/ml)	0.0016
107	Bortezomib (nM)	4.056634
107	CHZ868 (nM)	20000
107	Cytarabine (µM)	0
107	Dasatinib (nM)	2579.613
107	Daunorubicin (µM)	0.02544719
107	Dexamethasone  (µM)	0
107	Ibrutinib (µM)	1.638249
107	Mercaptopurine (µM)	5876
107	Nelarabine (µM)	0
107	Panobinostat (nM)	3.226156
107	Prednisolone (µM)	0.04303951
107	Ruxolitinib (nM)	5932.8
107	Thioguanine (µM)	0
107	Trametinib (nM)	0.0151096
107	Venetoclax (nM)	0.0005
107	Vincristine (µM)	0.025
107	Vorinostat (nM)	101.0463
107	asparagise_normalized	0
107	bortezomib_normalized	0.205
107	CHZ868_normalized	1
107	dasatinib_normalized	0.8823
107	daunorubicin_normalized	0.3021
107	ibrutinib_normalized	0.0137
107	mercaptopurine_normalized	1
107	panobinostat_normalized	0.172
107	prednisolone_normalized	0.1012
107	ruxolitinib_normalized	0.9547
107	trametinib_normalized	0.0359
107	venetoclax_normalized	0
107	vincristine_normalized	0
107	vorinostat_normalized	0.4009
108	immunophenotype	B
108	molecular subtype	Near haploid
108	Protocol	T17
108	NCI risk	SR
108	Age at diagnosis	4.4
108	WBC at diagnosis	4.5
108	Sex	F
108	Genetically-defined race	Asian/Other
108	Asparaginase (IU/ml)	0.0016
108	Bortezomib (nM)	71.82235
108	CHZ868 (nM)	2.892312
108	Cytarabine (µM)	0
108	Dasatinib (nM)	20000
108	Daunorubicin (µM)	0.03719062
108	Dexamethasone  (µM)	0
108	Ibrutinib (µM)	7.760979
108	Mercaptopurine (µM)	505.2559
108	Nelarabine (µM)	0
108	Panobinostat (nM)	3.930908
108	Prednisolone (µM)	0.2888258
108	Ruxolitinib (nM)	5767.538
108	Thioguanine (µM)	0
108	Trametinib (nM)	214.163
108	Venetoclax (nM)	0.0005
108	Vincristine (µM)	0.025
108	Vorinostat (nM)	245.139
108	asparagise_normalized	0
108	bortezomib_normalized	0.6199
108	CHZ868_normalized	0.2922
108	dasatinib_normalized	1
108	daunorubicin_normalized	0.3558
108	ibrutinib_normalized	0.4625
108	mercaptopurine_normalized	0.4921
108	panobinostat_normalized	0.2005
108	prednisolone_normalized	0.2838
108	ruxolitinib_normalized	0.9522
108	trametinib_normalized	0.8661
108	venetoclax_normalized	0
108	vincristine_normalized	0
108	vorinostat_normalized	0.4779
109	immunophenotype	B
109	molecular subtype	Hyperdiploid
109	Protocol	T17
109	NCI risk	SR
109	Age at diagnosis	2.5
109	WBC at diagnosis	15.2
109	Sex	M
109	Genetically-defined race	Asian/Other
109	Asparaginase (IU/ml)	0.0016
109	Bortezomib (nM)	745.0583907
109	CHZ868 (nM)	0.9796652
109	Cytarabine (µM)	0
109	Dasatinib (nM)	4808.929
109	Daunorubicin (µM)	0.3843149
109	Dexamethasone  (µM)	0
109	Ibrutinib (µM)	6.453909
109	Mercaptopurine (µM)	142.2356
109	Nelarabine (µM)	0
109	Panobinostat (nM)	2.785845
109	Prednisolone (µM)	0.0075
109	Ruxolitinib (nM)	8866.385
109	Thioguanine (µM)	0
109	Trametinib (nM)	0.005
109	Venetoclax (nM)	0.0005
109	Vincristine (µM)	0.025
109	Vorinostat (nM)	389.1626
109	asparagise_normalized	0
109	bortezomib_normalized	0.9575
109	CHZ868_normalized	0.1982
109	dasatinib_normalized	0.9364
109	daunorubicin_normalized	0.6858
109	ibrutinib_normalized	0.4093
109	mercaptopurine_normalized	0.1263
109	panobinostat_normalized	0.1508
109	prednisolone_normalized	0
109	ruxolitinib_normalized	0.9895
109	trametinib_normalized	0
109	venetoclax_normalized	0
109	vincristine_normalized	0
109	vorinostat_normalized	0.518
110	immunophenotype	B
110	molecular subtype	ETV6-RUNX1
110	Protocol	T17
110	NCI risk	SR
110	Age at diagnosis	3.9
110	WBC at diagnosis	2.2
110	Sex	F
110	Genetically-defined race	White
110	Asparaginase (IU/ml)	0.0016
110	Bortezomib (nM)	143.4237
110	CHZ868 (nM)	726.3547
110	Cytarabine (µM)	0
110	Dasatinib (nM)	20000
110	Daunorubicin (µM)	0.8870568
110	Dexamethasone  (µM)	0
110	Ibrutinib (µM)	9.074168
110	Mercaptopurine (µM)	856.3924
110	Nelarabine (µM)	0
110	Panobinostat (nM)	16.34501
110	Prednisolone (µM)	0.09462907
110	Ruxolitinib (nM)	20000
110	Thioguanine (µM)	0
110	Trametinib (nM)	2000
110	Venetoclax (nM)	0.2125407
110	Vincristine (µM)	1.011618
110	Vorinostat (nM)	1366.124
110	asparagise_normalized	0
110	bortezomib_normalized	0.7197
110	CHZ868_normalized	0.7722
110	dasatinib_normalized	1
110	daunorubicin_normalized	0.804
110	ibrutinib_normalized	0.5076
110	mercaptopurine_normalized	0.6443
110	panobinostat_normalized	0.4062
110	prednisolone_normalized	0.1768
110	ruxolitinib_normalized	1
110	trametinib_normalized	1
110	venetoclax_normalized	0.4655
110	vincristine_normalized	0.4304
110	vorinostat_normalized	0.6271
111	immunophenotype	B
111	molecular subtype	Hyperdiploid
111	Protocol	T17
111	NCI risk	SR
111	Age at diagnosis	3.5
111	WBC at diagnosis	10.1
111	Sex	M
111	Genetically-defined race	White
111	Asparaginase (IU/ml)	0.0016
111	Bortezomib (nM)	18.57758
111	CHZ868 (nM)	0.4452094
111	Cytarabine (µM)	0
111	Dasatinib (nM)	20000
111	Daunorubicin (µM)	0
111	Dexamethasone  (µM)	0
111	Ibrutinib (µM)	9.687642
111	Mercaptopurine (µM)	296.9724764
111	Nelarabine (µM)	0
111	Panobinostat (nM)	0
111	Prednisolone (µM)	0.03880347
111	Ruxolitinib (nM)	5029.947
111	Thioguanine (µM)	0
111	Trametinib (nM)	141.1259
111	Venetoclax (nM)	0.0005
111	Vincristine (µM)	0.025
111	Vorinostat (nM)	0
111	asparagise_normalized	0
111	bortezomib_normalized	0.4247
111	CHZ868_normalized	0.1297
111	dasatinib_normalized	1
111	ibrutinib_normalized	0.5265
111	mercaptopurine_normalized	0.3387
111	prednisolone_normalized	0.0912
111	ruxolitinib_normalized	0.9403
111	trametinib_normalized	0.8299
111	venetoclax_normalized	0
111	vincristine_normalized	0
112	immunophenotype	B
112	molecular subtype	Hyperdiploid
112	Protocol	T17
112	NCI risk	SR
112	Age at diagnosis	3.2
112	WBC at diagnosis	6.4
112	Sex	F
112	Genetically-defined race	Asian/Other
112	Asparaginase (IU/ml)	0.0016
112	Bortezomib (nM)	11.06889
112	CHZ868 (nM)	1.176124
112	Cytarabine (µM)	0
112	Dasatinib (nM)	0
112	Daunorubicin (µM)	0.246576066
112	Dexamethasone  (µM)	0
112	Ibrutinib (µM)	0.78125
112	Mercaptopurine (µM)	289.0191
112	Nelarabine (µM)	0
112	Panobinostat (nM)	3.797795
112	Prednisolone (µM)	0.02414146
112	Ruxolitinib (nM)	0
112	Thioguanine (µM)	0
112	Trametinib (nM)	0.005
112	Venetoclax (nM)	0.0005
112	Vincristine (µM)	11.57923
112	Vorinostat (nM)	1399.65428
112	asparagise_normalized	0
112	bortezomib_normalized	0.3499
112	CHZ868_normalized	0.2141
112	daunorubicin_normalized	0.6231
112	ibrutinib_normalized	0
112	mercaptopurine_normalized	0.3309
112	panobinostat_normalized	0.1955
112	prednisolone_normalized	0.0457
112	trametinib_normalized	0
112	venetoclax_normalized	0
112	vincristine_normalized	0.7792
112	vorinostat_normalized	0.6292
113	immunophenotype	B
113	molecular subtype	B-other
113	Protocol	T17
113	NCI risk	HR
113	Age at diagnosis	15.7
113	WBC at diagnosis	8.7
113	Sex	M
113	Genetically-defined race	White
113	Asparaginase (IU/ml)	4.375456
113	Bortezomib (nM)	12.59918509
113	CHZ868 (nM)	0.2422276
113	Cytarabine (µM)	0
113	Dasatinib (nM)	2.173597
113	Daunorubicin (µM)	1.051055
113	Dexamethasone  (µM)	0
113	Ibrutinib (µM)	3.248638
113	Mercaptopurine (µM)	1258.177
113	Nelarabine (µM)	0
113	Panobinostat (nM)	0
113	Prednisolone (µM)	1006
113	Ruxolitinib (nM)	139.2822
113	Thioguanine (µM)	0
113	Trametinib (nM)	0.1127189
113	Venetoclax (nM)	0.07338022
113	Vincristine (µM)	0.2577485
113	Vorinostat (nM)	658.2384
113	asparagise_normalized	0.8973
113	bortezomib_normalized	0.3686
113	CHZ868_normalized	0.0768
113	dasatinib_normalized	0.2674
113	daunorubicin_normalized	0.828
113	ibrutinib_normalized	0.2112
113	mercaptopurine_normalized	0.7553
113	prednisolone_normalized	1
113	ruxolitinib_normalized	0.6288
113	trametinib_normalized	0.2104
113	venetoclax_normalized	0.3731
113	vincristine_normalized	0.2347
113	vorinostat_normalized	0.5637
114	immunophenotype	B
114	molecular subtype	ETV6-RUNX1-like
114	Protocol	T17
114	NCI risk	SR
114	Age at diagnosis	1.6
114	WBC at diagnosis	27.1
114	Sex	F
114	Genetically-defined race	White
114	Asparaginase (IU/ml)	0.2877763
114	Bortezomib (nM)	4.2689
114	CHZ868 (nM)	5.430251
114	Cytarabine (µM)	0
114	Dasatinib (nM)	135.2333
114	Daunorubicin (µM)	0.147288
114	Dexamethasone  (µM)	0
114	Ibrutinib (µM)	3.790426
114	Mercaptopurine (µM)	245.2819
114	Nelarabine (µM)	0
114	Panobinostat (nM)	0
114	Prednisolone (µM)	1006
114	Ruxolitinib (nM)	55.77165
114	Thioguanine (µM)	0
114	Trametinib (nM)	0.9560185
114	Venetoclax (nM)	0.0005
114	Vincristine (µM)	108.34
114	Vorinostat (nM)	0
114	asparagise_normalized	0.5591
114	bortezomib_normalized	0.2124
114	CHZ868_normalized	0.347
114	dasatinib_normalized	0.6262
114	daunorubicin_normalized	0.5503
114	ibrutinib_normalized	0.2557
114	mercaptopurine_normalized	0.2836
114	prednisolone_normalized	1
114	ruxolitinib_normalized	0.5493
114	trametinib_normalized	0.3961
114	venetoclax_normalized	0
114	vincristine_normalized	1
115	immunophenotype	B
115	molecular subtype	Ph-like_CRLF2
115	Protocol	T17
115	NCI risk	SR
115	Age at diagnosis	3.9
115	WBC at diagnosis	23
115	Sex	M
115	Genetically-defined race	White
115	Asparaginase (IU/ml)	20
115	Bortezomib (nM)	4.998226
115	CHZ868 (nM)	0
115	Cytarabine (µM)	0
115	Dasatinib (nM)	12.64887
115	Daunorubicin (µM)	3.479547
115	Dexamethasone  (µM)	0
115	Ibrutinib (µM)	2.123245
115	Mercaptopurine (µM)	1452.151557
115	Nelarabine (µM)	0
115	Panobinostat (nM)	7.673034
115	Prednisolone (µM)	1006
115	Ruxolitinib (nM)	3611.042
115	Thioguanine (µM)	0
115	Trametinib (nM)	1.274335
115	Venetoclax (nM)	0.0005
115	Vincristine (µM)	0
115	Vorinostat (nM)	5337.934
115	asparagise_normalized	1
115	bortezomib_normalized	0.2352
115	dasatinib_normalized	0.4204
115	daunorubicin_normalized	0.9972
115	ibrutinib_normalized	0.0885
115	mercaptopurine_normalized	0.7967
115	panobinostat_normalized	0.297
115	prednisolone_normalized	1
115	ruxolitinib_normalized	0.9115
115	trametinib_normalized	0.4211
115	venetoclax_normalized	0
115	vorinostat_normalized	0.7455
116	immunophenotype	T
116	molecular subtype	T-ALL
116	Protocol	T17
116	NCI risk	SR
116	Age at diagnosis	6.7
116	WBC at diagnosis	6.9
116	Sex	M
116	Genetically-defined race	White
116	Asparaginase (IU/ml)	0.0016
116	Bortezomib (nM)	0
116	CHZ868 (nM)	0
116	Cytarabine (µM)	0
116	Dasatinib (nM)	0
116	Daunorubicin (µM)	0
116	Dexamethasone  (µM)	0
116	Ibrutinib (µM)	0
116	Mercaptopurine (µM)	1063.92
116	Nelarabine (µM)	0
116	Panobinostat (nM)	0
116	Prednisolone (µM)	1006
116	Ruxolitinib (nM)	0
116	Thioguanine (µM)	0
116	Trametinib (nM)	0
116	Venetoclax (nM)	0
116	Vincristine (µM)	0.025
116	Vorinostat (nM)	0
116	asparagise_normalized	0
116	mercaptopurine_normalized	0.7069
116	prednisolone_normalized	1
116	vincristine_normalized	0
117	immunophenotype	B
117	molecular subtype	ETV6-RUNX1
117	Protocol	T17
117	NCI risk	HR
117	Age at diagnosis	3.9
117	WBC at diagnosis	59.4
117	Sex	F
117	Genetically-defined race	White
117	Asparaginase (IU/ml)	0.816255764
117	Bortezomib (nM)	16.2456
117	CHZ868 (nM)	18.29567
117	Cytarabine (µM)	0
117	Dasatinib (nM)	20000
117	Daunorubicin (µM)	0.1444021
117	Dexamethasone  (µM)	0
117	Ibrutinib (µM)	13.69153
117	Mercaptopurine (µM)	715.1449
117	Nelarabine (µM)	0
117	Panobinostat (nM)	17.51091
117	Prednisolone (µM)	0.05266816
117	Ruxolitinib (nM)	20000
117	Thioguanine (µM)	0
117	Trametinib (nM)	2000
117	Venetoclax (nM)	0.4034614
117	Vincristine (µM)	0.2350191
117	Vorinostat (nM)	2948.219
117	asparagise_normalized	0.6886
117	bortezomib_normalized	0.4053
117	CHZ868_normalized	0.4525
117	dasatinib_normalized	1
117	daunorubicin_normalized	0.5475
117	ibrutinib_normalized	0.6263
117	mercaptopurine_normalized	0.5923
117	panobinostat_normalized	0.4161
117	prednisolone_normalized	0.1205
117	ruxolitinib_normalized	1
117	trametinib_normalized	1
117	venetoclax_normalized	0.5212
117	vincristine_normalized	0.2215
117	vorinostat_normalized	0.6939
118	immunophenotype	B
118	molecular subtype	B-other
118	Protocol	T17
118	NCI risk	SR
118	Age at diagnosis	4.9
118	WBC at diagnosis	32.3
118	Sex	F
118	Genetically-defined race	black
118	Asparaginase (IU/ml)	0.4167612
118	Bortezomib (nM)	13.22784166
118	CHZ868 (nM)	57.43394
118	Cytarabine (µM)	0
118	Dasatinib (nM)	3184.181
118	Daunorubicin (µM)	0.009410786
118	Dexamethasone  (µM)	0
118	Ibrutinib (µM)	17.91084
118	Mercaptopurine (µM)	437.601
118	Nelarabine (µM)	0
118	Panobinostat (nM)	5.22379
118	Prednisolone (µM)	0.320280197
118	Ruxolitinib (nM)	20000
118	Thioguanine (µM)	0
118	Trametinib (nM)	2000
118	Venetoclax (nM)	45.12837
118	Vincristine (µM)	0.025
118	Vorinostat (nM)	943.9104
118	asparagise_normalized	0.6051
118	bortezomib_normalized	0.3757
118	CHZ868_normalized	0.5518
118	dasatinib_normalized	0.9006
118	daunorubicin_normalized	0.1616
118	ibrutinib_normalized	0.7038
118	mercaptopurine_normalized	0.4506
118	panobinostat_normalized	0.2415
118	prednisolone_normalized	0.2938
118	ruxolitinib_normalized	1
118	trametinib_normalized	1
118	venetoclax_normalized	0.9309
118	vincristine_normalized	0
118	vorinostat_normalized	0.595
119	immunophenotype	B
119	molecular subtype	ETV6-RUNX1
119	Protocol	T17
119	NCI risk	SR
119	Age at diagnosis	1.9
119	WBC at diagnosis	10.6
119	Sex	M
119	Genetically-defined race	White
119	Asparaginase (IU/ml)	0.0016
119	Bortezomib (nM)	4.123152
119	CHZ868 (nM)	20000
119	Cytarabine (µM)	0
119	Dasatinib (nM)	20000
119	Daunorubicin (µM)	0.0359349
119	Dexamethasone  (µM)	0
119	Ibrutinib (µM)	5.775917
119	Mercaptopurine (µM)	469.3217
119	Nelarabine (µM)	44.62156
119	Panobinostat (nM)	0
119	Prednisolone (µM)	0.0075
119	Ruxolitinib (nM)	20000
119	Thioguanine (µM)	0
119	Trametinib (nM)	289.6617
119	Venetoclax (nM)	0.0005
119	Vincristine (µM)	9.194957
119	Vorinostat (nM)	535.4169
119	asparagise_normalized	0
119	bortezomib_normalized	0.2074
119	CHZ868_normalized	1
119	dasatinib_normalized	1
119	daunorubicin_normalized	0.3509
119	ibrutinib_normalized	0.3772
119	mercaptopurine_normalized	0.4708
119	nelarabine_normalized	0.9158
119	prednisolone_normalized	0
119	ruxolitinib_normalized	1
119	trametinib_normalized	0.8924
119	venetoclax_normalized	0
119	vincristine_normalized	0.7462
119	vorinostat_normalized	0.5457
120	immunophenotype	B
120	molecular subtype	ETV6-RUNX1
120	Protocol	T17
120	NCI risk	SR
120	Age at diagnosis	3.7
120	WBC at diagnosis	25.8
120	Sex	M
120	Genetically-defined race	Asian/Other
120	Asparaginase (IU/ml)	0.0016
120	Bortezomib (nM)	7.468868
120	CHZ868 (nM)	1765.05
120	Cytarabine (µM)	0
120	Dasatinib (nM)	20000
120	Daunorubicin (µM)	0.01272803
120	Dexamethasone  (µM)	0
120	Ibrutinib (µM)	16.63542
120	Mercaptopurine (µM)	125.9405
120	Nelarabine (µM)	15.7209
120	Panobinostat (nM)	0
120	Prednisolone (µM)	0.04797124
120	Ruxolitinib (nM)	20000
120	Thioguanine (µM)	0
120	Trametinib (nM)	2000
120	Venetoclax (nM)	4.086223
120	Vincristine (µM)	0.025
120	Vorinostat (nM)	956.8336
120	asparagise_normalized	0
120	bortezomib_normalized	0.2932
120	CHZ868_normalized	0.8494
120	dasatinib_normalized	1
120	daunorubicin_normalized	0.2042
120	ibrutinib_normalized	0.6825
120	mercaptopurine_normalized	0.0912
120	nelarabine_normalized	0.7653
120	prednisolone_normalized	0.1116
120	ruxolitinib_normalized	1
120	trametinib_normalized	1
120	venetoclax_normalized	0.7223
120	vincristine_normalized	0
120	vorinostat_normalized	0.5962
121	immunophenotype	B
121	molecular subtype	ETV6-RUNX1
121	Protocol	T17
121	NCI risk	SR
121	Age at diagnosis	7.2
121	WBC at diagnosis	3.2
121	Sex	F
121	Genetically-defined race	White
121	Asparaginase (IU/ml)	0.0016
121	Bortezomib (nM)	1.496993
121	CHZ868 (nM)	641.2938
121	Cytarabine (µM)	0
121	Dasatinib (nM)	20000
121	Daunorubicin (µM)	0.01854174
121	Dexamethasone  (µM)	0
121	Ibrutinib (µM)	11.6229
121	Mercaptopurine (µM)	397.8283
121	Nelarabine (µM)	70.38928307
121	Panobinostat (nM)	0
121	Prednisolone (µM)	0.02551725
121	Ruxolitinib (nM)	20000
121	Thioguanine (µM)	0
121	Trametinib (nM)	2000
121	Venetoclax (nM)	0.8521723
121	Vincristine (µM)	0.0504497
121	Vorinostat (nM)	1780.316
121	asparagise_normalized	0
121	bortezomib_normalized	0.0612
121	CHZ868_normalized	0.7614
121	dasatinib_normalized	1
121	daunorubicin_normalized	0.2574
121	ibrutinib_normalized	0.579
121	mercaptopurine_normalized	0.4231
121	nelarabine_normalized	0.9815
121	prednisolone_normalized	0.051
121	ruxolitinib_normalized	1
121	trametinib_normalized	1
121	venetoclax_normalized	0.5861
121	vincristine_normalized	0.0013
121	vorinostat_normalized	0.6501
122	immunophenotype	B
122	molecular subtype	BCR-ABL1
122	Protocol	T17
122	NCI risk	HR
122	Age at diagnosis	5.9
122	WBC at diagnosis	61.6
122	Sex	F
122	Genetically-defined race	White
122	Asparaginase (IU/ml)	0.0016
122	Bortezomib (nM)	12.32308
122	CHZ868 (nM)	23.71624
122	Cytarabine (µM)	0
122	Dasatinib (nM)	0.05
122	Daunorubicin (µM)	0.03247495
122	Dexamethasone  (µM)	0
122	Ibrutinib (µM)	0.78125
122	Mercaptopurine (µM)	431.6231
122	Nelarabine (µM)	12.62543
122	Panobinostat (nM)	0
122	Prednisolone (µM)	1006
122	Ruxolitinib (nM)	20000
122	Thioguanine (µM)	0
122	Trametinib (nM)	8.31693
122	Venetoclax (nM)	10.45031
122	Vincristine (µM)	0.025
122	Vorinostat (nM)	522.4574
122	asparagise_normalized	0
122	bortezomib_normalized	0.3654
122	CHZ868_normalized	0.475
122	dasatinib_normalized	0
122	daunorubicin_normalized	0.3366
122	ibrutinib_normalized	0
122	mercaptopurine_normalized	0.4466
122	nelarabine_normalized	0.7336
122	prednisolone_normalized	1
122	ruxolitinib_normalized	1
122	trametinib_normalized	0.584
122	venetoclax_normalized	0.8038
122	vincristine_normalized	0
122	vorinostat_normalized	0.5436
123	immunophenotype	B
123	molecular subtype	Hyperdiploid
123	Protocol	T17
123	NCI risk	HR
123	Age at diagnosis	4.3
123	WBC at diagnosis	59.1
123	Sex	F
123	Genetically-defined race	White
123	Asparaginase (IU/ml)	0.787680328
123	Bortezomib (nM)	51.03757
123	CHZ868 (nM)	20000
123	Cytarabine (µM)	0
123	Dasatinib (nM)	20000
123	Daunorubicin (µM)	0.1663309
123	Dexamethasone  (µM)	0
123	Ibrutinib (µM)	17.11908
123	Mercaptopurine (µM)	750.9281
123	Nelarabine (µM)	160
123	Panobinostat (nM)	0
123	Prednisolone (µM)	0.05278696
123	Ruxolitinib (nM)	20000
123	Thioguanine (µM)	0
123	Trametinib (nM)	2000
123	Venetoclax (nM)	1.42163
123	Vincristine (µM)	0.025
123	Vorinostat (nM)	1642.904
123	asparagise_normalized	0.6842
123	bortezomib_normalized	0.5706
123	CHZ868_normalized	1
123	dasatinib_normalized	1
123	daunorubicin_normalized	0.5675
123	ibrutinib_normalized	0.6907
123	mercaptopurine_normalized	0.6064
123	nelarabine_normalized	1
123	prednisolone_normalized	0.1207
123	ruxolitinib_normalized	1
123	trametinib_normalized	1
123	venetoclax_normalized	0.6306
123	vincristine_normalized	0
123	vorinostat_normalized	0.6431
124	immunophenotype	B
124	molecular subtype	DUX4
124	Protocol	T17
124	NCI risk	SR
124	Age at diagnosis	3.1
124	WBC at diagnosis	25.7
124	Sex	M
124	Genetically-defined race	White
124	Asparaginase (IU/ml)	1.228502
124	Bortezomib (nM)	12.2924675
124	CHZ868 (nM)	66.71154
124	Cytarabine (µM)	0
124	Dasatinib (nM)	2219.370151
124	Daunorubicin (µM)	0.04431154
124	Dexamethasone  (µM)	0
124	Ibrutinib (µM)	11.70899
124	Mercaptopurine (µM)	371.1521
124	Nelarabine (µM)	19.55428
124	Panobinostat (nM)	0
124	Prednisolone (µM)	0.0075
124	Ruxolitinib (nM)	20000
124	Thioguanine (µM)	0
124	Trametinib (nM)	657.1207
124	Venetoclax (nM)	3.469977
124	Vincristine (µM)	0.025
124	Vorinostat (nM)	1564.998
124	asparagise_normalized	0.7394
124	bortezomib_normalized	0.3651
124	CHZ868_normalized	0.5648
124	dasatinib_normalized	0.8692
124	daunorubicin_normalized	0.3805
124	ibrutinib_normalized	0.5811
124	mercaptopurine_normalized	0.4031
124	nelarabine_normalized	0.7967
124	prednisolone_normalized	0
124	ruxolitinib_normalized	1
124	trametinib_normalized	0.9635
124	venetoclax_normalized	0.7081
124	vincristine_normalized	0
124	vorinostat_normalized	0.6389
125	immunophenotype	B
125	molecular subtype	Hyperdiploid
125	Protocol	T17
125	NCI risk	SR
125	Age at diagnosis	1.8
125	WBC at diagnosis	25.6
125	Sex	F
125	Genetically-defined race	Hispanic
125	Asparaginase (IU/ml)	0.046366323
125	Bortezomib (nM)	11.25799
125	CHZ868 (nM)	14.43879
125	Cytarabine (µM)	0
125	Dasatinib (nM)	2552.716
125	Daunorubicin (µM)	0.03081865
125	Dexamethasone  (µM)	0
125	Ibrutinib (µM)	4.536688
125	Mercaptopurine (µM)	689.3053
125	Nelarabine (µM)	57.45619
125	Panobinostat (nM)	0
125	Prednisolone (µM)	0.1504323
125	Ruxolitinib (nM)	20000
125	Thioguanine (µM)	0
125	Trametinib (nM)	0.005
125	Venetoclax (nM)	0.0005
125	Vincristine (µM)	0.025
125	Vorinostat (nM)	543.4589
125	asparagise_normalized	0.3322
125	bortezomib_normalized	0.3524
125	CHZ868_normalized	0.4319
125	dasatinib_normalized	0.8814
125	daunorubicin_normalized	0.3292
125	ibrutinib_normalized	0.3076
125	mercaptopurine_normalized	0.5817
125	nelarabine_normalized	0.9522
125	prednisolone_normalized	0.2212
125	ruxolitinib_normalized	1
125	trametinib_normalized	0
125	venetoclax_normalized	0
125	vincristine_normalized	0
125	vorinostat_normalized	0.547
126	immunophenotype	B
126	molecular subtype	ETV6-RUNX1
126	Protocol	T17
126	NCI risk	SR
126	Age at diagnosis	4.3
126	WBC at diagnosis	17.5
126	Sex	M
126	Genetically-defined race	White
126	Asparaginase (IU/ml)	0.0016
126	Bortezomib (nM)	5.914381
126	CHZ868 (nM)	1.590064
126	Cytarabine (µM)	0
126	Dasatinib (nM)	20000
126	Daunorubicin (µM)	0.03285739
126	Dexamethasone  (µM)	0
126	Ibrutinib (µM)	15.04693138
126	Mercaptopurine (µM)	326.7833
126	Nelarabine (µM)	160
126	Panobinostat (nM)	0
126	Prednisolone (µM)	0.08185675
126	Ruxolitinib (nM)	20000
126	Thioguanine (µM)	0
126	Trametinib (nM)	2000
126	Venetoclax (nM)	1.056577
126	Vincristine (µM)	0.1972037
126	Vorinostat (nM)	2143.605
126	asparagise_normalized	0
126	bortezomib_normalized	0.2595
126	CHZ868_normalized	0.2403
126	dasatinib_normalized	1
126	daunorubicin_normalized	0.3383
126	ibrutinib_normalized	0.6535
126	mercaptopurine_normalized	0.3663
126	nelarabine_normalized	1
126	prednisolone_normalized	0.1628
126	ruxolitinib_normalized	1
126	trametinib_normalized	1
126	venetoclax_normalized	0.6048
126	vincristine_normalized	0.1964
126	vorinostat_normalized	0.6662
127	immunophenotype	B
127	molecular subtype	ETV6-RUNX1
127	Protocol	T17
127	NCI risk	SR
127	Age at diagnosis	3.7
127	WBC at diagnosis	11
127	Sex	F
127	Genetically-defined race	Hispanic
127	Asparaginase (IU/ml)	0.2517711
127	Bortezomib (nM)	9.346096
127	CHZ868 (nM)	20000
127	Cytarabine (µM)	0
127	Dasatinib (nM)	20000
127	Daunorubicin (µM)	0.05017667
127	Dexamethasone  (µM)	0
127	Ibrutinib (µM)	13.67621
127	Mercaptopurine (µM)	1503.221894
127	Nelarabine (µM)	160
127	Panobinostat (nM)	0
127	Prednisolone (µM)	0.08376224
127	Ruxolitinib (nM)	20000
127	Thioguanine (µM)	0
127	Trametinib (nM)	308.6817
127	Venetoclax (nM)	0.1290421
127	Vincristine (µM)	0.3828107
127	Vorinostat (nM)	1356.988
127	asparagise_normalized	0.5425
127	bortezomib_normalized	0.3255
127	CHZ868_normalized	1
127	dasatinib_normalized	1
127	daunorubicin_normalized	0.3981
127	ibrutinib_normalized	0.6259
127	mercaptopurine_normalized	0.8067
127	nelarabine_normalized	1
127	prednisolone_normalized	0.1651
127	ruxolitinib_normalized	1
127	trametinib_normalized	0.8979
127	venetoclax_normalized	0.4221
127	vincristine_normalized	0.2913
127	vorinostat_normalized	0.6265
128	immunophenotype	B
128	molecular subtype	Hyperdiploid
128	Protocol	T17
128	NCI risk	HR
128	Age at diagnosis	1.6
128	WBC at diagnosis	92.6
128	Sex	M
128	Genetically-defined race	White
128	Asparaginase (IU/ml)	0.0016
128	Bortezomib (nM)	32.45289
128	CHZ868 (nM)	2.873661
128	Cytarabine (µM)	0
128	Dasatinib (nM)	1059.158
128	Daunorubicin (µM)	0.8163833
128	Dexamethasone  (µM)	0
128	Ibrutinib (µM)	5.861456
128	Mercaptopurine (µM)	45.9
128	Nelarabine (µM)	2.29417
128	Panobinostat (nM)	0
128	Prednisolone (µM)	0.08406714
128	Ruxolitinib (nM)	20000
128	Thioguanine (µM)	0
128	Trametinib (nM)	11.53902
128	Venetoclax (nM)	0.0005
128	Vincristine (µM)	3.329648064
128	Vorinostat (nM)	724.4377
128	asparagise_normalized	0
128	bortezomib_normalized	0.5052
128	CHZ868_normalized	0.2917
128	dasatinib_normalized	0.805
128	daunorubicin_normalized	0.7923
128	ibrutinib_normalized	0.3815
128	mercaptopurine_normalized	0
128	nelarabine_normalized	0.4876
128	prednisolone_normalized	0.1654
128	ruxolitinib_normalized	1
128	trametinib_normalized	0.6124
128	venetoclax_normalized	0
128	vincristine_normalized	0.6008
128	vorinostat_normalized	0.572
129	immunophenotype	B
129	molecular subtype	ETV6-RUNX1
129	Protocol	T17
129	NCI risk	SR
129	Age at diagnosis	4.8
129	WBC at diagnosis	3.9
129	Sex	F
129	Genetically-defined race	black
129	Asparaginase (IU/ml)	0.0016
129	Bortezomib (nM)	3.195708899
129	CHZ868 (nM)	0
129	Cytarabine (µM)	0
129	Dasatinib (nM)	20000
129	Daunorubicin (µM)	0.03136186
129	Dexamethasone  (µM)	0
129	Ibrutinib (µM)	9.222373
129	Mercaptopurine (µM)	731.6074
129	Nelarabine (µM)	160
129	Panobinostat (nM)	0
129	Prednisolone (µM)	0.08751612
129	Ruxolitinib (nM)	0
129	Thioguanine (µM)	0
129	Trametinib (nM)	2000
129	Venetoclax (nM)	0.7222986
129	Vincristine (µM)	0.1409708
129	Vorinostat (nM)	633.6597
129	asparagise_normalized	0
129	bortezomib_normalized	0.1706
129	dasatinib_normalized	1
129	daunorubicin_normalized	0.3317
129	ibrutinib_normalized	0.5123
129	mercaptopurine_normalized	0.5989
129	nelarabine_normalized	1
129	prednisolone_normalized	0.1693
129	trametinib_normalized	1
129	venetoclax_normalized	0.5717
129	vincristine_normalized	0.1483
129	vorinostat_normalized	0.5604
130	immunophenotype	B
130	molecular subtype	PAX5alt
130	Protocol	T17
130	NCI risk	HR
130	Age at diagnosis	12.7
130	WBC at diagnosis	10.7
130	Sex	M
130	Genetically-defined race	White
130	Asparaginase (IU/ml)	0.0016
130	Bortezomib (nM)	4.015937
130	CHZ868 (nM)	20000
130	Cytarabine (µM)	0
130	Dasatinib (nM)	20000
130	Daunorubicin (µM)	0.01250813
130	Dexamethasone  (µM)	0
130	Ibrutinib (µM)	22.42377
130	Mercaptopurine (µM)	1520.502
130	Nelarabine (µM)	70.45131
130	Panobinostat (nM)	0
130	Prednisolone (µM)	1006
130	Ruxolitinib (nM)	20000
130	Thioguanine (µM)	0
130	Trametinib (nM)	53.45948
130	Venetoclax (nM)	1.737618
130	Vincristine (µM)	0.025
130	Vorinostat (nM)	1581.745
130	asparagise_normalized	0
130	bortezomib_normalized	0.2036
130	CHZ868_normalized	1
130	dasatinib_normalized	1
130	daunorubicin_normalized	0.2018
130	ibrutinib_normalized	0.7686
130	mercaptopurine_normalized	0.81
130	nelarabine_normalized	0.9817
130	prednisolone_normalized	1
130	ruxolitinib_normalized	1
130	trametinib_normalized	0.7456
130	venetoclax_normalized	0.648
130	vincristine_normalized	0
130	vorinostat_normalized	0.6398
131	immunophenotype	B
131	molecular subtype	KMT2A
131	Protocol	T17
131	NCI risk	HR
131	Age at diagnosis	11.8
131	WBC at diagnosis	5.8
131	Sex	M
131	Genetically-defined race	black
131	Asparaginase (IU/ml)	1.619429
131	Bortezomib (nM)	4.701652
131	CHZ868 (nM)	20000
131	Cytarabine (µM)	0
131	Dasatinib (nM)	3409.358
131	Daunorubicin (µM)	0.004929034
131	Dexamethasone  (µM)	0
131	Ibrutinib (µM)	12.4715
131	Mercaptopurine (µM)	0
131	Nelarabine (µM)	160
131	Panobinostat (nM)	0
131	Prednisolone (µM)	0
131	Ruxolitinib (nM)	20000
131	Thioguanine (µM)	0
131	Trametinib (nM)	2000
131	Venetoclax (nM)	0.1950771
131	Vincristine (µM)	0.2929381
131	Vorinostat (nM)	1094.720813
131	asparagise_normalized	0.7738
131	bortezomib_normalized	0.2263
131	CHZ868_normalized	1
131	dasatinib_normalized	0.9065
131	daunorubicin_normalized	0.0702
131	ibrutinib_normalized	0.5993
131	nelarabine_normalized	1
131	ruxolitinib_normalized	1
131	trametinib_normalized	1
131	venetoclax_normalized	0.458
131	vincristine_normalized	0.253
131	vorinostat_normalized	0.6079
132	immunophenotype	T
132	molecular subtype	T-ALL
132	Protocol	T17
132	NCI risk	SR
132	Age at diagnosis	5.8
132	WBC at diagnosis	44.6
132	Sex	M
132	Genetically-defined race	black
132	Asparaginase (IU/ml)	0.4437369
132	Bortezomib (nM)	25.05111
132	CHZ868 (nM)	0
132	Cytarabine (µM)	0
132	Dasatinib (nM)	6234.474
132	Daunorubicin (µM)	0.182350964
132	Dexamethasone  (µM)	0
132	Ibrutinib (µM)	14.55116
132	Mercaptopurine (µM)	5876
132	Nelarabine (µM)	62.0992
132	Panobinostat (nM)	0
132	Prednisolone (µM)	1006
132	Ruxolitinib (nM)	0
132	Thioguanine (µM)	0
132	Trametinib (nM)	2000
132	Venetoclax (nM)	0.580495
132	Vincristine (µM)	0.8351365
132	Vorinostat (nM)	1333.671
132	asparagise_normalized	0.6129
132	bortezomib_normalized	0.4678
132	dasatinib_normalized	0.959
132	daunorubicin_normalized	0.5805
132	ibrutinib_normalized	0.6438
132	mercaptopurine_normalized	1
132	nelarabine_normalized	0.9635
132	prednisolone_normalized	1
132	trametinib_normalized	1
132	venetoclax_normalized	0.5528
132	vincristine_normalized	0.4029
132	vorinostat_normalized	0.625
133	immunophenotype	B
133	molecular subtype	KMT2A
133	Protocol	T17
133	NCI risk	HR
133	Age at diagnosis	1.2
133	WBC at diagnosis	63.9
133	Sex	F
133	Genetically-defined race	White
133	Asparaginase (IU/ml)	1.888366
133	Bortezomib (nM)	88.9355
133	CHZ868 (nM)	20000
133	Cytarabine (µM)	0
133	Dasatinib (nM)	724.8352
133	Daunorubicin (µM)	0.2592925
133	Dexamethasone  (µM)	0
133	Ibrutinib (µM)	10.26934
133	Mercaptopurine (µM)	1235.075
133	Nelarabine (µM)	71.90099
133	Panobinostat (nM)	0
133	Prednisolone (µM)	166.5689
133	Ruxolitinib (nM)	20000
133	Thioguanine (µM)	0
133	Trametinib (nM)	0.8400947
133	Venetoclax (nM)	0.2201885
133	Vincristine (µM)	0.1627501
133	Vorinostat (nM)	679.809
133	asparagise_normalized	0.7929
133	bortezomib_normalized	0.6507
133	CHZ868_normalized	1
133	dasatinib_normalized	0.772
133	daunorubicin_normalized	0.6302
133	ibrutinib_normalized	0.5433
133	mercaptopurine_normalized	0.75
133	nelarabine_normalized	0.9846
133	prednisolone_normalized	0.8939
133	ruxolitinib_normalized	1
133	trametinib_normalized	0.3849
133	venetoclax_normalized	0.4686
133	vincristine_normalized	0.1689
133	vorinostat_normalized	0.5665
134	immunophenotype	B
134	molecular subtype	B-other
134	Protocol	T17
134	NCI risk	HR
134	Age at diagnosis	12.2
134	WBC at diagnosis	202.3
134	Sex	M
134	Genetically-defined race	black
134	Asparaginase (IU/ml)	0.2331279
134	Bortezomib (nM)	7.221149
134	CHZ868 (nM)	9.912077
134	Cytarabine (µM)	0
134	Dasatinib (nM)	2647.277
134	Daunorubicin (µM)	0.04843317
134	Dexamethasone  (µM)	0
134	Ibrutinib (µM)	8.502297
134	Mercaptopurine (µM)	1001.894
134	Nelarabine (µM)	160
134	Panobinostat (nM)	0
134	Prednisolone (µM)	0.0762523
134	Ruxolitinib (nM)	20000
134	Thioguanine (µM)	0
134	Trametinib (nM)	10.58055
134	Venetoclax (nM)	0.022918702
134	Vincristine (µM)	0.025
134	Vorinostat (nM)	1256.403
134	asparagise_normalized	0.5329
134	bortezomib_normalized	0.2883
134	CHZ868_normalized	0.3992
134	dasatinib_normalized	0.8846
134	daunorubicin_normalized	0.3931
134	ibrutinib_normalized	0.4888
134	mercaptopurine_normalized	0.6896
134	nelarabine_normalized	1
134	prednisolone_normalized	0.156
134	ruxolitinib_normalized	1
134	trametinib_normalized	0.6049
134	venetoclax_normalized	0.272
134	vincristine_normalized	0
134	vorinostat_normalized	0.6198
135	immunophenotype	B
135	molecular subtype	ETV6-RUNX1
135	Protocol	T17
135	NCI risk	SR
135	Age at diagnosis	2.7
135	WBC at diagnosis	9.1
135	Sex	F
135	Genetically-defined race	White
135	Asparaginase (IU/ml)	0.327274274
135	Bortezomib (nM)	8.865046
135	CHZ868 (nM)	761.7646
135	Cytarabine (µM)	0
135	Dasatinib (nM)	20000
135	Daunorubicin (µM)	0.112133
135	Dexamethasone  (µM)	0
135	Ibrutinib (µM)	13.14882395
135	Mercaptopurine (µM)	1372.324
135	Nelarabine (µM)	160
135	Panobinostat (nM)	0
135	Prednisolone (µM)	0.07452631
135	Ruxolitinib (nM)	20000
135	Thioguanine (µM)	0
135	Trametinib (nM)	2000
135	Venetoclax (nM)	0.5839293
135	Vincristine (µM)	0.8065378
135	Vorinostat (nM)	4914.435
135	asparagise_normalized	0.5751
135	bortezomib_normalized	0.3179
135	CHZ868_normalized	0.7764
135	dasatinib_normalized	1
135	daunorubicin_normalized	0.5117
135	ibrutinib_normalized	0.6146
135	mercaptopurine_normalized	0.7804
135	nelarabine_normalized	1
135	prednisolone_normalized	0.1538
135	ruxolitinib_normalized	1
135	trametinib_normalized	1
135	venetoclax_normalized	0.5533
135	vincristine_normalized	0.3979
135	vorinostat_normalized	0.7383
136	immunophenotype	T
136	molecular subtype	T-ALL
136	Protocol	T17
136	NCI risk	HR
136	Age at diagnosis	8.8
136	WBC at diagnosis	142.6
136	Sex	M
136	Genetically-defined race	White
136	Asparaginase (IU/ml)	20
136	Bortezomib (nM)	6.879467231
136	CHZ868 (nM)	20000
136	Cytarabine (µM)	0
136	Dasatinib (nM)	0.05
136	Daunorubicin (µM)	0.1284461
136	Dexamethasone  (µM)	0
136	Ibrutinib (µM)	0.78125
136	Mercaptopurine (µM)	516.2441
136	Nelarabine (µM)	160
136	Panobinostat (nM)	0
136	Prednisolone (µM)	10.29508
136	Ruxolitinib (nM)	20000
136	Thioguanine (µM)	0
136	Trametinib (nM)	1.348472
136	Venetoclax (nM)	200
136	Vincristine (µM)	108.34
136	Vorinostat (nM)	1871.534
136	asparagise_normalized	1
136	bortezomib_normalized	0.2813
136	CHZ868_normalized	1
136	dasatinib_normalized	0
136	daunorubicin_normalized	0.5309
136	ibrutinib_normalized	0
136	mercaptopurine_normalized	0.4983
136	nelarabine_normalized	1
136	prednisolone_normalized	0.6268
136	ruxolitinib_normalized	1
136	trametinib_normalized	0.426
136	venetoclax_normalized	1
136	vincristine_normalized	1
136	vorinostat_normalized	0.6544
137	immunophenotype	T
137	molecular subtype	T-ALL
137	Protocol	T17
137	NCI risk	SR
137	Age at diagnosis	8.1
137	WBC at diagnosis	49.4
137	Sex	M
137	Genetically-defined race	White
137	Asparaginase (IU/ml)	0.06344456
137	Bortezomib (nM)	0
137	CHZ868 (nM)	0
137	Cytarabine (µM)	0
137	Dasatinib (nM)	9614.324
137	Daunorubicin (µM)	0
137	Dexamethasone  (µM)	0
137	Ibrutinib (µM)	0
137	Mercaptopurine (µM)	0
137	Nelarabine (µM)	0
137	Panobinostat (nM)	0
137	Prednisolone (µM)	1006
137	Ruxolitinib (nM)	0
137	Thioguanine (µM)	0
137	Trametinib (nM)	0
137	Venetoclax (nM)	0
137	Vincristine (µM)	22.48148
137	Vorinostat (nM)	0
137	asparagise_normalized	0.3712
137	dasatinib_normalized	0.9966
137	prednisolone_normalized	1
137	vincristine_normalized	0.8741
138	immunophenotype	B
138	molecular subtype	Ph-like_non_CRLF2
138	Protocol	T17
138	NCI risk	SR
138	Age at diagnosis	9.2
138	WBC at diagnosis	34
138	Sex	M
138	Genetically-defined race	Hispanic
138	Asparaginase (IU/ml)	20
138	Bortezomib (nM)	16.75288
138	CHZ868 (nM)	0.1566535
138	Cytarabine (µM)	0
138	Dasatinib (nM)	0.692471
138	Daunorubicin (µM)	0.3633916
138	Dexamethasone  (µM)	0
138	Ibrutinib (µM)	3.199023
138	Mercaptopurine (µM)	5876
138	Nelarabine (µM)	46.95714129
138	Panobinostat (nM)	0
138	Prednisolone (µM)	1006
138	Ruxolitinib (nM)	8558.618
138	Thioguanine (µM)	0
138	Trametinib (nM)	1.629202
138	Venetoclax (nM)	9.819736
138	Vincristine (µM)	108.34
138	Vorinostat (nM)	1705.097
138	asparagise_normalized	1
138	bortezomib_normalized	0.4098
138	CHZ868_normalized	0.039
138	dasatinib_normalized	0.1681
138	daunorubicin_normalized	0.6779
138	ibrutinib_normalized	0.2068
138	mercaptopurine_normalized	1
138	nelarabine_normalized	0.9231
138	prednisolone_normalized	1
138	ruxolitinib_normalized	0.9865
138	trametinib_normalized	0.4424
138	venetoclax_normalized	0.7984
138	vincristine_normalized	1
138	vorinostat_normalized	0.6463
139	immunophenotype	B
139	molecular subtype	Hyperdiploid
139	Protocol	T17
139	NCI risk	SR
139	Age at diagnosis	3
139	WBC at diagnosis	7.8
139	Sex	F
139	Genetically-defined race	White
139	Asparaginase (IU/ml)	0
139	Bortezomib (nM)	0
139	CHZ868 (nM)	0
139	Cytarabine (µM)	0
139	Dasatinib (nM)	0
139	Daunorubicin (µM)	0
139	Dexamethasone  (µM)	0
139	Ibrutinib (µM)	0
139	Mercaptopurine (µM)	490.8688
139	Nelarabine (µM)	0
139	Panobinostat (nM)	0
139	Prednisolone (µM)	0.1020304
139	Ruxolitinib (nM)	0
139	Thioguanine (µM)	0
139	Trametinib (nM)	0
139	Venetoclax (nM)	0
139	Vincristine (µM)	0
139	Vorinostat (nM)	0
139	mercaptopurine_normalized	0.4837
139	prednisolone_normalized	0.184
140	immunophenotype	B
140	molecular subtype	Hyperdiploid
140	Protocol	T17
140	NCI risk	SR
140	Age at diagnosis	5.4
140	WBC at diagnosis	44.3
140	Sex	M
140	Genetically-defined race	Hispanic
140	Asparaginase (IU/ml)	0.0016
140	Bortezomib (nM)	4.663627
140	CHZ868 (nM)	11.56656
140	Cytarabine (µM)	0
140	Dasatinib (nM)	20000
140	Daunorubicin (µM)	0.6840405
140	Dexamethasone  (µM)	0
140	Ibrutinib (µM)	10.08371
140	Mercaptopurine (µM)	559.0038
140	Nelarabine (µM)	160
140	Panobinostat (nM)	0
140	Prednisolone (µM)	0.01718414
140	Ruxolitinib (nM)	20000
140	Thioguanine (µM)	0
140	Trametinib (nM)	4.10645
140	Venetoclax (nM)	0.0005
140	Vincristine (µM)	0.8486253
140	Vorinostat (nM)	600.0866
140	asparagise_normalized	0
140	bortezomib_normalized	0.2252
140	CHZ868_normalized	0.4126
140	dasatinib_normalized	1
140	daunorubicin_normalized	0.7673
140	ibrutinib_normalized	0.538
140	mercaptopurine_normalized	0.5212
140	nelarabine_normalized	1
140	prednisolone_normalized	0.013
140	ruxolitinib_normalized	1
140	trametinib_normalized	0.5227
140	venetoclax_normalized	0
140	vincristine_normalized	0.4052
140	vorinostat_normalized	0.5556
141	immunophenotype	B
141	molecular subtype	ZNF384
141	Protocol	T17
141	NCI risk	HR
141	Age at diagnosis	16.8
141	WBC at diagnosis	5.9
141	Sex	F
141	Genetically-defined race	White
141	Asparaginase (IU/ml)	2.769163
141	Bortezomib (nM)	19.13629
141	CHZ868 (nM)	22.42884
141	Cytarabine (µM)	0
141	Dasatinib (nM)	20000
141	Daunorubicin (µM)	0.676388734
141	Dexamethasone  (µM)	0
141	Ibrutinib (µM)	7.752086
141	Mercaptopurine (µM)	0
141	Nelarabine (µM)	0
141	Panobinostat (nM)	0
141	Prednisolone (µM)	1006
141	Ruxolitinib (nM)	20000
141	Thioguanine (µM)	0
141	Trametinib (nM)	10.43871615
141	Venetoclax (nM)	0.104558269
141	Vincristine (µM)	0
141	Vorinostat (nM)	784.3756924
141	asparagise_normalized	0.8404
141	bortezomib_normalized	0.429
141	CHZ868_normalized	0.4702
141	dasatinib_normalized	1
141	daunorubicin_normalized	0.7657
141	ibrutinib_normalized	0.4621
141	prednisolone_normalized	1
141	ruxolitinib_normalized	1
141	trametinib_normalized	0.6037
141	venetoclax_normalized	0.4039
141	vorinostat_normalized	0.5789
142	immunophenotype	B
142	molecular subtype	DUX4
142	Protocol	T17
142	NCI risk	SR
142	Age at diagnosis	4
142	WBC at diagnosis	8.4
142	Sex	F
142	Genetically-defined race	White
142	Asparaginase (IU/ml)	0.4254803
142	Bortezomib (nM)	4.571254
142	CHZ868 (nM)	96.14958
142	Cytarabine (µM)	0
142	Dasatinib (nM)	17.66550155
142	Daunorubicin (µM)	0.008152693
142	Dexamethasone  (µM)	0
142	Ibrutinib (µM)	3.693376
142	Mercaptopurine (µM)	394.8188
142	Nelarabine (µM)	39.7404
142	Panobinostat (nM)	0
142	Prednisolone (µM)	0.0075
142	Ruxolitinib (nM)	20000
142	Thioguanine (µM)	0
142	Trametinib (nM)	1.617668
142	Venetoclax (nM)	0.6167503
142	Vincristine (µM)	0.025
142	Vorinostat (nM)	368.2046
142	asparagise_normalized	0.6077
142	bortezomib_normalized	0.2223
142	CHZ868_normalized	0.5966
142	dasatinib_normalized	0.4494
142	daunorubicin_normalized	0.1413
142	ibrutinib_normalized	0.2482
142	mercaptopurine_normalized	0.4209
142	nelarabine_normalized	0.8991
142	prednisolone_normalized	0
142	ruxolitinib_normalized	1
142	trametinib_normalized	0.4418
142	venetoclax_normalized	0.558
142	vincristine_normalized	0
142	vorinostat_normalized	0.5132
143	immunophenotype	B
143	molecular subtype	B-other
143	Protocol	T15
143	NCI risk	HR
143	Age at diagnosis	16.9
143	WBC at diagnosis	62.8
143	Sex	M
143	Genetically-defined race	White
143	Asparaginase (IU/ml)	0
143	Bortezomib (nM)	0
143	CHZ868 (nM)	0
143	Cytarabine (µM)	0
143	Dasatinib (nM)	0
143	Daunorubicin (µM)	0
143	Dexamethasone  (µM)	0
143	Ibrutinib (µM)	0
143	Mercaptopurine (µM)	461.2499
143	Nelarabine (µM)	0
143	Panobinostat (nM)	0
143	Prednisolone (µM)	0
143	Ruxolitinib (nM)	0
143	Thioguanine (µM)	0
143	Trametinib (nM)	0
143	Venetoclax (nM)	0
143	Vincristine (µM)	0
143	Vorinostat (nM)	0
143	mercaptopurine_normalized	0.4658
144	immunophenotype	B
144	molecular subtype	Hyperdiploid
144	Protocol	T17
144	NCI risk	SR
144	Age at diagnosis	5.9
144	WBC at diagnosis	3
144	Sex	M
144	Genetically-defined race	White
144	Asparaginase (IU/ml)	0.5032698
144	Bortezomib (nM)	0
144	CHZ868 (nM)	0
144	Cytarabine (µM)	0
144	Dasatinib (nM)	20000
144	Daunorubicin (µM)	0
144	Dexamethasone  (µM)	0
144	Ibrutinib (µM)	12.9559
144	Mercaptopurine (µM)	390.1508
144	Nelarabine (µM)	0
144	Panobinostat (nM)	0
144	Prednisolone (µM)	0.08468578
144	Ruxolitinib (nM)	0
144	Thioguanine (µM)	0
144	Trametinib (nM)	15.66023
144	Venetoclax (nM)	0.0005
144	Vincristine (µM)	3.86506758
144	Vorinostat (nM)	0
144	asparagise_normalized	0.6285
144	dasatinib_normalized	1
144	ibrutinib_normalized	0.6103
144	mercaptopurine_normalized	0.4175
144	prednisolone_normalized	0.1661
144	trametinib_normalized	0.639
144	venetoclax_normalized	0
144	vincristine_normalized	0.6222
145	immunophenotype	B
145	molecular subtype	Hyperdiploid
145	Protocol	T17
145	NCI risk	SR
145	Age at diagnosis	2.3
145	WBC at diagnosis	15.5
145	Sex	M
145	Genetically-defined race	White
145	Asparaginase (IU/ml)	0.01004933
145	Bortezomib (nM)	8.999053
145	CHZ868 (nM)	0.5672007
145	Cytarabine (µM)	0
145	Dasatinib (nM)	941.9788
145	Daunorubicin (µM)	0.02981152
145	Dexamethasone  (µM)	0
145	Ibrutinib (µM)	7.587132
145	Mercaptopurine (µM)	354.3296
145	Nelarabine (µM)	160
145	Panobinostat (nM)	0
145	Prednisolone (µM)	0.1140148
145	Ruxolitinib (nM)	20000
145	Thioguanine (µM)	0
145	Trametinib (nM)	0.6596992
145	Venetoclax (nM)	0.0005
145	Vincristine (µM)	0.025
145	Vorinostat (nM)	676.9619
145	asparagise_normalized	0.1422
145	bortezomib_normalized	0.3201
145	CHZ868_normalized	0.1507
145	dasatinib_normalized	0.7948
145	daunorubicin_normalized	0.3245
145	ibrutinib_normalized	0.4559
145	mercaptopurine_normalized	0.3897
145	nelarabine_normalized	1
145	prednisolone_normalized	0.1946
145	ruxolitinib_normalized	1
145	trametinib_normalized	0.3639
145	venetoclax_normalized	0
145	vincristine_normalized	0
145	vorinostat_normalized	0.5661
146	immunophenotype	B
146	molecular subtype	ETV6-RUNX1
146	Protocol	T17
146	NCI risk	HR
146	Age at diagnosis	1.9
146	WBC at diagnosis	131.1
146	Sex	F
146	Genetically-defined race	White
146	Asparaginase (IU/ml)	0.0016
146	Bortezomib (nM)	7.869942
146	CHZ868 (nM)	12.67916
146	Cytarabine (µM)	0
146	Dasatinib (nM)	20000
146	Daunorubicin (µM)	0.04493259
146	Dexamethasone  (µM)	0
146	Ibrutinib (µM)	8.453592
146	Mercaptopurine (µM)	553.1576
146	Nelarabine (µM)	160
146	Panobinostat (nM)	0
146	Prednisolone (µM)	0.0075
146	Ruxolitinib (nM)	20000
146	Thioguanine (µM)	0
146	Trametinib (nM)	26.19505
146	Venetoclax (nM)	0.03886817
146	Vincristine (µM)	0.5172539
146	Vorinostat (nM)	594.6881
146	asparagise_normalized	0
146	bortezomib_normalized	0.3007
146	CHZ868_normalized	0.4206
146	dasatinib_normalized	1
146	daunorubicin_normalized	0.3825
146	ibrutinib_normalized	0.4871
146	mercaptopurine_normalized	0.5182
146	nelarabine_normalized	1
146	prednisolone_normalized	0
146	ruxolitinib_normalized	1
146	trametinib_normalized	0.6836
146	venetoclax_normalized	0.3179
146	vincristine_normalized	0.3344
146	vorinostat_normalized	0.5549
147	immunophenotype	T
147	molecular subtype	ETP
147	Protocol	T17
147	NCI risk	HR
147	Age at diagnosis	18.5
147	WBC at diagnosis	68.2
147	Sex	M
147	Genetically-defined race	White
147	Asparaginase (IU/ml)	0.0016
147	Bortezomib (nM)	22.37619
147	CHZ868 (nM)	0
147	Cytarabine (µM)	0
147	Dasatinib (nM)	2007.796
147	Daunorubicin (µM)	0.2987968
147	Dexamethasone  (µM)	0
147	Ibrutinib (µM)	10.46222
147	Mercaptopurine (µM)	260.2506
147	Nelarabine (µM)	160
147	Panobinostat (nM)	0
147	Prednisolone (µM)	111.5647
147	Ruxolitinib (nM)	20000
147	Thioguanine (µM)	0
147	Trametinib (nM)	2000
147	Venetoclax (nM)	0.08757081
147	Vincristine (µM)	19.03133
147	Vorinostat (nM)	1412.343983
147	asparagise_normalized	0
147	bortezomib_normalized	0.4515
147	dasatinib_normalized	0.8605
147	daunorubicin_normalized	0.6502
147	ibrutinib_normalized	0.5487
147	mercaptopurine_normalized	0.3007
147	nelarabine_normalized	1
147	prednisolone_normalized	0.8555
147	ruxolitinib_normalized	1
147	trametinib_normalized	1
147	venetoclax_normalized	0.3885
147	vincristine_normalized	0.8503
147	vorinostat_normalized	0.63
148	immunophenotype	B
148	molecular subtype	iAMP21
148	Protocol	T17
148	NCI risk	SR
148	Age at diagnosis	7.7
148	WBC at diagnosis	22.6
148	Sex	F
148	Genetically-defined race	White
148	Asparaginase (IU/ml)	0.0016
148	Bortezomib (nM)	78.33155
148	CHZ868 (nM)	20000
148	Cytarabine (µM)	0
148	Dasatinib (nM)	68.50172
148	Daunorubicin (µM)	0.2245767
148	Dexamethasone  (µM)	0
148	Ibrutinib (µM)	5.062306
148	Mercaptopurine (µM)	463.0291
148	Nelarabine (µM)	160
148	Panobinostat (nM)	0
148	Prednisolone (µM)	1.11594
148	Ruxolitinib (nM)	20000
148	Thioguanine (µM)	0
148	Trametinib (nM)	32.04051
148	Venetoclax (nM)	0.1027392
148	Vincristine (µM)	0.1082582
148	Vorinostat (nM)	464.2251
148	asparagise_normalized	0
148	bortezomib_normalized	0.6324
148	CHZ868_normalized	1
148	dasatinib_normalized	0.5671
148	daunorubicin_normalized	0.6099
148	ibrutinib_normalized	0.3392
148	mercaptopurine_normalized	0.4669
148	nelarabine_normalized	1
148	prednisolone_normalized	0.4136
148	ruxolitinib_normalized	1
148	trametinib_normalized	0.7011
148	venetoclax_normalized	0.4023
148	vincristine_normalized	0.1105
148	vorinostat_normalized	0.5333
149	immunophenotype	B
149	molecular subtype	Ph-like_non_CRLF2
149	Protocol	T17
149	NCI risk	HR
149	Age at diagnosis	15.5
149	WBC at diagnosis	15.4
149	Sex	M
149	Genetically-defined race	White
149	Asparaginase (IU/ml)	1.011437
149	Bortezomib (nM)	21.41731
149	CHZ868 (nM)	0
149	Cytarabine (µM)	0
149	Dasatinib (nM)	0
149	Daunorubicin (µM)	0.0015
149	Dexamethasone  (µM)	0
149	Ibrutinib (µM)	0
149	Mercaptopurine (µM)	680.0072
149	Nelarabine (µM)	44.23524
149	Panobinostat (nM)	0
149	Prednisolone (µM)	1006
149	Ruxolitinib (nM)	0
149	Thioguanine (µM)	0
149	Trametinib (nM)	0
149	Venetoclax (nM)	0
149	Vincristine (µM)	0.025
149	Vorinostat (nM)	620.9802
149	asparagise_normalized	0.7153
149	bortezomib_normalized	0.4452
149	daunorubicin_normalized	0
149	mercaptopurine_normalized	0.5778
149	nelarabine_normalized	0.9145
149	prednisolone_normalized	1
149	vincristine_normalized	0
149	vorinostat_normalized	0.5586
150	immunophenotype	B
150	molecular subtype	ETV6-RUNX1
150	Protocol	T17
150	NCI risk	SR
150	Age at diagnosis	4.9
150	WBC at diagnosis	13.9
150	Sex	F
150	Genetically-defined race	White
150	Asparaginase (IU/ml)	0.0016
150	Bortezomib (nM)	62.65135
150	CHZ868 (nM)	20000
150	Cytarabine (µM)	0
150	Dasatinib (nM)	20000
150	Daunorubicin (µM)	0.1006186
150	Dexamethasone  (µM)	0
150	Ibrutinib (µM)	5.475857
150	Mercaptopurine (µM)	211.5421
150	Nelarabine (µM)	160
150	Panobinostat (nM)	0
150	Prednisolone (µM)	0.07602975
150	Ruxolitinib (nM)	20000
150	Thioguanine (µM)	0
150	Trametinib (nM)	8.106851
150	Venetoclax (nM)	0.005371292
150	Vincristine (µM)	0.2015968
150	Vorinostat (nM)	655.6627
150	asparagise_normalized	0
150	bortezomib_normalized	0.6001
150	CHZ868_normalized	1
150	dasatinib_normalized	1
150	daunorubicin_normalized	0.4964
150	ibrutinib_normalized	0.3618
150	mercaptopurine_normalized	0.2409
150	nelarabine_normalized	1
150	prednisolone_normalized	0.1558
150	ruxolitinib_normalized	1
150	trametinib_normalized	0.5818
150	venetoclax_normalized	0.146
150	vincristine_normalized	0.1995
150	vorinostat_normalized	0.5633
151	immunophenotype	B
151	molecular subtype	B-other
151	Protocol	T17
151	NCI risk	HR
151	Age at diagnosis	6.5
151	WBC at diagnosis	107
151	Sex	M
151	Genetically-defined race	White
151	Asparaginase (IU/ml)	0
151	Bortezomib (nM)	230.9471
151	CHZ868 (nM)	1.690692
151	Cytarabine (µM)	0
151	Dasatinib (nM)	7377.088
151	Daunorubicin (µM)	0.1337577
151	Dexamethasone  (µM)	0
151	Ibrutinib (µM)	2.960545
151	Mercaptopurine (µM)	0
151	Nelarabine (µM)	0
151	Panobinostat (nM)	0
151	Prednisolone (µM)	0
151	Ruxolitinib (nM)	9514.539
151	Thioguanine (µM)	0
151	Trametinib (nM)	0.005
151	Venetoclax (nM)	0.004374494
151	Vincristine (µM)	0
151	Vorinostat (nM)	0
151	bortezomib_normalized	0.7885
151	CHZ868_normalized	0.2456
151	dasatinib_normalized	0.9736
151	daunorubicin_normalized	0.5367
151	ibrutinib_normalized	0.1844
151	ruxolitinib_normalized	0.9957
151	trametinib_normalized	0
151	venetoclax_normalized	0.1282
152	immunophenotype	B
152	molecular subtype	Hyperdiploid
152	Protocol	T17
152	NCI risk	HR
152	Age at diagnosis	1.9
152	WBC at diagnosis	53.8
152	Sex	M
152	Genetically-defined race	White
152	Asparaginase (IU/ml)	0.04176917
152	Bortezomib (nM)	29.22615
152	CHZ868 (nM)	20000
152	Cytarabine (µM)	0
152	Dasatinib (nM)	20000
152	Daunorubicin (µM)	0.05203198
152	Dexamethasone  (µM)	0
152	Ibrutinib (µM)	14.82554653
152	Mercaptopurine (µM)	45.9
152	Nelarabine (µM)	10.91225327
152	Panobinostat (nM)	0
152	Prednisolone (µM)	0.0075
152	Ruxolitinib (nM)	20000
152	Thioguanine (µM)	0
152	Trametinib (nM)	2000
152	Venetoclax (nM)	2.145603
152	Vincristine (µM)	0.8775267
152	Vorinostat (nM)	561.0187
152	asparagise_normalized	0.3192
152	bortezomib_normalized	0.4901
152	CHZ868_normalized	1
152	dasatinib_normalized	1
152	daunorubicin_normalized	0.4032
152	ibrutinib_normalized	0.6492
152	mercaptopurine_normalized	0
152	nelarabine_normalized	0.7126
152	prednisolone_normalized	0
152	ruxolitinib_normalized	1
152	trametinib_normalized	1
152	venetoclax_normalized	0.6663
152	vincristine_normalized	0.41
152	vorinostat_normalized	0.5498
153	immunophenotype	B
153	molecular subtype	Hyperdiploid
153	Protocol	T17
153	NCI risk	SR
153	Age at diagnosis	4.6
153	WBC at diagnosis	2.2
153	Sex	F
153	Genetically-defined race	Hispanic
153	Asparaginase (IU/ml)	0.01389391
153	Bortezomib (nM)	15.76125
153	CHZ868 (nM)	215.3599576
153	Cytarabine (µM)	0
153	Dasatinib (nM)	4381.208
153	Daunorubicin (µM)	0.08311728
153	Dexamethasone  (µM)	0
153	Ibrutinib (µM)	14.84152
153	Mercaptopurine (µM)	0
153	Nelarabine (µM)	35.07978
153	Panobinostat (nM)	0
153	Prednisolone (µM)	4.52251
153	Ruxolitinib (nM)	717.2011
153	Thioguanine (µM)	0
153	Trametinib (nM)	2.671036
153	Venetoclax (nM)	7.166135
153	Vincristine (µM)	0.025
153	Vorinostat (nM)	250.6646
153	asparagise_normalized	0.1825
153	bortezomib_normalized	0.4009
153	CHZ868_normalized	0.6666
153	dasatinib_normalized	0.9283
153	daunorubicin_normalized	0.4694
153	ibrutinib_normalized	0.6495
153	nelarabine_normalized	0.8811
153	prednisolone_normalized	0.5479
153	ruxolitinib_normalized	0.7711
153	trametinib_normalized	0.4853
153	venetoclax_normalized	0.7711
153	vincristine_normalized	0
153	vorinostat_normalized	0.4798
154	immunophenotype	B
154	molecular subtype	Hyperdiploid
154	Protocol	T17
154	NCI risk	SR
154	Age at diagnosis	2.5
154	WBC at diagnosis	43.4
154	Sex	M
154	Genetically-defined race	Asian/Other
154	Asparaginase (IU/ml)	0.0016
154	Bortezomib (nM)	4.27766
154	CHZ868 (nM)	26.82113
154	Cytarabine (µM)	0
154	Dasatinib (nM)	3624.093
154	Daunorubicin (µM)	0.05020401
154	Dexamethasone  (µM)	0
154	Ibrutinib (µM)	6.433577
154	Mercaptopurine (µM)	174.0367
154	Nelarabine (µM)	160
154	Panobinostat (nM)	0
154	Prednisolone (µM)	0
154	Ruxolitinib (nM)	20000
154	Thioguanine (µM)	0
154	Trametinib (nM)	0.005
154	Venetoclax (nM)	0.0005
154	Vincristine (µM)	0.025
154	Vorinostat (nM)	188.7978
154	asparagise_normalized	0
154	bortezomib_normalized	0.2127
154	CHZ868_normalized	0.4857
154	dasatinib_normalized	0.9118
154	daunorubicin_normalized	0.3982
154	ibrutinib_normalized	0.4084
154	mercaptopurine_normalized	0.1846
154	nelarabine_normalized	1
154	ruxolitinib_normalized	1
154	trametinib_normalized	0
154	venetoclax_normalized	0
154	vincristine_normalized	0
154	vorinostat_normalized	0.4552
155	immunophenotype	B
155	molecular subtype	Hyperdiploid
155	Protocol	T17
155	NCI risk	SR
155	Age at diagnosis	1.8
155	WBC at diagnosis	8.7
155	Sex	F
155	Genetically-defined race	Asian/Other
155	Asparaginase (IU/ml)	0
155	Bortezomib (nM)	0
155	CHZ868 (nM)	0
155	Cytarabine (µM)	0
155	Dasatinib (nM)	0
155	Daunorubicin (µM)	0
155	Dexamethasone  (µM)	0
155	Ibrutinib (µM)	0
155	Mercaptopurine (µM)	103.2422
155	Nelarabine (µM)	0
155	Panobinostat (nM)	0
155	Prednisolone (µM)	0.1011869
155	Ruxolitinib (nM)	0
155	Thioguanine (µM)	0
155	Trametinib (nM)	0
155	Venetoclax (nM)	0
155	Vincristine (µM)	0
155	Vorinostat (nM)	0
155	mercaptopurine_normalized	0.0339
155	prednisolone_normalized	0.1832
156	immunophenotype	T
156	molecular subtype	T-ALL
156	Protocol	T17
156	NCI risk	HR
156	Age at diagnosis	10.5
156	WBC at diagnosis	304
156	Sex	F
156	Genetically-defined race	black
156	Asparaginase (IU/ml)	0
156	Bortezomib (nM)	0
156	CHZ868 (nM)	6.280239
156	Cytarabine (µM)	0
156	Dasatinib (nM)	7866.178
156	Daunorubicin (µM)	0
156	Dexamethasone  (µM)	0
156	Ibrutinib (µM)	5.19045
156	Mercaptopurine (µM)	0
156	Nelarabine (µM)	0
156	Panobinostat (nM)	0
156	Prednisolone (µM)	0
156	Ruxolitinib (nM)	103.7561
156	Thioguanine (µM)	0
156	Trametinib (nM)	0.005
156	Venetoclax (nM)	0.020355
156	Vincristine (µM)	0
156	Vorinostat (nM)	0
156	CHZ868_normalized	0.3596
156	dasatinib_normalized	0.9792
156	ibrutinib_normalized	0.3464
156	ruxolitinib_normalized	0.6032
156	trametinib_normalized	0
156	venetoclax_normalized	0.2617
157	immunophenotype	B
157	molecular subtype	ETV6-RUNX1
157	Protocol	T17
157	NCI risk	SR
157	Age at diagnosis	4.5
157	WBC at diagnosis	11
157	Sex	F
157	Genetically-defined race	White
157	Asparaginase (IU/ml)	0.0016
157	Bortezomib (nM)	12.94287
157	CHZ868 (nM)	20000
157	Cytarabine (µM)	0
157	Dasatinib (nM)	20000
157	Daunorubicin (µM)	0.0504479
157	Dexamethasone  (µM)	0
157	Ibrutinib (µM)	13.17745
157	Mercaptopurine (µM)	530.4118
157	Nelarabine (µM)	69.36157
157	Panobinostat (nM)	0
157	Prednisolone (µM)	0.04122984
157	Ruxolitinib (nM)	20000
157	Thioguanine (µM)	0
157	Trametinib (nM)	2000
157	Venetoclax (nM)	0.0005
157	Vincristine (µM)	0.1402563
157	Vorinostat (nM)	1204.497
157	asparagise_normalized	0
157	bortezomib_normalized	0.3725
157	CHZ868_normalized	1
157	dasatinib_normalized	1
157	daunorubicin_normalized	0.3989
157	ibrutinib_normalized	0.6152
157	mercaptopurine_normalized	0.5061
157	nelarabine_normalized	0.9794
157	prednisolone_normalized	0.097
157	ruxolitinib_normalized	1
157	trametinib_normalized	1
157	venetoclax_normalized	0
157	vincristine_normalized	0.1476
157	vorinostat_normalized	0.6162
158	immunophenotype	B
158	molecular subtype	Hyperdiploid
158	Protocol	T17
158	NCI risk	SR
158	Age at diagnosis	3.4
158	WBC at diagnosis	4.7
158	Sex	F
158	Genetically-defined race	Hispanic
158	Asparaginase (IU/ml)	0.0016
158	Bortezomib (nM)	55.47268
158	CHZ868 (nM)	0.2376825
158	Cytarabine (µM)	0
158	Dasatinib (nM)	1870.015
158	Daunorubicin (µM)	0.1720461
158	Dexamethasone  (µM)	0
158	Ibrutinib (µM)	5.492719
158	Mercaptopurine (µM)	222.8176
158	Nelarabine (µM)	160
158	Panobinostat (nM)	0
158	Prednisolone (µM)	0.068037231
158	Ruxolitinib (nM)	20000
158	Thioguanine (µM)	0
158	Trametinib (nM)	0.005
158	Venetoclax (nM)	0.0005
158	Vincristine (µM)	44.72036
158	Vorinostat (nM)	133.6568
158	asparagise_normalized	0
158	bortezomib_normalized	0.5826
158	CHZ868_normalized	0.0752
158	dasatinib_normalized	0.8544
158	daunorubicin_normalized	0.5722
158	ibrutinib_normalized	0.3627
158	mercaptopurine_normalized	0.2558
158	nelarabine_normalized	1
158	prednisolone_normalized	0.1451
158	ruxolitinib_normalized	1
158	trametinib_normalized	0
158	venetoclax_normalized	0
158	vincristine_normalized	0.9726
158	vorinostat_normalized	0.4252
159	immunophenotype	B
159	molecular subtype	PAX5alt
159	Protocol	T17
159	NCI risk	HR
159	Age at diagnosis	18.4
159	WBC at diagnosis	3.4
159	Sex	F
159	Genetically-defined race	White
159	Asparaginase (IU/ml)	0.0016
159	Bortezomib (nM)	31.37377
159	CHZ868 (nM)	0
159	Cytarabine (µM)	0
159	Dasatinib (nM)	9076.477859
159	Daunorubicin (µM)	0.090711914
159	Dexamethasone  (µM)	0
159	Ibrutinib (µM)	12.36898
159	Mercaptopurine (µM)	240.8666
159	Nelarabine (µM)	5.414274
159	Panobinostat (nM)	0
159	Prednisolone (µM)	100.2468
159	Ruxolitinib (nM)	20000
159	Thioguanine (µM)	0
159	Trametinib (nM)	10.23927046
159	Venetoclax (nM)	1.839596
159	Vincristine (µM)	0.025
159	Vorinostat (nM)	750.545
159	asparagise_normalized	0
159	bortezomib_normalized	0.5003
159	dasatinib_normalized	0.9916
159	daunorubicin_normalized	0.4818
159	ibrutinib_normalized	0.597
159	mercaptopurine_normalized	0.2783
159	nelarabine_normalized	0.6115
159	prednisolone_normalized	0.8452
159	ruxolitinib_normalized	1
159	trametinib_normalized	0.6021
159	venetoclax_normalized	0.6529
159	vincristine_normalized	0
159	vorinostat_normalized	0.5751
160	immunophenotype	B
160	molecular subtype	Hyperdiploid
160	Protocol	T17
160	NCI risk	SR
160	Age at diagnosis	5.5
160	WBC at diagnosis	3.8
160	Sex	F
160	Genetically-defined race	White
160	Asparaginase (IU/ml)	0.4093149
160	Bortezomib (nM)	9.566203
160	CHZ868 (nM)	0
160	Cytarabine (µM)	0
160	Dasatinib (nM)	20000
160	Daunorubicin (µM)	0.1171476
160	Dexamethasone  (µM)	0
160	Ibrutinib (µM)	11.16408
160	Mercaptopurine (µM)	391.8892
160	Nelarabine (µM)	39.14421261
160	Panobinostat (nM)	0
160	Prednisolone (µM)	0.09176227
160	Ruxolitinib (nM)	0
160	Thioguanine (µM)	0
160	Trametinib (nM)	86.69481158
160	Venetoclax (nM)	0
160	Vincristine (µM)	0.025
160	Vorinostat (nM)	119.858766
160	asparagise_normalized	0.6029
160	bortezomib_normalized	0.3289
160	dasatinib_normalized	1
160	daunorubicin_normalized	0.5179
160	ibrutinib_normalized	0.5674
160	mercaptopurine_normalized	0.4188
160	nelarabine_normalized	0.8969
160	prednisolone_normalized	0.1738
160	trametinib_normalized	0.7876
160	vincristine_normalized	0
160	vorinostat_normalized	0.4157
161	immunophenotype	B
161	molecular subtype	Hyperdiploid
161	Protocol	T17
161	NCI risk	SR
161	Age at diagnosis	2.4
161	WBC at diagnosis	10.4
161	Sex	F
161	Genetically-defined race	Hispanic
161	Asparaginase (IU/ml)	0
161	Bortezomib (nM)	0
161	CHZ868 (nM)	9.217546
161	Cytarabine (µM)	0
161	Dasatinib (nM)	61.0977
161	Daunorubicin (µM)	0
161	Dexamethasone  (µM)	0
161	Ibrutinib (µM)	0.78125
161	Mercaptopurine (µM)	0
161	Nelarabine (µM)	0
161	Panobinostat (nM)	0
161	Prednisolone (µM)	0
161	Ruxolitinib (nM)	20000
161	Thioguanine (µM)	0
161	Trametinib (nM)	0.005
161	Venetoclax (nM)	0.0005
161	Vincristine (µM)	0
161	Vorinostat (nM)	0
161	CHZ868_normalized	0.3929
161	dasatinib_normalized	0.5572
161	ibrutinib_normalized	0
161	ruxolitinib_normalized	1
161	trametinib_normalized	0
161	venetoclax_normalized	0
162	immunophenotype	B
162	molecular subtype	MEF2D
162	Protocol	T17
162	NCI risk	HR
162	Age at diagnosis	11.8
162	WBC at diagnosis	9.4
162	Sex	M
162	Genetically-defined race	black
162	Asparaginase (IU/ml)	0
162	Bortezomib (nM)	0
162	CHZ868 (nM)	11.85324
162	Cytarabine (µM)	0
162	Dasatinib (nM)	97.09099
162	Daunorubicin (µM)	0
162	Dexamethasone  (µM)	0
162	Ibrutinib (µM)	9.052996
162	Mercaptopurine (µM)	0
162	Nelarabine (µM)	0
162	Panobinostat (nM)	0
162	Prednisolone (µM)	0
162	Ruxolitinib (nM)	20000
162	Thioguanine (µM)	0
162	Trametinib (nM)	2000
162	Venetoclax (nM)	8.372778
162	Vincristine (µM)	0
162	Vorinostat (nM)	0
162	CHZ868_normalized	0.4148
162	dasatinib_normalized	0.5974
162	ibrutinib_normalized	0.5069
162	ruxolitinib_normalized	1
162	trametinib_normalized	1
162	venetoclax_normalized	0.7846
163	immunophenotype	B
163	molecular subtype	Hyperdiploid
163	Protocol	T17
163	NCI risk	HR
163	Age at diagnosis	3
163	WBC at diagnosis	56.1
163	Sex	F
163	Genetically-defined race	White
163	Asparaginase (IU/ml)	0.0016
163	Bortezomib (nM)	0
163	CHZ868 (nM)	0
163	Cytarabine (µM)	0
163	Dasatinib (nM)	20000
163	Daunorubicin (µM)	0
163	Dexamethasone  (µM)	0
163	Ibrutinib (µM)	15.35489
163	Mercaptopurine (µM)	332.4853
163	Nelarabine (µM)	0
163	Panobinostat (nM)	0
163	Prednisolone (µM)	0.04262077
163	Ruxolitinib (nM)	0
163	Thioguanine (µM)	0
163	Trametinib (nM)	83.70219
163	Venetoclax (nM)	0
163	Vincristine (µM)	108.34
163	Vorinostat (nM)	0
163	asparagise_normalized	0
163	dasatinib_normalized	1
163	ibrutinib_normalized	0.6594
163	mercaptopurine_normalized	0.3713
163	prednisolone_normalized	0.1002
163	trametinib_normalized	0.7845
163	vincristine_normalized	1
164	immunophenotype	B
164	molecular subtype	ETV6-RUNX1
164	Protocol	T17
164	NCI risk	SR
164	Age at diagnosis	2.7
164	WBC at diagnosis	49.5
164	Sex	M
164	Genetically-defined race	Asian/Other
164	Asparaginase (IU/ml)	0.0016
164	Bortezomib (nM)	0
164	CHZ868 (nM)	0
164	Cytarabine (µM)	0
164	Dasatinib (nM)	3507.618541
164	Daunorubicin (µM)	0
164	Dexamethasone  (µM)	0
164	Ibrutinib (µM)	5.38059
164	Mercaptopurine (µM)	231.572
164	Nelarabine (µM)	77.30363
164	Panobinostat (nM)	0
164	Prednisolone (µM)	0.01887841
164	Ruxolitinib (nM)	0
164	Thioguanine (µM)	0
164	Trametinib (nM)	554.3993
164	Venetoclax (nM)	0.683186
164	Vincristine (µM)	0.1450444
164	Vorinostat (nM)	0
164	asparagise_normalized	0
164	dasatinib_normalized	0.909
164	ibrutinib_normalized	0.3568
164	mercaptopurine_normalized	0.267
164	nelarabine_normalized	0.9951
164	prednisolone_normalized	0.0221
164	trametinib_normalized	0.9488
164	venetoclax_normalized	0.5669
164	vincristine_normalized	0.1524
165	immunophenotype	B
165	molecular subtype	ETV6-RUNX1
165	Protocol	T15
165	NCI risk	SR
165	Age at diagnosis	4.2
165	WBC at diagnosis	24.9
165	Sex	M
165	Genetically-defined race	White
165	Asparaginase (IU/ml)	0
165	Bortezomib (nM)	0
165	CHZ868 (nM)	0
165	Cytarabine (µM)	0
165	Dasatinib (nM)	0
165	Daunorubicin (µM)	0
165	Dexamethasone  (µM)	0.002804291
165	Ibrutinib (µM)	0
165	Mercaptopurine (µM)	1535.796
165	Nelarabine (µM)	0
165	Panobinostat (nM)	0
165	Prednisolone (µM)	0
165	Ruxolitinib (nM)	0
165	Thioguanine (µM)	33.81477
165	Trametinib (nM)	0
165	Venetoclax (nM)	0
165	Vincristine (µM)	0
165	Vorinostat (nM)	0
165	dexamethasone_normalized	0.1999
165	mercaptopurine_normalized	0.8128
165	thioguanine_normalized	0.371
166	immunophenotype	B
166	molecular subtype	Hyperdiploid
166	Protocol	T17
166	NCI risk	SR
166	Age at diagnosis	3.3
166	WBC at diagnosis	19.1
166	Sex	F
166	Genetically-defined race	White
166	Asparaginase (IU/ml)	20
166	Bortezomib (nM)	0
166	CHZ868 (nM)	0
166	Cytarabine (µM)	0
166	Dasatinib (nM)	18.47652
166	Daunorubicin (µM)	0
166	Dexamethasone  (µM)	0
166	Ibrutinib (µM)	2.437595
166	Mercaptopurine (µM)	5876
166	Nelarabine (µM)	160
166	Panobinostat (nM)	0
166	Prednisolone (µM)	1006
166	Ruxolitinib (nM)	0
166	Thioguanine (µM)	0
166	Trametinib (nM)	0.121945
166	Venetoclax (nM)	0.0005
166	Vincristine (µM)	14.61099
166	Vorinostat (nM)	0
166	asparagise_normalized	1
166	dasatinib_normalized	0.4533
166	ibrutinib_normalized	0.1283
166	mercaptopurine_normalized	1
166	nelarabine_normalized	1
166	prednisolone_normalized	1
166	trametinib_normalized	0.2172
166	venetoclax_normalized	0
166	vincristine_normalized	0.8125
167	immunophenotype	B
167	molecular subtype	ETV6-RUNX1
167	Protocol	T17
167	NCI risk	SR
167	Age at diagnosis	1
167	WBC at diagnosis	19.7
167	Sex	F
167	Genetically-defined race	White
167	Asparaginase (IU/ml)	4.931947362
167	Bortezomib (nM)	0
167	CHZ868 (nM)	0
167	Cytarabine (µM)	0
167	Dasatinib (nM)	5923.139
167	Daunorubicin (µM)	0
167	Dexamethasone  (µM)	0
167	Ibrutinib (µM)	11.68784
167	Mercaptopurine (µM)	1179.689
167	Nelarabine (µM)	0
167	Panobinostat (nM)	0
167	Prednisolone (µM)	1006
167	Ruxolitinib (nM)	0
167	Thioguanine (µM)	0
167	Trametinib (nM)	2000
167	Venetoclax (nM)	0.6102656
167	Vincristine (µM)	1.103851
167	Vorinostat (nM)	0
167	asparagise_normalized	0.9122
167	dasatinib_normalized	0.9545
167	ibrutinib_normalized	0.5806
167	mercaptopurine_normalized	0.7367
167	prednisolone_normalized	1
167	trametinib_normalized	1
167	venetoclax_normalized	0.5571
167	vincristine_normalized	0.4428
168	immunophenotype	B
168	molecular subtype	ETV6-RUNX1
168	Protocol	T17
168	NCI risk	HR
168	Age at diagnosis	5.4
168	WBC at diagnosis	119.4
168	Sex	M
168	Genetically-defined race	White
168	Asparaginase (IU/ml)	0.0016
168	Bortezomib (nM)	71.78668
168	CHZ868 (nM)	34.75775
168	Cytarabine (µM)	0
168	Dasatinib (nM)	4419.83
168	Daunorubicin (µM)	0.04275191
168	Dexamethasone  (µM)	0
168	Ibrutinib (µM)	7.700016
168	Mercaptopurine (µM)	45.9
168	Nelarabine (µM)	160
168	Panobinostat (nM)	0
168	Prednisolone (µM)	0.05854743
168	Ruxolitinib (nM)	20000
168	Thioguanine (µM)	0
168	Trametinib (nM)	2000
168	Venetoclax (nM)	0.03905271
168	Vincristine (µM)	0.2355478
168	Vorinostat (nM)	708.2735167
168	asparagise_normalized	0
168	bortezomib_normalized	0.6198
168	CHZ868_normalized	0.5082
168	dasatinib_normalized	0.9291
168	daunorubicin_normalized	0.3755
168	ibrutinib_normalized	0.4602
168	mercaptopurine_normalized	0
168	nelarabine_normalized	1
168	prednisolone_normalized	0.1307
168	ruxolitinib_normalized	1
168	trametinib_normalized	1
168	venetoclax_normalized	0.3183
168	vincristine_normalized	0.2218
168	vorinostat_normalized	0.57
169	immunophenotype	B
169	molecular subtype	Ph-like_non_CRLF2
169	Protocol	T17
169	NCI risk	HR
169	Age at diagnosis	5.7
169	WBC at diagnosis	114
169	Sex	M
169	Genetically-defined race	black
169	Asparaginase (IU/ml)	20
169	Bortezomib (nM)	0
169	CHZ868 (nM)	0
169	Cytarabine (µM)	0
169	Dasatinib (nM)	0
169	Daunorubicin (µM)	0
169	Dexamethasone  (µM)	0
169	Ibrutinib (µM)	0
169	Mercaptopurine (µM)	5876
169	Nelarabine (µM)	0
169	Panobinostat (nM)	0
169	Prednisolone (µM)	1006
169	Ruxolitinib (nM)	0
169	Thioguanine (µM)	0
169	Trametinib (nM)	0
169	Venetoclax (nM)	0
169	Vincristine (µM)	0
169	Vorinostat (nM)	0
169	asparagise_normalized	1
169	mercaptopurine_normalized	1
169	prednisolone_normalized	1
170	immunophenotype	B
170	molecular subtype	ETV6-RUNX1
170	Protocol	T17
170	NCI risk	SR
170	Age at diagnosis	6.7
170	WBC at diagnosis	3.4
170	Sex	F
170	Genetically-defined race	Asian/Other
170	Asparaginase (IU/ml)	0.0016
170	Bortezomib (nM)	0
170	CHZ868 (nM)	0
170	Cytarabine (µM)	0
170	Dasatinib (nM)	124.5135
170	Daunorubicin (µM)	0
170	Dexamethasone  (µM)	0
170	Ibrutinib (µM)	11.01455
170	Mercaptopurine (µM)	169.8026
170	Nelarabine (µM)	0
170	Panobinostat (nM)	0
170	Prednisolone (µM)	0.02039166
170	Ruxolitinib (nM)	0
170	Thioguanine (µM)	0
170	Trametinib (nM)	1.593566
170	Venetoclax (nM)	0.01302098
170	Vincristine (µM)	0.025
170	Vorinostat (nM)	0
170	asparagise_normalized	0
170	dasatinib_normalized	0.619
170	ibrutinib_normalized	0.5635
170	mercaptopurine_normalized	0.1775
170	prednisolone_normalized	0.0295
170	trametinib_normalized	0.4405
170	venetoclax_normalized	0.2229
170	vincristine_normalized	0
171	immunophenotype	B
171	molecular subtype	DUX4
171	Protocol	T17
171	NCI risk	HR
171	Age at diagnosis	13.7
171	WBC at diagnosis	3.8
171	Sex	M
171	Genetically-defined race	White
171	Asparaginase (IU/ml)	20
171	Bortezomib (nM)	15.89337
171	CHZ868 (nM)	26.00889
171	Cytarabine (µM)	0
171	Dasatinib (nM)	20000
171	Daunorubicin (µM)	0.1411344
171	Dexamethasone  (µM)	0
171	Ibrutinib (µM)	5.573514
171	Mercaptopurine (µM)	936.8467
171	Nelarabine (µM)	39.3898
171	Panobinostat (nM)	0
171	Prednisolone (µM)	1006
171	Ruxolitinib (nM)	20000
171	Thioguanine (µM)	0
171	Trametinib (nM)	19.95327
171	Venetoclax (nM)	0.0005
171	Vincristine (µM)	0.025
171	Vorinostat (nM)	995.7856945
171	asparagise_normalized	1
171	bortezomib_normalized	0.4022
171	CHZ868_normalized	0.483
171	dasatinib_normalized	1
171	daunorubicin_normalized	0.5442
171	ibrutinib_normalized	0.3669
171	mercaptopurine_normalized	0.6702
171	nelarabine_normalized	0.8978
171	prednisolone_normalized	1
171	ruxolitinib_normalized	1
171	trametinib_normalized	0.66
171	venetoclax_normalized	0
171	vincristine_normalized	0
171	vorinostat_normalized	0.5996
172	immunophenotype	B
172	molecular subtype	Hyperdiploid
172	Protocol	T17
172	NCI risk	SR
172	Age at diagnosis	1.4
172	WBC at diagnosis	35
172	Sex	M
172	Genetically-defined race	White
172	Asparaginase (IU/ml)	0.0016
172	Bortezomib (nM)	62.43777
172	CHZ868 (nM)	25.23945
172	Cytarabine (µM)	0
172	Dasatinib (nM)	2151.57
172	Daunorubicin (µM)	0.3605594
172	Dexamethasone  (µM)	0
172	Ibrutinib (µM)	16.28252
172	Mercaptopurine (µM)	231.2475
172	Nelarabine (µM)	33.50872
172	Panobinostat (nM)	0
172	Prednisolone (µM)	0.09160893
172	Ruxolitinib (nM)	20000
172	Thioguanine (µM)	0
172	Trametinib (nM)	34.28385
172	Venetoclax (nM)	0.3551312
172	Vincristine (µM)	0.2916599
172	Vorinostat (nM)	974.3668
172	asparagise_normalized	0
172	bortezomib_normalized	0.5997
172	CHZ868_normalized	0.4804
172	dasatinib_normalized	0.8666
172	daunorubicin_normalized	0.6768
172	ibrutinib_normalized	0.6763
172	mercaptopurine_normalized	0.2666
172	nelarabine_normalized	0.8745
172	prednisolone_normalized	0.1736
172	ruxolitinib_normalized	1
172	trametinib_normalized	0.707
172	venetoclax_normalized	0.5101
172	vincristine_normalized	0.2524
172	vorinostat_normalized	0.5977
173	immunophenotype	B
173	molecular subtype	Hyperdiploid
173	Protocol	T17
173	NCI risk	SR
173	Age at diagnosis	1.8
173	WBC at diagnosis	5.7
173	Sex	M
173	Genetically-defined race	White
173	Asparaginase (IU/ml)	0.0016
173	Bortezomib (nM)	39.7694947
173	CHZ868 (nM)	12.57739
173	Cytarabine (µM)	0
173	Dasatinib (nM)	0
173	Daunorubicin (µM)	0.03380109
173	Dexamethasone  (µM)	0
173	Ibrutinib (µM)	0.78125
173	Mercaptopurine (µM)	179.5737
173	Nelarabine (µM)	160
173	Panobinostat (nM)	0
173	Prednisolone (µM)	0.09136263
173	Ruxolitinib (nM)	20000
173	Thioguanine (µM)	0
173	Trametinib (nM)	31.80437
173	Venetoclax (nM)	0.0005
173	Vincristine (µM)	0.025
173	Vorinostat (nM)	335.9072
173	asparagise_normalized	0
173	bortezomib_normalized	0.5345
173	CHZ868_normalized	0.4199
173	daunorubicin_normalized	0.3423
173	ibrutinib_normalized	0
173	mercaptopurine_normalized	0.1936
173	nelarabine_normalized	1
173	prednisolone_normalized	0.1734
173	ruxolitinib_normalized	1
173	trametinib_normalized	0.7005
173	venetoclax_normalized	0
173	vincristine_normalized	0
173	vorinostat_normalized	0.5052
174	immunophenotype	T
174	molecular subtype	ETP
174	Protocol	T17
174	NCI risk	HR
174	Age at diagnosis	14.3
174	WBC at diagnosis	7.9
174	Sex	M
174	Genetically-defined race	White
174	Asparaginase (IU/ml)	0
174	Bortezomib (nM)	41.74703
174	CHZ868 (nM)	0
174	Cytarabine (µM)	0
174	Dasatinib (nM)	20000
174	Daunorubicin (µM)	0.1591135
174	Dexamethasone  (µM)	0
174	Ibrutinib (µM)	0
174	Mercaptopurine (µM)	5876
174	Nelarabine (µM)	27.22931
174	Panobinostat (nM)	0
174	Prednisolone (µM)	1006
174	Ruxolitinib (nM)	0
174	Thioguanine (µM)	0
174	Trametinib (nM)	0
174	Venetoclax (nM)	0
174	Vincristine (µM)	0
174	Vorinostat (nM)	5492.362
174	bortezomib_normalized	0.5415
174	dasatinib_normalized	1
174	daunorubicin_normalized	0.5612
174	mercaptopurine_normalized	1
174	nelarabine_normalized	0.8445
174	prednisolone_normalized	1
174	vorinostat_normalized	0.748
175	immunophenotype	B
175	molecular subtype	Ph-like_CRLF2
175	Protocol	T17
175	NCI risk	SR
175	Age at diagnosis	2.7
175	WBC at diagnosis	5.4
175	Sex	F
175	Genetically-defined race	White
175	Asparaginase (IU/ml)	0.0354217
175	Bortezomib (nM)	10.30065
175	CHZ868 (nM)	12.90609
175	Cytarabine (µM)	0
175	Dasatinib (nM)	5.220371
175	Daunorubicin (µM)	0.023497764
175	Dexamethasone  (µM)	0
175	Ibrutinib (µM)	4.651039
175	Mercaptopurine (µM)	342.0237
175	Nelarabine (µM)	15.20104
175	Panobinostat (nM)	0
175	Prednisolone (µM)	0.0075
175	Ruxolitinib (nM)	5238.841
175	Thioguanine (µM)	0
175	Trametinib (nM)	0.4726407
175	Venetoclax (nM)	0.428981372
175	Vincristine (µM)	0.025
175	Vorinostat (nM)	334.5882
175	asparagise_normalized	0.2988
175	bortezomib_normalized	0.3396
175	CHZ868_normalized	0.4222
175	dasatinib_normalized	0.3435
175	daunorubicin_normalized	0.2909
175	ibrutinib_normalized	0.3147
175	mercaptopurine_normalized	0.3795
175	nelarabine_normalized	0.7604
175	prednisolone_normalized	0
175	ruxolitinib_normalized	0.9438
175	trametinib_normalized	0.3349
175	venetoclax_normalized	0.5265
175	vincristine_normalized	0
175	vorinostat_normalized	0.5049
176	immunophenotype	B
176	molecular subtype	Hyperdiploid
176	Protocol	T17
176	NCI risk	SR
176	Age at diagnosis	2.2
176	WBC at diagnosis	34.7
176	Sex	F
176	Genetically-defined race	White
176	Asparaginase (IU/ml)	0.0016
176	Bortezomib (nM)	13.72742
176	CHZ868 (nM)	104.6076
176	Cytarabine (µM)	0
176	Dasatinib (nM)	685.2047
176	Daunorubicin (µM)	0.0786091
176	Dexamethasone  (µM)	0
176	Ibrutinib (µM)	11.18385
176	Mercaptopurine (µM)	596.0814049
176	Nelarabine (µM)	160
176	Panobinostat (nM)	0
176	Prednisolone (µM)	0.0932878
176	Ruxolitinib (nM)	20000
176	Thioguanine (µM)	0
176	Trametinib (nM)	3.348416
176	Venetoclax (nM)	0.7403124
176	Vincristine (µM)	17.43835
176	Vorinostat (nM)	524.2329
176	asparagise_normalized	0
176	bortezomib_normalized	0.381
176	CHZ868_normalized	0.6039
176	dasatinib_normalized	0.7672
176	daunorubicin_normalized	0.4615
176	ibrutinib_normalized	0.5679
176	mercaptopurine_normalized	0.5398
176	nelarabine_normalized	1
176	prednisolone_normalized	0.1754
176	ruxolitinib_normalized	1
176	trametinib_normalized	0.505
176	venetoclax_normalized	0.5739
176	vincristine_normalized	0.8378
176	vorinostat_normalized	0.5439
177	immunophenotype	B
177	molecular subtype	ETV6-RUNX1
177	Protocol	T17
177	NCI risk	SR
177	Age at diagnosis	2.6
177	WBC at diagnosis	20.7
177	Sex	M
177	Genetically-defined race	White
177	Asparaginase (IU/ml)	0.01007572
177	Bortezomib (nM)	302.9856
177	CHZ868 (nM)	0
177	Cytarabine (µM)	0
177	Dasatinib (nM)	0
177	Daunorubicin (µM)	0.5010415
177	Dexamethasone  (µM)	0
177	Ibrutinib (µM)	0
177	Mercaptopurine (µM)	1583.699
177	Nelarabine (µM)	160
177	Panobinostat (nM)	0
177	Prednisolone (µM)	0.1126667
177	Ruxolitinib (nM)	0
177	Thioguanine (µM)	0
177	Trametinib (nM)	0
177	Venetoclax (nM)	0
177	Vincristine (µM)	8.317728
177	Vorinostat (nM)	5089.796
177	asparagise_normalized	0.1425
177	bortezomib_normalized	0.8276
177	daunorubicin_normalized	0.7233
177	mercaptopurine_normalized	0.8217
177	nelarabine_normalized	1
177	prednisolone_normalized	0.1935
177	vincristine_normalized	0.7319
177	vorinostat_normalized	0.7413
178	immunophenotype	B
178	molecular subtype	DUX4
178	Protocol	T17
178	NCI risk	SR
178	Age at diagnosis	8
178	WBC at diagnosis	13.9
178	Sex	F
178	Genetically-defined race	White
178	Asparaginase (IU/ml)	0.5531997
178	Bortezomib (nM)	7.527651
178	CHZ868 (nM)	0
178	Cytarabine (µM)	0
178	Dasatinib (nM)	944.1050686
178	Daunorubicin (µM)	0.1102944
178	Dexamethasone  (µM)	0
178	Ibrutinib (µM)	8.232979
178	Mercaptopurine (µM)	336.5079462
178	Nelarabine (µM)	160
178	Panobinostat (nM)	0
178	Prednisolone (µM)	1006
178	Ruxolitinib (nM)	0
178	Thioguanine (µM)	0
178	Trametinib (nM)	0
178	Venetoclax (nM)	4.522333
178	Vincristine (µM)	0.025
178	Vorinostat (nM)	891.8202
178	asparagise_normalized	0.6403
178	bortezomib_normalized	0.2943
178	dasatinib_normalized	0.795
178	daunorubicin_normalized	0.5094
178	ibrutinib_normalized	0.4795
178	mercaptopurine_normalized	0.3748
178	nelarabine_normalized	1
178	prednisolone_normalized	1
178	venetoclax_normalized	0.7311
178	vincristine_normalized	0
178	vorinostat_normalized	0.5901
179	immunophenotype	B
179	molecular subtype	PAX5alt
179	Protocol	T17
179	NCI risk	SR
179	Age at diagnosis	2.7
179	WBC at diagnosis	14.4
179	Sex	M
179	Genetically-defined race	White
179	Asparaginase (IU/ml)	7.182271332
179	Bortezomib (nM)	7.263771
179	CHZ868 (nM)	994.2782
179	Cytarabine (µM)	0
179	Dasatinib (nM)	1208.098
179	Daunorubicin (µM)	0.1648579
179	Dexamethasone  (µM)	0
179	Ibrutinib (µM)	21.19569
179	Mercaptopurine (µM)	1326.914
179	Nelarabine (µM)	53.58935
179	Panobinostat (nM)	0
179	Prednisolone (µM)	6.725612
179	Ruxolitinib (nM)	20000
179	Thioguanine (µM)	0
179	Trametinib (nM)	46.60177
179	Venetoclax (nM)	1.656303987
179	Vincristine (µM)	0.025
179	Vorinostat (nM)	610.0108
179	asparagise_normalized	0.9589
179	bortezomib_normalized	0.2891
179	CHZ868_normalized	0.7995
179	dasatinib_normalized	0.8164
179	daunorubicin_normalized	0.5662
179	ibrutinib_normalized	0.7524
179	mercaptopurine_normalized	0.7707
179	nelarabine_normalized	0.9422
179	prednisolone_normalized	0.5859
179	ruxolitinib_normalized	1
179	trametinib_normalized	0.7337
179	venetoclax_normalized	0.6438
179	vincristine_normalized	0
179	vorinostat_normalized	0.5571
180	immunophenotype	B
180	molecular subtype	Ph-like_CRLF2
180	Protocol	T17
180	NCI risk	SR
180	Age at diagnosis	6.5
180	WBC at diagnosis	10.8
180	Sex	M
180	Genetically-defined race	White
180	Asparaginase (IU/ml)	0.2237155
180	Bortezomib (nM)	0
180	CHZ868 (nM)	0
180	Cytarabine (µM)	0
180	Dasatinib (nM)	20000
180	Daunorubicin (µM)	0
180	Dexamethasone  (µM)	0
180	Ibrutinib (µM)	17.40572
180	Mercaptopurine (µM)	560.1333
180	Nelarabine (µM)	0
180	Panobinostat (nM)	0
180	Prednisolone (µM)	78.10722
180	Ruxolitinib (nM)	0
180	Thioguanine (µM)	0
180	Trametinib (nM)	459.7397
180	Venetoclax (nM)	0
180	Vincristine (µM)	0.1353525
180	Vorinostat (nM)	0
180	asparagise_normalized	0.5278
180	dasatinib_normalized	1
180	ibrutinib_normalized	0.6955
180	mercaptopurine_normalized	0.5218
180	prednisolone_normalized	0.8213
180	trametinib_normalized	0.9325
180	vincristine_normalized	0.1425
181	immunophenotype	T
181	molecular subtype	T-ALL
181	Protocol	T17
181	NCI risk	HR
181	Age at diagnosis	10.7
181	WBC at diagnosis	183
181	Sex	M
181	Genetically-defined race	White
181	Asparaginase (IU/ml)	0.0016
181	Bortezomib (nM)	498.6947
181	CHZ868 (nM)	0
181	Cytarabine (µM)	0
181	Dasatinib (nM)	5795.450309
181	Daunorubicin (µM)	0.3989206
181	Dexamethasone  (µM)	0
181	Ibrutinib (µM)	14.4743
181	Mercaptopurine (µM)	286.4285
181	Nelarabine (µM)	15.39938
181	Panobinostat (nM)	0
181	Prednisolone (µM)	0.1249491
181	Ruxolitinib (nM)	0
181	Thioguanine (µM)	0
181	Trametinib (nM)	2000
181	Venetoclax (nM)	0.006345225
181	Vincristine (µM)	0.4045873
181	Vorinostat (nM)	494.6384
181	asparagise_normalized	0
181	bortezomib_normalized	0.8996
181	dasatinib_normalized	0.9526
181	daunorubicin_normalized	0.6911
181	ibrutinib_normalized	0.6423
181	mercaptopurine_normalized	0.3283
181	nelarabine_normalized	0.7623
181	prednisolone_normalized	0.2034
181	trametinib_normalized	1
181	venetoclax_normalized	0.1605
181	vincristine_normalized	0.2992
181	vorinostat_normalized	0.5389
182	immunophenotype	B
182	molecular subtype	Ph-like_CRLF2
182	Protocol	T17
182	NCI risk	HR
182	Age at diagnosis	16.5
182	WBC at diagnosis	51.1
182	Sex	M
182	Genetically-defined race	White
182	Asparaginase (IU/ml)	0
182	Bortezomib (nM)	0
182	CHZ868 (nM)	57.11232
182	Cytarabine (µM)	0
182	Dasatinib (nM)	2939.433
182	Daunorubicin (µM)	0
182	Dexamethasone  (µM)	0
182	Ibrutinib (µM)	7.051708
182	Mercaptopurine (µM)	0
182	Nelarabine (µM)	0
182	Panobinostat (nM)	0
182	Prednisolone (µM)	0
182	Ruxolitinib (nM)	20000
182	Thioguanine (µM)	0
182	Trametinib (nM)	0.005
182	Venetoclax (nM)	0.1503464
182	Vincristine (µM)	0
182	Vorinostat (nM)	0
182	CHZ868_normalized	0.5513
182	dasatinib_normalized	0.8937
182	ibrutinib_normalized	0.4348
182	ruxolitinib_normalized	1
182	trametinib_normalized	0
182	venetoclax_normalized	0.4354
183	immunophenotype	T
183	molecular subtype	T-ALL
183	Protocol	T17
183	NCI risk	HR
183	Age at diagnosis	10.6
183	WBC at diagnosis	328.2
183	Sex	F
183	Genetically-defined race	Asian/Other
183	Asparaginase (IU/ml)	0.0016
183	Bortezomib (nM)	120.3404
183	CHZ868 (nM)	0
183	Cytarabine (µM)	0
183	Dasatinib (nM)	0
183	Daunorubicin (µM)	0.1366661
183	Dexamethasone  (µM)	0
183	Ibrutinib (µM)	0
183	Mercaptopurine (µM)	147.7678
183	Nelarabine (µM)	11.3803321
183	Panobinostat (nM)	0
183	Prednisolone (µM)	0.1108734
183	Ruxolitinib (nM)	0
183	Thioguanine (µM)	0
183	Trametinib (nM)	0
183	Venetoclax (nM)	0
183	Vincristine (µM)	0.8212852
183	Vorinostat (nM)	1199.641
183	asparagise_normalized	0
183	bortezomib_normalized	0.6944
183	daunorubicin_normalized	0.5397
183	mercaptopurine_normalized	0.1373
183	nelarabine_normalized	0.7187
183	prednisolone_normalized	0.192
183	vincristine_normalized	0.4005
183	vorinostat_normalized	0.6158
184	immunophenotype	B
184	molecular subtype	B-other
184	Protocol	T17
184	NCI risk	HR
184	Age at diagnosis	3.3
184	WBC at diagnosis	111.8
184	Sex	M
184	Genetically-defined race	Hispanic
184	Asparaginase (IU/ml)	0.0016
184	Bortezomib (nM)	228.9162
184	CHZ868 (nM)	0.05
184	Cytarabine (µM)	0
184	Dasatinib (nM)	261.8337
184	Daunorubicin (µM)	0.494501
184	Dexamethasone  (µM)	0
184	Ibrutinib (µM)	8.401461
184	Mercaptopurine (µM)	391.1368
184	Nelarabine (µM)	160
184	Panobinostat (nM)	0
184	Prednisolone (µM)	0.025678851
184	Ruxolitinib (nM)	20000
184	Thioguanine (µM)	0
184	Trametinib (nM)	0.4171425
184	Venetoclax (nM)	0.0005
184	Vincristine (µM)	0.1532317
184	Vorinostat (nM)	191.1381
184	asparagise_normalized	0
184	bortezomib_normalized	0.7872
184	CHZ868_normalized	0
184	dasatinib_normalized	0.6836
184	daunorubicin_normalized	0.7214
184	ibrutinib_normalized	0.4854
184	mercaptopurine_normalized	0.4182
184	nelarabine_normalized	1
184	prednisolone_normalized	0.0516
184	ruxolitinib_normalized	1
184	trametinib_normalized	0.3241
184	venetoclax_normalized	0
184	vincristine_normalized	0.1603
184	vorinostat_normalized	0.4563
185	immunophenotype	T
185	molecular subtype	T-ALL
185	Protocol	T15
185	NCI risk	HR
185	Age at diagnosis	8.6
185	WBC at diagnosis	142.6
185	Sex	F
185	Genetically-defined race	black
185	Asparaginase (IU/ml)	0.09141634
185	Bortezomib (nM)	0
185	CHZ868 (nM)	0
185	Cytarabine (µM)	0.04101213
185	Dasatinib (nM)	0
185	Daunorubicin (µM)	0
185	Dexamethasone  (µM)	0.208717462
185	Ibrutinib (µM)	0
185	Mercaptopurine (µM)	0
185	Nelarabine (µM)	0
185	Panobinostat (nM)	0
185	Prednisolone (µM)	4.922034
185	Ruxolitinib (nM)	0
185	Thioguanine (µM)	31.08493
185	Trametinib (nM)	0
185	Venetoclax (nM)	0
185	Vincristine (µM)	0.7757156
185	Vorinostat (nM)	0
185	asparagise_normalized	0.4166
185	cytarabine_normalized	0.0036
185	dexamethasone_normalized	0.614
185	prednisolone_normalized	0.556
185	thioguanine_normalized	0.3467
185	vincristine_normalized	0.3924
186	immunophenotype	B
186	molecular subtype	B-other
186	Protocol	T17
186	NCI risk	HR
186	Age at diagnosis	11.7
186	WBC at diagnosis	157
186	Sex	M
186	Genetically-defined race	White
186	Asparaginase (IU/ml)	0
186	Bortezomib (nM)	0
186	CHZ868 (nM)	57.35983
186	Cytarabine (µM)	0
186	Dasatinib (nM)	0.05
186	Daunorubicin (µM)	0
186	Dexamethasone  (µM)	0
186	Ibrutinib (µM)	12.10342
186	Mercaptopurine (µM)	0
186	Nelarabine (µM)	0
186	Panobinostat (nM)	0
186	Prednisolone (µM)	0
186	Ruxolitinib (nM)	20000
186	Thioguanine (µM)	0
186	Trametinib (nM)	0.005
186	Venetoclax (nM)	0.0005
186	Vincristine (µM)	0
186	Vorinostat (nM)	0
186	CHZ868_normalized	0.5517
186	dasatinib_normalized	0
186	ibrutinib_normalized	0.5907
186	ruxolitinib_normalized	1
186	trametinib_normalized	0
186	venetoclax_normalized	0
187	immunophenotype	B
187	molecular subtype	Hyperdiploid
187	Protocol	T17
187	NCI risk	SR
187	Age at diagnosis	3.6
187	WBC at diagnosis	10.7
187	Sex	F
187	Genetically-defined race	White
187	Asparaginase (IU/ml)	0.0016
187	Bortezomib (nM)	80.87301
187	CHZ868 (nM)	4.25796
187	Cytarabine (µM)	0
187	Dasatinib (nM)	20000
187	Daunorubicin (µM)	0.2540785
187	Dexamethasone  (µM)	0
187	Ibrutinib (µM)	15.09294
187	Mercaptopurine (µM)	465.751
187	Nelarabine (µM)	160
187	Panobinostat (nM)	0
187	Prednisolone (µM)	0.1319525
187	Ruxolitinib (nM)	20000
187	Thioguanine (µM)	0
187	Trametinib (nM)	2000
187	Venetoclax (nM)	0.004257001
187	Vincristine (µM)	0.1479872
187	Vorinostat (nM)	2212.722
187	asparagise_normalized	0
187	bortezomib_normalized	0.637
187	CHZ868_normalized	0.3258
187	dasatinib_normalized	1
187	daunorubicin_normalized	0.6273
187	ibrutinib_normalized	0.6544
187	mercaptopurine_normalized	0.4686
187	nelarabine_normalized	1
187	prednisolone_normalized	0.2087
187	ruxolitinib_normalized	1
187	trametinib_normalized	1
187	venetoclax_normalized	0.1258
187	vincristine_normalized	0.1553
187	vorinostat_normalized	0.669
188	immunophenotype	B
188	molecular subtype	B-other
188	Protocol	T17
188	NCI risk	SR
188	Age at diagnosis	6.3
188	WBC at diagnosis	23.5
188	Sex	F
188	Genetically-defined race	Hispanic
188	Asparaginase (IU/ml)	1.043003
188	Bortezomib (nM)	283.8467
188	CHZ868 (nM)	11.8763
188	Cytarabine (µM)	0
188	Dasatinib (nM)	6011.764
188	Daunorubicin (µM)	0.1239185
188	Dexamethasone  (µM)	0
188	Ibrutinib (µM)	6.261226
188	Mercaptopurine (µM)	847.6985
188	Nelarabine (µM)	160
188	Panobinostat (nM)	0
188	Prednisolone (µM)	1006
188	Ruxolitinib (nM)	20000
188	Thioguanine (µM)	0
188	Trametinib (nM)	2000
188	Venetoclax (nM)	0.0005
188	Vincristine (µM)	0.1023009
188	Vorinostat (nM)	1328.184674
188	asparagise_normalized	0.7191
188	bortezomib_normalized	0.8182
188	CHZ868_normalized	0.4149
188	dasatinib_normalized	0.9558
188	daunorubicin_normalized	0.5259
188	ibrutinib_normalized	0.4005
188	mercaptopurine_normalized	0.6414
188	nelarabine_normalized	1
188	prednisolone_normalized	1
188	ruxolitinib_normalized	1
188	trametinib_normalized	1
188	venetoclax_normalized	0
188	vincristine_normalized	0.1024
188	vorinostat_normalized	0.6247
189	immunophenotype	T
189	molecular subtype	T-ALL
189	Protocol	T15
189	NCI risk	HR
189	Age at diagnosis	8.9
189	WBC at diagnosis	52
189	Sex	M
189	Genetically-defined race	Asian/Other
189	Asparaginase (IU/ml)	0.5648468
189	Bortezomib (nM)	0
189	CHZ868 (nM)	0
189	Cytarabine (µM)	0.02682564
189	Dasatinib (nM)	0
189	Daunorubicin (µM)	0
189	Dexamethasone  (µM)	23.2
189	Ibrutinib (µM)	0
189	Mercaptopurine (µM)	1309.382
189	Nelarabine (µM)	0
189	Panobinostat (nM)	0
189	Prednisolone (µM)	1006
189	Ruxolitinib (nM)	0
189	Thioguanine (µM)	16.27776
189	Trametinib (nM)	0
189	Venetoclax (nM)	0
189	Vincristine (µM)	2.505731227
189	Vorinostat (nM)	0
189	asparagise_normalized	0.6429
189	cytarabine_normalized	0
189	dexamethasone_normalized	1
189	mercaptopurine_normalized	0.7668
189	prednisolone_normalized	1
189	thioguanine_normalized	0.16
189	vincristine_normalized	0.5602
190	immunophenotype	B
190	molecular subtype	B-other
190	Protocol	T17
190	NCI risk	HR
190	Age at diagnosis	9.5
190	WBC at diagnosis	65.9
190	Sex	M
190	Genetically-defined race	Hispanic
190	Asparaginase (IU/ml)	0
190	Bortezomib (nM)	0
190	CHZ868 (nM)	0.05
190	Cytarabine (µM)	0
190	Dasatinib (nM)	20000
190	Daunorubicin (µM)	0
190	Dexamethasone  (µM)	0
190	Ibrutinib (µM)	26.61154
190	Mercaptopurine (µM)	0
190	Nelarabine (µM)	0
190	Panobinostat (nM)	0
190	Prednisolone (µM)	0
190	Ruxolitinib (nM)	0
190	Thioguanine (µM)	0
190	Trametinib (nM)	175.9130042
190	Venetoclax (nM)	0.0005
190	Vincristine (µM)	0
190	Vorinostat (nM)	0
190	CHZ868_normalized	0
190	dasatinib_normalized	1
190	ibrutinib_normalized	0.818
190	trametinib_normalized	0.8491
190	venetoclax_normalized	0
191	immunophenotype	B
191	molecular subtype	ETV6-RUNX1
191	Protocol	T17
191	NCI risk	SR
191	Age at diagnosis	3
191	WBC at diagnosis	9.3
191	Sex	F
191	Genetically-defined race	White
191	Asparaginase (IU/ml)	0.0016
191	Bortezomib (nM)	20.2937
191	CHZ868 (nM)	3194.632
191	Cytarabine (µM)	0
191	Dasatinib (nM)	20000
191	Daunorubicin (µM)	0.2392627
191	Dexamethasone  (µM)	0
191	Ibrutinib (µM)	21.2679
191	Mercaptopurine (µM)	320.6556
191	Nelarabine (µM)	160
191	Panobinostat (nM)	0
191	Prednisolone (µM)	0.09565477
191	Ruxolitinib (nM)	80.31718
191	Thioguanine (µM)	0
191	Trametinib (nM)	2000
191	Venetoclax (nM)	0.006357403
191	Vincristine (µM)	0.401513
191	Vorinostat (nM)	8280.588326
191	asparagise_normalized	0
191	bortezomib_normalized	0.4374
191	CHZ868_normalized	0.9009
191	dasatinib_normalized	1
191	daunorubicin_normalized	0.6188
191	ibrutinib_normalized	0.7533
191	mercaptopurine_normalized	0.3609
191	nelarabine_normalized	1
191	prednisolone_normalized	0.1778
191	ruxolitinib_normalized	0.581
191	trametinib_normalized	1
191	venetoclax_normalized	0.1607
191	vincristine_normalized	0.2981
191	vorinostat_normalized	0.7836
192	immunophenotype	B
192	molecular subtype	DUX4
192	Protocol	T17
192	NCI risk	HR
192	Age at diagnosis	12.8
192	WBC at diagnosis	3.2
192	Sex	F
192	Genetically-defined race	Hispanic
192	Asparaginase (IU/ml)	0
192	Bortezomib (nM)	0
192	CHZ868 (nM)	0
192	Cytarabine (µM)	0
192	Dasatinib (nM)	20000
192	Daunorubicin (µM)	0
192	Dexamethasone  (µM)	0
192	Ibrutinib (µM)	0
192	Mercaptopurine (µM)	0
192	Nelarabine (µM)	0
192	Panobinostat (nM)	0
192	Prednisolone (µM)	0
192	Ruxolitinib (nM)	0
192	Thioguanine (µM)	0
192	Trametinib (nM)	0
192	Venetoclax (nM)	0
192	Vincristine (µM)	0
192	Vorinostat (nM)	0
192	dasatinib_normalized	1
193	immunophenotype	B
193	molecular subtype	B-other
193	Protocol	T17
193	NCI risk	HR
193	Age at diagnosis	14.6
193	WBC at diagnosis	77.3
193	Sex	M
193	Genetically-defined race	White
193	Asparaginase (IU/ml)	0
193	Bortezomib (nM)	0
193	CHZ868 (nM)	11.91456
193	Cytarabine (µM)	0
193	Dasatinib (nM)	20000
193	Daunorubicin (µM)	0
193	Dexamethasone  (µM)	0
193	Ibrutinib (µM)	13.78526
193	Mercaptopurine (µM)	0
193	Nelarabine (µM)	0
193	Panobinostat (nM)	0
193	Prednisolone (µM)	0
193	Ruxolitinib (nM)	0
193	Thioguanine (µM)	0
193	Trametinib (nM)	0.005
193	Venetoclax (nM)	0.0005
193	Vincristine (µM)	0
193	Vorinostat (nM)	0
193	CHZ868_normalized	0.4152
193	dasatinib_normalized	1
193	ibrutinib_normalized	0.6282
193	trametinib_normalized	0
193	venetoclax_normalized	0
194	immunophenotype	B
194	molecular subtype	Ph-like_CRLF2
194	Protocol	T17
194	NCI risk	HR
194	Age at diagnosis	9.8
194	WBC at diagnosis	50.4
194	Sex	F
194	Genetically-defined race	Hispanic
194	Asparaginase (IU/ml)	0
194	Bortezomib (nM)	0
194	CHZ868 (nM)	10.52042
194	Cytarabine (µM)	0
194	Dasatinib (nM)	1052.162
194	Daunorubicin (µM)	0
194	Dexamethasone  (µM)	0
194	Ibrutinib (µM)	6.50114
194	Mercaptopurine (µM)	0
194	Nelarabine (µM)	0
194	Panobinostat (nM)	0
194	Prednisolone (µM)	0
194	Ruxolitinib (nM)	0
194	Thioguanine (µM)	0
194	Trametinib (nM)	24.45337
194	Venetoclax (nM)	0.1870012
194	Vincristine (µM)	0
194	Vorinostat (nM)	0
194	CHZ868_normalized	0.4044
194	dasatinib_normalized	0.8044
194	ibrutinib_normalized	0.4114
194	trametinib_normalized	0.6777
194	venetoclax_normalized	0.4544
195	immunophenotype	T
195	molecular subtype	ETP
195	Protocol	T17
195	NCI risk	HR
195	Age at diagnosis	10.4
195	WBC at diagnosis	113.6
195	Sex	M
195	Genetically-defined race	White
195	Asparaginase (IU/ml)	0
195	Bortezomib (nM)	0
195	CHZ868 (nM)	0
195	Cytarabine (µM)	0
195	Dasatinib (nM)	2337.613
195	Daunorubicin (µM)	0
195	Dexamethasone  (µM)	0
195	Ibrutinib (µM)	13.0039
195	Mercaptopurine (µM)	0
195	Nelarabine (µM)	0
195	Panobinostat (nM)	0
195	Prednisolone (µM)	0
195	Ruxolitinib (nM)	0
195	Thioguanine (µM)	0
195	Trametinib (nM)	2000
195	Venetoclax (nM)	0.4715062
195	Vincristine (µM)	0
195	Vorinostat (nM)	0
195	dasatinib_normalized	0.8738
195	ibrutinib_normalized	0.6114
195	trametinib_normalized	1
195	venetoclax_normalized	0.5347
196	immunophenotype	B
196	molecular subtype	B-other
196	Protocol	T17
196	NCI risk	HR
196	Age at diagnosis	15.8
196	WBC at diagnosis	34.9
196	Sex	M
196	Genetically-defined race	Asian/Other
196	Asparaginase (IU/ml)	9.147212
196	Bortezomib (nM)	18.9124626
196	CHZ868 (nM)	20000
196	Cytarabine (µM)	0
196	Dasatinib (nM)	7201.377
196	Daunorubicin (µM)	0.08285801
196	Dexamethasone  (µM)	0
196	Ibrutinib (µM)	23.40408159
196	Mercaptopurine (µM)	376.4615
196	Nelarabine (µM)	160
196	Panobinostat (nM)	0
196	Prednisolone (µM)	0.1157079
196	Ruxolitinib (nM)	0
196	Thioguanine (µM)	0
196	Trametinib (nM)	2000
196	Venetoclax (nM)	0.2231241
196	Vincristine (µM)	0.07344046
196	Vorinostat (nM)	132.2246
196	asparagise_normalized	0.9889
196	bortezomib_normalized	0.4273
196	CHZ868_normalized	1
196	dasatinib_normalized	0.9715
196	daunorubicin_normalized	0.469
196	ibrutinib_normalized	0.781
196	mercaptopurine_normalized	0.4072
196	nelarabine_normalized	1
196	prednisolone_normalized	0.1961
196	trametinib_normalized	1
196	venetoclax_normalized	0.4697
196	vincristine_normalized	0.055
196	vorinostat_normalized	0.4243
197	immunophenotype	B
197	molecular subtype	BCR-ABL1
197	Protocol	T17
197	NCI risk	HR
197	Age at diagnosis	2.5
197	WBC at diagnosis	627.4
197	Sex	M
197	Genetically-defined race	Hispanic
197	Asparaginase (IU/ml)	1.291137
197	Bortezomib (nM)	55.28492
197	CHZ868 (nM)	34.80154
197	Cytarabine (µM)	0
197	Dasatinib (nM)	0.5412867
197	Daunorubicin (µM)	0.09286408
197	Dexamethasone  (µM)	0
197	Ibrutinib (µM)	2.132461
197	Mercaptopurine (µM)	2036.602
197	Nelarabine (µM)	36.37378
197	Panobinostat (nM)	0
197	Prednisolone (µM)	3.986418
197	Ruxolitinib (nM)	0
197	Thioguanine (µM)	0
197	Trametinib (nM)	22.80013
197	Venetoclax (nM)	0.0005
197	Vincristine (µM)	0.02473075
197	Vorinostat (nM)	127.8043
197	asparagise_normalized	0.7456
197	bortezomib_normalized	0.5821
197	CHZ868_normalized	0.5083
197	dasatinib_normalized	0.1467
197	daunorubicin_normalized	0.4851
197	ibrutinib_normalized	0.0897
197	mercaptopurine_normalized	0.8943
197	nelarabine_normalized	0.8863
197	prednisolone_normalized	0.5357
197	trametinib_normalized	0.6716
197	venetoclax_normalized	0
197	vincristine_normalized	0
197	vorinostat_normalized	0.4213
198	immunophenotype	B
198	molecular subtype	ETV6-RUNX1
198	Protocol	T17
198	NCI risk	SR
198	Age at diagnosis	5.7
198	WBC at diagnosis	41.6
198	Sex	M
198	Genetically-defined race	Hispanic
198	Asparaginase (IU/ml)	0
198	Bortezomib (nM)	0
198	CHZ868 (nM)	57.08057
198	Cytarabine (µM)	0
198	Dasatinib (nM)	3943.276
198	Daunorubicin (µM)	0
198	Dexamethasone  (µM)	0
198	Ibrutinib (µM)	11.18893
198	Mercaptopurine (µM)	0
198	Nelarabine (µM)	0
198	Panobinostat (nM)	0
198	Prednisolone (µM)	0
198	Ruxolitinib (nM)	0
198	Thioguanine (µM)	0
198	Trametinib (nM)	2000
198	Venetoclax (nM)	0.0005
198	Vincristine (µM)	0
198	Vorinostat (nM)	0
198	CHZ868_normalized	0.5513
198	dasatinib_normalized	0.9192
198	ibrutinib_normalized	0.568
198	trametinib_normalized	1
198	venetoclax_normalized	0
199	immunophenotype	B
199	molecular subtype	ETV6-RUNX1
199	Protocol	T17
199	NCI risk	SR
199	Age at diagnosis	4.3
199	WBC at diagnosis	34.6
199	Sex	F
199	Genetically-defined race	White
199	Asparaginase (IU/ml)	0.2064809
199	Bortezomib (nM)	125.3898
199	CHZ868 (nM)	20000
199	Cytarabine (µM)	0
199	Dasatinib (nM)	20000
199	Daunorubicin (µM)	0.115884
199	Dexamethasone  (µM)	0
199	Ibrutinib (µM)	23.099
199	Mercaptopurine (µM)	1993.549
199	Nelarabine (µM)	78.5624
199	Panobinostat (nM)	0
199	Prednisolone (µM)	0.1618611
199	Ruxolitinib (nM)	0
199	Thioguanine (µM)	0
199	Trametinib (nM)	2000
199	Venetoclax (nM)	2.509672
199	Vincristine (µM)	0.2088671
199	Vorinostat (nM)	1274.283
199	asparagise_normalized	0.5178
199	bortezomib_normalized	0.7003
199	CHZ868_normalized	1
199	dasatinib_normalized	1
199	daunorubicin_normalized	0.5164
199	ibrutinib_normalized	0.7772
199	mercaptopurine_normalized	0.8881
199	nelarabine_normalized	0.9974
199	prednisolone_normalized	0.2283
199	trametinib_normalized	1
199	venetoclax_normalized	0.6799
199	vincristine_normalized	0.2046
199	vorinostat_normalized	0.6211
200	immunophenotype	B
200	molecular subtype	TCF3-PBX1
200	Protocol	T17
200	NCI risk	SR
200	Age at diagnosis	7.8
200	WBC at diagnosis	17.6
200	Sex	M
200	Genetically-defined race	Asian/Other
200	Asparaginase (IU/ml)	0.05054351
200	Bortezomib (nM)	31.82407
200	CHZ868 (nM)	0
200	Cytarabine (µM)	0
200	Dasatinib (nM)	0
200	Daunorubicin (µM)	0.1457169
200	Dexamethasone  (µM)	0
200	Ibrutinib (µM)	0
200	Mercaptopurine (µM)	519.4835711
200	Nelarabine (µM)	7.192474
200	Panobinostat (nM)	0
200	Prednisolone (µM)	470.0307
200	Ruxolitinib (nM)	0
200	Thioguanine (µM)	0
200	Trametinib (nM)	0
200	Venetoclax (nM)	0
200	Vincristine (µM)	108.34
200	Vorinostat (nM)	539.6065143
200	asparagise_normalized	0.3429
200	bortezomib_normalized	0.5024
200	daunorubicin_normalized	0.5488
200	mercaptopurine_normalized	0.5001
200	nelarabine_normalized	0.6525
200	prednisolone_normalized	0.9935
200	vincristine_normalized	1
200	vorinostat_normalized	0.5464
201	immunophenotype	B
201	molecular subtype	B-other
201	Protocol	T17
201	NCI risk	HR
201	Age at diagnosis	12.7
201	WBC at diagnosis	478.4
201	Sex	F
201	Genetically-defined race	White
201	Asparaginase (IU/ml)	0.0016
201	Bortezomib (nM)	13.50339
201	CHZ868 (nM)	115.8359
201	Cytarabine (µM)	0
201	Dasatinib (nM)	20000
201	Daunorubicin (µM)	0.739486
201	Dexamethasone  (µM)	0
201	Ibrutinib (µM)	21.81377
201	Mercaptopurine (µM)	1751.663
201	Nelarabine (µM)	160
201	Panobinostat (nM)	0
201	Prednisolone (µM)	180.4318
201	Ruxolitinib (nM)	0
201	Thioguanine (µM)	0
201	Trametinib (nM)	4.801328
201	Venetoclax (nM)	1.159066
201	Vincristine (µM)	108.34
201	Vorinostat (nM)	503.8662
201	asparagise_normalized	0
201	bortezomib_normalized	0.3786
201	CHZ868_normalized	0.6128
201	dasatinib_normalized	1
201	daunorubicin_normalized	0.7783
201	ibrutinib_normalized	0.7607
201	mercaptopurine_normalized	0.8508
201	nelarabine_normalized	1
201	prednisolone_normalized	0.9016
201	trametinib_normalized	0.5363
201	venetoclax_normalized	0.6128
201	vincristine_normalized	1
201	vorinostat_normalized	0.5405
202	immunophenotype	B
202	molecular subtype	TCF3-PBX1
202	Protocol	T15
202	NCI risk	SR
202	Age at diagnosis	5
202	WBC at diagnosis	5
202	Sex	F
202	Genetically-defined race	Hispanic
202	Asparaginase (IU/ml)	0.0016
202	Bortezomib (nM)	0
202	CHZ868 (nM)	0
202	Cytarabine (µM)	0
202	Dasatinib (nM)	0
202	Daunorubicin (µM)	0
202	Dexamethasone  (µM)	0.012912084
202	Ibrutinib (µM)	0
202	Mercaptopurine (µM)	0
202	Nelarabine (µM)	0
202	Panobinostat (nM)	0
202	Prednisolone (µM)	0
202	Ruxolitinib (nM)	0
202	Thioguanine (µM)	4.675
202	Trametinib (nM)	0
202	Venetoclax (nM)	0
202	Vincristine (µM)	0.025
202	Vorinostat (nM)	0
202	asparagise_normalized	0
202	dexamethasone_normalized	0.3466
202	thioguanine_normalized	0
202	vincristine_normalized	0
203	immunophenotype	B
203	molecular subtype	Hyperdiploid
203	Protocol	T17
203	NCI risk	SR
203	Age at diagnosis	5.9
203	WBC at diagnosis	7.2
203	Sex	F
203	Genetically-defined race	White
203	Asparaginase (IU/ml)	0.0016
203	Bortezomib (nM)	2000
203	CHZ868 (nM)	0
203	Cytarabine (µM)	0
203	Dasatinib (nM)	0
203	Daunorubicin (µM)	0.3969158
203	Dexamethasone  (µM)	0
203	Ibrutinib (µM)	0
203	Mercaptopurine (µM)	177.7936
203	Nelarabine (µM)	20.17117
203	Panobinostat (nM)	0
203	Prednisolone (µM)	0.0075
203	Ruxolitinib (nM)	0
203	Thioguanine (µM)	0
203	Trametinib (nM)	0
203	Venetoclax (nM)	0
203	Vincristine (µM)	0.1104951
203	Vorinostat (nM)	538.8814554
203	asparagise_normalized	0
203	bortezomib_normalized	1
203	daunorubicin_normalized	0.6904
203	mercaptopurine_normalized	0.1907
203	nelarabine_normalized	0.8012
203	prednisolone_normalized	0
203	vincristine_normalized	0.1135
203	vorinostat_normalized	0.5463
204	immunophenotype	B
204	molecular subtype	Ph-like_CRLF2
204	Protocol	T17
204	NCI risk	SR
204	Age at diagnosis	2.6
204	WBC at diagnosis	13.9
204	Sex	M
204	Genetically-defined race	White
204	Asparaginase (IU/ml)	0
204	Bortezomib (nM)	0
204	CHZ868 (nM)	0
204	Cytarabine (µM)	0
204	Dasatinib (nM)	15.61679
204	Daunorubicin (µM)	0
204	Dexamethasone  (µM)	0
204	Ibrutinib (µM)	5.4824
204	Mercaptopurine (µM)	0
204	Nelarabine (µM)	0
204	Panobinostat (nM)	0
204	Prednisolone (µM)	0
204	Ruxolitinib (nM)	0
204	Thioguanine (µM)	0
204	Trametinib (nM)	0
204	Venetoclax (nM)	0
204	Vincristine (µM)	0
204	Vorinostat (nM)	0
204	dasatinib_normalized	0.4387
204	ibrutinib_normalized	0.3622
205	immunophenotype	B
205	molecular subtype	KMT2A
205	Protocol	T17
205	NCI risk	HR
205	Age at diagnosis	5.1
205	WBC at diagnosis	426.9
205	Sex	M
205	Genetically-defined race	White
205	Asparaginase (IU/ml)	0
205	Bortezomib (nM)	0
205	CHZ868 (nM)	189.1424
205	Cytarabine (µM)	0
205	Dasatinib (nM)	1352.783873
205	Daunorubicin (µM)	0
205	Dexamethasone  (µM)	0
205	Ibrutinib (µM)	18.20572
205	Mercaptopurine (µM)	0
205	Nelarabine (µM)	0
205	Panobinostat (nM)	0
205	Prednisolone (µM)	0
205	Ruxolitinib (nM)	0
205	Thioguanine (µM)	0
205	Trametinib (nM)	2000
205	Venetoclax (nM)	0.0005
205	Vincristine (µM)	0
205	Vorinostat (nM)	0
205	CHZ868_normalized	0.6554
205	dasatinib_normalized	0.8262
205	ibrutinib_normalized	0.7085
205	trametinib_normalized	1
205	venetoclax_normalized	0
206	immunophenotype	B
206	molecular subtype	DUX4
206	Protocol	T17
206	NCI risk	HR
206	Age at diagnosis	11
206	WBC at diagnosis	17.9
206	Sex	F
206	Genetically-defined race	Asian/Other
206	Asparaginase (IU/ml)	20
206	Bortezomib (nM)	16.6447
206	CHZ868 (nM)	139.2124
206	Cytarabine (µM)	0
206	Dasatinib (nM)	20000
206	Daunorubicin (µM)	0.1203139
206	Dexamethasone  (µM)	0
206	Ibrutinib (µM)	25.62206
206	Mercaptopurine (µM)	1901.004
206	Nelarabine (µM)	68.45297
206	Panobinostat (nM)	0
206	Prednisolone (µM)	0.1042158
206	Ruxolitinib (nM)	0
206	Thioguanine (µM)	0
206	Trametinib (nM)	2000
206	Venetoclax (nM)	0.0005
206	Vincristine (µM)	0.1207935
206	Vorinostat (nM)	1156.235
206	asparagise_normalized	1
206	bortezomib_normalized	0.4088
206	CHZ868_normalized	0.6287
206	dasatinib_normalized	1
206	daunorubicin_normalized	0.5217
206	ibrutinib_normalized	0.8071
206	mercaptopurine_normalized	0.8744
206	nelarabine_normalized	0.9775
206	prednisolone_normalized	0.186
206	trametinib_normalized	1
206	venetoclax_normalized	0
206	vincristine_normalized	0.1262
206	vorinostat_normalized	0.6126
207	immunophenotype	B
207	molecular subtype	KMT2A
207	Protocol	T17
207	NCI risk	HR
207	Age at diagnosis	1.5
207	WBC at diagnosis	99.5
207	Sex	M
207	Genetically-defined race	black
207	Asparaginase (IU/ml)	20
207	Bortezomib (nM)	21.62416
207	CHZ868 (nM)	0
207	Cytarabine (µM)	0
207	Dasatinib (nM)	0
207	Daunorubicin (µM)	0.3757776
207	Dexamethasone  (µM)	0
207	Ibrutinib (µM)	0
207	Mercaptopurine (µM)	5876
207	Nelarabine (µM)	93.06726
207	Panobinostat (nM)	0
207	Prednisolone (µM)	0.345193
207	Ruxolitinib (nM)	0
207	Thioguanine (µM)	0
207	Trametinib (nM)	0
207	Venetoclax (nM)	0
207	Vincristine (µM)	0.409249
207	Vorinostat (nM)	1287.147
207	asparagise_normalized	1
207	bortezomib_normalized	0.4466
207	daunorubicin_normalized	0.6826
207	mercaptopurine_normalized	1
207	nelarabine_normalized	1
207	prednisolone_normalized	0.301
207	vincristine_normalized	0.3009
207	vorinostat_normalized	0.6219
208	immunophenotype	B
208	molecular subtype	ETV6-RUNX1
208	Protocol	T17
208	NCI risk	SR
208	Age at diagnosis	7.5
208	WBC at diagnosis	17.5
208	Sex	F
208	Genetically-defined race	White
208	Asparaginase (IU/ml)	0.387848421
208	Bortezomib (nM)	7.984857
208	CHZ868 (nM)	2938.978
208	Cytarabine (µM)	0
208	Dasatinib (nM)	20000
208	Daunorubicin (µM)	0.167139292
208	Dexamethasone  (µM)	0
208	Ibrutinib (µM)	14.02329
208	Mercaptopurine (µM)	1395.649
208	Nelarabine (µM)	118.5517
208	Panobinostat (nM)	0
208	Prednisolone (µM)	0.05684384
208	Ruxolitinib (nM)	0
208	Thioguanine (µM)	0
208	Trametinib (nM)	2000
208	Venetoclax (nM)	0.0005
208	Vincristine (µM)	0.3040299
208	Vorinostat (nM)	959.9672
208	asparagise_normalized	0.5962
208	bortezomib_normalized	0.3028
208	CHZ868_normalized	0.8936
208	dasatinib_normalized	1
208	daunorubicin_normalized	0.5681
208	ibrutinib_normalized	0.6332
208	mercaptopurine_normalized	0.7852
208	nelarabine_normalized	1
208	prednisolone_normalized	0.1279
208	trametinib_normalized	1
208	venetoclax_normalized	0
208	vincristine_normalized	0.2583
208	vorinostat_normalized	0.5965
209	immunophenotype	B
209	molecular subtype	iAMP21
209	Protocol	T17
209	NCI risk	SR
209	Age at diagnosis	9.1
209	WBC at diagnosis	5.2
209	Sex	F
209	Genetically-defined race	White
209	Asparaginase (IU/ml)	0.0016
209	Bortezomib (nM)	55.23872
209	CHZ868 (nM)	0
209	Cytarabine (µM)	0
209	Dasatinib (nM)	0
209	Daunorubicin (µM)	0.01926344
209	Dexamethasone  (µM)	0
209	Ibrutinib (µM)	0
209	Mercaptopurine (µM)	471.1963
209	Nelarabine (µM)	40.64718
209	Panobinostat (nM)	0
209	Prednisolone (µM)	0.0412454
209	Ruxolitinib (nM)	0
209	Thioguanine (µM)	0
209	Trametinib (nM)	0
209	Venetoclax (nM)	0
209	Vincristine (µM)	0.05372021
209	Vorinostat (nM)	150.3388
209	asparagise_normalized	0
209	bortezomib_normalized	0.582
209	daunorubicin_normalized	0.2628
209	mercaptopurine_normalized	0.4719
209	nelarabine_normalized	0.9023
209	prednisolone_normalized	0.0971
209	vincristine_normalized	0.0103
209	vorinostat_normalized	0.4354
210	immunophenotype	T
210	molecular subtype	T-ALL
210	Protocol	T17
210	NCI risk	HR
210	Age at diagnosis	13
210	WBC at diagnosis	199.5
210	Sex	M
210	Genetically-defined race	White
210	Asparaginase (IU/ml)	0.0016
210	Bortezomib (nM)	20.87573
210	CHZ868 (nM)	0
210	Cytarabine (µM)	0
210	Dasatinib (nM)	0
210	Daunorubicin (µM)	0.1142175
210	Dexamethasone  (µM)	0
210	Ibrutinib (µM)	0
210	Mercaptopurine (µM)	1382.372
210	Nelarabine (µM)	14.74498
210	Panobinostat (nM)	0
210	Prednisolone (µM)	265.6678
210	Ruxolitinib (nM)	0
210	Thioguanine (µM)	0
210	Trametinib (nM)	0
210	Venetoclax (nM)	0
210	Vincristine (µM)	0.03774375
210	Vorinostat (nM)	461.059
210	asparagise_normalized	0
210	bortezomib_normalized	0.4415
210	daunorubicin_normalized	0.5143
210	mercaptopurine_normalized	0.7825
210	nelarabine_normalized	0.756
210	prednisolone_normalized	0.9387
210	vincristine_normalized	0
210	vorinostat_normalized	0.5328
211	immunophenotype	B
211	molecular subtype	Hyperdiploid
211	Protocol	T17
211	NCI risk	SR
211	Age at diagnosis	2.5
211	WBC at diagnosis	33.5
211	Sex	F
211	Genetically-defined race	White
211	Asparaginase (IU/ml)	0.06992336
211	Bortezomib (nM)	14.01919
211	CHZ868 (nM)	0
211	Cytarabine (µM)	0
211	Dasatinib (nM)	0
211	Daunorubicin (µM)	0.1021372
211	Dexamethasone  (µM)	0
211	Ibrutinib (µM)	0
211	Mercaptopurine (µM)	261.2958
211	Nelarabine (µM)	124.4582
211	Panobinostat (nM)	0
211	Prednisolone (µM)	0.04816235
211	Ruxolitinib (nM)	0
211	Thioguanine (µM)	0
211	Trametinib (nM)	0
211	Venetoclax (nM)	0
211	Vincristine (µM)	0.020491412
211	Vorinostat (nM)	144.9344
211	asparagise_normalized	0.3833
211	bortezomib_normalized	0.384
211	daunorubicin_normalized	0.4985
211	mercaptopurine_normalized	0.3018
211	nelarabine_normalized	1
211	prednisolone_normalized	0.1119
211	vincristine_normalized	0
211	vorinostat_normalized	0.4322
212	immunophenotype	B
212	molecular subtype	ETV6-RUNX1
212	Protocol	T17
212	NCI risk	SR
212	Age at diagnosis	7.7
212	WBC at diagnosis	2.2
212	Sex	F
212	Genetically-defined race	Hispanic
212	Asparaginase (IU/ml)	0.0016
212	Bortezomib (nM)	26.34255
212	CHZ868 (nM)	0
212	Cytarabine (µM)	0
212	Dasatinib (nM)	0
212	Daunorubicin (µM)	0.03858502
212	Dexamethasone  (µM)	0
212	Ibrutinib (µM)	0
212	Mercaptopurine (µM)	878.8221
212	Nelarabine (µM)	61.3317
212	Panobinostat (nM)	0
212	Prednisolone (µM)	0.01805327
212	Ruxolitinib (nM)	0
212	Thioguanine (µM)	0
212	Trametinib (nM)	0
212	Venetoclax (nM)	0
212	Vincristine (µM)	0.1578502
212	Vorinostat (nM)	1416.161
212	asparagise_normalized	0
212	bortezomib_normalized	0.4751
212	daunorubicin_normalized	0.361
212	mercaptopurine_normalized	0.6518
212	nelarabine_normalized	0.9617
212	prednisolone_normalized	0.0178
212	vincristine_normalized	0.1645
212	vorinostat_normalized	0.6302
213	immunophenotype	B
213	molecular subtype	ETV6-RUNX1
213	Protocol	T17
213	NCI risk	SR
213	Age at diagnosis	4.4
213	WBC at diagnosis	42.6
213	Sex	F
213	Genetically-defined race	black
213	Asparaginase (IU/ml)	0.0016
213	Bortezomib (nM)	0
213	CHZ868 (nM)	0
213	Cytarabine (µM)	0
213	Dasatinib (nM)	0
213	Daunorubicin (µM)	0
213	Dexamethasone  (µM)	0
213	Ibrutinib (µM)	0
213	Mercaptopurine (µM)	5876
213	Nelarabine (µM)	0
213	Panobinostat (nM)	0
213	Prednisolone (µM)	0.07856845
213	Ruxolitinib (nM)	0
213	Thioguanine (µM)	0
213	Trametinib (nM)	0
213	Venetoclax (nM)	0
213	Vincristine (µM)	2.506507
213	Vorinostat (nM)	0
213	asparagise_normalized	0
213	mercaptopurine_normalized	1
213	prednisolone_normalized	0.1589
213	vincristine_normalized	0.5602
214	immunophenotype	B
214	molecular subtype	ETV6-RUNX1
214	Protocol	T17
214	NCI risk	SR
214	Age at diagnosis	8.3
214	WBC at diagnosis	8.9
214	Sex	M
214	Genetically-defined race	White
214	Asparaginase (IU/ml)	0.0016
214	Bortezomib (nM)	150.8974966
214	CHZ868 (nM)	20000
214	Cytarabine (µM)	0
214	Dasatinib (nM)	8827.091
214	Daunorubicin (µM)	0.182694
214	Dexamethasone  (µM)	0
214	Ibrutinib (µM)	10.59061
214	Mercaptopurine (µM)	1147.46
214	Nelarabine (µM)	120.5545
214	Panobinostat (nM)	0
214	Prednisolone (µM)	0.1914523
214	Ruxolitinib (nM)	0
214	Thioguanine (µM)	0
214	Trametinib (nM)	2000
214	Venetoclax (nM)	0.4412968
214	Vincristine (µM)	0.2455552
214	Vorinostat (nM)	996.1449
214	asparagise_normalized	0
214	bortezomib_normalized	0.727
214	CHZ868_normalized	1
214	dasatinib_normalized	0.9892
214	daunorubicin_normalized	0.5807
214	ibrutinib_normalized	0.5522
214	mercaptopurine_normalized	0.7287
214	nelarabine_normalized	1
214	prednisolone_normalized	0.2444
214	trametinib_normalized	1
214	venetoclax_normalized	0.5289
214	vincristine_normalized	0.2278
214	vorinostat_normalized	0.5997
215	immunophenotype	T
215	molecular subtype	T-ALL
215	Protocol	T17
215	NCI risk	HR
215	Age at diagnosis	9.6
215	WBC at diagnosis	162.3
215	Sex	F
215	Genetically-defined race	Hispanic
215	Asparaginase (IU/ml)	0
215	Bortezomib (nM)	0
215	CHZ868 (nM)	20000
215	Cytarabine (µM)	0
215	Dasatinib (nM)	0.05
215	Daunorubicin (µM)	0
215	Dexamethasone  (µM)	0
215	Ibrutinib (µM)	3.034617
215	Mercaptopurine (µM)	0
215	Nelarabine (µM)	0
215	Panobinostat (nM)	0
215	Prednisolone (µM)	0
215	Ruxolitinib (nM)	0
215	Thioguanine (µM)	0
215	Trametinib (nM)	337.9989
215	Venetoclax (nM)	200
215	Vincristine (µM)	0
215	Vorinostat (nM)	0
215	CHZ868_normalized	1
215	dasatinib_normalized	0
215	ibrutinib_normalized	0.1915
215	trametinib_normalized	0.9058
215	venetoclax_normalized	1
216	immunophenotype	B
216	molecular subtype	DUX4
216	Protocol	T17
216	NCI risk	SR
216	Age at diagnosis	6.1
216	WBC at diagnosis	6.5
216	Sex	F
216	Genetically-defined race	Asian/Other
216	Asparaginase (IU/ml)	20
216	Bortezomib (nM)	935.9127
216	CHZ868 (nM)	92.63973
216	Cytarabine (µM)	0
216	Dasatinib (nM)	20000
216	Daunorubicin (µM)	2.178402
216	Dexamethasone  (µM)	0
216	Ibrutinib (µM)	14.9225
216	Mercaptopurine (µM)	5876
216	Nelarabine (µM)	160
216	Panobinostat (nM)	0
216	Prednisolone (µM)	0.1683299
216	Ruxolitinib (nM)	0
216	Thioguanine (µM)	0
216	Trametinib (nM)	22.43854
216	Venetoclax (nM)	0.0005
216	Vincristine (µM)	0.1369622
216	Vorinostat (nM)	1143.741
216	asparagise_normalized	1
216	bortezomib_normalized	0.9904
216	CHZ868_normalized	0.5934
216	dasatinib_normalized	1
216	daunorubicin_normalized	0.931
216	ibrutinib_normalized	0.6511
216	mercaptopurine_normalized	1
216	nelarabine_normalized	1
216	prednisolone_normalized	0.232
216	trametinib_normalized	0.6702
216	venetoclax_normalized	0
216	vincristine_normalized	0.1442
216	vorinostat_normalized	0.6117
217	immunophenotype	B
217	molecular subtype	IKZF1 N159Y
217	Protocol	T17
217	NCI risk	SR
217	Age at diagnosis	1.3
217	WBC at diagnosis	34
217	Sex	M
217	Genetically-defined race	White
217	Asparaginase (IU/ml)	0.5587383
217	Bortezomib (nM)	17.2321
217	CHZ868 (nM)	0
217	Cytarabine (µM)	0
217	Dasatinib (nM)	0
217	Daunorubicin (µM)	0.03077114
217	Dexamethasone  (µM)	0
217	Ibrutinib (µM)	0
217	Mercaptopurine (µM)	277.3324
217	Nelarabine (µM)	6.144538
217	Panobinostat (nM)	0
217	Prednisolone (µM)	0.3790563
217	Ruxolitinib (nM)	0
217	Thioguanine (µM)	0
217	Trametinib (nM)	0
217	Venetoclax (nM)	0
217	Vincristine (µM)	0.6737821
217	Vorinostat (nM)	390.3843
217	asparagise_normalized	0.6415
217	bortezomib_normalized	0.4138
217	daunorubicin_normalized	0.329
217	mercaptopurine_normalized	0.319
217	nelarabine_normalized	0.6297
217	prednisolone_normalized	0.3099
217	vincristine_normalized	0.3722
217	vorinostat_normalized	0.5183
218	immunophenotype	B
218	molecular subtype	ETV6-RUNX1
218	Protocol	T17
218	NCI risk	SR
218	Age at diagnosis	3
218	WBC at diagnosis	23.4
218	Sex	M
218	Genetically-defined race	White
218	Asparaginase (IU/ml)	0.3582955
218	Bortezomib (nM)	103.4285
218	CHZ868 (nM)	20000
218	Cytarabine (µM)	0
218	Dasatinib (nM)	20000
218	Daunorubicin (µM)	0.1172236
218	Dexamethasone  (µM)	0
218	Ibrutinib (µM)	21.75954
218	Mercaptopurine (µM)	315.8308
218	Nelarabine (µM)	169.3672
218	Panobinostat (nM)	0
218	Prednisolone (µM)	0.0075
218	Ruxolitinib (nM)	0
218	Thioguanine (µM)	0
218	Trametinib (nM)	2000
218	Venetoclax (nM)	2.759964
218	Vincristine (µM)	0.5824658
218	Vorinostat (nM)	1804.114
218	asparagise_normalized	0.5863
218	bortezomib_normalized	0.6725
218	CHZ868_normalized	1
218	dasatinib_normalized	1
218	daunorubicin_normalized	0.518
218	ibrutinib_normalized	0.7599
218	mercaptopurine_normalized	0.3565
218	nelarabine_normalized	1
218	prednisolone_normalized	0
218	trametinib_normalized	1
218	venetoclax_normalized	0.6882
218	vincristine_normalized	0.3514
218	vorinostat_normalized	0.6513
219	immunophenotype	B
219	molecular subtype	Ph-like_non_CRLF2
219	Protocol	T17
219	NCI risk	HR
219	Age at diagnosis	11.5
219	WBC at diagnosis	7
219	Sex	M
219	Genetically-defined race	White
219	Asparaginase (IU/ml)	0.5967751
219	Bortezomib (nM)	36.82364
219	CHZ868 (nM)	7107.397
219	Cytarabine (µM)	0
219	Dasatinib (nM)	20000
219	Daunorubicin (µM)	0.2582891
219	Dexamethasone  (µM)	0
219	Ibrutinib (µM)	25.81772
219	Mercaptopurine (µM)	376.3175
219	Nelarabine (µM)	85.35170285
219	Panobinostat (nM)	0
219	Prednisolone (µM)	0.09705523
219	Ruxolitinib (nM)	0
219	Thioguanine (µM)	0
219	Trametinib (nM)	78.62647
219	Venetoclax (nM)	1.456265
219	Vincristine (µM)	0.667008712
219	Vorinostat (nM)	240.4289
219	asparagise_normalized	0.6497
219	bortezomib_normalized	0.5234
219	CHZ868_normalized	0.9703
219	dasatinib_normalized	1
219	daunorubicin_normalized	0.6297
219	ibrutinib_normalized	0.8093
219	mercaptopurine_normalized	0.4071
219	nelarabine_normalized	1
219	prednisolone_normalized	0.1792
219	trametinib_normalized	0.7791
219	venetoclax_normalized	0.6326
219	vincristine_normalized	0.3708
219	vorinostat_normalized	0.4762
220	immunophenotype	B
220	molecular subtype	BCR-ABL1
220	Protocol	T17
220	NCI risk	HR
220	Age at diagnosis	7.8
220	WBC at diagnosis	383.8
220	Sex	M
220	Genetically-defined race	Asian/Other
220	Asparaginase (IU/ml)	1.969873
220	Bortezomib (nM)	188.9875
220	CHZ868 (nM)	17.74047118
220	Cytarabine (µM)	0
220	Dasatinib (nM)	0.05
220	Daunorubicin (µM)	0.08789542
220	Dexamethasone  (µM)	0
220	Ibrutinib (µM)	10.53203
220	Mercaptopurine (µM)	782.2855
220	Nelarabine (µM)	4.639129
220	Panobinostat (nM)	0
220	Prednisolone (µM)	6.849909
220	Ruxolitinib (nM)	0
220	Thioguanine (µM)	0
220	Trametinib (nM)	2000
220	Venetoclax (nM)	5.79472
220	Vincristine (µM)	0.0532452
220	Vorinostat (nM)	641.6056
220	asparagise_normalized	0.7981
220	bortezomib_normalized	0.7595
220	CHZ868_normalized	0.4498
220	dasatinib_normalized	0
220	daunorubicin_normalized	0.4773
220	ibrutinib_normalized	0.5506
220	mercaptopurine_normalized	0.6182
220	nelarabine_normalized	0.5892
220	prednisolone_normalized	0.5877
220	trametinib_normalized	1
220	venetoclax_normalized	0.7526
220	vincristine_normalized	0.009
220	vorinostat_normalized	0.5615
221	immunophenotype	B
221	molecular subtype	TCF3-PBX1
221	Protocol	T17
221	NCI risk	HR
221	Age at diagnosis	15.8
221	WBC at diagnosis	16.4
221	Sex	F
221	Genetically-defined race	White
221	Asparaginase (IU/ml)	20
221	Bortezomib (nM)	38.4741
221	CHZ868 (nM)	0.05
221	Cytarabine (µM)	0
221	Dasatinib (nM)	2.652886
221	Daunorubicin (µM)	0.009243771
221	Dexamethasone  (µM)	0
221	Ibrutinib (µM)	16.25286
221	Mercaptopurine (µM)	0
221	Nelarabine (µM)	43.65823
221	Panobinostat (nM)	0
221	Prednisolone (µM)	0.7181045
221	Ruxolitinib (nM)	0
221	Thioguanine (µM)	0
221	Trametinib (nM)	2000
221	Venetoclax (nM)	9.869074
221	Vincristine (µM)	0.02414504
221	Vorinostat (nM)	52.40404
221	asparagise_normalized	1
221	bortezomib_normalized	0.5298
221	CHZ868_normalized	0
221	dasatinib_normalized	0.2847
221	daunorubicin_normalized	0.159
221	ibrutinib_normalized	0.6758
221	nelarabine_normalized	0.9126
221	prednisolone_normalized	0.3713
221	trametinib_normalized	1
221	venetoclax_normalized	0.7989
221	vincristine_normalized	0
221	vorinostat_normalized	0.3439
222	immunophenotype	B
222	molecular subtype	TCF3-PBX1
222	Protocol	T15
222	NCI risk	SR
222	Age at diagnosis	3.6
222	WBC at diagnosis	8.4
222	Sex	F
222	Genetically-defined race	White
222	Asparaginase (IU/ml)	0.000346412
222	Bortezomib (nM)	0
222	CHZ868 (nM)	0
222	Cytarabine (µM)	0.012430683
222	Dasatinib (nM)	0
222	Daunorubicin (µM)	0
222	Dexamethasone  (µM)	0.00614244
222	Ibrutinib (µM)	0
222	Mercaptopurine (µM)	0
222	Nelarabine (µM)	0
222	Panobinostat (nM)	0
222	Prednisolone (µM)	0.0075
222	Ruxolitinib (nM)	0
222	Thioguanine (µM)	4.675
222	Trametinib (nM)	0
222	Venetoclax (nM)	0
222	Vincristine (µM)	0.025
222	Vorinostat (nM)	0
222	asparagise_normalized	0
222	cytarabine_normalized	0
222	dexamethasone_normalized	0.2753
222	prednisolone_normalized	0
222	thioguanine_normalized	0
222	vincristine_normalized	0
223	immunophenotype	B
223	molecular subtype	Ph-like_CRLF2
223	Protocol	T17
223	NCI risk	HR
223	Age at diagnosis	14.1
223	WBC at diagnosis	119.8
223	Sex	M
223	Genetically-defined race	White
223	Asparaginase (IU/ml)	1.250635
223	Bortezomib (nM)	17.79874419
223	CHZ868 (nM)	20000
223	Cytarabine (µM)	0
223	Dasatinib (nM)	20000
223	Daunorubicin (µM)	0.2969963
223	Dexamethasone  (µM)	0
223	Ibrutinib (µM)	3.726115
223	Mercaptopurine (µM)	5876
223	Nelarabine (µM)	158.121
223	Panobinostat (nM)	0
223	Prednisolone (µM)	1.999686
223	Ruxolitinib (nM)	0
223	Thioguanine (µM)	0
223	Trametinib (nM)	2000
223	Venetoclax (nM)	3.664356
223	Vincristine (µM)	0.5475846
223	Vorinostat (nM)	1614.338
223	asparagise_normalized	0.7417
223	bortezomib_normalized	0.4185
223	CHZ868_normalized	1
223	dasatinib_normalized	1
223	daunorubicin_normalized	0.6494
223	ibrutinib_normalized	0.2508
223	mercaptopurine_normalized	1
223	nelarabine_normalized	1
223	prednisolone_normalized	0.4695
223	trametinib_normalized	1
223	venetoclax_normalized	0.7128
223	vincristine_normalized	0.3425
223	vorinostat_normalized	0.6416
224	immunophenotype	B
224	molecular subtype	ETV6-RUNX1
224	Protocol	T17
224	NCI risk	SR
224	Age at diagnosis	6
224	WBC at diagnosis	1.9
224	Sex	M
224	Genetically-defined race	White
224	Asparaginase (IU/ml)	0.0016
224	Bortezomib (nM)	10.68517783
224	CHZ868 (nM)	0
224	Cytarabine (µM)	0
224	Dasatinib (nM)	0
224	Daunorubicin (µM)	0.2947249
224	Dexamethasone  (µM)	0
224	Ibrutinib (µM)	0
224	Mercaptopurine (µM)	604.0658
224	Nelarabine (µM)	160
224	Panobinostat (nM)	0
224	Prednisolone (µM)	8.618495
224	Ruxolitinib (nM)	0
224	Thioguanine (µM)	0
224	Trametinib (nM)	0
224	Venetoclax (nM)	0
224	Vincristine (µM)	0.06485848
224	Vorinostat (nM)	1066.323
224	asparagise_normalized	0
224	bortezomib_normalized	0.3448
224	daunorubicin_normalized	0.6483
224	mercaptopurine_normalized	0.5436
224	nelarabine_normalized	1
224	prednisolone_normalized	0.6097
224	vincristine_normalized	0.0372
224	vorinostat_normalized	0.6056
225	immunophenotype	B
225	molecular subtype	Hyperdiploid
225	Protocol	T17
225	NCI risk	SR
225	Age at diagnosis	1.5
225	WBC at diagnosis	17.1
225	Sex	M
225	Genetically-defined race	White
225	Asparaginase (IU/ml)	1.359235
225	Bortezomib (nM)	0
225	CHZ868 (nM)	0
225	Cytarabine (µM)	0
225	Dasatinib (nM)	0
225	Daunorubicin (µM)	0
225	Dexamethasone  (µM)	0
225	Ibrutinib (µM)	0
225	Mercaptopurine (µM)	0
225	Nelarabine (µM)	0
225	Panobinostat (nM)	0
225	Prednisolone (µM)	0
225	Ruxolitinib (nM)	0
225	Thioguanine (µM)	0
225	Trametinib (nM)	0
225	Venetoclax (nM)	0
225	Vincristine (µM)	0.09627579
225	Vorinostat (nM)	0
225	asparagise_normalized	0.752
225	vincristine_normalized	0.0938
226	immunophenotype	B
226	molecular subtype	B-other
226	Protocol	T17
226	NCI risk	HR
226	Age at diagnosis	15.4
226	WBC at diagnosis	27.9
226	Sex	M
226	Genetically-defined race	White
226	Asparaginase (IU/ml)	0.5310769
226	Bortezomib (nM)	0
226	CHZ868 (nM)	0
226	Cytarabine (µM)	0
226	Dasatinib (nM)	0
226	Daunorubicin (µM)	0
226	Dexamethasone  (µM)	0
226	Ibrutinib (µM)	0
226	Mercaptopurine (µM)	0
226	Nelarabine (µM)	0
226	Panobinostat (nM)	0
226	Prednisolone (µM)	0.0075
226	Ruxolitinib (nM)	0
226	Thioguanine (µM)	0
226	Trametinib (nM)	0
226	Venetoclax (nM)	0
226	Vincristine (µM)	0.02033329
226	Vorinostat (nM)	0
226	asparagise_normalized	0.6352
226	prednisolone_normalized	0
226	vincristine_normalized	0
227	immunophenotype	B
227	molecular subtype	ETV6-RUNX1
227	Protocol	T17
227	NCI risk	SR
227	Age at diagnosis	9.6
227	WBC at diagnosis	7.2
227	Sex	M
227	Genetically-defined race	White
227	Asparaginase (IU/ml)	0.0016
227	Bortezomib (nM)	14.28711
227	CHZ868 (nM)	0
227	Cytarabine (µM)	0
227	Dasatinib (nM)	0
227	Daunorubicin (µM)	0.1599913
227	Dexamethasone  (µM)	0
227	Ibrutinib (µM)	0
227	Mercaptopurine (µM)	1468.941
227	Nelarabine (µM)	154.4852
227	Panobinostat (nM)	0
227	Prednisolone (µM)	130.1713
227	Ruxolitinib (nM)	0
227	Thioguanine (µM)	0
227	Trametinib (nM)	0
227	Venetoclax (nM)	0
227	Vincristine (µM)	1.16463
227	Vorinostat (nM)	1227.352
227	asparagise_normalized	0
227	bortezomib_normalized	0.3868
227	daunorubicin_normalized	0.562
227	mercaptopurine_normalized	0.8
227	nelarabine_normalized	1
227	prednisolone_normalized	0.8703
227	vincristine_normalized	0.4505
227	vorinostat_normalized	0.6178
228	immunophenotype	B
228	molecular subtype	Hyperdiploid
228	Protocol	T17
228	NCI risk	SR
228	Age at diagnosis	4.8
228	WBC at diagnosis	4.4
228	Sex	F
228	Genetically-defined race	White
228	Asparaginase (IU/ml)	0.6365716
228	Bortezomib (nM)	0
228	CHZ868 (nM)	0
228	Cytarabine (µM)	0
228	Dasatinib (nM)	0
228	Daunorubicin (µM)	0
228	Dexamethasone  (µM)	0
228	Ibrutinib (µM)	0
228	Mercaptopurine (µM)	0
228	Nelarabine (µM)	0
228	Panobinostat (nM)	0
228	Prednisolone (µM)	0.05358519
228	Ruxolitinib (nM)	0
228	Thioguanine (µM)	0
228	Trametinib (nM)	0
228	Venetoclax (nM)	0
228	Vincristine (µM)	0.05073318
228	Vorinostat (nM)	0
228	asparagise_normalized	0.6577
228	prednisolone_normalized	0.1222
228	vincristine_normalized	0.0021
229	immunophenotype	B
229	molecular subtype	Hyperdiploid
229	Protocol	T17
229	NCI risk	HR
229	Age at diagnosis	2.8
229	WBC at diagnosis	144
229	Sex	F
229	Genetically-defined race	White
229	Asparaginase (IU/ml)	0.0016
229	Bortezomib (nM)	12.73121
229	CHZ868 (nM)	0
229	Cytarabine (µM)	0
229	Dasatinib (nM)	0
229	Daunorubicin (µM)	0.05231824
229	Dexamethasone  (µM)	0
229	Ibrutinib (µM)	0
229	Mercaptopurine (µM)	359.1209
229	Nelarabine (µM)	160
229	Panobinostat (nM)	0
229	Prednisolone (µM)	0.9402645
229	Ruxolitinib (nM)	0
229	Thioguanine (µM)	0
229	Trametinib (nM)	0
229	Venetoclax (nM)	0
229	Vincristine (µM)	0.009894266
229	Vorinostat (nM)	128.0871
229	asparagise_normalized	0
229	bortezomib_normalized	0.3701
229	daunorubicin_normalized	0.404
229	mercaptopurine_normalized	0.3936
229	nelarabine_normalized	1
229	prednisolone_normalized	0.3971
229	vincristine_normalized	0
229	vorinostat_normalized	0.4215
230	immunophenotype	B
230	molecular subtype	Hyperdiploid
230	Protocol	T17
230	NCI risk	HR
230	Age at diagnosis	15.7
230	WBC at diagnosis	47.6
230	Sex	M
230	Genetically-defined race	White
230	Asparaginase (IU/ml)	0.0016
230	Bortezomib (nM)	15.41275
230	CHZ868 (nM)	0
230	Cytarabine (µM)	0
230	Dasatinib (nM)	0
230	Daunorubicin (µM)	0.1375795
230	Dexamethasone  (µM)	0
230	Ibrutinib (µM)	0
230	Mercaptopurine (µM)	344.0818
230	Nelarabine (µM)	163.7027
230	Panobinostat (nM)	0
230	Prednisolone (µM)	0.1281769
230	Ruxolitinib (nM)	0
230	Thioguanine (µM)	0
230	Trametinib (nM)	0
230	Venetoclax (nM)	0
230	Vincristine (µM)	0.4693791
230	Vorinostat (nM)	503.2467
230	asparagise_normalized	0
230	bortezomib_normalized	0.3977
230	daunorubicin_normalized	0.5406
230	mercaptopurine_normalized	0.3812
230	nelarabine_normalized	1
230	prednisolone_normalized	0.2059
230	vincristine_normalized	0.3205
230	vorinostat_normalized	0.5404
231	immunophenotype	B
231	molecular subtype	Hyperdiploid
231	Protocol	T17
231	NCI risk	HR
231	Age at diagnosis	2.7
231	WBC at diagnosis	82.9
231	Sex	F
231	Genetically-defined race	White
231	Asparaginase (IU/ml)	0.0016
231	Bortezomib (nM)	6.187368
231	CHZ868 (nM)	0
231	Cytarabine (µM)	0
231	Dasatinib (nM)	0
231	Daunorubicin (µM)	0.01614392
231	Dexamethasone  (µM)	0
231	Ibrutinib (µM)	0
231	Mercaptopurine (µM)	164.7449
231	Nelarabine (µM)	102.4137
231	Panobinostat (nM)	0
231	Prednisolone (µM)	0.0338765
231	Ruxolitinib (nM)	0
231	Thioguanine (µM)	0
231	Trametinib (nM)	0
231	Venetoclax (nM)	0
231	Vincristine (µM)	0.07128545
231	Vorinostat (nM)	634.1601
231	asparagise_normalized	0
231	bortezomib_normalized	0.266
231	daunorubicin_normalized	0.2378
231	mercaptopurine_normalized	0.1687
231	nelarabine_normalized	1
231	prednisolone_normalized	0.0782
231	vincristine_normalized	0.0508
231	vorinostat_normalized	0.5604
232	immunophenotype	B
232	molecular subtype	Ph-like_CRLF2
232	Protocol	T15
232	NCI risk	HR
232	Age at diagnosis	1.9
232	WBC at diagnosis	258.3
232	Sex	F
232	Genetically-defined race	White
232	Asparaginase (IU/ml)	0.3202259
232	Bortezomib (nM)	0
232	CHZ868 (nM)	0
232	Cytarabine (µM)	0.01586264
232	Dasatinib (nM)	0
232	Daunorubicin (µM)	0
232	Dexamethasone  (µM)	0.05239525
232	Ibrutinib (µM)	0
232	Mercaptopurine (µM)	0
232	Nelarabine (µM)	0
232	Panobinostat (nM)	0
232	Prednisolone (µM)	0.0075
232	Ruxolitinib (nM)	0
232	Thioguanine (µM)	4.675
232	Trametinib (nM)	0
232	Venetoclax (nM)	0
232	Vincristine (µM)	3.428335
232	Vorinostat (nM)	0
232	asparagise_normalized	0.5724
232	cytarabine_normalized	0
232	dexamethasone_normalized	0.4812
232	prednisolone_normalized	0
232	thioguanine_normalized	0
232	vincristine_normalized	0.605
233	immunophenotype	B
233	molecular subtype	ETV6-RUNX1
233	Protocol	T17
233	NCI risk	SR
233	Age at diagnosis	3.8
233	WBC at diagnosis	14.1
233	Sex	F
233	Genetically-defined race	White
233	Asparaginase (IU/ml)	0.0016
233	Bortezomib (nM)	18.32142
233	CHZ868 (nM)	0
233	Cytarabine (µM)	0
233	Dasatinib (nM)	0
233	Daunorubicin (µM)	0.032904587
233	Dexamethasone  (µM)	0
233	Ibrutinib (µM)	0
233	Mercaptopurine (µM)	267.089
233	Nelarabine (µM)	46.54403
233	Panobinostat (nM)	0
233	Prednisolone (µM)	0.0075
233	Ruxolitinib (nM)	0
233	Thioguanine (µM)	0
233	Trametinib (nM)	0
233	Venetoclax (nM)	0
233	Vincristine (µM)	0.2642864
233	Vorinostat (nM)	926.7355
233	asparagise_normalized	0
233	bortezomib_normalized	0.4227
233	daunorubicin_normalized	0.3385
233	mercaptopurine_normalized	0.3081
233	nelarabine_normalized	0.9219
233	prednisolone_normalized	0
233	vincristine_normalized	0.2383
233	vorinostat_normalized	0.5934
234	immunophenotype	B
234	molecular subtype	Hyperdiploid
234	Protocol	T17
234	NCI risk	HR
234	Age at diagnosis	3.2
234	WBC at diagnosis	84.7
234	Sex	M
234	Genetically-defined race	White
234	Asparaginase (IU/ml)	0.0016
234	Bortezomib (nM)	0
234	CHZ868 (nM)	0
234	Cytarabine (µM)	0
234	Dasatinib (nM)	0
234	Daunorubicin (µM)	0
234	Dexamethasone  (µM)	0
234	Ibrutinib (µM)	0
234	Mercaptopurine (µM)	0
234	Nelarabine (µM)	0
234	Panobinostat (nM)	0
234	Prednisolone (µM)	0.5688238
234	Ruxolitinib (nM)	0
234	Thioguanine (µM)	0
234	Trametinib (nM)	0
234	Venetoclax (nM)	0
234	Vincristine (µM)	0.02660122
234	Vorinostat (nM)	0
234	asparagise_normalized	0
234	prednisolone_normalized	0.3489
234	vincristine_normalized	0
235	immunophenotype	T
235	molecular subtype	ETP
235	Protocol	T17
235	NCI risk	HR
235	Age at diagnosis	6.4
235	WBC at diagnosis	260.7
235	Sex	M
235	Genetically-defined race	White
235	Asparaginase (IU/ml)	0.4989417
235	Bortezomib (nM)	118.1857
235	CHZ868 (nM)	0
235	Cytarabine (µM)	0
235	Dasatinib (nM)	0
235	Daunorubicin (µM)	0.6670097
235	Dexamethasone  (µM)	0
235	Ibrutinib (µM)	0
235	Mercaptopurine (µM)	812.9174
235	Nelarabine (µM)	29.86101
235	Panobinostat (nM)	0
235	Prednisolone (µM)	0.3470393
235	Ruxolitinib (nM)	0
235	Thioguanine (µM)	0
235	Trametinib (nM)	0
235	Venetoclax (nM)	0
235	Vincristine (µM)	1.136415
235	Vorinostat (nM)	1846.122482
235	asparagise_normalized	0.6275
235	bortezomib_normalized	0.6918
235	daunorubicin_normalized	0.7637
235	mercaptopurine_normalized	0.6293
235	nelarabine_normalized	0.8578
235	prednisolone_normalized	0.3015
235	vincristine_normalized	0.447
235	vorinostat_normalized	0.6533
236	immunophenotype	B
236	molecular subtype	Hyperdiploid
236	Protocol	T17
236	NCI risk	HR
236	Age at diagnosis	6.8
236	WBC at diagnosis	58.6
236	Sex	F
236	Genetically-defined race	White
236	Asparaginase (IU/ml)	0.0016
236	Bortezomib (nM)	0
236	CHZ868 (nM)	0
236	Cytarabine (µM)	0
236	Dasatinib (nM)	0
236	Daunorubicin (µM)	0
236	Dexamethasone  (µM)	0
236	Ibrutinib (µM)	0
236	Mercaptopurine (µM)	0
236	Nelarabine (µM)	58.85848
236	Panobinostat (nM)	0
236	Prednisolone (µM)	0.1044687
236	Ruxolitinib (nM)	0
236	Thioguanine (µM)	0
236	Trametinib (nM)	0
236	Venetoclax (nM)	0
236	Vincristine (µM)	0.018336357
236	Vorinostat (nM)	0
236	asparagise_normalized	0
236	nelarabine_normalized	0.9557
236	prednisolone_normalized	0.1863
236	vincristine_normalized	0
237	immunophenotype	T
237	molecular subtype	T-ALL
237	Protocol	T17
237	NCI risk	HR
237	Age at diagnosis	2.5
237	WBC at diagnosis	62.4
237	Sex	M
237	Genetically-defined race	Asian/Other
237	Asparaginase (IU/ml)	0.3910186
237	Bortezomib (nM)	143.5575
237	CHZ868 (nM)	20000
237	Cytarabine (µM)	0
237	Dasatinib (nM)	85.30963
237	Daunorubicin (µM)	0.3038978
237	Dexamethasone  (µM)	0
237	Ibrutinib (µM)	16.43972
237	Mercaptopurine (µM)	249.2259
237	Nelarabine (µM)	13.92535
237	Panobinostat (nM)	0
237	Prednisolone (µM)	0.09899049
237	Ruxolitinib (nM)	0
237	Thioguanine (µM)	0
237	Trametinib (nM)	2000
237	Venetoclax (nM)	200
237	Vincristine (µM)	0.09387856
237	Vorinostat (nM)	1761.179
237	asparagise_normalized	0.5972
237	bortezomib_normalized	0.7198
237	CHZ868_normalized	1
237	dasatinib_normalized	0.5862
237	daunorubicin_normalized	0.6526
237	ibrutinib_normalized	0.6791
237	mercaptopurine_normalized	0.2882
237	nelarabine_normalized	0.7478
237	prednisolone_normalized	0.1811
237	trametinib_normalized	1
237	venetoclax_normalized	1
237	vincristine_normalized	0.0902
237	vorinostat_normalized	0.6492
238	immunophenotype	B
238	molecular subtype	Hyperdiploid
238	Protocol	T17
238	NCI risk	HR
238	Age at diagnosis	3.8
238	WBC at diagnosis	54
238	Sex	F
238	Genetically-defined race	White
238	Asparaginase (IU/ml)	20
238	Bortezomib (nM)	0
238	CHZ868 (nM)	20000
238	Cytarabine (µM)	0
238	Dasatinib (nM)	20000
238	Daunorubicin (µM)	0
238	Dexamethasone  (µM)	0
238	Ibrutinib (µM)	20.65945
238	Mercaptopurine (µM)	166.7662
238	Nelarabine (µM)	0
238	Panobinostat (nM)	0
238	Prednisolone (µM)	0.21421824
238	Ruxolitinib (nM)	0
238	Thioguanine (µM)	0
238	Trametinib (nM)	2000
238	Venetoclax (nM)	11.57782
238	Vincristine (µM)	1.341345
238	Vorinostat (nM)	0
238	asparagise_normalized	1
238	CHZ868_normalized	1
238	dasatinib_normalized	1
238	ibrutinib_normalized	0.745
238	mercaptopurine_normalized	0.1722
238	prednisolone_normalized	0.2552
238	trametinib_normalized	1
238	venetoclax_normalized	0.8127
238	vincristine_normalized	0.4707
239	immunophenotype	B
239	molecular subtype	B-other
239	Protocol	T17
239	NCI risk	SR
239	Age at diagnosis	8.8
239	WBC at diagnosis	4.9
239	Sex	M
239	Genetically-defined race	Hispanic
239	Asparaginase (IU/ml)	20
239	Bortezomib (nM)	55.40861
239	CHZ868 (nM)	20000
239	Cytarabine (µM)	0
239	Dasatinib (nM)	6438.457
239	Daunorubicin (µM)	0.1921464
239	Dexamethasone  (µM)	0
239	Ibrutinib (µM)	12.44858
239	Mercaptopurine (µM)	5876
239	Nelarabine (µM)	175.868
239	Panobinostat (nM)	0
239	Prednisolone (µM)	17.04356
239	Ruxolitinib (nM)	0
239	Thioguanine (µM)	0
239	Trametinib (nM)	399.1534
239	Venetoclax (nM)	4.311372
239	Vincristine (µM)	0.452909
239	Vorinostat (nM)	0
239	asparagise_normalized	1
239	bortezomib_normalized	0.5824
239	CHZ868_normalized	1
239	dasatinib_normalized	0.9618
239	daunorubicin_normalized	0.5878
239	ibrutinib_normalized	0.5988
239	mercaptopurine_normalized	1
239	nelarabine_normalized	1
239	prednisolone_normalized	0.6752
239	trametinib_normalized	0.9202
239	venetoclax_normalized	0.7269
239	vincristine_normalized	0.3154
240	immunophenotype	B
240	molecular subtype	PAX5alt
240	Protocol	T17
240	NCI risk	HR
240	Age at diagnosis	15.8
240	WBC at diagnosis	16.7
240	Sex	F
240	Genetically-defined race	White
240	Asparaginase (IU/ml)	0.0016
240	Bortezomib (nM)	50.17193
240	CHZ868 (nM)	0
240	Cytarabine (µM)	0
240	Dasatinib (nM)	0
240	Daunorubicin (µM)	0
240	Dexamethasone  (µM)	0
240	Ibrutinib (µM)	0
240	Mercaptopurine (µM)	1130.692
240	Nelarabine (µM)	26.24815
240	Panobinostat (nM)	0
240	Prednisolone (µM)	0.0209441
240	Ruxolitinib (nM)	0
240	Thioguanine (µM)	0
240	Trametinib (nM)	0
240	Venetoclax (nM)	0
240	Vincristine (µM)	0.02403103
240	Vorinostat (nM)	1041.764
240	asparagise_normalized	0
240	bortezomib_normalized	0.5681
240	mercaptopurine_normalized	0.7245
240	nelarabine_normalized	0.8392
240	prednisolone_normalized	0.032
240	vincristine_normalized	0
240	vorinostat_normalized	0.6036
241	immunophenotype	B
241	molecular subtype	ETV6-RUNX1
241	Protocol	T17
241	NCI risk	SR
241	Age at diagnosis	3.9
241	WBC at diagnosis	4.7
241	Sex	M
241	Genetically-defined race	Unknown
241	Asparaginase (IU/ml)	0.0016
241	Bortezomib (nM)	19.10552
241	CHZ868 (nM)	1691.515
241	Cytarabine (µM)	0
241	Dasatinib (nM)	3020.813
241	Daunorubicin (µM)	0.08462217
241	Dexamethasone  (µM)	0
241	Ibrutinib (µM)	7.313643
241	Mercaptopurine (µM)	1256.491
241	Nelarabine (µM)	188.1659
241	Panobinostat (nM)	0
241	Prednisolone (µM)	0.0075
241	Ruxolitinib (nM)	0
241	Thioguanine (µM)	0
241	Trametinib (nM)	2000
241	Venetoclax (nM)	0.785071012
241	Vincristine (µM)	1.100016
241	Vorinostat (nM)	1640.818
241	asparagise_normalized	0
241	bortezomib_normalized	0.4287
241	CHZ868_normalized	0.8457
241	dasatinib_normalized	0.896
241	daunorubicin_normalized	0.472
241	ibrutinib_normalized	0.4453
241	mercaptopurine_normalized	0.7549
241	nelarabine_normalized	1
241	prednisolone_normalized	0
241	trametinib_normalized	1
241	venetoclax_normalized	0.579
241	vincristine_normalized	0.4423
241	vorinostat_normalized	0.643
242	immunophenotype	B
242	molecular subtype	Hyperdiploid
242	Protocol	T17
242	NCI risk	HR
242	Age at diagnosis	13.8
242	WBC at diagnosis	19.8
242	Sex	F
242	Genetically-defined race	White
242	Asparaginase (IU/ml)	0.0016
242	Bortezomib (nM)	106.9551
242	CHZ868 (nM)	0
242	Cytarabine (µM)	0
242	Dasatinib (nM)	0
242	Daunorubicin (µM)	0.3348839
242	Dexamethasone  (µM)	0
242	Ibrutinib (µM)	0
242	Mercaptopurine (µM)	1091.921
242	Nelarabine (µM)	160
242	Panobinostat (nM)	0
242	Prednisolone (µM)	0.03981415
242	Ruxolitinib (nM)	0
242	Thioguanine (µM)	0
242	Trametinib (nM)	0
242	Venetoclax (nM)	0
242	Vincristine (µM)	108.34
242	Vorinostat (nM)	362.9181
242	asparagise_normalized	0
242	bortezomib_normalized	0.6773
242	daunorubicin_normalized	0.6664
242	mercaptopurine_normalized	0.7144
242	nelarabine_normalized	1
242	prednisolone_normalized	0.0937
242	vincristine_normalized	1
242	vorinostat_normalized	0.512
243	immunophenotype	B
243	molecular subtype	ETV6-RUNX1
243	Protocol	T17
243	NCI risk	SR
243	Age at diagnosis	2.9
243	WBC at diagnosis	11.5
243	Sex	F
243	Genetically-defined race	White
243	Asparaginase (IU/ml)	0.0016
243	Bortezomib (nM)	35.30956
243	CHZ868 (nM)	9700.054
243	Cytarabine (µM)	0
243	Dasatinib (nM)	3890.104
243	Daunorubicin (µM)	0.1363976
243	Dexamethasone  (µM)	0
243	Ibrutinib (µM)	19.34363
243	Mercaptopurine (µM)	2581.063
243	Nelarabine (µM)	112.8353
243	Panobinostat (nM)	0
243	Prednisolone (µM)	0.02985981
243	Ruxolitinib (nM)	0
243	Thioguanine (µM)	0
243	Trametinib (nM)	2000
243	Venetoclax (nM)	4.560958
243	Vincristine (µM)	0.5750493
243	Vorinostat (nM)	963.7852
243	asparagise_normalized	0
243	bortezomib_normalized	0.5174
243	CHZ868_normalized	0.9974
243	dasatinib_normalized	0.918
243	daunorubicin_normalized	0.5394
243	ibrutinib_normalized	0.726
243	mercaptopurine_normalized	0.9626
243	nelarabine_normalized	1
243	prednisolone_normalized	0.0661
243	trametinib_normalized	1
243	venetoclax_normalized	0.7318
243	vincristine_normalized	0.3495
243	vorinostat_normalized	0.5968
244	immunophenotype	B
244	molecular subtype	MEF2D
244	Protocol	T17
244	NCI risk	HR
244	Age at diagnosis	13.2
244	WBC at diagnosis	21.9
244	Sex	F
244	Genetically-defined race	White
244	Asparaginase (IU/ml)	0.0016
244	Bortezomib (nM)	81.49283
244	CHZ868 (nM)	0
244	Cytarabine (µM)	0
244	Dasatinib (nM)	0
244	Daunorubicin (µM)	0.1558554
244	Dexamethasone  (µM)	0
244	Ibrutinib (µM)	0
244	Mercaptopurine (µM)	160.4807
244	Nelarabine (µM)	17.8405
244	Panobinostat (nM)	0
244	Prednisolone (µM)	0.03238369
244	Ruxolitinib (nM)	0
244	Thioguanine (µM)	0
244	Trametinib (nM)	0
244	Venetoclax (nM)	0
244	Vincristine (µM)	0.02228571
244	Vorinostat (nM)	0.5
244	asparagise_normalized	0
244	bortezomib_normalized	0.6381
244	daunorubicin_normalized	0.5583
244	mercaptopurine_normalized	0.1612
244	nelarabine_normalized	0.7835
244	prednisolone_normalized	0.0739
244	vincristine_normalized	0
244	vorinostat_normalized	0
245	immunophenotype	T
245	molecular subtype	T-ALL
245	Protocol	T15
245	NCI risk	HR
245	Age at diagnosis	4.3
245	WBC at diagnosis	65
245	Sex	M
245	Genetically-defined race	White
245	Asparaginase (IU/ml)	2.096438164
245	Bortezomib (nM)	0
245	CHZ868 (nM)	0
245	Cytarabine (µM)	0
245	Dasatinib (nM)	0
245	Daunorubicin (µM)	0
245	Dexamethasone  (µM)	23.2
245	Ibrutinib (µM)	0
245	Mercaptopurine (µM)	114.5729
245	Nelarabine (µM)	0
245	Panobinostat (nM)	0
245	Prednisolone (µM)	0
245	Ruxolitinib (nM)	0
245	Thioguanine (µM)	20.27102
245	Trametinib (nM)	0
245	Venetoclax (nM)	0
245	Vincristine (µM)	1.070588
245	Vorinostat (nM)	0
245	asparagise_normalized	0.8059
245	dexamethasone_normalized	1
245	mercaptopurine_normalized	0.0639
245	thioguanine_normalized	0.2233
245	vincristine_normalized	0.4385
246	immunophenotype	B
246	molecular subtype	B-other
246	Protocol	T17
246	NCI risk	HR
246	Age at diagnosis	3.8
246	WBC at diagnosis	53.7
246	Sex	F
246	Genetically-defined race	White
246	Asparaginase (IU/ml)	0.0016
246	Bortezomib (nM)	174.8865
246	CHZ868 (nM)	10.43844
246	Cytarabine (µM)	0
246	Dasatinib (nM)	2136.847
246	Daunorubicin (µM)	0.04701811
246	Dexamethasone  (µM)	0
246	Ibrutinib (µM)	11.27434
246	Mercaptopurine (µM)	271.0296
246	Nelarabine (µM)	56.57772
246	Panobinostat (nM)	0
246	Prednisolone (µM)	0.03458723
246	Ruxolitinib (nM)	0
246	Thioguanine (µM)	0
246	Trametinib (nM)	2000
246	Venetoclax (nM)	8.500448
246	Vincristine (µM)	8.772884
246	Vorinostat (nM)	935.9551
246	asparagise_normalized	0
246	bortezomib_normalized	0.7483
246	CHZ868_normalized	0.4037
246	dasatinib_normalized	0.866
246	daunorubicin_normalized	0.3889
246	ibrutinib_normalized	0.5702
246	mercaptopurine_normalized	0.3124
246	nelarabine_normalized	0.95
246	prednisolone_normalized	0.0802
246	trametinib_normalized	1
246	venetoclax_normalized	0.7859
246	vincristine_normalized	0.7395
246	vorinostat_normalized	0.5943
247	immunophenotype	B
247	molecular subtype	ETV6-RUNX1
247	Protocol	T17
247	NCI risk	SR
247	Age at diagnosis	4.4
247	WBC at diagnosis	11.8
247	Sex	F
247	Genetically-defined race	White
247	Asparaginase (IU/ml)	0.0016
247	Bortezomib (nM)	455.7681
247	CHZ868 (nM)	20000
247	Cytarabine (µM)	0
247	Dasatinib (nM)	20000
247	Daunorubicin (µM)	0.08769403
247	Dexamethasone  (µM)	0
247	Ibrutinib (µM)	19.47875
247	Mercaptopurine (µM)	2908.738
247	Nelarabine (µM)	160
247	Panobinostat (nM)	0
247	Prednisolone (µM)	0.0944283
247	Ruxolitinib (nM)	0
247	Thioguanine (µM)	0
247	Trametinib (nM)	2000
247	Venetoclax (nM)	0.5375964
247	Vincristine (µM)	0.5951422
247	Vorinostat (nM)	994.1745
247	asparagise_normalized	0
247	bortezomib_normalized	0.8866
247	CHZ868_normalized	1
247	dasatinib_normalized	1
247	daunorubicin_normalized	0.477
247	ibrutinib_normalized	0.728
247	mercaptopurine_normalized	0.9971
247	nelarabine_normalized	1
247	prednisolone_normalized	0.1766
247	trametinib_normalized	1
247	venetoclax_normalized	0.5461
247	vincristine_normalized	0.3544
247	vorinostat_normalized	0.5995
248	immunophenotype	B
248	molecular subtype	ETV6-RUNX1
248	Protocol	T17
248	NCI risk	SR
248	Age at diagnosis	4
248	WBC at diagnosis	8.9
248	Sex	F
248	Genetically-defined race	Asian/Other
248	Asparaginase (IU/ml)	0.0016
248	Bortezomib (nM)	226.1254
248	CHZ868 (nM)	0
248	Cytarabine (µM)	0
248	Dasatinib (nM)	0
248	Daunorubicin (µM)	0.1132821
248	Dexamethasone  (µM)	0
248	Ibrutinib (µM)	0
248	Mercaptopurine (µM)	623.5474
248	Nelarabine (µM)	100.399
248	Panobinostat (nM)	0
248	Prednisolone (µM)	0.02936493
248	Ruxolitinib (nM)	0
248	Thioguanine (µM)	0
248	Trametinib (nM)	0
248	Venetoclax (nM)	0
248	Vincristine (µM)	0.8297929
248	Vorinostat (nM)	560.7725
248	asparagise_normalized	0
248	bortezomib_normalized	0.7854
248	daunorubicin_normalized	0.5132
248	mercaptopurine_normalized	0.5528
248	nelarabine_normalized	1
248	prednisolone_normalized	0.0645
248	vincristine_normalized	0.402
248	vorinostat_normalized	0.5498
249	immunophenotype	B
249	molecular subtype	B-other
249	Protocol	T17
249	NCI risk	SR
249	Age at diagnosis	6.1
249	WBC at diagnosis	7.2
249	Sex	M
249	Genetically-defined race	White
249	Asparaginase (IU/ml)	0.402087597
249	Bortezomib (nM)	2000
249	CHZ868 (nM)	0
249	Cytarabine (µM)	0
249	Dasatinib (nM)	0
249	Daunorubicin (µM)	0.07038778
249	Dexamethasone  (µM)	0
249	Ibrutinib (µM)	0
249	Mercaptopurine (µM)	341.5975
249	Nelarabine (µM)	78.38669
249	Panobinostat (nM)	0
249	Prednisolone (µM)	0.025101022
249	Ruxolitinib (nM)	0
249	Thioguanine (µM)	0
249	Trametinib (nM)	0
249	Venetoclax (nM)	0
249	Vincristine (µM)	0.303713985
249	Vorinostat (nM)	452.7264
249	asparagise_normalized	0.6006
249	bortezomib_normalized	1
249	daunorubicin_normalized	0.4459
249	mercaptopurine_normalized	0.3791
249	nelarabine_normalized	0.9971
249	prednisolone_normalized	0.0494
249	vincristine_normalized	0.2582
249	vorinostat_normalized	0.5312
250	immunophenotype	B
250	molecular subtype	ETV6-RUNX1
250	Protocol	T17
250	NCI risk	HR
250	Age at diagnosis	10.4
250	WBC at diagnosis	67.6
250	Sex	M
250	Genetically-defined race	White
250	Asparaginase (IU/ml)	0.0016
250	Bortezomib (nM)	551.1136
250	CHZ868 (nM)	0
250	Cytarabine (µM)	0
250	Dasatinib (nM)	0
250	Daunorubicin (µM)	0.2574492
250	Dexamethasone  (µM)	0
250	Ibrutinib (µM)	0
250	Mercaptopurine (µM)	1030.611281
250	Nelarabine (µM)	160
250	Panobinostat (nM)	0
250	Prednisolone (µM)	0.05284181
250	Ruxolitinib (nM)	0
250	Thioguanine (µM)	0
250	Trametinib (nM)	0
250	Venetoclax (nM)	0
250	Vincristine (µM)	2.61603162
250	Vorinostat (nM)	915.1444
250	asparagise_normalized	0
250	bortezomib_normalized	0.914
250	daunorubicin_normalized	0.6292
250	mercaptopurine_normalized	0.6977
250	nelarabine_normalized	1
250	prednisolone_normalized	0.1208
250	vincristine_normalized	0.5663
250	vorinostat_normalized	0.5923
251	immunophenotype	B
251	molecular subtype	TCF3-PBX1
251	Protocol	T17
251	NCI risk	HR
251	Age at diagnosis	8.8
251	WBC at diagnosis	112
251	Sex	F
251	Genetically-defined race	White
251	Asparaginase (IU/ml)	0.2797673
251	Bortezomib (nM)	217.0818866
251	CHZ868 (nM)	20000
251	Cytarabine (µM)	0
251	Dasatinib (nM)	0.3328579
251	Daunorubicin (µM)	0.1326168
251	Dexamethasone  (µM)	0
251	Ibrutinib (µM)	9.682032
251	Mercaptopurine (µM)	335.2563
251	Nelarabine (µM)	108.4927
251	Panobinostat (nM)	0
251	Prednisolone (µM)	0.0075
251	Ruxolitinib (nM)	0
251	Thioguanine (µM)	0
251	Trametinib (nM)	2000
251	Venetoclax (nM)	7.507156
251	Vincristine (µM)	0.03917906
251	Vorinostat (nM)	136.9359995
251	asparagise_normalized	0.5556
251	bortezomib_normalized	0.7795
251	CHZ868_normalized	1
251	dasatinib_normalized	0.1045
251	daunorubicin_normalized	0.5354
251	ibrutinib_normalized	0.5263
251	mercaptopurine_normalized	0.3737
251	nelarabine_normalized	1
251	prednisolone_normalized	0
251	trametinib_normalized	1
251	venetoclax_normalized	0.7751
251	vincristine_normalized	0
251	vorinostat_normalized	0.4273
252	immunophenotype	B
252	molecular subtype	ETV6-RUNX1
252	Protocol	T17
252	NCI risk	SR
252	Age at diagnosis	4.6
252	WBC at diagnosis	4.6
252	Sex	M
252	Genetically-defined race	Hispanic
252	Asparaginase (IU/ml)	0.0016
252	Bortezomib (nM)	106.2
252	CHZ868 (nM)	478.9481
252	Cytarabine (µM)	0
252	Dasatinib (nM)	7266.152
252	Daunorubicin (µM)	0.219906989
252	Dexamethasone  (µM)	0
252	Ibrutinib (µM)	6.994874
252	Mercaptopurine (µM)	1572.1
252	Nelarabine (µM)	160
252	Panobinostat (nM)	0
252	Prednisolone (µM)	52.41312
252	Ruxolitinib (nM)	0
252	Thioguanine (µM)	0
252	Trametinib (nM)	1.358397
252	Venetoclax (nM)	0.3696488
252	Vincristine (µM)	0.308549715
252	Vorinostat (nM)	898.2571
252	asparagise_normalized	0
252	bortezomib_normalized	0.6763
252	CHZ868_normalized	0.7361
252	dasatinib_normalized	0.9723
252	daunorubicin_normalized	0.6069
252	ibrutinib_normalized	0.4325
252	mercaptopurine_normalized	0.8196
252	nelarabine_normalized	1
252	prednisolone_normalized	0.783
252	trametinib_normalized	0.4266
252	venetoclax_normalized	0.5136
252	vincristine_normalized	0.2604
252	vorinostat_normalized	0.5907
253	immunophenotype	B
253	molecular subtype	ETV6-RUNX1
253	Protocol	T17
253	NCI risk	HR
253	Age at diagnosis	13.8
253	WBC at diagnosis	4.5
253	Sex	F
253	Genetically-defined race	Hispanic
253	Asparaginase (IU/ml)	20
253	Bortezomib (nM)	39.71838
253	CHZ868 (nM)	0
253	Cytarabine (µM)	0
253	Dasatinib (nM)	0
253	Daunorubicin (µM)	0
253	Dexamethasone  (µM)	0
253	Ibrutinib (µM)	0
253	Mercaptopurine (µM)	0
253	Nelarabine (µM)	115.2963
253	Panobinostat (nM)	0
253	Prednisolone (µM)	0.03556091
253	Ruxolitinib (nM)	0
253	Thioguanine (µM)	0
253	Trametinib (nM)	2000
253	Venetoclax (nM)	1.783458
253	Vincristine (µM)	1.080631
253	Vorinostat (nM)	0
253	asparagise_normalized	1
253	bortezomib_normalized	0.5344
253	nelarabine_normalized	1
253	prednisolone_normalized	0.0828
253	trametinib_normalized	1
253	venetoclax_normalized	0.6503
253	vincristine_normalized	0.4398
254	immunophenotype	B
254	molecular subtype	ETV6-RUNX1
254	Protocol	T17
254	NCI risk	SR
254	Age at diagnosis	2.5
254	WBC at diagnosis	20.4
254	Sex	F
254	Genetically-defined race	White
254	Asparaginase (IU/ml)	0.7477355
254	Bortezomib (nM)	59.42265
254	CHZ868 (nM)	0
254	Cytarabine (µM)	0
254	Dasatinib (nM)	0
254	Daunorubicin (µM)	0.2753195
254	Dexamethasone  (µM)	0
254	Ibrutinib (µM)	0
254	Mercaptopurine (µM)	668.5931295
254	Nelarabine (µM)	190.0051
254	Panobinostat (nM)	0
254	Prednisolone (µM)	0.04208856
254	Ruxolitinib (nM)	0
254	Thioguanine (µM)	0
254	Trametinib (nM)	0
254	Venetoclax (nM)	0
254	Vincristine (µM)	0.3790642
254	Vorinostat (nM)	927.2892
254	asparagise_normalized	0.6777
254	bortezomib_normalized	0.5925
254	daunorubicin_normalized	0.6387
254	mercaptopurine_normalized	0.5729
254	nelarabine_normalized	1
254	prednisolone_normalized	0.099
254	vincristine_normalized	0.2899
254	vorinostat_normalized	0.5934
255	immunophenotype	T
255	molecular subtype	ETP
255	Protocol	T17
255	NCI risk	SR
255	Age at diagnosis	5.2
255	WBC at diagnosis	19.9
255	Sex	M
255	Genetically-defined race	White
255	Asparaginase (IU/ml)	20
255	Bortezomib (nM)	974.3958
255	CHZ868 (nM)	0
255	Cytarabine (µM)	0
255	Dasatinib (nM)	0
255	Daunorubicin (µM)	1.515728
255	Dexamethasone  (µM)	0
255	Ibrutinib (µM)	0
255	Mercaptopurine (µM)	1352.86
255	Nelarabine (µM)	160
255	Panobinostat (nM)	0
255	Prednisolone (µM)	1.58072
255	Ruxolitinib (nM)	0
255	Thioguanine (µM)	0
255	Trametinib (nM)	0
255	Venetoclax (nM)	0
255	Vincristine (µM)	35.75143
255	Vorinostat (nM)	1056.14
255	asparagise_normalized	1
255	bortezomib_normalized	0.9963
255	daunorubicin_normalized	0.8797
255	mercaptopurine_normalized	0.7762
255	nelarabine_normalized	1
255	prednisolone_normalized	0.447
255	vincristine_normalized	0.9405
255	vorinostat_normalized	0.6047
256	immunophenotype	B
256	molecular subtype	ETV6-RUNX1
256	Protocol	T17
256	NCI risk	HR
256	Age at diagnosis	14.1
256	WBC at diagnosis	9.3
256	Sex	M
256	Genetically-defined race	Hispanic
256	Asparaginase (IU/ml)	20
256	Bortezomib (nM)	0
256	CHZ868 (nM)	0
256	Cytarabine (µM)	0
256	Dasatinib (nM)	0
256	Daunorubicin (µM)	0
256	Dexamethasone  (µM)	0
256	Ibrutinib (µM)	0
256	Mercaptopurine (µM)	0
256	Nelarabine (µM)	160
256	Panobinostat (nM)	0
256	Prednisolone (µM)	0.213985655
256	Ruxolitinib (nM)	0
256	Thioguanine (µM)	0
256	Trametinib (nM)	0
256	Venetoclax (nM)	0
256	Vincristine (µM)	0.03658493
256	Vorinostat (nM)	0
256	asparagise_normalized	1
256	nelarabine_normalized	1
256	prednisolone_normalized	0.2551
256	vincristine_normalized	0
257	immunophenotype	B
257	molecular subtype	Hyperdiploid
257	Protocol	T15
257	NCI risk	HR
257	Age at diagnosis	4.8
257	WBC at diagnosis	72.9
257	Sex	F
257	Genetically-defined race	White
257	Asparaginase (IU/ml)	0.8447786
257	Bortezomib (nM)	0
257	CHZ868 (nM)	0
257	Cytarabine (µM)	0.6670466
257	Dasatinib (nM)	0
257	Daunorubicin (µM)	0
257	Dexamethasone  (µM)	0.02091534
257	Ibrutinib (µM)	0
257	Mercaptopurine (µM)	0
257	Nelarabine (µM)	0
257	Panobinostat (nM)	0
257	Prednisolone (µM)	0.08778306
257	Ruxolitinib (nM)	0
257	Thioguanine (µM)	0
257	Trametinib (nM)	0
257	Venetoclax (nM)	0
257	Vincristine (µM)	1.558727
257	Vorinostat (nM)	0
257	asparagise_normalized	0.6929
257	cytarabine_normalized	0.4058
257	dexamethasone_normalized	0.393
257	prednisolone_normalized	0.1696
257	vincristine_normalized	0.4922
258	immunophenotype	B
258	molecular subtype	ETV6-RUNX1
258	Protocol	T17
258	NCI risk	HR
258	Age at diagnosis	4.4
258	WBC at diagnosis	133.6
258	Sex	M
258	Genetically-defined race	black
258	Asparaginase (IU/ml)	0.0016
258	Bortezomib (nM)	27.23750713
258	CHZ868 (nM)	0
258	Cytarabine (µM)	0
258	Dasatinib (nM)	0
258	Daunorubicin (µM)	0.06734099
258	Dexamethasone  (µM)	0
258	Ibrutinib (µM)	0
258	Mercaptopurine (µM)	45.9
258	Nelarabine (µM)	80.42312
258	Panobinostat (nM)	0
258	Prednisolone (µM)	0.4432933
258	Ruxolitinib (nM)	0
258	Thioguanine (µM)	0
258	Trametinib (nM)	0
258	Venetoclax (nM)	0
258	Vincristine (µM)	0.006427745
258	Vorinostat (nM)	993.3969
258	asparagise_normalized	0
258	bortezomib_normalized	0.4799
258	daunorubicin_normalized	0.4397
258	mercaptopurine_normalized	0
258	nelarabine_normalized	1
258	prednisolone_normalized	0.325
258	vincristine_normalized	0
258	vorinostat_normalized	0.5994
259	immunophenotype	B
259	molecular subtype	ETV6-RUNX1
259	Protocol	T17
259	NCI risk	HR
259	Age at diagnosis	14.1
259	WBC at diagnosis	13.8
259	Sex	M
259	Genetically-defined race	White
259	Asparaginase (IU/ml)	0.0016
259	Bortezomib (nM)	13.37938
259	CHZ868 (nM)	0
259	Cytarabine (µM)	0
259	Dasatinib (nM)	0
259	Daunorubicin (µM)	0.2570876
259	Dexamethasone  (µM)	0
259	Ibrutinib (µM)	0
259	Mercaptopurine (µM)	2810.507
259	Nelarabine (µM)	160
259	Panobinostat (nM)	0
259	Prednisolone (µM)	455.7872
259	Ruxolitinib (nM)	0
259	Thioguanine (µM)	0
259	Trametinib (nM)	0
259	Venetoclax (nM)	0
259	Vincristine (µM)	0.3272451
259	Vorinostat (nM)	1174.211
259	asparagise_normalized	0
259	bortezomib_normalized	0.3773
259	daunorubicin_normalized	0.629
259	mercaptopurine_normalized	0.9872
259	nelarabine_normalized	1
259	prednisolone_normalized	0.9905
259	vincristine_normalized	0.2689
259	vorinostat_normalized	0.6139
260	immunophenotype	B
260	molecular subtype	ETV6-RUNX1
260	Protocol	T17
260	NCI risk	SR
260	Age at diagnosis	3.4
260	WBC at diagnosis	10.6
260	Sex	M
260	Genetically-defined race	White
260	Asparaginase (IU/ml)	0.0016
260	Bortezomib (nM)	74.10142
260	CHZ868 (nM)	0
260	Cytarabine (µM)	0
260	Dasatinib (nM)	0
260	Daunorubicin (µM)	0.1954807
260	Dexamethasone  (µM)	0
260	Ibrutinib (µM)	0
260	Mercaptopurine (µM)	274.0143
260	Nelarabine (µM)	121.0542
260	Panobinostat (nM)	0
260	Prednisolone (µM)	0.01588797
260	Ruxolitinib (nM)	0
260	Thioguanine (µM)	0
260	Trametinib (nM)	0
260	Venetoclax (nM)	0
260	Vincristine (µM)	0.2912439
260	Vorinostat (nM)	932.1419
260	asparagise_normalized	0
260	bortezomib_normalized	0.6244
260	daunorubicin_normalized	0.5903
260	mercaptopurine_normalized	0.3155
260	nelarabine_normalized	1
260	prednisolone_normalized	0.0055
260	vincristine_normalized	0.2522
260	vorinostat_normalized	0.5939
261	immunophenotype	B
261	molecular subtype	KMT2A
261	Protocol	T17
261	NCI risk	SR
261	Age at diagnosis	9.8
261	WBC at diagnosis	7.3
261	Sex	F
261	Genetically-defined race	White
261	Asparaginase (IU/ml)	2.514201
261	Bortezomib (nM)	0
261	CHZ868 (nM)	0
261	Cytarabine (µM)	0
261	Dasatinib (nM)	0
261	Daunorubicin (µM)	0
261	Dexamethasone  (µM)	0
261	Ibrutinib (µM)	0
261	Mercaptopurine (µM)	0
261	Nelarabine (µM)	0
261	Panobinostat (nM)	0
261	Prednisolone (µM)	78.27016
261	Ruxolitinib (nM)	0
261	Thioguanine (µM)	0
261	Trametinib (nM)	0
261	Venetoclax (nM)	0
261	Vincristine (µM)	38.69865
261	Vorinostat (nM)	0
261	asparagise_normalized	0.8284
261	prednisolone_normalized	0.8215
261	vincristine_normalized	0.9519
262	immunophenotype	T
262	molecular subtype	T-ALL
262	Protocol	T15
262	NCI risk	HR
262	Age at diagnosis	10.1
262	WBC at diagnosis	285.2
262	Sex	M
262	Genetically-defined race	White
262	Asparaginase (IU/ml)	0
262	Bortezomib (nM)	0
262	CHZ868 (nM)	0
262	Cytarabine (µM)	2.235177
262	Dasatinib (nM)	0
262	Daunorubicin (µM)	0
262	Dexamethasone  (µM)	0
262	Ibrutinib (µM)	0
262	Mercaptopurine (µM)	0
262	Nelarabine (µM)	0
262	Panobinostat (nM)	0
262	Prednisolone (µM)	0.0075
262	Ruxolitinib (nM)	0
262	Thioguanine (µM)	0
262	Trametinib (nM)	0
262	Venetoclax (nM)	0
262	Vincristine (µM)	2.643739
262	Vorinostat (nM)	0
262	cytarabine_normalized	0.5801
262	prednisolone_normalized	0
262	vincristine_normalized	0.5678
263	immunophenotype	B
263	molecular subtype	B-other
263	Protocol	T15
263	NCI risk	HR
263	Age at diagnosis	13.5
263	WBC at diagnosis	91.2
263	Sex	M
263	Genetically-defined race	Asian/Other
263	Asparaginase (IU/ml)	0.7560286
263	Bortezomib (nM)	0
263	CHZ868 (nM)	0
263	Cytarabine (µM)	0
263	Dasatinib (nM)	0
263	Daunorubicin (µM)	0
263	Dexamethasone  (µM)	0
263	Ibrutinib (µM)	0
263	Mercaptopurine (µM)	358.6105
263	Nelarabine (µM)	0
263	Panobinostat (nM)	0
263	Prednisolone (µM)	0
263	Ruxolitinib (nM)	0
263	Thioguanine (µM)	0
263	Trametinib (nM)	0
263	Venetoclax (nM)	0
263	Vincristine (µM)	0
263	Vorinostat (nM)	0
263	asparagise_normalized	0.6791
263	mercaptopurine_normalized	0.3932
264	immunophenotype	T
264	molecular subtype	T-ALL
264	Protocol	T15
264	NCI risk	SR
264	Age at diagnosis	5.9
264	WBC at diagnosis	14.2
264	Sex	M
264	Genetically-defined race	White
264	Asparaginase (IU/ml)	0.055677334
264	Bortezomib (nM)	0
264	CHZ868 (nM)	0
264	Cytarabine (µM)	0.1937733
264	Dasatinib (nM)	0
264	Daunorubicin (µM)	0
264	Dexamethasone  (µM)	1.396293
264	Ibrutinib (µM)	0
264	Mercaptopurine (µM)	5876
264	Nelarabine (µM)	0
264	Panobinostat (nM)	0
264	Prednisolone (µM)	181.6189
264	Ruxolitinib (nM)	0
264	Thioguanine (µM)	84.09122
264	Trametinib (nM)	0
264	Venetoclax (nM)	0
264	Vincristine (µM)	0.08604366
264	Vorinostat (nM)	0
264	asparagise_normalized	0.355
264	cytarabine_normalized	0.2275
264	dexamethasone_normalized	0.7966
264	mercaptopurine_normalized	1
264	prednisolone_normalized	0.9022
264	thioguanine_normalized	0.6339
264	vincristine_normalized	0.0777
265	immunophenotype	B
265	molecular subtype	TCF3-PBX1
265	Protocol	T15
265	NCI risk	SR
265	Age at diagnosis	5.1
265	WBC at diagnosis	31.6
265	Sex	F
265	Genetically-defined race	White
265	Asparaginase (IU/ml)	20
265	Bortezomib (nM)	0
265	CHZ868 (nM)	0
265	Cytarabine (µM)	0
265	Dasatinib (nM)	0
265	Daunorubicin (µM)	0
265	Dexamethasone  (µM)	0
265	Ibrutinib (µM)	0
265	Mercaptopurine (µM)	5876
265	Nelarabine (µM)	0
265	Panobinostat (nM)	0
265	Prednisolone (µM)	0.0075
265	Ruxolitinib (nM)	0
265	Thioguanine (µM)	0
265	Trametinib (nM)	0
265	Venetoclax (nM)	0
265	Vincristine (µM)	3.148135194
265	Vorinostat (nM)	0
265	asparagise_normalized	1
265	mercaptopurine_normalized	1
265	prednisolone_normalized	0
265	vincristine_normalized	0.5928
266	immunophenotype	B
266	molecular subtype	KMT2A
266	Protocol	T15
266	NCI risk	HR
266	Age at diagnosis	16.8
266	WBC at diagnosis	90.2
266	Sex	M
266	Genetically-defined race	Asian/Other
266	Asparaginase (IU/ml)	0
266	Bortezomib (nM)	0
266	CHZ868 (nM)	0
266	Cytarabine (µM)	1.521949
266	Dasatinib (nM)	0
266	Daunorubicin (µM)	0
266	Dexamethasone  (µM)	3.695085
266	Ibrutinib (µM)	0
266	Mercaptopurine (µM)	0
266	Nelarabine (µM)	0
266	Panobinostat (nM)	0
266	Prednisolone (µM)	1006
266	Ruxolitinib (nM)	0
266	Thioguanine (µM)	0
266	Trametinib (nM)	0
266	Venetoclax (nM)	0
266	Vincristine (µM)	3.090347
266	Vorinostat (nM)	0
266	cytarabine_normalized	0.5247
266	dexamethasone_normalized	0.8901
266	prednisolone_normalized	1
266	vincristine_normalized	0.5902
267	immunophenotype	B
267	molecular subtype	ETV6-RUNX1
267	Protocol	T15
267	NCI risk	SR
267	Age at diagnosis	3.9
267	WBC at diagnosis	16.5
267	Sex	F
267	Genetically-defined race	White
267	Asparaginase (IU/ml)	0.2345328
267	Bortezomib (nM)	0
267	CHZ868 (nM)	0
267	Cytarabine (µM)	0.4533372
267	Dasatinib (nM)	0
267	Daunorubicin (µM)	0
267	Dexamethasone  (µM)	0.2494184
267	Ibrutinib (µM)	0
267	Mercaptopurine (µM)	414.1967
267	Nelarabine (µM)	0
267	Panobinostat (nM)	0
267	Prednisolone (µM)	0.06113279
267	Ruxolitinib (nM)	0
267	Thioguanine (µM)	58.08647
267	Trametinib (nM)	0
267	Venetoclax (nM)	0
267	Vincristine (µM)	5.513983
267	Vorinostat (nM)	0
267	asparagise_normalized	0.5337
267	cytarabine_normalized	0.3501
267	dexamethasone_normalized	0.6311
267	mercaptopurine_normalized	0.4347
267	prednisolone_normalized	0.1348
267	thioguanine_normalized	0.5271
267	vincristine_normalized	0.673
268	immunophenotype	B
268	molecular subtype	ETV6-RUNX1
268	Protocol	T15
268	NCI risk	SR
268	Age at diagnosis	2.8
268	WBC at diagnosis	4.9
268	Sex	F
268	Genetically-defined race	Unknown
268	Asparaginase (IU/ml)	0.5800822
268	Bortezomib (nM)	0
268	CHZ868 (nM)	0
268	Cytarabine (µM)	0
268	Dasatinib (nM)	0
268	Daunorubicin (µM)	0
268	Dexamethasone  (µM)	0.05522109
268	Ibrutinib (µM)	0
268	Mercaptopurine (µM)	436.2387
268	Nelarabine (µM)	0
268	Panobinostat (nM)	0
268	Prednisolone (µM)	0.1262024
268	Ruxolitinib (nM)	0
268	Thioguanine (µM)	46.74272
268	Trametinib (nM)	0
268	Venetoclax (nM)	0
268	Vincristine (µM)	2.335288
268	Vorinostat (nM)	0
268	asparagise_normalized	0.6462
268	dexamethasone_normalized	0.4862
268	mercaptopurine_normalized	0.4497
268	prednisolone_normalized	0.2044
268	thioguanine_normalized	0.4644
268	vincristine_normalized	0.5501
269	immunophenotype	B
269	molecular subtype	PAX5 P80R
269	Protocol	T15
269	NCI risk	SR
269	Age at diagnosis	9.6
269	WBC at diagnosis	15.3
269	Sex	F
269	Genetically-defined race	White
269	Asparaginase (IU/ml)	0.0016
269	Bortezomib (nM)	0
269	CHZ868 (nM)	0
269	Cytarabine (µM)	0
269	Dasatinib (nM)	0
269	Daunorubicin (µM)	0
269	Dexamethasone  (µM)	0.000175
269	Ibrutinib (µM)	0
269	Mercaptopurine (µM)	0
269	Nelarabine (µM)	0
269	Panobinostat (nM)	0
269	Prednisolone (µM)	1006
269	Ruxolitinib (nM)	0
269	Thioguanine (µM)	0
269	Trametinib (nM)	0
269	Venetoclax (nM)	0
269	Vincristine (µM)	0
269	Vorinostat (nM)	0
269	asparagise_normalized	0
269	dexamethasone_normalized	0
269	prednisolone_normalized	1
270	immunophenotype	B
270	molecular subtype	ETV6-RUNX1
270	Protocol	T15
270	NCI risk	SR
270	Age at diagnosis	5.2
270	WBC at diagnosis	6.9
270	Sex	F
270	Genetically-defined race	White
270	Asparaginase (IU/ml)	0.0016
270	Bortezomib (nM)	0
270	CHZ868 (nM)	0
270	Cytarabine (µM)	7.26399
270	Dasatinib (nM)	0
270	Daunorubicin (µM)	0
270	Dexamethasone  (µM)	0.04419054
270	Ibrutinib (µM)	0
270	Mercaptopurine (µM)	587.9397
270	Nelarabine (µM)	0
270	Panobinostat (nM)	0
270	Prednisolone (µM)	0.0491616
270	Ruxolitinib (nM)	0
270	Thioguanine (µM)	16.69196
270	Trametinib (nM)	0
270	Venetoclax (nM)	0
270	Vincristine (µM)	27.44563
270	Vorinostat (nM)	0
270	asparagise_normalized	0
270	cytarabine_normalized	0.7501
270	dexamethasone_normalized	0.4648
270	mercaptopurine_normalized	0.5358
270	prednisolone_normalized	0.1139
270	thioguanine_normalized	0.1673
270	vincristine_normalized	0.9027
271	immunophenotype	T
271	molecular subtype	T-ALL
271	Protocol	T15
271	NCI risk	HR
271	Age at diagnosis	8.5
271	WBC at diagnosis	98.8
271	Sex	F
271	Genetically-defined race	White
271	Asparaginase (IU/ml)	0.0016
271	Bortezomib (nM)	0
271	CHZ868 (nM)	0
271	Cytarabine (µM)	0
271	Dasatinib (nM)	0
271	Daunorubicin (µM)	0
271	Dexamethasone  (µM)	0
271	Ibrutinib (µM)	0
271	Mercaptopurine (µM)	0
271	Nelarabine (µM)	0
271	Panobinostat (nM)	0
271	Prednisolone (µM)	0
271	Ruxolitinib (nM)	0
271	Thioguanine (µM)	0
271	Trametinib (nM)	0
271	Venetoclax (nM)	0
271	Vincristine (µM)	0
271	Vorinostat (nM)	0
271	asparagise_normalized	0
272	immunophenotype	B
272	molecular subtype	PAX5alt
272	Protocol	T15
272	NCI risk	SR
272	Age at diagnosis	6.8
272	WBC at diagnosis	36.7
272	Sex	F
272	Genetically-defined race	White
272	Asparaginase (IU/ml)	20
272	Bortezomib (nM)	0
272	CHZ868 (nM)	0
272	Cytarabine (µM)	0
272	Dasatinib (nM)	0
272	Daunorubicin (µM)	0
272	Dexamethasone  (µM)	23.2
272	Ibrutinib (µM)	0
272	Mercaptopurine (µM)	0
272	Nelarabine (µM)	0
272	Panobinostat (nM)	0
272	Prednisolone (µM)	1006
272	Ruxolitinib (nM)	0
272	Thioguanine (µM)	0
272	Trametinib (nM)	0
272	Venetoclax (nM)	0
272	Vincristine (µM)	108.34
272	Vorinostat (nM)	0
272	asparagise_normalized	1
272	dexamethasone_normalized	1
272	prednisolone_normalized	1
272	vincristine_normalized	1
273	immunophenotype	B
273	molecular subtype	PAX5alt
273	Protocol	T15
273	NCI risk	HR
273	Age at diagnosis	2
273	WBC at diagnosis	86.2
273	Sex	M
273	Genetically-defined race	black
273	Asparaginase (IU/ml)	0.296698
273	Bortezomib (nM)	0
273	CHZ868 (nM)	0
273	Cytarabine (µM)	82.2
273	Dasatinib (nM)	0
273	Daunorubicin (µM)	0
273	Dexamethasone  (µM)	0.1650842
273	Ibrutinib (µM)	0
273	Mercaptopurine (µM)	5876
273	Nelarabine (µM)	0
273	Panobinostat (nM)	0
273	Prednisolone (µM)	0
273	Ruxolitinib (nM)	0
273	Thioguanine (µM)	598
273	Trametinib (nM)	0
273	Venetoclax (nM)	0
273	Vincristine (µM)	0
273	Vorinostat (nM)	0
273	asparagise_normalized	0.5629
273	cytarabine_normalized	1
273	dexamethasone_normalized	0.5915
273	mercaptopurine_normalized	1
273	thioguanine_normalized	1
274	immunophenotype	B
274	molecular subtype	ETV6-RUNX1
274	Protocol	T15
274	NCI risk	SR
274	Age at diagnosis	2.2
274	WBC at diagnosis	22.9
274	Sex	F
274	Genetically-defined race	White
274	Asparaginase (IU/ml)	20
274	Bortezomib (nM)	0
274	CHZ868 (nM)	0
274	Cytarabine (µM)	0
274	Dasatinib (nM)	0
274	Daunorubicin (µM)	0
274	Dexamethasone  (µM)	0
274	Ibrutinib (µM)	0
274	Mercaptopurine (µM)	5876
274	Nelarabine (µM)	0
274	Panobinostat (nM)	0
274	Prednisolone (µM)	0
274	Ruxolitinib (nM)	0
274	Thioguanine (µM)	0
274	Trametinib (nM)	0
274	Venetoclax (nM)	0
274	Vincristine (µM)	0
274	Vorinostat (nM)	0
274	asparagise_normalized	1
274	mercaptopurine_normalized	1
275	immunophenotype	B
275	molecular subtype	BCR-ABL1
275	Protocol	T15
275	NCI risk	HR
275	Age at diagnosis	11.9
275	WBC at diagnosis	418
275	Sex	F
275	Genetically-defined race	White
275	Asparaginase (IU/ml)	1.957033
275	Bortezomib (nM)	0
275	CHZ868 (nM)	0
275	Cytarabine (µM)	0
275	Dasatinib (nM)	0
275	Daunorubicin (µM)	0
275	Dexamethasone  (µM)	0.03637265
275	Ibrutinib (µM)	0
275	Mercaptopurine (µM)	5876
275	Nelarabine (µM)	0
275	Panobinostat (nM)	0
275	Prednisolone (µM)	1006
275	Ruxolitinib (nM)	0
275	Thioguanine (µM)	21.08146
275	Trametinib (nM)	0
275	Venetoclax (nM)	0
275	Vincristine (µM)	0
275	Vorinostat (nM)	0
275	asparagise_normalized	0.7973
275	dexamethasone_normalized	0.4461
275	mercaptopurine_normalized	1
275	prednisolone_normalized	1
275	thioguanine_normalized	0.2346
276	immunophenotype	B
276	molecular subtype	DUX4
276	Protocol	T15
276	NCI risk	HR
276	Age at diagnosis	5
276	WBC at diagnosis	105
276	Sex	F
276	Genetically-defined race	black
276	Asparaginase (IU/ml)	20
276	Bortezomib (nM)	0
276	CHZ868 (nM)	0
276	Cytarabine (µM)	0
276	Dasatinib (nM)	0
276	Daunorubicin (µM)	0
276	Dexamethasone  (µM)	0.01635947
276	Ibrutinib (µM)	0
276	Mercaptopurine (µM)	152.5748
276	Nelarabine (µM)	0
276	Panobinostat (nM)	0
276	Prednisolone (µM)	0
276	Ruxolitinib (nM)	0
276	Thioguanine (µM)	12.2879
276	Trametinib (nM)	0
276	Venetoclax (nM)	0
276	Vincristine (µM)	0
276	Vorinostat (nM)	0
276	asparagise_normalized	1
276	dexamethasone_normalized	0.3694
276	mercaptopurine_normalized	0.1466
276	thioguanine_normalized	0.0789
277	immunophenotype	B
277	molecular subtype	Ph-like_non_CRLF2
277	Protocol	T15
277	NCI risk	HR
277	Age at diagnosis	18
277	WBC at diagnosis	6.6
277	Sex	M
277	Genetically-defined race	Unknown
277	Asparaginase (IU/ml)	20
277	Bortezomib (nM)	0
277	CHZ868 (nM)	0
277	Cytarabine (µM)	0
277	Dasatinib (nM)	0
277	Daunorubicin (µM)	0
277	Dexamethasone  (µM)	23.2
277	Ibrutinib (µM)	0
277	Mercaptopurine (µM)	5876
277	Nelarabine (µM)	0
277	Panobinostat (nM)	0
277	Prednisolone (µM)	0
277	Ruxolitinib (nM)	0
277	Thioguanine (µM)	598
277	Trametinib (nM)	0
277	Venetoclax (nM)	0
277	Vincristine (µM)	0
277	Vorinostat (nM)	0
277	asparagise_normalized	1
277	dexamethasone_normalized	1
277	mercaptopurine_normalized	1
277	thioguanine_normalized	1
278	immunophenotype	B
278	molecular subtype	TCF3-PBX1
278	Protocol	T15
278	NCI risk	HR
278	Age at diagnosis	12.3
278	WBC at diagnosis	76.1
278	Sex	F
278	Genetically-defined race	Hispanic
278	Asparaginase (IU/ml)	20
278	Bortezomib (nM)	0
278	CHZ868 (nM)	0
278	Cytarabine (µM)	0
278	Dasatinib (nM)	0
278	Daunorubicin (µM)	0
278	Dexamethasone  (µM)	0.003422121
278	Ibrutinib (µM)	0
278	Mercaptopurine (µM)	171.3067
278	Nelarabine (µM)	0
278	Panobinostat (nM)	0
278	Prednisolone (µM)	1006
278	Ruxolitinib (nM)	0
278	Thioguanine (µM)	6.023139
278	Trametinib (nM)	0
278	Venetoclax (nM)	0
278	Vincristine (µM)	0
278	Vorinostat (nM)	0
278	asparagise_normalized	1
278	dexamethasone_normalized	0.2191
278	mercaptopurine_normalized	0.18
278	prednisolone_normalized	1
278	thioguanine_normalized	0
279	immunophenotype	B
279	molecular subtype	ETV6-RUNX1
279	Protocol	T15
279	NCI risk	HR
279	Age at diagnosis	3.6
279	WBC at diagnosis	122
279	Sex	M
279	Genetically-defined race	Hispanic
279	Asparaginase (IU/ml)	0
279	Bortezomib (nM)	0
279	CHZ868 (nM)	0
279	Cytarabine (µM)	0
279	Dasatinib (nM)	0
279	Daunorubicin (µM)	0
279	Dexamethasone  (µM)	0
279	Ibrutinib (µM)	0
279	Mercaptopurine (µM)	45.9
279	Nelarabine (µM)	0
279	Panobinostat (nM)	0
279	Prednisolone (µM)	0.0075
279	Ruxolitinib (nM)	0
279	Thioguanine (µM)	4.675
279	Trametinib (nM)	0
279	Venetoclax (nM)	0
279	Vincristine (µM)	0
279	Vorinostat (nM)	0
279	mercaptopurine_normalized	0
279	prednisolone_normalized	0
279	thioguanine_normalized	0
280	immunophenotype	B
280	molecular subtype	KMT2A
280	Protocol	T15
280	NCI risk	HR
280	Age at diagnosis	1.9
280	WBC at diagnosis	347
280	Sex	F
280	Genetically-defined race	White
280	Asparaginase (IU/ml)	0.03058748
280	Bortezomib (nM)	0
280	CHZ868 (nM)	0
280	Cytarabine (µM)	0
280	Dasatinib (nM)	0
280	Daunorubicin (µM)	0
280	Dexamethasone  (µM)	0.053737352
280	Ibrutinib (µM)	0
280	Mercaptopurine (µM)	133.7366
280	Nelarabine (µM)	0
280	Panobinostat (nM)	0
280	Prednisolone (µM)	0
280	Ruxolitinib (nM)	0
280	Thioguanine (µM)	5.218587641
280	Trametinib (nM)	0
280	Venetoclax (nM)	0
280	Vincristine (µM)	0
280	Vorinostat (nM)	0
280	asparagise_normalized	0.2805
280	dexamethasone_normalized	0.4836
280	mercaptopurine_normalized	0.1086
280	thioguanine_normalized	0
281	immunophenotype	B
281	molecular subtype	ETV6-RUNX1
281	Protocol	T15
281	NCI risk	SR
281	Age at diagnosis	4.6
281	WBC at diagnosis	2.9
281	Sex	M
281	Genetically-defined race	White
281	Asparaginase (IU/ml)	0.1929382
281	Bortezomib (nM)	0
281	CHZ868 (nM)	0
281	Cytarabine (µM)	0
281	Dasatinib (nM)	0
281	Daunorubicin (µM)	0
281	Dexamethasone  (µM)	0.05872173
281	Ibrutinib (µM)	0
281	Mercaptopurine (µM)	86.72035
281	Nelarabine (µM)	0
281	Panobinostat (nM)	0
281	Prednisolone (µM)	0
281	Ruxolitinib (nM)	0
281	Thioguanine (µM)	0
281	Trametinib (nM)	0
281	Venetoclax (nM)	0
281	Vincristine (µM)	0
281	Vorinostat (nM)	0
281	asparagise_normalized	0.5094
281	dexamethasone_normalized	0.4922
281	mercaptopurine_normalized	0
282	immunophenotype	B
282	molecular subtype	ETV6-RUNX1
282	Protocol	T15
282	NCI risk	SR
282	Age at diagnosis	2.4
282	WBC at diagnosis	16.8
282	Sex	M
282	Genetically-defined race	White
282	Asparaginase (IU/ml)	0.350929807
282	Bortezomib (nM)	0
282	CHZ868 (nM)	0
282	Cytarabine (µM)	0
282	Dasatinib (nM)	0
282	Daunorubicin (µM)	0
282	Dexamethasone  (µM)	23.2
282	Ibrutinib (µM)	0
282	Mercaptopurine (µM)	5876
282	Nelarabine (µM)	0
282	Panobinostat (nM)	0
282	Prednisolone (µM)	0
282	Ruxolitinib (nM)	0
282	Thioguanine (µM)	41.70536
282	Trametinib (nM)	0
282	Venetoclax (nM)	0
282	Vincristine (µM)	0
282	Vorinostat (nM)	0
282	asparagise_normalized	0.5837
282	dexamethasone_normalized	1
282	mercaptopurine_normalized	1
282	thioguanine_normalized	0.4315
283	immunophenotype	B
283	molecular subtype	B-other
283	Protocol	T15
283	NCI risk	SR
283	Age at diagnosis	4.6
283	WBC at diagnosis	40.8
283	Sex	M
283	Genetically-defined race	White
283	Asparaginase (IU/ml)	0.0016
283	Bortezomib (nM)	0
283	CHZ868 (nM)	0
283	Cytarabine (µM)	0.133885
283	Dasatinib (nM)	0
283	Daunorubicin (µM)	0
283	Dexamethasone  (µM)	0.003815036
283	Ibrutinib (µM)	0
283	Mercaptopurine (µM)	45.9
283	Nelarabine (µM)	0
283	Panobinostat (nM)	0
283	Prednisolone (µM)	0.07080689
283	Ruxolitinib (nM)	0
283	Thioguanine (µM)	9.390632
283	Trametinib (nM)	0
283	Venetoclax (nM)	0
283	Vincristine (µM)	0.025
283	Vorinostat (nM)	0
283	asparagise_normalized	0
283	cytarabine_normalized	0.1742
283	dexamethasone_normalized	0.2295
283	mercaptopurine_normalized	0
283	prednisolone_normalized	0.1489
283	thioguanine_normalized	0.0013
283	vincristine_normalized	0
284	immunophenotype	B
284	molecular subtype	Ph-like_non_CRLF2
284	Protocol	T15
284	NCI risk	SR
284	Age at diagnosis	4
284	WBC at diagnosis	41.8
284	Sex	M
284	Genetically-defined race	White
284	Asparaginase (IU/ml)	0.1594546
284	Bortezomib (nM)	0
284	CHZ868 (nM)	0
284	Cytarabine (µM)	0
284	Dasatinib (nM)	0
284	Daunorubicin (µM)	0
284	Dexamethasone  (µM)	0.06657667
284	Ibrutinib (µM)	0
284	Mercaptopurine (µM)	5876
284	Nelarabine (µM)	0
284	Panobinostat (nM)	0
284	Prednisolone (µM)	0
284	Ruxolitinib (nM)	0
284	Thioguanine (µM)	48.59695
284	Trametinib (nM)	0
284	Venetoclax (nM)	0
284	Vincristine (µM)	0
284	Vorinostat (nM)	0
284	asparagise_normalized	0.4857
284	dexamethasone_normalized	0.5042
284	mercaptopurine_normalized	1
284	thioguanine_normalized	0.4757
285	immunophenotype	B
285	molecular subtype	ETV6-RUNX1
285	Protocol	T15
285	NCI risk	HR
285	Age at diagnosis	3.6
285	WBC at diagnosis	77.7
285	Sex	F
285	Genetically-defined race	Asian/Other
285	Asparaginase (IU/ml)	0.0016
285	Bortezomib (nM)	0
285	CHZ868 (nM)	0
285	Cytarabine (µM)	0
285	Dasatinib (nM)	0
285	Daunorubicin (µM)	0
285	Dexamethasone  (µM)	23.2
285	Ibrutinib (µM)	0
285	Mercaptopurine (µM)	5876
285	Nelarabine (µM)	0
285	Panobinostat (nM)	0
285	Prednisolone (µM)	0
285	Ruxolitinib (nM)	0
285	Thioguanine (µM)	4.675
285	Trametinib (nM)	0
285	Venetoclax (nM)	0
285	Vincristine (µM)	0
285	Vorinostat (nM)	0
285	asparagise_normalized	0
285	dexamethasone_normalized	1
285	mercaptopurine_normalized	1
285	thioguanine_normalized	0
286	immunophenotype	B
286	molecular subtype	DUX4
286	Protocol	T15
286	NCI risk	HR
286	Age at diagnosis	15.7
286	WBC at diagnosis	3.8
286	Sex	M
286	Genetically-defined race	White
286	Asparaginase (IU/ml)	0
286	Bortezomib (nM)	0
286	CHZ868 (nM)	0
286	Cytarabine (µM)	0
286	Dasatinib (nM)	0
286	Daunorubicin (µM)	0
286	Dexamethasone  (µM)	0.000164503
286	Ibrutinib (µM)	0
286	Mercaptopurine (µM)	0
286	Nelarabine (µM)	0
286	Panobinostat (nM)	0
286	Prednisolone (µM)	1006
286	Ruxolitinib (nM)	0
286	Thioguanine (µM)	0
286	Trametinib (nM)	0
286	Venetoclax (nM)	0
286	Vincristine (µM)	0
286	Vorinostat (nM)	0
286	dexamethasone_normalized	0
286	prednisolone_normalized	1
287	immunophenotype	B
287	molecular subtype	ETV6-RUNX1-like
287	Protocol	T15
287	NCI risk	SR
287	Age at diagnosis	1.6
287	WBC at diagnosis	4.1
287	Sex	F
287	Genetically-defined race	Hispanic
287	Asparaginase (IU/ml)	0
287	Bortezomib (nM)	0
287	CHZ868 (nM)	0
287	Cytarabine (µM)	0
287	Dasatinib (nM)	0
287	Daunorubicin (µM)	0
287	Dexamethasone  (µM)	0.01211582
287	Ibrutinib (µM)	0
287	Mercaptopurine (µM)	0
287	Nelarabine (µM)	0
287	Panobinostat (nM)	0
287	Prednisolone (µM)	0
287	Ruxolitinib (nM)	0
287	Thioguanine (µM)	598
287	Trametinib (nM)	0
287	Venetoclax (nM)	0
287	Vincristine (µM)	0
287	Vorinostat (nM)	0
287	dexamethasone_normalized	0.3405
287	thioguanine_normalized	1
288	immunophenotype	B
288	molecular subtype	ETV6-RUNX1
288	Protocol	T15
288	NCI risk	SR
288	Age at diagnosis	2.4
288	WBC at diagnosis	10.1
288	Sex	M
288	Genetically-defined race	Hispanic
288	Asparaginase (IU/ml)	0
288	Bortezomib (nM)	0
288	CHZ868 (nM)	0
288	Cytarabine (µM)	0
288	Dasatinib (nM)	0
288	Daunorubicin (µM)	0
288	Dexamethasone  (µM)	0.02779814
288	Ibrutinib (µM)	0
288	Mercaptopurine (µM)	5876
288	Nelarabine (µM)	0
288	Panobinostat (nM)	0
288	Prednisolone (µM)	0.1734069
288	Ruxolitinib (nM)	0
288	Thioguanine (µM)	46.35154
288	Trametinib (nM)	0
288	Venetoclax (nM)	0
288	Vincristine (µM)	0.3411156
288	Vorinostat (nM)	0
288	dexamethasone_normalized	0.4203
288	mercaptopurine_normalized	1
288	prednisolone_normalized	0.2349
288	thioguanine_normalized	0.462
288	vincristine_normalized	0.2748
289	immunophenotype	B
289	molecular subtype	ETV6-RUNX1
289	Protocol	T15
289	NCI risk	SR
289	Age at diagnosis	3.4
289	WBC at diagnosis	4.2
289	Sex	F
289	Genetically-defined race	Hispanic
289	Asparaginase (IU/ml)	0
289	Bortezomib (nM)	0
289	CHZ868 (nM)	0
289	Cytarabine (µM)	0
289	Dasatinib (nM)	0
289	Daunorubicin (µM)	0
289	Dexamethasone  (µM)	0.06672212
289	Ibrutinib (µM)	0
289	Mercaptopurine (µM)	5876
289	Nelarabine (µM)	0
289	Panobinostat (nM)	0
289	Prednisolone (µM)	0
289	Ruxolitinib (nM)	0
289	Thioguanine (µM)	0
289	Trametinib (nM)	0
289	Venetoclax (nM)	0
289	Vincristine (µM)	0
289	Vorinostat (nM)	0
289	dexamethasone_normalized	0.5044
289	mercaptopurine_normalized	1
290	immunophenotype	B
290	molecular subtype	BCR-ABL1
290	Protocol	T15
290	NCI risk	SR
290	Age at diagnosis	6.4
290	WBC at diagnosis	48
290	Sex	M
290	Genetically-defined race	White
290	Asparaginase (IU/ml)	20
290	Bortezomib (nM)	0
290	CHZ868 (nM)	0
290	Cytarabine (µM)	0
290	Dasatinib (nM)	0
290	Daunorubicin (µM)	0
290	Dexamethasone  (µM)	4.675355619
290	Ibrutinib (µM)	0
290	Mercaptopurine (µM)	0
290	Nelarabine (µM)	0
290	Panobinostat (nM)	0
290	Prednisolone (µM)	0
290	Ruxolitinib (nM)	0
290	Thioguanine (µM)	40.39596
290	Trametinib (nM)	0
290	Venetoclax (nM)	0
290	Vincristine (µM)	0
290	Vorinostat (nM)	0
290	asparagise_normalized	1
290	dexamethasone_normalized	0.9127
290	thioguanine_normalized	0.4223
291	immunophenotype	B
291	molecular subtype	PAX5alt
291	Protocol	T15
291	NCI risk	SR
291	Age at diagnosis	3.7
291	WBC at diagnosis	19.3
291	Sex	M
291	Genetically-defined race	White
291	Asparaginase (IU/ml)	0.3314194
291	Bortezomib (nM)	0
291	CHZ868 (nM)	0
291	Cytarabine (µM)	0
291	Dasatinib (nM)	0
291	Daunorubicin (µM)	0
291	Dexamethasone  (µM)	0.001577105
291	Ibrutinib (µM)	0
291	Mercaptopurine (µM)	162.4613
291	Nelarabine (µM)	0
291	Panobinostat (nM)	0
291	Prednisolone (µM)	0
291	Ruxolitinib (nM)	0
291	Thioguanine (µM)	14.15001
291	Trametinib (nM)	0
291	Venetoclax (nM)	0
291	Vincristine (µM)	0
291	Vorinostat (nM)	0
291	asparagise_normalized	0.5766
291	dexamethasone_normalized	0.1446
291	mercaptopurine_normalized	0.1647
291	thioguanine_normalized	0.1196
292	immunophenotype	T
292	molecular subtype	T-ALL
292	Protocol	T15
292	NCI risk	HR
292	Age at diagnosis	6.1
292	WBC at diagnosis	86.3
292	Sex	M
292	Genetically-defined race	White
292	Asparaginase (IU/ml)	0
292	Bortezomib (nM)	0
292	CHZ868 (nM)	0
292	Cytarabine (µM)	0
292	Dasatinib (nM)	0
292	Daunorubicin (µM)	0
292	Dexamethasone  (µM)	0
292	Ibrutinib (µM)	0
292	Mercaptopurine (µM)	0
292	Nelarabine (µM)	0
292	Panobinostat (nM)	0
292	Prednisolone (µM)	1006
292	Ruxolitinib (nM)	0
292	Thioguanine (µM)	0
292	Trametinib (nM)	0
292	Venetoclax (nM)	0
292	Vincristine (µM)	0.6777723
292	Vorinostat (nM)	0
292	prednisolone_normalized	1
292	vincristine_normalized	0.373
293	immunophenotype	B
293	molecular subtype	B-other
293	Protocol	T15
293	NCI risk	HR
293	Age at diagnosis	12.5
293	WBC at diagnosis	36.9
293	Sex	F
293	Genetically-defined race	Hispanic
293	Asparaginase (IU/ml)	0
293	Bortezomib (nM)	0
293	CHZ868 (nM)	0
293	Cytarabine (µM)	0
293	Dasatinib (nM)	0
293	Daunorubicin (µM)	0
293	Dexamethasone  (µM)	23.2
293	Ibrutinib (µM)	0
293	Mercaptopurine (µM)	5876
293	Nelarabine (µM)	0
293	Panobinostat (nM)	0
293	Prednisolone (µM)	1006
293	Ruxolitinib (nM)	0
293	Thioguanine (µM)	46.1495
293	Trametinib (nM)	0
293	Venetoclax (nM)	0
293	Vincristine (µM)	0.1186397
293	Vorinostat (nM)	0
293	dexamethasone_normalized	1
293	mercaptopurine_normalized	1
293	prednisolone_normalized	1
293	thioguanine_normalized	0.4607
293	vincristine_normalized	0.1237
294	immunophenotype	B
294	molecular subtype	PAX5alt
294	Protocol	T15
294	NCI risk	HR
294	Age at diagnosis	2.2
294	WBC at diagnosis	74.7
294	Sex	F
294	Genetically-defined race	White
294	Asparaginase (IU/ml)	0
294	Bortezomib (nM)	0
294	CHZ868 (nM)	0
294	Cytarabine (µM)	0
294	Dasatinib (nM)	0
294	Daunorubicin (µM)	0
294	Dexamethasone  (µM)	0.01480657
294	Ibrutinib (µM)	0
294	Mercaptopurine (µM)	388.5599
294	Nelarabine (µM)	0
294	Panobinostat (nM)	0
294	Prednisolone (µM)	0.0075
294	Ruxolitinib (nM)	0
294	Thioguanine (µM)	48.14381
294	Trametinib (nM)	0
294	Venetoclax (nM)	0
294	Vincristine (µM)	0.025
294	Vorinostat (nM)	0
294	dexamethasone_normalized	0.3598
294	mercaptopurine_normalized	0.4163
294	prednisolone_normalized	0
294	thioguanine_normalized	0.473
294	vincristine_normalized	0
295	immunophenotype	T
295	molecular subtype	T-ALL
295	Protocol	T15
295	NCI risk	HR
295	Age at diagnosis	5.6
295	WBC at diagnosis	1014
295	Sex	M
295	Genetically-defined race	Unknown
295	Asparaginase (IU/ml)	0.001944386
295	Bortezomib (nM)	0
295	CHZ868 (nM)	0
295	Cytarabine (µM)	0.016309404
295	Dasatinib (nM)	0
295	Daunorubicin (µM)	0
295	Dexamethasone  (µM)	0.01131524
295	Ibrutinib (µM)	0
295	Mercaptopurine (µM)	63.94788
295	Nelarabine (µM)	0
295	Panobinostat (nM)	0
295	Prednisolone (µM)	1006
295	Ruxolitinib (nM)	0
295	Thioguanine (µM)	9.663072
295	Trametinib (nM)	0
295	Venetoclax (nM)	0
295	Vincristine (µM)	0.081982515
295	Vorinostat (nM)	0
295	asparagise_normalized	0
295	cytarabine_normalized	0
295	dexamethasone_normalized	0.334
295	mercaptopurine_normalized	0
295	prednisolone_normalized	1
295	thioguanine_normalized	0.0095
295	vincristine_normalized	0.0708
296	immunophenotype	B
296	molecular subtype	ETV6-RUNX1-like
296	Protocol	T15
296	NCI risk	SR
296	Age at diagnosis	7.2
296	WBC at diagnosis	14.6
296	Sex	F
296	Genetically-defined race	White
296	Asparaginase (IU/ml)	0.2733425
296	Bortezomib (nM)	0
296	CHZ868 (nM)	0
296	Cytarabine (µM)	0
296	Dasatinib (nM)	0
296	Daunorubicin (µM)	0
296	Dexamethasone  (µM)	0.043163547
296	Ibrutinib (µM)	0
296	Mercaptopurine (µM)	5876
296	Nelarabine (µM)	0
296	Panobinostat (nM)	0
296	Prednisolone (µM)	0
296	Ruxolitinib (nM)	0
296	Thioguanine (µM)	0
296	Trametinib (nM)	0
296	Venetoclax (nM)	0
296	Vincristine (µM)	0
296	Vorinostat (nM)	0
296	asparagise_normalized	0.5527
296	dexamethasone_normalized	0.4626
296	mercaptopurine_normalized	1
297	immunophenotype	T
297	molecular subtype	T-ALL
297	Protocol	T15
297	NCI risk	HR
297	Age at diagnosis	6.3
297	WBC at diagnosis	357
297	Sex	M
297	Genetically-defined race	White
297	Asparaginase (IU/ml)	20
297	Bortezomib (nM)	0
297	CHZ868 (nM)	0
297	Cytarabine (µM)	0
297	Dasatinib (nM)	0
297	Daunorubicin (µM)	0
297	Dexamethasone  (µM)	0.004789171
297	Ibrutinib (µM)	0
297	Mercaptopurine (µM)	32.76716
297	Nelarabine (µM)	0
297	Panobinostat (nM)	0
297	Prednisolone (µM)	0
297	Ruxolitinib (nM)	0
297	Thioguanine (µM)	21.05543
297	Trametinib (nM)	0
297	Venetoclax (nM)	0
297	Vincristine (µM)	0
297	Vorinostat (nM)	0
297	asparagise_normalized	1
297	dexamethasone_normalized	0.2513
297	mercaptopurine_normalized	0
297	thioguanine_normalized	0.2343
298	immunophenotype	B
298	molecular subtype	B-other
298	Protocol	T15
298	NCI risk	HR
298	Age at diagnosis	12.6
298	WBC at diagnosis	1.4
298	Sex	M
298	Genetically-defined race	Hispanic
298	Asparaginase (IU/ml)	0
298	Bortezomib (nM)	0
298	CHZ868 (nM)	0
298	Cytarabine (µM)	0
298	Dasatinib (nM)	0
298	Daunorubicin (µM)	0
298	Dexamethasone  (µM)	0.1498642
298	Ibrutinib (µM)	0
298	Mercaptopurine (µM)	294.5641
298	Nelarabine (µM)	0
298	Panobinostat (nM)	0
298	Prednisolone (µM)	0
298	Ruxolitinib (nM)	0
298	Thioguanine (µM)	11.08471
298	Trametinib (nM)	0
298	Venetoclax (nM)	0
298	Vincristine (µM)	0
298	Vorinostat (nM)	0
298	dexamethasone_normalized	0.5822
298	mercaptopurine_normalized	0.3364
298	thioguanine_normalized	0.0491
299	immunophenotype	B
299	molecular subtype	Hyperdiploid
299	Protocol	T15
299	NCI risk	SR
299	Age at diagnosis	5.4
299	WBC at diagnosis	10.4
299	Sex	M
299	Genetically-defined race	Hispanic
299	Asparaginase (IU/ml)	0
299	Bortezomib (nM)	0
299	CHZ868 (nM)	0
299	Cytarabine (µM)	0
299	Dasatinib (nM)	0
299	Daunorubicin (µM)	0
299	Dexamethasone  (µM)	0
299	Ibrutinib (µM)	0
299	Mercaptopurine (µM)	1706.17
299	Nelarabine (µM)	0
299	Panobinostat (nM)	0
299	Prednisolone (µM)	0
299	Ruxolitinib (nM)	0
299	Thioguanine (µM)	102.3313
299	Trametinib (nM)	0
299	Venetoclax (nM)	0
299	Vincristine (µM)	0
299	Vorinostat (nM)	0
299	mercaptopurine_normalized	0.8432
299	thioguanine_normalized	0.6906
300	immunophenotype	T
300	molecular subtype	T-ALL
300	Protocol	T15
300	NCI risk	SR
300	Age at diagnosis	5.8
300	WBC at diagnosis	16.2
300	Sex	M
300	Genetically-defined race	White
300	Asparaginase (IU/ml)	0.0016
300	Bortezomib (nM)	0
300	CHZ868 (nM)	0
300	Cytarabine (µM)	0
300	Dasatinib (nM)	0
300	Daunorubicin (µM)	0
300	Dexamethasone  (µM)	0
300	Ibrutinib (µM)	0
300	Mercaptopurine (µM)	275.5541
300	Nelarabine (µM)	0
300	Panobinostat (nM)	0
300	Prednisolone (µM)	0
300	Ruxolitinib (nM)	0
300	Thioguanine (µM)	0
300	Trametinib (nM)	0
300	Venetoclax (nM)	0
300	Vincristine (µM)	0.025
300	Vorinostat (nM)	0
300	asparagise_normalized	0
300	mercaptopurine_normalized	0.3171
300	vincristine_normalized	0
301	immunophenotype	B
301	molecular subtype	Hyperdiploid
301	Protocol	T15
301	NCI risk	SR
301	Age at diagnosis	7.7
301	WBC at diagnosis	8.2
301	Sex	F
301	Genetically-defined race	Hispanic
301	Asparaginase (IU/ml)	0
301	Bortezomib (nM)	0
301	CHZ868 (nM)	0
301	Cytarabine (µM)	0
301	Dasatinib (nM)	0
301	Daunorubicin (µM)	0
301	Dexamethasone  (µM)	0
301	Ibrutinib (µM)	0
301	Mercaptopurine (µM)	5876
301	Nelarabine (µM)	0
301	Panobinostat (nM)	0
301	Prednisolone (µM)	0
301	Ruxolitinib (nM)	0
301	Thioguanine (µM)	0
301	Trametinib (nM)	0
301	Venetoclax (nM)	0
301	Vincristine (µM)	0
301	Vorinostat (nM)	0
301	mercaptopurine_normalized	1
302	immunophenotype	B
302	molecular subtype	ETV6-RUNX1
302	Protocol	T15
302	NCI risk	SR
302	Age at diagnosis	3.7
302	WBC at diagnosis	3.1
302	Sex	M
302	Genetically-defined race	black
302	Asparaginase (IU/ml)	0.244035
302	Bortezomib (nM)	0
302	CHZ868 (nM)	0
302	Cytarabine (µM)	1.69801
302	Dasatinib (nM)	0
302	Daunorubicin (µM)	0
302	Dexamethasone  (µM)	0.00402967
302	Ibrutinib (µM)	0
302	Mercaptopurine (µM)	0
302	Nelarabine (µM)	0
302	Panobinostat (nM)	0
302	Prednisolone (µM)	0.0440873
302	Ruxolitinib (nM)	0
302	Thioguanine (µM)	0
302	Trametinib (nM)	0
302	Venetoclax (nM)	0
302	Vincristine (µM)	5.077686
302	Vorinostat (nM)	0
302	asparagise_normalized	0.5386
302	cytarabine_normalized	0.5405
302	dexamethasone_normalized	0.2348
302	prednisolone_normalized	0.1035
302	vincristine_normalized	0.6612
303	immunophenotype	B
303	molecular subtype	Hyperdiploid
303	Protocol	T15
303	NCI risk	SR
303	Age at diagnosis	6.6
303	WBC at diagnosis	5.4
303	Sex	M
303	Genetically-defined race	White
303	Asparaginase (IU/ml)	0.0016
303	Bortezomib (nM)	0
303	CHZ868 (nM)	0
303	Cytarabine (µM)	1.321034
303	Dasatinib (nM)	0
303	Daunorubicin (µM)	0
303	Dexamethasone  (µM)	0.08770022
303	Ibrutinib (µM)	0
303	Mercaptopurine (µM)	1155.126017
303	Nelarabine (µM)	0
303	Panobinostat (nM)	0
303	Prednisolone (µM)	5.754233
303	Ruxolitinib (nM)	0
303	Thioguanine (µM)	19.57393269
303	Trametinib (nM)	0
303	Venetoclax (nM)	0
303	Vincristine (µM)	0.2971763
303	Vorinostat (nM)	0
303	asparagise_normalized	0
303	cytarabine_normalized	0.5043
303	dexamethasone_normalized	0.5307
303	mercaptopurine_normalized	0.7307
303	prednisolone_normalized	0.571
303	thioguanine_normalized	0.2132
303	vincristine_normalized	0.2551
304	immunophenotype	B
304	molecular subtype	B-other
304	Protocol	T15
304	NCI risk	HR
304	Age at diagnosis	14.2
304	WBC at diagnosis	10.9
304	Sex	M
304	Genetically-defined race	Hispanic
304	Asparaginase (IU/ml)	0
304	Bortezomib (nM)	0
304	CHZ868 (nM)	0
304	Cytarabine (µM)	0
304	Dasatinib (nM)	0
304	Daunorubicin (µM)	0
304	Dexamethasone  (µM)	23.2
304	Ibrutinib (µM)	0
304	Mercaptopurine (µM)	0
304	Nelarabine (µM)	0
304	Panobinostat (nM)	0
304	Prednisolone (µM)	1006
304	Ruxolitinib (nM)	0
304	Thioguanine (µM)	0
304	Trametinib (nM)	0
304	Venetoclax (nM)	0
304	Vincristine (µM)	0
304	Vorinostat (nM)	0
304	dexamethasone_normalized	1
304	prednisolone_normalized	1
305	immunophenotype	B
305	molecular subtype	Hyperdiploid
305	Protocol	T15
305	NCI risk	HR
305	Age at diagnosis	2.1
305	WBC at diagnosis	87.6
305	Sex	F
305	Genetically-defined race	White
305	Asparaginase (IU/ml)	0.0016
305	Bortezomib (nM)	0
305	CHZ868 (nM)	0
305	Cytarabine (µM)	0
305	Dasatinib (nM)	0
305	Daunorubicin (µM)	0
305	Dexamethasone  (µM)	0.00951683
305	Ibrutinib (µM)	0
305	Mercaptopurine (µM)	0
305	Nelarabine (µM)	0
305	Panobinostat (nM)	0
305	Prednisolone (µM)	0.119686733
305	Ruxolitinib (nM)	0
305	Thioguanine (µM)	2.421761
305	Trametinib (nM)	0
305	Venetoclax (nM)	0
305	Vincristine (µM)	0.05225351
305	Vorinostat (nM)	0
305	asparagise_normalized	0
305	dexamethasone_normalized	0.3173
305	prednisolone_normalized	0.1993
305	thioguanine_normalized	0
305	vincristine_normalized	0.0063
306	immunophenotype	B
306	molecular subtype	Hyperdiploid
306	Protocol	T15
306	NCI risk	SR
306	Age at diagnosis	8.5
306	WBC at diagnosis	31.1
306	Sex	F
306	Genetically-defined race	Hispanic
306	Asparaginase (IU/ml)	0
306	Bortezomib (nM)	0
306	CHZ868 (nM)	0
306	Cytarabine (µM)	0
306	Dasatinib (nM)	0
306	Daunorubicin (µM)	0
306	Dexamethasone  (µM)	23.2
306	Ibrutinib (µM)	0
306	Mercaptopurine (µM)	5876
306	Nelarabine (µM)	0
306	Panobinostat (nM)	0
306	Prednisolone (µM)	383.0507
306	Ruxolitinib (nM)	0
306	Thioguanine (µM)	43.41493
306	Trametinib (nM)	0
306	Venetoclax (nM)	0
306	Vincristine (µM)	0
306	Vorinostat (nM)	0
306	dexamethasone_normalized	1
306	mercaptopurine_normalized	1
306	prednisolone_normalized	0.9739
306	thioguanine_normalized	0.4431
307	immunophenotype	B
307	molecular subtype	Ph-like_CRLF2
307	Protocol	T15
307	NCI risk	HR
307	Age at diagnosis	3.9
307	WBC at diagnosis	53.1
307	Sex	M
307	Genetically-defined race	White
307	Asparaginase (IU/ml)	0
307	Bortezomib (nM)	0
307	CHZ868 (nM)	0
307	Cytarabine (µM)	0
307	Dasatinib (nM)	0
307	Daunorubicin (µM)	0
307	Dexamethasone  (µM)	0.008150116
307	Ibrutinib (µM)	0
307	Mercaptopurine (µM)	148.772
307	Nelarabine (µM)	0
307	Panobinostat (nM)	0
307	Prednisolone (µM)	0.0075
307	Ruxolitinib (nM)	0
307	Thioguanine (µM)	0
307	Trametinib (nM)	0
307	Venetoclax (nM)	0
307	Vincristine (µM)	0
307	Vorinostat (nM)	0
307	dexamethasone_normalized	0.3024
307	mercaptopurine_normalized	0.1393
307	prednisolone_normalized	0
308	immunophenotype	B
308	molecular subtype	Near haploid
308	Protocol	T15
308	NCI risk	SR
308	Age at diagnosis	2.6
308	WBC at diagnosis	5.5
308	Sex	F
308	Genetically-defined race	White
308	Asparaginase (IU/ml)	0.001435771
308	Bortezomib (nM)	0
308	CHZ868 (nM)	0
308	Cytarabine (µM)	0
308	Dasatinib (nM)	0
308	Daunorubicin (µM)	0
308	Dexamethasone  (µM)	0
308	Ibrutinib (µM)	0
308	Mercaptopurine (µM)	456.0149686
308	Nelarabine (µM)	0
308	Panobinostat (nM)	0
308	Prednisolone (µM)	0
308	Ruxolitinib (nM)	0
308	Thioguanine (µM)	0
308	Trametinib (nM)	0
308	Venetoclax (nM)	0
308	Vincristine (µM)	0
308	Vorinostat (nM)	0
308	asparagise_normalized	0
308	mercaptopurine_normalized	0.4625
309	immunophenotype	B
309	molecular subtype	ETV6-RUNX1
309	Protocol	T15
309	NCI risk	SR
309	Age at diagnosis	4.8
309	WBC at diagnosis	19.5
309	Sex	F
309	Genetically-defined race	black
309	Asparaginase (IU/ml)	0.1700933
309	Bortezomib (nM)	0
309	CHZ868 (nM)	0
309	Cytarabine (µM)	0
309	Dasatinib (nM)	0
309	Daunorubicin (µM)	0
309	Dexamethasone  (µM)	0.031434662
309	Ibrutinib (µM)	0
309	Mercaptopurine (µM)	0
309	Nelarabine (µM)	0
309	Panobinostat (nM)	0
309	Prednisolone (µM)	1006
309	Ruxolitinib (nM)	0
309	Thioguanine (µM)	598
309	Trametinib (nM)	0
309	Venetoclax (nM)	0
309	Vincristine (µM)	2.706517
309	Vorinostat (nM)	0
309	asparagise_normalized	0.4937
309	dexamethasone_normalized	0.4321
309	prednisolone_normalized	1
309	thioguanine_normalized	1
309	vincristine_normalized	0.5712
310	immunophenotype	B
310	molecular subtype	NUTM1
310	Protocol	T15
310	NCI risk	SR
310	Age at diagnosis	7.7
310	WBC at diagnosis	16.7
310	Sex	F
310	Genetically-defined race	White
310	Asparaginase (IU/ml)	20
310	Bortezomib (nM)	0
310	CHZ868 (nM)	0
310	Cytarabine (µM)	0
310	Dasatinib (nM)	0
310	Daunorubicin (µM)	0
310	Dexamethasone  (µM)	0.001498216
310	Ibrutinib (µM)	0
310	Mercaptopurine (µM)	209.8689
310	Nelarabine (µM)	0
310	Panobinostat (nM)	0
310	Prednisolone (µM)	0.0075
310	Ruxolitinib (nM)	0
310	Thioguanine (µM)	6.228037187
310	Trametinib (nM)	0
310	Venetoclax (nM)	0
310	Vincristine (µM)	0.025
310	Vorinostat (nM)	0
310	asparagise_normalized	1
310	dexamethasone_normalized	0.1397
310	mercaptopurine_normalized	0.2386
310	prednisolone_normalized	0
310	thioguanine_normalized	0
310	vincristine_normalized	0
311	immunophenotype	B
311	molecular subtype	ETV6-RUNX1
311	Protocol	T15
311	NCI risk	HR
311	Age at diagnosis	3.6
311	WBC at diagnosis	215
311	Sex	M
311	Genetically-defined race	black
311	Asparaginase (IU/ml)	0.005395314
311	Bortezomib (nM)	0
311	CHZ868 (nM)	0
311	Cytarabine (µM)	82.2
311	Dasatinib (nM)	0
311	Daunorubicin (µM)	0
311	Dexamethasone  (µM)	0.006179534
311	Ibrutinib (µM)	0
311	Mercaptopurine (µM)	5876
311	Nelarabine (µM)	0
311	Panobinostat (nM)	0
311	Prednisolone (µM)	0.0075
311	Ruxolitinib (nM)	0
311	Thioguanine (µM)	26.61675
311	Trametinib (nM)	0
311	Venetoclax (nM)	0
311	Vincristine (µM)	0.3390269
311	Vorinostat (nM)	0
311	asparagise_normalized	0.0649
311	cytarabine_normalized	1
311	dexamethasone_normalized	0.2758
311	mercaptopurine_normalized	1
311	prednisolone_normalized	0
311	thioguanine_normalized	0.3019
311	vincristine_normalized	0.2739
312	immunophenotype	B
312	molecular subtype	ETV6-RUNX1
312	Protocol	T15
312	NCI risk	HR
312	Age at diagnosis	2.7
312	WBC at diagnosis	70
312	Sex	F
312	Genetically-defined race	White
312	Asparaginase (IU/ml)	0
312	Bortezomib (nM)	0
312	CHZ868 (nM)	0
312	Cytarabine (µM)	0
312	Dasatinib (nM)	0
312	Daunorubicin (µM)	0
312	Dexamethasone  (µM)	0.004481375
312	Ibrutinib (µM)	0
312	Mercaptopurine (µM)	129.2038872
312	Nelarabine (µM)	0
312	Panobinostat (nM)	0
312	Prednisolone (µM)	0.0075
312	Ruxolitinib (nM)	0
312	Thioguanine (µM)	18.16111
312	Trametinib (nM)	0
312	Venetoclax (nM)	0
312	Vincristine (µM)	0.0307872
312	Vorinostat (nM)	0
312	dexamethasone_normalized	0.245
312	mercaptopurine_normalized	0.0986
312	prednisolone_normalized	0
312	thioguanine_normalized	0.1916
312	vincristine_normalized	0
313	immunophenotype	B
313	molecular subtype	TCF3-PBX1
313	Protocol	T15
313	NCI risk	SR
313	Age at diagnosis	4.9
313	WBC at diagnosis	24.2
313	Sex	M
313	Genetically-defined race	Hispanic
313	Asparaginase (IU/ml)	0.227812786
313	Bortezomib (nM)	0
313	CHZ868 (nM)	0
313	Cytarabine (µM)	0
313	Dasatinib (nM)	0
313	Daunorubicin (µM)	0
313	Dexamethasone  (µM)	0.002528482
313	Ibrutinib (µM)	0
313	Mercaptopurine (µM)	424.0358498
313	Nelarabine (µM)	0
313	Panobinostat (nM)	0
313	Prednisolone (µM)	0.0075
313	Ruxolitinib (nM)	0
313	Thioguanine (µM)	18.27071
313	Trametinib (nM)	0
313	Venetoclax (nM)	0
313	Vincristine (µM)	0.05722082
313	Vorinostat (nM)	0
313	asparagise_normalized	0.53
313	dexamethasone_normalized	0.19
313	mercaptopurine_normalized	0.4415
313	prednisolone_normalized	0
313	thioguanine_normalized	0.1933
313	vincristine_normalized	0.0193
314	immunophenotype	B
314	molecular subtype	Hyperdiploid
314	Protocol	T15
314	NCI risk	SR
314	Age at diagnosis	3.3
314	WBC at diagnosis	7.5
314	Sex	F
314	Genetically-defined race	Hispanic
314	Asparaginase (IU/ml)	0.3730095
314	Bortezomib (nM)	0
314	CHZ868 (nM)	0
314	Cytarabine (µM)	0
314	Dasatinib (nM)	0
314	Daunorubicin (µM)	0
314	Dexamethasone  (µM)	23.2
314	Ibrutinib (µM)	0
314	Mercaptopurine (µM)	5876
314	Nelarabine (µM)	0
314	Panobinostat (nM)	0
314	Prednisolone (µM)	57.39686
314	Ruxolitinib (nM)	0
314	Thioguanine (µM)	25.45272
314	Trametinib (nM)	0
314	Venetoclax (nM)	0
314	Vincristine (µM)	0
314	Vorinostat (nM)	0
314	asparagise_normalized	0.5913
314	dexamethasone_normalized	1
314	mercaptopurine_normalized	1
314	prednisolone_normalized	0.7917
314	thioguanine_normalized	0.289
315	immunophenotype	B
315	molecular subtype	B-other
315	Protocol	T15
315	NCI risk	HR
315	Age at diagnosis	10.7
315	WBC at diagnosis	1.7
315	Sex	M
315	Genetically-defined race	White
315	Asparaginase (IU/ml)	0
315	Bortezomib (nM)	0
315	CHZ868 (nM)	0
315	Cytarabine (µM)	0
315	Dasatinib (nM)	0
315	Daunorubicin (µM)	0
315	Dexamethasone  (µM)	23.2
315	Ibrutinib (µM)	0
315	Mercaptopurine (µM)	5876
315	Nelarabine (µM)	0
315	Panobinostat (nM)	0
315	Prednisolone (µM)	1006
315	Ruxolitinib (nM)	0
315	Thioguanine (µM)	55.5813
315	Trametinib (nM)	0
315	Venetoclax (nM)	0
315	Vincristine (µM)	0.1812342
315	Vorinostat (nM)	0
315	dexamethasone_normalized	1
315	mercaptopurine_normalized	1
315	prednisolone_normalized	1
315	thioguanine_normalized	0.5144
315	vincristine_normalized	0.1843
316	immunophenotype	T
316	molecular subtype	T-ALL
316	Protocol	T15
316	NCI risk	SR
316	Age at diagnosis	6.9
316	WBC at diagnosis	20
316	Sex	M
316	Genetically-defined race	White
316	Asparaginase (IU/ml)	0.0016
316	Bortezomib (nM)	0
316	CHZ868 (nM)	0
316	Cytarabine (µM)	0
316	Dasatinib (nM)	0
316	Daunorubicin (µM)	0
316	Dexamethasone  (µM)	0
316	Ibrutinib (µM)	0
316	Mercaptopurine (µM)	0
316	Nelarabine (µM)	0
316	Panobinostat (nM)	0
316	Prednisolone (µM)	0.03091398
316	Ruxolitinib (nM)	0
316	Thioguanine (µM)	0
316	Trametinib (nM)	0
316	Venetoclax (nM)	0
316	Vincristine (µM)	0.417305
316	Vorinostat (nM)	0
316	asparagise_normalized	0
316	prednisolone_normalized	0.0694
316	vincristine_normalized	0.3036
317	immunophenotype	B
317	molecular subtype	Ph-like_CRLF2
317	Protocol	T15
317	NCI risk	SR
317	Age at diagnosis	3.9
317	WBC at diagnosis	5
317	Sex	M
317	Genetically-defined race	White
317	Asparaginase (IU/ml)	0
317	Bortezomib (nM)	0
317	CHZ868 (nM)	0
317	Cytarabine (µM)	0
317	Dasatinib (nM)	0
317	Daunorubicin (µM)	0
317	Dexamethasone  (µM)	0.039357741
317	Ibrutinib (µM)	0
317	Mercaptopurine (µM)	825.3813
317	Nelarabine (µM)	0
317	Panobinostat (nM)	0
317	Prednisolone (µM)	0
317	Ruxolitinib (nM)	0
317	Thioguanine (µM)	59.72816
317	Trametinib (nM)	0
317	Venetoclax (nM)	0
317	Vincristine (µM)	108.34
317	Vorinostat (nM)	0
317	dexamethasone_normalized	0.4537
317	mercaptopurine_normalized	0.6337
317	thioguanine_normalized	0.5352
317	vincristine_normalized	1
318	immunophenotype	B
318	molecular subtype	ETV6-RUNX1
318	Protocol	T15
318	NCI risk	SR
318	Age at diagnosis	2.1
318	WBC at diagnosis	12.2
318	Sex	M
318	Genetically-defined race	White
318	Asparaginase (IU/ml)	0.0016
318	Bortezomib (nM)	0
318	CHZ868 (nM)	0
318	Cytarabine (µM)	4.543479
318	Dasatinib (nM)	0
318	Daunorubicin (µM)	0
318	Dexamethasone  (µM)	0.04959518
318	Ibrutinib (µM)	0
318	Mercaptopurine (µM)	1435.873
318	Nelarabine (µM)	0
318	Panobinostat (nM)	0
318	Prednisolone (µM)	0.02368728
318	Ruxolitinib (nM)	0
318	Thioguanine (µM)	36.87607
318	Trametinib (nM)	0
318	Venetoclax (nM)	0
318	Vincristine (µM)	0.8934702
318	Vorinostat (nM)	0
318	asparagise_normalized	0
318	cytarabine_normalized	0.6824
318	dexamethasone_normalized	0.4759
318	mercaptopurine_normalized	0.7934
318	prednisolone_normalized	0.0438
318	thioguanine_normalized	0.396
318	vincristine_normalized	0.4126
319	immunophenotype	B
319	molecular subtype	ETV6-RUNX1-like
319	Protocol	T15
319	NCI risk	SR
319	Age at diagnosis	3.9
319	WBC at diagnosis	33
319	Sex	F
319	Genetically-defined race	White
319	Asparaginase (IU/ml)	0
319	Bortezomib (nM)	0
319	CHZ868 (nM)	0
319	Cytarabine (µM)	0
319	Dasatinib (nM)	0
319	Daunorubicin (µM)	0
319	Dexamethasone  (µM)	0.03463762
319	Ibrutinib (µM)	0
319	Mercaptopurine (µM)	1344.148
319	Nelarabine (µM)	0
319	Panobinostat (nM)	0
319	Prednisolone (µM)	0.0075
319	Ruxolitinib (nM)	0
319	Thioguanine (µM)	37.70071
319	Trametinib (nM)	0
319	Venetoclax (nM)	0
319	Vincristine (µM)	0
319	Vorinostat (nM)	0
319	dexamethasone_normalized	0.4414
319	mercaptopurine_normalized	0.7744
319	prednisolone_normalized	0
319	thioguanine_normalized	0.4024
320	immunophenotype	B
320	molecular subtype	Ph-like_CRLF2
320	Protocol	T15
320	NCI risk	SR
320	Age at diagnosis	2.9
320	WBC at diagnosis	5.2
320	Sex	F
320	Genetically-defined race	White
320	Asparaginase (IU/ml)	0.006494521
320	Bortezomib (nM)	0
320	CHZ868 (nM)	0
320	Cytarabine (µM)	0
320	Dasatinib (nM)	0
320	Daunorubicin (µM)	0
320	Dexamethasone  (µM)	23.2
320	Ibrutinib (µM)	0
320	Mercaptopurine (µM)	0
320	Nelarabine (µM)	0
320	Panobinostat (nM)	0
320	Prednisolone (µM)	0
320	Ruxolitinib (nM)	0
320	Thioguanine (µM)	51.78312
320	Trametinib (nM)	0
320	Venetoclax (nM)	0
320	Vincristine (µM)	0.2248847
320	Vorinostat (nM)	0
320	asparagise_normalized	0.088
320	dexamethasone_normalized	1
320	thioguanine_normalized	0.494
320	vincristine_normalized	0.2152
321	immunophenotype	B
321	molecular subtype	Hyperdiploid
321	Protocol	T15
321	NCI risk	SR
321	Age at diagnosis	3.5
321	WBC at diagnosis	26.9
321	Sex	M
321	Genetically-defined race	black
321	Asparaginase (IU/ml)	0.2424301
321	Bortezomib (nM)	0
321	CHZ868 (nM)	0
321	Cytarabine (µM)	0.3117486
321	Dasatinib (nM)	0
321	Daunorubicin (µM)	0
321	Dexamethasone  (µM)	0.006255253
321	Ibrutinib (µM)	0
321	Mercaptopurine (µM)	367.7122
321	Nelarabine (µM)	0
321	Panobinostat (nM)	0
321	Prednisolone (µM)	0.09841936
321	Ruxolitinib (nM)	0
321	Thioguanine (µM)	37.52815
321	Trametinib (nM)	0
321	Venetoclax (nM)	0
321	Vincristine (µM)	1.141917
321	Vorinostat (nM)	0
321	asparagise_normalized	0.5378
321	cytarabine_normalized	0.2961
321	dexamethasone_normalized	0.277
321	mercaptopurine_normalized	0.4004
321	prednisolone_normalized	0.1805
321	thioguanine_normalized	0.4011
321	vincristine_normalized	0.4477
322	immunophenotype	B
322	molecular subtype	Hyperdiploid
322	Protocol	T15
322	NCI risk	HR
322	Age at diagnosis	5.7
322	WBC at diagnosis	80.7
322	Sex	M
322	Genetically-defined race	White
322	Asparaginase (IU/ml)	0
322	Bortezomib (nM)	0
322	CHZ868 (nM)	0
322	Cytarabine (µM)	0
322	Dasatinib (nM)	0
322	Daunorubicin (µM)	0
322	Dexamethasone  (µM)	0.3089661
322	Ibrutinib (µM)	0
322	Mercaptopurine (µM)	502.5297
322	Nelarabine (µM)	0
322	Panobinostat (nM)	0
322	Prednisolone (µM)	0
322	Ruxolitinib (nM)	0
322	Thioguanine (µM)	59.82096
322	Trametinib (nM)	0
322	Venetoclax (nM)	0
322	Vincristine (µM)	0
322	Vorinostat (nM)	0
322	dexamethasone_normalized	0.6517
322	mercaptopurine_normalized	0.4905
322	thioguanine_normalized	0.5356
323	immunophenotype	B
323	molecular subtype	BCR-ABL1
323	Protocol	T15
323	NCI risk	HR
323	Age at diagnosis	12.7
323	WBC at diagnosis	1.3
323	Sex	M
323	Genetically-defined race	White
323	Asparaginase (IU/ml)	0
323	Bortezomib (nM)	0
323	CHZ868 (nM)	0
323	Cytarabine (µM)	0
323	Dasatinib (nM)	0
323	Daunorubicin (µM)	0
323	Dexamethasone  (µM)	0
323	Ibrutinib (µM)	0
323	Mercaptopurine (µM)	151.3225
323	Nelarabine (µM)	0
323	Panobinostat (nM)	0
323	Prednisolone (µM)	0
323	Ruxolitinib (nM)	0
323	Thioguanine (µM)	13.87537
323	Trametinib (nM)	0
323	Venetoclax (nM)	0
323	Vincristine (µM)	0
323	Vorinostat (nM)	0
323	mercaptopurine_normalized	0.1442
323	thioguanine_normalized	0.1139
324	immunophenotype	B
324	molecular subtype	Hyperdiploid
324	Protocol	T15
324	NCI risk	SR
324	Age at diagnosis	1
324	WBC at diagnosis	19.1
324	Sex	F
324	Genetically-defined race	White
324	Asparaginase (IU/ml)	0
324	Bortezomib (nM)	0
324	CHZ868 (nM)	0
324	Cytarabine (µM)	0
324	Dasatinib (nM)	0
324	Daunorubicin (µM)	0
324	Dexamethasone  (µM)	0.01294419
324	Ibrutinib (µM)	0
324	Mercaptopurine (µM)	144.4434
324	Nelarabine (µM)	0
324	Panobinostat (nM)	0
324	Prednisolone (µM)	0
324	Ruxolitinib (nM)	0
324	Thioguanine (µM)	34.01216
324	Trametinib (nM)	0
324	Venetoclax (nM)	0
324	Vincristine (µM)	0
324	Vorinostat (nM)	0
324	dexamethasone_normalized	0.3469
324	mercaptopurine_normalized	0.1308
324	thioguanine_normalized	0.3727
325	immunophenotype	B
325	molecular subtype	Near haploid
325	Protocol	T15
325	NCI risk	SR
325	Age at diagnosis	8.3
325	WBC at diagnosis	3
325	Sex	F
325	Genetically-defined race	White
325	Asparaginase (IU/ml)	0
325	Bortezomib (nM)	0
325	CHZ868 (nM)	0
325	Cytarabine (µM)	0
325	Dasatinib (nM)	0
325	Daunorubicin (µM)	0
325	Dexamethasone  (µM)	0.5215023
325	Ibrutinib (µM)	0
325	Mercaptopurine (µM)	350.8225
325	Nelarabine (µM)	0
325	Panobinostat (nM)	0
325	Prednisolone (µM)	10.46985
325	Ruxolitinib (nM)	0
325	Thioguanine (µM)	10.98071
325	Trametinib (nM)	0
325	Venetoclax (nM)	0
325	Vincristine (µM)	0
325	Vorinostat (nM)	0
325	dexamethasone_normalized	0.702
325	mercaptopurine_normalized	0.3868
325	prednisolone_normalized	0.6284
325	thioguanine_normalized	0.0464
326	immunophenotype	B
326	molecular subtype	ETV6-RUNX1
326	Protocol	T15
326	NCI risk	SR
326	Age at diagnosis	4.5
326	WBC at diagnosis	8.7
326	Sex	M
326	Genetically-defined race	White
326	Asparaginase (IU/ml)	0.2931824
326	Bortezomib (nM)	0
326	CHZ868 (nM)	0
326	Cytarabine (µM)	0
326	Dasatinib (nM)	0
326	Daunorubicin (µM)	0
326	Dexamethasone  (µM)	23.2
326	Ibrutinib (µM)	0
326	Mercaptopurine (µM)	1289.698
326	Nelarabine (µM)	0
326	Panobinostat (nM)	0
326	Prednisolone (µM)	0.4292099
326	Ruxolitinib (nM)	0
326	Thioguanine (µM)	37.13255
326	Trametinib (nM)	0
326	Venetoclax (nM)	0
326	Vincristine (µM)	0.6015844
326	Vorinostat (nM)	0
326	asparagise_normalized	0.5614
326	dexamethasone_normalized	1
326	mercaptopurine_normalized	0.7624
326	prednisolone_normalized	0.3219
326	thioguanine_normalized	0.398
326	vincristine_normalized	0.356
327	immunophenotype	T
327	molecular subtype	T-ALL
327	Protocol	T15
327	NCI risk	HR
327	Age at diagnosis	3.5
327	WBC at diagnosis	101.7
327	Sex	M
327	Genetically-defined race	black
327	Asparaginase (IU/ml)	0
327	Bortezomib (nM)	0
327	CHZ868 (nM)	0
327	Cytarabine (µM)	0
327	Dasatinib (nM)	0
327	Daunorubicin (µM)	0
327	Dexamethasone  (µM)	0
327	Ibrutinib (µM)	0
327	Mercaptopurine (µM)	0
327	Nelarabine (µM)	0
327	Panobinostat (nM)	0
327	Prednisolone (µM)	1006
327	Ruxolitinib (nM)	0
327	Thioguanine (µM)	0
327	Trametinib (nM)	0
327	Venetoclax (nM)	0
327	Vincristine (µM)	0.1622864
327	Vorinostat (nM)	0
327	prednisolone_normalized	1
327	vincristine_normalized	0.1685
328	immunophenotype	B
328	molecular subtype	Near haploid
328	Protocol	T15
328	NCI risk	SR
328	Age at diagnosis	2.5
328	WBC at diagnosis	34.6
328	Sex	M
328	Genetically-defined race	White
328	Asparaginase (IU/ml)	0
328	Bortezomib (nM)	0
328	CHZ868 (nM)	0
328	Cytarabine (µM)	0
328	Dasatinib (nM)	0
328	Daunorubicin (µM)	0
328	Dexamethasone  (µM)	9.532414
328	Ibrutinib (µM)	0
328	Mercaptopurine (µM)	421.3906
328	Nelarabine (µM)	0
328	Panobinostat (nM)	0
328	Prednisolone (µM)	1006
328	Ruxolitinib (nM)	0
328	Thioguanine (µM)	42.33674
328	Trametinib (nM)	0
328	Venetoclax (nM)	0
328	Vincristine (µM)	0
328	Vorinostat (nM)	0
328	dexamethasone_normalized	0.9811
328	mercaptopurine_normalized	0.4397
328	prednisolone_normalized	1
328	thioguanine_normalized	0.4359
329	immunophenotype	B
329	molecular subtype	Hyperdiploid
329	Protocol	T15
329	NCI risk	HR
329	Age at diagnosis	18.5
329	WBC at diagnosis	5.4
329	Sex	M
329	Genetically-defined race	White
329	Asparaginase (IU/ml)	0.0016
329	Bortezomib (nM)	0
329	CHZ868 (nM)	0
329	Cytarabine (µM)	0.5072542
329	Dasatinib (nM)	0
329	Daunorubicin (µM)	0
329	Dexamethasone  (µM)	0.05416992
329	Ibrutinib (µM)	0
329	Mercaptopurine (µM)	271.5096
329	Nelarabine (µM)	0
329	Panobinostat (nM)	0
329	Prednisolone (µM)	0
329	Ruxolitinib (nM)	0
329	Thioguanine (µM)	53.164
329	Trametinib (nM)	0
329	Venetoclax (nM)	0
329	Vincristine (µM)	0.1949474
329	Vorinostat (nM)	0
329	asparagise_normalized	0
329	cytarabine_normalized	0.3663
329	dexamethasone_normalized	0.4844
329	mercaptopurine_normalized	0.3129
329	thioguanine_normalized	0.5016
329	vincristine_normalized	0.1947
330	immunophenotype	B
330	molecular subtype	PAX5alt
330	Protocol	T15
330	NCI risk	HR
330	Age at diagnosis	2
330	WBC at diagnosis	54.2
330	Sex	M
330	Genetically-defined race	Hispanic
330	Asparaginase (IU/ml)	0.0016
330	Bortezomib (nM)	0
330	CHZ868 (nM)	0
330	Cytarabine (µM)	0.1855928
330	Dasatinib (nM)	0
330	Daunorubicin (µM)	0
330	Dexamethasone  (µM)	0.01393083
330	Ibrutinib (µM)	0
330	Mercaptopurine (µM)	429.8439
330	Nelarabine (µM)	0
330	Panobinostat (nM)	0
330	Prednisolone (µM)	0.0075
330	Ruxolitinib (nM)	0
330	Thioguanine (µM)	4.675
330	Trametinib (nM)	0
330	Venetoclax (nM)	0
330	Vincristine (µM)	0.025
330	Vorinostat (nM)	0
330	asparagise_normalized	0
330	cytarabine_normalized	0.2213
330	dexamethasone_normalized	0.3539
330	mercaptopurine_normalized	0.4454
330	prednisolone_normalized	0
330	thioguanine_normalized	0
330	vincristine_normalized	0
331	immunophenotype	B
331	molecular subtype	ETV6-RUNX1
331	Protocol	T15
331	NCI risk	SR
331	Age at diagnosis	3.5
331	WBC at diagnosis	5
331	Sex	F
331	Genetically-defined race	Asian/Other
331	Asparaginase (IU/ml)	0
331	Bortezomib (nM)	0
331	CHZ868 (nM)	0
331	Cytarabine (µM)	0
331	Dasatinib (nM)	0
331	Daunorubicin (µM)	0
331	Dexamethasone  (µM)	0.007355783
331	Ibrutinib (µM)	0
331	Mercaptopurine (µM)	532.867018
331	Nelarabine (µM)	0
331	Panobinostat (nM)	0
331	Prednisolone (µM)	0
331	Ruxolitinib (nM)	0
331	Thioguanine (µM)	26.14031
331	Trametinib (nM)	0
331	Venetoclax (nM)	0
331	Vincristine (µM)	0
331	Vorinostat (nM)	0
331	dexamethasone_normalized	0.2926
331	mercaptopurine_normalized	0.5074
331	thioguanine_normalized	0.2967
332	immunophenotype	B
332	molecular subtype	ETV6-RUNX1
332	Protocol	T15
332	NCI risk	SR
332	Age at diagnosis	3.9
332	WBC at diagnosis	22.7
332	Sex	F
332	Genetically-defined race	black
332	Asparaginase (IU/ml)	0.05836867
332	Bortezomib (nM)	0
332	CHZ868 (nM)	0
332	Cytarabine (µM)	0
332	Dasatinib (nM)	0
332	Daunorubicin (µM)	0
332	Dexamethasone  (µM)	0.4975812
332	Ibrutinib (µM)	0
332	Mercaptopurine (µM)	0
332	Nelarabine (µM)	0
332	Panobinostat (nM)	0
332	Prednisolone (µM)	0.032285594
332	Ruxolitinib (nM)	0
332	Thioguanine (µM)	14.8128
332	Trametinib (nM)	0
332	Venetoclax (nM)	0
332	Vincristine (µM)	0.08197189
332	Vorinostat (nM)	0
332	asparagise_normalized	0.3608
332	dexamethasone_normalized	0.6975
332	prednisolone_normalized	0.0736
332	thioguanine_normalized	0.1328
332	vincristine_normalized	0.0707
333	immunophenotype	B
333	molecular subtype	TCF3-PBX1
333	Protocol	T15
333	NCI risk	SR
333	Age at diagnosis	2.2
333	WBC at diagnosis	34
333	Sex	F
333	Genetically-defined race	black
333	Asparaginase (IU/ml)	0
333	Bortezomib (nM)	0
333	CHZ868 (nM)	0
333	Cytarabine (µM)	0
333	Dasatinib (nM)	0
333	Daunorubicin (µM)	0
333	Dexamethasone  (µM)	0.037809634
333	Ibrutinib (µM)	0
333	Mercaptopurine (µM)	277.5237
333	Nelarabine (µM)	0
333	Panobinostat (nM)	0
333	Prednisolone (µM)	0.0075
333	Ruxolitinib (nM)	0
333	Thioguanine (µM)	0
333	Trametinib (nM)	0
333	Venetoclax (nM)	0
333	Vincristine (µM)	0
333	Vorinostat (nM)	0
333	dexamethasone_normalized	0.4499
333	mercaptopurine_normalized	0.3192
333	prednisolone_normalized	0
334	immunophenotype	B
334	molecular subtype	Hyperdiploid
334	Protocol	T15
334	NCI risk	SR
334	Age at diagnosis	2.9
334	WBC at diagnosis	11
334	Sex	M
334	Genetically-defined race	White
334	Asparaginase (IU/ml)	0
334	Bortezomib (nM)	0
334	CHZ868 (nM)	0
334	Cytarabine (µM)	0
334	Dasatinib (nM)	0
334	Daunorubicin (µM)	0
334	Dexamethasone  (µM)	23.2
334	Ibrutinib (µM)	0
334	Mercaptopurine (µM)	5876
334	Nelarabine (µM)	0
334	Panobinostat (nM)	0
334	Prednisolone (µM)	166.7642
334	Ruxolitinib (nM)	0
334	Thioguanine (µM)	598
334	Trametinib (nM)	0
334	Venetoclax (nM)	0
334	Vincristine (µM)	108.34
334	Vorinostat (nM)	0
334	dexamethasone_normalized	1
334	mercaptopurine_normalized	1
334	prednisolone_normalized	0.8941
334	thioguanine_normalized	1
334	vincristine_normalized	1
335	immunophenotype	B
335	molecular subtype	ETV6-RUNX1
335	Protocol	T15
335	NCI risk	SR
335	Age at diagnosis	4.2
335	WBC at diagnosis	10.7
335	Sex	F
335	Genetically-defined race	White
335	Asparaginase (IU/ml)	0.0016
335	Bortezomib (nM)	0
335	CHZ868 (nM)	0
335	Cytarabine (µM)	0.5969852
335	Dasatinib (nM)	0
335	Daunorubicin (µM)	0
335	Dexamethasone  (µM)	0.01374299
335	Ibrutinib (µM)	0
335	Mercaptopurine (µM)	670.0292
335	Nelarabine (µM)	0
335	Panobinostat (nM)	0
335	Prednisolone (µM)	0.0075
335	Ruxolitinib (nM)	0
335	Thioguanine (µM)	4.675
335	Trametinib (nM)	0
335	Venetoclax (nM)	0
335	Vincristine (µM)	0.025
335	Vorinostat (nM)	0
335	asparagise_normalized	0
335	cytarabine_normalized	0.3898
335	dexamethasone_normalized	0.3526
335	mercaptopurine_normalized	0.5735
335	prednisolone_normalized	0
335	thioguanine_normalized	0
335	vincristine_normalized	0
336	immunophenotype	B
336	molecular subtype	ETV6-RUNX1
336	Protocol	T15
336	NCI risk	SR
336	Age at diagnosis	3.5
336	WBC at diagnosis	2.3
336	Sex	F
336	Genetically-defined race	White
336	Asparaginase (IU/ml)	0
336	Bortezomib (nM)	0
336	CHZ868 (nM)	0
336	Cytarabine (µM)	0
336	Dasatinib (nM)	0
336	Daunorubicin (µM)	0
336	Dexamethasone  (µM)	0.0161189
336	Ibrutinib (µM)	0
336	Mercaptopurine (µM)	450.9129
336	Nelarabine (µM)	0
336	Panobinostat (nM)	0
336	Prednisolone (µM)	0
336	Ruxolitinib (nM)	0
336	Thioguanine (µM)	21.43415
336	Trametinib (nM)	0
336	Venetoclax (nM)	0
336	Vincristine (µM)	0
336	Vorinostat (nM)	0
336	dexamethasone_normalized	0.3679
336	mercaptopurine_normalized	0.4592
336	thioguanine_normalized	0.2394
337	immunophenotype	B
337	molecular subtype	TCF3-PBX1
337	Protocol	T15
337	NCI risk	SR
337	Age at diagnosis	4.1
337	WBC at diagnosis	17.8
337	Sex	F
337	Genetically-defined race	Hispanic
337	Asparaginase (IU/ml)	0.047270251
337	Bortezomib (nM)	0
337	CHZ868 (nM)	0
337	Cytarabine (µM)	0.1227342
337	Dasatinib (nM)	0
337	Daunorubicin (µM)	0
337	Dexamethasone  (µM)	0.02705302
337	Ibrutinib (µM)	0
337	Mercaptopurine (µM)	117.4289
337	Nelarabine (µM)	0
337	Panobinostat (nM)	0
337	Prednisolone (µM)	0.03245637
337	Ruxolitinib (nM)	0
337	Thioguanine (µM)	4.675
337	Trametinib (nM)	0
337	Venetoclax (nM)	0
337	Vincristine (µM)	0.025
337	Vorinostat (nM)	0
337	asparagise_normalized	0.3346
337	cytarabine_normalized	0.1617
337	dexamethasone_normalized	0.4177
337	mercaptopurine_normalized	0.071
337	prednisolone_normalized	0.0741
337	thioguanine_normalized	0
337	vincristine_normalized	0
338	immunophenotype	B
338	molecular subtype	Hyperdiploid
338	Protocol	T15
338	NCI risk	SR
338	Age at diagnosis	7.9
338	WBC at diagnosis	7.3
338	Sex	F
338	Genetically-defined race	Hispanic
338	Asparaginase (IU/ml)	0
338	Bortezomib (nM)	0
338	CHZ868 (nM)	0
338	Cytarabine (µM)	0
338	Dasatinib (nM)	0
338	Daunorubicin (µM)	0
338	Dexamethasone  (µM)	0.007638312
338	Ibrutinib (µM)	0
338	Mercaptopurine (µM)	0
338	Nelarabine (µM)	0
338	Panobinostat (nM)	0
338	Prednisolone (µM)	0.0924801
338	Ruxolitinib (nM)	0
338	Thioguanine (µM)	60.45317
338	Trametinib (nM)	0
338	Venetoclax (nM)	0
338	Vincristine (µM)	0
338	Vorinostat (nM)	0
338	dexamethasone_normalized	0.2962
338	prednisolone_normalized	0.1746
338	thioguanine_normalized	0.5387
339	immunophenotype	T
339	molecular subtype	T-ALL
339	Protocol	T15
339	NCI risk	HR
339	Age at diagnosis	3.5
339	WBC at diagnosis	163.1
339	Sex	M
339	Genetically-defined race	White
339	Asparaginase (IU/ml)	0.4171718
339	Bortezomib (nM)	0
339	CHZ868 (nM)	0
339	Cytarabine (µM)	3.225763
339	Dasatinib (nM)	0
339	Daunorubicin (µM)	0.01946885
339	Dexamethasone  (µM)	0.4871907
339	Ibrutinib (µM)	0
339	Mercaptopurine (µM)	1303.849
339	Nelarabine (µM)	0
339	Panobinostat (nM)	0
339	Prednisolone (µM)	1006
339	Ruxolitinib (nM)	0
339	Thioguanine (µM)	81.57693
339	Trametinib (nM)	0
339	Venetoclax (nM)	0
339	Vincristine (µM)	0.3957647
339	Vorinostat (nM)	0
339	asparagise_normalized	0.6052
339	cytarabine_normalized	0.633
339	daunorubicin_normalized	0.2643
339	dexamethasone_normalized	0.6954
339	mercaptopurine_normalized	0.7656
339	prednisolone_normalized	1
339	thioguanine_normalized	0.6251
339	vincristine_normalized	0.2961
340	immunophenotype	B
340	molecular subtype	ETV6-RUNX1
340	Protocol	T15
340	NCI risk	SR
340	Age at diagnosis	3.7
340	WBC at diagnosis	14.1
340	Sex	F
340	Genetically-defined race	White
340	Asparaginase (IU/ml)	0
340	Bortezomib (nM)	0
340	CHZ868 (nM)	0
340	Cytarabine (µM)	0
340	Dasatinib (nM)	0
340	Daunorubicin (µM)	0
340	Dexamethasone  (µM)	0.0322166
340	Ibrutinib (µM)	0
340	Mercaptopurine (µM)	478.9951712
340	Nelarabine (µM)	0
340	Panobinostat (nM)	0
340	Prednisolone (µM)	0
340	Ruxolitinib (nM)	0
340	Thioguanine (µM)	35.82553
340	Trametinib (nM)	0
340	Venetoclax (nM)	0
340	Vincristine (µM)	0
340	Vorinostat (nM)	0
340	dexamethasone_normalized	0.4345
340	mercaptopurine_normalized	0.4767
340	thioguanine_normalized	0.3877
341	immunophenotype	B
341	molecular subtype	ETV6-RUNX1
341	Protocol	T15
341	NCI risk	SR
341	Age at diagnosis	7.1
341	WBC at diagnosis	11.7
341	Sex	F
341	Genetically-defined race	White
341	Asparaginase (IU/ml)	0
341	Bortezomib (nM)	0
341	CHZ868 (nM)	0
341	Cytarabine (µM)	0
341	Dasatinib (nM)	0
341	Daunorubicin (µM)	0
341	Dexamethasone  (µM)	0.004741013
341	Ibrutinib (µM)	0
341	Mercaptopurine (µM)	575.8781
341	Nelarabine (µM)	0
341	Panobinostat (nM)	0
341	Prednisolone (µM)	0
341	Ruxolitinib (nM)	0
341	Thioguanine (µM)	49.11027
341	Trametinib (nM)	0
341	Venetoclax (nM)	0
341	Vincristine (µM)	0
341	Vorinostat (nM)	0
341	dexamethasone_normalized	0.2504
341	mercaptopurine_normalized	0.5298
341	thioguanine_normalized	0.4787
342	immunophenotype	B
342	molecular subtype	Hyperdiploid
342	Protocol	T15
342	NCI risk	SR
342	Age at diagnosis	4.1
342	WBC at diagnosis	16.8
342	Sex	M
342	Genetically-defined race	Unknown
342	Asparaginase (IU/ml)	0.0016
342	Bortezomib (nM)	0
342	CHZ868 (nM)	0
342	Cytarabine (µM)	0.6393196
342	Dasatinib (nM)	0
342	Daunorubicin (µM)	0
342	Dexamethasone  (µM)	0.000763882
342	Ibrutinib (µM)	0
342	Mercaptopurine (µM)	336.387179
342	Nelarabine (µM)	0
342	Panobinostat (nM)	0
342	Prednisolone (µM)	0.0075
342	Ruxolitinib (nM)	0
342	Thioguanine (µM)	21.70431
342	Trametinib (nM)	0
342	Venetoclax (nM)	0
342	Vincristine (µM)	0.025
342	Vorinostat (nM)	0
342	asparagise_normalized	0
342	cytarabine_normalized	0.3996
342	dexamethasone_normalized	0.075
342	mercaptopurine_normalized	0.3747
342	prednisolone_normalized	0
342	thioguanine_normalized	0.243
342	vincristine_normalized	0
343	immunophenotype	B
343	molecular subtype	ETV6-RUNX1
343	Protocol	T15
343	NCI risk	SR
343	Age at diagnosis	2.8
343	WBC at diagnosis	7.4
343	Sex	F
343	Genetically-defined race	White
343	Asparaginase (IU/ml)	0
343	Bortezomib (nM)	0
343	CHZ868 (nM)	0
343	Cytarabine (µM)	0
343	Dasatinib (nM)	0
343	Daunorubicin (µM)	0
343	Dexamethasone  (µM)	23.2
343	Ibrutinib (µM)	0
343	Mercaptopurine (µM)	1800.314
343	Nelarabine (µM)	0
343	Panobinostat (nM)	0
343	Prednisolone (µM)	0.1322818
343	Ruxolitinib (nM)	0
343	Thioguanine (µM)	55.78265
343	Trametinib (nM)	0
343	Venetoclax (nM)	0
343	Vincristine (µM)	0.3420525
343	Vorinostat (nM)	0
343	dexamethasone_normalized	1
343	mercaptopurine_normalized	0.8587
343	prednisolone_normalized	0.2089
343	thioguanine_normalized	0.5155
343	vincristine_normalized	0.2752
344	immunophenotype	T
344	molecular subtype	T-ALL
344	Protocol	T15
344	NCI risk	HR
344	Age at diagnosis	16.4
344	WBC at diagnosis	80.9
344	Sex	F
344	Genetically-defined race	White
344	Asparaginase (IU/ml)	0.0016
344	Bortezomib (nM)	0
344	CHZ868 (nM)	0
344	Cytarabine (µM)	0
344	Dasatinib (nM)	0
344	Daunorubicin (µM)	7.1
344	Dexamethasone  (µM)	0
344	Ibrutinib (µM)	0
344	Mercaptopurine (µM)	225.7962
344	Nelarabine (µM)	0
344	Panobinostat (nM)	0
344	Prednisolone (µM)	0.0075
344	Ruxolitinib (nM)	0
344	Thioguanine (µM)	0
344	Trametinib (nM)	0
344	Venetoclax (nM)	0
344	Vincristine (µM)	0.025
344	Vorinostat (nM)	0
344	asparagise_normalized	0
344	daunorubicin_normalized	1
344	mercaptopurine_normalized	0.2597
344	prednisolone_normalized	0
344	vincristine_normalized	0
345	immunophenotype	B
345	molecular subtype	Hyperdiploid
345	Protocol	T15
345	NCI risk	HR
345	Age at diagnosis	2.2
345	WBC at diagnosis	63
345	Sex	F
345	Genetically-defined race	White
345	Asparaginase (IU/ml)	0.09363657
345	Bortezomib (nM)	0
345	CHZ868 (nM)	0
345	Cytarabine (µM)	0
345	Dasatinib (nM)	0
345	Daunorubicin (µM)	0
345	Dexamethasone  (µM)	0.003631842
345	Ibrutinib (µM)	0
345	Mercaptopurine (µM)	232.2478
345	Nelarabine (µM)	0
345	Panobinostat (nM)	0
345	Prednisolone (µM)	0.0075
345	Ruxolitinib (nM)	0
345	Thioguanine (µM)	109.9748
345	Trametinib (nM)	0
345	Venetoclax (nM)	0
345	Vincristine (µM)	0.7058209
345	Vorinostat (nM)	0
345	asparagise_normalized	0.4196
345	dexamethasone_normalized	0.2248
345	mercaptopurine_normalized	0.2678
345	prednisolone_normalized	0
345	thioguanine_normalized	0.7113
345	vincristine_normalized	0.3788
346	immunophenotype	B
346	molecular subtype	ETV6-RUNX1
346	Protocol	T15
346	NCI risk	SR
346	Age at diagnosis	1.8
346	WBC at diagnosis	10.1
346	Sex	F
346	Genetically-defined race	White
346	Asparaginase (IU/ml)	0
346	Bortezomib (nM)	0
346	CHZ868 (nM)	0
346	Cytarabine (µM)	0
346	Dasatinib (nM)	0
346	Daunorubicin (µM)	0
346	Dexamethasone  (µM)	0.02061301
346	Ibrutinib (µM)	0
346	Mercaptopurine (µM)	898.1377
346	Nelarabine (µM)	0
346	Panobinostat (nM)	0
346	Prednisolone (µM)	0.0075
346	Ruxolitinib (nM)	0
346	Thioguanine (µM)	35.63349
346	Trametinib (nM)	0
346	Venetoclax (nM)	0
346	Vincristine (µM)	0.1885717
346	Vorinostat (nM)	0
346	dexamethasone_normalized	0.3916
346	mercaptopurine_normalized	0.658
346	prednisolone_normalized	0
346	thioguanine_normalized	0.3861
346	vincristine_normalized	0.19
347	immunophenotype	B
347	molecular subtype	Hyperdiploid
347	Protocol	T15
347	NCI risk	SR
347	Age at diagnosis	5.8
347	WBC at diagnosis	2.8
347	Sex	M
347	Genetically-defined race	Asian/Other
347	Asparaginase (IU/ml)	0
347	Bortezomib (nM)	0
347	CHZ868 (nM)	0
347	Cytarabine (µM)	0
347	Dasatinib (nM)	0
347	Daunorubicin (µM)	0
347	Dexamethasone  (µM)	0.1798122
347	Ibrutinib (µM)	0
347	Mercaptopurine (µM)	0
347	Nelarabine (µM)	0
347	Panobinostat (nM)	0
347	Prednisolone (µM)	0.06977335
347	Ruxolitinib (nM)	0
347	Thioguanine (µM)	15.2128
347	Trametinib (nM)	0
347	Venetoclax (nM)	0
347	Vincristine (µM)	0
347	Vorinostat (nM)	0
347	dexamethasone_normalized	0.5997
347	prednisolone_normalized	0.1475
347	thioguanine_normalized	0.1405
348	immunophenotype	B
348	molecular subtype	PAX5alt
348	Protocol	T15
348	NCI risk	SR
348	Age at diagnosis	1.7
348	WBC at diagnosis	14.5
348	Sex	F
348	Genetically-defined race	White
348	Asparaginase (IU/ml)	0
348	Bortezomib (nM)	0
348	CHZ868 (nM)	0
348	Cytarabine (µM)	0
348	Dasatinib (nM)	0
348	Daunorubicin (µM)	0
348	Dexamethasone  (µM)	23.2
348	Ibrutinib (µM)	0
348	Mercaptopurine (µM)	923.7883
348	Nelarabine (µM)	0
348	Panobinostat (nM)	0
348	Prednisolone (µM)	1006
348	Ruxolitinib (nM)	0
348	Thioguanine (µM)	67.35277
348	Trametinib (nM)	0
348	Venetoclax (nM)	0
348	Vincristine (µM)	0
348	Vorinostat (nM)	0
348	dexamethasone_normalized	1
348	mercaptopurine_normalized	0.6662
348	prednisolone_normalized	1
348	thioguanine_normalized	0.5698
349	immunophenotype	B
349	molecular subtype	Near haploid
349	Protocol	T15
349	NCI risk	SR
349	Age at diagnosis	3.4
349	WBC at diagnosis	5.9
349	Sex	M
349	Genetically-defined race	White
349	Asparaginase (IU/ml)	0.0016
349	Bortezomib (nM)	0
349	CHZ868 (nM)	0
349	Cytarabine (µM)	0
349	Dasatinib (nM)	0
349	Daunorubicin (µM)	0
349	Dexamethasone  (µM)	23.2
349	Ibrutinib (µM)	0
349	Mercaptopurine (µM)	468.749
349	Nelarabine (µM)	0
349	Panobinostat (nM)	0
349	Prednisolone (µM)	1006
349	Ruxolitinib (nM)	0
349	Thioguanine (µM)	11.95044
349	Trametinib (nM)	0
349	Venetoclax (nM)	0
349	Vincristine (µM)	0.025
349	Vorinostat (nM)	0
349	asparagise_normalized	0
349	dexamethasone_normalized	1
349	mercaptopurine_normalized	0.4704
349	prednisolone_normalized	1
349	thioguanine_normalized	0.0708
349	vincristine_normalized	0
350	immunophenotype	B
350	molecular subtype	PAX5alt
350	Protocol	T15
350	NCI risk	HR
350	Age at diagnosis	2.1
350	WBC at diagnosis	75.2
350	Sex	F
350	Genetically-defined race	Hispanic
350	Asparaginase (IU/ml)	0
350	Bortezomib (nM)	0
350	CHZ868 (nM)	0
350	Cytarabine (µM)	0.908023468
350	Dasatinib (nM)	0
350	Daunorubicin (µM)	0
350	Dexamethasone  (µM)	0.02569244
350	Ibrutinib (µM)	0
350	Mercaptopurine (µM)	174.3923
350	Nelarabine (µM)	0
350	Panobinostat (nM)	0
350	Prednisolone (µM)	0.06492861
350	Ruxolitinib (nM)	0
350	Thioguanine (µM)	17.99044
350	Trametinib (nM)	0
350	Venetoclax (nM)	0
350	Vincristine (µM)	0.476297367
350	Vorinostat (nM)	0
350	cytarabine_normalized	0.4502
350	dexamethasone_normalized	0.4127
350	mercaptopurine_normalized	0.1851
350	prednisolone_normalized	0.1406
350	thioguanine_normalized	0.1889
350	vincristine_normalized	0.3226
351	immunophenotype	B
351	molecular subtype	ETV6-RUNX1
351	Protocol	T15
351	NCI risk	SR
351	Age at diagnosis	2.5
351	WBC at diagnosis	3.3
351	Sex	F
351	Genetically-defined race	black
351	Asparaginase (IU/ml)	0
351	Bortezomib (nM)	0
351	CHZ868 (nM)	0
351	Cytarabine (µM)	0
351	Dasatinib (nM)	0
351	Daunorubicin (µM)	0
351	Dexamethasone  (µM)	0.003662011
351	Ibrutinib (µM)	0
351	Mercaptopurine (µM)	413.1684
351	Nelarabine (µM)	0
351	Panobinostat (nM)	0
351	Prednisolone (µM)	0
351	Ruxolitinib (nM)	0
351	Thioguanine (µM)	4.675
351	Trametinib (nM)	0
351	Venetoclax (nM)	0
351	Vincristine (µM)	0
351	Vorinostat (nM)	0
351	dexamethasone_normalized	0.2256
351	mercaptopurine_normalized	0.434
351	thioguanine_normalized	0
352	immunophenotype	T
352	molecular subtype	T-ALL
352	Protocol	T15
352	NCI risk	HR
352	Age at diagnosis	14.7
352	WBC at diagnosis	1.4
352	Sex	M
352	Genetically-defined race	White
352	Asparaginase (IU/ml)	20
352	Bortezomib (nM)	0
352	CHZ868 (nM)	0
352	Cytarabine (µM)	82.2
352	Dasatinib (nM)	0
352	Daunorubicin (µM)	0
352	Dexamethasone  (µM)	0.5929103
352	Ibrutinib (µM)	0
352	Mercaptopurine (µM)	1554.227
352	Nelarabine (µM)	0
352	Panobinostat (nM)	0
352	Prednisolone (µM)	0.5350899
352	Ruxolitinib (nM)	0
352	Thioguanine (µM)	51.754
352	Trametinib (nM)	0
352	Venetoclax (nM)	0
352	Vincristine (µM)	108.34
352	Vorinostat (nM)	0
352	asparagise_normalized	1
352	cytarabine_normalized	1
352	dexamethasone_normalized	0.7143
352	mercaptopurine_normalized	0.8163
352	prednisolone_normalized	0.343
352	thioguanine_normalized	0.4938
352	vincristine_normalized	1
353	immunophenotype	B
353	molecular subtype	ETV6-RUNX1
353	Protocol	T15
353	NCI risk	SR
353	Age at diagnosis	4.9
353	WBC at diagnosis	8.2
353	Sex	M
353	Genetically-defined race	White
353	Asparaginase (IU/ml)	0
353	Bortezomib (nM)	0
353	CHZ868 (nM)	0
353	Cytarabine (µM)	0
353	Dasatinib (nM)	0
353	Daunorubicin (µM)	0
353	Dexamethasone  (µM)	0.01221997
353	Ibrutinib (µM)	0
353	Mercaptopurine (µM)	600.3573015
353	Nelarabine (µM)	0
353	Panobinostat (nM)	0
353	Prednisolone (µM)	0.0075
353	Ruxolitinib (nM)	0
353	Thioguanine (µM)	21.95365
353	Trametinib (nM)	0
353	Venetoclax (nM)	0
353	Vincristine (µM)	0
353	Vorinostat (nM)	0
353	dexamethasone_normalized	0.3413
353	mercaptopurine_normalized	0.5418
353	prednisolone_normalized	0
353	thioguanine_normalized	0.2463
354	immunophenotype	B
354	molecular subtype	Hyperdiploid
354	Protocol	T15
354	NCI risk	SR
354	Age at diagnosis	3.2
354	WBC at diagnosis	2.3
354	Sex	M
354	Genetically-defined race	White
354	Asparaginase (IU/ml)	0
354	Bortezomib (nM)	0
354	CHZ868 (nM)	0
354	Cytarabine (µM)	0
354	Dasatinib (nM)	0
354	Daunorubicin (µM)	0
354	Dexamethasone  (µM)	23.2
354	Ibrutinib (µM)	0
354	Mercaptopurine (µM)	425.9204
354	Nelarabine (µM)	0
354	Panobinostat (nM)	0
354	Prednisolone (µM)	0
354	Ruxolitinib (nM)	0
354	Thioguanine (µM)	11.48659
354	Trametinib (nM)	0
354	Venetoclax (nM)	0
354	Vincristine (µM)	0
354	Vorinostat (nM)	0
354	dexamethasone_normalized	1
354	mercaptopurine_normalized	0.4428
354	thioguanine_normalized	0.0594
355	immunophenotype	B
355	molecular subtype	TCF3-HLF
355	Protocol	T15
355	NCI risk	HR
355	Age at diagnosis	15.3
355	WBC at diagnosis	34
355	Sex	M
355	Genetically-defined race	Hispanic
355	Asparaginase (IU/ml)	0
355	Bortezomib (nM)	0
355	CHZ868 (nM)	0
355	Cytarabine (µM)	0
355	Dasatinib (nM)	0
355	Daunorubicin (µM)	0
355	Dexamethasone  (µM)	23.2
355	Ibrutinib (µM)	0
355	Mercaptopurine (µM)	0
355	Nelarabine (µM)	0
355	Panobinostat (nM)	0
355	Prednisolone (µM)	196.9318
355	Ruxolitinib (nM)	0
355	Thioguanine (µM)	0
355	Trametinib (nM)	0
355	Venetoclax (nM)	0
355	Vincristine (µM)	11.43682
355	Vorinostat (nM)	0
355	dexamethasone_normalized	1
355	prednisolone_normalized	0.91
355	vincristine_normalized	0.7774
356	immunophenotype	B
356	molecular subtype	B-other
356	Protocol	T15
356	NCI risk	HR
356	Age at diagnosis	1.7
356	WBC at diagnosis	114.2
356	Sex	M
356	Genetically-defined race	White
356	Asparaginase (IU/ml)	0.3797671
356	Bortezomib (nM)	0
356	CHZ868 (nM)	0
356	Cytarabine (µM)	0.5571466
356	Dasatinib (nM)	0
356	Daunorubicin (µM)	0
356	Dexamethasone  (µM)	0.1739257
356	Ibrutinib (µM)	0
356	Mercaptopurine (µM)	908.8742
356	Nelarabine (µM)	0
356	Panobinostat (nM)	0
356	Prednisolone (µM)	1.080575
356	Ruxolitinib (nM)	0
356	Thioguanine (µM)	54.25294
356	Trametinib (nM)	0
356	Venetoclax (nM)	0
356	Vincristine (µM)	7.261315
356	Vorinostat (nM)	0
356	asparagise_normalized	0.5935
356	cytarabine_normalized	0.3798
356	dexamethasone_normalized	0.5965
356	mercaptopurine_normalized	0.6615
356	prednisolone_normalized	0.4105
356	thioguanine_normalized	0.5074
356	vincristine_normalized	0.7124
357	immunophenotype	B
357	molecular subtype	Hyperdiploid
357	Protocol	T15
357	NCI risk	SR
357	Age at diagnosis	6
357	WBC at diagnosis	35
357	Sex	M
357	Genetically-defined race	White
357	Asparaginase (IU/ml)	0.2009427
357	Bortezomib (nM)	0
357	CHZ868 (nM)	0
357	Cytarabine (µM)	0
357	Dasatinib (nM)	0
357	Daunorubicin (µM)	0
357	Dexamethasone  (µM)	23.2
357	Ibrutinib (µM)	0
357	Mercaptopurine (µM)	423.0017
357	Nelarabine (µM)	0
357	Panobinostat (nM)	0
357	Prednisolone (µM)	0
357	Ruxolitinib (nM)	0
357	Thioguanine (µM)	21.13594
357	Trametinib (nM)	0
357	Venetoclax (nM)	0
357	Vincristine (µM)	0.3116741
357	Vorinostat (nM)	0
357	asparagise_normalized	0.5144
357	dexamethasone_normalized	1
357	mercaptopurine_normalized	0.4408
357	thioguanine_normalized	0.2354
357	vincristine_normalized	0.2619
358	immunophenotype	B
358	molecular subtype	TCF3-PBX1
358	Protocol	T15
358	NCI risk	SR
358	Age at diagnosis	8.3
358	WBC at diagnosis	16.9
358	Sex	F
358	Genetically-defined race	White
358	Asparaginase (IU/ml)	0.008596663
358	Bortezomib (nM)	0
358	CHZ868 (nM)	0
358	Cytarabine (µM)	0.337613394
358	Dasatinib (nM)	0
358	Daunorubicin (µM)	0
358	Dexamethasone  (µM)	0.002468154
358	Ibrutinib (µM)	0
358	Mercaptopurine (µM)	185.3139
358	Nelarabine (µM)	0
358	Panobinostat (nM)	0
358	Prednisolone (µM)	0.08942388
358	Ruxolitinib (nM)	0
358	Thioguanine (µM)	4.675
358	Trametinib (nM)	0
358	Venetoclax (nM)	0
358	Vincristine (µM)	0.025
358	Vorinostat (nM)	0
358	asparagise_normalized	0.1228
358	cytarabine_normalized	0.3076
358	dexamethasone_normalized	0.1877
358	mercaptopurine_normalized	0.2027
358	prednisolone_normalized	0.1713
358	thioguanine_normalized	0
358	vincristine_normalized	0
359	immunophenotype	B
359	molecular subtype	ETV6-RUNX1
359	Protocol	T15
359	NCI risk	SR
359	Age at diagnosis	2.5
359	WBC at diagnosis	45
359	Sex	F
359	Genetically-defined race	White
359	Asparaginase (IU/ml)	0.1441508
359	Bortezomib (nM)	0
359	CHZ868 (nM)	0
359	Cytarabine (µM)	7.290827
359	Dasatinib (nM)	0
359	Daunorubicin (µM)	0
359	Dexamethasone  (µM)	0.005172053
359	Ibrutinib (µM)	0
359	Mercaptopurine (µM)	718.3011
359	Nelarabine (µM)	0
359	Panobinostat (nM)	0
359	Prednisolone (µM)	0.0075
359	Ruxolitinib (nM)	0
359	Thioguanine (µM)	20.29236
359	Trametinib (nM)	0
359	Venetoclax (nM)	0
359	Vincristine (µM)	0.6407394
359	Vorinostat (nM)	0
359	asparagise_normalized	0.4732
359	cytarabine_normalized	0.7506
359	dexamethasone_normalized	0.2587
359	mercaptopurine_normalized	0.5936
359	prednisolone_normalized	0
359	thioguanine_normalized	0.2236
359	vincristine_normalized	0.365
360	immunophenotype	T
360	molecular subtype	ETP
360	Protocol	T15
360	NCI risk	HR
360	Age at diagnosis	12.7
360	WBC at diagnosis	16.6
360	Sex	F
360	Genetically-defined race	black
360	Asparaginase (IU/ml)	0.0016
360	Bortezomib (nM)	0
360	CHZ868 (nM)	0
360	Cytarabine (µM)	0
360	Dasatinib (nM)	0
360	Daunorubicin (µM)	0
360	Dexamethasone  (µM)	0
360	Ibrutinib (µM)	0
360	Mercaptopurine (µM)	495.9296
360	Nelarabine (µM)	0
360	Panobinostat (nM)	0
360	Prednisolone (µM)	1006
360	Ruxolitinib (nM)	0
360	Thioguanine (µM)	0
360	Trametinib (nM)	0
360	Venetoclax (nM)	0
360	Vincristine (µM)	0.9119214
360	Vorinostat (nM)	0
360	asparagise_normalized	0
360	mercaptopurine_normalized	0.4867
360	prednisolone_normalized	1
360	vincristine_normalized	0.4155
361	immunophenotype	B
361	molecular subtype	Hyperdiploid
361	Protocol	T15
361	NCI risk	SR
361	Age at diagnosis	3.1
361	WBC at diagnosis	3.4
361	Sex	M
361	Genetically-defined race	black
361	Asparaginase (IU/ml)	0
361	Bortezomib (nM)	0
361	CHZ868 (nM)	0
361	Cytarabine (µM)	0
361	Dasatinib (nM)	0
361	Daunorubicin (µM)	0
361	Dexamethasone  (µM)	23.2
361	Ibrutinib (µM)	0
361	Mercaptopurine (µM)	0
361	Nelarabine (µM)	0
361	Panobinostat (nM)	0
361	Prednisolone (µM)	1006
361	Ruxolitinib (nM)	0
361	Thioguanine (µM)	18.60206
361	Trametinib (nM)	0
361	Venetoclax (nM)	0
361	Vincristine (µM)	0.313648908
361	Vorinostat (nM)	0
361	dexamethasone_normalized	1
361	prednisolone_normalized	1
361	thioguanine_normalized	0.1985
361	vincristine_normalized	0.2628
362	immunophenotype	B
362	molecular subtype	MEF2D
362	Protocol	T15
362	NCI risk	HR
362	Age at diagnosis	11.6
362	WBC at diagnosis	214.1
362	Sex	F
362	Genetically-defined race	black
362	Asparaginase (IU/ml)	0
362	Bortezomib (nM)	0
362	CHZ868 (nM)	0
362	Cytarabine (µM)	0
362	Dasatinib (nM)	0
362	Daunorubicin (µM)	0
362	Dexamethasone  (µM)	0.1725637
362	Ibrutinib (µM)	0
362	Mercaptopurine (µM)	1191.824
362	Nelarabine (µM)	0
362	Panobinostat (nM)	0
362	Prednisolone (µM)	0.473884646
362	Ruxolitinib (nM)	0
362	Thioguanine (µM)	30.73052
362	Trametinib (nM)	0
362	Venetoclax (nM)	0
362	Vincristine (µM)	0
362	Vorinostat (nM)	0
362	dexamethasone_normalized	0.5957
362	mercaptopurine_normalized	0.7397
362	prednisolone_normalized	0.3314
362	thioguanine_normalized	0.3434
363	immunophenotype	T
363	molecular subtype	T-ALL
363	Protocol	T15
363	NCI risk	HR
363	Age at diagnosis	17.2
363	WBC at diagnosis	123.9
363	Sex	M
363	Genetically-defined race	White
363	Asparaginase (IU/ml)	0.01494239
363	Bortezomib (nM)	0
363	CHZ868 (nM)	0
363	Cytarabine (µM)	0
363	Dasatinib (nM)	0
363	Daunorubicin (µM)	0.1866479
363	Dexamethasone  (µM)	0
363	Ibrutinib (µM)	0
363	Mercaptopurine (µM)	611.5273
363	Nelarabine (µM)	0
363	Panobinostat (nM)	0
363	Prednisolone (µM)	1006
363	Ruxolitinib (nM)	0
363	Thioguanine (µM)	38.1869
363	Trametinib (nM)	0
363	Venetoclax (nM)	0
363	Vincristine (µM)	0.2081339
363	Vorinostat (nM)	0
363	asparagise_normalized	0.1915
363	daunorubicin_normalized	0.5837
363	mercaptopurine_normalized	0.5471
363	prednisolone_normalized	1
363	thioguanine_normalized	0.4061
363	vincristine_normalized	0.2041
364	immunophenotype	B
364	molecular subtype	NUTM1
364	Protocol	T15
364	NCI risk	HR
364	Age at diagnosis	1.2
364	WBC at diagnosis	172
364	Sex	M
364	Genetically-defined race	White
364	Asparaginase (IU/ml)	0
364	Bortezomib (nM)	0
364	CHZ868 (nM)	0
364	Cytarabine (µM)	0
364	Dasatinib (nM)	0
364	Daunorubicin (µM)	0
364	Dexamethasone  (µM)	0.003833895
364	Ibrutinib (µM)	0
364	Mercaptopurine (µM)	142.6932
364	Nelarabine (µM)	0
364	Panobinostat (nM)	0
364	Prednisolone (µM)	0.0075
364	Ruxolitinib (nM)	0
364	Thioguanine (µM)	4.675
364	Trametinib (nM)	0
364	Venetoclax (nM)	0
364	Vincristine (µM)	0
364	Vorinostat (nM)	0
364	dexamethasone_normalized	0.23
364	mercaptopurine_normalized	0.1273
364	prednisolone_normalized	0
364	thioguanine_normalized	0
365	immunophenotype	B
365	molecular subtype	DUX4
365	Protocol	T15
365	NCI risk	SR
365	Age at diagnosis	3.9
365	WBC at diagnosis	8.3
365	Sex	F
365	Genetically-defined race	Hispanic
365	Asparaginase (IU/ml)	0.1525118
365	Bortezomib (nM)	0
365	CHZ868 (nM)	0
365	Cytarabine (µM)	2.589374
365	Dasatinib (nM)	0
365	Daunorubicin (µM)	0
365	Dexamethasone  (µM)	0.000425121
365	Ibrutinib (µM)	0
365	Mercaptopurine (µM)	381.3861
365	Nelarabine (µM)	0
365	Panobinostat (nM)	0
365	Prednisolone (µM)	0.05729504
365	Ruxolitinib (nM)	0
365	Thioguanine (µM)	21.59692
365	Trametinib (nM)	0
365	Venetoclax (nM)	0
365	Vincristine (µM)	0.025
365	Vorinostat (nM)	0
365	asparagise_normalized	0.4802
365	cytarabine_normalized	0.6013
365	dexamethasone_normalized	0.0187
365	mercaptopurine_normalized	0.4109
365	prednisolone_normalized	0.1286
365	thioguanine_normalized	0.2416
365	vincristine_normalized	0
366	immunophenotype	B
366	molecular subtype	Hyperdiploid
366	Protocol	T15
366	NCI risk	SR
366	Age at diagnosis	5
366	WBC at diagnosis	8.6
366	Sex	M
366	Genetically-defined race	Hispanic
366	Asparaginase (IU/ml)	0.0016
366	Bortezomib (nM)	0
366	CHZ868 (nM)	0
366	Cytarabine (µM)	0.8985162
366	Dasatinib (nM)	0
366	Daunorubicin (µM)	0
366	Dexamethasone  (µM)	0.017457985
366	Ibrutinib (µM)	0
366	Mercaptopurine (µM)	358.8065
366	Nelarabine (µM)	0
366	Panobinostat (nM)	0
366	Prednisolone (µM)	0.2511535
366	Ruxolitinib (nM)	0
366	Thioguanine (µM)	27.56409
366	Trametinib (nM)	0
366	Venetoclax (nM)	0
366	Vincristine (µM)	0.025
366	Vorinostat (nM)	0
366	asparagise_normalized	0
366	cytarabine_normalized	0.4487
366	dexamethasone_normalized	0.3756
366	mercaptopurine_normalized	0.3933
366	prednisolone_normalized	0.2704
366	thioguanine_normalized	0.312
366	vincristine_normalized	0
367	immunophenotype	T
367	molecular subtype	T-ALL
367	Protocol	T15
367	NCI risk	HR
367	Age at diagnosis	8.4
367	WBC at diagnosis	293.3
367	Sex	M
367	Genetically-defined race	Hispanic
367	Asparaginase (IU/ml)	0.0016
367	Bortezomib (nM)	0
367	CHZ868 (nM)	0
367	Cytarabine (µM)	0
367	Dasatinib (nM)	0
367	Daunorubicin (µM)	0.1005225
367	Dexamethasone  (µM)	0
367	Ibrutinib (µM)	0
367	Mercaptopurine (µM)	45.9
367	Nelarabine (µM)	0
367	Panobinostat (nM)	0
367	Prednisolone (µM)	0.0075
367	Ruxolitinib (nM)	0
367	Thioguanine (µM)	4.675
367	Trametinib (nM)	0
367	Venetoclax (nM)	0
367	Vincristine (µM)	0.025
367	Vorinostat (nM)	0
367	asparagise_normalized	0
367	daunorubicin_normalized	0.4963
367	mercaptopurine_normalized	0
367	prednisolone_normalized	0
367	thioguanine_normalized	0
367	vincristine_normalized	0
368	immunophenotype	B
368	molecular subtype	DUX4
368	Protocol	T15
368	NCI risk	HR
368	Age at diagnosis	12.1
368	WBC at diagnosis	11.8
368	Sex	M
368	Genetically-defined race	White
368	Asparaginase (IU/ml)	0
368	Bortezomib (nM)	0
368	CHZ868 (nM)	0
368	Cytarabine (µM)	0
368	Dasatinib (nM)	0
368	Daunorubicin (µM)	0
368	Dexamethasone  (µM)	0.000974806
368	Ibrutinib (µM)	0
368	Mercaptopurine (µM)	407.3521
368	Nelarabine (µM)	0
368	Panobinostat (nM)	0
368	Prednisolone (µM)	0.0075
368	Ruxolitinib (nM)	0
368	Thioguanine (µM)	59.4641
368	Trametinib (nM)	0
368	Venetoclax (nM)	0
368	Vincristine (µM)	0
368	Vorinostat (nM)	0
368	dexamethasone_normalized	0.0984
368	mercaptopurine_normalized	0.4299
368	prednisolone_normalized	0
368	thioguanine_normalized	0.5339
369	immunophenotype	B
369	molecular subtype	Hyperdiploid
369	Protocol	T15
369	NCI risk	SR
369	Age at diagnosis	3.7
369	WBC at diagnosis	40
369	Sex	F
369	Genetically-defined race	Hispanic
369	Asparaginase (IU/ml)	0.07641234
369	Bortezomib (nM)	0
369	CHZ868 (nM)	0
369	Cytarabine (µM)	0.187446
369	Dasatinib (nM)	0
369	Daunorubicin (µM)	0
369	Dexamethasone  (µM)	0.02528297
369	Ibrutinib (µM)	0
369	Mercaptopurine (µM)	316.1363
369	Nelarabine (µM)	0
369	Panobinostat (nM)	0
369	Prednisolone (µM)	1006
369	Ruxolitinib (nM)	0
369	Thioguanine (µM)	15.14415
369	Trametinib (nM)	0
369	Venetoclax (nM)	0
369	Vincristine (µM)	0.9125998
369	Vorinostat (nM)	0
369	asparagise_normalized	0.3943
369	cytarabine_normalized	0.2227
369	dexamethasone_normalized	0.4112
369	mercaptopurine_normalized	0.3568
369	prednisolone_normalized	1
369	thioguanine_normalized	0.1392
369	vincristine_normalized	0.4156
370	immunophenotype	B
370	molecular subtype	Hyperdiploid
370	Protocol	T15
370	NCI risk	SR
370	Age at diagnosis	2
370	WBC at diagnosis	3.5
370	Sex	M
370	Genetically-defined race	White
370	Asparaginase (IU/ml)	0
370	Bortezomib (nM)	0
370	CHZ868 (nM)	0
370	Cytarabine (µM)	0
370	Dasatinib (nM)	0
370	Daunorubicin (µM)	0
370	Dexamethasone  (µM)	0.0308283
370	Ibrutinib (µM)	0
370	Mercaptopurine (µM)	314.8299
370	Nelarabine (µM)	0
370	Panobinostat (nM)	0
370	Prednisolone (µM)	0.042877703
370	Ruxolitinib (nM)	0
370	Thioguanine (µM)	16.13533
370	Trametinib (nM)	0
370	Venetoclax (nM)	0
370	Vincristine (µM)	0.05063382
370	Vorinostat (nM)	0
370	dexamethasone_normalized	0.4302
370	mercaptopurine_normalized	0.3556
370	prednisolone_normalized	0.1008
370	thioguanine_normalized	0.1575
370	vincristine_normalized	0.0018
371	immunophenotype	T
371	molecular subtype	T-ALL
371	Protocol	T15
371	NCI risk	SR
371	Age at diagnosis	6.1
371	WBC at diagnosis	3.4
371	Sex	M
371	Genetically-defined race	White
371	Asparaginase (IU/ml)	0.3238722
371	Bortezomib (nM)	0
371	CHZ868 (nM)	0
371	Cytarabine (µM)	0
371	Dasatinib (nM)	0
371	Daunorubicin (µM)	0
371	Dexamethasone  (µM)	0
371	Ibrutinib (µM)	0
371	Mercaptopurine (µM)	171.5243
371	Nelarabine (µM)	0
371	Panobinostat (nM)	0
371	Prednisolone (µM)	9.315097
371	Ruxolitinib (nM)	0
371	Thioguanine (µM)	0
371	Trametinib (nM)	0
371	Venetoclax (nM)	0
371	Vincristine (µM)	0.025
371	Vorinostat (nM)	0
371	asparagise_normalized	0.5738
371	mercaptopurine_normalized	0.1804
371	prednisolone_normalized	0.6172
371	vincristine_normalized	0
372	immunophenotype	B
372	molecular subtype	Ph-like_CRLF2
372	Protocol	T15
372	NCI risk	HR
372	Age at diagnosis	5.4
372	WBC at diagnosis	245.4
372	Sex	M
372	Genetically-defined race	White
372	Asparaginase (IU/ml)	0
372	Bortezomib (nM)	0
372	CHZ868 (nM)	0
372	Cytarabine (µM)	0
372	Dasatinib (nM)	0
372	Daunorubicin (µM)	0
372	Dexamethasone  (µM)	0.003364204
372	Ibrutinib (µM)	0
372	Mercaptopurine (µM)	137.5370742
372	Nelarabine (µM)	0
372	Panobinostat (nM)	0
372	Prednisolone (µM)	0.0075
372	Ruxolitinib (nM)	0
372	Thioguanine (µM)	26.71081
372	Trametinib (nM)	0
372	Venetoclax (nM)	0
372	Vincristine (µM)	0
372	Vorinostat (nM)	0
372	dexamethasone_normalized	0.2174
372	mercaptopurine_normalized	0.1166
372	prednisolone_normalized	0
372	thioguanine_normalized	0.3029
373	immunophenotype	T
373	molecular subtype	T-ALL
373	Protocol	T15
373	NCI risk	HR
373	Age at diagnosis	14.3
373	WBC at diagnosis	200
373	Sex	M
373	Genetically-defined race	White
373	Asparaginase (IU/ml)	0.004813509
373	Bortezomib (nM)	0
373	CHZ868 (nM)	0
373	Cytarabine (µM)	0
373	Dasatinib (nM)	0
373	Daunorubicin (µM)	0
373	Dexamethasone  (µM)	0
373	Ibrutinib (µM)	0
373	Mercaptopurine (µM)	111.4491
373	Nelarabine (µM)	0
373	Panobinostat (nM)	0
373	Prednisolone (µM)	0.07238756
373	Ruxolitinib (nM)	0
373	Thioguanine (µM)	0
373	Trametinib (nM)	0
373	Venetoclax (nM)	0
373	Vincristine (µM)	0.08303471
373	Vorinostat (nM)	0
373	asparagise_normalized	0.0507
373	mercaptopurine_normalized	0.056
373	prednisolone_normalized	0.151
373	vincristine_normalized	0.0726
374	immunophenotype	B
374	molecular subtype	Near haploid
374	Protocol	T15
374	NCI risk	HR
374	Age at diagnosis	2.7
374	WBC at diagnosis	52
374	Sex	M
374	Genetically-defined race	White
374	Asparaginase (IU/ml)	0
374	Bortezomib (nM)	0
374	CHZ868 (nM)	0
374	Cytarabine (µM)	0
374	Dasatinib (nM)	0
374	Daunorubicin (µM)	0
374	Dexamethasone  (µM)	23.2
374	Ibrutinib (µM)	0
374	Mercaptopurine (µM)	5876
374	Nelarabine (µM)	0
374	Panobinostat (nM)	0
374	Prednisolone (µM)	0.377269154
374	Ruxolitinib (nM)	0
374	Thioguanine (µM)	17.95059
374	Trametinib (nM)	0
374	Venetoclax (nM)	0
374	Vincristine (µM)	0.025
374	Vorinostat (nM)	0
374	dexamethasone_normalized	1
374	mercaptopurine_normalized	1
374	prednisolone_normalized	0.3095
374	thioguanine_normalized	0.1882
374	vincristine_normalized	0
375	immunophenotype	B
375	molecular subtype	Hyperdiploid
375	Protocol	T15
375	NCI risk	HR
375	Age at diagnosis	12.1
375	WBC at diagnosis	2.6
375	Sex	M
375	Genetically-defined race	White
375	Asparaginase (IU/ml)	0
375	Bortezomib (nM)	0
375	CHZ868 (nM)	0
375	Cytarabine (µM)	0
375	Dasatinib (nM)	0
375	Daunorubicin (µM)	0
375	Dexamethasone  (µM)	0.2051475
375	Ibrutinib (µM)	0
375	Mercaptopurine (µM)	5876
375	Nelarabine (µM)	0
375	Panobinostat (nM)	0
375	Prednisolone (µM)	0
375	Ruxolitinib (nM)	0
375	Thioguanine (µM)	4.675
375	Trametinib (nM)	0
375	Venetoclax (nM)	0
375	Vincristine (µM)	0
375	Vorinostat (nM)	0
375	dexamethasone_normalized	0.6123
375	mercaptopurine_normalized	1
375	thioguanine_normalized	0
376	immunophenotype	B
376	molecular subtype	TCF3-PBX1
376	Protocol	T15
376	NCI risk	SR
376	Age at diagnosis	2.2
376	WBC at diagnosis	12.7
376	Sex	M
376	Genetically-defined race	Hispanic
376	Asparaginase (IU/ml)	0
376	Bortezomib (nM)	0
376	CHZ868 (nM)	0
376	Cytarabine (µM)	0
376	Dasatinib (nM)	0
376	Daunorubicin (µM)	0
376	Dexamethasone  (µM)	0.004959246
376	Ibrutinib (µM)	0
376	Mercaptopurine (µM)	158.625
376	Nelarabine (µM)	0
376	Panobinostat (nM)	0
376	Prednisolone (µM)	0
376	Ruxolitinib (nM)	0
376	Thioguanine (µM)	0
376	Trametinib (nM)	0
376	Venetoclax (nM)	0
376	Vincristine (µM)	0
376	Vorinostat (nM)	0
376	dexamethasone_normalized	0.2547
376	mercaptopurine_normalized	0.1578
377	immunophenotype	T
377	molecular subtype	T-ALL
377	Protocol	T15
377	NCI risk	HR
377	Age at diagnosis	5.7
377	WBC at diagnosis	52
377	Sex	M
377	Genetically-defined race	White
377	Asparaginase (IU/ml)	0.02102748
377	Bortezomib (nM)	0
377	CHZ868 (nM)	0
377	Cytarabine (µM)	0
377	Dasatinib (nM)	0
377	Daunorubicin (µM)	0
377	Dexamethasone  (µM)	0
377	Ibrutinib (µM)	0
377	Mercaptopurine (µM)	189.0999
377	Nelarabine (µM)	0
377	Panobinostat (nM)	0
377	Prednisolone (µM)	0.05217878
377	Ruxolitinib (nM)	0
377	Thioguanine (µM)	0
377	Trametinib (nM)	0
377	Venetoclax (nM)	0
377	Vincristine (µM)	0
377	Vorinostat (nM)	0
377	asparagise_normalized	0.234
377	mercaptopurine_normalized	0.2085
377	prednisolone_normalized	0.1196
378	immunophenotype	T
378	molecular subtype	ETP
378	Protocol	T15
378	NCI risk	HR
378	Age at diagnosis	6.1
378	WBC at diagnosis	63.8
378	Sex	F
378	Genetically-defined race	White
378	Asparaginase (IU/ml)	0.0016
378	Bortezomib (nM)	0
378	CHZ868 (nM)	0
378	Cytarabine (µM)	0
378	Dasatinib (nM)	0
378	Daunorubicin (µM)	0.06404479
378	Dexamethasone  (µM)	0
378	Ibrutinib (µM)	0
378	Mercaptopurine (µM)	1198.626
378	Nelarabine (µM)	0
378	Panobinostat (nM)	0
378	Prednisolone (µM)	1006
378	Ruxolitinib (nM)	0
378	Thioguanine (µM)	29.56961
378	Trametinib (nM)	0
378	Venetoclax (nM)	0
378	Vincristine (µM)	0.3833326
378	Vorinostat (nM)	0
378	asparagise_normalized	0
378	daunorubicin_normalized	0.4326
378	mercaptopurine_normalized	0.7413
378	prednisolone_normalized	1
378	thioguanine_normalized	0.3323
378	vincristine_normalized	0.2915
379	immunophenotype	B
379	molecular subtype	ETV6-RUNX1
379	Protocol	T15
379	NCI risk	SR
379	Age at diagnosis	6.2
379	WBC at diagnosis	16.5
379	Sex	M
379	Genetically-defined race	black
379	Asparaginase (IU/ml)	0
379	Bortezomib (nM)	0
379	CHZ868 (nM)	0
379	Cytarabine (µM)	0
379	Dasatinib (nM)	0
379	Daunorubicin (µM)	0
379	Dexamethasone  (µM)	0
379	Ibrutinib (µM)	0
379	Mercaptopurine (µM)	527.3932
379	Nelarabine (µM)	0
379	Panobinostat (nM)	0
379	Prednisolone (µM)	0
379	Ruxolitinib (nM)	0
379	Thioguanine (µM)	15.22325
379	Trametinib (nM)	0
379	Venetoclax (nM)	0
379	Vincristine (µM)	0
379	Vorinostat (nM)	0
379	mercaptopurine_normalized	0.5044
379	thioguanine_normalized	0.1407
380	immunophenotype	B
380	molecular subtype	ETV6-RUNX1
380	Protocol	T15
380	NCI risk	SR
380	Age at diagnosis	1.9
380	WBC at diagnosis	8
380	Sex	F
380	Genetically-defined race	White
380	Asparaginase (IU/ml)	0
380	Bortezomib (nM)	0
380	CHZ868 (nM)	0
380	Cytarabine (µM)	0
380	Dasatinib (nM)	0
380	Daunorubicin (µM)	0
380	Dexamethasone  (µM)	0.036161057
380	Ibrutinib (µM)	0
380	Mercaptopurine (µM)	967.9750891
380	Nelarabine (µM)	0
380	Panobinostat (nM)	0
380	Prednisolone (µM)	0.09242815
380	Ruxolitinib (nM)	0
380	Thioguanine (µM)	20.83802
380	Trametinib (nM)	0
380	Venetoclax (nM)	0
380	Vincristine (µM)	0
380	Vorinostat (nM)	0
380	dexamethasone_normalized	0.4456
380	mercaptopurine_normalized	0.6797
380	prednisolone_normalized	0.1745
380	thioguanine_normalized	0.2313
381	immunophenotype	B
381	molecular subtype	KMT2A
381	Protocol	T15
381	NCI risk	HR
381	Age at diagnosis	1.3
381	WBC at diagnosis	118.3
381	Sex	M
381	Genetically-defined race	White
381	Asparaginase (IU/ml)	0
381	Bortezomib (nM)	0
381	CHZ868 (nM)	0
381	Cytarabine (µM)	0
381	Dasatinib (nM)	0
381	Daunorubicin (µM)	0
381	Dexamethasone  (µM)	0.007278787
381	Ibrutinib (µM)	0
381	Mercaptopurine (µM)	390.6964
381	Nelarabine (µM)	0
381	Panobinostat (nM)	0
381	Prednisolone (µM)	0.1132699
381	Ruxolitinib (nM)	0
381	Thioguanine (µM)	45.95551
381	Trametinib (nM)	0
381	Venetoclax (nM)	0
381	Vincristine (µM)	0
381	Vorinostat (nM)	0
381	dexamethasone_normalized	0.2916
381	mercaptopurine_normalized	0.4179
381	prednisolone_normalized	0.194
381	thioguanine_normalized	0.4595
382	immunophenotype	B
382	molecular subtype	ETV6-RUNX1
382	Protocol	T15
382	NCI risk	SR
382	Age at diagnosis	3.3
382	WBC at diagnosis	35.3
382	Sex	M
382	Genetically-defined race	Hispanic
382	Asparaginase (IU/ml)	0
382	Bortezomib (nM)	0
382	CHZ868 (nM)	0
382	Cytarabine (µM)	0
382	Dasatinib (nM)	0
382	Daunorubicin (µM)	0
382	Dexamethasone  (µM)	0.008371838
382	Ibrutinib (µM)	0
382	Mercaptopurine (µM)	264.8358
382	Nelarabine (µM)	0
382	Panobinostat (nM)	0
382	Prednisolone (µM)	0.001068707
382	Ruxolitinib (nM)	0
382	Thioguanine (µM)	27.14409
382	Trametinib (nM)	0
382	Venetoclax (nM)	0
382	Vincristine (µM)	0
382	Vorinostat (nM)	0
382	dexamethasone_normalized	0.305
382	mercaptopurine_normalized	0.3057
382	prednisolone_normalized	0
382	thioguanine_normalized	0.3076
383	immunophenotype	B
383	molecular subtype	ETV6-RUNX1
383	Protocol	T15
383	NCI risk	SR
383	Age at diagnosis	2.1
383	WBC at diagnosis	9
383	Sex	F
383	Genetically-defined race	White
383	Asparaginase (IU/ml)	0
383	Bortezomib (nM)	0
383	CHZ868 (nM)	0
383	Cytarabine (µM)	0
383	Dasatinib (nM)	0
383	Daunorubicin (µM)	0
383	Dexamethasone  (µM)	23.2
383	Ibrutinib (µM)	0
383	Mercaptopurine (µM)	1367.884345
383	Nelarabine (µM)	0
383	Panobinostat (nM)	0
383	Prednisolone (µM)	0
383	Ruxolitinib (nM)	0
383	Thioguanine (µM)	40.83491
383	Trametinib (nM)	0
383	Venetoclax (nM)	0
383	Vincristine (µM)	0
383	Vorinostat (nM)	0
383	dexamethasone_normalized	1
383	mercaptopurine_normalized	0.7794
383	thioguanine_normalized	0.4254
384	immunophenotype	B
384	molecular subtype	ETV6-RUNX1
384	Protocol	T15
384	NCI risk	SR
384	Age at diagnosis	3.5
384	WBC at diagnosis	6.7
384	Sex	F
384	Genetically-defined race	White
384	Asparaginase (IU/ml)	0
384	Bortezomib (nM)	0
384	CHZ868 (nM)	0
384	Cytarabine (µM)	0
384	Dasatinib (nM)	0
384	Daunorubicin (µM)	0
384	Dexamethasone  (µM)	0.05142508
384	Ibrutinib (µM)	0
384	Mercaptopurine (µM)	756.278
384	Nelarabine (µM)	0
384	Panobinostat (nM)	0
384	Prednisolone (µM)	0
384	Ruxolitinib (nM)	0
384	Thioguanine (µM)	27.82164
384	Trametinib (nM)	0
384	Venetoclax (nM)	0
384	Vincristine (µM)	0
384	Vorinostat (nM)	0
384	dexamethasone_normalized	0.4794
384	mercaptopurine_normalized	0.6084
384	thioguanine_normalized	0.3147
385	immunophenotype	B
385	molecular subtype	ZNF384
385	Protocol	T15
385	NCI risk	SR
385	Age at diagnosis	1.3
385	WBC at diagnosis	40.8
385	Sex	M
385	Genetically-defined race	White
385	Asparaginase (IU/ml)	0
385	Bortezomib (nM)	0
385	CHZ868 (nM)	0
385	Cytarabine (µM)	0
385	Dasatinib (nM)	0
385	Daunorubicin (µM)	0
385	Dexamethasone  (µM)	23.2
385	Ibrutinib (µM)	0
385	Mercaptopurine (µM)	1005.591
385	Nelarabine (µM)	0
385	Panobinostat (nM)	0
385	Prednisolone (µM)	1006
385	Ruxolitinib (nM)	0
385	Thioguanine (µM)	73.85018
385	Trametinib (nM)	0
385	Venetoclax (nM)	0
385	Vincristine (µM)	0
385	Vorinostat (nM)	0
385	dexamethasone_normalized	1
385	mercaptopurine_normalized	0.6907
385	prednisolone_normalized	1
385	thioguanine_normalized	0.5964
386	immunophenotype	B
386	molecular subtype	Hyperdiploid
386	Protocol	T15
386	NCI risk	SR
386	Age at diagnosis	4.7
386	WBC at diagnosis	7.1
386	Sex	F
386	Genetically-defined race	White
386	Asparaginase (IU/ml)	0.0016
386	Bortezomib (nM)	0
386	CHZ868 (nM)	0
386	Cytarabine (µM)	0
386	Dasatinib (nM)	0
386	Daunorubicin (µM)	0
386	Dexamethasone  (µM)	0.02938551
386	Ibrutinib (µM)	0
386	Mercaptopurine (µM)	657.9906625
386	Nelarabine (µM)	0
386	Panobinostat (nM)	0
386	Prednisolone (µM)	0.0975974
386	Ruxolitinib (nM)	0
386	Thioguanine (µM)	32.87378
386	Trametinib (nM)	0
386	Venetoclax (nM)	0
386	Vincristine (µM)	14.05917
386	Vorinostat (nM)	0
386	asparagise_normalized	0
386	dexamethasone_normalized	0.4256
386	mercaptopurine_normalized	0.5683
386	prednisolone_normalized	0.1797
386	thioguanine_normalized	0.3628
386	vincristine_normalized	0.807
387	immunophenotype	B
387	molecular subtype	iAMP21
387	Protocol	T15
387	NCI risk	SR
387	Age at diagnosis	9.2
387	WBC at diagnosis	1.5
387	Sex	F
387	Genetically-defined race	White
387	Asparaginase (IU/ml)	0
387	Bortezomib (nM)	0
387	CHZ868 (nM)	0
387	Cytarabine (µM)	0
387	Dasatinib (nM)	0
387	Daunorubicin (µM)	0
387	Dexamethasone  (µM)	0.01748373
387	Ibrutinib (µM)	0
387	Mercaptopurine (µM)	0
387	Nelarabine (µM)	0
387	Panobinostat (nM)	0
387	Prednisolone (µM)	0.02889913
387	Ruxolitinib (nM)	0
387	Thioguanine (µM)	121.1186
387	Trametinib (nM)	0
387	Venetoclax (nM)	0
387	Vincristine (µM)	0.2276886
387	Vorinostat (nM)	0
387	dexamethasone_normalized	0.3758
387	prednisolone_normalized	0.0629
387	thioguanine_normalized	0.7392
387	vincristine_normalized	0.2169
388	immunophenotype	B
388	molecular subtype	PAX5alt
388	Protocol	T15
388	NCI risk	HR
388	Age at diagnosis	14.4
388	WBC at diagnosis	2.3
388	Sex	M
388	Genetically-defined race	White
388	Asparaginase (IU/ml)	0.2540759
388	Bortezomib (nM)	0
388	CHZ868 (nM)	0
388	Cytarabine (µM)	0
388	Dasatinib (nM)	0
388	Daunorubicin (µM)	0
388	Dexamethasone  (µM)	0.3616979
388	Ibrutinib (µM)	0
388	Mercaptopurine (µM)	301.8639
388	Nelarabine (µM)	0
388	Panobinostat (nM)	0
388	Prednisolone (µM)	0.4834387
388	Ruxolitinib (nM)	0
388	Thioguanine (µM)	22.88961
388	Trametinib (nM)	0
388	Venetoclax (nM)	0
388	Vincristine (µM)	0
388	Vorinostat (nM)	0
388	asparagise_normalized	0.5436
388	dexamethasone_normalized	0.6668
388	mercaptopurine_normalized	0.3435
388	prednisolone_normalized	0.3333
388	thioguanine_normalized	0.2584
389	immunophenotype	B
389	molecular subtype	Hyperdiploid
389	Protocol	T15
389	NCI risk	SR
389	Age at diagnosis	5.2
389	WBC at diagnosis	3.9
389	Sex	F
389	Genetically-defined race	White
389	Asparaginase (IU/ml)	0
389	Bortezomib (nM)	0
389	CHZ868 (nM)	0
389	Cytarabine (µM)	0
389	Dasatinib (nM)	0
389	Daunorubicin (µM)	0
389	Dexamethasone  (µM)	23.2
389	Ibrutinib (µM)	0
389	Mercaptopurine (µM)	605.9390861
389	Nelarabine (µM)	0
389	Panobinostat (nM)	0
389	Prednisolone (µM)	1006
389	Ruxolitinib (nM)	0
389	Thioguanine (µM)	49.28164482
389	Trametinib (nM)	0
389	Venetoclax (nM)	0
389	Vincristine (µM)	0
389	Vorinostat (nM)	0
389	dexamethasone_normalized	1
389	mercaptopurine_normalized	0.5445
389	prednisolone_normalized	1
389	thioguanine_normalized	0.4797
390	immunophenotype	B
390	molecular subtype	ETV6-RUNX1
390	Protocol	T15
390	NCI risk	SR
390	Age at diagnosis	5.2
390	WBC at diagnosis	3.4
390	Sex	F
390	Genetically-defined race	Asian/Other
390	Asparaginase (IU/ml)	0.08416949
390	Bortezomib (nM)	0
390	CHZ868 (nM)	0
390	Cytarabine (µM)	0
390	Dasatinib (nM)	0
390	Daunorubicin (µM)	0
390	Dexamethasone  (µM)	0.02769124
390	Ibrutinib (µM)	0
390	Mercaptopurine (µM)	256.7818085
390	Nelarabine (µM)	0
390	Panobinostat (nM)	0
390	Prednisolone (µM)	0.1032663
390	Ruxolitinib (nM)	0
390	Thioguanine (µM)	22.03845
390	Trametinib (nM)	0
390	Venetoclax (nM)	0
390	Vincristine (µM)	43.74688
390	Vorinostat (nM)	0
390	asparagise_normalized	0.4063
390	dexamethasone_normalized	0.4199
390	mercaptopurine_normalized	0.2968
390	prednisolone_normalized	0.1851
390	thioguanine_normalized	0.2474
390	vincristine_normalized	0.9694
391	immunophenotype	B
391	molecular subtype	Hyperdiploid
391	Protocol	T15
391	NCI risk	SR
391	Age at diagnosis	7
391	WBC at diagnosis	15.3
391	Sex	M
391	Genetically-defined race	black
391	Asparaginase (IU/ml)	0
391	Bortezomib (nM)	0
391	CHZ868 (nM)	0
391	Cytarabine (µM)	0
391	Dasatinib (nM)	0
391	Daunorubicin (µM)	0
391	Dexamethasone  (µM)	23.2
391	Ibrutinib (µM)	0
391	Mercaptopurine (µM)	0
391	Nelarabine (µM)	0
391	Panobinostat (nM)	0
391	Prednisolone (µM)	76.24788
391	Ruxolitinib (nM)	0
391	Thioguanine (µM)	11.36634
391	Trametinib (nM)	0
391	Venetoclax (nM)	0
391	Vincristine (µM)	13.85697
391	Vorinostat (nM)	0
391	dexamethasone_normalized	1
391	prednisolone_normalized	0.8189
391	thioguanine_normalized	0.0564
391	vincristine_normalized	0.8049
392	immunophenotype	B
392	molecular subtype	B-other
392	Protocol	T15
392	NCI risk	HR
392	Age at diagnosis	16.2
392	WBC at diagnosis	8.3
392	Sex	F
392	Genetically-defined race	White
392	Asparaginase (IU/ml)	20
392	Bortezomib (nM)	0
392	CHZ868 (nM)	0
392	Cytarabine (µM)	5.565298578
392	Dasatinib (nM)	0
392	Daunorubicin (µM)	0
392	Dexamethasone  (µM)	0.05329075
392	Ibrutinib (µM)	0
392	Mercaptopurine (µM)	503.6348
392	Nelarabine (µM)	0
392	Panobinostat (nM)	0
392	Prednisolone (µM)	0.1153991
392	Ruxolitinib (nM)	0
392	Thioguanine (µM)	50.59863
392	Trametinib (nM)	0
392	Venetoclax (nM)	0
392	Vincristine (µM)	0.5692322
392	Vorinostat (nM)	0
392	asparagise_normalized	1
392	cytarabine_normalized	0.7117
392	dexamethasone_normalized	0.4828
392	mercaptopurine_normalized	0.4911
392	prednisolone_normalized	0.1958
392	thioguanine_normalized	0.4873
392	vincristine_normalized	0.3481
393	immunophenotype	B
393	molecular subtype	DUX4
393	Protocol	T15
393	NCI risk	HR
393	Age at diagnosis	18.7
393	WBC at diagnosis	74.2
393	Sex	F
393	Genetically-defined race	White
393	Asparaginase (IU/ml)	20
393	Bortezomib (nM)	0
393	CHZ868 (nM)	0
393	Cytarabine (µM)	8.497475
393	Dasatinib (nM)	0
393	Daunorubicin (µM)	0
393	Dexamethasone  (µM)	0.3256107
393	Ibrutinib (µM)	0
393	Mercaptopurine (µM)	5876
393	Nelarabine (µM)	0
393	Panobinostat (nM)	0
393	Prednisolone (µM)	0.539172864
393	Ruxolitinib (nM)	0
393	Thioguanine (µM)	85.89036
393	Trametinib (nM)	0
393	Venetoclax (nM)	0
393	Vincristine (µM)	0.135673675
393	Vorinostat (nM)	0
393	asparagise_normalized	1
393	cytarabine_normalized	0.7727
393	dexamethasone_normalized	0.6567
393	mercaptopurine_normalized	1
393	prednisolone_normalized	0.3438
393	thioguanine_normalized	0.64
393	vincristine_normalized	0.1429
394	immunophenotype	B
394	molecular subtype	ETV6-RUNX1
394	Protocol	T15
394	NCI risk	SR
394	Age at diagnosis	5.5
394	WBC at diagnosis	27.1
394	Sex	M
394	Genetically-defined race	White
394	Asparaginase (IU/ml)	0.0016
394	Bortezomib (nM)	0
394	CHZ868 (nM)	0
394	Cytarabine (µM)	9.588804
394	Dasatinib (nM)	0
394	Daunorubicin (µM)	0
394	Dexamethasone  (µM)	0.04513611
394	Ibrutinib (µM)	0
394	Mercaptopurine (µM)	5876
394	Nelarabine (µM)	0
394	Panobinostat (nM)	0
394	Prednisolone (µM)	0.1310171
394	Ruxolitinib (nM)	0
394	Thioguanine (µM)	38.38088
394	Trametinib (nM)	0
394	Venetoclax (nM)	0
394	Vincristine (µM)	0.9224166
394	Vorinostat (nM)	0
394	asparagise_normalized	0
394	cytarabine_normalized	0.7901
394	dexamethasone_normalized	0.4669
394	mercaptopurine_normalized	1
394	prednisolone_normalized	0.208
394	thioguanine_normalized	0.4075
394	vincristine_normalized	0.4171
395	immunophenotype	B
395	molecular subtype	B-other
395	Protocol	T15
395	NCI risk	SR
395	Age at diagnosis	4.5
395	WBC at diagnosis	22.6
395	Sex	F
395	Genetically-defined race	White
395	Asparaginase (IU/ml)	0.06916602
395	Bortezomib (nM)	0
395	CHZ868 (nM)	0
395	Cytarabine (µM)	24.27511848
395	Dasatinib (nM)	0
395	Daunorubicin (µM)	0
395	Dexamethasone  (µM)	0.02210663
395	Ibrutinib (µM)	0
395	Mercaptopurine (µM)	290.3319104
395	Nelarabine (µM)	0
395	Panobinostat (nM)	0
395	Prednisolone (µM)	0.061709738
395	Ruxolitinib (nM)	0
395	Thioguanine (µM)	13.37896
395	Trametinib (nM)	0
395	Venetoclax (nM)	0
395	Vincristine (µM)	31.91992
395	Vorinostat (nM)	0
395	asparagise_normalized	0.3819
395	cytarabine_normalized	0.9241
395	dexamethasone_normalized	0.3983
395	mercaptopurine_normalized	0.3322
395	prednisolone_normalized	0.1357
395	thioguanine_normalized	0.1034
395	vincristine_normalized	0.9243
396	immunophenotype	B
396	molecular subtype	ETV6-RUNX1
396	Protocol	T15
396	NCI risk	HR
396	Age at diagnosis	3.5
396	WBC at diagnosis	61.1
396	Sex	F
396	Genetically-defined race	black
396	Asparaginase (IU/ml)	0.0016
396	Bortezomib (nM)	0
396	CHZ868 (nM)	0
396	Cytarabine (µM)	0.356701
396	Dasatinib (nM)	0
396	Daunorubicin (µM)	0
396	Dexamethasone  (µM)	0.014668898
396	Ibrutinib (µM)	0
396	Mercaptopurine (µM)	174.6466
396	Nelarabine (µM)	0
396	Panobinostat (nM)	0
396	Prednisolone (µM)	0.043274118
396	Ruxolitinib (nM)	0
396	Thioguanine (µM)	16.85911
396	Trametinib (nM)	0
396	Venetoclax (nM)	0
396	Vincristine (µM)	0.2789004
396	Vorinostat (nM)	0
396	asparagise_normalized	0
396	cytarabine_normalized	0.3155
396	dexamethasone_normalized	0.3589
396	mercaptopurine_normalized	0.1856
396	prednisolone_normalized	0.1017
396	thioguanine_normalized	0.1701
396	vincristine_normalized	0.246
397	immunophenotype	T
397	molecular subtype	T-ALL
397	Protocol	T15
397	NCI risk	HR
397	Age at diagnosis	10.6
397	WBC at diagnosis	259.9
397	Sex	F
397	Genetically-defined race	White
397	Asparaginase (IU/ml)	0
397	Bortezomib (nM)	0
397	CHZ868 (nM)	0
397	Cytarabine (µM)	0
397	Dasatinib (nM)	0
397	Daunorubicin (µM)	0
397	Dexamethasone  (µM)	0
397	Ibrutinib (µM)	0
397	Mercaptopurine (µM)	0
397	Nelarabine (µM)	0
397	Panobinostat (nM)	0
397	Prednisolone (µM)	0
397	Ruxolitinib (nM)	0
397	Thioguanine (µM)	0
397	Trametinib (nM)	0
397	Venetoclax (nM)	0
397	Vincristine (µM)	108.34
397	Vorinostat (nM)	0
397	vincristine_normalized	1
398	immunophenotype	B
398	molecular subtype	ETV6-RUNX1
398	Protocol	T15
398	NCI risk	HR
398	Age at diagnosis	4.1
398	WBC at diagnosis	88.6
398	Sex	F
398	Genetically-defined race	White
398	Asparaginase (IU/ml)	0.0016
398	Bortezomib (nM)	0
398	CHZ868 (nM)	0
398	Cytarabine (µM)	0.4706654
398	Dasatinib (nM)	0
398	Daunorubicin (µM)	0
398	Dexamethasone  (µM)	0.003402493
398	Ibrutinib (µM)	0
398	Mercaptopurine (µM)	315.0004
398	Nelarabine (µM)	0
398	Panobinostat (nM)	0
398	Prednisolone (µM)	0.0075
398	Ruxolitinib (nM)	0
398	Thioguanine (µM)	16.01132
398	Trametinib (nM)	0
398	Venetoclax (nM)	0
398	Vincristine (µM)	0.025
398	Vorinostat (nM)	0
398	asparagise_normalized	0
398	cytarabine_normalized	0.3555
398	dexamethasone_normalized	0.2185
398	mercaptopurine_normalized	0.3557
398	prednisolone_normalized	0
398	thioguanine_normalized	0.1552
398	vincristine_normalized	0
399	immunophenotype	T
399	molecular subtype	T-ALL
399	Protocol	T15
399	NCI risk	HR
399	Age at diagnosis	8.9
399	WBC at diagnosis	53
399	Sex	M
399	Genetically-defined race	White
399	Asparaginase (IU/ml)	0.0016
399	Bortezomib (nM)	0
399	CHZ868 (nM)	0
399	Cytarabine (µM)	0.02
399	Dasatinib (nM)	0
399	Daunorubicin (µM)	0
399	Dexamethasone  (µM)	0.00518486
399	Ibrutinib (µM)	0
399	Mercaptopurine (µM)	45.9
399	Nelarabine (µM)	0
399	Panobinostat (nM)	0
399	Prednisolone (µM)	0.0075
399	Ruxolitinib (nM)	0
399	Thioguanine (µM)	4.675
399	Trametinib (nM)	0
399	Venetoclax (nM)	0
399	Vincristine (µM)	0.025
399	Vorinostat (nM)	0
399	asparagise_normalized	0
399	cytarabine_normalized	0
399	dexamethasone_normalized	0.259
399	mercaptopurine_normalized	0
399	prednisolone_normalized	0
399	thioguanine_normalized	0
399	vincristine_normalized	0
400	immunophenotype	B
400	molecular subtype	ETV6-RUNX1
400	Protocol	T15
400	NCI risk	HR
400	Age at diagnosis	4.1
400	WBC at diagnosis	60
400	Sex	F
400	Genetically-defined race	White
400	Asparaginase (IU/ml)	0
400	Bortezomib (nM)	0
400	CHZ868 (nM)	0
400	Cytarabine (µM)	1.109934
400	Dasatinib (nM)	0
400	Daunorubicin (µM)	0
400	Dexamethasone  (µM)	0.03983616
400	Ibrutinib (µM)	0
400	Mercaptopurine (µM)	353.8314469
400	Nelarabine (µM)	0
400	Panobinostat (nM)	0
400	Prednisolone (µM)	0.09009133
400	Ruxolitinib (nM)	0
400	Thioguanine (µM)	41.3761
400	Trametinib (nM)	0
400	Venetoclax (nM)	0
400	Vincristine (µM)	0.1956299
400	Vorinostat (nM)	0
400	cytarabine_normalized	0.4792
400	dexamethasone_normalized	0.4549
400	mercaptopurine_normalized	0.3893
400	prednisolone_normalized	0.172
400	thioguanine_normalized	0.4292
400	vincristine_normalized	0.1952
401	immunophenotype	B
401	molecular subtype	Hyperdiploid
401	Protocol	T15
401	NCI risk	HR
401	Age at diagnosis	11.9
401	WBC at diagnosis	4.6
401	Sex	M
401	Genetically-defined race	White
401	Asparaginase (IU/ml)	0.0016
401	Bortezomib (nM)	0
401	CHZ868 (nM)	0
401	Cytarabine (µM)	0.932265
401	Dasatinib (nM)	0
401	Daunorubicin (µM)	0
401	Dexamethasone  (µM)	0.03236847
401	Ibrutinib (µM)	0
401	Mercaptopurine (µM)	0
401	Nelarabine (µM)	0
401	Panobinostat (nM)	0
401	Prednisolone (µM)	0.0423426
401	Ruxolitinib (nM)	0
401	Thioguanine (µM)	21.28406
401	Trametinib (nM)	0
401	Venetoclax (nM)	0
401	Vincristine (µM)	0.025
401	Vorinostat (nM)	0
401	asparagise_normalized	0
401	cytarabine_normalized	0.454
401	dexamethasone_normalized	0.4349
401	prednisolone_normalized	0.0996
401	thioguanine_normalized	0.2374
401	vincristine_normalized	0
402	immunophenotype	B
402	molecular subtype	ETV6-RUNX1-like
402	Protocol	T15
402	NCI risk	SR
402	Age at diagnosis	7.1
402	WBC at diagnosis	4.3
402	Sex	M
402	Genetically-defined race	White
402	Asparaginase (IU/ml)	0.0016
402	Bortezomib (nM)	0
402	CHZ868 (nM)	0
402	Cytarabine (µM)	1.42201
402	Dasatinib (nM)	0
402	Daunorubicin (µM)	0
402	Dexamethasone  (µM)	0
402	Ibrutinib (µM)	0
402	Mercaptopurine (µM)	628.1491
402	Nelarabine (µM)	0
402	Panobinostat (nM)	0
402	Prednisolone (µM)	1006
402	Ruxolitinib (nM)	0
402	Thioguanine (µM)	13.92033
402	Trametinib (nM)	0
402	Venetoclax (nM)	0
402	Vincristine (µM)	0.8235213
402	Vorinostat (nM)	0
402	asparagise_normalized	0
402	cytarabine_normalized	0.5149
402	mercaptopurine_normalized	0.5549
402	prednisolone_normalized	1
402	thioguanine_normalized	0.1149
402	vincristine_normalized	0.4009
403	immunophenotype	B
403	molecular subtype	ETV6-RUNX1
403	Protocol	T15
403	NCI risk	SR
403	Age at diagnosis	2.9
403	WBC at diagnosis	27.3
403	Sex	F
403	Genetically-defined race	black
403	Asparaginase (IU/ml)	20
403	Bortezomib (nM)	0
403	CHZ868 (nM)	0
403	Cytarabine (µM)	1.157292
403	Dasatinib (nM)	0
403	Daunorubicin (µM)	0
403	Dexamethasone  (µM)	0
403	Ibrutinib (µM)	0
403	Mercaptopurine (µM)	0
403	Nelarabine (µM)	0
403	Panobinostat (nM)	0
403	Prednisolone (µM)	0
403	Ruxolitinib (nM)	0
403	Thioguanine (µM)	0
403	Trametinib (nM)	0
403	Venetoclax (nM)	0
403	Vincristine (µM)	0.2637273
403	Vorinostat (nM)	0
403	asparagise_normalized	1
403	cytarabine_normalized	0.4852
403	vincristine_normalized	0.238
404	immunophenotype	B
404	molecular subtype	Hyperdiploid
404	Protocol	T15
404	NCI risk	SR
404	Age at diagnosis	4.4
404	WBC at diagnosis	15.1
404	Sex	M
404	Genetically-defined race	White
404	Asparaginase (IU/ml)	1.584361
404	Bortezomib (nM)	0
404	CHZ868 (nM)	0
404	Cytarabine (µM)	0.3839002
404	Dasatinib (nM)	0
404	Daunorubicin (µM)	0
404	Dexamethasone  (µM)	23.2
404	Ibrutinib (µM)	0
404	Mercaptopurine (µM)	1862.124
404	Nelarabine (µM)	0
404	Panobinostat (nM)	0
404	Prednisolone (µM)	64.55492
404	Ruxolitinib (nM)	0
404	Thioguanine (µM)	41.26818
404	Trametinib (nM)	0
404	Venetoclax (nM)	0
404	Vincristine (µM)	10.62829826
404	Vorinostat (nM)	0
404	asparagise_normalized	0.7711
404	cytarabine_normalized	0.3261
404	dexamethasone_normalized	1
404	mercaptopurine_normalized	0.8684
404	prednisolone_normalized	0.803
404	thioguanine_normalized	0.4285
404	vincristine_normalized	0.7669
405	immunophenotype	B
405	molecular subtype	Hyperdiploid
405	Protocol	T15
405	NCI risk	SR
405	Age at diagnosis	3.9
405	WBC at diagnosis	5.3
405	Sex	M
405	Genetically-defined race	White
405	Asparaginase (IU/ml)	20
405	Bortezomib (nM)	0
405	CHZ868 (nM)	0
405	Cytarabine (µM)	2.756982
405	Dasatinib (nM)	0
405	Daunorubicin (µM)	0
405	Dexamethasone  (µM)	23.2
405	Ibrutinib (µM)	0
405	Mercaptopurine (µM)	5876
405	Nelarabine (µM)	0
405	Panobinostat (nM)	0
405	Prednisolone (µM)	0
405	Ruxolitinib (nM)	0
405	Thioguanine (µM)	206.2477
405	Trametinib (nM)	0
405	Venetoclax (nM)	0
405	Vincristine (µM)	0.05790748
405	Vorinostat (nM)	0
405	asparagise_normalized	1
405	cytarabine_normalized	0.6104
405	dexamethasone_normalized	1
405	mercaptopurine_normalized	1
405	thioguanine_normalized	0.8928
405	vincristine_normalized	0.021
406	immunophenotype	T
406	molecular subtype	T-ALL
406	Protocol	T15
406	NCI risk	HR
406	Age at diagnosis	12.6
406	WBC at diagnosis	155.3
406	Sex	F
406	Genetically-defined race	Hispanic
406	Asparaginase (IU/ml)	0.0016
406	Bortezomib (nM)	0
406	CHZ868 (nM)	0
406	Cytarabine (µM)	0
406	Dasatinib (nM)	0
406	Daunorubicin (µM)	0
406	Dexamethasone  (µM)	0
406	Ibrutinib (µM)	0
406	Mercaptopurine (µM)	100.343
406	Nelarabine (µM)	0
406	Panobinostat (nM)	0
406	Prednisolone (µM)	0
406	Ruxolitinib (nM)	0
406	Thioguanine (µM)	0
406	Trametinib (nM)	0
406	Venetoclax (nM)	0
406	Vincristine (µM)	0.06522412
406	Vorinostat (nM)	0
406	asparagise_normalized	0
406	mercaptopurine_normalized	0.0257
406	vincristine_normalized	0.038
407	immunophenotype	B
407	molecular subtype	TCF3-PBX1
407	Protocol	T15
407	NCI risk	HR
407	Age at diagnosis	10.5
407	WBC at diagnosis	10.5
407	Sex	F
407	Genetically-defined race	White
407	Asparaginase (IU/ml)	0.7162861
407	Bortezomib (nM)	0
407	CHZ868 (nM)	0
407	Cytarabine (µM)	1.70483
407	Dasatinib (nM)	0
407	Daunorubicin (µM)	0
407	Dexamethasone  (µM)	0.092486541
407	Ibrutinib (µM)	0
407	Mercaptopurine (µM)	0
407	Nelarabine (µM)	0
407	Panobinostat (nM)	0
407	Prednisolone (µM)	0.0075
407	Ruxolitinib (nM)	0
407	Thioguanine (µM)	17.20064376
407	Trametinib (nM)	0
407	Venetoclax (nM)	0
407	Vincristine (µM)	0.025
407	Vorinostat (nM)	0
407	asparagise_normalized	0.6724
407	cytarabine_normalized	0.5411
407	dexamethasone_normalized	0.5358
407	prednisolone_normalized	0
407	thioguanine_normalized	0.1759
407	vincristine_normalized	0
408	immunophenotype	B
408	molecular subtype	Hyperdiploid
408	Protocol	T15
408	NCI risk	SR
408	Age at diagnosis	1.8
408	WBC at diagnosis	20.9
408	Sex	F
408	Genetically-defined race	White
408	Asparaginase (IU/ml)	0.1168431
408	Bortezomib (nM)	0
408	CHZ868 (nM)	0
408	Cytarabine (µM)	0.374424
408	Dasatinib (nM)	0
408	Daunorubicin (µM)	0
408	Dexamethasone  (µM)	23.2
408	Ibrutinib (µM)	0
408	Mercaptopurine (µM)	0
408	Nelarabine (µM)	0
408	Panobinostat (nM)	0
408	Prednisolone (µM)	0.01905983
408	Ruxolitinib (nM)	0
408	Thioguanine (µM)	17.4189
408	Trametinib (nM)	0
408	Venetoclax (nM)	0
408	Vincristine (µM)	2.570694
408	Vorinostat (nM)	0
408	asparagise_normalized	0.4471
408	cytarabine_normalized	0.3225
408	dexamethasone_normalized	1
408	prednisolone_normalized	0.023
408	thioguanine_normalized	0.1796
408	vincristine_normalized	0.5638
409	immunophenotype	B
409	molecular subtype	Hyperdiploid
409	Protocol	T15
409	NCI risk	SR
409	Age at diagnosis	4.4
409	WBC at diagnosis	4.4
409	Sex	M
409	Genetically-defined race	White
409	Asparaginase (IU/ml)	0.849988611
409	Bortezomib (nM)	0
409	CHZ868 (nM)	0
409	Cytarabine (µM)	1.373291
409	Dasatinib (nM)	0
409	Daunorubicin (µM)	0
409	Dexamethasone  (µM)	0.03203559
409	Ibrutinib (µM)	0
409	Mercaptopurine (µM)	210.9219
409	Nelarabine (µM)	0
409	Panobinostat (nM)	0
409	Prednisolone (µM)	0.1009215
409	Ruxolitinib (nM)	0
409	Thioguanine (µM)	25.1702
409	Trametinib (nM)	0
409	Venetoclax (nM)	0
409	Vincristine (µM)	0.1665252
409	Vorinostat (nM)	0
409	asparagise_normalized	0.6937
409	cytarabine_normalized	0.5099
409	dexamethasone_normalized	0.4339
409	mercaptopurine_normalized	0.24
409	prednisolone_normalized	0.1829
409	thioguanine_normalized	0.2858
409	vincristine_normalized	0.1722
410	immunophenotype	B
410	molecular subtype	Hyperdiploid
410	Protocol	T15
410	NCI risk	SR
410	Age at diagnosis	3.2
410	WBC at diagnosis	10.2
410	Sex	F
410	Genetically-defined race	White
410	Asparaginase (IU/ml)	0.177034658
410	Bortezomib (nM)	0
410	CHZ868 (nM)	0
410	Cytarabine (µM)	0.556219
410	Dasatinib (nM)	0
410	Daunorubicin (µM)	0
410	Dexamethasone  (µM)	0.007419832
410	Ibrutinib (µM)	0
410	Mercaptopurine (µM)	927.5141
410	Nelarabine (µM)	0
410	Panobinostat (nM)	0
410	Prednisolone (µM)	0.5296383
410	Ruxolitinib (nM)	0
410	Thioguanine (µM)	20.90045
410	Trametinib (nM)	0
410	Venetoclax (nM)	0
410	Vincristine (µM)	0.7094847
410	Vorinostat (nM)	0
410	asparagise_normalized	0.4987
410	cytarabine_normalized	0.3796
410	dexamethasone_normalized	0.2934
410	mercaptopurine_normalized	0.6673
410	prednisolone_normalized	0.342
410	thioguanine_normalized	0.2321
410	vincristine_normalized	0.3796
411	immunophenotype	B
411	molecular subtype	ETV6-RUNX1
411	Protocol	T15
411	NCI risk	SR
411	Age at diagnosis	2.2
411	WBC at diagnosis	1.5
411	Sex	F
411	Genetically-defined race	White
411	Asparaginase (IU/ml)	0.07276295
411	Bortezomib (nM)	0
411	CHZ868 (nM)	0
411	Cytarabine (µM)	0.929062435
411	Dasatinib (nM)	0
411	Daunorubicin (µM)	0
411	Dexamethasone  (µM)	0.001788714
411	Ibrutinib (µM)	0
411	Mercaptopurine (µM)	477.2835
411	Nelarabine (µM)	0
411	Panobinostat (nM)	0
411	Prednisolone (µM)	0.0075
411	Ruxolitinib (nM)	0
411	Thioguanine (µM)	20.74471
411	Trametinib (nM)	0
411	Venetoclax (nM)	0
411	Vincristine (µM)	11.87514
411	Vorinostat (nM)	0
411	asparagise_normalized	0.3882
411	cytarabine_normalized	0.4535
411	dexamethasone_normalized	0.1567
411	mercaptopurine_normalized	0.4756
411	prednisolone_normalized	0
411	thioguanine_normalized	0.23
411	vincristine_normalized	0.7828
412	immunophenotype	B
412	molecular subtype	BCR-ABL1
412	Protocol	T15
412	NCI risk	HR
412	Age at diagnosis	2.4
412	WBC at diagnosis	62.8
412	Sex	M
412	Genetically-defined race	black
412	Asparaginase (IU/ml)	0.1256999
412	Bortezomib (nM)	0
412	CHZ868 (nM)	0
412	Cytarabine (µM)	0.8062211
412	Dasatinib (nM)	0
412	Daunorubicin (µM)	0
412	Dexamethasone  (µM)	0.006987349
412	Ibrutinib (µM)	0
412	Mercaptopurine (µM)	604.595464
412	Nelarabine (µM)	0
412	Panobinostat (nM)	0
412	Prednisolone (µM)	0.15213566
412	Ruxolitinib (nM)	0
412	Thioguanine (µM)	27.5807
412	Trametinib (nM)	0
412	Venetoclax (nM)	0
412	Vincristine (µM)	1.212278
412	Vorinostat (nM)	0
412	asparagise_normalized	0.4562
412	cytarabine_normalized	0.4331
412	dexamethasone_normalized	0.2876
412	mercaptopurine_normalized	0.5439
412	prednisolone_normalized	0.2223
412	thioguanine_normalized	0.3122
412	vincristine_normalized	0.4563
413	immunophenotype	T
413	molecular subtype	T-ALL
413	Protocol	T15
413	NCI risk	HR
413	Age at diagnosis	5.9
413	WBC at diagnosis	364.2
413	Sex	M
413	Genetically-defined race	black
413	Asparaginase (IU/ml)	0.2470379
413	Bortezomib (nM)	0
413	CHZ868 (nM)	0
413	Cytarabine (µM)	0.696930798
413	Dasatinib (nM)	0
413	Daunorubicin (µM)	0.145817962
413	Dexamethasone  (µM)	0.07352069
413	Ibrutinib (µM)	0
413	Mercaptopurine (µM)	386.1758
413	Nelarabine (µM)	0
413	Panobinostat (nM)	0
413	Prednisolone (µM)	6.784611
413	Ruxolitinib (nM)	0
413	Thioguanine (µM)	19.89916283
413	Trametinib (nM)	0
413	Venetoclax (nM)	0
413	Vincristine (µM)	3.744625
413	Vorinostat (nM)	0
413	asparagise_normalized	0.5401
413	cytarabine_normalized	0.4121
413	daunorubicin_normalized	0.5489
413	dexamethasone_normalized	0.5137
413	mercaptopurine_normalized	0.4145
413	prednisolone_normalized	0.5868
413	thioguanine_normalized	0.218
413	vincristine_normalized	0.6177
414	immunophenotype	B
414	molecular subtype	Hyperdiploid
414	Protocol	T15
414	NCI risk	SR
414	Age at diagnosis	3
414	WBC at diagnosis	3.8
414	Sex	F
414	Genetically-defined race	White
414	Asparaginase (IU/ml)	0.0016
414	Bortezomib (nM)	0
414	CHZ868 (nM)	0
414	Cytarabine (µM)	1.09526
414	Dasatinib (nM)	0
414	Daunorubicin (µM)	0
414	Dexamethasone  (µM)	0.007827077
414	Ibrutinib (µM)	0
414	Mercaptopurine (µM)	593.4608
414	Nelarabine (µM)	0
414	Panobinostat (nM)	0
414	Prednisolone (µM)	0.08891439
414	Ruxolitinib (nM)	0
414	Thioguanine (µM)	33.6524627
414	Trametinib (nM)	0
414	Venetoclax (nM)	0
414	Vincristine (µM)	0.1717927
414	Vorinostat (nM)	0
414	asparagise_normalized	0
414	cytarabine_normalized	0.4773
414	dexamethasone_normalized	0.2985
414	mercaptopurine_normalized	0.5385
414	prednisolone_normalized	0.1708
414	thioguanine_normalized	0.3696
414	vincristine_normalized	0.1766
415	immunophenotype	B
415	molecular subtype	TCF3-PBX1
415	Protocol	T15
415	NCI risk	SR
415	Age at diagnosis	8.4
415	WBC at diagnosis	19.4
415	Sex	F
415	Genetically-defined race	black
415	Asparaginase (IU/ml)	0.0016
415	Bortezomib (nM)	0
415	CHZ868 (nM)	0
415	Cytarabine (µM)	0.1239674
415	Dasatinib (nM)	0
415	Daunorubicin (µM)	0
415	Dexamethasone  (µM)	0.002251558
415	Ibrutinib (µM)	0
415	Mercaptopurine (µM)	217.0938
415	Nelarabine (µM)	0
415	Panobinostat (nM)	0
415	Prednisolone (µM)	0.01732008
415	Ruxolitinib (nM)	0
415	Thioguanine (µM)	4.675
415	Trametinib (nM)	0
415	Venetoclax (nM)	0
415	Vincristine (µM)	0.025
415	Vorinostat (nM)	0
415	asparagise_normalized	0
415	cytarabine_normalized	0.1631
415	dexamethasone_normalized	0.1788
415	mercaptopurine_normalized	0.2483
415	prednisolone_normalized	0.0138
415	thioguanine_normalized	0
415	vincristine_normalized	0
416	immunophenotype	B
416	molecular subtype	PAX5alt
416	Protocol	T16
416	NCI risk	SR
416	Age at diagnosis	2.5
416	WBC at diagnosis	18.6
416	Sex	F
416	Genetically-defined race	black
416	Asparaginase (IU/ml)	0.1297101
416	Bortezomib (nM)	0
416	CHZ868 (nM)	0
416	Cytarabine (µM)	0
416	Dasatinib (nM)	0
416	Daunorubicin (µM)	0
416	Dexamethasone  (µM)	0
416	Ibrutinib (µM)	0
416	Mercaptopurine (µM)	0
416	Nelarabine (µM)	0
416	Panobinostat (nM)	0
416	Prednisolone (µM)	2.415223001
416	Ruxolitinib (nM)	0
416	Thioguanine (µM)	56.25886
416	Trametinib (nM)	0
416	Venetoclax (nM)	0
416	Vincristine (µM)	0.025
416	Vorinostat (nM)	0
416	asparagise_normalized	0.4601
416	prednisolone_normalized	0.4877
416	thioguanine_normalized	0.5179
416	vincristine_normalized	0
417	immunophenotype	B
417	molecular subtype	Hyperdiploid
417	Protocol	T15
417	NCI risk	HR
417	Age at diagnosis	3.3
417	WBC at diagnosis	60
417	Sex	M
417	Genetically-defined race	White
417	Asparaginase (IU/ml)	0.1041984
417	Bortezomib (nM)	0
417	CHZ868 (nM)	0
417	Cytarabine (µM)	0.2620376
417	Dasatinib (nM)	0
417	Daunorubicin (µM)	0
417	Dexamethasone  (µM)	0.004056523
417	Ibrutinib (µM)	0
417	Mercaptopurine (µM)	261.604
417	Nelarabine (µM)	0
417	Panobinostat (nM)	0
417	Prednisolone (µM)	0.08175348
417	Ruxolitinib (nM)	0
417	Thioguanine (µM)	15.30954
417	Trametinib (nM)	0
417	Venetoclax (nM)	0
417	Vincristine (µM)	0.7643239
417	Vorinostat (nM)	0
417	asparagise_normalized	0.4328
417	cytarabine_normalized	0.271
417	dexamethasone_normalized	0.2354
417	mercaptopurine_normalized	0.3022
417	prednisolone_normalized	0.1627
417	thioguanine_normalized	0.1423
417	vincristine_normalized	0.3902
418	immunophenotype	B
418	molecular subtype	Hyperdiploid
418	Protocol	T15
418	NCI risk	SR
418	Age at diagnosis	4.2
418	WBC at diagnosis	12.6
418	Sex	M
418	Genetically-defined race	White
418	Asparaginase (IU/ml)	0
418	Bortezomib (nM)	0
418	CHZ868 (nM)	0
418	Cytarabine (µM)	0
418	Dasatinib (nM)	0
418	Daunorubicin (µM)	0
418	Dexamethasone  (µM)	0
418	Ibrutinib (µM)	0
418	Mercaptopurine (µM)	729.5986
418	Nelarabine (µM)	0
418	Panobinostat (nM)	0
418	Prednisolone (µM)	0
418	Ruxolitinib (nM)	0
418	Thioguanine (µM)	54.51059
418	Trametinib (nM)	0
418	Venetoclax (nM)	0
418	Vincristine (µM)	0
418	Vorinostat (nM)	0
418	mercaptopurine_normalized	0.5981
418	thioguanine_normalized	0.5088
419	immunophenotype	T
419	molecular subtype	T-ALL
419	Protocol	T15
419	NCI risk	HR
419	Age at diagnosis	8
419	WBC at diagnosis	314.5
419	Sex	M
419	Genetically-defined race	White
419	Asparaginase (IU/ml)	0.0016
419	Bortezomib (nM)	0
419	CHZ868 (nM)	0
419	Cytarabine (µM)	1.784046
419	Dasatinib (nM)	0
419	Daunorubicin (µM)	0.1284063
419	Dexamethasone  (µM)	0.002954448
419	Ibrutinib (µM)	0
419	Mercaptopurine (µM)	206.2514
419	Nelarabine (µM)	0
419	Panobinostat (nM)	0
419	Prednisolone (µM)	0.7699986
419	Ruxolitinib (nM)	0
419	Thioguanine (µM)	12.83469
419	Trametinib (nM)	0
419	Venetoclax (nM)	0
419	Vincristine (µM)	30.81891
419	Vorinostat (nM)	0
419	asparagise_normalized	0
419	cytarabine_normalized	0.5476
419	daunorubicin_normalized	0.5309
419	dexamethasone_normalized	0.2049
419	mercaptopurine_normalized	0.2336
419	prednisolone_normalized	0.3779
419	thioguanine_normalized	0.0914
419	vincristine_normalized	0.9193
420	immunophenotype	T
420	molecular subtype	T-ALL
420	Protocol	T15
420	NCI risk	HR
420	Age at diagnosis	14.3
420	WBC at diagnosis	298.4
420	Sex	M
420	Genetically-defined race	White
420	Asparaginase (IU/ml)	0.02215665
420	Bortezomib (nM)	0
420	CHZ868 (nM)	0
420	Cytarabine (µM)	0
420	Dasatinib (nM)	0
420	Daunorubicin (µM)	0
420	Dexamethasone  (µM)	0
420	Ibrutinib (µM)	0
420	Mercaptopurine (µM)	45.9
420	Nelarabine (µM)	0
420	Panobinostat (nM)	0
420	Prednisolone (µM)	0.06462906
420	Ruxolitinib (nM)	0
420	Thioguanine (µM)	0
420	Trametinib (nM)	0
420	Venetoclax (nM)	0
420	Vincristine (µM)	0.025
420	Vorinostat (nM)	0
420	asparagise_normalized	0.2405
420	mercaptopurine_normalized	0
420	prednisolone_normalized	0.1402
420	vincristine_normalized	0
421	immunophenotype	B
421	molecular subtype	ETV6-RUNX1
421	Protocol	T15
421	NCI risk	SR
421	Age at diagnosis	6.5
421	WBC at diagnosis	1.7
421	Sex	M
421	Genetically-defined race	black
421	Asparaginase (IU/ml)	0.0016
421	Bortezomib (nM)	0
421	CHZ868 (nM)	0
421	Cytarabine (µM)	8.514424
421	Dasatinib (nM)	0
421	Daunorubicin (µM)	0
421	Dexamethasone  (µM)	0.007948255
421	Ibrutinib (µM)	0
421	Mercaptopurine (µM)	690.6148
421	Nelarabine (µM)	0
421	Panobinostat (nM)	0
421	Prednisolone (µM)	0.08500742
421	Ruxolitinib (nM)	0
421	Thioguanine (µM)	27.77812
421	Trametinib (nM)	0
421	Venetoclax (nM)	0
421	Vincristine (µM)	1.592102
421	Vorinostat (nM)	0
421	asparagise_normalized	0
421	cytarabine_normalized	0.773
421	dexamethasone_normalized	0.3
421	mercaptopurine_normalized	0.5822
421	prednisolone_normalized	0.1665
421	thioguanine_normalized	0.3142
421	vincristine_normalized	0.4953
422	immunophenotype	B
422	molecular subtype	PAX5alt
422	Protocol	T15
422	NCI risk	SR
422	Age at diagnosis	3.6
422	WBC at diagnosis	42.8
422	Sex	F
422	Genetically-defined race	Hispanic
422	Asparaginase (IU/ml)	0.0016
422	Bortezomib (nM)	0
422	CHZ868 (nM)	0
422	Cytarabine (µM)	0.7143214
422	Dasatinib (nM)	0
422	Daunorubicin (µM)	0
422	Dexamethasone  (µM)	0.003127813
422	Ibrutinib (µM)	0
422	Mercaptopurine (µM)	189.2189
422	Nelarabine (µM)	0
422	Panobinostat (nM)	0
422	Prednisolone (µM)	0.09989396
422	Ruxolitinib (nM)	0
422	Thioguanine (µM)	56.02756
422	Trametinib (nM)	0
422	Venetoclax (nM)	0
422	Vincristine (µM)	0.025
422	Vorinostat (nM)	0
422	asparagise_normalized	0
422	cytarabine_normalized	0.4156
422	dexamethasone_normalized	0.2104
422	mercaptopurine_normalized	0.2087
422	prednisolone_normalized	0.182
422	thioguanine_normalized	0.5167
422	vincristine_normalized	0
423	immunophenotype	B
423	molecular subtype	Hyperdiploid
423	Protocol	T15
423	NCI risk	SR
423	Age at diagnosis	1.6
423	WBC at diagnosis	7.3
423	Sex	M
423	Genetically-defined race	White
423	Asparaginase (IU/ml)	0.3081212
423	Bortezomib (nM)	0
423	CHZ868 (nM)	0
423	Cytarabine (µM)	1.418238
423	Dasatinib (nM)	0
423	Daunorubicin (µM)	0
423	Dexamethasone  (µM)	23.2
423	Ibrutinib (µM)	0
423	Mercaptopurine (µM)	1692.445
423	Nelarabine (µM)	0
423	Panobinostat (nM)	0
423	Prednisolone (µM)	1006
423	Ruxolitinib (nM)	0
423	Thioguanine (µM)	41.42848
423	Trametinib (nM)	0
423	Venetoclax (nM)	0
423	Vincristine (µM)	20.69805
423	Vorinostat (nM)	0
423	asparagise_normalized	0.5676
423	cytarabine_normalized	0.5145
423	dexamethasone_normalized	1
423	mercaptopurine_normalized	0.8409
423	prednisolone_normalized	1
423	thioguanine_normalized	0.4296
423	vincristine_normalized	0.8623
424	immunophenotype	B
424	molecular subtype	B-other
424	Protocol	T15
424	NCI risk	SR
424	Age at diagnosis	2.6
424	WBC at diagnosis	3.4
424	Sex	F
424	Genetically-defined race	White
424	Asparaginase (IU/ml)	0
424	Bortezomib (nM)	0
424	CHZ868 (nM)	0
424	Cytarabine (µM)	0
424	Dasatinib (nM)	0
424	Daunorubicin (µM)	0
424	Dexamethasone  (µM)	0.003285615
424	Ibrutinib (µM)	0
424	Mercaptopurine (µM)	528.7486
424	Nelarabine (µM)	0
424	Panobinostat (nM)	0
424	Prednisolone (µM)	0.1068392
424	Ruxolitinib (nM)	0
424	Thioguanine (µM)	36.20634
424	Trametinib (nM)	0
424	Venetoclax (nM)	0
424	Vincristine (µM)	0.3981129
424	Vorinostat (nM)	0
424	dexamethasone_normalized	0.2151
424	mercaptopurine_normalized	0.5052
424	prednisolone_normalized	0.1884
424	thioguanine_normalized	0.3907
424	vincristine_normalized	0.2969
425	immunophenotype	B
425	molecular subtype	MEF2D
425	Protocol	T15
425	NCI risk	SR
425	Age at diagnosis	7.9
425	WBC at diagnosis	20.2
425	Sex	F
425	Genetically-defined race	White
425	Asparaginase (IU/ml)	0.2881688
425	Bortezomib (nM)	0
425	CHZ868 (nM)	0
425	Cytarabine (µM)	1.184748
425	Dasatinib (nM)	0
425	Daunorubicin (µM)	0
425	Dexamethasone  (µM)	0.001937304
425	Ibrutinib (µM)	0
425	Mercaptopurine (µM)	877.3148
425	Nelarabine (µM)	0
425	Panobinostat (nM)	0
425	Prednisolone (µM)	0.01515857
425	Ruxolitinib (nM)	0
425	Thioguanine (µM)	23.02241
425	Trametinib (nM)	0
425	Venetoclax (nM)	0
425	Vincristine (µM)	0.07092279
425	Vorinostat (nM)	0
425	asparagise_normalized	0.5593
425	cytarabine_normalized	0.4886
425	dexamethasone_normalized	0.1644
425	mercaptopurine_normalized	0.6513
425	prednisolone_normalized	0.001
425	thioguanine_normalized	0.2601
425	vincristine_normalized	0.05
426	immunophenotype	B
426	molecular subtype	ETV6-RUNX1
426	Protocol	T15
426	NCI risk	HR
426	Age at diagnosis	4.4
426	WBC at diagnosis	104
426	Sex	F
426	Genetically-defined race	black
426	Asparaginase (IU/ml)	0.0016
426	Bortezomib (nM)	0
426	CHZ868 (nM)	0
426	Cytarabine (µM)	2.670138
426	Dasatinib (nM)	0
426	Daunorubicin (µM)	0
426	Dexamethasone  (µM)	0.001610885
426	Ibrutinib (µM)	0
426	Mercaptopurine (µM)	173.8211
426	Nelarabine (µM)	0
426	Panobinostat (nM)	0
426	Prednisolone (µM)	0.0075
426	Ruxolitinib (nM)	0
426	Thioguanine (µM)	4.675
426	Trametinib (nM)	0
426	Venetoclax (nM)	0
426	Vincristine (µM)	0.3785247
426	Vorinostat (nM)	0
426	asparagise_normalized	0
426	cytarabine_normalized	0.6058
426	dexamethasone_normalized	0.1467
426	mercaptopurine_normalized	0.1842
426	prednisolone_normalized	0
426	thioguanine_normalized	0
426	vincristine_normalized	0.2897
427	immunophenotype	B
427	molecular subtype	Hyperdiploid
427	Protocol	T15
427	NCI risk	HR
427	Age at diagnosis	13.5
427	WBC at diagnosis	2.8
427	Sex	F
427	Genetically-defined race	White
427	Asparaginase (IU/ml)	0.0016
427	Bortezomib (nM)	0
427	CHZ868 (nM)	0
427	Cytarabine (µM)	1.122146
427	Dasatinib (nM)	0
427	Daunorubicin (µM)	0
427	Dexamethasone  (µM)	0.02373462
427	Ibrutinib (µM)	0
427	Mercaptopurine (µM)	494.856
427	Nelarabine (µM)	0
427	Panobinostat (nM)	0
427	Prednisolone (µM)	0.07721134
427	Ruxolitinib (nM)	0
427	Thioguanine (µM)	22.14798816
427	Trametinib (nM)	0
427	Venetoclax (nM)	0
427	Vincristine (µM)	0.8104929
427	Vorinostat (nM)	0
427	asparagise_normalized	0
427	cytarabine_normalized	0.4808
427	dexamethasone_normalized	0.4051
427	mercaptopurine_normalized	0.4861
427	prednisolone_normalized	0.1572
427	thioguanine_normalized	0.2489
427	vincristine_normalized	0.3986
428	immunophenotype	B
428	molecular subtype	DUX4
428	Protocol	T15
428	NCI risk	SR
428	Age at diagnosis	4.8
428	WBC at diagnosis	2.7
428	Sex	M
428	Genetically-defined race	White
428	Asparaginase (IU/ml)	20
428	Bortezomib (nM)	0
428	CHZ868 (nM)	0
428	Cytarabine (µM)	1.15916391
428	Dasatinib (nM)	0
428	Daunorubicin (µM)	0
428	Dexamethasone  (µM)	0.002225861
428	Ibrutinib (µM)	0
428	Mercaptopurine (µM)	794.079
428	Nelarabine (µM)	0
428	Panobinostat (nM)	0
428	Prednisolone (µM)	0.0075
428	Ruxolitinib (nM)	0
428	Thioguanine (µM)	31.12865
428	Trametinib (nM)	0
428	Venetoclax (nM)	0
428	Vincristine (µM)	0.025
428	Vorinostat (nM)	0
428	asparagise_normalized	1
428	cytarabine_normalized	0.4855
428	dexamethasone_normalized	0.1777
428	mercaptopurine_normalized	0.6225
428	prednisolone_normalized	0
428	thioguanine_normalized	0.3471
428	vincristine_normalized	0
429	immunophenotype	T
429	molecular subtype	ETP
429	Protocol	T15
429	NCI risk	HR
429	Age at diagnosis	14.4
429	WBC at diagnosis	58.1
429	Sex	M
429	Genetically-defined race	black
429	Asparaginase (IU/ml)	0.09484599
429	Bortezomib (nM)	0
429	CHZ868 (nM)	0
429	Cytarabine (µM)	1.851995
429	Dasatinib (nM)	0
429	Daunorubicin (µM)	0
429	Dexamethasone  (µM)	0.008950958
429	Ibrutinib (µM)	0
429	Mercaptopurine (µM)	448.3374
429	Nelarabine (µM)	0
429	Panobinostat (nM)	0
429	Prednisolone (µM)	0.1737438
429	Ruxolitinib (nM)	0
429	Thioguanine (µM)	53.38942
429	Trametinib (nM)	0
429	Venetoclax (nM)	0
429	Vincristine (µM)	0.9311686
429	Vorinostat (nM)	0
429	asparagise_normalized	0.4212
429	cytarabine_normalized	0.553
429	dexamethasone_normalized	0.3114
429	mercaptopurine_normalized	0.4576
429	prednisolone_normalized	0.2351
429	thioguanine_normalized	0.5028
429	vincristine_normalized	0.4185
430	immunophenotype	B
430	molecular subtype	B-other
430	Protocol	T15
430	NCI risk	HR
430	Age at diagnosis	16.5
430	WBC at diagnosis	4.3
430	Sex	M
430	Genetically-defined race	White
430	Asparaginase (IU/ml)	1.775095426
430	Bortezomib (nM)	0
430	CHZ868 (nM)	0
430	Cytarabine (µM)	2.012495
430	Dasatinib (nM)	0
430	Daunorubicin (µM)	0
430	Dexamethasone  (µM)	0.000175
430	Ibrutinib (µM)	0
430	Mercaptopurine (µM)	483.5317
430	Nelarabine (µM)	0
430	Panobinostat (nM)	0
430	Prednisolone (µM)	0.104604
430	Ruxolitinib (nM)	0
430	Thioguanine (µM)	59.74431
430	Trametinib (nM)	0
430	Venetoclax (nM)	0
430	Vincristine (µM)	0.9960645
430	Vorinostat (nM)	0
430	asparagise_normalized	0.7852
430	cytarabine_normalized	0.565
430	dexamethasone_normalized	0
430	mercaptopurine_normalized	0.4794
430	prednisolone_normalized	0.1864
430	thioguanine_normalized	0.5353
430	vincristine_normalized	0.4281
431	immunophenotype	B
431	molecular subtype	DUX4
431	Protocol	T15
431	NCI risk	HR
431	Age at diagnosis	10.8
431	WBC at diagnosis	51.9
431	Sex	F
431	Genetically-defined race	Asian/Other
431	Asparaginase (IU/ml)	0.04490346
431	Bortezomib (nM)	0
431	CHZ868 (nM)	0
431	Cytarabine (µM)	0.8124226
431	Dasatinib (nM)	0
431	Daunorubicin (µM)	0
431	Dexamethasone  (µM)	0.001596666
431	Ibrutinib (µM)	0
431	Mercaptopurine (µM)	337.0059
431	Nelarabine (µM)	0
431	Panobinostat (nM)	0
431	Prednisolone (µM)	0.1475314
431	Ruxolitinib (nM)	0
431	Thioguanine (µM)	19.03568
431	Trametinib (nM)	0
431	Venetoclax (nM)	0
431	Vincristine (µM)	0.9813614
431	Vorinostat (nM)	0
431	asparagise_normalized	0.3282
431	cytarabine_normalized	0.4342
431	dexamethasone_normalized	0.1458
431	mercaptopurine_normalized	0.3752
431	prednisolone_normalized	0.2194
431	thioguanine_normalized	0.2052
431	vincristine_normalized	0.426
432	immunophenotype	B
432	molecular subtype	Hyperdiploid
432	Protocol	T15
432	NCI risk	SR
432	Age at diagnosis	3.5
432	WBC at diagnosis	10.3
432	Sex	M
432	Genetically-defined race	White
432	Asparaginase (IU/ml)	0.07498872
432	Bortezomib (nM)	0
432	CHZ868 (nM)	0
432	Cytarabine (µM)	1.764157
432	Dasatinib (nM)	0
432	Daunorubicin (µM)	0
432	Dexamethasone  (µM)	0.005883566
432	Ibrutinib (µM)	0
432	Mercaptopurine (µM)	537.4687
432	Nelarabine (µM)	0
432	Panobinostat (nM)	0
432	Prednisolone (µM)	0.07364005
432	Ruxolitinib (nM)	0
432	Thioguanine (µM)	40.5143
432	Trametinib (nM)	0
432	Venetoclax (nM)	0
432	Vincristine (µM)	0.7609466
432	Vorinostat (nM)	0
432	asparagise_normalized	0.392
432	cytarabine_normalized	0.546
432	dexamethasone_normalized	0.2711
432	mercaptopurine_normalized	0.5099
432	prednisolone_normalized	0.1527
432	thioguanine_normalized	0.4232
432	vincristine_normalized	0.3896
433	immunophenotype	B
433	molecular subtype	KMT2A
433	Protocol	T15
433	NCI risk	SR
433	Age at diagnosis	3.5
433	WBC at diagnosis	1.2
433	Sex	M
433	Genetically-defined race	White
433	Asparaginase (IU/ml)	20
433	Bortezomib (nM)	0
433	CHZ868 (nM)	0
433	Cytarabine (µM)	1.758991843
433	Dasatinib (nM)	0
433	Daunorubicin (µM)	0
433	Dexamethasone  (µM)	0
433	Ibrutinib (µM)	0
433	Mercaptopurine (µM)	763.0278
433	Nelarabine (µM)	0
433	Panobinostat (nM)	0
433	Prednisolone (µM)	1006
433	Ruxolitinib (nM)	0
433	Thioguanine (µM)	44.72735
433	Trametinib (nM)	0
433	Venetoclax (nM)	0
433	Vincristine (µM)	108.34
433	Vorinostat (nM)	0
433	asparagise_normalized	1
433	cytarabine_normalized	0.5456
433	mercaptopurine_normalized	0.611
433	prednisolone_normalized	1
433	thioguanine_normalized	0.4517
433	vincristine_normalized	1
434	immunophenotype	B
434	molecular subtype	Hyperdiploid
434	Protocol	T15
434	NCI risk	SR
434	Age at diagnosis	1.3
434	WBC at diagnosis	16.1
434	Sex	F
434	Genetically-defined race	Asian/Other
434	Asparaginase (IU/ml)	20
434	Bortezomib (nM)	0
434	CHZ868 (nM)	0
434	Cytarabine (µM)	82.2
434	Dasatinib (nM)	0
434	Daunorubicin (µM)	0
434	Dexamethasone  (µM)	23.2
434	Ibrutinib (µM)	0
434	Mercaptopurine (µM)	412.5435
434	Nelarabine (µM)	0
434	Panobinostat (nM)	0
434	Prednisolone (µM)	1006
434	Ruxolitinib (nM)	0
434	Thioguanine (µM)	73.16970234
434	Trametinib (nM)	0
434	Venetoclax (nM)	0
434	Vincristine (µM)	108.34
434	Vorinostat (nM)	0
434	asparagise_normalized	1
434	cytarabine_normalized	1
434	dexamethasone_normalized	1
434	mercaptopurine_normalized	0.4336
434	prednisolone_normalized	1
434	thioguanine_normalized	0.5938
434	vincristine_normalized	1
435	immunophenotype	B
435	molecular subtype	Hyperdiploid
435	Protocol	T15
435	NCI risk	SR
435	Age at diagnosis	2.3
435	WBC at diagnosis	6.3
435	Sex	F
435	Genetically-defined race	White
435	Asparaginase (IU/ml)	0
435	Bortezomib (nM)	0
435	CHZ868 (nM)	0
435	Cytarabine (µM)	0.5919299
435	Dasatinib (nM)	0
435	Daunorubicin (µM)	0
435	Dexamethasone  (µM)	0
435	Ibrutinib (µM)	0
435	Mercaptopurine (µM)	523.7576
435	Nelarabine (µM)	0
435	Panobinostat (nM)	0
435	Prednisolone (µM)	0
435	Ruxolitinib (nM)	0
435	Thioguanine (µM)	598
435	Trametinib (nM)	0
435	Venetoclax (nM)	0
435	Vincristine (µM)	0
435	Vorinostat (nM)	0
435	cytarabine_normalized	0.3885
435	mercaptopurine_normalized	0.5024
435	thioguanine_normalized	1
436	immunophenotype	B
436	molecular subtype	KMT2A
436	Protocol	T15
436	NCI risk	HR
436	Age at diagnosis	14.6
436	WBC at diagnosis	238.1
436	Sex	M
436	Genetically-defined race	black
436	Asparaginase (IU/ml)	20
436	Bortezomib (nM)	0
436	CHZ868 (nM)	0
436	Cytarabine (µM)	0
436	Dasatinib (nM)	0
436	Daunorubicin (µM)	0
436	Dexamethasone  (µM)	0.06637016
436	Ibrutinib (µM)	0
436	Mercaptopurine (µM)	1090.655115
436	Nelarabine (µM)	0
436	Panobinostat (nM)	0
436	Prednisolone (µM)	0.0075
436	Ruxolitinib (nM)	0
436	Thioguanine (µM)	72.13035
436	Trametinib (nM)	0
436	Venetoclax (nM)	0
436	Vincristine (µM)	0.1510529
436	Vorinostat (nM)	0
436	asparagise_normalized	1
436	dexamethasone_normalized	0.5039
436	mercaptopurine_normalized	0.7141
436	prednisolone_normalized	0
436	thioguanine_normalized	0.5896
436	vincristine_normalized	0.1582
437	immunophenotype	B
437	molecular subtype	ETV6-RUNX1
437	Protocol	T15
437	NCI risk	SR
437	Age at diagnosis	8.6
437	WBC at diagnosis	30.6
437	Sex	F
437	Genetically-defined race	White
437	Asparaginase (IU/ml)	0.0016
437	Bortezomib (nM)	0
437	CHZ868 (nM)	0
437	Cytarabine (µM)	1.476612
437	Dasatinib (nM)	0
437	Daunorubicin (µM)	0
437	Dexamethasone  (µM)	0.03213512
437	Ibrutinib (µM)	0
437	Mercaptopurine (µM)	668.2403
437	Nelarabine (µM)	0
437	Panobinostat (nM)	0
437	Prednisolone (µM)	0.0075
437	Ruxolitinib (nM)	0
437	Thioguanine (µM)	30.43651596
437	Trametinib (nM)	0
437	Venetoclax (nM)	0
437	Vincristine (µM)	0.025
437	Vorinostat (nM)	0
437	asparagise_normalized	0
437	cytarabine_normalized	0.5204
437	dexamethasone_normalized	0.4342
437	mercaptopurine_normalized	0.5727
437	prednisolone_normalized	0
437	thioguanine_normalized	0.3406
437	vincristine_normalized	0
438	immunophenotype	B
438	molecular subtype	Hyperdiploid
438	Protocol	T15
438	NCI risk	SR
438	Age at diagnosis	5.6
438	WBC at diagnosis	5.8
438	Sex	F
438	Genetically-defined race	White
438	Asparaginase (IU/ml)	0.0016
438	Bortezomib (nM)	0
438	CHZ868 (nM)	0
438	Cytarabine (µM)	0.8312503
438	Dasatinib (nM)	0
438	Daunorubicin (µM)	0
438	Dexamethasone  (µM)	0.2121688
438	Ibrutinib (µM)	0
438	Mercaptopurine (µM)	1577.044
438	Nelarabine (µM)	0
438	Panobinostat (nM)	0
438	Prednisolone (µM)	1006
438	Ruxolitinib (nM)	0
438	Thioguanine (µM)	85.17539
438	Trametinib (nM)	0
438	Venetoclax (nM)	0
438	Vincristine (µM)	17.55603
438	Vorinostat (nM)	0
438	asparagise_normalized	0
438	cytarabine_normalized	0.4375
438	dexamethasone_normalized	0.6156
438	mercaptopurine_normalized	0.8205
438	prednisolone_normalized	1
438	thioguanine_normalized	0.6376
438	vincristine_normalized	0.8388
439	immunophenotype	T
439	molecular subtype	T-ALL
439	Protocol	T15
439	NCI risk	HR
439	Age at diagnosis	15.3
439	WBC at diagnosis	79.7
439	Sex	M
439	Genetically-defined race	White
439	Asparaginase (IU/ml)	20
439	Bortezomib (nM)	0
439	CHZ868 (nM)	0
439	Cytarabine (µM)	7.079962998
439	Dasatinib (nM)	0
439	Daunorubicin (µM)	0
439	Dexamethasone  (µM)	23.2
439	Ibrutinib (µM)	0
439	Mercaptopurine (µM)	809.7521066
439	Nelarabine (µM)	0
439	Panobinostat (nM)	0
439	Prednisolone (µM)	1006
439	Ruxolitinib (nM)	0
439	Thioguanine (µM)	29.56901
439	Trametinib (nM)	0
439	Venetoclax (nM)	0
439	Vincristine (µM)	13.25371
439	Vorinostat (nM)	0
439	asparagise_normalized	1
439	cytarabine_normalized	0.7464
439	dexamethasone_normalized	1
439	mercaptopurine_normalized	0.6282
439	prednisolone_normalized	1
439	thioguanine_normalized	0.3323
439	vincristine_normalized	0.7985
440	immunophenotype	T
440	molecular subtype	T-ALL
440	Protocol	T15
440	NCI risk	HR
440	Age at diagnosis	9.5
440	WBC at diagnosis	107
440	Sex	F
440	Genetically-defined race	White
440	Asparaginase (IU/ml)	0
440	Bortezomib (nM)	0
440	CHZ868 (nM)	0
440	Cytarabine (µM)	0
440	Dasatinib (nM)	0
440	Daunorubicin (µM)	0
440	Dexamethasone  (µM)	0
440	Ibrutinib (µM)	0
440	Mercaptopurine (µM)	0
440	Nelarabine (µM)	0
440	Panobinostat (nM)	0
440	Prednisolone (µM)	1006
440	Ruxolitinib (nM)	0
440	Thioguanine (µM)	0
440	Trametinib (nM)	0
440	Venetoclax (nM)	0
440	Vincristine (µM)	0
440	Vorinostat (nM)	0
440	prednisolone_normalized	1
441	immunophenotype	B
441	molecular subtype	Ph-like_CRLF2
441	Protocol	T15
441	NCI risk	HR
441	Age at diagnosis	13.7
441	WBC at diagnosis	2.7
441	Sex	F
441	Genetically-defined race	White
441	Asparaginase (IU/ml)	0.6854838
441	Bortezomib (nM)	0
441	CHZ868 (nM)	0
441	Cytarabine (µM)	1.191764
441	Dasatinib (nM)	0
441	Daunorubicin (µM)	0
441	Dexamethasone  (µM)	0.1787012
441	Ibrutinib (µM)	0
441	Mercaptopurine (µM)	541.4098
441	Nelarabine (µM)	0
441	Panobinostat (nM)	0
441	Prednisolone (µM)	0.05639651
441	Ruxolitinib (nM)	0
441	Thioguanine (µM)	29.99583
441	Trametinib (nM)	0
441	Venetoclax (nM)	0
441	Vincristine (µM)	0.07491631
441	Vorinostat (nM)	0
441	asparagise_normalized	0.6669
441	cytarabine_normalized	0.4895
441	dexamethasone_normalized	0.5991
441	mercaptopurine_normalized	0.512
441	prednisolone_normalized	0.1271
441	thioguanine_normalized	0.3364
441	vincristine_normalized	0.0579
442	immunophenotype	B
442	molecular subtype	iAMP21
442	Protocol	T15
442	NCI risk	SR
442	Age at diagnosis	9.2
442	WBC at diagnosis	10.4
442	Sex	F
442	Genetically-defined race	White
442	Asparaginase (IU/ml)	20
442	Bortezomib (nM)	0
442	CHZ868 (nM)	0
442	Cytarabine (µM)	1.714625
442	Dasatinib (nM)	0
442	Daunorubicin (µM)	0
442	Dexamethasone  (µM)	0.06317013
442	Ibrutinib (µM)	0
442	Mercaptopurine (µM)	820.9744
442	Nelarabine (µM)	0
442	Panobinostat (nM)	0
442	Prednisolone (µM)	0.05291335
442	Ruxolitinib (nM)	0
442	Thioguanine (µM)	96.03777
442	Trametinib (nM)	0
442	Venetoclax (nM)	0
442	Vincristine (µM)	0.08352113
442	Vorinostat (nM)	0
442	asparagise_normalized	1
442	cytarabine_normalized	0.5419
442	dexamethasone_normalized	0.4992
442	mercaptopurine_normalized	0.6321
442	prednisolone_normalized	0.121
442	thioguanine_normalized	0.6722
442	vincristine_normalized	0.0734
443	immunophenotype	B
443	molecular subtype	Hyperdiploid
443	Protocol	T15
443	NCI risk	SR
443	Age at diagnosis	3.9
443	WBC at diagnosis	15.9
443	Sex	M
443	Genetically-defined race	White
443	Asparaginase (IU/ml)	20
443	Bortezomib (nM)	0
443	CHZ868 (nM)	0
443	Cytarabine (µM)	4.091769
443	Dasatinib (nM)	0
443	Daunorubicin (µM)	0
443	Dexamethasone  (µM)	0.002417477
443	Ibrutinib (µM)	0
443	Mercaptopurine (µM)	0
443	Nelarabine (µM)	0
443	Panobinostat (nM)	0
443	Prednisolone (µM)	0.1006713
443	Ruxolitinib (nM)	0
443	Thioguanine (µM)	598
443	Trametinib (nM)	0
443	Venetoclax (nM)	0
443	Vincristine (µM)	0.2042734
443	Vorinostat (nM)	0
443	asparagise_normalized	1
443	cytarabine_normalized	0.6673
443	dexamethasone_normalized	0.1857
443	prednisolone_normalized	0.1827
443	thioguanine_normalized	1
443	vincristine_normalized	0.2014
444	immunophenotype	B
444	molecular subtype	MEF2D
444	Protocol	T15
444	NCI risk	HR
444	Age at diagnosis	11.2
444	WBC at diagnosis	5.6
444	Sex	F
444	Genetically-defined race	black
444	Asparaginase (IU/ml)	0
444	Bortezomib (nM)	0
444	CHZ868 (nM)	0
444	Cytarabine (µM)	0
444	Dasatinib (nM)	0
444	Daunorubicin (µM)	0
444	Dexamethasone  (µM)	0
444	Ibrutinib (µM)	0
444	Mercaptopurine (µM)	0
444	Nelarabine (µM)	0
444	Panobinostat (nM)	0
444	Prednisolone (µM)	1006
444	Ruxolitinib (nM)	0
444	Thioguanine (µM)	0
444	Trametinib (nM)	0
444	Venetoclax (nM)	0
444	Vincristine (µM)	0
444	Vorinostat (nM)	0
444	prednisolone_normalized	1
445	immunophenotype	B
445	molecular subtype	TCF3-PBX1
445	Protocol	T15
445	NCI risk	HR
445	Age at diagnosis	6.7
445	WBC at diagnosis	54.6
445	Sex	M
445	Genetically-defined race	White
445	Asparaginase (IU/ml)	0.038982659
445	Bortezomib (nM)	0
445	CHZ868 (nM)	0
445	Cytarabine (µM)	1.087708
445	Dasatinib (nM)	0
445	Daunorubicin (µM)	0
445	Dexamethasone  (µM)	0.001031482
445	Ibrutinib (µM)	0
445	Mercaptopurine (µM)	457.5805371
445	Nelarabine (µM)	0
445	Panobinostat (nM)	0
445	Prednisolone (µM)	0.00587554
445	Ruxolitinib (nM)	0
445	Thioguanine (µM)	37.70575
445	Trametinib (nM)	0
445	Venetoclax (nM)	0
445	Vincristine (µM)	0.1214949
445	Vorinostat (nM)	0
445	asparagise_normalized	0.3107
445	cytarabine_normalized	0.4763
445	dexamethasone_normalized	0.1038
445	mercaptopurine_normalized	0.4635
445	prednisolone_normalized	0
445	thioguanine_normalized	0.4024
445	vincristine_normalized	0.1271
446	immunophenotype	B
446	molecular subtype	Hyperdiploid
446	Protocol	T16
446	NCI risk	SR
446	Age at diagnosis	3.4
446	WBC at diagnosis	15.8
446	Sex	F
446	Genetically-defined race	black
446	Asparaginase (IU/ml)	0.0016
446	Bortezomib (nM)	0
446	CHZ868 (nM)	0
446	Cytarabine (µM)	0.4340408
446	Dasatinib (nM)	0
446	Daunorubicin (µM)	0
446	Dexamethasone  (µM)	0.002546028
446	Ibrutinib (µM)	0
446	Mercaptopurine (µM)	264.5803
446	Nelarabine (µM)	0
446	Panobinostat (nM)	0
446	Prednisolone (µM)	0.05192849
446	Ruxolitinib (nM)	0
446	Thioguanine (µM)	12.33116
446	Trametinib (nM)	0
446	Venetoclax (nM)	0
446	Vincristine (µM)	0.1464204
446	Vorinostat (nM)	0
446	asparagise_normalized	0
446	cytarabine_normalized	0.3438
446	dexamethasone_normalized	0.1906
446	mercaptopurine_normalized	0.3054
446	prednisolone_normalized	0.1192
446	thioguanine_normalized	0.0799
446	vincristine_normalized	0.1538
447	immunophenotype	B
447	molecular subtype	B-other
447	Protocol	T16
447	NCI risk	SR
447	Age at diagnosis	4.4
447	WBC at diagnosis	27.8
447	Sex	M
447	Genetically-defined race	White
447	Asparaginase (IU/ml)	0
447	Bortezomib (nM)	0
447	CHZ868 (nM)	0
447	Cytarabine (µM)	9.195737
447	Dasatinib (nM)	0
447	Daunorubicin (µM)	0
447	Dexamethasone  (µM)	0.005653
447	Ibrutinib (µM)	0
447	Mercaptopurine (µM)	269.9538
447	Nelarabine (µM)	0
447	Panobinostat (nM)	0
447	Prednisolone (µM)	0.03166205
447	Ruxolitinib (nM)	0
447	Thioguanine (µM)	4.675
447	Trametinib (nM)	0
447	Venetoclax (nM)	0
447	Vincristine (µM)	0.3599649
447	Vorinostat (nM)	0
447	cytarabine_normalized	0.7841
447	dexamethasone_normalized	0.2673
447	mercaptopurine_normalized	0.3112
447	prednisolone_normalized	0.0717
447	thioguanine_normalized	0
447	vincristine_normalized	0.2825
448	immunophenotype	B
448	molecular subtype	Hyperdiploid
448	Protocol	T16
448	NCI risk	SR
448	Age at diagnosis	3.4
448	WBC at diagnosis	8.1
448	Sex	F
448	Genetically-defined race	White
448	Asparaginase (IU/ml)	0.0016
448	Bortezomib (nM)	0
448	CHZ868 (nM)	0
448	Cytarabine (µM)	0.9054161
448	Dasatinib (nM)	0
448	Daunorubicin (µM)	0
448	Dexamethasone  (µM)	0.06230134
448	Ibrutinib (µM)	0
448	Mercaptopurine (µM)	374.757
448	Nelarabine (µM)	0
448	Panobinostat (nM)	0
448	Prednisolone (µM)	1006
448	Ruxolitinib (nM)	0
448	Thioguanine (µM)	16.28996
448	Trametinib (nM)	0
448	Venetoclax (nM)	0
448	Vincristine (µM)	0.1485598
448	Vorinostat (nM)	0
448	asparagise_normalized	0
448	cytarabine_normalized	0.4498
448	dexamethasone_normalized	0.4978
448	mercaptopurine_normalized	0.4059
448	prednisolone_normalized	1
448	thioguanine_normalized	0.1602
448	vincristine_normalized	0.1558
449	immunophenotype	B
449	molecular subtype	DUX4
449	Protocol	T15
449	NCI risk	SR
449	Age at diagnosis	8.4
449	WBC at diagnosis	2.6
449	Sex	M
449	Genetically-defined race	Hispanic
449	Asparaginase (IU/ml)	0
449	Bortezomib (nM)	0
449	CHZ868 (nM)	0
449	Cytarabine (µM)	0
449	Dasatinib (nM)	0
449	Daunorubicin (µM)	0
449	Dexamethasone  (µM)	0.01238791
449	Ibrutinib (µM)	0
449	Mercaptopurine (µM)	516.0009
449	Nelarabine (µM)	0
449	Panobinostat (nM)	0
449	Prednisolone (µM)	0.08720366
449	Ruxolitinib (nM)	0
449	Thioguanine (µM)	43.63254
449	Trametinib (nM)	0
449	Venetoclax (nM)	0
449	Vincristine (µM)	0
449	Vorinostat (nM)	0
449	dexamethasone_normalized	0.3427
449	mercaptopurine_normalized	0.4981
449	prednisolone_normalized	0.1689
449	thioguanine_normalized	0.4446
450	immunophenotype	B
450	molecular subtype	KMT2A
450	Protocol	T16
450	NCI risk	HR
450	Age at diagnosis	18.7
450	WBC at diagnosis	266.1
450	Sex	F
450	Genetically-defined race	White
450	Asparaginase (IU/ml)	0.8593859
450	Bortezomib (nM)	0
450	CHZ868 (nM)	0
450	Cytarabine (µM)	3.747867
450	Dasatinib (nM)	0
450	Daunorubicin (µM)	0
450	Dexamethasone  (µM)	0.01744156
450	Ibrutinib (µM)	0
450	Mercaptopurine (µM)	0
450	Nelarabine (µM)	0
450	Panobinostat (nM)	0
450	Prednisolone (µM)	0.0828953
450	Ruxolitinib (nM)	0
450	Thioguanine (µM)	0
450	Trametinib (nM)	0
450	Venetoclax (nM)	0
450	Vincristine (µM)	0.2294347
450	Vorinostat (nM)	0
450	asparagise_normalized	0.695
450	cytarabine_normalized	0.6547
450	dexamethasone_normalized	0.3755
450	prednisolone_normalized	0.1641
450	vincristine_normalized	0.218
451	immunophenotype	B
451	molecular subtype	B-other
451	Protocol	T16
451	NCI risk	HR
451	Age at diagnosis	7.6
451	WBC at diagnosis	78.9
451	Sex	F
451	Genetically-defined race	White
451	Asparaginase (IU/ml)	0.5186747
451	Bortezomib (nM)	0
451	CHZ868 (nM)	0
451	Cytarabine (µM)	0.6308737
451	Dasatinib (nM)	0
451	Daunorubicin (µM)	0
451	Dexamethasone  (µM)	23.2
451	Ibrutinib (µM)	0
451	Mercaptopurine (µM)	5876
451	Nelarabine (µM)	0
451	Panobinostat (nM)	0
451	Prednisolone (µM)	1006
451	Ruxolitinib (nM)	0
451	Thioguanine (µM)	17.09228
451	Trametinib (nM)	0
451	Venetoclax (nM)	0
451	Vincristine (µM)	108.34
451	Vorinostat (nM)	0
451	asparagise_normalized	0.6323
451	cytarabine_normalized	0.3977
451	dexamethasone_normalized	1
451	mercaptopurine_normalized	1
451	prednisolone_normalized	1
451	thioguanine_normalized	0.1741
451	vincristine_normalized	1
452	immunophenotype	T
452	molecular subtype	T-ALL
452	Protocol	T16
452	NCI risk	SR
452	Age at diagnosis	5.9
452	WBC at diagnosis	2.2
452	Sex	F
452	Genetically-defined race	black
452	Asparaginase (IU/ml)	0.2384488
452	Bortezomib (nM)	0
452	CHZ868 (nM)	0
452	Cytarabine (µM)	11.19448
452	Dasatinib (nM)	0
452	Daunorubicin (µM)	0.1471788
452	Dexamethasone  (µM)	0.004039633
452	Ibrutinib (µM)	0
452	Mercaptopurine (µM)	203.0524
452	Nelarabine (µM)	0
452	Panobinostat (nM)	0
452	Prednisolone (µM)	0
452	Ruxolitinib (nM)	0
452	Thioguanine (µM)	12.97841
452	Trametinib (nM)	0
452	Venetoclax (nM)	0
452	Vincristine (µM)	0.09619136
452	Vorinostat (nM)	0
452	asparagise_normalized	0.5357
452	cytarabine_normalized	0.8125
452	daunorubicin_normalized	0.5502
452	dexamethasone_normalized	0.235
452	mercaptopurine_normalized	0.229
452	thioguanine_normalized	0.0946
452	vincristine_normalized	0.0936
453	immunophenotype	B
453	molecular subtype	DUX4
453	Protocol	T16
453	NCI risk	HR
453	Age at diagnosis	5.5
453	WBC at diagnosis	60.8
453	Sex	F
453	Genetically-defined race	White
453	Asparaginase (IU/ml)	2.306765
453	Bortezomib (nM)	0
453	CHZ868 (nM)	0
453	Cytarabine (µM)	2.857976
453	Dasatinib (nM)	0
453	Daunorubicin (µM)	0
453	Dexamethasone  (µM)	0.000874506
453	Ibrutinib (µM)	0
453	Mercaptopurine (µM)	5876
453	Nelarabine (µM)	0
453	Panobinostat (nM)	0
453	Prednisolone (µM)	0.004804486
453	Ruxolitinib (nM)	0
453	Thioguanine (µM)	20.95109
453	Trametinib (nM)	0
453	Venetoclax (nM)	0
453	Vincristine (µM)	0.1170064
453	Vorinostat (nM)	0
453	asparagise_normalized	0.8177
453	cytarabine_normalized	0.6156
453	dexamethasone_normalized	0.088
453	mercaptopurine_normalized	1
453	prednisolone_normalized	0
453	thioguanine_normalized	0.2328
453	vincristine_normalized	0.1217
454	immunophenotype	T
454	molecular subtype	T-ALL
454	Protocol	T16
454	NCI risk	HR
454	Age at diagnosis	16.7
454	WBC at diagnosis	211.3
454	Sex	M
454	Genetically-defined race	White
454	Asparaginase (IU/ml)	20
454	Bortezomib (nM)	0
454	CHZ868 (nM)	0
454	Cytarabine (µM)	0
454	Dasatinib (nM)	0
454	Daunorubicin (µM)	7.1
454	Dexamethasone  (µM)	23.2
454	Ibrutinib (µM)	0
454	Mercaptopurine (µM)	0
454	Nelarabine (µM)	0
454	Panobinostat (nM)	0
454	Prednisolone (µM)	1006
454	Ruxolitinib (nM)	0
454	Thioguanine (µM)	0
454	Trametinib (nM)	0
454	Venetoclax (nM)	0
454	Vincristine (µM)	0
454	Vorinostat (nM)	0
454	asparagise_normalized	1
454	daunorubicin_normalized	1
454	dexamethasone_normalized	1
454	prednisolone_normalized	1
455	immunophenotype	B
455	molecular subtype	PAX5alt
455	Protocol	T16
455	NCI risk	HR
455	Age at diagnosis	3.7
455	WBC at diagnosis	90.6
455	Sex	M
455	Genetically-defined race	White
455	Asparaginase (IU/ml)	0
455	Bortezomib (nM)	0
455	CHZ868 (nM)	0
455	Cytarabine (µM)	13.54227
455	Dasatinib (nM)	0
455	Daunorubicin (µM)	0
455	Dexamethasone  (µM)	23.2
455	Ibrutinib (µM)	0
455	Mercaptopurine (µM)	527.9579961
455	Nelarabine (µM)	0
455	Panobinostat (nM)	0
455	Prednisolone (µM)	1006
455	Ruxolitinib (nM)	0
455	Thioguanine (µM)	34.92616
455	Trametinib (nM)	0
455	Venetoclax (nM)	0
455	Vincristine (µM)	0
455	Vorinostat (nM)	0
455	cytarabine_normalized	0.8399
455	dexamethasone_normalized	1
455	mercaptopurine_normalized	0.5048
455	prednisolone_normalized	1
455	thioguanine_normalized	0.3803
456	immunophenotype	B
456	molecular subtype	ETV6-RUNX1
456	Protocol	T16
456	NCI risk	SR
456	Age at diagnosis	2.1
456	WBC at diagnosis	23.2
456	Sex	M
456	Genetically-defined race	White
456	Asparaginase (IU/ml)	0.0016
456	Bortezomib (nM)	0
456	CHZ868 (nM)	0
456	Cytarabine (µM)	2.061392
456	Dasatinib (nM)	0
456	Daunorubicin (µM)	0
456	Dexamethasone  (µM)	0.002523757
456	Ibrutinib (µM)	0
456	Mercaptopurine (µM)	563.9571
456	Nelarabine (µM)	0
456	Panobinostat (nM)	0
456	Prednisolone (µM)	0.009288097
456	Ruxolitinib (nM)	0
456	Thioguanine (µM)	18.33823
456	Trametinib (nM)	0
456	Venetoclax (nM)	0
456	Vincristine (µM)	0.6494622
456	Vorinostat (nM)	0
456	asparagise_normalized	0
456	cytarabine_normalized	0.5685
456	dexamethasone_normalized	0.1898
456	mercaptopurine_normalized	0.5238
456	prednisolone_normalized	0
456	thioguanine_normalized	0.1944
456	vincristine_normalized	0.3669
457	immunophenotype	B
457	molecular subtype	PAX5alt
457	Protocol	T16
457	NCI risk	SR
457	Age at diagnosis	1.2
457	WBC at diagnosis	45.6
457	Sex	F
457	Genetically-defined race	Hispanic
457	Asparaginase (IU/ml)	20
457	Bortezomib (nM)	0
457	CHZ868 (nM)	0
457	Cytarabine (µM)	82.2
457	Dasatinib (nM)	0
457	Daunorubicin (µM)	0
457	Dexamethasone  (µM)	0.009529332
457	Ibrutinib (µM)	0
457	Mercaptopurine (µM)	5876
457	Nelarabine (µM)	0
457	Panobinostat (nM)	0
457	Prednisolone (µM)	0.03916958
457	Ruxolitinib (nM)	0
457	Thioguanine (µM)	0
457	Trametinib (nM)	0
457	Venetoclax (nM)	0
457	Vincristine (µM)	0
457	Vorinostat (nM)	0
457	asparagise_normalized	1
457	cytarabine_normalized	1
457	dexamethasone_normalized	0.3174
457	mercaptopurine_normalized	1
457	prednisolone_normalized	0.0921
458	immunophenotype	T
458	molecular subtype	T-ALL
458	Protocol	T16
458	NCI risk	HR
458	Age at diagnosis	17.6
458	WBC at diagnosis	12.8
458	Sex	M
458	Genetically-defined race	White
458	Asparaginase (IU/ml)	0
458	Bortezomib (nM)	0
458	CHZ868 (nM)	0
458	Cytarabine (µM)	0
458	Dasatinib (nM)	0
458	Daunorubicin (µM)	0
458	Dexamethasone  (µM)	0
458	Ibrutinib (µM)	0
458	Mercaptopurine (µM)	0
458	Nelarabine (µM)	0
458	Panobinostat (nM)	0
458	Prednisolone (µM)	1006
458	Ruxolitinib (nM)	0
458	Thioguanine (µM)	0
458	Trametinib (nM)	0
458	Venetoclax (nM)	0
458	Vincristine (µM)	0
458	Vorinostat (nM)	0
458	prednisolone_normalized	1
459	immunophenotype	B
459	molecular subtype	KMT2A
459	Protocol	T16
459	NCI risk	HR
459	Age at diagnosis	0.7
459	WBC at diagnosis	31.1
459	Sex	F
459	Genetically-defined race	White
459	Asparaginase (IU/ml)	0.4069698
459	Bortezomib (nM)	0
459	CHZ868 (nM)	0
459	Cytarabine (µM)	0.8165483
459	Dasatinib (nM)	0
459	Daunorubicin (µM)	0
459	Dexamethasone  (µM)	23.2
459	Ibrutinib (µM)	0
459	Mercaptopurine (µM)	5876
459	Nelarabine (µM)	0
459	Panobinostat (nM)	0
459	Prednisolone (µM)	1006
459	Ruxolitinib (nM)	0
459	Thioguanine (µM)	34.96831
459	Trametinib (nM)	0
459	Venetoclax (nM)	0
459	Vincristine (µM)	0
459	Vorinostat (nM)	0
459	asparagise_normalized	0.6021
459	cytarabine_normalized	0.4349
459	dexamethasone_normalized	1
459	mercaptopurine_normalized	1
459	prednisolone_normalized	1
459	thioguanine_normalized	0.3807
460	immunophenotype	B
460	molecular subtype	ZNF384
460	Protocol	T16
460	NCI risk	HR
460	Age at diagnosis	10.3
460	WBC at diagnosis	18.7
460	Sex	F
460	Genetically-defined race	White
460	Asparaginase (IU/ml)	0.5160053
460	Bortezomib (nM)	0
460	CHZ868 (nM)	0
460	Cytarabine (µM)	0
460	Dasatinib (nM)	0
460	Daunorubicin (µM)	0
460	Dexamethasone  (µM)	23.2
460	Ibrutinib (µM)	0
460	Mercaptopurine (µM)	0
460	Nelarabine (µM)	0
460	Panobinostat (nM)	0
460	Prednisolone (µM)	1006
460	Ruxolitinib (nM)	0
460	Thioguanine (µM)	0
460	Trametinib (nM)	0
460	Venetoclax (nM)	0
460	Vincristine (µM)	0
460	Vorinostat (nM)	0
460	asparagise_normalized	0.6316
460	dexamethasone_normalized	1
460	prednisolone_normalized	1
461	immunophenotype	B
461	molecular subtype	DUX4
461	Protocol	T16
461	NCI risk	SR
461	Age at diagnosis	7.5
461	WBC at diagnosis	26.7
461	Sex	M
461	Genetically-defined race	White
461	Asparaginase (IU/ml)	0
461	Bortezomib (nM)	0
461	CHZ868 (nM)	0
461	Cytarabine (µM)	82.2
461	Dasatinib (nM)	0
461	Daunorubicin (µM)	0
461	Dexamethasone  (µM)	0
461	Ibrutinib (µM)	0
461	Mercaptopurine (µM)	0
461	Nelarabine (µM)	0
461	Panobinostat (nM)	0
461	Prednisolone (µM)	0.5316672
461	Ruxolitinib (nM)	0
461	Thioguanine (µM)	0
461	Trametinib (nM)	0
461	Venetoclax (nM)	0
461	Vincristine (µM)	0
461	Vorinostat (nM)	0
461	cytarabine_normalized	1
461	prednisolone_normalized	0.3424
462	immunophenotype	B
462	molecular subtype	ETV6-RUNX1
462	Protocol	T16
462	NCI risk	SR
462	Age at diagnosis	4.2
462	WBC at diagnosis	5.2
462	Sex	F
462	Genetically-defined race	White
462	Asparaginase (IU/ml)	0.0016
462	Bortezomib (nM)	0
462	CHZ868 (nM)	0
462	Cytarabine (µM)	82.2
462	Dasatinib (nM)	0
462	Daunorubicin (µM)	0
462	Dexamethasone  (µM)	23.2
462	Ibrutinib (µM)	0
462	Mercaptopurine (µM)	5876
462	Nelarabine (µM)	0
462	Panobinostat (nM)	0
462	Prednisolone (µM)	1006
462	Ruxolitinib (nM)	0
462	Thioguanine (µM)	598
462	Trametinib (nM)	0
462	Venetoclax (nM)	0
462	Vincristine (µM)	0
462	Vorinostat (nM)	0
462	asparagise_normalized	0
462	cytarabine_normalized	1
462	dexamethasone_normalized	1
462	mercaptopurine_normalized	1
462	prednisolone_normalized	1
462	thioguanine_normalized	1
463	immunophenotype	B
463	molecular subtype	Hyperdiploid
463	Protocol	T16
463	NCI risk	SR
463	Age at diagnosis	4.1
463	WBC at diagnosis	6.4
463	Sex	M
463	Genetically-defined race	White
463	Asparaginase (IU/ml)	0
463	Bortezomib (nM)	0
463	CHZ868 (nM)	0
463	Cytarabine (µM)	82.2
463	Dasatinib (nM)	0
463	Daunorubicin (µM)	0
463	Dexamethasone  (µM)	0
463	Ibrutinib (µM)	0
463	Mercaptopurine (µM)	0
463	Nelarabine (µM)	0
463	Panobinostat (nM)	0
463	Prednisolone (µM)	0
463	Ruxolitinib (nM)	0
463	Thioguanine (µM)	0
463	Trametinib (nM)	0
463	Venetoclax (nM)	0
463	Vincristine (µM)	0
463	Vorinostat (nM)	0
463	cytarabine_normalized	1
464	immunophenotype	B
464	molecular subtype	ETV6-RUNX1
464	Protocol	T16
464	NCI risk	SR
464	Age at diagnosis	6.1
464	WBC at diagnosis	27.7
464	Sex	F
464	Genetically-defined race	White
464	Asparaginase (IU/ml)	0.0016
464	Bortezomib (nM)	0
464	CHZ868 (nM)	0
464	Cytarabine (µM)	29.48809
464	Dasatinib (nM)	0
464	Daunorubicin (µM)	0
464	Dexamethasone  (µM)	0.469278267
464	Ibrutinib (µM)	0
464	Mercaptopurine (µM)	0
464	Nelarabine (µM)	0
464	Panobinostat (nM)	0
464	Prednisolone (µM)	0.01812429
464	Ruxolitinib (nM)	0
464	Thioguanine (µM)	25.23902596
464	Trametinib (nM)	0
464	Venetoclax (nM)	0
464	Vincristine (µM)	0.06223635
464	Vorinostat (nM)	0
464	asparagise_normalized	0
464	cytarabine_normalized	0.9521
464	dexamethasone_normalized	0.6918
464	prednisolone_normalized	0.0182
464	thioguanine_normalized	0.2866
464	vincristine_normalized	0.0313
465	immunophenotype	B
465	molecular subtype	ETV6-RUNX1
465	Protocol	T16
465	NCI risk	SR
465	Age at diagnosis	7.4
465	WBC at diagnosis	9.5
465	Sex	F
465	Genetically-defined race	White
465	Asparaginase (IU/ml)	0
465	Bortezomib (nM)	0
465	CHZ868 (nM)	0
465	Cytarabine (µM)	0
465	Dasatinib (nM)	0
465	Daunorubicin (µM)	0
465	Dexamethasone  (µM)	0
465	Ibrutinib (µM)	0
465	Mercaptopurine (µM)	314.0527
465	Nelarabine (µM)	0
465	Panobinostat (nM)	0
465	Prednisolone (µM)	0
465	Ruxolitinib (nM)	0
465	Thioguanine (µM)	0
465	Trametinib (nM)	0
465	Venetoclax (nM)	0
465	Vincristine (µM)	0
465	Vorinostat (nM)	0
465	mercaptopurine_normalized	0.3549
466	immunophenotype	T
466	molecular subtype	T-ALL
466	Protocol	T16
466	NCI risk	HR
466	Age at diagnosis	6.1
466	WBC at diagnosis	63.4
466	Sex	F
466	Genetically-defined race	White
466	Asparaginase (IU/ml)	0.0016
466	Bortezomib (nM)	0
466	CHZ868 (nM)	0
466	Cytarabine (µM)	0.3763895
466	Dasatinib (nM)	0
466	Daunorubicin (µM)	0.8424243
466	Dexamethasone  (µM)	0
466	Ibrutinib (µM)	0
466	Mercaptopurine (µM)	249.4064
466	Nelarabine (µM)	0
466	Panobinostat (nM)	0
466	Prednisolone (µM)	0.08251612
466	Ruxolitinib (nM)	0
466	Thioguanine (µM)	25.21275903
466	Trametinib (nM)	0
466	Venetoclax (nM)	0
466	Vincristine (µM)	7.306247
466	Vorinostat (nM)	0
466	asparagise_normalized	0
466	cytarabine_normalized	0.3233
466	daunorubicin_normalized	0.7967
466	mercaptopurine_normalized	0.2884
466	prednisolone_normalized	0.1636
466	thioguanine_normalized	0.2863
466	vincristine_normalized	0.7133
467	immunophenotype	B
467	molecular subtype	Hyperdiploid
467	Protocol	T16
467	NCI risk	SR
467	Age at diagnosis	2.2
467	WBC at diagnosis	29.9
467	Sex	F
467	Genetically-defined race	White
467	Asparaginase (IU/ml)	0
467	Bortezomib (nM)	0
467	CHZ868 (nM)	0
467	Cytarabine (µM)	0
467	Dasatinib (nM)	0
467	Daunorubicin (µM)	0
467	Dexamethasone  (µM)	0
467	Ibrutinib (µM)	0
467	Mercaptopurine (µM)	0
467	Nelarabine (µM)	0
467	Panobinostat (nM)	0
467	Prednisolone (µM)	1006
467	Ruxolitinib (nM)	0
467	Thioguanine (µM)	0
467	Trametinib (nM)	0
467	Venetoclax (nM)	0
467	Vincristine (µM)	0
467	Vorinostat (nM)	0
467	prednisolone_normalized	1
468	immunophenotype	B
468	molecular subtype	Hyperdiploid
468	Protocol	T16
468	NCI risk	HR
468	Age at diagnosis	9.9
468	WBC at diagnosis	55
468	Sex	M
468	Genetically-defined race	black
468	Asparaginase (IU/ml)	0
468	Bortezomib (nM)	0
468	CHZ868 (nM)	0
468	Cytarabine (µM)	0.4439205
468	Dasatinib (nM)	0
468	Daunorubicin (µM)	0
468	Dexamethasone  (µM)	0.002427259
468	Ibrutinib (µM)	0
468	Mercaptopurine (µM)	522.4934
468	Nelarabine (µM)	0
468	Panobinostat (nM)	0
468	Prednisolone (µM)	0.0075
468	Ruxolitinib (nM)	0
468	Thioguanine (µM)	0
468	Trametinib (nM)	0
468	Venetoclax (nM)	0
468	Vincristine (µM)	0.18866
468	Vorinostat (nM)	0
468	cytarabine_normalized	0.3471
468	dexamethasone_normalized	0.1861
468	mercaptopurine_normalized	0.5017
468	prednisolone_normalized	0
468	vincristine_normalized	0.19
469	immunophenotype	B
469	molecular subtype	Hyperdiploid
469	Protocol	T16
469	NCI risk	HR
469	Age at diagnosis	15.3
469	WBC at diagnosis	0.9
469	Sex	F
469	Genetically-defined race	White
469	Asparaginase (IU/ml)	20
469	Bortezomib (nM)	0
469	CHZ868 (nM)	0
469	Cytarabine (µM)	0
469	Dasatinib (nM)	0
469	Daunorubicin (µM)	0
469	Dexamethasone  (µM)	23.2
469	Ibrutinib (µM)	0
469	Mercaptopurine (µM)	0
469	Nelarabine (µM)	0
469	Panobinostat (nM)	0
469	Prednisolone (µM)	0
469	Ruxolitinib (nM)	0
469	Thioguanine (µM)	598
469	Trametinib (nM)	0
469	Venetoclax (nM)	0
469	Vincristine (µM)	0
469	Vorinostat (nM)	0
469	asparagise_normalized	1
469	dexamethasone_normalized	1
469	thioguanine_normalized	1
470	immunophenotype	B
470	molecular subtype	ZNF384
470	Protocol	T16
470	NCI risk	SR
470	Age at diagnosis	2.9
470	WBC at diagnosis	41.4
470	Sex	M
470	Genetically-defined race	White
470	Asparaginase (IU/ml)	0
470	Bortezomib (nM)	0
470	CHZ868 (nM)	0
470	Cytarabine (µM)	1.522785
470	Dasatinib (nM)	0
470	Daunorubicin (µM)	0
470	Dexamethasone  (µM)	0.02875952
470	Ibrutinib (µM)	0
470	Mercaptopurine (µM)	1789.249
470	Nelarabine (µM)	0
470	Panobinostat (nM)	0
470	Prednisolone (µM)	0.0075
470	Ruxolitinib (nM)	0
470	Thioguanine (µM)	57.87624
470	Trametinib (nM)	0
470	Venetoclax (nM)	0
470	Vincristine (µM)	0.025
470	Vorinostat (nM)	0
470	cytarabine_normalized	0.5248
470	dexamethasone_normalized	0.4236
470	mercaptopurine_normalized	0.8569
470	prednisolone_normalized	0
470	thioguanine_normalized	0.5261
470	vincristine_normalized	0
471	immunophenotype	B
471	molecular subtype	ETV6-RUNX1
471	Protocol	T16
471	NCI risk	HR
471	Age at diagnosis	2.3
471	WBC at diagnosis	66
471	Sex	F
471	Genetically-defined race	black
471	Asparaginase (IU/ml)	0.0016
471	Bortezomib (nM)	0
471	CHZ868 (nM)	0
471	Cytarabine (µM)	0
471	Dasatinib (nM)	0
471	Daunorubicin (µM)	0
471	Dexamethasone  (µM)	0.1107498
471	Ibrutinib (µM)	0
471	Mercaptopurine (µM)	425.4243
471	Nelarabine (µM)	0
471	Panobinostat (nM)	0
471	Prednisolone (µM)	0.08769349
471	Ruxolitinib (nM)	0
471	Thioguanine (µM)	14.91789
471	Trametinib (nM)	0
471	Venetoclax (nM)	0
471	Vincristine (µM)	1.712035
471	Vorinostat (nM)	0
471	asparagise_normalized	0
471	dexamethasone_normalized	0.5531
471	mercaptopurine_normalized	0.4424
471	prednisolone_normalized	0.1695
471	thioguanine_normalized	0.1348
471	vincristine_normalized	0.5057
472	immunophenotype	B
472	molecular subtype	Hyperdiploid
472	Protocol	T16
472	NCI risk	HR
472	Age at diagnosis	12.1
472	WBC at diagnosis	29.8
472	Sex	M
472	Genetically-defined race	Asian/Other
472	Asparaginase (IU/ml)	20
472	Bortezomib (nM)	0
472	CHZ868 (nM)	0
472	Cytarabine (µM)	82.2
472	Dasatinib (nM)	0
472	Daunorubicin (µM)	0
472	Dexamethasone  (µM)	23.2
472	Ibrutinib (µM)	0
472	Mercaptopurine (µM)	5876
472	Nelarabine (µM)	0
472	Panobinostat (nM)	0
472	Prednisolone (µM)	1006
472	Ruxolitinib (nM)	0
472	Thioguanine (µM)	598
472	Trametinib (nM)	0
472	Venetoclax (nM)	0
472	Vincristine (µM)	108.34
472	Vorinostat (nM)	0
472	asparagise_normalized	1
472	cytarabine_normalized	1
472	dexamethasone_normalized	1
472	mercaptopurine_normalized	1
472	prednisolone_normalized	1
472	thioguanine_normalized	1
472	vincristine_normalized	1
473	immunophenotype	B
473	molecular subtype	Hyperdiploid
473	Protocol	T16
473	NCI risk	SR
473	Age at diagnosis	6.7
473	WBC at diagnosis	31.1
473	Sex	F
473	Genetically-defined race	White
473	Asparaginase (IU/ml)	0.0016
473	Bortezomib (nM)	0
473	CHZ868 (nM)	0
473	Cytarabine (µM)	3.546676
473	Dasatinib (nM)	0
473	Daunorubicin (µM)	0
473	Dexamethasone  (µM)	23.2
473	Ibrutinib (µM)	0
473	Mercaptopurine (µM)	631.8381
473	Nelarabine (µM)	0
473	Panobinostat (nM)	0
473	Prednisolone (µM)	1006
473	Ruxolitinib (nM)	0
473	Thioguanine (µM)	74.56744067
473	Trametinib (nM)	0
473	Venetoclax (nM)	0
473	Vincristine (µM)	22.65913
473	Vorinostat (nM)	0
473	asparagise_normalized	0
473	cytarabine_normalized	0.6467
473	dexamethasone_normalized	1
473	mercaptopurine_normalized	0.5566
473	prednisolone_normalized	1
473	thioguanine_normalized	0.5992
473	vincristine_normalized	0.8753
474	immunophenotype	B
474	molecular subtype	Hyperdiploid
474	Protocol	T16
474	NCI risk	SR
474	Age at diagnosis	3
474	WBC at diagnosis	5.8
474	Sex	F
474	Genetically-defined race	White
474	Asparaginase (IU/ml)	0
474	Bortezomib (nM)	0
474	CHZ868 (nM)	0
474	Cytarabine (µM)	0
474	Dasatinib (nM)	0
474	Daunorubicin (µM)	0
474	Dexamethasone  (µM)	23.2
474	Ibrutinib (µM)	0
474	Mercaptopurine (µM)	5876
474	Nelarabine (µM)	0
474	Panobinostat (nM)	0
474	Prednisolone (µM)	0.226577808
474	Ruxolitinib (nM)	0
474	Thioguanine (µM)	42.0262
474	Trametinib (nM)	0
474	Venetoclax (nM)	0
474	Vincristine (µM)	40.16277
474	Vorinostat (nM)	0
474	dexamethasone_normalized	1
474	mercaptopurine_normalized	1
474	prednisolone_normalized	0.2606
474	thioguanine_normalized	0.4337
474	vincristine_normalized	0.9572
475	immunophenotype	T
475	molecular subtype	T-ALL
475	Protocol	T16
475	NCI risk	SR
475	Age at diagnosis	6.9
475	WBC at diagnosis	13.9
475	Sex	M
475	Genetically-defined race	White
475	Asparaginase (IU/ml)	0.0016
475	Bortezomib (nM)	0
475	CHZ868 (nM)	0
475	Cytarabine (µM)	0
475	Dasatinib (nM)	0
475	Daunorubicin (µM)	0.0015
475	Dexamethasone  (µM)	0
475	Ibrutinib (µM)	0
475	Mercaptopurine (µM)	0
475	Nelarabine (µM)	0
475	Panobinostat (nM)	0
475	Prednisolone (µM)	0
475	Ruxolitinib (nM)	0
475	Thioguanine (µM)	0
475	Trametinib (nM)	0
475	Venetoclax (nM)	0
475	Vincristine (µM)	0
475	Vorinostat (nM)	0
475	asparagise_normalized	0
475	daunorubicin_normalized	0
476	immunophenotype	B
476	molecular subtype	TCF3-PBX1
476	Protocol	T16
476	NCI risk	SR
476	Age at diagnosis	1.8
476	WBC at diagnosis	37.2
476	Sex	M
476	Genetically-defined race	White
476	Asparaginase (IU/ml)	0.4963683
476	Bortezomib (nM)	0
476	CHZ868 (nM)	0
476	Cytarabine (µM)	4.223274
476	Dasatinib (nM)	0
476	Daunorubicin (µM)	0
476	Dexamethasone  (µM)	23.2
476	Ibrutinib (µM)	0
476	Mercaptopurine (µM)	5876
476	Nelarabine (µM)	0
476	Panobinostat (nM)	0
476	Prednisolone (µM)	0
476	Ruxolitinib (nM)	0
476	Thioguanine (µM)	36.74162
476	Trametinib (nM)	0
476	Venetoclax (nM)	0
476	Vincristine (µM)	0
476	Vorinostat (nM)	0
476	asparagise_normalized	0.6268
476	cytarabine_normalized	0.6719
476	dexamethasone_normalized	1
476	mercaptopurine_normalized	1
476	thioguanine_normalized	0.395
477	immunophenotype	B
477	molecular subtype	B-other
477	Protocol	T16
477	NCI risk	SR
477	Age at diagnosis	1.2
477	WBC at diagnosis	23.6
477	Sex	F
477	Genetically-defined race	White
477	Asparaginase (IU/ml)	0.4480594
477	Bortezomib (nM)	0
477	CHZ868 (nM)	0
477	Cytarabine (µM)	2.620087
477	Dasatinib (nM)	0
477	Daunorubicin (µM)	0
477	Dexamethasone  (µM)	0.0308276
477	Ibrutinib (µM)	0
477	Mercaptopurine (µM)	175.5417
477	Nelarabine (µM)	0
477	Panobinostat (nM)	0
477	Prednisolone (µM)	0.0075
477	Ruxolitinib (nM)	0
477	Thioguanine (µM)	13.03905797
477	Trametinib (nM)	0
477	Venetoclax (nM)	0
477	Vincristine (µM)	3.538806
477	Vorinostat (nM)	0
477	asparagise_normalized	0.6141
477	cytarabine_normalized	0.6031
477	dexamethasone_normalized	0.4302
477	mercaptopurine_normalized	0.187
477	prednisolone_normalized	0
477	thioguanine_normalized	0.096
477	vincristine_normalized	0.6096
478	immunophenotype	B
478	molecular subtype	ETV6-RUNX1
478	Protocol	T16
478	NCI risk	HR
478	Age at diagnosis	12
478	WBC at diagnosis	2
478	Sex	F
478	Genetically-defined race	White
478	Asparaginase (IU/ml)	0
478	Bortezomib (nM)	0
478	CHZ868 (nM)	0
478	Cytarabine (µM)	0
478	Dasatinib (nM)	0
478	Daunorubicin (µM)	0
478	Dexamethasone  (µM)	0
478	Ibrutinib (µM)	0
478	Mercaptopurine (µM)	5876
478	Nelarabine (µM)	0
478	Panobinostat (nM)	0
478	Prednisolone (µM)	0.1256381
478	Ruxolitinib (nM)	0
478	Thioguanine (µM)	12.61153
478	Trametinib (nM)	0
478	Venetoclax (nM)	0
478	Vincristine (µM)	0.1187399
478	Vorinostat (nM)	0
478	mercaptopurine_normalized	1
478	prednisolone_normalized	0.204
478	thioguanine_normalized	0.0864
478	vincristine_normalized	0.1238
479	immunophenotype	B
479	molecular subtype	TCF3-PBX1
479	Protocol	T16
479	NCI risk	HR
479	Age at diagnosis	3.3
479	WBC at diagnosis	109.5
479	Sex	M
479	Genetically-defined race	black
479	Asparaginase (IU/ml)	0.190189329
479	Bortezomib (nM)	0
479	CHZ868 (nM)	0
479	Cytarabine (µM)	0.6360636
479	Dasatinib (nM)	0
479	Daunorubicin (µM)	0
479	Dexamethasone  (µM)	0.1501308
479	Ibrutinib (µM)	0
479	Mercaptopurine (µM)	0
479	Nelarabine (µM)	0
479	Panobinostat (nM)	0
479	Prednisolone (µM)	0.01539256
479	Ruxolitinib (nM)	0
479	Thioguanine (µM)	0
479	Trametinib (nM)	0
479	Venetoclax (nM)	0
479	Vincristine (µM)	0
479	Vorinostat (nM)	0
479	asparagise_normalized	0.5076
479	cytarabine_normalized	0.3989
479	dexamethasone_normalized	0.5823
479	prednisolone_normalized	0.0025
480	immunophenotype	B
480	molecular subtype	B-other
480	Protocol	T16
480	NCI risk	SR
480	Age at diagnosis	2.7
480	WBC at diagnosis	7.8
480	Sex	F
480	Genetically-defined race	black
480	Asparaginase (IU/ml)	20
480	Bortezomib (nM)	0
480	CHZ868 (nM)	0
480	Cytarabine (µM)	21.23189968
480	Dasatinib (nM)	0
480	Daunorubicin (µM)	0
480	Dexamethasone  (µM)	0.1293533
480	Ibrutinib (µM)	0
480	Mercaptopurine (µM)	1316.281
480	Nelarabine (µM)	0
480	Panobinostat (nM)	0
480	Prednisolone (µM)	0.0075
480	Ruxolitinib (nM)	0
480	Thioguanine (µM)	26.06849
480	Trametinib (nM)	0
480	Venetoclax (nM)	0
480	Vincristine (µM)	1.171268
480	Vorinostat (nM)	0
480	asparagise_normalized	1
480	cytarabine_normalized	0.9048
480	dexamethasone_normalized	0.568
480	mercaptopurine_normalized	0.7683
480	prednisolone_normalized	0
480	thioguanine_normalized	0.2959
480	vincristine_normalized	0.4513
481	immunophenotype	B
481	molecular subtype	TCF3-PBX1
481	Protocol	T16
481	NCI risk	HR
481	Age at diagnosis	15
481	WBC at diagnosis	3.2
481	Sex	F
481	Genetically-defined race	Hispanic
481	Asparaginase (IU/ml)	0.1426947
481	Bortezomib (nM)	0
481	CHZ868 (nM)	0
481	Cytarabine (µM)	0
481	Dasatinib (nM)	0
481	Daunorubicin (µM)	0
481	Dexamethasone  (µM)	0.1143033
481	Ibrutinib (µM)	0
481	Mercaptopurine (µM)	601.8632
481	Nelarabine (µM)	0
481	Panobinostat (nM)	0
481	Prednisolone (µM)	0.0075
481	Ruxolitinib (nM)	0
481	Thioguanine (µM)	4.675
481	Trametinib (nM)	0
481	Venetoclax (nM)	0
481	Vincristine (µM)	0.025
481	Vorinostat (nM)	0
481	asparagise_normalized	0.4719
481	dexamethasone_normalized	0.5561
481	mercaptopurine_normalized	0.5426
481	prednisolone_normalized	0
481	thioguanine_normalized	0
481	vincristine_normalized	0
482	immunophenotype	B
482	molecular subtype	Hyperdiploid
482	Protocol	T16
482	NCI risk	HR
482	Age at diagnosis	16
482	WBC at diagnosis	3.5
482	Sex	M
482	Genetically-defined race	White
482	Asparaginase (IU/ml)	0
482	Bortezomib (nM)	0
482	CHZ868 (nM)	0
482	Cytarabine (µM)	0
482	Dasatinib (nM)	0
482	Daunorubicin (µM)	0
482	Dexamethasone  (µM)	0.02375364
482	Ibrutinib (µM)	0
482	Mercaptopurine (µM)	2314.178
482	Nelarabine (µM)	0
482	Panobinostat (nM)	0
482	Prednisolone (µM)	0.0075
482	Ruxolitinib (nM)	0
482	Thioguanine (µM)	37.23419
482	Trametinib (nM)	0
482	Venetoclax (nM)	0
482	Vincristine (µM)	0
482	Vorinostat (nM)	0
482	dexamethasone_normalized	0.4052
482	mercaptopurine_normalized	0.9311
482	prednisolone_normalized	0
482	thioguanine_normalized	0.3988
483	immunophenotype	B
483	molecular subtype	Hyperdiploid
483	Protocol	T16
483	NCI risk	SR
483	Age at diagnosis	2.9
483	WBC at diagnosis	4.4
483	Sex	F
483	Genetically-defined race	White
483	Asparaginase (IU/ml)	0.0016
483	Bortezomib (nM)	0
483	CHZ868 (nM)	0
483	Cytarabine (µM)	3.730954
483	Dasatinib (nM)	0
483	Daunorubicin (µM)	0
483	Dexamethasone  (µM)	0.1816926
483	Ibrutinib (µM)	0
483	Mercaptopurine (µM)	206.6854
483	Nelarabine (µM)	0
483	Panobinostat (nM)	0
483	Prednisolone (µM)	0.1048683
483	Ruxolitinib (nM)	0
483	Thioguanine (µM)	16.09172
483	Trametinib (nM)	0
483	Venetoclax (nM)	0
483	Vincristine (µM)	0.025
483	Vorinostat (nM)	0
483	asparagise_normalized	0
483	cytarabine_normalized	0.654
483	dexamethasone_normalized	0.6007
483	mercaptopurine_normalized	0.2342
483	prednisolone_normalized	0.1866
483	thioguanine_normalized	0.1567
483	vincristine_normalized	0
484	immunophenotype	T
484	molecular subtype	T-ALL
484	Protocol	T16
484	NCI risk	HR
484	Age at diagnosis	12
484	WBC at diagnosis	18
484	Sex	M
484	Genetically-defined race	White
484	Asparaginase (IU/ml)	0
484	Bortezomib (nM)	0
484	CHZ868 (nM)	0
484	Cytarabine (µM)	0.2256369
484	Dasatinib (nM)	0
484	Daunorubicin (µM)	1.227509
484	Dexamethasone  (µM)	10.83222
484	Ibrutinib (µM)	0
484	Mercaptopurine (µM)	0
484	Nelarabine (µM)	0
484	Panobinostat (nM)	0
484	Prednisolone (µM)	0
484	Ruxolitinib (nM)	0
484	Thioguanine (µM)	0
484	Trametinib (nM)	0
484	Venetoclax (nM)	0
484	Vincristine (µM)	108.34
484	Vorinostat (nM)	0
484	cytarabine_normalized	0.2495
484	daunorubicin_normalized	0.8499
484	dexamethasone_normalized	0.9934
484	vincristine_normalized	1
485	immunophenotype	B
485	molecular subtype	Hyperdiploid
485	Protocol	T16
485	NCI risk	SR
485	Age at diagnosis	5.4
485	WBC at diagnosis	3.3
485	Sex	F
485	Genetically-defined race	White
485	Asparaginase (IU/ml)	20
485	Bortezomib (nM)	0
485	CHZ868 (nM)	0
485	Cytarabine (µM)	0.6162863
485	Dasatinib (nM)	0
485	Daunorubicin (µM)	0
485	Dexamethasone  (µM)	23.2
485	Ibrutinib (µM)	0
485	Mercaptopurine (µM)	957.356
485	Nelarabine (µM)	0
485	Panobinostat (nM)	0
485	Prednisolone (µM)	365.6389536
485	Ruxolitinib (nM)	0
485	Thioguanine (µM)	34.67876
485	Trametinib (nM)	0
485	Venetoclax (nM)	0
485	Vincristine (µM)	0.2875735
485	Vorinostat (nM)	0
485	asparagise_normalized	1
485	cytarabine_normalized	0.3944
485	dexamethasone_normalized	1
485	mercaptopurine_normalized	0.6765
485	prednisolone_normalized	0.9694
485	thioguanine_normalized	0.3783
485	vincristine_normalized	0.2504
486	immunophenotype	B
486	molecular subtype	BCR-ABL1
486	Protocol	T16
486	NCI risk	HR
486	Age at diagnosis	15.9
486	WBC at diagnosis	181.3
486	Sex	F
486	Genetically-defined race	Asian/Other
486	Asparaginase (IU/ml)	0.3571349
486	Bortezomib (nM)	0
486	CHZ868 (nM)	0
486	Cytarabine (µM)	0.08117136
486	Dasatinib (nM)	0
486	Daunorubicin (µM)	0
486	Dexamethasone  (µM)	0
486	Ibrutinib (µM)	0
486	Mercaptopurine (µM)	0
486	Nelarabine (µM)	0
486	Panobinostat (nM)	0
486	Prednisolone (µM)	0.0075
486	Ruxolitinib (nM)	0
486	Thioguanine (µM)	4.675
486	Trametinib (nM)	0
486	Venetoclax (nM)	0
486	Vincristine (µM)	0.025
486	Vorinostat (nM)	0
486	asparagise_normalized	0.5859
486	cytarabine_normalized	0.102
486	prednisolone_normalized	0
486	thioguanine_normalized	0
486	vincristine_normalized	0
487	immunophenotype	B
487	molecular subtype	DUX4
487	Protocol	T16
487	NCI risk	HR
487	Age at diagnosis	14.5
487	WBC at diagnosis	29.7
487	Sex	M
487	Genetically-defined race	White
487	Asparaginase (IU/ml)	0.3401521
487	Bortezomib (nM)	0
487	CHZ868 (nM)	0
487	Cytarabine (µM)	0.1581696
487	Dasatinib (nM)	0
487	Daunorubicin (µM)	0
487	Dexamethasone  (µM)	0.01809234
487	Ibrutinib (µM)	0
487	Mercaptopurine (µM)	170.0349852
487	Nelarabine (µM)	0
487	Panobinostat (nM)	0
487	Prednisolone (µM)	0.0075
487	Ruxolitinib (nM)	0
487	Thioguanine (µM)	10.74608
487	Trametinib (nM)	0
487	Venetoclax (nM)	0
487	Vincristine (µM)	0.025
487	Vorinostat (nM)	0
487	asparagise_normalized	0.5799
487	cytarabine_normalized	0.1982
487	dexamethasone_normalized	0.379
487	mercaptopurine_normalized	0.1778
487	prednisolone_normalized	0
487	thioguanine_normalized	0.0402
487	vincristine_normalized	0
488	immunophenotype	B
488	molecular subtype	Hyperdiploid
488	Protocol	T16
488	NCI risk	SR
488	Age at diagnosis	3.1
488	WBC at diagnosis	16.7
488	Sex	F
488	Genetically-defined race	White
488	Asparaginase (IU/ml)	0
488	Bortezomib (nM)	0
488	CHZ868 (nM)	0
488	Cytarabine (µM)	82.2
488	Dasatinib (nM)	0
488	Daunorubicin (µM)	0
488	Dexamethasone  (µM)	23.2
488	Ibrutinib (µM)	0
488	Mercaptopurine (µM)	0
488	Nelarabine (µM)	0
488	Panobinostat (nM)	0
488	Prednisolone (µM)	1006
488	Ruxolitinib (nM)	0
488	Thioguanine (µM)	0
488	Trametinib (nM)	0
488	Venetoclax (nM)	0
488	Vincristine (µM)	0
488	Vorinostat (nM)	0
488	cytarabine_normalized	1
488	dexamethasone_normalized	1
488	prednisolone_normalized	1
489	immunophenotype	B
489	molecular subtype	ETV6-RUNX1
489	Protocol	T16
489	NCI risk	SR
489	Age at diagnosis	4.6
489	WBC at diagnosis	3.9
489	Sex	M
489	Genetically-defined race	White
489	Asparaginase (IU/ml)	0.0016
489	Bortezomib (nM)	0
489	CHZ868 (nM)	0
489	Cytarabine (µM)	12.53421
489	Dasatinib (nM)	0
489	Daunorubicin (µM)	0
489	Dexamethasone  (µM)	0.670983972
489	Ibrutinib (µM)	0
489	Mercaptopurine (µM)	5876
489	Nelarabine (µM)	0
489	Panobinostat (nM)	0
489	Prednisolone (µM)	0.1028904
489	Ruxolitinib (nM)	0
489	Thioguanine (µM)	598
489	Trametinib (nM)	0
489	Venetoclax (nM)	0
489	Vincristine (µM)	34.45408
489	Vorinostat (nM)	0
489	asparagise_normalized	0
489	cytarabine_normalized	0.8288
489	dexamethasone_normalized	0.7262
489	mercaptopurine_normalized	1
489	prednisolone_normalized	0.1848
489	thioguanine_normalized	1
489	vincristine_normalized	0.9352
490	immunophenotype	B
490	molecular subtype	ETV6-RUNX1
490	Protocol	T16
490	NCI risk	SR
490	Age at diagnosis	8.9
490	WBC at diagnosis	12.5
490	Sex	M
490	Genetically-defined race	White
490	Asparaginase (IU/ml)	0
490	Bortezomib (nM)	0
490	CHZ868 (nM)	0
490	Cytarabine (µM)	0.9443621
490	Dasatinib (nM)	0
490	Daunorubicin (µM)	0
490	Dexamethasone  (µM)	0.09402142
490	Ibrutinib (µM)	0
490	Mercaptopurine (µM)	150.3956
490	Nelarabine (µM)	0
490	Panobinostat (nM)	0
490	Prednisolone (µM)	0.06025895
490	Ruxolitinib (nM)	0
490	Thioguanine (µM)	4.675
490	Trametinib (nM)	0
490	Venetoclax (nM)	0
490	Vincristine (µM)	0.1864178
490	Vorinostat (nM)	0
490	cytarabine_normalized	0.4559
490	dexamethasone_normalized	0.5374
490	mercaptopurine_normalized	0.1424
490	prednisolone_normalized	0.1335
490	thioguanine_normalized	0
490	vincristine_normalized	0.1883
491	immunophenotype	T
491	molecular subtype	T-ALL
491	Protocol	T16
491	NCI risk	HR
491	Age at diagnosis	4.4
491	WBC at diagnosis	197.7
491	Sex	F
491	Genetically-defined race	White
491	Asparaginase (IU/ml)	0
491	Bortezomib (nM)	0
491	CHZ868 (nM)	0
491	Cytarabine (µM)	0.02
491	Dasatinib (nM)	0
491	Daunorubicin (µM)	0.04953678
491	Dexamethasone  (µM)	0
491	Ibrutinib (µM)	0
491	Mercaptopurine (µM)	45.9
491	Nelarabine (µM)	0
491	Panobinostat (nM)	0
491	Prednisolone (µM)	4.977195
491	Ruxolitinib (nM)	0
491	Thioguanine (µM)	0
491	Trametinib (nM)	0
491	Venetoclax (nM)	0
491	Vincristine (µM)	0.1715004
491	Vorinostat (nM)	0
491	cytarabine_normalized	0
491	daunorubicin_normalized	0.3963
491	mercaptopurine_normalized	0
491	prednisolone_normalized	0.557
491	vincristine_normalized	0.1764
492	immunophenotype	B
492	molecular subtype	ETV6-RUNX1
492	Protocol	T16
492	NCI risk	SR
492	Age at diagnosis	3.8
492	WBC at diagnosis	30.9
492	Sex	M
492	Genetically-defined race	White
492	Asparaginase (IU/ml)	0.0016
492	Bortezomib (nM)	0
492	CHZ868 (nM)	0
492	Cytarabine (µM)	1.251033
492	Dasatinib (nM)	0
492	Daunorubicin (µM)	0
492	Dexamethasone  (µM)	0.4404942
492	Ibrutinib (µM)	0
492	Mercaptopurine (µM)	45.9
492	Nelarabine (µM)	0
492	Panobinostat (nM)	0
492	Prednisolone (µM)	0.04727305
492	Ruxolitinib (nM)	0
492	Thioguanine (µM)	4.675
492	Trametinib (nM)	0
492	Venetoclax (nM)	0
492	Vincristine (µM)	51.82893
492	Vorinostat (nM)	0
492	asparagise_normalized	0
492	cytarabine_normalized	0.4965
492	dexamethasone_normalized	0.6858
492	mercaptopurine_normalized	0
492	prednisolone_normalized	0.1102
492	thioguanine_normalized	0
492	vincristine_normalized	0.9937
493	immunophenotype	T
493	molecular subtype	T-ALL
493	Protocol	T16
493	NCI risk	HR
493	Age at diagnosis	7.5
493	WBC at diagnosis	72.6
493	Sex	M
493	Genetically-defined race	Asian/Other
493	Asparaginase (IU/ml)	20
493	Bortezomib (nM)	0
493	CHZ868 (nM)	0
493	Cytarabine (µM)	20.23284138
493	Dasatinib (nM)	0
493	Daunorubicin (µM)	0.445289317
493	Dexamethasone  (µM)	23.2
493	Ibrutinib (µM)	0
493	Mercaptopurine (µM)	5876
493	Nelarabine (µM)	0
493	Panobinostat (nM)	0
493	Prednisolone (µM)	1006
493	Ruxolitinib (nM)	0
493	Thioguanine (µM)	0
493	Trametinib (nM)	0
493	Venetoclax (nM)	0
493	Vincristine (µM)	3.205845
493	Vorinostat (nM)	0
493	asparagise_normalized	1
493	cytarabine_normalized	0.8978
493	daunorubicin_normalized	0.7066
493	dexamethasone_normalized	1
493	mercaptopurine_normalized	1
493	prednisolone_normalized	1
493	vincristine_normalized	0.5954
494	immunophenotype	B
494	molecular subtype	DUX4
494	Protocol	T16
494	NCI risk	SR
494	Age at diagnosis	8.8
494	WBC at diagnosis	5.9
494	Sex	F
494	Genetically-defined race	White
494	Asparaginase (IU/ml)	20
494	Bortezomib (nM)	0
494	CHZ868 (nM)	0
494	Cytarabine (µM)	0
494	Dasatinib (nM)	0
494	Daunorubicin (µM)	0
494	Dexamethasone  (µM)	0
494	Ibrutinib (µM)	0
494	Mercaptopurine (µM)	0
494	Nelarabine (µM)	0
494	Panobinostat (nM)	0
494	Prednisolone (µM)	1006
494	Ruxolitinib (nM)	0
494	Thioguanine (µM)	598
494	Trametinib (nM)	0
494	Venetoclax (nM)	0
494	Vincristine (µM)	108.34
494	Vorinostat (nM)	0
494	asparagise_normalized	1
494	prednisolone_normalized	1
494	thioguanine_normalized	1
494	vincristine_normalized	1
495	immunophenotype	B
495	molecular subtype	PAX5alt
495	Protocol	T16
495	NCI risk	SR
495	Age at diagnosis	7.9
495	WBC at diagnosis	9.5
495	Sex	M
495	Genetically-defined race	White
495	Asparaginase (IU/ml)	0.0016
495	Bortezomib (nM)	0
495	CHZ868 (nM)	0
495	Cytarabine (µM)	3.878351
495	Dasatinib (nM)	0
495	Daunorubicin (µM)	0
495	Dexamethasone  (µM)	0.08340437
495	Ibrutinib (µM)	0
495	Mercaptopurine (µM)	180.9801
495	Nelarabine (µM)	0
495	Panobinostat (nM)	0
495	Prednisolone (µM)	0.0229625
495	Ruxolitinib (nM)	0
495	Thioguanine (µM)	14.9143
495	Trametinib (nM)	0
495	Venetoclax (nM)	0
495	Vincristine (µM)	0
495	Vorinostat (nM)	0
495	asparagise_normalized	0
495	cytarabine_normalized	0.6596
495	dexamethasone_normalized	0.5259
495	mercaptopurine_normalized	0.1958
495	prednisolone_normalized	0.0409
495	thioguanine_normalized	0.1348
496	immunophenotype	B
496	molecular subtype	ETV6-RUNX1
496	Protocol	T16
496	NCI risk	SR
496	Age at diagnosis	4.1
496	WBC at diagnosis	24.3
496	Sex	F
496	Genetically-defined race	White
496	Asparaginase (IU/ml)	0
496	Bortezomib (nM)	0
496	CHZ868 (nM)	0
496	Cytarabine (µM)	82.2
496	Dasatinib (nM)	0
496	Daunorubicin (µM)	0
496	Dexamethasone  (µM)	0.02124655
496	Ibrutinib (µM)	0
496	Mercaptopurine (µM)	108.9452
496	Nelarabine (µM)	0
496	Panobinostat (nM)	0
496	Prednisolone (µM)	0.06872794
496	Ruxolitinib (nM)	0
496	Thioguanine (µM)	13.462
496	Trametinib (nM)	0
496	Venetoclax (nM)	0
496	Vincristine (µM)	0
496	Vorinostat (nM)	0
496	cytarabine_normalized	1
496	dexamethasone_normalized	0.3945
496	mercaptopurine_normalized	0.0494
496	prednisolone_normalized	0.1461
496	thioguanine_normalized	0.1052
497	immunophenotype	B
497	molecular subtype	ETV6-RUNX1
497	Protocol	T16
497	NCI risk	SR
497	Age at diagnosis	3.9
497	WBC at diagnosis	15.4
497	Sex	M
497	Genetically-defined race	White
497	Asparaginase (IU/ml)	0.0016
497	Bortezomib (nM)	0
497	CHZ868 (nM)	0
497	Cytarabine (µM)	4.385008
497	Dasatinib (nM)	0
497	Daunorubicin (µM)	0
497	Dexamethasone  (µM)	0.3389667
497	Ibrutinib (µM)	0
497	Mercaptopurine (µM)	1533.572112
497	Nelarabine (µM)	0
497	Panobinostat (nM)	0
497	Prednisolone (µM)	0.1278671
497	Ruxolitinib (nM)	0
497	Thioguanine (µM)	33.91381065
497	Trametinib (nM)	0
497	Venetoclax (nM)	0
497	Vincristine (µM)	13.29277
497	Vorinostat (nM)	0
497	asparagise_normalized	0
497	cytarabine_normalized	0.6773
497	dexamethasone_normalized	0.6606
497	mercaptopurine_normalized	0.8124
497	prednisolone_normalized	0.2057
497	thioguanine_normalized	0.3718
497	vincristine_normalized	0.799
498	immunophenotype	B
498	molecular subtype	PAX5alt
498	Protocol	T16
498	NCI risk	HR
498	Age at diagnosis	2
498	WBC at diagnosis	96.9
498	Sex	F
498	Genetically-defined race	White
498	Asparaginase (IU/ml)	20
498	Bortezomib (nM)	0
498	CHZ868 (nM)	0
498	Cytarabine (µM)	0.3263627
498	Dasatinib (nM)	0
498	Daunorubicin (µM)	0
498	Dexamethasone  (µM)	0.02082694
498	Ibrutinib (µM)	0
498	Mercaptopurine (µM)	0
498	Nelarabine (µM)	0
498	Panobinostat (nM)	0
498	Prednisolone (µM)	0
498	Ruxolitinib (nM)	0
498	Thioguanine (µM)	0
498	Trametinib (nM)	0
498	Venetoclax (nM)	0
498	Vincristine (µM)	0
498	Vorinostat (nM)	0
498	asparagise_normalized	1
498	cytarabine_normalized	0.3027
498	dexamethasone_normalized	0.3926
499	immunophenotype	B
499	molecular subtype	ETV6-RUNX1
499	Protocol	T16
499	NCI risk	SR
499	Age at diagnosis	4.4
499	WBC at diagnosis	3.1
499	Sex	M
499	Genetically-defined race	White
499	Asparaginase (IU/ml)	0.0016
499	Bortezomib (nM)	0
499	CHZ868 (nM)	0
499	Cytarabine (µM)	2.931234
499	Dasatinib (nM)	0
499	Daunorubicin (µM)	0
499	Dexamethasone  (µM)	0.00551946
499	Ibrutinib (µM)	0
499	Mercaptopurine (µM)	0
499	Nelarabine (µM)	0
499	Panobinostat (nM)	0
499	Prednisolone (µM)	1006
499	Ruxolitinib (nM)	0
499	Thioguanine (µM)	107.3138
499	Trametinib (nM)	0
499	Venetoclax (nM)	0
499	Vincristine (µM)	0.8359909
499	Vorinostat (nM)	0
499	asparagise_normalized	0
499	cytarabine_normalized	0.6192
499	dexamethasone_normalized	0.265
499	prednisolone_normalized	1
499	thioguanine_normalized	0.7043
499	vincristine_normalized	0.4031
500	immunophenotype	B
500	molecular subtype	Hyperdiploid
500	Protocol	T16
500	NCI risk	SR
500	Age at diagnosis	3.2
500	WBC at diagnosis	7
500	Sex	M
500	Genetically-defined race	Hispanic
500	Asparaginase (IU/ml)	0.03197369
500	Bortezomib (nM)	0
500	CHZ868 (nM)	0
500	Cytarabine (µM)	3.698573
500	Dasatinib (nM)	0
500	Daunorubicin (µM)	0
500	Dexamethasone  (µM)	0.6081097
500	Ibrutinib (µM)	0
500	Mercaptopurine (µM)	0
500	Nelarabine (µM)	0
500	Panobinostat (nM)	0
500	Prednisolone (µM)	0
500	Ruxolitinib (nM)	0
500	Thioguanine (µM)	31.60833
500	Trametinib (nM)	0
500	Venetoclax (nM)	0
500	Vincristine (µM)	0
500	Vorinostat (nM)	0
500	asparagise_normalized	0.286
500	cytarabine_normalized	0.6528
500	dexamethasone_normalized	0.7167
500	thioguanine_normalized	0.3515
501	immunophenotype	T
501	molecular subtype	T-ALL
501	Protocol	T16
501	NCI risk	HR
501	Age at diagnosis	18.6
501	WBC at diagnosis	59.1
501	Sex	M
501	Genetically-defined race	White
501	Asparaginase (IU/ml)	0.3612153
501	Bortezomib (nM)	0
501	CHZ868 (nM)	0
501	Cytarabine (µM)	0.2299979
501	Dasatinib (nM)	0
501	Daunorubicin (µM)	0.2114643
501	Dexamethasone  (µM)	0.000449558
501	Ibrutinib (µM)	0
501	Mercaptopurine (µM)	96.97221
501	Nelarabine (µM)	0
501	Panobinostat (nM)	0
501	Prednisolone (µM)	0.08811619
501	Ruxolitinib (nM)	0
501	Thioguanine (µM)	4.675
501	Trametinib (nM)	0
501	Venetoclax (nM)	0
501	Vincristine (µM)	8.674714358
501	Vorinostat (nM)	0
501	asparagise_normalized	0.5873
501	cytarabine_normalized	0.2522
501	daunorubicin_normalized	0.6014
501	dexamethasone_normalized	0.0241
501	mercaptopurine_normalized	0.0158
501	prednisolone_normalized	0.1699
501	thioguanine_normalized	0
501	vincristine_normalized	0.7379
502	immunophenotype	T
502	molecular subtype	ETP
502	Protocol	T16
502	NCI risk	HR
502	Age at diagnosis	8.5
502	WBC at diagnosis	345.6
502	Sex	F
502	Genetically-defined race	White
502	Asparaginase (IU/ml)	20
502	Bortezomib (nM)	0
502	CHZ868 (nM)	0
502	Cytarabine (µM)	0
502	Dasatinib (nM)	0
502	Daunorubicin (µM)	7.1
502	Dexamethasone  (µM)	0
502	Ibrutinib (µM)	0
502	Mercaptopurine (µM)	5876
502	Nelarabine (µM)	0
502	Panobinostat (nM)	0
502	Prednisolone (µM)	1006
502	Ruxolitinib (nM)	0
502	Thioguanine (µM)	598
502	Trametinib (nM)	0
502	Venetoclax (nM)	0
502	Vincristine (µM)	108.34
502	Vorinostat (nM)	0
502	asparagise_normalized	1
502	daunorubicin_normalized	1
502	mercaptopurine_normalized	1
502	prednisolone_normalized	1
502	thioguanine_normalized	1
502	vincristine_normalized	1
503	immunophenotype	B
503	molecular subtype	TCF3-PBX1
503	Protocol	T16
503	NCI risk	HR
503	Age at diagnosis	13.7
503	WBC at diagnosis	9.6
503	Sex	M
503	Genetically-defined race	black
503	Asparaginase (IU/ml)	0
503	Bortezomib (nM)	0
503	CHZ868 (nM)	0
503	Cytarabine (µM)	0
503	Dasatinib (nM)	0
503	Daunorubicin (µM)	0
503	Dexamethasone  (µM)	0.02883099
503	Ibrutinib (µM)	0
503	Mercaptopurine (µM)	139.2043
503	Nelarabine (µM)	0
503	Panobinostat (nM)	0
503	Prednisolone (µM)	0
503	Ruxolitinib (nM)	0
503	Thioguanine (µM)	4.675
503	Trametinib (nM)	0
503	Venetoclax (nM)	0
503	Vincristine (µM)	0
503	Vorinostat (nM)	0
503	dexamethasone_normalized	0.4238
503	mercaptopurine_normalized	0.1201
503	thioguanine_normalized	0
504	immunophenotype	B
504	molecular subtype	NUTM1
504	Protocol	T16
504	NCI risk	HR
504	Age at diagnosis	0.8
504	WBC at diagnosis	17.2
504	Sex	M
504	Genetically-defined race	Hispanic
504	Asparaginase (IU/ml)	0.4522501
504	Bortezomib (nM)	0
504	CHZ868 (nM)	0
504	Cytarabine (µM)	0.4544683
504	Dasatinib (nM)	0
504	Daunorubicin (µM)	0
504	Dexamethasone  (µM)	0.03520354
504	Ibrutinib (µM)	0
504	Mercaptopurine (µM)	157.6241
504	Nelarabine (µM)	0
504	Panobinostat (nM)	0
504	Prednisolone (µM)	0.0075
504	Ruxolitinib (nM)	0
504	Thioguanine (µM)	4.675
504	Trametinib (nM)	0
504	Venetoclax (nM)	0
504	Vincristine (µM)	0.06785989
504	Vorinostat (nM)	0
504	asparagise_normalized	0.6153
504	cytarabine_normalized	0.3504
504	dexamethasone_normalized	0.443
504	mercaptopurine_normalized	0.156
504	prednisolone_normalized	0
504	thioguanine_normalized	0
504	vincristine_normalized	0.0437
505	immunophenotype	B
505	molecular subtype	Hyperdiploid
505	Protocol	T16
505	NCI risk	SR
505	Age at diagnosis	4.2
505	WBC at diagnosis	20.5
505	Sex	M
505	Genetically-defined race	Asian/Other
505	Asparaginase (IU/ml)	0.0016
505	Bortezomib (nM)	0
505	CHZ868 (nM)	0
505	Cytarabine (µM)	5.012822
505	Dasatinib (nM)	0
505	Daunorubicin (µM)	0
505	Dexamethasone  (µM)	0
505	Ibrutinib (µM)	0
505	Mercaptopurine (µM)	1832.311
505	Nelarabine (µM)	0
505	Panobinostat (nM)	0
505	Prednisolone (µM)	1006
505	Ruxolitinib (nM)	0
505	Thioguanine (µM)	51.70081
505	Trametinib (nM)	0
505	Venetoclax (nM)	0
505	Vincristine (µM)	20.13418
505	Vorinostat (nM)	0
505	asparagise_normalized	0
505	cytarabine_normalized	0.6966
505	mercaptopurine_normalized	0.8638
505	prednisolone_normalized	1
505	thioguanine_normalized	0.4935
505	vincristine_normalized	0.8584
506	immunophenotype	B
506	molecular subtype	ETV6-RUNX1
506	Protocol	T16
506	NCI risk	SR
506	Age at diagnosis	3.6
506	WBC at diagnosis	4.3
506	Sex	F
506	Genetically-defined race	White
506	Asparaginase (IU/ml)	0.0016
506	Bortezomib (nM)	0
506	CHZ868 (nM)	0
506	Cytarabine (µM)	5.394464
506	Dasatinib (nM)	0
506	Daunorubicin (µM)	0
506	Dexamethasone  (µM)	0
506	Ibrutinib (µM)	0
506	Mercaptopurine (µM)	367.0074729
506	Nelarabine (µM)	0
506	Panobinostat (nM)	0
506	Prednisolone (µM)	0.0075
506	Ruxolitinib (nM)	0
506	Thioguanine (µM)	0
506	Trametinib (nM)	0
506	Venetoclax (nM)	0
506	Vincristine (µM)	0.08849094
506	Vorinostat (nM)	0
506	asparagise_normalized	0
506	cytarabine_normalized	0.7072
506	mercaptopurine_normalized	0.3998
506	prednisolone_normalized	0
506	vincristine_normalized	0.0817
507	immunophenotype	B
507	molecular subtype	Hyperdiploid
507	Protocol	T16
507	NCI risk	SR
507	Age at diagnosis	2.3
507	WBC at diagnosis	7
507	Sex	M
507	Genetically-defined race	black
507	Asparaginase (IU/ml)	20
507	Bortezomib (nM)	0
507	CHZ868 (nM)	0
507	Cytarabine (µM)	82.2
507	Dasatinib (nM)	0
507	Daunorubicin (µM)	0
507	Dexamethasone  (µM)	23.2
507	Ibrutinib (µM)	0
507	Mercaptopurine (µM)	5876
507	Nelarabine (µM)	0
507	Panobinostat (nM)	0
507	Prednisolone (µM)	1006
507	Ruxolitinib (nM)	0
507	Thioguanine (µM)	598
507	Trametinib (nM)	0
507	Venetoclax (nM)	0
507	Vincristine (µM)	108.34
507	Vorinostat (nM)	0
507	asparagise_normalized	1
507	cytarabine_normalized	1
507	dexamethasone_normalized	1
507	mercaptopurine_normalized	1
507	prednisolone_normalized	1
507	thioguanine_normalized	1
507	vincristine_normalized	1
508	immunophenotype	B
508	molecular subtype	PAX5alt
508	Protocol	T16
508	NCI risk	SR
508	Age at diagnosis	2.7
508	WBC at diagnosis	38.7
508	Sex	F
508	Genetically-defined race	Asian/Other
508	Asparaginase (IU/ml)	20
508	Bortezomib (nM)	0
508	CHZ868 (nM)	0
508	Cytarabine (µM)	0
508	Dasatinib (nM)	0
508	Daunorubicin (µM)	0
508	Dexamethasone  (µM)	23.2
508	Ibrutinib (µM)	0
508	Mercaptopurine (µM)	5876
508	Nelarabine (µM)	0
508	Panobinostat (nM)	0
508	Prednisolone (µM)	1006
508	Ruxolitinib (nM)	0
508	Thioguanine (µM)	598
508	Trametinib (nM)	0
508	Venetoclax (nM)	0
508	Vincristine (µM)	108.34
508	Vorinostat (nM)	0
508	asparagise_normalized	1
508	dexamethasone_normalized	1
508	mercaptopurine_normalized	1
508	prednisolone_normalized	1
508	thioguanine_normalized	1
508	vincristine_normalized	1
509	immunophenotype	B
509	molecular subtype	ETV6-RUNX1
509	Protocol	T16
509	NCI risk	SR
509	Age at diagnosis	5.2
509	WBC at diagnosis	3.7
509	Sex	F
509	Genetically-defined race	black
509	Asparaginase (IU/ml)	0
509	Bortezomib (nM)	0
509	CHZ868 (nM)	0
509	Cytarabine (µM)	0
509	Dasatinib (nM)	0
509	Daunorubicin (µM)	0
509	Dexamethasone  (µM)	0.02380261
509	Ibrutinib (µM)	0
509	Mercaptopurine (µM)	216.4514
509	Nelarabine (µM)	0
509	Panobinostat (nM)	0
509	Prednisolone (µM)	0.0075
509	Ruxolitinib (nM)	0
509	Thioguanine (µM)	26.83033
509	Trametinib (nM)	0
509	Venetoclax (nM)	0
509	Vincristine (µM)	108.34
509	Vorinostat (nM)	0
509	dexamethasone_normalized	0.4054
509	mercaptopurine_normalized	0.2475
509	prednisolone_normalized	0
509	thioguanine_normalized	0.3042
509	vincristine_normalized	1
510	immunophenotype	B
510	molecular subtype	KMT2A
510	Protocol	T15
510	NCI risk	HR
510	Age at diagnosis	15.6
510	WBC at diagnosis	57.4
510	Sex	M
510	Genetically-defined race	Hispanic
510	Asparaginase (IU/ml)	20
510	Bortezomib (nM)	0
510	CHZ868 (nM)	0
510	Cytarabine (µM)	1.565622
510	Dasatinib (nM)	0
510	Daunorubicin (µM)	0
510	Dexamethasone  (µM)	23.2
510	Ibrutinib (µM)	0
510	Mercaptopurine (µM)	1037.471
510	Nelarabine (µM)	0
510	Panobinostat (nM)	0
510	Prednisolone (µM)	3.516532
510	Ruxolitinib (nM)	0
510	Thioguanine (µM)	0
510	Trametinib (nM)	0
510	Venetoclax (nM)	0
510	Vincristine (µM)	10.87565
510	Vorinostat (nM)	0
510	asparagise_normalized	1
510	cytarabine_normalized	0.5288
510	dexamethasone_normalized	1
510	mercaptopurine_normalized	0.6997
510	prednisolone_normalized	0.5237
510	vincristine_normalized	0.7702
511	immunophenotype	B
511	molecular subtype	PAX5alt
511	Protocol	T16
511	NCI risk	HR
511	Age at diagnosis	7.3
511	WBC at diagnosis	54.1
511	Sex	M
511	Genetically-defined race	White
511	Asparaginase (IU/ml)	0
511	Bortezomib (nM)	0
511	CHZ868 (nM)	0
511	Cytarabine (µM)	2.404293
511	Dasatinib (nM)	0
511	Daunorubicin (µM)	0
511	Dexamethasone  (µM)	0.378339711
511	Ibrutinib (µM)	0
511	Mercaptopurine (µM)	0
511	Nelarabine (µM)	0
511	Panobinostat (nM)	0
511	Prednisolone (µM)	0.3441951
511	Ruxolitinib (nM)	0
511	Thioguanine (µM)	0
511	Trametinib (nM)	0
511	Venetoclax (nM)	0
511	Vincristine (µM)	108.34
511	Vorinostat (nM)	0
511	cytarabine_normalized	0.5907
511	dexamethasone_normalized	0.6711
511	prednisolone_normalized	0.3007
511	vincristine_normalized	1
512	immunophenotype	B
512	molecular subtype	ETV6-RUNX1
512	Protocol	T16
512	NCI risk	SR
512	Age at diagnosis	3.1
512	WBC at diagnosis	2.5
512	Sex	M
512	Genetically-defined race	White
512	Asparaginase (IU/ml)	0.3956621
512	Bortezomib (nM)	0
512	CHZ868 (nM)	0
512	Cytarabine (µM)	0
512	Dasatinib (nM)	0
512	Daunorubicin (µM)	0
512	Dexamethasone  (µM)	0.3569084
512	Ibrutinib (µM)	0
512	Mercaptopurine (µM)	315.0998
512	Nelarabine (µM)	0
512	Panobinostat (nM)	0
512	Prednisolone (µM)	0.09903709
512	Ruxolitinib (nM)	0
512	Thioguanine (µM)	22.43658
512	Trametinib (nM)	0
512	Venetoclax (nM)	0
512	Vincristine (µM)	3.917436
512	Vorinostat (nM)	0
512	asparagise_normalized	0.5986
512	dexamethasone_normalized	0.6655
512	mercaptopurine_normalized	0.3558
512	prednisolone_normalized	0.1811
512	thioguanine_normalized	0.2526
512	vincristine_normalized	0.6241
513	immunophenotype	B
513	molecular subtype	ETV6-RUNX1
513	Protocol	T16
513	NCI risk	HR
513	Age at diagnosis	16.7
513	WBC at diagnosis	1.4
513	Sex	F
513	Genetically-defined race	Hispanic
513	Asparaginase (IU/ml)	0.0016
513	Bortezomib (nM)	0
513	CHZ868 (nM)	0
513	Cytarabine (µM)	24.85494
513	Dasatinib (nM)	0
513	Daunorubicin (µM)	0
513	Dexamethasone  (µM)	0.09583833
513	Ibrutinib (µM)	0
513	Mercaptopurine (µM)	128.3184
513	Nelarabine (µM)	0
513	Panobinostat (nM)	0
513	Prednisolone (µM)	0.0075
513	Ruxolitinib (nM)	0
513	Thioguanine (µM)	15.42568
513	Trametinib (nM)	0
513	Venetoclax (nM)	0
513	Vincristine (µM)	0.2456178
513	Vorinostat (nM)	0
513	asparagise_normalized	0
513	cytarabine_normalized	0.9275
513	dexamethasone_normalized	0.5392
513	mercaptopurine_normalized	0.0966
513	prednisolone_normalized	0
513	thioguanine_normalized	0.1445
513	vincristine_normalized	0.2278
514	immunophenotype	T
514	molecular subtype	T-ALL
514	Protocol	T16
514	NCI risk	HR
514	Age at diagnosis	7.8
514	WBC at diagnosis	256.5
514	Sex	F
514	Genetically-defined race	White
514	Asparaginase (IU/ml)	0.016950955
514	Bortezomib (nM)	0
514	CHZ868 (nM)	0
514	Cytarabine (µM)	2.4511
514	Dasatinib (nM)	0
514	Daunorubicin (µM)	0.01032782
514	Dexamethasone  (µM)	3.394159
514	Ibrutinib (µM)	0
514	Mercaptopurine (µM)	45.9
514	Nelarabine (µM)	0
514	Panobinostat (nM)	0
514	Prednisolone (µM)	0.1220483
514	Ruxolitinib (nM)	0
514	Thioguanine (µM)	4.675
514	Trametinib (nM)	0
514	Venetoclax (nM)	0
514	Vincristine (µM)	0.7024267
514	Vorinostat (nM)	0
514	asparagise_normalized	0.2072
514	cytarabine_normalized	0.5934
514	daunorubicin_normalized	0.1747
514	dexamethasone_normalized	0.8819
514	mercaptopurine_normalized	0
514	prednisolone_normalized	0.2012
514	thioguanine_normalized	0
514	vincristine_normalized	0.3782
515	immunophenotype	T
515	molecular subtype	T-ALL
515	Protocol	T16
515	NCI risk	HR
515	Age at diagnosis	5.4
515	WBC at diagnosis	261
515	Sex	M
515	Genetically-defined race	White
515	Asparaginase (IU/ml)	0.004274517
515	Bortezomib (nM)	0
515	CHZ868 (nM)	0
515	Cytarabine (µM)	0.02
515	Dasatinib (nM)	0
515	Daunorubicin (µM)	0.09686187
515	Dexamethasone  (µM)	0.02561162
515	Ibrutinib (µM)	0
515	Mercaptopurine (µM)	5876
515	Nelarabine (µM)	0
515	Panobinostat (nM)	0
515	Prednisolone (µM)	0.01744958
515	Ruxolitinib (nM)	0
515	Thioguanine (µM)	4.675
515	Trametinib (nM)	0
515	Venetoclax (nM)	0
515	Vincristine (µM)	0.9634967
515	Vorinostat (nM)	0
515	asparagise_normalized	0.036
515	cytarabine_normalized	0
515	daunorubicin_normalized	0.491
515	dexamethasone_normalized	0.4124
515	mercaptopurine_normalized	1
515	prednisolone_normalized	0.0145
515	thioguanine_normalized	0
515	vincristine_normalized	0.4234
516	immunophenotype	B
516	molecular subtype	BCR-ABL1
516	Protocol	T16
516	NCI risk	SR
516	Age at diagnosis	7.7
516	WBC at diagnosis	20.6
516	Sex	M
516	Genetically-defined race	White
516	Asparaginase (IU/ml)	0
516	Bortezomib (nM)	0
516	CHZ868 (nM)	0
516	Cytarabine (µM)	0
516	Dasatinib (nM)	0
516	Daunorubicin (µM)	0
516	Dexamethasone  (µM)	0
516	Ibrutinib (µM)	0
516	Mercaptopurine (µM)	269.9941
516	Nelarabine (µM)	0
516	Panobinostat (nM)	0
516	Prednisolone (µM)	0
516	Ruxolitinib (nM)	0
516	Thioguanine (µM)	0
516	Trametinib (nM)	0
516	Venetoclax (nM)	0
516	Vincristine (µM)	0
516	Vorinostat (nM)	0
516	mercaptopurine_normalized	0.3113
517	immunophenotype	B
517	molecular subtype	ETV6-RUNX1
517	Protocol	T16
517	NCI risk	SR
517	Age at diagnosis	9.9
517	WBC at diagnosis	29.7
517	Sex	F
517	Genetically-defined race	White
517	Asparaginase (IU/ml)	0.08156469
517	Bortezomib (nM)	0
517	CHZ868 (nM)	0
517	Cytarabine (µM)	2.458027
517	Dasatinib (nM)	0
517	Daunorubicin (µM)	0
517	Dexamethasone  (µM)	0.1901257
517	Ibrutinib (µM)	0
517	Mercaptopurine (µM)	597.6632
517	Nelarabine (µM)	0
517	Panobinostat (nM)	0
517	Prednisolone (µM)	0.07992595
517	Ruxolitinib (nM)	0
517	Thioguanine (µM)	36.90297612
517	Trametinib (nM)	0
517	Venetoclax (nM)	0
517	Vincristine (µM)	2.081313294
517	Vorinostat (nM)	0
517	asparagise_normalized	0.4024
517	cytarabine_normalized	0.5938
517	dexamethasone_normalized	0.605
517	mercaptopurine_normalized	0.5405
517	prednisolone_normalized	0.1606
517	thioguanine_normalized	0.3962
517	vincristine_normalized	0.5336
518	immunophenotype	T
518	molecular subtype	ETP
518	Protocol	T16
518	NCI risk	HR
518	Age at diagnosis	15.8
518	WBC at diagnosis	6.9
518	Sex	F
518	Genetically-defined race	White
518	Asparaginase (IU/ml)	0.083514071
518	Bortezomib (nM)	0
518	CHZ868 (nM)	0
518	Cytarabine (µM)	3.609449
518	Dasatinib (nM)	0
518	Daunorubicin (µM)	0.2747201
518	Dexamethasone  (µM)	23.2
518	Ibrutinib (µM)	0
518	Mercaptopurine (µM)	0
518	Nelarabine (µM)	0
518	Panobinostat (nM)	0
518	Prednisolone (µM)	1006
518	Ruxolitinib (nM)	0
518	Thioguanine (µM)	40.90943
518	Trametinib (nM)	0
518	Venetoclax (nM)	0
518	Vincristine (µM)	108.34
518	Vorinostat (nM)	0
518	asparagise_normalized	0.4053
518	cytarabine_normalized	0.6492
518	daunorubicin_normalized	0.6384
518	dexamethasone_normalized	1
518	prednisolone_normalized	1
518	thioguanine_normalized	0.426
518	vincristine_normalized	1
519	immunophenotype	T
519	molecular subtype	T-ALL
519	Protocol	T16
519	NCI risk	HR
519	Age at diagnosis	5
519	WBC at diagnosis	356.8
519	Sex	M
519	Genetically-defined race	White
519	Asparaginase (IU/ml)	0.00373144
519	Bortezomib (nM)	0
519	CHZ868 (nM)	0
519	Cytarabine (µM)	0.4245199
519	Dasatinib (nM)	0
519	Daunorubicin (µM)	0.008665045
519	Dexamethasone  (µM)	0.1556158
519	Ibrutinib (µM)	0
519	Mercaptopurine (µM)	45.9
519	Nelarabine (µM)	0
519	Panobinostat (nM)	0
519	Prednisolone (µM)	0.01509304
519	Ruxolitinib (nM)	0
519	Thioguanine (µM)	21.27826
519	Trametinib (nM)	0
519	Venetoclax (nM)	0
519	Vincristine (µM)	0.111285
519	Vorinostat (nM)	0
519	asparagise_normalized	0.0191
519	cytarabine_normalized	0.3406
519	daunorubicin_normalized	0.1499
519	dexamethasone_normalized	0.5858
519	mercaptopurine_normalized	0
519	prednisolone_normalized	0.0006
519	thioguanine_normalized	0.2373
519	vincristine_normalized	0.1145
520	immunophenotype	B
520	molecular subtype	ETV6-RUNX1
520	Protocol	T16
520	NCI risk	SR
520	Age at diagnosis	3.1
520	WBC at diagnosis	31.7
520	Sex	M
520	Genetically-defined race	Hispanic
520	Asparaginase (IU/ml)	0.1918017
520	Bortezomib (nM)	0
520	CHZ868 (nM)	0
520	Cytarabine (µM)	1.851383429
520	Dasatinib (nM)	0
520	Daunorubicin (µM)	0
520	Dexamethasone  (µM)	0.04467468
520	Ibrutinib (µM)	0
520	Mercaptopurine (µM)	435.018
520	Nelarabine (µM)	0
520	Panobinostat (nM)	0
520	Prednisolone (µM)	0.02209727
520	Ruxolitinib (nM)	0
520	Thioguanine (µM)	20.73172
520	Trametinib (nM)	0
520	Venetoclax (nM)	0
520	Vincristine (µM)	0.2418745
520	Vorinostat (nM)	0
520	asparagise_normalized	0.5087
520	cytarabine_normalized	0.553
520	dexamethasone_normalized	0.4659
520	mercaptopurine_normalized	0.4489
520	prednisolone_normalized	0.0372
520	thioguanine_normalized	0.2298
520	vincristine_normalized	0.2256
521	immunophenotype	B
521	molecular subtype	Hyperdiploid
521	Protocol	T16
521	NCI risk	HR
521	Age at diagnosis	4.3
521	WBC at diagnosis	177.8
521	Sex	M
521	Genetically-defined race	White
521	Asparaginase (IU/ml)	20
521	Bortezomib (nM)	0
521	CHZ868 (nM)	0
521	Cytarabine (µM)	82.2
521	Dasatinib (nM)	0
521	Daunorubicin (µM)	0
521	Dexamethasone  (µM)	23.2
521	Ibrutinib (µM)	0
521	Mercaptopurine (µM)	567.7538
521	Nelarabine (µM)	0
521	Panobinostat (nM)	0
521	Prednisolone (µM)	1006
521	Ruxolitinib (nM)	0
521	Thioguanine (µM)	31.60401291
521	Trametinib (nM)	0
521	Venetoclax (nM)	0
521	Vincristine (µM)	108.34
521	Vorinostat (nM)	0
521	asparagise_normalized	1
521	cytarabine_normalized	1
521	dexamethasone_normalized	1
521	mercaptopurine_normalized	0.5257
521	prednisolone_normalized	1
521	thioguanine_normalized	0.3515
521	vincristine_normalized	1
522	immunophenotype	B
522	molecular subtype	Hyperdiploid
522	Protocol	T16
522	NCI risk	SR
522	Age at diagnosis	2
522	WBC at diagnosis	8.7
522	Sex	F
522	Genetically-defined race	White
522	Asparaginase (IU/ml)	0.4240688
522	Bortezomib (nM)	0
522	CHZ868 (nM)	0
522	Cytarabine (µM)	1.273209
522	Dasatinib (nM)	0
522	Daunorubicin (µM)	0
522	Dexamethasone  (µM)	0.1807993
522	Ibrutinib (µM)	0
522	Mercaptopurine (µM)	273.2743
522	Nelarabine (µM)	0
522	Panobinostat (nM)	0
522	Prednisolone (µM)	0.0884068
522	Ruxolitinib (nM)	0
522	Thioguanine (µM)	20.00513
522	Trametinib (nM)	0
522	Venetoclax (nM)	0
522	Vincristine (µM)	0.1546653
522	Vorinostat (nM)	0
522	asparagise_normalized	0.6073
522	cytarabine_normalized	0.499
522	dexamethasone_normalized	0.6002
522	mercaptopurine_normalized	0.3147
522	prednisolone_normalized	0.1702
522	thioguanine_normalized	0.2195
522	vincristine_normalized	0.1616
523	immunophenotype	B
523	molecular subtype	ETV6-RUNX1
523	Protocol	T16
523	NCI risk	SR
523	Age at diagnosis	5.2
523	WBC at diagnosis	23.6
523	Sex	M
523	Genetically-defined race	White
523	Asparaginase (IU/ml)	0.2214386
523	Bortezomib (nM)	0
523	CHZ868 (nM)	0
523	Cytarabine (µM)	12.40264709
523	Dasatinib (nM)	0
523	Daunorubicin (µM)	0
523	Dexamethasone  (µM)	23.2
523	Ibrutinib (µM)	0
523	Mercaptopurine (µM)	1595.357302
523	Nelarabine (µM)	0
523	Panobinostat (nM)	0
523	Prednisolone (µM)	1006
523	Ruxolitinib (nM)	0
523	Thioguanine (µM)	21.88322683
523	Trametinib (nM)	0
523	Venetoclax (nM)	0
523	Vincristine (µM)	0.2792162
523	Vorinostat (nM)	0
523	asparagise_normalized	0.5265
523	cytarabine_normalized	0.8272
523	dexamethasone_normalized	1
523	mercaptopurine_normalized	0.8238
523	prednisolone_normalized	1
523	thioguanine_normalized	0.2454
523	vincristine_normalized	0.2461
524	immunophenotype	B
524	molecular subtype	ETV6-RUNX1
524	Protocol	T16
524	NCI risk	SR
524	Age at diagnosis	2.5
524	WBC at diagnosis	20
524	Sex	F
524	Genetically-defined race	White
524	Asparaginase (IU/ml)	0.03561475
524	Bortezomib (nM)	0
524	CHZ868 (nM)	0
524	Cytarabine (µM)	9.133952
524	Dasatinib (nM)	0
524	Daunorubicin (µM)	0
524	Dexamethasone  (µM)	0.1664598
524	Ibrutinib (µM)	0
524	Mercaptopurine (µM)	2801.69347
524	Nelarabine (µM)	0
524	Panobinostat (nM)	0
524	Prednisolone (µM)	0.0075
524	Ruxolitinib (nM)	0
524	Thioguanine (µM)	14.70354931
524	Trametinib (nM)	0
524	Venetoclax (nM)	0
524	Vincristine (µM)	0.5572873
524	Vorinostat (nM)	0
524	asparagise_normalized	0.2994
524	cytarabine_normalized	0.7831
524	dexamethasone_normalized	0.5923
524	mercaptopurine_normalized	0.9863
524	prednisolone_normalized	0
524	thioguanine_normalized	0.1307
524	vincristine_normalized	0.345
525	immunophenotype	T
525	molecular subtype	T-ALL
525	Protocol	T16
525	NCI risk	HR
525	Age at diagnosis	8.4
525	WBC at diagnosis	77.6
525	Sex	M
525	Genetically-defined race	Asian/Other
525	Asparaginase (IU/ml)	20
525	Bortezomib (nM)	0
525	CHZ868 (nM)	0
525	Cytarabine (µM)	82.2
525	Dasatinib (nM)	0
525	Daunorubicin (µM)	0.01852427
525	Dexamethasone  (µM)	23.2
525	Ibrutinib (µM)	0
525	Mercaptopurine (µM)	363.9658
525	Nelarabine (µM)	0
525	Panobinostat (nM)	0
525	Prednisolone (µM)	0.101246
525	Ruxolitinib (nM)	0
525	Thioguanine (µM)	23.85313
525	Trametinib (nM)	0
525	Venetoclax (nM)	0
525	Vincristine (µM)	2.445729227
525	Vorinostat (nM)	0
525	asparagise_normalized	1
525	cytarabine_normalized	1
525	daunorubicin_normalized	0.2573
525	dexamethasone_normalized	1
525	mercaptopurine_normalized	0.3974
525	prednisolone_normalized	0.1832
525	thioguanine_normalized	0.2703
525	vincristine_normalized	0.5567
526	immunophenotype	B
526	molecular subtype	ETV6-RUNX1
526	Protocol	T16
526	NCI risk	SR
526	Age at diagnosis	3.8
526	WBC at diagnosis	21.3
526	Sex	F
526	Genetically-defined race	black
526	Asparaginase (IU/ml)	0.2325186
526	Bortezomib (nM)	0
526	CHZ868 (nM)	0
526	Cytarabine (µM)	5.202328
526	Dasatinib (nM)	0
526	Daunorubicin (µM)	0
526	Dexamethasone  (µM)	0.07602124
526	Ibrutinib (µM)	0
526	Mercaptopurine (µM)	0
526	Nelarabine (µM)	0
526	Panobinostat (nM)	0
526	Prednisolone (µM)	0.04459517
526	Ruxolitinib (nM)	0
526	Thioguanine (µM)	29.25644
526	Trametinib (nM)	0
526	Venetoclax (nM)	0
526	Vincristine (µM)	8.253259262
526	Vorinostat (nM)	0
526	asparagise_normalized	0.5326
526	cytarabine_normalized	0.702
526	dexamethasone_normalized	0.517
526	prednisolone_normalized	0.1046
526	thioguanine_normalized	0.3292
526	vincristine_normalized	0.7307
527	immunophenotype	B
527	molecular subtype	Ph-like_non_CRLF2
527	Protocol	T16
527	NCI risk	HR
527	Age at diagnosis	15.5
527	WBC at diagnosis	121.2
527	Sex	M
527	Genetically-defined race	Asian/Other
527	Asparaginase (IU/ml)	0.4599568
527	Bortezomib (nM)	0
527	CHZ868 (nM)	0
527	Cytarabine (µM)	4.895381375
527	Dasatinib (nM)	0
527	Daunorubicin (µM)	0
527	Dexamethasone  (µM)	23.2
527	Ibrutinib (µM)	0
527	Mercaptopurine (µM)	5876
527	Nelarabine (µM)	0
527	Panobinostat (nM)	0
527	Prednisolone (µM)	1006
527	Ruxolitinib (nM)	0
527	Thioguanine (µM)	598
527	Trametinib (nM)	0
527	Venetoclax (nM)	0
527	Vincristine (µM)	0
527	Vorinostat (nM)	0
527	asparagise_normalized	0.6174
527	cytarabine_normalized	0.6932
527	dexamethasone_normalized	1
527	mercaptopurine_normalized	1
527	prednisolone_normalized	1
527	thioguanine_normalized	1
528	immunophenotype	B
528	molecular subtype	B-other
528	Protocol	T16
528	NCI risk	SR
528	Age at diagnosis	1.7
528	WBC at diagnosis	8
528	Sex	M
528	Genetically-defined race	White
528	Asparaginase (IU/ml)	20
528	Bortezomib (nM)	0
528	CHZ868 (nM)	0
528	Cytarabine (µM)	3.698517
528	Dasatinib (nM)	0
528	Daunorubicin (µM)	0
528	Dexamethasone  (µM)	2.549532
528	Ibrutinib (µM)	0
528	Mercaptopurine (µM)	481.278
528	Nelarabine (µM)	0
528	Panobinostat (nM)	0
528	Prednisolone (µM)	0
528	Ruxolitinib (nM)	0
528	Thioguanine (µM)	30.02074
528	Trametinib (nM)	0
528	Venetoclax (nM)	0
528	Vincristine (µM)	0
528	Vorinostat (nM)	0
528	asparagise_normalized	1
528	cytarabine_normalized	0.6528
528	dexamethasone_normalized	0.8544
528	mercaptopurine_normalized	0.478
528	thioguanine_normalized	0.3366
529	immunophenotype	T
529	molecular subtype	T-ALL
529	Protocol	T16
529	NCI risk	SR
529	Age at diagnosis	7.7
529	WBC at diagnosis	27.5
529	Sex	F
529	Genetically-defined race	White
529	Asparaginase (IU/ml)	0.0016
529	Bortezomib (nM)	0
529	CHZ868 (nM)	0
529	Cytarabine (µM)	0.4601511
529	Dasatinib (nM)	0
529	Daunorubicin (µM)	0.09124802
529	Dexamethasone  (µM)	23.2
529	Ibrutinib (µM)	0
529	Mercaptopurine (µM)	129.5848
529	Nelarabine (µM)	0
529	Panobinostat (nM)	0
529	Prednisolone (µM)	0
529	Ruxolitinib (nM)	0
529	Thioguanine (µM)	4.675
529	Trametinib (nM)	0
529	Venetoclax (nM)	0
529	Vincristine (µM)	108.34
529	Vorinostat (nM)	0
529	asparagise_normalized	0
529	cytarabine_normalized	0.3522
529	daunorubicin_normalized	0.4826
529	dexamethasone_normalized	1
529	mercaptopurine_normalized	0.0995
529	thioguanine_normalized	0
529	vincristine_normalized	1
530	immunophenotype	T
530	molecular subtype	T-ALL
530	Protocol	T16
530	NCI risk	SR
530	Age at diagnosis	5.6
530	WBC at diagnosis	17.3
530	Sex	F
530	Genetically-defined race	White
530	Asparaginase (IU/ml)	0
530	Bortezomib (nM)	0
530	CHZ868 (nM)	0
530	Cytarabine (µM)	0
530	Dasatinib (nM)	0
530	Daunorubicin (µM)	0
530	Dexamethasone  (µM)	0
530	Ibrutinib (µM)	0
530	Mercaptopurine (µM)	0
530	Nelarabine (µM)	0
530	Panobinostat (nM)	0
530	Prednisolone (µM)	0
530	Ruxolitinib (nM)	0
530	Thioguanine (µM)	0
530	Trametinib (nM)	0
530	Venetoclax (nM)	0
530	Vincristine (µM)	0.05989781
530	Vorinostat (nM)	0
530	vincristine_normalized	0.0258
531	immunophenotype	B
531	molecular subtype	ETV6-RUNX1-like
531	Protocol	T16
531	NCI risk	SR
531	Age at diagnosis	1.9
531	WBC at diagnosis	10.9
531	Sex	M
531	Genetically-defined race	White
531	Asparaginase (IU/ml)	0.03727256
531	Bortezomib (nM)	0
531	CHZ868 (nM)	0
531	Cytarabine (µM)	19.18697
531	Dasatinib (nM)	0
531	Daunorubicin (µM)	0
531	Dexamethasone  (µM)	0.1895327
531	Ibrutinib (µM)	0
531	Mercaptopurine (µM)	623.2085
531	Nelarabine (µM)	0
531	Panobinostat (nM)	0
531	Prednisolone (µM)	0.05279209
531	Ruxolitinib (nM)	0
531	Thioguanine (µM)	23.34706
531	Trametinib (nM)	0
531	Venetoclax (nM)	0
531	Vincristine (µM)	1.777764
531	Vorinostat (nM)	0
531	asparagise_normalized	0.3051
531	cytarabine_normalized	0.8902
531	dexamethasone_normalized	0.6047
531	mercaptopurine_normalized	0.5526
531	prednisolone_normalized	0.1208
531	thioguanine_normalized	0.2641
531	vincristine_normalized	0.511
532	immunophenotype	B
532	molecular subtype	PAX5alt
532	Protocol	T16
532	NCI risk	SR
532	Age at diagnosis	1.8
532	WBC at diagnosis	12.1
532	Sex	F
532	Genetically-defined race	Hispanic
532	Asparaginase (IU/ml)	3.577107
532	Bortezomib (nM)	0
532	CHZ868 (nM)	0
532	Cytarabine (µM)	0.6532001
532	Dasatinib (nM)	0
532	Daunorubicin (µM)	0
532	Dexamethasone  (µM)	1.668454
532	Ibrutinib (µM)	0
532	Mercaptopurine (µM)	837.2426
532	Nelarabine (µM)	0
532	Panobinostat (nM)	0
532	Prednisolone (µM)	0.4366251
532	Ruxolitinib (nM)	0
532	Thioguanine (µM)	52.17717
532	Trametinib (nM)	0
532	Venetoclax (nM)	0
532	Vincristine (µM)	0.1166124
532	Vorinostat (nM)	0
532	asparagise_normalized	0.8722
532	cytarabine_normalized	0.4027
532	dexamethasone_normalized	0.8137
532	mercaptopurine_normalized	0.6378
532	prednisolone_normalized	0.3235
532	thioguanine_normalized	0.4962
532	vincristine_normalized	0.1212
533	immunophenotype	B
533	molecular subtype	ETV6-RUNX1
533	Protocol	T16
533	NCI risk	SR
533	Age at diagnosis	4.3
533	WBC at diagnosis	24.2
533	Sex	F
533	Genetically-defined race	White
533	Asparaginase (IU/ml)	0.0016
533	Bortezomib (nM)	0
533	CHZ868 (nM)	0
533	Cytarabine (µM)	0.5916743
533	Dasatinib (nM)	0
533	Daunorubicin (µM)	0
533	Dexamethasone  (µM)	0.8271951
533	Ibrutinib (µM)	0
533	Mercaptopurine (µM)	375.7298
533	Nelarabine (µM)	0
533	Panobinostat (nM)	0
533	Prednisolone (µM)	0.149268332
533	Ruxolitinib (nM)	0
533	Thioguanine (µM)	16.28446
533	Trametinib (nM)	0
533	Venetoclax (nM)	0
533	Vincristine (µM)	0.08127246
533	Vorinostat (nM)	0
533	asparagise_normalized	0
533	cytarabine_normalized	0.3885
533	dexamethasone_normalized	0.7463
533	mercaptopurine_normalized	0.4066
533	prednisolone_normalized	0.2205
533	thioguanine_normalized	0.1601
533	vincristine_normalized	0.0695
534	immunophenotype	B
534	molecular subtype	B-other
534	Protocol	T15
534	NCI risk	SR
534	Age at diagnosis	8.7
534	WBC at diagnosis	23.4
534	Sex	M
534	Genetically-defined race	Unknown
534	Asparaginase (IU/ml)	20
534	Bortezomib (nM)	0
534	CHZ868 (nM)	0
534	Cytarabine (µM)	0
534	Dasatinib (nM)	0
534	Daunorubicin (µM)	0
534	Dexamethasone  (µM)	0.04690737
534	Ibrutinib (µM)	0
534	Mercaptopurine (µM)	425.8817551
534	Nelarabine (µM)	0
534	Panobinostat (nM)	0
534	Prednisolone (µM)	1006
534	Ruxolitinib (nM)	0
534	Thioguanine (µM)	19.32393
534	Trametinib (nM)	0
534	Venetoclax (nM)	0
534	Vincristine (µM)	0.1542605
534	Vorinostat (nM)	0
534	asparagise_normalized	1
534	dexamethasone_normalized	0.4706
534	mercaptopurine_normalized	0.4428
534	prednisolone_normalized	1
534	thioguanine_normalized	0.2095
534	vincristine_normalized	0.1612
535	immunophenotype	B
535	molecular subtype	Hyperdiploid
535	Protocol	T16
535	NCI risk	SR
535	Age at diagnosis	3.2
535	WBC at diagnosis	20.8
535	Sex	F
535	Genetically-defined race	Asian/Other
535	Asparaginase (IU/ml)	5.26872
535	Bortezomib (nM)	0
535	CHZ868 (nM)	0
535	Cytarabine (µM)	1.705639
535	Dasatinib (nM)	0
535	Daunorubicin (µM)	0
535	Dexamethasone  (µM)	0.6163989
535	Ibrutinib (µM)	0
535	Mercaptopurine (µM)	560.4575
535	Nelarabine (µM)	0
535	Panobinostat (nM)	0
535	Prednisolone (µM)	0.5335659
535	Ruxolitinib (nM)	0
535	Thioguanine (µM)	22.88094
535	Trametinib (nM)	0
535	Venetoclax (nM)	0
535	Vincristine (µM)	7.171292
535	Vorinostat (nM)	0
535	asparagise_normalized	0.9204
535	cytarabine_normalized	0.5412
535	dexamethasone_normalized	0.718
535	mercaptopurine_normalized	0.522
535	prednisolone_normalized	0.3427
535	thioguanine_normalized	0.2583
535	vincristine_normalized	0.7106
536	immunophenotype	B
536	molecular subtype	KMT2A
536	Protocol	T16
536	NCI risk	SR
536	Age at diagnosis	1.3
536	WBC at diagnosis	9.2
536	Sex	F
536	Genetically-defined race	White
536	Asparaginase (IU/ml)	20
536	Bortezomib (nM)	0
536	CHZ868 (nM)	0
536	Cytarabine (µM)	1.182389
536	Dasatinib (nM)	0
536	Daunorubicin (µM)	0
536	Dexamethasone  (µM)	0.00156546
536	Ibrutinib (µM)	0
536	Mercaptopurine (µM)	0
536	Nelarabine (µM)	0
536	Panobinostat (nM)	0
536	Prednisolone (µM)	0
536	Ruxolitinib (nM)	0
536	Thioguanine (µM)	0
536	Trametinib (nM)	0
536	Venetoclax (nM)	0
536	Vincristine (µM)	0.1014382
536	Vorinostat (nM)	0
536	asparagise_normalized	1
536	cytarabine_normalized	0.4883
536	dexamethasone_normalized	0.1439
536	vincristine_normalized	0.1012
537	immunophenotype	T
537	molecular subtype	T-ALL
537	Protocol	T16
537	NCI risk	HR
537	Age at diagnosis	10.8
537	WBC at diagnosis	4.6
537	Sex	F
537	Genetically-defined race	White
537	Asparaginase (IU/ml)	0
537	Bortezomib (nM)	0
537	CHZ868 (nM)	0
537	Cytarabine (µM)	0
537	Dasatinib (nM)	0
537	Daunorubicin (µM)	0
537	Dexamethasone  (µM)	23.2
537	Ibrutinib (µM)	0
537	Mercaptopurine (µM)	270.9394
537	Nelarabine (µM)	0
537	Panobinostat (nM)	0
537	Prednisolone (µM)	0
537	Ruxolitinib (nM)	0
537	Thioguanine (µM)	4.675
537	Trametinib (nM)	0
537	Venetoclax (nM)	0
537	Vincristine (µM)	0
537	Vorinostat (nM)	0
537	dexamethasone_normalized	1
537	mercaptopurine_normalized	0.3123
537	thioguanine_normalized	0
538	immunophenotype	B
538	molecular subtype	B-other
538	Protocol	T16
538	NCI risk	HR
538	Age at diagnosis	2.6
538	WBC at diagnosis	86.6
538	Sex	F
538	Genetically-defined race	White
538	Asparaginase (IU/ml)	1.029832
538	Bortezomib (nM)	0
538	CHZ868 (nM)	0
538	Cytarabine (µM)	0
538	Dasatinib (nM)	0
538	Daunorubicin (µM)	0
538	Dexamethasone  (µM)	0
538	Ibrutinib (µM)	0
538	Mercaptopurine (µM)	208.8576
538	Nelarabine (µM)	0
538	Panobinostat (nM)	0
538	Prednisolone (µM)	0.0075
538	Ruxolitinib (nM)	0
538	Thioguanine (µM)	15.61034
538	Trametinib (nM)	0
538	Venetoclax (nM)	0
538	Vincristine (µM)	0
538	Vorinostat (nM)	0
538	asparagise_normalized	0.7175
538	mercaptopurine_normalized	0.2372
538	prednisolone_normalized	0
538	thioguanine_normalized	0.1479
539	immunophenotype	B
539	molecular subtype	B-other
539	Protocol	T16
539	NCI risk	HR
539	Age at diagnosis	12.2
539	WBC at diagnosis	4.8
539	Sex	M
539	Genetically-defined race	White
539	Asparaginase (IU/ml)	0
539	Bortezomib (nM)	0
539	CHZ868 (nM)	0
539	Cytarabine (µM)	0.212197
539	Dasatinib (nM)	0
539	Daunorubicin (µM)	0
539	Dexamethasone  (µM)	0.2105798
539	Ibrutinib (µM)	0
539	Mercaptopurine (µM)	45.9
539	Nelarabine (µM)	0
539	Panobinostat (nM)	0
539	Prednisolone (µM)	1.495856244
539	Ruxolitinib (nM)	0
539	Thioguanine (µM)	4.675
539	Trametinib (nM)	0
539	Venetoclax (nM)	0
539	Vincristine (µM)	0
539	Vorinostat (nM)	0
539	cytarabine_normalized	0.2406
539	dexamethasone_normalized	0.6148
539	mercaptopurine_normalized	0
539	prednisolone_normalized	0.4417
539	thioguanine_normalized	0
540	immunophenotype	B
540	molecular subtype	KMT2A
540	Protocol	T16
540	NCI risk	SR
540	Age at diagnosis	1.3
540	WBC at diagnosis	20.8
540	Sex	M
540	Genetically-defined race	Hispanic
540	Asparaginase (IU/ml)	0.0016
540	Bortezomib (nM)	0
540	CHZ868 (nM)	0
540	Cytarabine (µM)	0.978529652
540	Dasatinib (nM)	0
540	Daunorubicin (µM)	0
540	Dexamethasone  (µM)	0.01147199
540	Ibrutinib (µM)	0
540	Mercaptopurine (µM)	217.423
540	Nelarabine (µM)	0
540	Panobinostat (nM)	0
540	Prednisolone (µM)	0.0075
540	Ruxolitinib (nM)	0
540	Thioguanine (µM)	11.42829
540	Trametinib (nM)	0
540	Venetoclax (nM)	0
540	Vincristine (µM)	0.1505103
540	Vorinostat (nM)	0
540	asparagise_normalized	0
540	cytarabine_normalized	0.461
540	dexamethasone_normalized	0.3353
540	mercaptopurine_normalized	0.2488
540	prednisolone_normalized	0
540	thioguanine_normalized	0.0579
540	vincristine_normalized	0.1577
541	immunophenotype	T
541	molecular subtype	T-ALL
541	Protocol	T16
541	NCI risk	SR
541	Age at diagnosis	9.7
541	WBC at diagnosis	3.2
541	Sex	F
541	Genetically-defined race	black
541	Asparaginase (IU/ml)	0.0016
541	Bortezomib (nM)	0
541	CHZ868 (nM)	0
541	Cytarabine (µM)	0.499820855
541	Dasatinib (nM)	0
541	Daunorubicin (µM)	0.274527117
541	Dexamethasone  (µM)	23.2
541	Ibrutinib (µM)	0
541	Mercaptopurine (µM)	196.7991788
541	Nelarabine (µM)	0
541	Panobinostat (nM)	0
541	Prednisolone (µM)	1006
541	Ruxolitinib (nM)	0
541	Thioguanine (µM)	12.69212
541	Trametinib (nM)	0
541	Venetoclax (nM)	0
541	Vincristine (µM)	0.5393006
541	Vorinostat (nM)	0
541	asparagise_normalized	0
541	cytarabine_normalized	0.3642
541	daunorubicin_normalized	0.6383
541	dexamethasone_normalized	1
541	mercaptopurine_normalized	0.22
541	prednisolone_normalized	1
541	thioguanine_normalized	0.0882
541	vincristine_normalized	0.3403
542	immunophenotype	B
542	molecular subtype	KMT2A
542	Protocol	T16
542	NCI risk	HR
542	Age at diagnosis	18.3
542	WBC at diagnosis	15.4
542	Sex	M
542	Genetically-defined race	black
542	Asparaginase (IU/ml)	0.0016
542	Bortezomib (nM)	0
542	CHZ868 (nM)	0
542	Cytarabine (µM)	0.174898
542	Dasatinib (nM)	0
542	Daunorubicin (µM)	0
542	Dexamethasone  (µM)	0.02833795
542	Ibrutinib (µM)	0
542	Mercaptopurine (µM)	164.3184
542	Nelarabine (µM)	0
542	Panobinostat (nM)	0
542	Prednisolone (µM)	0.01536284
542	Ruxolitinib (nM)	0
542	Thioguanine (µM)	4.675
542	Trametinib (nM)	0
542	Venetoclax (nM)	0
542	Vincristine (µM)	0.025
542	Vorinostat (nM)	0
542	asparagise_normalized	0
542	cytarabine_normalized	0.2127
542	dexamethasone_normalized	0.4222
542	mercaptopurine_normalized	0.168
542	prednisolone_normalized	0.0023
542	thioguanine_normalized	0
542	vincristine_normalized	0
543	immunophenotype	B
543	molecular subtype	KMT2A
543	Protocol	T16
543	NCI risk	HR
543	Age at diagnosis	0.2
543	WBC at diagnosis	0.8
543	Sex	F
543	Genetically-defined race	Asian/Other
543	Asparaginase (IU/ml)	0
543	Bortezomib (nM)	0
543	CHZ868 (nM)	0
543	Cytarabine (µM)	0
543	Dasatinib (nM)	0
543	Daunorubicin (µM)	0
543	Dexamethasone  (µM)	23.2
543	Ibrutinib (µM)	0
543	Mercaptopurine (µM)	0
543	Nelarabine (µM)	0
543	Panobinostat (nM)	0
543	Prednisolone (µM)	257.0268
543	Ruxolitinib (nM)	0
543	Thioguanine (µM)	19.42786009
543	Trametinib (nM)	0
543	Venetoclax (nM)	0
543	Vincristine (µM)	0.025
543	Vorinostat (nM)	0
543	dexamethasone_normalized	1
543	prednisolone_normalized	0.9356
543	thioguanine_normalized	0.2111
543	vincristine_normalized	0
544	immunophenotype	B
544	molecular subtype	Hyperdiploid
544	Protocol	T16
544	NCI risk	SR
544	Age at diagnosis	2.5
544	WBC at diagnosis	13
544	Sex	M
544	Genetically-defined race	White
544	Asparaginase (IU/ml)	0
544	Bortezomib (nM)	0
544	CHZ868 (nM)	0
544	Cytarabine (µM)	0
544	Dasatinib (nM)	0
544	Daunorubicin (µM)	0
544	Dexamethasone  (µM)	0.0274815
544	Ibrutinib (µM)	0
544	Mercaptopurine (µM)	0
544	Nelarabine (µM)	0
544	Panobinostat (nM)	0
544	Prednisolone (µM)	0.070294803
544	Ruxolitinib (nM)	0
544	Thioguanine (µM)	0
544	Trametinib (nM)	0
544	Venetoclax (nM)	0
544	Vincristine (µM)	0
544	Vorinostat (nM)	0
544	dexamethasone_normalized	0.4192
544	prednisolone_normalized	0.1482
545	immunophenotype	B
545	molecular subtype	ETV6-RUNX1-like
545	Protocol	T16
545	NCI risk	SR
545	Age at diagnosis	1.6
545	WBC at diagnosis	11.9
545	Sex	M
545	Genetically-defined race	White
545	Asparaginase (IU/ml)	0.2155522
545	Bortezomib (nM)	0
545	CHZ868 (nM)	0
545	Cytarabine (µM)	11.79605
545	Dasatinib (nM)	0
545	Daunorubicin (µM)	0
545	Dexamethasone  (µM)	0
545	Ibrutinib (µM)	0
545	Mercaptopurine (µM)	408.9591
545	Nelarabine (µM)	0
545	Panobinostat (nM)	0
545	Prednisolone (µM)	1006
545	Ruxolitinib (nM)	0
545	Thioguanine (µM)	85.59274
545	Trametinib (nM)	0
545	Venetoclax (nM)	0
545	Vincristine (µM)	108.34
545	Vorinostat (nM)	0
545	asparagise_normalized	0.5232
545	cytarabine_normalized	0.82
545	mercaptopurine_normalized	0.4311
545	prednisolone_normalized	1
545	thioguanine_normalized	0.639
545	vincristine_normalized	1
546	immunophenotype	B
546	molecular subtype	ETV6-RUNX1
546	Protocol	T16
546	NCI risk	SR
546	Age at diagnosis	3.3
546	WBC at diagnosis	48.3
546	Sex	M
546	Genetically-defined race	White
546	Asparaginase (IU/ml)	20
546	Bortezomib (nM)	0
546	CHZ868 (nM)	0
546	Cytarabine (µM)	2.546997
546	Dasatinib (nM)	0
546	Daunorubicin (µM)	0
546	Dexamethasone  (µM)	0
546	Ibrutinib (µM)	0
546	Mercaptopurine (µM)	45.9
546	Nelarabine (µM)	0
546	Panobinostat (nM)	0
546	Prednisolone (µM)	0
546	Ruxolitinib (nM)	0
546	Thioguanine (µM)	36.75428
546	Trametinib (nM)	0
546	Venetoclax (nM)	0
546	Vincristine (µM)	0
546	Vorinostat (nM)	0
546	asparagise_normalized	1
546	cytarabine_normalized	0.599
546	mercaptopurine_normalized	0
546	thioguanine_normalized	0.3951
547	immunophenotype	B
547	molecular subtype	Ph-like_non_CRLF2
547	Protocol	T16
547	NCI risk	SR
547	Age at diagnosis	6.5
547	WBC at diagnosis	38.8
547	Sex	M
547	Genetically-defined race	White
547	Asparaginase (IU/ml)	0.196643
547	Bortezomib (nM)	0
547	CHZ868 (nM)	0
547	Cytarabine (µM)	1.279601
547	Dasatinib (nM)	0
547	Daunorubicin (µM)	0
547	Dexamethasone  (µM)	0.3178097
547	Ibrutinib (µM)	0
547	Mercaptopurine (µM)	177.0771
547	Nelarabine (µM)	0
547	Panobinostat (nM)	0
547	Prednisolone (µM)	1006
547	Ruxolitinib (nM)	0
547	Thioguanine (µM)	23.02496
547	Trametinib (nM)	0
547	Venetoclax (nM)	0
547	Vincristine (µM)	0.2343507
547	Vorinostat (nM)	0
547	asparagise_normalized	0.5118
547	cytarabine_normalized	0.4997
547	dexamethasone_normalized	0.6544
547	mercaptopurine_normalized	0.1896
547	prednisolone_normalized	1
547	thioguanine_normalized	0.2601
547	vincristine_normalized	0.2211
548	immunophenotype	T
548	molecular subtype	T-ALL
548	Protocol	T16
548	NCI risk	SR
548	Age at diagnosis	7.8
548	WBC at diagnosis	42.8
548	Sex	M
548	Genetically-defined race	White
548	Asparaginase (IU/ml)	0.06479873
548	Bortezomib (nM)	0
548	CHZ868 (nM)	0
548	Cytarabine (µM)	2.71068
548	Dasatinib (nM)	0
548	Daunorubicin (µM)	0.1715375
548	Dexamethasone  (µM)	0
548	Ibrutinib (µM)	0
548	Mercaptopurine (µM)	45.9
548	Nelarabine (µM)	0
548	Panobinostat (nM)	0
548	Prednisolone (µM)	1006
548	Ruxolitinib (nM)	0
548	Thioguanine (µM)	28.39864
548	Trametinib (nM)	0
548	Venetoclax (nM)	0
548	Vincristine (µM)	108.34
548	Vorinostat (nM)	0
548	asparagise_normalized	0.3738
548	cytarabine_normalized	0.608
548	daunorubicin_normalized	0.5718
548	mercaptopurine_normalized	0
548	prednisolone_normalized	1
548	thioguanine_normalized	0.3206
548	vincristine_normalized	1
549	immunophenotype	B
549	molecular subtype	ETV6-RUNX1-like
549	Protocol	T16
549	NCI risk	HR
549	Age at diagnosis	11.5
549	WBC at diagnosis	59.6
549	Sex	F
549	Genetically-defined race	White
549	Asparaginase (IU/ml)	0.8419347
549	Bortezomib (nM)	0
549	CHZ868 (nM)	0
549	Cytarabine (µM)	7.681592
549	Dasatinib (nM)	0
549	Daunorubicin (µM)	0
549	Dexamethasone  (µM)	23.2
549	Ibrutinib (µM)	0
549	Mercaptopurine (µM)	5876
549	Nelarabine (µM)	0
549	Panobinostat (nM)	0
549	Prednisolone (µM)	0.1188785
549	Ruxolitinib (nM)	0
549	Thioguanine (µM)	10.80086
549	Trametinib (nM)	0
549	Venetoclax (nM)	0
549	Vincristine (µM)	108.34
549	Vorinostat (nM)	0
549	asparagise_normalized	0.6925
549	cytarabine_normalized	0.7582
549	dexamethasone_normalized	1
549	mercaptopurine_normalized	1
549	prednisolone_normalized	0.1987
549	thioguanine_normalized	0.0416
549	vincristine_normalized	1
550	immunophenotype	B
550	molecular subtype	ETV6-RUNX1-like
550	Protocol	T16
550	NCI risk	HR
550	Age at diagnosis	2.9
550	WBC at diagnosis	98.4
550	Sex	F
550	Genetically-defined race	White
550	Asparaginase (IU/ml)	0.4440056
550	Bortezomib (nM)	0
550	CHZ868 (nM)	0
550	Cytarabine (µM)	2.739786
550	Dasatinib (nM)	0
550	Daunorubicin (µM)	0
550	Dexamethasone  (µM)	0.044655445
550	Ibrutinib (µM)	0
550	Mercaptopurine (µM)	233.3623
550	Nelarabine (µM)	0
550	Panobinostat (nM)	0
550	Prednisolone (µM)	0.08404199
550	Ruxolitinib (nM)	0
550	Thioguanine (µM)	17.17751863
550	Trametinib (nM)	0
550	Venetoclax (nM)	0
550	Vincristine (µM)	0.319315451
550	Vorinostat (nM)	0
550	asparagise_normalized	0.613
550	cytarabine_normalized	0.6095
550	dexamethasone_normalized	0.4658
550	mercaptopurine_normalized	0.2692
550	prednisolone_normalized	0.1654
550	thioguanine_normalized	0.1755
550	vincristine_normalized	0.2653
551	immunophenotype	B
551	molecular subtype	Hyperdiploid
551	Protocol	T16
551	NCI risk	HR
551	Age at diagnosis	17.9
551	WBC at diagnosis	1.2
551	Sex	M
551	Genetically-defined race	White
551	Asparaginase (IU/ml)	0
551	Bortezomib (nM)	0
551	CHZ868 (nM)	0
551	Cytarabine (µM)	0
551	Dasatinib (nM)	0
551	Daunorubicin (µM)	0
551	Dexamethasone  (µM)	0
551	Ibrutinib (µM)	0
551	Mercaptopurine (µM)	428.1317
551	Nelarabine (µM)	0
551	Panobinostat (nM)	0
551	Prednisolone (µM)	0
551	Ruxolitinib (nM)	0
551	Thioguanine (µM)	19.17939
551	Trametinib (nM)	0
551	Venetoclax (nM)	0
551	Vincristine (µM)	0
551	Vorinostat (nM)	0
551	mercaptopurine_normalized	0.4443
551	thioguanine_normalized	0.2073
552	immunophenotype	B
552	molecular subtype	Hyperdiploid
552	Protocol	T16
552	NCI risk	SR
552	Age at diagnosis	4.7
552	WBC at diagnosis	3.3
552	Sex	M
552	Genetically-defined race	White
552	Asparaginase (IU/ml)	20
552	Bortezomib (nM)	0
552	CHZ868 (nM)	0
552	Cytarabine (µM)	2.179695473
552	Dasatinib (nM)	0
552	Daunorubicin (µM)	0
552	Dexamethasone  (µM)	0.5111143
552	Ibrutinib (µM)	0
552	Mercaptopurine (µM)	699.3241
552	Nelarabine (µM)	0
552	Panobinostat (nM)	0
552	Prednisolone (µM)	0.1199486
552	Ruxolitinib (nM)	0
552	Thioguanine (µM)	23.69149
552	Trametinib (nM)	0
552	Venetoclax (nM)	0
552	Vincristine (µM)	0.150064
552	Vorinostat (nM)	0
552	asparagise_normalized	1
552	cytarabine_normalized	0.5765
552	dexamethasone_normalized	0.7
552	mercaptopurine_normalized	0.5859
552	prednisolone_normalized	0.1995
552	thioguanine_normalized	0.2683
552	vincristine_normalized	0.1573
553	immunophenotype	B
553	molecular subtype	ETV6-RUNX1
553	Protocol	T16
553	NCI risk	SR
553	Age at diagnosis	2.6
553	WBC at diagnosis	20.6
553	Sex	M
553	Genetically-defined race	Hispanic
553	Asparaginase (IU/ml)	0.0016
553	Bortezomib (nM)	0
553	CHZ868 (nM)	0
553	Cytarabine (µM)	2.653748
553	Dasatinib (nM)	0
553	Daunorubicin (µM)	0
553	Dexamethasone  (µM)	23.2
553	Ibrutinib (µM)	0
553	Mercaptopurine (µM)	0
553	Nelarabine (µM)	0
553	Panobinostat (nM)	0
553	Prednisolone (µM)	26.49157
553	Ruxolitinib (nM)	0
553	Thioguanine (µM)	23.52106
553	Trametinib (nM)	0
553	Venetoclax (nM)	0
553	Vincristine (µM)	1.381499
553	Vorinostat (nM)	0
553	asparagise_normalized	0
553	cytarabine_normalized	0.6049
553	dexamethasone_normalized	1
553	prednisolone_normalized	0.7175
553	thioguanine_normalized	0.2662
553	vincristine_normalized	0.475
554	immunophenotype	B
554	molecular subtype	ZNF384
554	Protocol	T16
554	NCI risk	HR
554	Age at diagnosis	3.2
554	WBC at diagnosis	91
554	Sex	M
554	Genetically-defined race	White
554	Asparaginase (IU/ml)	20
554	Bortezomib (nM)	0
554	CHZ868 (nM)	0
554	Cytarabine (µM)	82.2
554	Dasatinib (nM)	0
554	Daunorubicin (µM)	0
554	Dexamethasone  (µM)	23.2
554	Ibrutinib (µM)	0
554	Mercaptopurine (µM)	5876
554	Nelarabine (µM)	0
554	Panobinostat (nM)	0
554	Prednisolone (µM)	1006
554	Ruxolitinib (nM)	0
554	Thioguanine (µM)	598
554	Trametinib (nM)	0
554	Venetoclax (nM)	0
554	Vincristine (µM)	108.34
554	Vorinostat (nM)	0
554	asparagise_normalized	1
554	cytarabine_normalized	1
554	dexamethasone_normalized	1
554	mercaptopurine_normalized	1
554	prednisolone_normalized	1
554	thioguanine_normalized	1
554	vincristine_normalized	1
555	immunophenotype	B
555	molecular subtype	ETV6-RUNX1
555	Protocol	T16
555	NCI risk	SR
555	Age at diagnosis	9
555	WBC at diagnosis	2.7
555	Sex	M
555	Genetically-defined race	White
555	Asparaginase (IU/ml)	2.500923
555	Bortezomib (nM)	0
555	CHZ868 (nM)	0
555	Cytarabine (µM)	4.297637
555	Dasatinib (nM)	0
555	Daunorubicin (µM)	0
555	Dexamethasone  (µM)	23.2
555	Ibrutinib (µM)	0
555	Mercaptopurine (µM)	0
555	Nelarabine (µM)	0
555	Panobinostat (nM)	0
555	Prednisolone (µM)	0.1344438
555	Ruxolitinib (nM)	0
555	Thioguanine (µM)	37.76329044
555	Trametinib (nM)	0
555	Venetoclax (nM)	0
555	Vincristine (µM)	0.2248912
555	Vorinostat (nM)	0
555	asparagise_normalized	0.8278
555	cytarabine_normalized	0.6744
555	dexamethasone_normalized	1
555	prednisolone_normalized	0.2105
555	thioguanine_normalized	0.4029
555	vincristine_normalized	0.2152
556	immunophenotype	B
556	molecular subtype	Hyperdiploid
556	Protocol	T16
556	NCI risk	SR
556	Age at diagnosis	1.9
556	WBC at diagnosis	22.4
556	Sex	M
556	Genetically-defined race	Asian/Other
556	Asparaginase (IU/ml)	0.0016
556	Bortezomib (nM)	0
556	CHZ868 (nM)	0
556	Cytarabine (µM)	1.167449
556	Dasatinib (nM)	0
556	Daunorubicin (µM)	0
556	Dexamethasone  (µM)	3.710294
556	Ibrutinib (µM)	0
556	Mercaptopurine (µM)	0
556	Nelarabine (µM)	0
556	Panobinostat (nM)	0
556	Prednisolone (µM)	0.06376308
556	Ruxolitinib (nM)	0
556	Thioguanine (µM)	11.28567
556	Trametinib (nM)	0
556	Venetoclax (nM)	0
556	Vincristine (µM)	0.07683539
556	Vorinostat (nM)	0
556	asparagise_normalized	0
556	cytarabine_normalized	0.4865
556	dexamethasone_normalized	0.8905
556	prednisolone_normalized	0.1389
556	thioguanine_normalized	0.0543
556	vincristine_normalized	0.0615
557	immunophenotype	T
557	molecular subtype	T-ALL
557	Protocol	T16
557	NCI risk	HR
557	Age at diagnosis	10.2
557	WBC at diagnosis	129.6
557	Sex	M
557	Genetically-defined race	White
557	Asparaginase (IU/ml)	0
557	Bortezomib (nM)	0
557	CHZ868 (nM)	0
557	Cytarabine (µM)	0
557	Dasatinib (nM)	0
557	Daunorubicin (µM)	0
557	Dexamethasone  (µM)	0
557	Ibrutinib (µM)	0
557	Mercaptopurine (µM)	0
557	Nelarabine (µM)	0
557	Panobinostat (nM)	0
557	Prednisolone (µM)	0
557	Ruxolitinib (nM)	0
557	Thioguanine (µM)	84.00542
557	Trametinib (nM)	0
557	Venetoclax (nM)	0
557	Vincristine (µM)	0
557	Vorinostat (nM)	0
557	thioguanine_normalized	0.6336
558	immunophenotype	B
558	molecular subtype	Ph-like_non_CRLF2
558	Protocol	T16
558	NCI risk	SR
558	Age at diagnosis	4.6
558	WBC at diagnosis	16.6
558	Sex	M
558	Genetically-defined race	White
558	Asparaginase (IU/ml)	0.0016
558	Bortezomib (nM)	0
558	CHZ868 (nM)	0
558	Cytarabine (µM)	2.504683
558	Dasatinib (nM)	0
558	Daunorubicin (µM)	0
558	Dexamethasone  (µM)	1.609007
558	Ibrutinib (µM)	0
558	Mercaptopurine (µM)	0
558	Nelarabine (µM)	0
558	Panobinostat (nM)	0
558	Prednisolone (µM)	0.1112788
558	Ruxolitinib (nM)	0
558	Thioguanine (µM)	17.94969
558	Trametinib (nM)	0
558	Venetoclax (nM)	0
558	Vincristine (µM)	0.1200476
558	Vorinostat (nM)	0
558	asparagise_normalized	0
558	cytarabine_normalized	0.5966
558	dexamethasone_normalized	0.8102
558	prednisolone_normalized	0.1923
558	thioguanine_normalized	0.1882
558	vincristine_normalized	0.1253
559	immunophenotype	B
559	molecular subtype	B-other
559	Protocol	T16
559	NCI risk	HR
559	Age at diagnosis	18.9
559	WBC at diagnosis	28.2
559	Sex	M
559	Genetically-defined race	Hispanic
559	Asparaginase (IU/ml)	0
559	Bortezomib (nM)	0
559	CHZ868 (nM)	0
559	Cytarabine (µM)	2.679629729
559	Dasatinib (nM)	0
559	Daunorubicin (µM)	0
559	Dexamethasone  (µM)	0.222088
559	Ibrutinib (µM)	0
559	Mercaptopurine (µM)	0
559	Nelarabine (µM)	0
559	Panobinostat (nM)	0
559	Prednisolone (µM)	0.1017662
559	Ruxolitinib (nM)	0
559	Thioguanine (µM)	25.48601
559	Trametinib (nM)	0
559	Venetoclax (nM)	0
559	Vincristine (µM)	0.025
559	Vorinostat (nM)	0
559	cytarabine_normalized	0.6063
559	dexamethasone_normalized	0.62
559	prednisolone_normalized	0.1837
559	thioguanine_normalized	0.2894
559	vincristine_normalized	0
560	immunophenotype	B
560	molecular subtype	ETV6-RUNX1
560	Protocol	T16
560	NCI risk	SR
560	Age at diagnosis	3
560	WBC at diagnosis	10.2
560	Sex	F
560	Genetically-defined race	black
560	Asparaginase (IU/ml)	0.0016
560	Bortezomib (nM)	0
560	CHZ868 (nM)	0
560	Cytarabine (µM)	2.851547
560	Dasatinib (nM)	0
560	Daunorubicin (µM)	0
560	Dexamethasone  (µM)	0.9133465
560	Ibrutinib (µM)	0
560	Mercaptopurine (µM)	0
560	Nelarabine (µM)	0
560	Panobinostat (nM)	0
560	Prednisolone (µM)	0.08010448
560	Ruxolitinib (nM)	0
560	Thioguanine (µM)	23.83713
560	Trametinib (nM)	0
560	Venetoclax (nM)	0
560	Vincristine (µM)	25.88862
560	Vorinostat (nM)	0
560	asparagise_normalized	0
560	cytarabine_normalized	0.6153
560	dexamethasone_normalized	0.7558
560	prednisolone_normalized	0.1608
560	thioguanine_normalized	0.2701
560	vincristine_normalized	0.8943
561	immunophenotype	B
561	molecular subtype	ZNF384
561	Protocol	T16
561	NCI risk	HR
561	Age at diagnosis	13.2
561	WBC at diagnosis	15.5
561	Sex	M
561	Genetically-defined race	White
561	Asparaginase (IU/ml)	20
561	Bortezomib (nM)	0
561	CHZ868 (nM)	0
561	Cytarabine (µM)	8.851459
561	Dasatinib (nM)	0
561	Daunorubicin (µM)	0
561	Dexamethasone  (µM)	0
561	Ibrutinib (µM)	0
561	Mercaptopurine (µM)	0
561	Nelarabine (µM)	0
561	Panobinostat (nM)	0
561	Prednisolone (µM)	1006
561	Ruxolitinib (nM)	0
561	Thioguanine (µM)	128.617
561	Trametinib (nM)	0
561	Venetoclax (nM)	0
561	Vincristine (µM)	0.1300268
561	Vorinostat (nM)	0
561	asparagise_normalized	1
561	cytarabine_normalized	0.7786
561	prednisolone_normalized	1
561	thioguanine_normalized	0.7565
561	vincristine_normalized	0.1368
562	immunophenotype	T
562	molecular subtype	T-ALL
562	Protocol	T16
562	NCI risk	SR
562	Age at diagnosis	4.9
562	WBC at diagnosis	48.7
562	Sex	M
562	Genetically-defined race	White
562	Asparaginase (IU/ml)	2.163546
562	Bortezomib (nM)	0
562	CHZ868 (nM)	0
562	Cytarabine (µM)	0
562	Dasatinib (nM)	0
562	Daunorubicin (µM)	0.01907803
562	Dexamethasone  (µM)	0.02244799
562	Ibrutinib (µM)	0
562	Mercaptopurine (µM)	0
562	Nelarabine (µM)	0
562	Panobinostat (nM)	0
562	Prednisolone (µM)	0.07599388
562	Ruxolitinib (nM)	0
562	Thioguanine (µM)	27.41417
562	Trametinib (nM)	0
562	Venetoclax (nM)	0
562	Vincristine (µM)	0.4407649
562	Vorinostat (nM)	0
562	asparagise_normalized	0.8098
562	daunorubicin_normalized	0.2614
562	dexamethasone_normalized	0.3998
562	prednisolone_normalized	0.1557
562	thioguanine_normalized	0.3104
562	vincristine_normalized	0.3115
563	immunophenotype	T
563	molecular subtype	T-ALL
563	Protocol	T16
563	NCI risk	SR
563	Age at diagnosis	4.5
563	WBC at diagnosis	10
563	Sex	F
563	Genetically-defined race	White
563	Asparaginase (IU/ml)	0
563	Bortezomib (nM)	0
563	CHZ868 (nM)	0
563	Cytarabine (µM)	82.2
563	Dasatinib (nM)	0
563	Daunorubicin (µM)	0
563	Dexamethasone  (µM)	0
563	Ibrutinib (µM)	0
563	Mercaptopurine (µM)	0
563	Nelarabine (µM)	0
563	Panobinostat (nM)	0
563	Prednisolone (µM)	0
563	Ruxolitinib (nM)	0
563	Thioguanine (µM)	0
563	Trametinib (nM)	0
563	Venetoclax (nM)	0
563	Vincristine (µM)	0
563	Vorinostat (nM)	0
563	cytarabine_normalized	1
564	immunophenotype	B
564	molecular subtype	ETV6-RUNX1
564	Protocol	T16
564	NCI risk	SR
564	Age at diagnosis	4.2
564	WBC at diagnosis	6.6
564	Sex	M
564	Genetically-defined race	black
564	Asparaginase (IU/ml)	0.0016
564	Bortezomib (nM)	0
564	CHZ868 (nM)	0
564	Cytarabine (µM)	0
564	Dasatinib (nM)	0
564	Daunorubicin (µM)	0
564	Dexamethasone  (µM)	0.07897161
564	Ibrutinib (µM)	0
564	Mercaptopurine (µM)	254.2216
564	Nelarabine (µM)	0
564	Panobinostat (nM)	0
564	Prednisolone (µM)	0.09478996
564	Ruxolitinib (nM)	0
564	Thioguanine (µM)	4.675
564	Trametinib (nM)	0
564	Venetoclax (nM)	0
564	Vincristine (µM)	1.616904
564	Vorinostat (nM)	0
564	asparagise_normalized	0
564	dexamethasone_normalized	0.5206
564	mercaptopurine_normalized	0.2939
564	prednisolone_normalized	0.1769
564	thioguanine_normalized	0
564	vincristine_normalized	0.4975
565	immunophenotype	B
565	molecular subtype	B-other
565	Protocol	T16
565	NCI risk	HR
565	Age at diagnosis	11.3
565	WBC at diagnosis	7
565	Sex	M
565	Genetically-defined race	White
565	Asparaginase (IU/ml)	0
565	Bortezomib (nM)	0
565	CHZ868 (nM)	0
565	Cytarabine (µM)	0
565	Dasatinib (nM)	0
565	Daunorubicin (µM)	0
565	Dexamethasone  (µM)	0
565	Ibrutinib (µM)	0
565	Mercaptopurine (µM)	5876
565	Nelarabine (µM)	0
565	Panobinostat (nM)	0
565	Prednisolone (µM)	0
565	Ruxolitinib (nM)	0
565	Thioguanine (µM)	31.94309
565	Trametinib (nM)	0
565	Venetoclax (nM)	0
565	Vincristine (µM)	108.34
565	Vorinostat (nM)	0
565	mercaptopurine_normalized	1
565	thioguanine_normalized	0.3546
565	vincristine_normalized	1
566	immunophenotype	T
566	molecular subtype	T-ALL
566	Protocol	T16
566	NCI risk	SR
566	Age at diagnosis	9.7
566	WBC at diagnosis	8.5
566	Sex	M
566	Genetically-defined race	black
566	Asparaginase (IU/ml)	0.018286824
566	Bortezomib (nM)	0
566	CHZ868 (nM)	0
566	Cytarabine (µM)	19.87737
566	Dasatinib (nM)	0
566	Daunorubicin (µM)	0.3384843
566	Dexamethasone  (µM)	0
566	Ibrutinib (µM)	0
566	Mercaptopurine (µM)	118.1540355
566	Nelarabine (µM)	0
566	Panobinostat (nM)	0
566	Prednisolone (µM)	0
566	Ruxolitinib (nM)	0
566	Thioguanine (µM)	20.2768
566	Trametinib (nM)	0
566	Venetoclax (nM)	0
566	Vincristine (µM)	0
566	Vorinostat (nM)	0
566	asparagise_normalized	0.2166
566	cytarabine_normalized	0.8953
566	daunorubicin_normalized	0.6679
566	mercaptopurine_normalized	0.0728
566	thioguanine_normalized	0.2234
567	immunophenotype	B
567	molecular subtype	ETV6-RUNX1
567	Protocol	T16
567	NCI risk	SR
567	Age at diagnosis	3
567	WBC at diagnosis	24.9
567	Sex	F
567	Genetically-defined race	White
567	Asparaginase (IU/ml)	0.1948917
567	Bortezomib (nM)	0
567	CHZ868 (nM)	0
567	Cytarabine (µM)	2.962441
567	Dasatinib (nM)	0
567	Daunorubicin (µM)	0
567	Dexamethasone  (µM)	0.008456653
567	Ibrutinib (µM)	0
567	Mercaptopurine (µM)	352.4246
567	Nelarabine (µM)	0
567	Panobinostat (nM)	0
567	Prednisolone (µM)	0.0075
567	Ruxolitinib (nM)	0
567	Thioguanine (µM)	14.87789
567	Trametinib (nM)	0
567	Venetoclax (nM)	0
567	Vincristine (µM)	0.3821668
567	Vorinostat (nM)	0
567	asparagise_normalized	0.5106
567	cytarabine_normalized	0.6208
567	dexamethasone_normalized	0.306
567	mercaptopurine_normalized	0.3881
567	prednisolone_normalized	0
567	thioguanine_normalized	0.1341
567	vincristine_normalized	0.2911
568	immunophenotype	T
568	molecular subtype	T-ALL
568	Protocol	T16
568	NCI risk	HR
568	Age at diagnosis	5.6
568	WBC at diagnosis	183.6
568	Sex	F
568	Genetically-defined race	White
568	Asparaginase (IU/ml)	0
568	Bortezomib (nM)	0
568	CHZ868 (nM)	0
568	Cytarabine (µM)	82.2
568	Dasatinib (nM)	0
568	Daunorubicin (µM)	0.4348834
568	Dexamethasone  (µM)	0
568	Ibrutinib (µM)	0
568	Mercaptopurine (µM)	0
568	Nelarabine (µM)	0
568	Panobinostat (nM)	0
568	Prednisolone (µM)	0
568	Ruxolitinib (nM)	0
568	Thioguanine (µM)	0
568	Trametinib (nM)	0
568	Venetoclax (nM)	0
568	Vincristine (µM)	0
568	Vorinostat (nM)	0
568	cytarabine_normalized	1
568	daunorubicin_normalized	0.7033
569	immunophenotype	T
569	molecular subtype	T-ALL
569	Protocol	T16
569	NCI risk	HR
569	Age at diagnosis	18
569	WBC at diagnosis	31.1
569	Sex	M
569	Genetically-defined race	White
569	Asparaginase (IU/ml)	20
569	Bortezomib (nM)	0
569	CHZ868 (nM)	0
569	Cytarabine (µM)	14.92045
569	Dasatinib (nM)	0
569	Daunorubicin (µM)	0.3042348
569	Dexamethasone  (µM)	23.2
569	Ibrutinib (µM)	0
569	Mercaptopurine (µM)	536.4949
569	Nelarabine (µM)	0
569	Panobinostat (nM)	0
569	Prednisolone (µM)	1006
569	Ruxolitinib (nM)	0
569	Thioguanine (µM)	18.77795
569	Trametinib (nM)	0
569	Venetoclax (nM)	0
569	Vincristine (µM)	108.34
569	Vorinostat (nM)	0
569	asparagise_normalized	1
569	cytarabine_normalized	0.8539
569	daunorubicin_normalized	0.6528
569	dexamethasone_normalized	1
569	mercaptopurine_normalized	0.5094
569	prednisolone_normalized	1
569	thioguanine_normalized	0.2012
569	vincristine_normalized	1
570	immunophenotype	B
570	molecular subtype	ETV6-RUNX1
570	Protocol	T16
570	NCI risk	SR
570	Age at diagnosis	2.9
570	WBC at diagnosis	19.9
570	Sex	M
570	Genetically-defined race	black
570	Asparaginase (IU/ml)	1.83004202
570	Bortezomib (nM)	0
570	CHZ868 (nM)	0
570	Cytarabine (µM)	3.886396355
570	Dasatinib (nM)	0
570	Daunorubicin (µM)	0
570	Dexamethasone  (µM)	0
570	Ibrutinib (µM)	0
570	Mercaptopurine (µM)	5876
570	Nelarabine (µM)	0
570	Panobinostat (nM)	0
570	Prednisolone (µM)	0
570	Ruxolitinib (nM)	0
570	Thioguanine (µM)	39.53486
570	Trametinib (nM)	0
570	Venetoclax (nM)	0
570	Vincristine (µM)	7.855181
570	Vorinostat (nM)	0
570	asparagise_normalized	0.789
570	cytarabine_normalized	0.6599
570	mercaptopurine_normalized	1
570	thioguanine_normalized	0.4161
570	vincristine_normalized	0.7237
571	immunophenotype	B
571	molecular subtype	TCF3-PBX1
571	Protocol	T16
571	NCI risk	HR
571	Age at diagnosis	2.6
571	WBC at diagnosis	141.6
571	Sex	M
571	Genetically-defined race	Hispanic
571	Asparaginase (IU/ml)	0.1675135
571	Bortezomib (nM)	0
571	CHZ868 (nM)	0
571	Cytarabine (µM)	0.1199288
571	Dasatinib (nM)	0
571	Daunorubicin (µM)	0
571	Dexamethasone  (µM)	0.03475731
571	Ibrutinib (µM)	0
571	Mercaptopurine (µM)	45.9
571	Nelarabine (µM)	0
571	Panobinostat (nM)	0
571	Prednisolone (µM)	0.0799685
571	Ruxolitinib (nM)	0
571	Thioguanine (µM)	4.675
571	Trametinib (nM)	0
571	Venetoclax (nM)	0
571	Vincristine (µM)	0.025
571	Vorinostat (nM)	0
571	asparagise_normalized	0.4918
571	cytarabine_normalized	0.1583
571	dexamethasone_normalized	0.4418
571	mercaptopurine_normalized	0
571	prednisolone_normalized	0.1606
571	thioguanine_normalized	0
571	vincristine_normalized	0
572	immunophenotype	B
572	molecular subtype	ETV6-RUNX1
572	Protocol	T16
572	NCI risk	SR
572	Age at diagnosis	8.1
572	WBC at diagnosis	39.1
572	Sex	F
572	Genetically-defined race	black
572	Asparaginase (IU/ml)	20
572	Bortezomib (nM)	0
572	CHZ868 (nM)	0
572	Cytarabine (µM)	0.02
572	Dasatinib (nM)	0
572	Daunorubicin (µM)	0
572	Dexamethasone  (µM)	0
572	Ibrutinib (µM)	0
572	Mercaptopurine (µM)	1300.1
572	Nelarabine (µM)	0
572	Panobinostat (nM)	0
572	Prednisolone (µM)	0.4790074
572	Ruxolitinib (nM)	0
572	Thioguanine (µM)	33.27203
572	Trametinib (nM)	0
572	Venetoclax (nM)	0
572	Vincristine (µM)	108.34
572	Vorinostat (nM)	0
572	asparagise_normalized	1
572	cytarabine_normalized	0
572	mercaptopurine_normalized	0.7648
572	prednisolone_normalized	0.3324
572	thioguanine_normalized	0.3663
572	vincristine_normalized	1
573	immunophenotype	B
573	molecular subtype	PAX5alt
573	Protocol	T16
573	NCI risk	HR
573	Age at diagnosis	17.7
573	WBC at diagnosis	1.8
573	Sex	M
573	Genetically-defined race	Asian/Other
573	Asparaginase (IU/ml)	20
573	Bortezomib (nM)	0
573	CHZ868 (nM)	0
573	Cytarabine (µM)	4.579889
573	Dasatinib (nM)	0
573	Daunorubicin (µM)	0
573	Dexamethasone  (µM)	0
573	Ibrutinib (µM)	0
573	Mercaptopurine (µM)	0
573	Nelarabine (µM)	0
573	Panobinostat (nM)	0
573	Prednisolone (µM)	0
573	Ruxolitinib (nM)	0
573	Thioguanine (µM)	598
573	Trametinib (nM)	0
573	Venetoclax (nM)	0
573	Vincristine (µM)	108.34
573	Vorinostat (nM)	0
573	asparagise_normalized	1
573	cytarabine_normalized	0.6836
573	thioguanine_normalized	1
573	vincristine_normalized	1
574	immunophenotype	B
574	molecular subtype	KMT2A
574	Protocol	T16
574	NCI risk	HR
574	Age at diagnosis	0.8
574	WBC at diagnosis	32.9
574	Sex	M
574	Genetically-defined race	Asian/Other
574	Asparaginase (IU/ml)	20
574	Bortezomib (nM)	0
574	CHZ868 (nM)	0
574	Cytarabine (µM)	0.2111309
574	Dasatinib (nM)	0
574	Daunorubicin (µM)	0
574	Dexamethasone  (µM)	0.015839614
574	Ibrutinib (µM)	0
574	Mercaptopurine (µM)	348.9218
574	Nelarabine (µM)	0
574	Panobinostat (nM)	0
574	Prednisolone (µM)	0.07182738
574	Ruxolitinib (nM)	0
574	Thioguanine (µM)	22.9833
574	Trametinib (nM)	0
574	Venetoclax (nM)	0
574	Vincristine (µM)	0.025
574	Vorinostat (nM)	0
574	asparagise_normalized	1
574	cytarabine_normalized	0.2399
574	dexamethasone_normalized	0.3663
574	mercaptopurine_normalized	0.3853
574	prednisolone_normalized	0.1503
574	thioguanine_normalized	0.2596
574	vincristine_normalized	0
575	immunophenotype	B
575	molecular subtype	KMT2A
575	Protocol	T16
575	NCI risk	HR
575	Age at diagnosis	1.5
575	WBC at diagnosis	56.7
575	Sex	F
575	Genetically-defined race	black
575	Asparaginase (IU/ml)	1.482403
575	Bortezomib (nM)	0
575	CHZ868 (nM)	0
575	Cytarabine (µM)	0.2793077
575	Dasatinib (nM)	0
575	Daunorubicin (µM)	0
575	Dexamethasone  (µM)	0
575	Ibrutinib (µM)	0
575	Mercaptopurine (µM)	241.5598
575	Nelarabine (µM)	0
575	Panobinostat (nM)	0
575	Prednisolone (µM)	0
575	Ruxolitinib (nM)	0
575	Thioguanine (µM)	0
575	Trametinib (nM)	0
575	Venetoclax (nM)	0
575	Vincristine (µM)	0
575	Vorinostat (nM)	0
575	asparagise_normalized	0.7628
575	cytarabine_normalized	0.2802
575	mercaptopurine_normalized	0.2792
576	immunophenotype	B
576	molecular subtype	PAX5 P80R
576	Protocol	T16
576	NCI risk	SR
576	Age at diagnosis	3.9
576	WBC at diagnosis	9.3
576	Sex	M
576	Genetically-defined race	White
576	Asparaginase (IU/ml)	20
576	Bortezomib (nM)	0
576	CHZ868 (nM)	0
576	Cytarabine (µM)	82.2
576	Dasatinib (nM)	0
576	Daunorubicin (µM)	0
576	Dexamethasone  (µM)	23.2
576	Ibrutinib (µM)	0
576	Mercaptopurine (µM)	5876
576	Nelarabine (µM)	0
576	Panobinostat (nM)	0
576	Prednisolone (µM)	1006
576	Ruxolitinib (nM)	0
576	Thioguanine (µM)	598
576	Trametinib (nM)	0
576	Venetoclax (nM)	0
576	Vincristine (µM)	108.34
576	Vorinostat (nM)	0
576	asparagise_normalized	1
576	cytarabine_normalized	1
576	dexamethasone_normalized	1
576	mercaptopurine_normalized	1
576	prednisolone_normalized	1
576	thioguanine_normalized	1
576	vincristine_normalized	1
577	immunophenotype	B
577	molecular subtype	Hyperdiploid
577	Protocol	T16
577	NCI risk	HR
577	Age at diagnosis	1.5
577	WBC at diagnosis	84.4
577	Sex	M
577	Genetically-defined race	White
577	Asparaginase (IU/ml)	20
577	Bortezomib (nM)	0
577	CHZ868 (nM)	0
577	Cytarabine (µM)	82.2
577	Dasatinib (nM)	0
577	Daunorubicin (µM)	0
577	Dexamethasone  (µM)	23.2
577	Ibrutinib (µM)	0
577	Mercaptopurine (µM)	5876
577	Nelarabine (µM)	0
577	Panobinostat (nM)	0
577	Prednisolone (µM)	1006
577	Ruxolitinib (nM)	0
577	Thioguanine (µM)	64.0317
577	Trametinib (nM)	0
577	Venetoclax (nM)	0
577	Vincristine (µM)	0
577	Vorinostat (nM)	0
577	asparagise_normalized	1
577	cytarabine_normalized	1
577	dexamethasone_normalized	1
577	mercaptopurine_normalized	1
577	prednisolone_normalized	1
577	thioguanine_normalized	0.5553
578	immunophenotype	B
578	molecular subtype	MEF2D
578	Protocol	T15
578	NCI risk	HR
578	Age at diagnosis	8.5
578	WBC at diagnosis	87.6
578	Sex	M
578	Genetically-defined race	black
578	Asparaginase (IU/ml)	0.0016
578	Bortezomib (nM)	0
578	CHZ868 (nM)	0
578	Cytarabine (µM)	0
578	Dasatinib (nM)	0
578	Daunorubicin (µM)	0
578	Dexamethasone  (µM)	0.003892491
578	Ibrutinib (µM)	0
578	Mercaptopurine (µM)	780.7116
578	Nelarabine (µM)	0
578	Panobinostat (nM)	0
578	Prednisolone (µM)	0.06614705
578	Ruxolitinib (nM)	0
578	Thioguanine (µM)	69.7037
578	Trametinib (nM)	0
578	Venetoclax (nM)	0
578	Vincristine (µM)	0.025
578	Vorinostat (nM)	0
578	asparagise_normalized	0
578	dexamethasone_normalized	0.2314
578	mercaptopurine_normalized	0.6176
578	prednisolone_normalized	0.1424
578	thioguanine_normalized	0.5798
578	vincristine_normalized	0
579	immunophenotype	B
579	molecular subtype	KMT2A
579	Protocol	T16
579	NCI risk	HR
579	Age at diagnosis	15
579	WBC at diagnosis	138.6
579	Sex	M
579	Genetically-defined race	black
579	Asparaginase (IU/ml)	0.03283363
579	Bortezomib (nM)	0
579	CHZ868 (nM)	0
579	Cytarabine (µM)	2.617102
579	Dasatinib (nM)	0
579	Daunorubicin (µM)	0
579	Dexamethasone  (µM)	0
579	Ibrutinib (µM)	0
579	Mercaptopurine (µM)	0
579	Nelarabine (µM)	0
579	Panobinostat (nM)	0
579	Prednisolone (µM)	1006
579	Ruxolitinib (nM)	0
579	Thioguanine (µM)	4.675
579	Trametinib (nM)	0
579	Venetoclax (nM)	0
579	Vincristine (µM)	0.1520641
579	Vorinostat (nM)	0
579	asparagise_normalized	0.2893
579	cytarabine_normalized	0.6029
579	prednisolone_normalized	1
579	thioguanine_normalized	0
579	vincristine_normalized	0.1592
580	immunophenotype	B
580	molecular subtype	ETV6-RUNX1
580	Protocol	T16
580	NCI risk	SR
580	Age at diagnosis	3.8
580	WBC at diagnosis	12.3
580	Sex	M
580	Genetically-defined race	White
580	Asparaginase (IU/ml)	0
580	Bortezomib (nM)	0
580	CHZ868 (nM)	0
580	Cytarabine (µM)	0
580	Dasatinib (nM)	0
580	Daunorubicin (µM)	0
580	Dexamethasone  (µM)	0.336387
580	Ibrutinib (µM)	0
580	Mercaptopurine (µM)	0
580	Nelarabine (µM)	0
580	Panobinostat (nM)	0
580	Prednisolone (µM)	0.0075
580	Ruxolitinib (nM)	0
580	Thioguanine (µM)	15.35631
580	Trametinib (nM)	0
580	Venetoclax (nM)	0
580	Vincristine (µM)	0
580	Vorinostat (nM)	0
580	dexamethasone_normalized	0.6598
580	prednisolone_normalized	0
580	thioguanine_normalized	0.1432
581	immunophenotype	B
581	molecular subtype	ETV6-RUNX1
581	Protocol	T16
581	NCI risk	SR
581	Age at diagnosis	2.6
581	WBC at diagnosis	4.7
581	Sex	F
581	Genetically-defined race	White
581	Asparaginase (IU/ml)	0
581	Bortezomib (nM)	0
581	CHZ868 (nM)	0
581	Cytarabine (µM)	0
581	Dasatinib (nM)	0
581	Daunorubicin (µM)	0
581	Dexamethasone  (µM)	0
581	Ibrutinib (µM)	0
581	Mercaptopurine (µM)	217.8601
581	Nelarabine (µM)	0
581	Panobinostat (nM)	0
581	Prednisolone (µM)	0
581	Ruxolitinib (nM)	0
581	Thioguanine (µM)	136.0046
581	Trametinib (nM)	0
581	Venetoclax (nM)	0
581	Vincristine (µM)	0
581	Vorinostat (nM)	0
581	mercaptopurine_normalized	0.2494
581	thioguanine_normalized	0.7727
582	immunophenotype	B
582	molecular subtype	Hyperdiploid
582	Protocol	T16
582	NCI risk	SR
582	Age at diagnosis	5.3
582	WBC at diagnosis	6.6
582	Sex	F
582	Genetically-defined race	White
582	Asparaginase (IU/ml)	0.0016
582	Bortezomib (nM)	0
582	CHZ868 (nM)	0
582	Cytarabine (µM)	0.323141
582	Dasatinib (nM)	0
582	Daunorubicin (µM)	0
582	Dexamethasone  (µM)	0.197704
582	Ibrutinib (µM)	0
582	Mercaptopurine (µM)	95.9182
582	Nelarabine (µM)	0
582	Panobinostat (nM)	0
582	Prednisolone (µM)	0.09586138
582	Ruxolitinib (nM)	0
582	Thioguanine (µM)	4.675
582	Trametinib (nM)	0
582	Venetoclax (nM)	0
582	Vincristine (µM)	0.025
582	Vorinostat (nM)	0
582	asparagise_normalized	0
582	cytarabine_normalized	0.3013
582	dexamethasone_normalized	0.6088
582	mercaptopurine_normalized	0.0127
582	prednisolone_normalized	0.178
582	thioguanine_normalized	0
582	vincristine_normalized	0
583	immunophenotype	B
583	molecular subtype	ETV6-RUNX1
583	Protocol	T16
583	NCI risk	SR
583	Age at diagnosis	2.8
583	WBC at diagnosis	20
583	Sex	M
583	Genetically-defined race	Hispanic
583	Asparaginase (IU/ml)	0.0016
583	Bortezomib (nM)	0
583	CHZ868 (nM)	0
583	Cytarabine (µM)	7.106521
583	Dasatinib (nM)	0
583	Daunorubicin (µM)	0
583	Dexamethasone  (µM)	0.0150253
583	Ibrutinib (µM)	0
583	Mercaptopurine (µM)	246.9701
583	Nelarabine (µM)	0
583	Panobinostat (nM)	0
583	Prednisolone (µM)	0.0075
583	Ruxolitinib (nM)	0
583	Thioguanine (µM)	12.16053
583	Trametinib (nM)	0
583	Venetoclax (nM)	0
583	Vincristine (µM)	2.085739
583	Vorinostat (nM)	0
583	asparagise_normalized	0
583	cytarabine_normalized	0.7469
583	dexamethasone_normalized	0.3612
583	mercaptopurine_normalized	0.2855
583	prednisolone_normalized	0
583	thioguanine_normalized	0.0758
583	vincristine_normalized	0.5339
584	immunophenotype	B
584	molecular subtype	TCF3-PBX1
584	Protocol	T16
584	NCI risk	SR
584	Age at diagnosis	6.2
584	WBC at diagnosis	32
584	Sex	F
584	Genetically-defined race	Hispanic
584	Asparaginase (IU/ml)	20
584	Bortezomib (nM)	0
584	CHZ868 (nM)	0
584	Cytarabine (µM)	0.3373494
584	Dasatinib (nM)	0
584	Daunorubicin (µM)	0
584	Dexamethasone  (µM)	0.000175
584	Ibrutinib (µM)	0
584	Mercaptopurine (µM)	45.9
584	Nelarabine (µM)	0
584	Panobinostat (nM)	0
584	Prednisolone (µM)	0.02664835
584	Ruxolitinib (nM)	0
584	Thioguanine (µM)	13.04437137
584	Trametinib (nM)	0
584	Venetoclax (nM)	0
584	Vincristine (µM)	0.1960361
584	Vorinostat (nM)	0
584	asparagise_normalized	1
584	cytarabine_normalized	0.3075
584	dexamethasone_normalized	0
584	mercaptopurine_normalized	0
584	prednisolone_normalized	0.0551
584	thioguanine_normalized	0.0961
584	vincristine_normalized	0.1955
585	immunophenotype	B
585	molecular subtype	Hyperdiploid
585	Protocol	T16
585	NCI risk	SR
585	Age at diagnosis	8.8
585	WBC at diagnosis	36.1
585	Sex	F
585	Genetically-defined race	White
585	Asparaginase (IU/ml)	0.3378627
585	Bortezomib (nM)	0
585	CHZ868 (nM)	0
585	Cytarabine (µM)	5.469541803
585	Dasatinib (nM)	0
585	Daunorubicin (µM)	0
585	Dexamethasone  (µM)	0.4360055
585	Ibrutinib (µM)	0
585	Mercaptopurine (µM)	623.887
585	Nelarabine (µM)	0
585	Panobinostat (nM)	0
585	Prednisolone (µM)	0.3489911
585	Ruxolitinib (nM)	0
585	Thioguanine (µM)	31.43368015
585	Trametinib (nM)	0
585	Venetoclax (nM)	0
585	Vincristine (µM)	108.34
585	Vorinostat (nM)	0
585	asparagise_normalized	0.579
585	cytarabine_normalized	0.7092
585	dexamethasone_normalized	0.6848
585	mercaptopurine_normalized	0.5529
585	prednisolone_normalized	0.302
585	thioguanine_normalized	0.3499
585	vincristine_normalized	1
586	immunophenotype	T
586	molecular subtype	ETP
586	Protocol	T16
586	NCI risk	SR
586	Age at diagnosis	8.9
586	WBC at diagnosis	29.3
586	Sex	M
586	Genetically-defined race	White
586	Asparaginase (IU/ml)	20
586	Bortezomib (nM)	0
586	CHZ868 (nM)	0
586	Cytarabine (µM)	82.2
586	Dasatinib (nM)	0
586	Daunorubicin (µM)	0
586	Dexamethasone  (µM)	2.833292956
586	Ibrutinib (µM)	0
586	Mercaptopurine (µM)	222.0985
586	Nelarabine (µM)	0
586	Panobinostat (nM)	0
586	Prednisolone (µM)	1006
586	Ruxolitinib (nM)	0
586	Thioguanine (µM)	14.28002
586	Trametinib (nM)	0
586	Venetoclax (nM)	0
586	Vincristine (µM)	108.34
586	Vorinostat (nM)	0
586	asparagise_normalized	1
586	cytarabine_normalized	1
586	dexamethasone_normalized	0.8646
586	mercaptopurine_normalized	0.2549
586	prednisolone_normalized	1
586	thioguanine_normalized	0.1222
586	vincristine_normalized	1
587	immunophenotype	B
587	molecular subtype	B-other
587	Protocol	T16
587	NCI risk	HR
587	Age at diagnosis	6.3
587	WBC at diagnosis	58.8
587	Sex	M
587	Genetically-defined race	White
587	Asparaginase (IU/ml)	0.129641
587	Bortezomib (nM)	0
587	CHZ868 (nM)	0
587	Cytarabine (µM)	1.447848
587	Dasatinib (nM)	0
587	Daunorubicin (µM)	0
587	Dexamethasone  (µM)	1.482766
587	Ibrutinib (µM)	0
587	Mercaptopurine (µM)	157.7243
587	Nelarabine (µM)	0
587	Panobinostat (nM)	0
587	Prednisolone (µM)	0.8980643
587	Ruxolitinib (nM)	0
587	Thioguanine (µM)	4.675
587	Trametinib (nM)	0
587	Venetoclax (nM)	0
587	Vincristine (µM)	0.1008686
587	Vorinostat (nM)	0
587	asparagise_normalized	0.46
587	cytarabine_normalized	0.5175
587	dexamethasone_normalized	0.8024
587	mercaptopurine_normalized	0.1562
587	prednisolone_normalized	0.3927
587	thioguanine_normalized	0
587	vincristine_normalized	0.1004
588	immunophenotype	B
588	molecular subtype	B-other
588	Protocol	T16
588	NCI risk	HR
588	Age at diagnosis	12.2
588	WBC at diagnosis	1.9
588	Sex	M
588	Genetically-defined race	White
588	Asparaginase (IU/ml)	0.0016
588	Bortezomib (nM)	0
588	CHZ868 (nM)	0
588	Cytarabine (µM)	11.82768
588	Dasatinib (nM)	0
588	Daunorubicin (µM)	0
588	Dexamethasone  (µM)	23.2
588	Ibrutinib (µM)	0
588	Mercaptopurine (µM)	1192.732
588	Nelarabine (µM)	0
588	Panobinostat (nM)	0
588	Prednisolone (µM)	298.3914
588	Ruxolitinib (nM)	0
588	Thioguanine (µM)	9.639951
588	Trametinib (nM)	0
588	Venetoclax (nM)	0
588	Vincristine (µM)	0.05819244
588	Vorinostat (nM)	0
588	asparagise_normalized	0
588	cytarabine_normalized	0.8204
588	dexamethasone_normalized	1
588	mercaptopurine_normalized	0.7399
588	prednisolone_normalized	0.9499
588	thioguanine_normalized	0.0088
588	vincristine_normalized	0.0217
589	immunophenotype	B
589	molecular subtype	ETV6-RUNX1
589	Protocol	T16
589	NCI risk	SR
589	Age at diagnosis	3.8
589	WBC at diagnosis	11.9
589	Sex	M
589	Genetically-defined race	White
589	Asparaginase (IU/ml)	0.1168296
589	Bortezomib (nM)	0
589	CHZ868 (nM)	0
589	Cytarabine (µM)	0.1855044
589	Dasatinib (nM)	0
589	Daunorubicin (µM)	0
589	Dexamethasone  (µM)	0.5776184
589	Ibrutinib (µM)	0
589	Mercaptopurine (µM)	2590.468
589	Nelarabine (µM)	0
589	Panobinostat (nM)	0
589	Prednisolone (µM)	0.07485599
589	Ruxolitinib (nM)	0
589	Thioguanine (µM)	4.675
589	Trametinib (nM)	0
589	Venetoclax (nM)	0
589	Vincristine (µM)	0.025
589	Vorinostat (nM)	0
589	asparagise_normalized	0.4471
589	cytarabine_normalized	0.2212
589	dexamethasone_normalized	0.7118
589	mercaptopurine_normalized	0.9637
589	prednisolone_normalized	0.1543
589	thioguanine_normalized	0
589	vincristine_normalized	0
590	immunophenotype	T
590	molecular subtype	ETP
590	Protocol	T16
590	NCI risk	HR
590	Age at diagnosis	10.6
590	WBC at diagnosis	13.9
590	Sex	M
590	Genetically-defined race	black
590	Asparaginase (IU/ml)	0.0322095
590	Bortezomib (nM)	0
590	CHZ868 (nM)	0
590	Cytarabine (µM)	82.2
590	Dasatinib (nM)	0
590	Daunorubicin (µM)	7.1
590	Dexamethasone  (µM)	1.023508
590	Ibrutinib (µM)	0
590	Mercaptopurine (µM)	242.9703
590	Nelarabine (µM)	0
590	Panobinostat (nM)	0
590	Prednisolone (µM)	1006
590	Ruxolitinib (nM)	0
590	Thioguanine (µM)	14.82961
590	Trametinib (nM)	0
590	Venetoclax (nM)	0
590	Vincristine (µM)	108.34
590	Vorinostat (nM)	0
590	asparagise_normalized	0.2869
590	cytarabine_normalized	1
590	daunorubicin_normalized	1
590	dexamethasone_normalized	0.7668
590	mercaptopurine_normalized	0.2808
590	prednisolone_normalized	1
590	thioguanine_normalized	0.1331
590	vincristine_normalized	1
591	immunophenotype	B
591	molecular subtype	Hyperdiploid
591	Protocol	T16
591	NCI risk	SR
591	Age at diagnosis	8
591	WBC at diagnosis	6.2
591	Sex	F
591	Genetically-defined race	White
591	Asparaginase (IU/ml)	0.3459314
591	Bortezomib (nM)	0
591	CHZ868 (nM)	0
591	Cytarabine (µM)	0.639178
591	Dasatinib (nM)	0
591	Daunorubicin (µM)	0
591	Dexamethasone  (µM)	23.2
591	Ibrutinib (µM)	0
591	Mercaptopurine (µM)	218.1489
591	Nelarabine (µM)	0
591	Panobinostat (nM)	0
591	Prednisolone (µM)	1006
591	Ruxolitinib (nM)	0
591	Thioguanine (µM)	12.44516
591	Trametinib (nM)	0
591	Venetoclax (nM)	0
591	Vincristine (µM)	3.912353
591	Vorinostat (nM)	0
591	asparagise_normalized	0.582
591	cytarabine_normalized	0.3996
591	dexamethasone_normalized	1
591	mercaptopurine_normalized	0.2497
591	prednisolone_normalized	1
591	thioguanine_normalized	0.0825
591	vincristine_normalized	0.6239
592	immunophenotype	T
592	molecular subtype	T-ALL
592	Protocol	T16
592	NCI risk	HR
592	Age at diagnosis	1.4
592	WBC at diagnosis	395
592	Sex	M
592	Genetically-defined race	black
592	Asparaginase (IU/ml)	0.0016
592	Bortezomib (nM)	0
592	CHZ868 (nM)	0
592	Cytarabine (µM)	4.81146
592	Dasatinib (nM)	0.05
592	Daunorubicin (µM)	0.126041
592	Dexamethasone  (µM)	23.2
592	Ibrutinib (µM)	0
592	Mercaptopurine (µM)	45.9
592	Nelarabine (µM)	0
592	Panobinostat (nM)	0
592	Prednisolone (µM)	0
592	Ruxolitinib (nM)	0
592	Thioguanine (µM)	4.675
592	Trametinib (nM)	0
592	Venetoclax (nM)	0
592	Vincristine (µM)	0.5064268
592	Vorinostat (nM)	0
592	asparagise_normalized	0
592	cytarabine_normalized	0.6907
592	dasatinib_normalized	0
592	daunorubicin_normalized	0.5283
592	dexamethasone_normalized	1
592	mercaptopurine_normalized	0
592	thioguanine_normalized	0
592	vincristine_normalized	0.3313
593	immunophenotype	B
593	molecular subtype	Hyperdiploid
593	Protocol	T16
593	NCI risk	HR
593	Age at diagnosis	14.7
593	WBC at diagnosis	2
593	Sex	M
593	Genetically-defined race	White
593	Asparaginase (IU/ml)	0
593	Bortezomib (nM)	0
593	CHZ868 (nM)	0
593	Cytarabine (µM)	0
593	Dasatinib (nM)	0
593	Daunorubicin (µM)	0
593	Dexamethasone  (µM)	0
593	Ibrutinib (µM)	0
593	Mercaptopurine (µM)	5876
593	Nelarabine (µM)	0
593	Panobinostat (nM)	0
593	Prednisolone (µM)	0
593	Ruxolitinib (nM)	0
593	Thioguanine (µM)	598
593	Trametinib (nM)	0
593	Venetoclax (nM)	0
593	Vincristine (µM)	0
593	Vorinostat (nM)	0
593	mercaptopurine_normalized	1
593	thioguanine_normalized	1
594	immunophenotype	B
594	molecular subtype	Hyperdiploid
594	Protocol	T16
594	NCI risk	HR
594	Age at diagnosis	11.9
594	WBC at diagnosis	4.4
594	Sex	F
594	Genetically-defined race	Hispanic
594	Asparaginase (IU/ml)	20
594	Bortezomib (nM)	0
594	CHZ868 (nM)	0
594	Cytarabine (µM)	3.442827
594	Dasatinib (nM)	0
594	Daunorubicin (µM)	0
594	Dexamethasone  (µM)	23.2
594	Ibrutinib (µM)	0
594	Mercaptopurine (µM)	536.8855
594	Nelarabine (µM)	0
594	Panobinostat (nM)	0
594	Prednisolone (µM)	1006
594	Ruxolitinib (nM)	0
594	Thioguanine (µM)	4.675
594	Trametinib (nM)	0
594	Venetoclax (nM)	0
594	Vincristine (µM)	0.025
594	Vorinostat (nM)	0
594	asparagise_normalized	1
594	cytarabine_normalized	0.6424
594	dexamethasone_normalized	1
594	mercaptopurine_normalized	0.5096
594	prednisolone_normalized	1
594	thioguanine_normalized	0
594	vincristine_normalized	0
595	immunophenotype	B
595	molecular subtype	B-other
595	Protocol	T16
595	NCI risk	SR
595	Age at diagnosis	5
595	WBC at diagnosis	26.6
595	Sex	M
595	Genetically-defined race	White
595	Asparaginase (IU/ml)	0.0016
595	Bortezomib (nM)	0
595	CHZ868 (nM)	0
595	Cytarabine (µM)	4.934926
595	Dasatinib (nM)	0
595	Daunorubicin (µM)	0
595	Dexamethasone  (µM)	0
595	Ibrutinib (µM)	0
595	Mercaptopurine (µM)	0
595	Nelarabine (µM)	0
595	Panobinostat (nM)	0
595	Prednisolone (µM)	0
595	Ruxolitinib (nM)	0
595	Thioguanine (µM)	9.548001
595	Trametinib (nM)	0
595	Venetoclax (nM)	0
595	Vincristine (µM)	0
595	Vorinostat (nM)	0
595	asparagise_normalized	0
595	cytarabine_normalized	0.6943
595	thioguanine_normalized	0.006
596	immunophenotype	T
596	molecular subtype	T-ALL
596	Protocol	T16
596	NCI risk	HR
596	Age at diagnosis	12.3
596	WBC at diagnosis	87.8
596	Sex	M
596	Genetically-defined race	black
596	Asparaginase (IU/ml)	20
596	Bortezomib (nM)	0
596	CHZ868 (nM)	0
596	Cytarabine (µM)	3.286993
596	Dasatinib (nM)	0
596	Daunorubicin (µM)	0.7627388
596	Dexamethasone  (µM)	23.2
596	Ibrutinib (µM)	0
596	Mercaptopurine (µM)	0
596	Nelarabine (µM)	0
596	Panobinostat (nM)	0
596	Prednisolone (µM)	0
596	Ruxolitinib (nM)	0
596	Thioguanine (µM)	0
596	Trametinib (nM)	0
596	Venetoclax (nM)	0
596	Vincristine (µM)	0
596	Vorinostat (nM)	0
596	asparagise_normalized	1
596	cytarabine_normalized	0.6357
596	daunorubicin_normalized	0.7827
596	dexamethasone_normalized	1
597	immunophenotype	T
597	molecular subtype	T-ALL
597	Protocol	T16
597	NCI risk	HR
597	Age at diagnosis	12.8
597	WBC at diagnosis	9.6
597	Sex	M
597	Genetically-defined race	White
597	Asparaginase (IU/ml)	0
597	Bortezomib (nM)	0
597	CHZ868 (nM)	0
597	Cytarabine (µM)	82.2
597	Dasatinib (nM)	0
597	Daunorubicin (µM)	0.3072379
597	Dexamethasone  (µM)	23.2
597	Ibrutinib (µM)	0
597	Mercaptopurine (µM)	0
597	Nelarabine (µM)	0
597	Panobinostat (nM)	0
597	Prednisolone (µM)	0
597	Ruxolitinib (nM)	0
597	Thioguanine (µM)	0
597	Trametinib (nM)	0
597	Venetoclax (nM)	0
597	Vincristine (µM)	0
597	Vorinostat (nM)	0
597	cytarabine_normalized	1
597	daunorubicin_normalized	0.6542
597	dexamethasone_normalized	1
598	immunophenotype	B
598	molecular subtype	Hyperdiploid
598	Protocol	T16
598	NCI risk	SR
598	Age at diagnosis	5.3
598	WBC at diagnosis	20.4
598	Sex	M
598	Genetically-defined race	White
598	Asparaginase (IU/ml)	0
598	Bortezomib (nM)	0
598	CHZ868 (nM)	0
598	Cytarabine (µM)	0
598	Dasatinib (nM)	0
598	Daunorubicin (µM)	0
598	Dexamethasone  (µM)	0.4676491
598	Ibrutinib (µM)	0
598	Mercaptopurine (µM)	402.7776
598	Nelarabine (µM)	0
598	Panobinostat (nM)	0
598	Prednisolone (µM)	0.04246995
598	Ruxolitinib (nM)	0
598	Thioguanine (µM)	12.5663
598	Trametinib (nM)	0
598	Venetoclax (nM)	0
598	Vincristine (µM)	0
598	Vorinostat (nM)	0
598	dexamethasone_normalized	0.6915
598	mercaptopurine_normalized	0.4267
598	prednisolone_normalized	0.0999
598	thioguanine_normalized	0.0853
599	immunophenotype	B
599	molecular subtype	TCF3-PBX1
599	Protocol	T16
599	NCI risk	HR
599	Age at diagnosis	2.9
599	WBC at diagnosis	153.3
599	Sex	F
599	Genetically-defined race	White
599	Asparaginase (IU/ml)	2.140941
599	Bortezomib (nM)	0
599	CHZ868 (nM)	0
599	Cytarabine (µM)	0
599	Dasatinib (nM)	0
599	Daunorubicin (µM)	0
599	Dexamethasone  (µM)	0
599	Ibrutinib (µM)	0
599	Mercaptopurine (µM)	45.9
599	Nelarabine (µM)	0
599	Panobinostat (nM)	0
599	Prednisolone (µM)	0.0075
599	Ruxolitinib (nM)	0
599	Thioguanine (µM)	0
599	Trametinib (nM)	0
599	Venetoclax (nM)	0
599	Vincristine (µM)	0.477997534
599	Vorinostat (nM)	0
599	asparagise_normalized	0.8085
599	mercaptopurine_normalized	0
599	prednisolone_normalized	0
599	vincristine_normalized	0.3231
600	immunophenotype	T
600	molecular subtype	T-ALL
600	Protocol	T16
600	NCI risk	HR
600	Age at diagnosis	3.1
600	WBC at diagnosis	168.2
600	Sex	F
600	Genetically-defined race	White
600	Asparaginase (IU/ml)	0.1706244
600	Bortezomib (nM)	0
600	CHZ868 (nM)	0
600	Cytarabine (µM)	1.958506
600	Dasatinib (nM)	0
600	Daunorubicin (µM)	0.072529609
600	Dexamethasone  (µM)	0.8946921
600	Ibrutinib (µM)	0
600	Mercaptopurine (µM)	285.3162
600	Nelarabine (µM)	0
600	Panobinostat (nM)	0
600	Prednisolone (µM)	0.1200965
600	Ruxolitinib (nM)	0
600	Thioguanine (µM)	4.675
600	Trametinib (nM)	0
600	Venetoclax (nM)	0
600	Vincristine (µM)	4.571402
600	Vorinostat (nM)	0
600	asparagise_normalized	0.4941
600	cytarabine_normalized	0.5611
600	daunorubicin_normalized	0.4502
600	dexamethasone_normalized	0.7538
600	mercaptopurine_normalized	0.3272
600	prednisolone_normalized	0.1996
600	thioguanine_normalized	0
600	vincristine_normalized	0.6462
601	immunophenotype	B
601	molecular subtype	iAMP21
601	Protocol	T16
601	NCI risk	HR
601	Age at diagnosis	4
601	WBC at diagnosis	58.2
601	Sex	M
601	Genetically-defined race	White
601	Asparaginase (IU/ml)	20
601	Bortezomib (nM)	0
601	CHZ868 (nM)	0
601	Cytarabine (µM)	6.701331
601	Dasatinib (nM)	0
601	Daunorubicin (µM)	0
601	Dexamethasone  (µM)	23.2
601	Ibrutinib (µM)	0
601	Mercaptopurine (µM)	5876
601	Nelarabine (µM)	0
601	Panobinostat (nM)	0
601	Prednisolone (µM)	0
601	Ruxolitinib (nM)	0
601	Thioguanine (µM)	598
601	Trametinib (nM)	0
601	Venetoclax (nM)	0
601	Vincristine (µM)	108.34
601	Vorinostat (nM)	0
601	asparagise_normalized	1
601	cytarabine_normalized	0.7385
601	dexamethasone_normalized	1
601	mercaptopurine_normalized	1
601	thioguanine_normalized	1
601	vincristine_normalized	1
602	immunophenotype	B
602	molecular subtype	ETV6-RUNX1
602	Protocol	T16
602	NCI risk	SR
602	Age at diagnosis	4.5
602	WBC at diagnosis	16.2
602	Sex	F
602	Genetically-defined race	White
602	Asparaginase (IU/ml)	0
602	Bortezomib (nM)	0
602	CHZ868 (nM)	0
602	Cytarabine (µM)	0
602	Dasatinib (nM)	0
602	Daunorubicin (µM)	0
602	Dexamethasone  (µM)	0
602	Ibrutinib (µM)	0
602	Mercaptopurine (µM)	424.0692
602	Nelarabine (µM)	0
602	Panobinostat (nM)	0
602	Prednisolone (µM)	0
602	Ruxolitinib (nM)	0
602	Thioguanine (µM)	10.78289
602	Trametinib (nM)	0
602	Venetoclax (nM)	0
602	Vincristine (µM)	0
602	Vorinostat (nM)	0
602	mercaptopurine_normalized	0.4415
602	thioguanine_normalized	0.0411
603	immunophenotype	B
603	molecular subtype	BCR-ABL1
603	Protocol	T16
603	NCI risk	HR
603	Age at diagnosis	6.2
603	WBC at diagnosis	175.4
603	Sex	F
603	Genetically-defined race	White
603	Asparaginase (IU/ml)	20
603	Bortezomib (nM)	0
603	CHZ868 (nM)	0
603	Cytarabine (µM)	3.153576
603	Dasatinib (nM)	0
603	Daunorubicin (µM)	0
603	Dexamethasone  (µM)	23.2
603	Ibrutinib (µM)	0
603	Mercaptopurine (µM)	1095.591
603	Nelarabine (µM)	0
603	Panobinostat (nM)	0
603	Prednisolone (µM)	1006
603	Ruxolitinib (nM)	0
603	Thioguanine (µM)	30.53902
603	Trametinib (nM)	0
603	Venetoclax (nM)	0
603	Vincristine (µM)	0.2531293
603	Vorinostat (nM)	0
603	asparagise_normalized	1
603	cytarabine_normalized	0.6298
603	dexamethasone_normalized	1
603	mercaptopurine_normalized	0.7154
603	prednisolone_normalized	1
603	thioguanine_normalized	0.3416
603	vincristine_normalized	0.2321
604	immunophenotype	B
604	molecular subtype	ETV6-RUNX1
604	Protocol	T16
604	NCI risk	SR
604	Age at diagnosis	3.3
604	WBC at diagnosis	5.3
604	Sex	M
604	Genetically-defined race	White
604	Asparaginase (IU/ml)	0
604	Bortezomib (nM)	0
604	CHZ868 (nM)	0
604	Cytarabine (µM)	0
604	Dasatinib (nM)	0
604	Daunorubicin (µM)	0
604	Dexamethasone  (µM)	0.3172982
604	Ibrutinib (µM)	0
604	Mercaptopurine (µM)	536.5236
604	Nelarabine (µM)	0
604	Panobinostat (nM)	0
604	Prednisolone (µM)	0
604	Ruxolitinib (nM)	0
604	Thioguanine (µM)	18.74794
604	Trametinib (nM)	0
604	Venetoclax (nM)	0
604	Vincristine (µM)	0
604	Vorinostat (nM)	0
604	dexamethasone_normalized	0.6542
604	mercaptopurine_normalized	0.5094
604	thioguanine_normalized	0.2008
605	immunophenotype	B
605	molecular subtype	B-other
605	Protocol	T16
605	NCI risk	SR
605	Age at diagnosis	7.1
605	WBC at diagnosis	5.1
605	Sex	M
605	Genetically-defined race	White
605	Asparaginase (IU/ml)	0.3742087
605	Bortezomib (nM)	0
605	CHZ868 (nM)	0
605	Cytarabine (µM)	1.239284
605	Dasatinib (nM)	0
605	Daunorubicin (µM)	0
605	Dexamethasone  (µM)	0.1384353
605	Ibrutinib (µM)	0
605	Mercaptopurine (µM)	831.2131
605	Nelarabine (µM)	0
605	Panobinostat (nM)	0
605	Prednisolone (µM)	0.08782692
605	Ruxolitinib (nM)	0
605	Thioguanine (µM)	21.23809
605	Trametinib (nM)	0
605	Venetoclax (nM)	0
605	Vincristine (µM)	0.05855565
605	Vorinostat (nM)	0
605	asparagise_normalized	0.5917
605	cytarabine_normalized	0.4951
605	dexamethasone_normalized	0.5745
605	mercaptopurine_normalized	0.6357
605	prednisolone_normalized	0.1696
605	thioguanine_normalized	0.2368
605	vincristine_normalized	0.0226
606	immunophenotype	B
606	molecular subtype	Hyperdiploid
606	Protocol	T16
606	NCI risk	SR
606	Age at diagnosis	7
606	WBC at diagnosis	14.4
606	Sex	F
606	Genetically-defined race	White
606	Asparaginase (IU/ml)	20
606	Bortezomib (nM)	0
606	CHZ868 (nM)	0
606	Cytarabine (µM)	82.2
606	Dasatinib (nM)	0
606	Daunorubicin (µM)	0
606	Dexamethasone  (µM)	0.609021513
606	Ibrutinib (µM)	0
606	Mercaptopurine (µM)	5876
606	Nelarabine (µM)	0
606	Panobinostat (nM)	0
606	Prednisolone (µM)	0
606	Ruxolitinib (nM)	0
606	Thioguanine (µM)	35.61051
606	Trametinib (nM)	0
606	Venetoclax (nM)	0
606	Vincristine (µM)	108.34
606	Vorinostat (nM)	0
606	asparagise_normalized	1
606	cytarabine_normalized	1
606	dexamethasone_normalized	0.7169
606	mercaptopurine_normalized	1
606	thioguanine_normalized	0.3859
606	vincristine_normalized	1
607	immunophenotype	B
607	molecular subtype	Hyperdiploid
607	Protocol	T16
607	NCI risk	SR
607	Age at diagnosis	8.7
607	WBC at diagnosis	6.5
607	Sex	M
607	Genetically-defined race	Hispanic
607	Asparaginase (IU/ml)	0
607	Bortezomib (nM)	0
607	CHZ868 (nM)	0
607	Cytarabine (µM)	0
607	Dasatinib (nM)	0
607	Daunorubicin (µM)	0
607	Dexamethasone  (µM)	0.1843971
607	Ibrutinib (µM)	0
607	Mercaptopurine (µM)	169.9092
607	Nelarabine (µM)	0
607	Panobinostat (nM)	0
607	Prednisolone (µM)	0.19571
607	Ruxolitinib (nM)	0
607	Thioguanine (µM)	4.675
607	Trametinib (nM)	0
607	Venetoclax (nM)	0
607	Vincristine (µM)	0.025
607	Vorinostat (nM)	0
607	dexamethasone_normalized	0.6021
607	mercaptopurine_normalized	0.1776
607	prednisolone_normalized	0.2465
607	thioguanine_normalized	0
607	vincristine_normalized	0
608	immunophenotype	B
608	molecular subtype	B-other
608	Protocol	T16
608	NCI risk	HR
608	Age at diagnosis	16.3
608	WBC at diagnosis	50.7
608	Sex	F
608	Genetically-defined race	White
608	Asparaginase (IU/ml)	20
608	Bortezomib (nM)	0
608	CHZ868 (nM)	0
608	Cytarabine (µM)	38.34303
608	Dasatinib (nM)	0
608	Daunorubicin (µM)	0
608	Dexamethasone  (µM)	23.2
608	Ibrutinib (µM)	0
608	Mercaptopurine (µM)	943.2263
608	Nelarabine (µM)	0
608	Panobinostat (nM)	0
608	Prednisolone (µM)	1006
608	Ruxolitinib (nM)	0
608	Thioguanine (µM)	19.10064
608	Trametinib (nM)	0
608	Venetoclax (nM)	0
608	Vincristine (µM)	0.025
608	Vorinostat (nM)	0
608	asparagise_normalized	1
608	cytarabine_normalized	0.99
608	dexamethasone_normalized	1
608	mercaptopurine_normalized	0.6722
608	prednisolone_normalized	1
608	thioguanine_normalized	0.2062
608	vincristine_normalized	0
609	immunophenotype	B
609	molecular subtype	TCF3-PBX1
609	Protocol	T16
609	NCI risk	HR
609	Age at diagnosis	6.2
609	WBC at diagnosis	143.4
609	Sex	M
609	Genetically-defined race	black
609	Asparaginase (IU/ml)	0.2163985
609	Bortezomib (nM)	0
609	CHZ868 (nM)	0
609	Cytarabine (µM)	0.7899351
609	Dasatinib (nM)	0
609	Daunorubicin (µM)	0
609	Dexamethasone  (µM)	0.059546955
609	Ibrutinib (µM)	0
609	Mercaptopurine (µM)	189.1393
609	Nelarabine (µM)	0
609	Panobinostat (nM)	0
609	Prednisolone (µM)	0.08225626
609	Ruxolitinib (nM)	0
609	Thioguanine (µM)	11.40967
609	Trametinib (nM)	0
609	Venetoclax (nM)	0
609	Vincristine (µM)	0.025
609	Vorinostat (nM)	0
609	asparagise_normalized	0.5237
609	cytarabine_normalized	0.4302
609	dexamethasone_normalized	0.4935
609	mercaptopurine_normalized	0.2086
609	prednisolone_normalized	0.1633
609	thioguanine_normalized	0.0575
609	vincristine_normalized	0
610	immunophenotype	B
610	molecular subtype	Hyperdiploid
610	Protocol	T16
610	NCI risk	SR
610	Age at diagnosis	7.1
610	WBC at diagnosis	1.7
610	Sex	F
610	Genetically-defined race	White
610	Asparaginase (IU/ml)	20
610	Bortezomib (nM)	0
610	CHZ868 (nM)	0
610	Cytarabine (µM)	1.051226
610	Dasatinib (nM)	0
610	Daunorubicin (µM)	0
610	Dexamethasone  (µM)	0
610	Ibrutinib (µM)	0
610	Mercaptopurine (µM)	0
610	Nelarabine (µM)	0
610	Panobinostat (nM)	0
610	Prednisolone (µM)	1006
610	Ruxolitinib (nM)	0
610	Thioguanine (µM)	0
610	Trametinib (nM)	0
610	Venetoclax (nM)	0
610	Vincristine (µM)	0
610	Vorinostat (nM)	0
610	asparagise_normalized	1
610	cytarabine_normalized	0.4714
610	prednisolone_normalized	1
611	immunophenotype	B
611	molecular subtype	MEF2D
611	Protocol	T16
611	NCI risk	HR
611	Age at diagnosis	12.4
611	WBC at diagnosis	4.1
611	Sex	M
611	Genetically-defined race	black
611	Asparaginase (IU/ml)	0.01664494
611	Bortezomib (nM)	0
611	CHZ868 (nM)	0
611	Cytarabine (µM)	0.02
611	Dasatinib (nM)	0
611	Daunorubicin (µM)	0
611	Dexamethasone  (µM)	0.01283945
611	Ibrutinib (µM)	0
611	Mercaptopurine (µM)	0
611	Nelarabine (µM)	0
611	Panobinostat (nM)	0
611	Prednisolone (µM)	0.0075
611	Ruxolitinib (nM)	0
611	Thioguanine (µM)	4.675
611	Trametinib (nM)	0
611	Venetoclax (nM)	0
611	Vincristine (µM)	0.025
611	Vorinostat (nM)	0
611	asparagise_normalized	0.2049
611	cytarabine_normalized	0
611	dexamethasone_normalized	0.3461
611	prednisolone_normalized	0
611	thioguanine_normalized	0
611	vincristine_normalized	0
612	immunophenotype	B
612	molecular subtype	Hyperdiploid
612	Protocol	T16
612	NCI risk	HR
612	Age at diagnosis	6.5
612	WBC at diagnosis	52.6
612	Sex	M
612	Genetically-defined race	White
612	Asparaginase (IU/ml)	0
612	Bortezomib (nM)	0
612	CHZ868 (nM)	0
612	Cytarabine (µM)	0.131298
612	Dasatinib (nM)	0
612	Daunorubicin (µM)	0
612	Dexamethasone  (µM)	0
612	Ibrutinib (µM)	0
612	Mercaptopurine (µM)	0
612	Nelarabine (µM)	0
612	Panobinostat (nM)	0
612	Prednisolone (µM)	0
612	Ruxolitinib (nM)	0
612	Thioguanine (µM)	43.41819008
612	Trametinib (nM)	0
612	Venetoclax (nM)	0
612	Vincristine (µM)	0
612	Vorinostat (nM)	0
612	cytarabine_normalized	0.1714
612	thioguanine_normalized	0.4431
613	immunophenotype	B
613	molecular subtype	ETV6-RUNX1
613	Protocol	T16
613	NCI risk	SR
613	Age at diagnosis	7.6
613	WBC at diagnosis	4
613	Sex	F
613	Genetically-defined race	White
613	Asparaginase (IU/ml)	0.0016
613	Bortezomib (nM)	0
613	CHZ868 (nM)	0
613	Cytarabine (µM)	0.1965352
613	Dasatinib (nM)	0
613	Daunorubicin (µM)	0
613	Dexamethasone  (µM)	0.1237712
613	Ibrutinib (µM)	0
613	Mercaptopurine (µM)	0
613	Nelarabine (µM)	0
613	Panobinostat (nM)	0
613	Prednisolone (µM)	0
613	Ruxolitinib (nM)	0
613	Thioguanine (µM)	9.920531
613	Trametinib (nM)	0
613	Venetoclax (nM)	0
613	Vincristine (µM)	0.7577604
613	Vorinostat (nM)	0
613	asparagise_normalized	0
613	cytarabine_normalized	0.2296
613	dexamethasone_normalized	0.5638
613	thioguanine_normalized	0.0171
613	vincristine_normalized	0.389
614	immunophenotype	T
614	molecular subtype	T-ALL
614	Protocol	T16
614	NCI risk	HR
614	Age at diagnosis	13.6
614	WBC at diagnosis	11
614	Sex	M
614	Genetically-defined race	White
614	Asparaginase (IU/ml)	0
614	Bortezomib (nM)	0
614	CHZ868 (nM)	0
614	Cytarabine (µM)	0
614	Dasatinib (nM)	0
614	Daunorubicin (µM)	0.06776791
614	Dexamethasone  (µM)	0.06097696
614	Ibrutinib (µM)	0
614	Mercaptopurine (µM)	0
614	Nelarabine (µM)	0
614	Panobinostat (nM)	0
614	Prednisolone (µM)	0
614	Ruxolitinib (nM)	0
614	Thioguanine (µM)	24.70986
614	Trametinib (nM)	0
614	Venetoclax (nM)	0
614	Vincristine (µM)	11.20158
614	Vorinostat (nM)	0
614	daunorubicin_normalized	0.4406
614	dexamethasone_normalized	0.4958
614	thioguanine_normalized	0.2805
614	vincristine_normalized	0.7745
615	immunophenotype	B
615	molecular subtype	ETV6-RUNX1
615	Protocol	T16
615	NCI risk	SR
615	Age at diagnosis	9
615	WBC at diagnosis	17.2
615	Sex	F
615	Genetically-defined race	black
615	Asparaginase (IU/ml)	0.2708214
615	Bortezomib (nM)	0
615	CHZ868 (nM)	0
615	Cytarabine (µM)	3.352541
615	Dasatinib (nM)	0
615	Daunorubicin (µM)	0
615	Dexamethasone  (µM)	0.03315127
615	Ibrutinib (µM)	0
615	Mercaptopurine (µM)	0
615	Nelarabine (µM)	0
615	Panobinostat (nM)	0
615	Prednisolone (µM)	0
615	Ruxolitinib (nM)	0
615	Thioguanine (µM)	22.95647
615	Trametinib (nM)	0
615	Venetoclax (nM)	0
615	Vincristine (µM)	0.2631636
615	Vorinostat (nM)	0
615	asparagise_normalized	0.5515
615	cytarabine_normalized	0.6386
615	dexamethasone_normalized	0.4372
615	thioguanine_normalized	0.2592
615	vincristine_normalized	0.2377
616	immunophenotype	B
616	molecular subtype	Hyperdiploid
616	Protocol	T16
616	NCI risk	SR
616	Age at diagnosis	6.7
616	WBC at diagnosis	11.4
616	Sex	M
616	Genetically-defined race	White
616	Asparaginase (IU/ml)	0.0016
616	Bortezomib (nM)	0
616	CHZ868 (nM)	0
616	Cytarabine (µM)	0
616	Dasatinib (nM)	0
616	Daunorubicin (µM)	0
616	Dexamethasone  (µM)	0.002549557
616	Ibrutinib (µM)	0
616	Mercaptopurine (µM)	100.6919072
616	Nelarabine (µM)	0
616	Panobinostat (nM)	0
616	Prednisolone (µM)	0.1101967
616	Ruxolitinib (nM)	0
616	Thioguanine (µM)	10.00092188
616	Trametinib (nM)	0
616	Venetoclax (nM)	0
616	Vincristine (µM)	0.07031237
616	Vorinostat (nM)	0
616	asparagise_normalized	0
616	dexamethasone_normalized	0.1908
616	mercaptopurine_normalized	0.0267
616	prednisolone_normalized	0.1914
616	thioguanine_normalized	0.0194
616	vincristine_normalized	0.0488
617	immunophenotype	B
617	molecular subtype	ETV6-RUNX1
617	Protocol	T16
617	NCI risk	SR
617	Age at diagnosis	4.6
617	WBC at diagnosis	4.8
617	Sex	M
617	Genetically-defined race	White
617	Asparaginase (IU/ml)	0.0016
617	Bortezomib (nM)	0
617	CHZ868 (nM)	0
617	Cytarabine (µM)	5.356567
617	Dasatinib (nM)	0
617	Daunorubicin (µM)	0
617	Dexamethasone  (µM)	23.2
617	Ibrutinib (µM)	0
617	Mercaptopurine (µM)	914.7271077
617	Nelarabine (µM)	0
617	Panobinostat (nM)	0
617	Prednisolone (µM)	44.20123
617	Ruxolitinib (nM)	0
617	Thioguanine (µM)	23.56867
617	Trametinib (nM)	0
617	Venetoclax (nM)	0
617	Vincristine (µM)	4.199704716
617	Vorinostat (nM)	0
617	asparagise_normalized	0
617	cytarabine_normalized	0.7062
617	dexamethasone_normalized	1
617	mercaptopurine_normalized	0.6633
617	prednisolone_normalized	0.7666
617	thioguanine_normalized	0.2668
617	vincristine_normalized	0.6341
618	immunophenotype	B
618	molecular subtype	B-other
618	Protocol	T16
618	NCI risk	SR
618	Age at diagnosis	4.7
618	WBC at diagnosis	4.9
618	Sex	M
618	Genetically-defined race	White
618	Asparaginase (IU/ml)	0
618	Bortezomib (nM)	0
618	CHZ868 (nM)	0
618	Cytarabine (µM)	0
618	Dasatinib (nM)	0
618	Daunorubicin (µM)	0
618	Dexamethasone  (µM)	0
618	Ibrutinib (µM)	0
618	Mercaptopurine (µM)	172.6817
618	Nelarabine (µM)	0
618	Panobinostat (nM)	0
618	Prednisolone (µM)	0
618	Ruxolitinib (nM)	0
618	Thioguanine (µM)	0
618	Trametinib (nM)	0
618	Venetoclax (nM)	0
618	Vincristine (µM)	0
618	Vorinostat (nM)	0
618	mercaptopurine_normalized	0.1823
619	immunophenotype	B
619	molecular subtype	DUX4
619	Protocol	T16
619	NCI risk	SR
619	Age at diagnosis	4.2
619	WBC at diagnosis	7.2
619	Sex	M
619	Genetically-defined race	Hispanic
619	Asparaginase (IU/ml)	20
619	Bortezomib (nM)	0
619	CHZ868 (nM)	0
619	Cytarabine (µM)	3.263061885
619	Dasatinib (nM)	0
619	Daunorubicin (µM)	0
619	Dexamethasone  (µM)	0.212331871
619	Ibrutinib (µM)	0
619	Mercaptopurine (µM)	0
619	Nelarabine (µM)	0
619	Panobinostat (nM)	0
619	Prednisolone (µM)	0
619	Ruxolitinib (nM)	0
619	Thioguanine (µM)	17.81064
619	Trametinib (nM)	0
619	Venetoclax (nM)	0
619	Vincristine (µM)	0.2620292
619	Vorinostat (nM)	0
619	asparagise_normalized	1
619	cytarabine_normalized	0.6347
619	dexamethasone_normalized	0.6156
619	thioguanine_normalized	0.186
619	vincristine_normalized	0.237
620	immunophenotype	B
620	molecular subtype	B-other
620	Protocol	T16
620	NCI risk	SR
620	Age at diagnosis	7.5
620	WBC at diagnosis	4.2
620	Sex	F
620	Genetically-defined race	White
620	Asparaginase (IU/ml)	0.4331643
620	Bortezomib (nM)	0
620	CHZ868 (nM)	0
620	Cytarabine (µM)	2.266837
620	Dasatinib (nM)	0
620	Daunorubicin (µM)	0
620	Dexamethasone  (µM)	23.2
620	Ibrutinib (µM)	0
620	Mercaptopurine (µM)	202.525069
620	Nelarabine (µM)	0
620	Panobinostat (nM)	0
620	Prednisolone (µM)	0
620	Ruxolitinib (nM)	0
620	Thioguanine (µM)	13.82073
620	Trametinib (nM)	0
620	Venetoclax (nM)	0
620	Vincristine (µM)	0.1037461
620	Vorinostat (nM)	0
620	asparagise_normalized	0.6099
620	cytarabine_normalized	0.5822
620	dexamethasone_normalized	1
620	mercaptopurine_normalized	0.2283
620	thioguanine_normalized	0.1128
620	vincristine_normalized	0.1045
621	immunophenotype	B
621	molecular subtype	PAX5alt
621	Protocol	T16
621	NCI risk	HR
621	Age at diagnosis	15.9
621	WBC at diagnosis	1.4
621	Sex	F
621	Genetically-defined race	black
621	Asparaginase (IU/ml)	0
621	Bortezomib (nM)	0
621	CHZ868 (nM)	0
621	Cytarabine (µM)	0
621	Dasatinib (nM)	0
621	Daunorubicin (µM)	0
621	Dexamethasone  (µM)	0
621	Ibrutinib (µM)	0
621	Mercaptopurine (µM)	1050.032
621	Nelarabine (µM)	0
621	Panobinostat (nM)	0
621	Prednisolone (µM)	0
621	Ruxolitinib (nM)	0
621	Thioguanine (µM)	19.30014
621	Trametinib (nM)	0
621	Venetoclax (nM)	0
621	Vincristine (µM)	0
621	Vorinostat (nM)	0
621	mercaptopurine_normalized	0.7031
621	thioguanine_normalized	0.2092
622	immunophenotype	B
622	molecular subtype	B-other
622	Protocol	T16
622	NCI risk	SR
622	Age at diagnosis	2.7
622	WBC at diagnosis	17.2
622	Sex	F
622	Genetically-defined race	White
622	Asparaginase (IU/ml)	0.0016
622	Bortezomib (nM)	0
622	CHZ868 (nM)	0
622	Cytarabine (µM)	0.6602289
622	Dasatinib (nM)	0
622	Daunorubicin (µM)	0
622	Dexamethasone  (µM)	0.04332802
622	Ibrutinib (µM)	0
622	Mercaptopurine (µM)	119.6478
622	Nelarabine (µM)	0
622	Panobinostat (nM)	0
622	Prednisolone (µM)	0.0075
622	Ruxolitinib (nM)	0
622	Thioguanine (µM)	12.56033794
622	Trametinib (nM)	0
622	Venetoclax (nM)	0
622	Vincristine (µM)	0.025
622	Vorinostat (nM)	0
622	asparagise_normalized	0
622	cytarabine_normalized	0.4043
622	dexamethasone_normalized	0.4629
622	mercaptopurine_normalized	0.0764
622	prednisolone_normalized	0
622	thioguanine_normalized	0.0852
622	vincristine_normalized	0
623	immunophenotype	B
623	molecular subtype	TCF3-PBX1
623	Protocol	T16
623	NCI risk	HR
623	Age at diagnosis	2.6
623	WBC at diagnosis	56.9
623	Sex	F
623	Genetically-defined race	Asian/Other
623	Asparaginase (IU/ml)	0.0016
623	Bortezomib (nM)	0
623	CHZ868 (nM)	0
623	Cytarabine (µM)	0.7454673
623	Dasatinib (nM)	0
623	Daunorubicin (µM)	0
623	Dexamethasone  (µM)	0.04335678
623	Ibrutinib (µM)	0
623	Mercaptopurine (µM)	357.9742
623	Nelarabine (µM)	0
623	Panobinostat (nM)	0
623	Prednisolone (µM)	0.0075
623	Ruxolitinib (nM)	0
623	Thioguanine (µM)	19.47864
623	Trametinib (nM)	0
623	Venetoclax (nM)	0
623	Vincristine (µM)	0.025
623	Vorinostat (nM)	0
623	asparagise_normalized	0
623	cytarabine_normalized	0.4218
623	dexamethasone_normalized	0.463
623	mercaptopurine_normalized	0.3926
623	prednisolone_normalized	0
623	thioguanine_normalized	0.2118
623	vincristine_normalized	0
624	immunophenotype	T
624	molecular subtype	T-ALL
624	Protocol	T16
624	NCI risk	HR
624	Age at diagnosis	13.7
624	WBC at diagnosis	638
624	Sex	M
624	Genetically-defined race	White
624	Asparaginase (IU/ml)	0
624	Bortezomib (nM)	0
624	CHZ868 (nM)	0
624	Cytarabine (µM)	0
624	Dasatinib (nM)	0
624	Daunorubicin (µM)	0.04134711
624	Dexamethasone  (µM)	0
624	Ibrutinib (µM)	0
624	Mercaptopurine (µM)	0
624	Nelarabine (µM)	0
624	Panobinostat (nM)	0
624	Prednisolone (µM)	0
624	Ruxolitinib (nM)	0
624	Thioguanine (µM)	99.17027
624	Trametinib (nM)	0
624	Venetoclax (nM)	0
624	Vincristine (µM)	0
624	Vorinostat (nM)	0
624	daunorubicin_normalized	0.3707
624	thioguanine_normalized	0.6815
625	immunophenotype	B
625	molecular subtype	ETV6-RUNX1
625	Protocol	T16
625	NCI risk	HR
625	Age at diagnosis	10.7
625	WBC at diagnosis	4.9
625	Sex	F
625	Genetically-defined race	White
625	Asparaginase (IU/ml)	0.116715555
625	Bortezomib (nM)	0
625	CHZ868 (nM)	0
625	Cytarabine (µM)	8.009075
625	Dasatinib (nM)	0
625	Daunorubicin (µM)	0
625	Dexamethasone  (µM)	0.05316092
625	Ibrutinib (µM)	0
625	Mercaptopurine (µM)	417.6661715
625	Nelarabine (µM)	0
625	Panobinostat (nM)	0
625	Prednisolone (µM)	0.01582522
625	Ruxolitinib (nM)	0
625	Thioguanine (µM)	12.64405
625	Trametinib (nM)	0
625	Venetoclax (nM)	0
625	Vincristine (µM)	0.6306605
625	Vorinostat (nM)	0
625	asparagise_normalized	0.4469
625	cytarabine_normalized	0.7642
625	dexamethasone_normalized	0.4826
625	mercaptopurine_normalized	0.4371
625	prednisolone_normalized	0.0051
625	thioguanine_normalized	0.0871
625	vincristine_normalized	0.3627
626	immunophenotype	T
626	molecular subtype	ETP
626	Protocol	T16
626	NCI risk	SR
626	Age at diagnosis	8
626	WBC at diagnosis	20.5
626	Sex	M
626	Genetically-defined race	White
626	Asparaginase (IU/ml)	0.0016
626	Bortezomib (nM)	0
626	CHZ868 (nM)	0
626	Cytarabine (µM)	3.551772896
626	Dasatinib (nM)	0
626	Daunorubicin (µM)	0.1111005
626	Dexamethasone  (µM)	5.133623
626	Ibrutinib (µM)	0
626	Mercaptopurine (µM)	535.8813
626	Nelarabine (µM)	0
626	Panobinostat (nM)	0
626	Prednisolone (µM)	4.302359
626	Ruxolitinib (nM)	0
626	Thioguanine (µM)	115.8741
626	Trametinib (nM)	0
626	Venetoclax (nM)	0
626	Vincristine (µM)	4.431381
626	Vorinostat (nM)	0
626	asparagise_normalized	0
626	cytarabine_normalized	0.6469
626	daunorubicin_normalized	0.5104
626	dexamethasone_normalized	0.9217
626	mercaptopurine_normalized	0.509
626	prednisolone_normalized	0.5431
626	thioguanine_normalized	0.7264
626	vincristine_normalized	0.6417
627	immunophenotype	B
627	molecular subtype	ZNF384
627	Protocol	T16
627	NCI risk	HR
627	Age at diagnosis	12.2
627	WBC at diagnosis	1.6
627	Sex	M
627	Genetically-defined race	White
627	Asparaginase (IU/ml)	0.09698334
627	Bortezomib (nM)	0
627	CHZ868 (nM)	0
627	Cytarabine (µM)	9.591422
627	Dasatinib (nM)	0
627	Daunorubicin (µM)	0
627	Dexamethasone  (µM)	0
627	Ibrutinib (µM)	0
627	Mercaptopurine (µM)	0
627	Nelarabine (µM)	0
627	Panobinostat (nM)	0
627	Prednisolone (µM)	0
627	Ruxolitinib (nM)	0
627	Thioguanine (µM)	24.41719
627	Trametinib (nM)	0
627	Venetoclax (nM)	0
627	Vincristine (µM)	0.1465198
627	Vorinostat (nM)	0
627	asparagise_normalized	0.4239
627	cytarabine_normalized	0.7902
627	thioguanine_normalized	0.277
627	vincristine_normalized	0.1539
628	immunophenotype	B
628	molecular subtype	Hyperdiploid
628	Protocol	T16
628	NCI risk	HR
628	Age at diagnosis	16.5
628	WBC at diagnosis	1.1
628	Sex	M
628	Genetically-defined race	White
628	Asparaginase (IU/ml)	0.1357411
628	Bortezomib (nM)	0
628	CHZ868 (nM)	0
628	Cytarabine (µM)	0.9478046
628	Dasatinib (nM)	0
628	Daunorubicin (µM)	0
628	Dexamethasone  (µM)	0.1562818
628	Ibrutinib (µM)	0
628	Mercaptopurine (µM)	216.6778
628	Nelarabine (µM)	0
628	Panobinostat (nM)	0
628	Prednisolone (µM)	0.08828146
628	Ruxolitinib (nM)	0
628	Thioguanine (µM)	11.04702
628	Trametinib (nM)	0
628	Venetoclax (nM)	0
628	Vincristine (µM)	0.025
628	Vorinostat (nM)	0
628	asparagise_normalized	0.4657
628	cytarabine_normalized	0.4564
628	dexamethasone_normalized	0.5862
628	mercaptopurine_normalized	0.2478
628	prednisolone_normalized	0.1701
628	thioguanine_normalized	0.0481
628	vincristine_normalized	0
629	immunophenotype	B
629	molecular subtype	ETV6-RUNX1
629	Protocol	T16
629	NCI risk	SR
629	Age at diagnosis	5.5
629	WBC at diagnosis	0.7
629	Sex	M
629	Genetically-defined race	White
629	Asparaginase (IU/ml)	0.0016
629	Bortezomib (nM)	0
629	CHZ868 (nM)	0
629	Cytarabine (µM)	7.064931
629	Dasatinib (nM)	0
629	Daunorubicin (µM)	0
629	Dexamethasone  (µM)	0.02906047
629	Ibrutinib (µM)	0
629	Mercaptopurine (µM)	5876
629	Nelarabine (µM)	0
629	Panobinostat (nM)	0
629	Prednisolone (µM)	0.0075
629	Ruxolitinib (nM)	0
629	Thioguanine (µM)	16.0265
629	Trametinib (nM)	0
629	Venetoclax (nM)	0
629	Vincristine (µM)	1.403039
629	Vorinostat (nM)	0
629	asparagise_normalized	0
629	cytarabine_normalized	0.7461
629	dexamethasone_normalized	0.4246
629	mercaptopurine_normalized	1
629	prednisolone_normalized	0
629	thioguanine_normalized	0.1555
629	vincristine_normalized	0.4772
630	immunophenotype	B
630	molecular subtype	B-other
630	Protocol	T16
630	NCI risk	SR
630	Age at diagnosis	2.2
630	WBC at diagnosis	10.4
630	Sex	M
630	Genetically-defined race	White
630	Asparaginase (IU/ml)	0.352082191
630	Bortezomib (nM)	0
630	CHZ868 (nM)	0
630	Cytarabine (µM)	1.1448
630	Dasatinib (nM)	0
630	Daunorubicin (µM)	0
630	Dexamethasone  (µM)	0.1793851
630	Ibrutinib (µM)	0
630	Mercaptopurine (µM)	287.987
630	Nelarabine (µM)	0
630	Panobinostat (nM)	0
630	Prednisolone (µM)	0.07692096
630	Ruxolitinib (nM)	0
630	Thioguanine (µM)	109.7673
630	Trametinib (nM)	0
630	Venetoclax (nM)	0
630	Vincristine (µM)	7.124125952
630	Vorinostat (nM)	0
630	asparagise_normalized	0.5841
630	cytarabine_normalized	0.4837
630	dexamethasone_normalized	0.5994
630	mercaptopurine_normalized	0.3299
630	prednisolone_normalized	0.1569
630	thioguanine_normalized	0.7108
630	vincristine_normalized	0.7097
631	immunophenotype	B
631	molecular subtype	ETV6-RUNX1
631	Protocol	T16
631	NCI risk	SR
631	Age at diagnosis	4.8
631	WBC at diagnosis	35.7
631	Sex	M
631	Genetically-defined race	White
631	Asparaginase (IU/ml)	0.05047399
631	Bortezomib (nM)	0
631	CHZ868 (nM)	0
631	Cytarabine (µM)	0.9233626
631	Dasatinib (nM)	0
631	Daunorubicin (µM)	0
631	Dexamethasone  (µM)	0.08865795
631	Ibrutinib (µM)	0
631	Mercaptopurine (µM)	45.9
631	Nelarabine (µM)	0
631	Panobinostat (nM)	0
631	Prednisolone (µM)	0.0571802
631	Ruxolitinib (nM)	0
631	Thioguanine (µM)	4.675
631	Trametinib (nM)	0
631	Venetoclax (nM)	0
631	Vincristine (µM)	0.025
631	Vorinostat (nM)	0
631	asparagise_normalized	0.3428
631	cytarabine_normalized	0.4527
631	dexamethasone_normalized	0.5317
631	mercaptopurine_normalized	0
631	prednisolone_normalized	0.1284
631	thioguanine_normalized	0
631	vincristine_normalized	0
632	immunophenotype	T
632	molecular subtype	T-ALL
632	Protocol	T16
632	NCI risk	HR
632	Age at diagnosis	11.4
632	WBC at diagnosis	160.2
632	Sex	M
632	Genetically-defined race	White
632	Asparaginase (IU/ml)	0.6314574
632	Bortezomib (nM)	0
632	CHZ868 (nM)	0
632	Cytarabine (µM)	7.036045
632	Dasatinib (nM)	0.1330967
632	Daunorubicin (µM)	0.01824121
632	Dexamethasone  (µM)	0.3922778
632	Ibrutinib (µM)	5.145526
632	Mercaptopurine (µM)	189.4378
632	Nelarabine (µM)	14.13521
632	Panobinostat (nM)	0
632	Prednisolone (µM)	0.3006895
632	Ruxolitinib (nM)	0
632	Thioguanine (µM)	4.675
632	Trametinib (nM)	0
632	Venetoclax (nM)	0.1348223
632	Vincristine (µM)	1.997849
632	Vorinostat (nM)	0
632	asparagise_normalized	0.6567
632	cytarabine_normalized	0.7455
632	dasatinib_normalized	0.0248
632	daunorubicin_normalized	0.2551
632	dexamethasone_normalized	0.6746
632	ibrutinib_normalized	0.3439
632	mercaptopurine_normalized	0.209
632	nelarabine_normalized	0.7499
632	prednisolone_normalized	0.2877
632	thioguanine_normalized	0
632	venetoclax_normalized	0.426
632	vincristine_normalized	0.5277
633	immunophenotype	B
633	molecular subtype	PAX5alt
633	Protocol	T16
633	NCI risk	SR
633	Age at diagnosis	2
633	WBC at diagnosis	9.6
633	Sex	F
633	Genetically-defined race	White
633	Asparaginase (IU/ml)	0
633	Bortezomib (nM)	0
633	CHZ868 (nM)	0
633	Cytarabine (µM)	0
633	Dasatinib (nM)	0
633	Daunorubicin (µM)	0
633	Dexamethasone  (µM)	3.306781337
633	Ibrutinib (µM)	0
633	Mercaptopurine (µM)	341.8119
633	Nelarabine (µM)	0
633	Panobinostat (nM)	0
633	Prednisolone (µM)	283.931
633	Ruxolitinib (nM)	0
633	Thioguanine (µM)	40.90928
633	Trametinib (nM)	0
633	Venetoclax (nM)	0
633	Vincristine (µM)	0
633	Vorinostat (nM)	0
633	dexamethasone_normalized	0.8794
633	mercaptopurine_normalized	0.3793
633	prednisolone_normalized	0.9451
633	thioguanine_normalized	0.426
634	immunophenotype	B
634	molecular subtype	ETV6-RUNX1
634	Protocol	T16
634	NCI risk	SR
634	Age at diagnosis	3.2
634	WBC at diagnosis	7.8
634	Sex	F
634	Genetically-defined race	White
634	Asparaginase (IU/ml)	0.0016
634	Bortezomib (nM)	0
634	CHZ868 (nM)	0
634	Cytarabine (µM)	3.538078189
634	Dasatinib (nM)	0
634	Daunorubicin (µM)	0
634	Dexamethasone  (µM)	0.100013
634	Ibrutinib (µM)	0
634	Mercaptopurine (µM)	408.7584
634	Nelarabine (µM)	0
634	Panobinostat (nM)	0
634	Prednisolone (µM)	0.02766525
634	Ruxolitinib (nM)	0
634	Thioguanine (µM)	16.1342
634	Trametinib (nM)	0
634	Venetoclax (nM)	0
634	Vincristine (µM)	0.2395133
634	Vorinostat (nM)	0
634	asparagise_normalized	0
634	cytarabine_normalized	0.6464
634	dexamethasone_normalized	0.5433
634	mercaptopurine_normalized	0.4309
634	prednisolone_normalized	0.0587
634	thioguanine_normalized	0.1574
634	vincristine_normalized	0.2242
635	immunophenotype	B
635	molecular subtype	BCL2/MYC
635	Protocol	T16
635	NCI risk	HR
635	Age at diagnosis	6.2
635	WBC at diagnosis	141.6
635	Sex	M
635	Genetically-defined race	White
635	Asparaginase (IU/ml)	0.1189297
635	Bortezomib (nM)	0
635	CHZ868 (nM)	0
635	Cytarabine (µM)	0.05914176
635	Dasatinib (nM)	0
635	Daunorubicin (µM)	0
635	Dexamethasone  (µM)	23.2
635	Ibrutinib (µM)	0
635	Mercaptopurine (µM)	45.9
635	Nelarabine (µM)	0
635	Panobinostat (nM)	0
635	Prednisolone (µM)	8.990491
635	Ruxolitinib (nM)	0
635	Thioguanine (µM)	4.675
635	Trametinib (nM)	0
635	Venetoclax (nM)	0
635	Vincristine (µM)	0
635	Vorinostat (nM)	0
635	asparagise_normalized	0.4493
635	cytarabine_normalized	0.0564
635	dexamethasone_normalized	1
635	mercaptopurine_normalized	0
635	prednisolone_normalized	0.6138
635	thioguanine_normalized	0
636	immunophenotype	B
636	molecular subtype	TCF3-PBX1
636	Protocol	T16
636	NCI risk	HR
636	Age at diagnosis	14.7
636	WBC at diagnosis	7.1
636	Sex	M
636	Genetically-defined race	Hispanic
636	Asparaginase (IU/ml)	0.4008077
636	Bortezomib (nM)	0
636	CHZ868 (nM)	0
636	Cytarabine (µM)	0.156631
636	Dasatinib (nM)	0
636	Daunorubicin (µM)	0
636	Dexamethasone  (µM)	0.08808673
636	Ibrutinib (µM)	0
636	Mercaptopurine (µM)	284.385
636	Nelarabine (µM)	0
636	Panobinostat (nM)	0
636	Prednisolone (µM)	0.070979633
636	Ruxolitinib (nM)	0
636	Thioguanine (µM)	10.20671
636	Trametinib (nM)	0
636	Venetoclax (nM)	0
636	Vincristine (µM)	0.025
636	Vorinostat (nM)	0
636	asparagise_normalized	0.6003
636	cytarabine_normalized	0.1968
636	dexamethasone_normalized	0.5311
636	mercaptopurine_normalized	0.3262
636	prednisolone_normalized	0.1492
636	thioguanine_normalized	0.0253
636	vincristine_normalized	0
637	immunophenotype	B
637	molecular subtype	BCR-ABL1
637	Protocol	T16
637	NCI risk	HR
637	Age at diagnosis	13.4
637	WBC at diagnosis	252.6
637	Sex	F
637	Genetically-defined race	White
637	Asparaginase (IU/ml)	0.5810397
637	Bortezomib (nM)	0
637	CHZ868 (nM)	0
637	Cytarabine (µM)	7.699749
637	Dasatinib (nM)	0
637	Daunorubicin (µM)	0
637	Dexamethasone  (µM)	0.08738267
637	Ibrutinib (µM)	0
637	Mercaptopurine (µM)	454.5873
637	Nelarabine (µM)	0
637	Panobinostat (nM)	0
637	Prednisolone (µM)	0.063121735
637	Ruxolitinib (nM)	0
637	Thioguanine (µM)	4.675
637	Trametinib (nM)	0
637	Venetoclax (nM)	0
637	Vincristine (µM)	0.06764577
637	Vorinostat (nM)	0
637	asparagise_normalized	0.6464
637	cytarabine_normalized	0.7585
637	dexamethasone_normalized	0.5303
637	mercaptopurine_normalized	0.4616
637	prednisolone_normalized	0.1379
637	thioguanine_normalized	0
637	vincristine_normalized	0.0433
638	immunophenotype	B
638	molecular subtype	ETV6-RUNX1
638	Protocol	T16
638	NCI risk	SR
638	Age at diagnosis	4
638	WBC at diagnosis	7
638	Sex	M
638	Genetically-defined race	White
638	Asparaginase (IU/ml)	0.0016
638	Bortezomib (nM)	0
638	CHZ868 (nM)	0
638	Cytarabine (µM)	0.2463687
638	Dasatinib (nM)	0
638	Daunorubicin (µM)	0
638	Dexamethasone  (µM)	0.0139924
638	Ibrutinib (µM)	0
638	Mercaptopurine (µM)	192.3241
638	Nelarabine (µM)	0
638	Panobinostat (nM)	0
638	Prednisolone (µM)	0.0075
638	Ruxolitinib (nM)	0
638	Thioguanine (µM)	4.675
638	Trametinib (nM)	0
638	Venetoclax (nM)	0
638	Vincristine (µM)	0.025
638	Vorinostat (nM)	0
638	asparagise_normalized	0
638	cytarabine_normalized	0.2621
638	dexamethasone_normalized	0.3544
638	mercaptopurine_normalized	0.2134
638	prednisolone_normalized	0
638	thioguanine_normalized	0
638	vincristine_normalized	0
639	immunophenotype	B
639	molecular subtype	ETV6-RUNX1
639	Protocol	T16
639	NCI risk	SR
639	Age at diagnosis	1.7
639	WBC at diagnosis	34.4
639	Sex	M
639	Genetically-defined race	Hispanic
639	Asparaginase (IU/ml)	0.0016
639	Bortezomib (nM)	0
639	CHZ868 (nM)	0
639	Cytarabine (µM)	2.168262
639	Dasatinib (nM)	0
639	Daunorubicin (µM)	0
639	Dexamethasone  (µM)	0.02447892
639	Ibrutinib (µM)	0
639	Mercaptopurine (µM)	171.8442548
639	Nelarabine (µM)	0
639	Panobinostat (nM)	0
639	Prednisolone (µM)	0.0075
639	Ruxolitinib (nM)	0
639	Thioguanine (µM)	10.08671
639	Trametinib (nM)	0
639	Venetoclax (nM)	0
639	Vincristine (µM)	0.025
639	Vorinostat (nM)	0
639	asparagise_normalized	0
639	cytarabine_normalized	0.5758
639	dexamethasone_normalized	0.4081
639	mercaptopurine_normalized	0.1809
639	prednisolone_normalized	0
639	thioguanine_normalized	0.0219
639	vincristine_normalized	0
640	immunophenotype	B
640	molecular subtype	Near haploid
640	Protocol	T16
640	NCI risk	SR
640	Age at diagnosis	7.4
640	WBC at diagnosis	6.9
640	Sex	F
640	Genetically-defined race	White
640	Asparaginase (IU/ml)	0.1244913
640	Bortezomib (nM)	0
640	CHZ868 (nM)	0
640	Cytarabine (µM)	0.5362982
640	Dasatinib (nM)	0
640	Daunorubicin (µM)	0
640	Dexamethasone  (µM)	0.3171737
640	Ibrutinib (µM)	0
640	Mercaptopurine (µM)	130.9412
640	Nelarabine (µM)	0
640	Panobinostat (nM)	0
640	Prednisolone (µM)	1006
640	Ruxolitinib (nM)	0
640	Thioguanine (µM)	4.675
640	Trametinib (nM)	0
640	Venetoclax (nM)	0
640	Vincristine (µM)	0.1239378
640	Vorinostat (nM)	0
640	asparagise_normalized	0.455
640	cytarabine_normalized	0.3743
640	dexamethasone_normalized	0.6542
640	mercaptopurine_normalized	0.1025
640	prednisolone_normalized	1
640	thioguanine_normalized	0
640	vincristine_normalized	0.1299
641	immunophenotype	B
641	molecular subtype	TCF3-PBX1
641	Protocol	T16
641	NCI risk	SR
641	Age at diagnosis	5.1
641	WBC at diagnosis	26.3
641	Sex	M
641	Genetically-defined race	White
641	Asparaginase (IU/ml)	0.1937907
641	Bortezomib (nM)	0
641	CHZ868 (nM)	0
641	Cytarabine (µM)	0.5324061
641	Dasatinib (nM)	0
641	Daunorubicin (µM)	0
641	Dexamethasone  (µM)	23.2
641	Ibrutinib (µM)	0
641	Mercaptopurine (µM)	167.4636
641	Nelarabine (µM)	0
641	Panobinostat (nM)	0
641	Prednisolone (µM)	1006
641	Ruxolitinib (nM)	0
641	Thioguanine (µM)	12.10101
641	Trametinib (nM)	0
641	Venetoclax (nM)	0
641	Vincristine (µM)	0.1162891
641	Vorinostat (nM)	0
641	asparagise_normalized	0.5099
641	cytarabine_normalized	0.3733
641	dexamethasone_normalized	1
641	mercaptopurine_normalized	0.1734
641	prednisolone_normalized	1
641	thioguanine_normalized	0.0744
641	vincristine_normalized	0.1208
642	immunophenotype	T
642	molecular subtype	T-ALL
642	Protocol	T16
642	NCI risk	HR
642	Age at diagnosis	12.9
642	WBC at diagnosis	42.4
642	Sex	M
642	Genetically-defined race	White
642	Asparaginase (IU/ml)	20
642	Bortezomib (nM)	0
642	CHZ868 (nM)	20000
642	Cytarabine (µM)	18.28944639
642	Dasatinib (nM)	7493.674
642	Daunorubicin (µM)	0.02816907
642	Dexamethasone  (µM)	0.295533
642	Ibrutinib (µM)	8.702197
642	Mercaptopurine (µM)	5876
642	Nelarabine (µM)	8.850142391
642	Panobinostat (nM)	0
642	Prednisolone (µM)	0
642	Ruxolitinib (nM)	0
642	Thioguanine (µM)	49.32481
642	Trametinib (nM)	2000
642	Venetoclax (nM)	12.4040378
642	Vincristine (µM)	2.189171
642	Vorinostat (nM)	995.4361
642	asparagise_normalized	1
642	CHZ868_normalized	1
642	cytarabine_normalized	0.8832
642	dasatinib_normalized	0.9749
642	daunorubicin_normalized	0.3165
642	dexamethasone_normalized	0.6474
642	ibrutinib_normalized	0.4955
642	mercaptopurine_normalized	1
642	nelarabine_normalized	0.6824
642	thioguanine_normalized	0.4799
642	trametinib_normalized	1
642	venetoclax_normalized	0.8187
642	vincristine_normalized	0.5408
642	vorinostat_normalized	0.5996
643	immunophenotype	B
643	molecular subtype	Hyperdiploid
643	Protocol	T16
643	NCI risk	HR
643	Age at diagnosis	16.5
643	WBC at diagnosis	1.6
643	Sex	F
643	Genetically-defined race	White
643	Asparaginase (IU/ml)	0.0016
643	Bortezomib (nM)	0
643	CHZ868 (nM)	0
643	Cytarabine (µM)	2.41058854
643	Dasatinib (nM)	0
643	Daunorubicin (µM)	0
643	Dexamethasone  (µM)	0.07137258
643	Ibrutinib (µM)	0
643	Mercaptopurine (µM)	45.9
643	Nelarabine (µM)	0
643	Panobinostat (nM)	0
643	Prednisolone (µM)	0.09692726
643	Ruxolitinib (nM)	0
643	Thioguanine (µM)	10.44386
643	Trametinib (nM)	0
643	Venetoclax (nM)	0
643	Vincristine (µM)	6.259331
643	Vorinostat (nM)	0
643	asparagise_normalized	0
643	cytarabine_normalized	0.591
643	dexamethasone_normalized	0.5109
643	mercaptopurine_normalized	0
643	prednisolone_normalized	0.1791
643	thioguanine_normalized	0.0319
643	vincristine_normalized	0.6912
644	immunophenotype	B
644	molecular subtype	PAX5alt
644	Protocol	T16
644	NCI risk	HR
644	Age at diagnosis	17.4
644	WBC at diagnosis	0.9
644	Sex	F
644	Genetically-defined race	White
644	Asparaginase (IU/ml)	0.1596433
644	Bortezomib (nM)	0
644	CHZ868 (nM)	0
644	Cytarabine (µM)	0.3480771
644	Dasatinib (nM)	0
644	Daunorubicin (µM)	0
644	Dexamethasone  (µM)	0.1350394
644	Ibrutinib (µM)	0
644	Mercaptopurine (µM)	344.5041
644	Nelarabine (µM)	0
644	Panobinostat (nM)	0
644	Prednisolone (µM)	0.1273762
644	Ruxolitinib (nM)	0
644	Thioguanine (µM)	4.675
644	Trametinib (nM)	0
644	Venetoclax (nM)	0
644	Vincristine (µM)	0.025
644	Vorinostat (nM)	0
644	asparagise_normalized	0.4859
644	cytarabine_normalized	0.312
644	dexamethasone_normalized	0.5722
644	mercaptopurine_normalized	0.3816
644	prednisolone_normalized	0.2053
644	thioguanine_normalized	0
644	vincristine_normalized	0
645	immunophenotype	B
645	molecular subtype	BCR-ABL1
645	Protocol	T16
645	NCI risk	HR
645	Age at diagnosis	16
645	WBC at diagnosis	2.8
645	Sex	M
645	Genetically-defined race	White
645	Asparaginase (IU/ml)	0.08064165
645	Bortezomib (nM)	0
645	CHZ868 (nM)	0
645	Cytarabine (µM)	2.760365
645	Dasatinib (nM)	0
645	Daunorubicin (µM)	0
645	Dexamethasone  (µM)	23.2
645	Ibrutinib (µM)	0
645	Mercaptopurine (µM)	261.0371
645	Nelarabine (µM)	0
645	Panobinostat (nM)	0
645	Prednisolone (µM)	1006
645	Ruxolitinib (nM)	0
645	Thioguanine (µM)	16.32057
645	Trametinib (nM)	0
645	Venetoclax (nM)	0
645	Vincristine (µM)	0.025
645	Vorinostat (nM)	0
645	asparagise_normalized	0.401
645	cytarabine_normalized	0.6106
645	dexamethasone_normalized	1
645	mercaptopurine_normalized	0.3015
645	prednisolone_normalized	1
645	thioguanine_normalized	0.1608
645	vincristine_normalized	0
646	immunophenotype	T
646	molecular subtype	T-ALL
646	Protocol	T16
646	NCI risk	HR
646	Age at diagnosis	6.3
646	WBC at diagnosis	58.9
646	Sex	M
646	Genetically-defined race	White
646	Asparaginase (IU/ml)	20
646	Bortezomib (nM)	0
646	CHZ868 (nM)	0
646	Cytarabine (µM)	0
646	Dasatinib (nM)	0
646	Daunorubicin (µM)	0
646	Dexamethasone  (µM)	0
646	Ibrutinib (µM)	0
646	Mercaptopurine (µM)	1118.124
646	Nelarabine (µM)	0
646	Panobinostat (nM)	0
646	Prednisolone (µM)	1006
646	Ruxolitinib (nM)	0
646	Thioguanine (µM)	32.33171151
646	Trametinib (nM)	0
646	Venetoclax (nM)	0
646	Vincristine (µM)	13.98924
646	Vorinostat (nM)	0
646	asparagise_normalized	1
646	mercaptopurine_normalized	0.7213
646	prednisolone_normalized	1
646	thioguanine_normalized	0.3581
646	vincristine_normalized	0.8063
647	immunophenotype	T
647	molecular subtype	T-ALL
647	Protocol	T16
647	NCI risk	HR
647	Age at diagnosis	15.1
647	WBC at diagnosis	296.6
647	Sex	F
647	Genetically-defined race	black
647	Asparaginase (IU/ml)	0.013360682
647	Bortezomib (nM)	0
647	CHZ868 (nM)	0
647	Cytarabine (µM)	1.294110279
647	Dasatinib (nM)	0
647	Daunorubicin (µM)	0.006151265
647	Dexamethasone  (µM)	0.117786
647	Ibrutinib (µM)	0
647	Mercaptopurine (µM)	128.1197
647	Nelarabine (µM)	0
647	Panobinostat (nM)	0
647	Prednisolone (µM)	0.1116326
647	Ruxolitinib (nM)	0
647	Thioguanine (µM)	10.29127
647	Trametinib (nM)	0
647	Venetoclax (nM)	0
647	Vincristine (µM)	0.1053117
647	Vorinostat (nM)	0
647	asparagise_normalized	0.1776
647	cytarabine_normalized	0.5013
647	daunorubicin_normalized	0.1015
647	dexamethasone_normalized	0.559
647	mercaptopurine_normalized	0.0962
647	prednisolone_normalized	0.1926
647	thioguanine_normalized	0.0277
647	vincristine_normalized	0.1066
648	immunophenotype	B
648	molecular subtype	PAX5 P80R
648	Protocol	T16
648	NCI risk	SR
648	Age at diagnosis	3.5
648	WBC at diagnosis	9
648	Sex	M
648	Genetically-defined race	Hispanic
648	Asparaginase (IU/ml)	0.3565764
648	Bortezomib (nM)	0
648	CHZ868 (nM)	0
648	Cytarabine (µM)	1.539509
648	Dasatinib (nM)	0
648	Daunorubicin (µM)	0
648	Dexamethasone  (µM)	23.2
648	Ibrutinib (µM)	0
648	Mercaptopurine (µM)	0
648	Nelarabine (µM)	0
648	Panobinostat (nM)	0
648	Prednisolone (µM)	0
648	Ruxolitinib (nM)	0
648	Thioguanine (µM)	102.0541
648	Trametinib (nM)	0
648	Venetoclax (nM)	0
648	Vincristine (µM)	108.34
648	Vorinostat (nM)	0
648	asparagise_normalized	0.5857
648	cytarabine_normalized	0.5264
648	dexamethasone_normalized	1
648	thioguanine_normalized	0.6898
648	vincristine_normalized	1
649	immunophenotype	B
649	molecular subtype	ETV6-RUNX1
649	Protocol	T16
649	NCI risk	SR
649	Age at diagnosis	2.3
649	WBC at diagnosis	11.7
649	Sex	F
649	Genetically-defined race	White
649	Asparaginase (IU/ml)	0.0016
649	Bortezomib (nM)	0
649	CHZ868 (nM)	0
649	Cytarabine (µM)	5.753547
649	Dasatinib (nM)	0
649	Daunorubicin (µM)	0
649	Dexamethasone  (µM)	0.3249558
649	Ibrutinib (µM)	0
649	Mercaptopurine (µM)	981.6008
649	Nelarabine (µM)	0
649	Panobinostat (nM)	0
649	Prednisolone (µM)	0.1352752
649	Ruxolitinib (nM)	0
649	Thioguanine (µM)	25.77610238
649	Trametinib (nM)	0
649	Venetoclax (nM)	0
649	Vincristine (µM)	4.885934994
649	Vorinostat (nM)	0
649	asparagise_normalized	0
649	cytarabine_normalized	0.7165
649	dexamethasone_normalized	0.6565
649	mercaptopurine_normalized	0.6837
649	prednisolone_normalized	0.2111
649	thioguanine_normalized	0.2927
649	vincristine_normalized	0.6557
650	immunophenotype	B
650	molecular subtype	ETV6-RUNX1
650	Protocol	T16
650	NCI risk	SR
650	Age at diagnosis	3.2
650	WBC at diagnosis	44.7
650	Sex	M
650	Genetically-defined race	black
650	Asparaginase (IU/ml)	0.0016
650	Bortezomib (nM)	0
650	CHZ868 (nM)	0
650	Cytarabine (µM)	0.7906468
650	Dasatinib (nM)	0
650	Daunorubicin (µM)	0
650	Dexamethasone  (µM)	0.04773097
650	Ibrutinib (µM)	0
650	Mercaptopurine (µM)	214.8084
650	Nelarabine (µM)	0
650	Panobinostat (nM)	0
650	Prednisolone (µM)	0.07146514
650	Ruxolitinib (nM)	0
650	Thioguanine (µM)	16.71849
650	Trametinib (nM)	0
650	Venetoclax (nM)	0
650	Vincristine (µM)	2.55711
650	Vorinostat (nM)	0
650	asparagise_normalized	0
650	cytarabine_normalized	0.4303
650	dexamethasone_normalized	0.4722
650	mercaptopurine_normalized	0.2453
650	prednisolone_normalized	0.1498
650	thioguanine_normalized	0.1677
650	vincristine_normalized	0.5631
651	immunophenotype	B
651	molecular subtype	Hyperdiploid
651	Protocol	T16
651	NCI risk	SR
651	Age at diagnosis	8
651	WBC at diagnosis	30.3
651	Sex	F
651	Genetically-defined race	black
651	Asparaginase (IU/ml)	0.1600834
651	Bortezomib (nM)	0
651	CHZ868 (nM)	0
651	Cytarabine (µM)	1.502264
651	Dasatinib (nM)	0
651	Daunorubicin (µM)	0
651	Dexamethasone  (µM)	23.2
651	Ibrutinib (µM)	0
651	Mercaptopurine (µM)	5876
651	Nelarabine (µM)	0
651	Panobinostat (nM)	0
651	Prednisolone (µM)	0.1486883
651	Ruxolitinib (nM)	0
651	Thioguanine (µM)	67.02938
651	Trametinib (nM)	0
651	Venetoclax (nM)	0
651	Vincristine (µM)	12.52962
651	Vorinostat (nM)	0
651	asparagise_normalized	0.4862
651	cytarabine_normalized	0.5228
651	dexamethasone_normalized	1
651	mercaptopurine_normalized	1
651	prednisolone_normalized	0.2201
651	thioguanine_normalized	0.5685
651	vincristine_normalized	0.7905
652	immunophenotype	B
652	molecular subtype	NUTM1
652	Protocol	T16
652	NCI risk	HR
652	Age at diagnosis	14.9
652	WBC at diagnosis	91.7
652	Sex	M
652	Genetically-defined race	Hispanic
652	Asparaginase (IU/ml)	0.340751
652	Bortezomib (nM)	0
652	CHZ868 (nM)	0
652	Cytarabine (µM)	0.07671593
652	Dasatinib (nM)	0
652	Daunorubicin (µM)	0
652	Dexamethasone  (µM)	0.0242914
652	Ibrutinib (µM)	0
652	Mercaptopurine (µM)	182.7617
652	Nelarabine (µM)	0
652	Panobinostat (nM)	0
652	Prednisolone (µM)	0.0075
652	Ruxolitinib (nM)	0
652	Thioguanine (µM)	9.518315
652	Trametinib (nM)	0
652	Venetoclax (nM)	0
652	Vincristine (µM)	0.025
652	Vorinostat (nM)	0
652	asparagise_normalized	0.5801
652	cytarabine_normalized	0.0939
652	dexamethasone_normalized	0.4074
652	mercaptopurine_normalized	0.1987
652	prednisolone_normalized	0
652	thioguanine_normalized	0.0051
652	vincristine_normalized	0
653	immunophenotype	B
653	molecular subtype	DUX4
653	Protocol	T16
653	NCI risk	SR
653	Age at diagnosis	8.3
653	WBC at diagnosis	5.1
653	Sex	M
653	Genetically-defined race	White
653	Asparaginase (IU/ml)	20
653	Bortezomib (nM)	0
653	CHZ868 (nM)	0
653	Cytarabine (µM)	6.7172
653	Dasatinib (nM)	0
653	Daunorubicin (µM)	0
653	Dexamethasone  (µM)	23.2
653	Ibrutinib (µM)	0
653	Mercaptopurine (µM)	5876
653	Nelarabine (µM)	0
653	Panobinostat (nM)	0
653	Prednisolone (µM)	0
653	Ruxolitinib (nM)	0
653	Thioguanine (µM)	123.0457
653	Trametinib (nM)	0
653	Venetoclax (nM)	0
653	Vincristine (µM)	0
653	Vorinostat (nM)	0
653	asparagise_normalized	1
653	cytarabine_normalized	0.7388
653	dexamethasone_normalized	1
653	mercaptopurine_normalized	1
653	thioguanine_normalized	0.7438
654	immunophenotype	B
654	molecular subtype	ETV6-RUNX1
654	Protocol	T16
654	NCI risk	HR
654	Age at diagnosis	3.2
654	WBC at diagnosis	66.5
654	Sex	M
654	Genetically-defined race	White
654	Asparaginase (IU/ml)	0.0016
654	Bortezomib (nM)	0
654	CHZ868 (nM)	0
654	Cytarabine (µM)	5.648561
654	Dasatinib (nM)	0
654	Daunorubicin (µM)	0
654	Dexamethasone  (µM)	0.02950794
654	Ibrutinib (µM)	0
654	Mercaptopurine (µM)	655.0731
654	Nelarabine (µM)	0
654	Panobinostat (nM)	0
654	Prednisolone (µM)	0.0075
654	Ruxolitinib (nM)	0
654	Thioguanine (µM)	25.47756
654	Trametinib (nM)	0
654	Venetoclax (nM)	0
654	Vincristine (µM)	0.2279001
654	Vorinostat (nM)	0
654	asparagise_normalized	0
654	cytarabine_normalized	0.7138
654	dexamethasone_normalized	0.426
654	mercaptopurine_normalized	0.567
654	prednisolone_normalized	0
654	thioguanine_normalized	0.2893
654	vincristine_normalized	0.2171
655	immunophenotype	B
655	molecular subtype	Ph-like_CRLF2
655	Protocol	T15
655	NCI risk	SR
655	Age at diagnosis	7
655	WBC at diagnosis	23.5
655	Sex	F
655	Genetically-defined race	Hispanic
655	Asparaginase (IU/ml)	0.9824777
655	Bortezomib (nM)	0
655	CHZ868 (nM)	0
655	Cytarabine (µM)	0.2312263
655	Dasatinib (nM)	0
655	Daunorubicin (µM)	0
655	Dexamethasone  (µM)	0.2857399
655	Ibrutinib (µM)	0
655	Mercaptopurine (µM)	213.2254
655	Nelarabine (µM)	0
655	Panobinostat (nM)	0
655	Prednisolone (µM)	1.040937
655	Ruxolitinib (nM)	0
655	Thioguanine (µM)	4.675
655	Trametinib (nM)	0
655	Venetoclax (nM)	0
655	Vincristine (µM)	0.025
655	Vorinostat (nM)	0
655	asparagise_normalized	0.7117
655	cytarabine_normalized	0.253
655	dexamethasone_normalized	0.6442
655	mercaptopurine_normalized	0.2432
655	prednisolone_normalized	0.4069
655	thioguanine_normalized	0
655	vincristine_normalized	0
656	immunophenotype	B
656	molecular subtype	ETV6-RUNX1
656	Protocol	T16
656	NCI risk	SR
656	Age at diagnosis	7.3
656	WBC at diagnosis	5.9
656	Sex	M
656	Genetically-defined race	White
656	Asparaginase (IU/ml)	0.0016
656	Bortezomib (nM)	0
656	CHZ868 (nM)	0
656	Cytarabine (µM)	1.234125
656	Dasatinib (nM)	0
656	Daunorubicin (µM)	0
656	Dexamethasone  (µM)	0.07289583
656	Ibrutinib (µM)	0
656	Mercaptopurine (µM)	339.9255675
656	Nelarabine (µM)	0
656	Panobinostat (nM)	0
656	Prednisolone (µM)	0.08159297
656	Ruxolitinib (nM)	0
656	Thioguanine (µM)	15.53324
656	Trametinib (nM)	0
656	Venetoclax (nM)	0
656	Vincristine (µM)	0.052668778
656	Vorinostat (nM)	0
656	asparagise_normalized	0
656	cytarabine_normalized	0.4945
656	dexamethasone_normalized	0.5129
656	mercaptopurine_normalized	0.3777
656	prednisolone_normalized	0.1625
656	thioguanine_normalized	0.1465
656	vincristine_normalized	0.0074
657	immunophenotype	T
657	molecular subtype	T-ALL
657	Protocol	T16
657	NCI risk	SR
657	Age at diagnosis	3.2
657	WBC at diagnosis	21
657	Sex	F
657	Genetically-defined race	White
657	Asparaginase (IU/ml)	0
657	Bortezomib (nM)	0
657	CHZ868 (nM)	0
657	Cytarabine (µM)	0.8759172
657	Dasatinib (nM)	0
657	Daunorubicin (µM)	0
657	Dexamethasone  (µM)	0
657	Ibrutinib (µM)	0
657	Mercaptopurine (µM)	0
657	Nelarabine (µM)	0
657	Panobinostat (nM)	0
657	Prednisolone (µM)	0.160037121
657	Ruxolitinib (nM)	0
657	Thioguanine (µM)	0
657	Trametinib (nM)	0
657	Venetoclax (nM)	0
657	Vincristine (µM)	0.025
657	Vorinostat (nM)	0
657	cytarabine_normalized	0.4451
657	prednisolone_normalized	0.2272
657	vincristine_normalized	0
658	immunophenotype	B
658	molecular subtype	KMT2A
658	Protocol	T16
658	NCI risk	HR
658	Age at diagnosis	0.7
658	WBC at diagnosis	450
658	Sex	M
658	Genetically-defined race	White
658	Asparaginase (IU/ml)	0.0016
658	Bortezomib (nM)	0
658	CHZ868 (nM)	0
658	Cytarabine (µM)	1.007407
658	Dasatinib (nM)	0
658	Daunorubicin (µM)	0
658	Dexamethasone  (µM)	0.08122681
658	Ibrutinib (µM)	0
658	Mercaptopurine (µM)	827.8814
658	Nelarabine (µM)	0
658	Panobinostat (nM)	0
658	Prednisolone (µM)	0
658	Ruxolitinib (nM)	0
658	Thioguanine (µM)	27.26915
658	Trametinib (nM)	0
658	Venetoclax (nM)	0
658	Vincristine (µM)	0.1590326
658	Vorinostat (nM)	0
658	asparagise_normalized	0
658	cytarabine_normalized	0.4652
658	dexamethasone_normalized	0.5233
658	mercaptopurine_normalized	0.6345
658	thioguanine_normalized	0.3089
658	vincristine_normalized	0.1656
659	immunophenotype	B
659	molecular subtype	PAX5alt
659	Protocol	T16
659	NCI risk	HR
659	Age at diagnosis	18
659	WBC at diagnosis	13.4
659	Sex	M
659	Genetically-defined race	White
659	Asparaginase (IU/ml)	0.2560785
659	Bortezomib (nM)	0
659	CHZ868 (nM)	0
659	Cytarabine (µM)	1.58889
659	Dasatinib (nM)	0
659	Daunorubicin (µM)	0
659	Dexamethasone  (µM)	23.2
659	Ibrutinib (µM)	0
659	Mercaptopurine (µM)	0
659	Nelarabine (µM)	0
659	Panobinostat (nM)	0
659	Prednisolone (µM)	1006
659	Ruxolitinib (nM)	0
659	Thioguanine (µM)	30.05226
659	Trametinib (nM)	0
659	Venetoclax (nM)	0
659	Vincristine (µM)	0
659	Vorinostat (nM)	0
659	asparagise_normalized	0.5446
659	cytarabine_normalized	0.5309
659	dexamethasone_normalized	1
659	prednisolone_normalized	1
659	thioguanine_normalized	0.337
660	immunophenotype	T
660	molecular subtype	T-ALL
660	Protocol	T16
660	NCI risk	SR
660	Age at diagnosis	1.9
660	WBC at diagnosis	45.5
660	Sex	M
660	Genetically-defined race	black
660	Asparaginase (IU/ml)	20
660	Bortezomib (nM)	0
660	CHZ868 (nM)	0
660	Cytarabine (µM)	1.30307
660	Dasatinib (nM)	0
660	Daunorubicin (µM)	0.2586545
660	Dexamethasone  (µM)	23.2
660	Ibrutinib (µM)	0
660	Mercaptopurine (µM)	5876
660	Nelarabine (µM)	0
660	Panobinostat (nM)	0
660	Prednisolone (µM)	0
660	Ruxolitinib (nM)	0
660	Thioguanine (µM)	75.72488204
660	Trametinib (nM)	0
660	Venetoclax (nM)	0
660	Vincristine (µM)	42.85877
660	Vorinostat (nM)	0
660	asparagise_normalized	1
660	cytarabine_normalized	0.5023
660	daunorubicin_normalized	0.6299
660	dexamethasone_normalized	1
660	mercaptopurine_normalized	1
660	thioguanine_normalized	0.6037
660	vincristine_normalized	0.9665
661	immunophenotype	B
661	molecular subtype	Hyperdiploid
661	Protocol	T16
661	NCI risk	SR
661	Age at diagnosis	6.5
661	WBC at diagnosis	39.4
661	Sex	M
661	Genetically-defined race	White
661	Asparaginase (IU/ml)	0.0016
661	Bortezomib (nM)	0
661	CHZ868 (nM)	0
661	Cytarabine (µM)	0.4125154
661	Dasatinib (nM)	0
661	Daunorubicin (µM)	0
661	Dexamethasone  (µM)	0.04010565
661	Ibrutinib (µM)	0
661	Mercaptopurine (µM)	232.02
661	Nelarabine (µM)	0
661	Panobinostat (nM)	0
661	Prednisolone (µM)	0.0075
661	Ruxolitinib (nM)	0
661	Thioguanine (µM)	24.9061
661	Trametinib (nM)	0
661	Venetoclax (nM)	0
661	Vincristine (µM)	0.025
661	Vorinostat (nM)	0
661	asparagise_normalized	0
661	cytarabine_normalized	0.3365
661	dexamethasone_normalized	0.4555
661	mercaptopurine_normalized	0.2675
661	prednisolone_normalized	0
661	thioguanine_normalized	0.2827
661	vincristine_normalized	0
662	immunophenotype	B
662	molecular subtype	TCF3-PBX1
662	Protocol	T16
662	NCI risk	HR
662	Age at diagnosis	10.6
662	WBC at diagnosis	3.8
662	Sex	F
662	Genetically-defined race	black
662	Asparaginase (IU/ml)	0
662	Bortezomib (nM)	0
662	CHZ868 (nM)	0
662	Cytarabine (µM)	0
662	Dasatinib (nM)	0
662	Daunorubicin (µM)	0
662	Dexamethasone  (µM)	0.1534962
662	Ibrutinib (µM)	0
662	Mercaptopurine (µM)	45.9
662	Nelarabine (µM)	0
662	Panobinostat (nM)	0
662	Prednisolone (µM)	0.08230566
662	Ruxolitinib (nM)	0
662	Thioguanine (µM)	4.675
662	Trametinib (nM)	0
662	Venetoclax (nM)	0
662	Vincristine (µM)	0
662	Vorinostat (nM)	0
662	dexamethasone_normalized	0.5845
662	mercaptopurine_normalized	0
662	prednisolone_normalized	0.1634
662	thioguanine_normalized	0
663	immunophenotype	B
663	molecular subtype	ETV6-RUNX1
663	Protocol	T16
663	NCI risk	HR
663	Age at diagnosis	2.6
663	WBC at diagnosis	77.4
663	Sex	F
663	Genetically-defined race	White
663	Asparaginase (IU/ml)	0.0016
663	Bortezomib (nM)	0
663	CHZ868 (nM)	0
663	Cytarabine (µM)	1.13089
663	Dasatinib (nM)	0
663	Daunorubicin (µM)	0
663	Dexamethasone  (µM)	0.0128649
663	Ibrutinib (µM)	0
663	Mercaptopurine (µM)	210.4021
663	Nelarabine (µM)	0
663	Panobinostat (nM)	0
663	Prednisolone (µM)	0.0075
663	Ruxolitinib (nM)	0
663	Thioguanine (µM)	9.358648
663	Trametinib (nM)	0
663	Venetoclax (nM)	0
663	Vincristine (µM)	0.05457344
663	Vorinostat (nM)	0
663	asparagise_normalized	0
663	cytarabine_normalized	0.4819
663	dexamethasone_normalized	0.3463
663	mercaptopurine_normalized	0.2393
663	prednisolone_normalized	0
663	thioguanine_normalized	0.0003
663	vincristine_normalized	0.0125
664	immunophenotype	B
664	molecular subtype	ETV6-RUNX1
664	Protocol	T16
664	NCI risk	SR
664	Age at diagnosis	2.3
664	WBC at diagnosis	27.3
664	Sex	M
664	Genetically-defined race	White
664	Asparaginase (IU/ml)	0.0016
664	Bortezomib (nM)	0
664	CHZ868 (nM)	0
664	Cytarabine (µM)	3.663608
664	Dasatinib (nM)	0
664	Daunorubicin (µM)	0
664	Dexamethasone  (µM)	23.2
664	Ibrutinib (µM)	0
664	Mercaptopurine (µM)	977.3348
664	Nelarabine (µM)	0
664	Panobinostat (nM)	0
664	Prednisolone (µM)	0
664	Ruxolitinib (nM)	0
664	Thioguanine (µM)	21.66328
664	Trametinib (nM)	0
664	Venetoclax (nM)	0
664	Vincristine (µM)	15.9949
664	Vorinostat (nM)	0
664	asparagise_normalized	0
664	cytarabine_normalized	0.6514
664	dexamethasone_normalized	1
664	mercaptopurine_normalized	0.6824
664	thioguanine_normalized	0.2425
664	vincristine_normalized	0.8254
665	immunophenotype	T
665	molecular subtype	T-ALL
665	Protocol	T16
665	NCI risk	HR
665	Age at diagnosis	14.1
665	WBC at diagnosis	33.5
665	Sex	M
665	Genetically-defined race	White
665	Asparaginase (IU/ml)	0.0016
665	Bortezomib (nM)	0
665	CHZ868 (nM)	0
665	Cytarabine (µM)	0.7734723
665	Dasatinib (nM)	0
665	Daunorubicin (µM)	0.01238204
665	Dexamethasone  (µM)	0.1503807
665	Ibrutinib (µM)	0
665	Mercaptopurine (µM)	45.9
665	Nelarabine (µM)	0
665	Panobinostat (nM)	0
665	Prednisolone (µM)	0
665	Ruxolitinib (nM)	0
665	Thioguanine (µM)	4.675
665	Trametinib (nM)	0
665	Venetoclax (nM)	0
665	Vincristine (µM)	0.5036778
665	Vorinostat (nM)	0
665	asparagise_normalized	0
665	cytarabine_normalized	0.4271
665	daunorubicin_normalized	0.2003
665	dexamethasone_normalized	0.5825
665	mercaptopurine_normalized	0
665	thioguanine_normalized	0
665	vincristine_normalized	0.3306
666	immunophenotype	B
666	molecular subtype	B-other
666	Protocol	T16
666	NCI risk	HR
666	Age at diagnosis	3
666	WBC at diagnosis	78.8
666	Sex	M
666	Genetically-defined race	White
666	Asparaginase (IU/ml)	0.1772369
666	Bortezomib (nM)	0
666	CHZ868 (nM)	0
666	Cytarabine (µM)	2.954077
666	Dasatinib (nM)	0
666	Daunorubicin (µM)	0
666	Dexamethasone  (µM)	23.2
666	Ibrutinib (µM)	0
666	Mercaptopurine (µM)	5876
666	Nelarabine (µM)	0
666	Panobinostat (nM)	0
666	Prednisolone (µM)	1006
666	Ruxolitinib (nM)	0
666	Thioguanine (µM)	46.88123459
666	Trametinib (nM)	0
666	Venetoclax (nM)	0
666	Vincristine (µM)	0.4437012
666	Vorinostat (nM)	0
666	asparagise_normalized	0.4988
666	cytarabine_normalized	0.6204
666	dexamethasone_normalized	1
666	mercaptopurine_normalized	1
666	prednisolone_normalized	1
666	thioguanine_normalized	0.4653
666	vincristine_normalized	0.3124
667	immunophenotype	B
667	molecular subtype	Hyperdiploid
667	Protocol	T16
667	NCI risk	SR
667	Age at diagnosis	2
667	WBC at diagnosis	16.7
667	Sex	M
667	Genetically-defined race	White
667	Asparaginase (IU/ml)	0.2096841
667	Bortezomib (nM)	0
667	CHZ868 (nM)	0
667	Cytarabine (µM)	1.170105
667	Dasatinib (nM)	0
667	Daunorubicin (µM)	0
667	Dexamethasone  (µM)	0
667	Ibrutinib (µM)	0
667	Mercaptopurine (µM)	222.4811
667	Nelarabine (µM)	0
667	Panobinostat (nM)	0
667	Prednisolone (µM)	1006
667	Ruxolitinib (nM)	0
667	Thioguanine (µM)	17.23789
667	Trametinib (nM)	0
667	Venetoclax (nM)	0
667	Vincristine (µM)	0
667	Vorinostat (nM)	0
667	asparagise_normalized	0.5197
667	cytarabine_normalized	0.4868
667	mercaptopurine_normalized	0.2554
667	prednisolone_normalized	1
667	thioguanine_normalized	0.1765
668	immunophenotype	B
668	molecular subtype	Hyperdiploid
668	Protocol	T16
668	NCI risk	SR
668	Age at diagnosis	2.6
668	WBC at diagnosis	15.9
668	Sex	F
668	Genetically-defined race	Asian/Other
668	Asparaginase (IU/ml)	0.0016
668	Bortezomib (nM)	0
668	CHZ868 (nM)	0
668	Cytarabine (µM)	0.4160033
668	Dasatinib (nM)	0
668	Daunorubicin (µM)	0
668	Dexamethasone  (µM)	0.1788374
668	Ibrutinib (µM)	0
668	Mercaptopurine (µM)	154.8541
668	Nelarabine (µM)	0
668	Panobinostat (nM)	0
668	Prednisolone (µM)	0
668	Ruxolitinib (nM)	0
668	Thioguanine (µM)	14.28619
668	Trametinib (nM)	0
668	Venetoclax (nM)	0
668	Vincristine (µM)	0.05014147
668	Vorinostat (nM)	0
668	asparagise_normalized	0
668	cytarabine_normalized	0.3377
668	dexamethasone_normalized	0.5991
668	mercaptopurine_normalized	0.1509
668	thioguanine_normalized	0.1223
668	vincristine_normalized	0.0004
669	immunophenotype	B
669	molecular subtype	TCF3-PBX1
669	Protocol	T16
669	NCI risk	SR
669	Age at diagnosis	8.2
669	WBC at diagnosis	8.1
669	Sex	M
669	Genetically-defined race	White
669	Asparaginase (IU/ml)	0.1227646
669	Bortezomib (nM)	0
669	CHZ868 (nM)	0
669	Cytarabine (µM)	0.2013559
669	Dasatinib (nM)	0
669	Daunorubicin (µM)	0
669	Dexamethasone  (µM)	0.03762915
669	Ibrutinib (µM)	0
669	Mercaptopurine (µM)	137.1494
669	Nelarabine (µM)	0
669	Panobinostat (nM)	0
669	Prednisolone (µM)	0.0075
669	Ruxolitinib (nM)	0
669	Thioguanine (µM)	4.675
669	Trametinib (nM)	0
669	Venetoclax (nM)	0
669	Vincristine (µM)	0.025
669	Vorinostat (nM)	0
669	asparagise_normalized	0.4532
669	cytarabine_normalized	0.2331
669	dexamethasone_normalized	0.4494
669	mercaptopurine_normalized	0.1158
669	prednisolone_normalized	0
669	thioguanine_normalized	0
669	vincristine_normalized	0
670	immunophenotype	T
670	molecular subtype	ETP
670	Protocol	T16
670	NCI risk	SR
670	Age at diagnosis	9.3
670	WBC at diagnosis	2.4
670	Sex	M
670	Genetically-defined race	Asian/Other
670	Asparaginase (IU/ml)	20
670	Bortezomib (nM)	0
670	CHZ868 (nM)	0
670	Cytarabine (µM)	15.98534
670	Dasatinib (nM)	0
670	Daunorubicin (µM)	0.2634802
670	Dexamethasone  (µM)	23.2
670	Ibrutinib (µM)	0
670	Mercaptopurine (µM)	0
670	Nelarabine (µM)	0
670	Panobinostat (nM)	0
670	Prednisolone (µM)	1006
670	Ruxolitinib (nM)	0
670	Thioguanine (µM)	39.07508
670	Trametinib (nM)	0
670	Venetoclax (nM)	0
670	Vincristine (µM)	4.5778
670	Vorinostat (nM)	0
670	asparagise_normalized	1
670	cytarabine_normalized	0.8638
670	daunorubicin_normalized	0.6325
670	dexamethasone_normalized	1
670	prednisolone_normalized	1
670	thioguanine_normalized	0.4127
670	vincristine_normalized	0.6464
671	immunophenotype	T
671	molecular subtype	T-ALL
671	Protocol	T16
671	NCI risk	SR
671	Age at diagnosis	5.7
671	WBC at diagnosis	10.3
671	Sex	M
671	Genetically-defined race	White
671	Asparaginase (IU/ml)	0.0016
671	Bortezomib (nM)	0
671	CHZ868 (nM)	0
671	Cytarabine (µM)	0.02
671	Dasatinib (nM)	0
671	Daunorubicin (µM)	0
671	Dexamethasone  (µM)	0.02528619
671	Ibrutinib (µM)	0
671	Mercaptopurine (µM)	45.9
671	Nelarabine (µM)	0
671	Panobinostat (nM)	0
671	Prednisolone (µM)	0.0075
671	Ruxolitinib (nM)	0
671	Thioguanine (µM)	4.675
671	Trametinib (nM)	0
671	Venetoclax (nM)	0
671	Vincristine (µM)	0.025
671	Vorinostat (nM)	0
671	asparagise_normalized	0
671	cytarabine_normalized	0
671	dexamethasone_normalized	0.4112
671	mercaptopurine_normalized	0
671	prednisolone_normalized	0
671	thioguanine_normalized	0
671	vincristine_normalized	0
672	immunophenotype	B
672	molecular subtype	ETV6-RUNX1
672	Protocol	T16
672	NCI risk	SR
672	Age at diagnosis	3.3
672	WBC at diagnosis	20
672	Sex	M
672	Genetically-defined race	black
672	Asparaginase (IU/ml)	0.1562593
672	Bortezomib (nM)	0
672	CHZ868 (nM)	0
672	Cytarabine (µM)	1.978651
672	Dasatinib (nM)	0
672	Daunorubicin (µM)	0
672	Dexamethasone  (µM)	0.06941573
672	Ibrutinib (µM)	0
672	Mercaptopurine (µM)	199.124
672	Nelarabine (µM)	0
672	Panobinostat (nM)	0
672	Prednisolone (µM)	0.05874515
672	Ruxolitinib (nM)	0
672	Thioguanine (µM)	14.42475
672	Trametinib (nM)	0
672	Venetoclax (nM)	0
672	Vincristine (µM)	1.195182
672	Vorinostat (nM)	0
672	asparagise_normalized	0.4832
672	cytarabine_normalized	0.5626
672	dexamethasone_normalized	0.5082
672	mercaptopurine_normalized	0.2234
672	prednisolone_normalized	0.131
672	thioguanine_normalized	0.1251
672	vincristine_normalized	0.4542
673	immunophenotype	B
673	molecular subtype	PAX5alt
673	Protocol	T16
673	NCI risk	SR
673	Age at diagnosis	7.5
673	WBC at diagnosis	4.2
673	Sex	F
673	Genetically-defined race	White
673	Asparaginase (IU/ml)	0
673	Bortezomib (nM)	0
673	CHZ868 (nM)	0
673	Cytarabine (µM)	0
673	Dasatinib (nM)	0
673	Daunorubicin (µM)	0
673	Dexamethasone  (µM)	0.2310992
673	Ibrutinib (µM)	0
673	Mercaptopurine (µM)	5876
673	Nelarabine (µM)	0
673	Panobinostat (nM)	0
673	Prednisolone (µM)	0.091904788
673	Ruxolitinib (nM)	0
673	Thioguanine (µM)	25.23131
673	Trametinib (nM)	0
673	Venetoclax (nM)	0
673	Vincristine (µM)	0
673	Vorinostat (nM)	0
673	dexamethasone_normalized	0.6238
673	mercaptopurine_normalized	1
673	prednisolone_normalized	0.174
673	thioguanine_normalized	0.2865
674	immunophenotype	B
674	molecular subtype	ZNF384
674	Protocol	T16
674	NCI risk	HR
674	Age at diagnosis	18.5
674	WBC at diagnosis	59.1
674	Sex	M
674	Genetically-defined race	Hispanic
674	Asparaginase (IU/ml)	0.2062446
674	Bortezomib (nM)	0
674	CHZ868 (nM)	0
674	Cytarabine (µM)	5.446348679
674	Dasatinib (nM)	0
674	Daunorubicin (µM)	0
674	Dexamethasone  (µM)	23.2
674	Ibrutinib (µM)	0
674	Mercaptopurine (µM)	5876
674	Nelarabine (µM)	0
674	Panobinostat (nM)	0
674	Prednisolone (µM)	0
674	Ruxolitinib (nM)	0
674	Thioguanine (µM)	219.7402061
674	Trametinib (nM)	0
674	Venetoclax (nM)	0
674	Vincristine (µM)	0.3978064
674	Vorinostat (nM)	0
674	asparagise_normalized	0.5177
674	cytarabine_normalized	0.7086
674	dexamethasone_normalized	1
674	mercaptopurine_normalized	1
674	thioguanine_normalized	0.9111
674	vincristine_normalized	0.2968
675	immunophenotype	B
675	molecular subtype	ETV6-RUNX1
675	Protocol	T16
675	NCI risk	SR
675	Age at diagnosis	2.9
675	WBC at diagnosis	5.3
675	Sex	F
675	Genetically-defined race	Asian/Other
675	Asparaginase (IU/ml)	0.05072246
675	Bortezomib (nM)	0
675	CHZ868 (nM)	0
675	Cytarabine (µM)	1.303764
675	Dasatinib (nM)	0
675	Daunorubicin (µM)	0
675	Dexamethasone  (µM)	0.03061493
675	Ibrutinib (µM)	0
675	Mercaptopurine (µM)	247.5621
675	Nelarabine (µM)	0
675	Panobinostat (nM)	0
675	Prednisolone (µM)	0
675	Ruxolitinib (nM)	0
675	Thioguanine (µM)	17.01502
675	Trametinib (nM)	0
675	Venetoclax (nM)	0
675	Vincristine (µM)	0.4757494
675	Vorinostat (nM)	0
675	asparagise_normalized	0.3434
675	cytarabine_normalized	0.5024
675	dexamethasone_normalized	0.4296
675	mercaptopurine_normalized	0.2862
675	thioguanine_normalized	0.1728
675	vincristine_normalized	0.3224
676	immunophenotype	T
676	molecular subtype	T-ALL
676	Protocol	T16
676	NCI risk	HR
676	Age at diagnosis	3.2
676	WBC at diagnosis	435
676	Sex	F
676	Genetically-defined race	White
676	Asparaginase (IU/ml)	20
676	Bortezomib (nM)	0
676	CHZ868 (nM)	0
676	Cytarabine (µM)	82.2
676	Dasatinib (nM)	0.2215075
676	Daunorubicin (µM)	0.3280742
676	Dexamethasone  (µM)	23.2
676	Ibrutinib (µM)	5.113269
676	Mercaptopurine (µM)	0
676	Nelarabine (µM)	1.448641
676	Panobinostat (nM)	0
676	Prednisolone (µM)	1006
676	Ruxolitinib (nM)	0
676	Thioguanine (µM)	133.6644
676	Trametinib (nM)	0.536414
676	Venetoclax (nM)	200
676	Vincristine (µM)	108.34
676	Vorinostat (nM)	0
676	asparagise_normalized	1
676	cytarabine_normalized	1
676	dasatinib_normalized	0.0691
676	daunorubicin_normalized	0.6634
676	dexamethasone_normalized	1
676	ibrutinib_normalized	0.3421
676	nelarabine_normalized	0.4213
676	prednisolone_normalized	1
676	thioguanine_normalized	0.7676
676	trametinib_normalized	0.3459
676	venetoclax_normalized	1
676	vincristine_normalized	1
677	immunophenotype	B
677	molecular subtype	B-other
677	Protocol	T16
677	NCI risk	SR
677	Age at diagnosis	9.8
677	WBC at diagnosis	11.2
677	Sex	M
677	Genetically-defined race	Asian/Other
677	Asparaginase (IU/ml)	20
677	Bortezomib (nM)	0
677	CHZ868 (nM)	0
677	Cytarabine (µM)	0
677	Dasatinib (nM)	0
677	Daunorubicin (µM)	0
677	Dexamethasone  (µM)	0.01986819
677	Ibrutinib (µM)	0
677	Mercaptopurine (µM)	0
677	Nelarabine (µM)	0
677	Panobinostat (nM)	0
677	Prednisolone (µM)	0
677	Ruxolitinib (nM)	0
677	Thioguanine (µM)	0
677	Trametinib (nM)	0
677	Venetoclax (nM)	0
677	Vincristine (µM)	0
677	Vorinostat (nM)	0
677	asparagise_normalized	1
677	dexamethasone_normalized	0.388
678	immunophenotype	B
678	molecular subtype	Hyperdiploid
678	Protocol	T16
678	NCI risk	SR
678	Age at diagnosis	7.7
678	WBC at diagnosis	14.6
678	Sex	F
678	Genetically-defined race	Hispanic
678	Asparaginase (IU/ml)	0.0016
678	Bortezomib (nM)	0
678	CHZ868 (nM)	0
678	Cytarabine (µM)	0.3473544
678	Dasatinib (nM)	0
678	Daunorubicin (µM)	0
678	Dexamethasone  (µM)	0.2928776
678	Ibrutinib (µM)	0
678	Mercaptopurine (µM)	206.6977
678	Nelarabine (µM)	0
678	Panobinostat (nM)	0
678	Prednisolone (µM)	0.1014834
678	Ruxolitinib (nM)	0
678	Thioguanine (µM)	4.675
678	Trametinib (nM)	0
678	Venetoclax (nM)	0
678	Vincristine (µM)	0.025
678	Vorinostat (nM)	0
678	asparagise_normalized	0
678	cytarabine_normalized	0.3117
678	dexamethasone_normalized	0.6465
678	mercaptopurine_normalized	0.2342
678	prednisolone_normalized	0.1835
678	thioguanine_normalized	0
678	vincristine_normalized	0
679	immunophenotype	B
679	molecular subtype	B-other
679	Protocol	T16
679	NCI risk	SR
679	Age at diagnosis	2.2
679	WBC at diagnosis	3.6
679	Sex	M
679	Genetically-defined race	Hispanic
679	Asparaginase (IU/ml)	0.0016
679	Bortezomib (nM)	0
679	CHZ868 (nM)	0
679	Cytarabine (µM)	0.5131011
679	Dasatinib (nM)	0
679	Daunorubicin (µM)	0
679	Dexamethasone  (µM)	23.2
679	Ibrutinib (µM)	0
679	Mercaptopurine (µM)	516.8337
679	Nelarabine (µM)	0
679	Panobinostat (nM)	0
679	Prednisolone (µM)	169.9594
679	Ruxolitinib (nM)	0
679	Thioguanine (µM)	15.10588
679	Trametinib (nM)	0
679	Venetoclax (nM)	0
679	Vincristine (µM)	0.2564426
679	Vorinostat (nM)	0
679	asparagise_normalized	0
679	cytarabine_normalized	0.3679
679	dexamethasone_normalized	1
679	mercaptopurine_normalized	0.4986
679	prednisolone_normalized	0.8959
679	thioguanine_normalized	0.1384
679	vincristine_normalized	0.234
680	immunophenotype	T
680	molecular subtype	T-ALL
680	Protocol	T16
680	NCI risk	SR
680	Age at diagnosis	5.1
680	WBC at diagnosis	31.5
680	Sex	F
680	Genetically-defined race	black
680	Asparaginase (IU/ml)	0.0016
680	Bortezomib (nM)	0
680	CHZ868 (nM)	0
680	Cytarabine (µM)	0.02
680	Dasatinib (nM)	0
680	Daunorubicin (µM)	0.01899842
680	Dexamethasone  (µM)	0.06122391
680	Ibrutinib (µM)	0
680	Mercaptopurine (µM)	45.9
680	Nelarabine (µM)	0
680	Panobinostat (nM)	0
680	Prednisolone (µM)	0.037218236
680	Ruxolitinib (nM)	0
680	Thioguanine (µM)	4.675
680	Trametinib (nM)	0
680	Venetoclax (nM)	0
680	Vincristine (µM)	0.025
680	Vorinostat (nM)	0
680	asparagise_normalized	0
680	cytarabine_normalized	0
680	daunorubicin_normalized	0.2608
680	dexamethasone_normalized	0.4962
680	mercaptopurine_normalized	0
680	prednisolone_normalized	0.0872
680	thioguanine_normalized	0
680	vincristine_normalized	0
681	immunophenotype	T
681	molecular subtype	T-ALL
681	Protocol	T16
681	NCI risk	HR
681	Age at diagnosis	4.3
681	WBC at diagnosis	139.9
681	Sex	F
681	Genetically-defined race	White
681	Asparaginase (IU/ml)	0
681	Bortezomib (nM)	0
681	CHZ868 (nM)	16.77821
681	Cytarabine (µM)	0.5146913
681	Dasatinib (nM)	1.115651
681	Daunorubicin (µM)	0.240521267
681	Dexamethasone  (µM)	23.2
681	Ibrutinib (µM)	2.782821
681	Mercaptopurine (µM)	0
681	Nelarabine (µM)	4.488506
681	Panobinostat (nM)	0
681	Prednisolone (µM)	1006
681	Ruxolitinib (nM)	1019.288
681	Thioguanine (µM)	0
681	Trametinib (nM)	1.512313
681	Venetoclax (nM)	2.669361
681	Vincristine (µM)	0
681	Vorinostat (nM)	841.0001
681	CHZ868_normalized	0.4449
681	cytarabine_normalized	0.3684
681	dasatinib_normalized	0.2095
681	daunorubicin_normalized	0.6196
681	dexamethasone_normalized	1
681	ibrutinib_normalized	0.1665
681	nelarabine_normalized	0.5844
681	prednisolone_normalized	1
681	ruxolitinib_normalized	0.8017
681	trametinib_normalized	0.4359
681	venetoclax_normalized	0.6853
681	vorinostat_normalized	0.585
682	immunophenotype	B
682	molecular subtype	DUX4
682	Protocol	T16
682	NCI risk	SR
682	Age at diagnosis	9.8
682	WBC at diagnosis	3.5
682	Sex	M
682	Genetically-defined race	White
682	Asparaginase (IU/ml)	0.1774044
682	Bortezomib (nM)	0
682	CHZ868 (nM)	0
682	Cytarabine (µM)	9.741965101
682	Dasatinib (nM)	0
682	Daunorubicin (µM)	0
682	Dexamethasone  (µM)	0.7335023
682	Ibrutinib (µM)	0
682	Mercaptopurine (µM)	2391.013
682	Nelarabine (µM)	0
682	Panobinostat (nM)	0
682	Prednisolone (µM)	0.133746
682	Ruxolitinib (nM)	0
682	Thioguanine (µM)	49.17042
682	Trametinib (nM)	0
682	Venetoclax (nM)	0
682	Vincristine (µM)	0
682	Vorinostat (nM)	0
682	asparagise_normalized	0.499
682	cytarabine_normalized	0.7924
682	dexamethasone_normalized	0.7347
682	mercaptopurine_normalized	0.9406
682	prednisolone_normalized	0.21
682	thioguanine_normalized	0.479
683	immunophenotype	B
683	molecular subtype	Hyperdiploid
683	Protocol	T16
683	NCI risk	SR
683	Age at diagnosis	7.4
683	WBC at diagnosis	7.8
683	Sex	F
683	Genetically-defined race	White
683	Asparaginase (IU/ml)	0.0016
683	Bortezomib (nM)	0
683	CHZ868 (nM)	0
683	Cytarabine (µM)	3.344953
683	Dasatinib (nM)	0
683	Daunorubicin (µM)	0
683	Dexamethasone  (µM)	23.2
683	Ibrutinib (µM)	0
683	Mercaptopurine (µM)	490.9812
683	Nelarabine (µM)	0
683	Panobinostat (nM)	0
683	Prednisolone (µM)	0
683	Ruxolitinib (nM)	0
683	Thioguanine (µM)	27.60053
683	Trametinib (nM)	0
683	Venetoclax (nM)	0
683	Vincristine (µM)	42.48089
683	Vorinostat (nM)	0
683	asparagise_normalized	0
683	cytarabine_normalized	0.6383
683	dexamethasone_normalized	1
683	mercaptopurine_normalized	0.4838
683	thioguanine_normalized	0.3124
683	vincristine_normalized	0.9652
684	immunophenotype	B
684	molecular subtype	Hyperdiploid
684	Protocol	T16
684	NCI risk	HR
684	Age at diagnosis	16.9
684	WBC at diagnosis	1
684	Sex	M
684	Genetically-defined race	White
684	Asparaginase (IU/ml)	0
684	Bortezomib (nM)	0
684	CHZ868 (nM)	0
684	Cytarabine (µM)	0
684	Dasatinib (nM)	0
684	Daunorubicin (µM)	0
684	Dexamethasone  (µM)	0.07046741
684	Ibrutinib (µM)	0
684	Mercaptopurine (µM)	545.863
684	Nelarabine (µM)	0
684	Panobinostat (nM)	0
684	Prednisolone (µM)	0.09667777
684	Ruxolitinib (nM)	0
684	Thioguanine (µM)	26.39763
684	Trametinib (nM)	0
684	Venetoclax (nM)	0
684	Vincristine (µM)	0
684	Vorinostat (nM)	0
684	dexamethasone_normalized	0.5097
684	mercaptopurine_normalized	0.5144
684	prednisolone_normalized	0.1788
684	thioguanine_normalized	0.2995
685	immunophenotype	B
685	molecular subtype	Hyperdiploid
685	Protocol	T16
685	NCI risk	SR
685	Age at diagnosis	1.4
685	WBC at diagnosis	5.2
685	Sex	F
685	Genetically-defined race	White
685	Asparaginase (IU/ml)	0
685	Bortezomib (nM)	0
685	CHZ868 (nM)	0
685	Cytarabine (µM)	0
685	Dasatinib (nM)	0
685	Daunorubicin (µM)	0
685	Dexamethasone  (µM)	0
685	Ibrutinib (µM)	0
685	Mercaptopurine (µM)	172.2802
685	Nelarabine (µM)	0
685	Panobinostat (nM)	0
685	Prednisolone (µM)	0
685	Ruxolitinib (nM)	0
685	Thioguanine (µM)	24.37966
685	Trametinib (nM)	0
685	Venetoclax (nM)	0
685	Vincristine (µM)	0
685	Vorinostat (nM)	0
685	mercaptopurine_normalized	0.1816
685	thioguanine_normalized	0.2766
686	immunophenotype	B
686	molecular subtype	DUX4
686	Protocol	T16
686	NCI risk	HR
686	Age at diagnosis	14.1
686	WBC at diagnosis	23.4
686	Sex	F
686	Genetically-defined race	White
686	Asparaginase (IU/ml)	0.2237622
686	Bortezomib (nM)	0
686	CHZ868 (nM)	0
686	Cytarabine (µM)	0.5162429
686	Dasatinib (nM)	0
686	Daunorubicin (µM)	0
686	Dexamethasone  (µM)	23.2
686	Ibrutinib (µM)	0
686	Mercaptopurine (µM)	5876
686	Nelarabine (µM)	0
686	Panobinostat (nM)	0
686	Prednisolone (µM)	1006
686	Ruxolitinib (nM)	0
686	Thioguanine (µM)	237.6226
686	Trametinib (nM)	0
686	Venetoclax (nM)	0
686	Vincristine (µM)	0.025
686	Vorinostat (nM)	0
686	asparagise_normalized	0.5278
686	cytarabine_normalized	0.3688
686	dexamethasone_normalized	1
686	mercaptopurine_normalized	1
686	prednisolone_normalized	1
686	thioguanine_normalized	0.9337
686	vincristine_normalized	0
687	immunophenotype	B
687	molecular subtype	ETV6-RUNX1
687	Protocol	T16
687	NCI risk	SR
687	Age at diagnosis	3.6
687	WBC at diagnosis	4.1
687	Sex	F
687	Genetically-defined race	black
687	Asparaginase (IU/ml)	0.0016
687	Bortezomib (nM)	0
687	CHZ868 (nM)	0
687	Cytarabine (µM)	0.8775199
687	Dasatinib (nM)	0
687	Daunorubicin (µM)	0
687	Dexamethasone  (µM)	0.06107316
687	Ibrutinib (µM)	0
687	Mercaptopurine (µM)	169.2372
687	Nelarabine (µM)	0
687	Panobinostat (nM)	0
687	Prednisolone (µM)	0.0075
687	Ruxolitinib (nM)	0
687	Thioguanine (µM)	4.675
687	Trametinib (nM)	0
687	Venetoclax (nM)	0
687	Vincristine (µM)	16.82201
687	Vorinostat (nM)	0
687	asparagise_normalized	0
687	cytarabine_normalized	0.4453
687	dexamethasone_normalized	0.4959
687	mercaptopurine_normalized	0.1765
687	prednisolone_normalized	0
687	thioguanine_normalized	0
687	vincristine_normalized	0.8326
688	immunophenotype	B
688	molecular subtype	Hyperdiploid
688	Protocol	T16
688	NCI risk	SR
688	Age at diagnosis	3
688	WBC at diagnosis	20.7
688	Sex	M
688	Genetically-defined race	White
688	Asparaginase (IU/ml)	0
688	Bortezomib (nM)	0
688	CHZ868 (nM)	0
688	Cytarabine (µM)	0
688	Dasatinib (nM)	0
688	Daunorubicin (µM)	0
688	Dexamethasone  (µM)	0.02636085
688	Ibrutinib (µM)	0
688	Mercaptopurine (µM)	256.0197
688	Nelarabine (µM)	0
688	Panobinostat (nM)	0
688	Prednisolone (µM)	0
688	Ruxolitinib (nM)	0
688	Thioguanine (µM)	0
688	Trametinib (nM)	0
688	Venetoclax (nM)	0
688	Vincristine (µM)	0
688	Vorinostat (nM)	0
688	dexamethasone_normalized	0.4152
688	mercaptopurine_normalized	0.2959
689	immunophenotype	B
689	molecular subtype	ETV6-RUNX1
689	Protocol	T16
689	NCI risk	SR
689	Age at diagnosis	5.6
689	WBC at diagnosis	3
689	Sex	F
689	Genetically-defined race	White
689	Asparaginase (IU/ml)	0
689	Bortezomib (nM)	0
689	CHZ868 (nM)	0
689	Cytarabine (µM)	0
689	Dasatinib (nM)	0
689	Daunorubicin (µM)	0
689	Dexamethasone  (µM)	0.1432159
689	Ibrutinib (µM)	0
689	Mercaptopurine (µM)	0
689	Nelarabine (µM)	0
689	Panobinostat (nM)	0
689	Prednisolone (µM)	0
689	Ruxolitinib (nM)	0
689	Thioguanine (µM)	0
689	Trametinib (nM)	0
689	Venetoclax (nM)	0
689	Vincristine (µM)	0
689	Vorinostat (nM)	0
689	dexamethasone_normalized	0.5778
690	immunophenotype	B
690	molecular subtype	ETV6-RUNX1
690	Protocol	T16
690	NCI risk	SR
690	Age at diagnosis	4.3
690	WBC at diagnosis	5.7
690	Sex	F
690	Genetically-defined race	black
690	Asparaginase (IU/ml)	0.454507865
690	Bortezomib (nM)	0
690	CHZ868 (nM)	0
690	Cytarabine (µM)	4.425876
690	Dasatinib (nM)	0
690	Daunorubicin (µM)	0
690	Dexamethasone  (µM)	0.05364401
690	Ibrutinib (µM)	0
690	Mercaptopurine (µM)	430.6091
690	Nelarabine (µM)	0
690	Panobinostat (nM)	0
690	Prednisolone (µM)	0.0075
690	Ruxolitinib (nM)	0
690	Thioguanine (µM)	20.433
690	Trametinib (nM)	0
690	Venetoclax (nM)	0
690	Vincristine (µM)	3.236685
690	Vorinostat (nM)	0
690	asparagise_normalized	0.6159
690	cytarabine_normalized	0.6786
690	dexamethasone_normalized	0.4835
690	mercaptopurine_normalized	0.4459
690	prednisolone_normalized	0
690	thioguanine_normalized	0.2256
690	vincristine_normalized	0.5968
691	immunophenotype	B
691	molecular subtype	PAX5alt
691	Protocol	T16
691	NCI risk	HR
691	Age at diagnosis	17.8
691	WBC at diagnosis	63.2
691	Sex	M
691	Genetically-defined race	black
691	Asparaginase (IU/ml)	0
691	Bortezomib (nM)	0
691	CHZ868 (nM)	0
691	Cytarabine (µM)	0
691	Dasatinib (nM)	0
691	Daunorubicin (µM)	0
691	Dexamethasone  (µM)	0.08897927
691	Ibrutinib (µM)	0
691	Mercaptopurine (µM)	736.2707
691	Nelarabine (µM)	0
691	Panobinostat (nM)	0
691	Prednisolone (µM)	0.01844501
691	Ruxolitinib (nM)	0
691	Thioguanine (µM)	71.30004853
691	Trametinib (nM)	0
691	Venetoclax (nM)	0
691	Vincristine (µM)	108.34
691	Vorinostat (nM)	0
691	dexamethasone_normalized	0.5321
691	mercaptopurine_normalized	0.6007
691	prednisolone_normalized	0.0198
691	thioguanine_normalized	0.5863
691	vincristine_normalized	1
692	immunophenotype	T
692	molecular subtype	T-ALL
692	Protocol	T16
692	NCI risk	HR
692	Age at diagnosis	14.1
692	WBC at diagnosis	52.3
692	Sex	F
692	Genetically-defined race	Asian/Other
692	Asparaginase (IU/ml)	20
692	Bortezomib (nM)	0
692	CHZ868 (nM)	0
692	Cytarabine (µM)	5.530615
692	Dasatinib (nM)	0
692	Daunorubicin (µM)	0.0527039
692	Dexamethasone  (µM)	23.2
692	Ibrutinib (µM)	0
692	Mercaptopurine (µM)	456.5715
692	Nelarabine (µM)	0
692	Panobinostat (nM)	0
692	Prednisolone (µM)	1006
692	Ruxolitinib (nM)	0
692	Thioguanine (µM)	68.07172
692	Trametinib (nM)	0
692	Venetoclax (nM)	0
692	Vincristine (µM)	108.34
692	Vorinostat (nM)	0
692	asparagise_normalized	1
692	cytarabine_normalized	0.7108
692	daunorubicin_normalized	0.405
692	dexamethasone_normalized	1
692	mercaptopurine_normalized	0.4628
692	prednisolone_normalized	1
692	thioguanine_normalized	0.5729
692	vincristine_normalized	1
693	immunophenotype	B
693	molecular subtype	Hyperdiploid
693	Protocol	T16
693	NCI risk	HR
693	Age at diagnosis	14.9
693	WBC at diagnosis	4.9
693	Sex	F
693	Genetically-defined race	black
693	Asparaginase (IU/ml)	0
693	Bortezomib (nM)	0
693	CHZ868 (nM)	0
693	Cytarabine (µM)	1.125436
693	Dasatinib (nM)	0
693	Daunorubicin (µM)	0
693	Dexamethasone  (µM)	0
693	Ibrutinib (µM)	0
693	Mercaptopurine (µM)	0
693	Nelarabine (µM)	0
693	Panobinostat (nM)	0
693	Prednisolone (µM)	0
693	Ruxolitinib (nM)	0
693	Thioguanine (µM)	0
693	Trametinib (nM)	0
693	Venetoclax (nM)	0
693	Vincristine (µM)	0
693	Vorinostat (nM)	0
693	cytarabine_normalized	0.4812
694	immunophenotype	B
694	molecular subtype	PAX5alt
694	Protocol	T16
694	NCI risk	HR
694	Age at diagnosis	1.8
694	WBC at diagnosis	112.7
694	Sex	M
694	Genetically-defined race	Asian/Other
694	Asparaginase (IU/ml)	0
694	Bortezomib (nM)	0
694	CHZ868 (nM)	0
694	Cytarabine (µM)	0
694	Dasatinib (nM)	0
694	Daunorubicin (µM)	0
694	Dexamethasone  (µM)	0
694	Ibrutinib (µM)	0
694	Mercaptopurine (µM)	0
694	Nelarabine (µM)	0
694	Panobinostat (nM)	0
694	Prednisolone (µM)	0
694	Ruxolitinib (nM)	0
694	Thioguanine (µM)	0
694	Trametinib (nM)	0
694	Venetoclax (nM)	0
694	Vincristine (µM)	6.734685
694	Vorinostat (nM)	0
694	vincristine_normalized	0.7016
695	immunophenotype	B
695	molecular subtype	Hyperdiploid
695	Protocol	T16
695	NCI risk	HR
695	Age at diagnosis	10
695	WBC at diagnosis	3.5
695	Sex	M
695	Genetically-defined race	White
695	Asparaginase (IU/ml)	7.190568
695	Bortezomib (nM)	0
695	CHZ868 (nM)	0
695	Cytarabine (µM)	2.707853
695	Dasatinib (nM)	0
695	Daunorubicin (µM)	0
695	Dexamethasone  (µM)	23.2
695	Ibrutinib (µM)	0
695	Mercaptopurine (µM)	863.8871
695	Nelarabine (µM)	0
695	Panobinostat (nM)	0
695	Prednisolone (µM)	158.2239
695	Ruxolitinib (nM)	0
695	Thioguanine (µM)	77.18261
695	Trametinib (nM)	0
695	Venetoclax (nM)	0
695	Vincristine (µM)	108.34
695	Vorinostat (nM)	0
695	asparagise_normalized	0.959
695	cytarabine_normalized	0.6078
695	dexamethasone_normalized	1
695	mercaptopurine_normalized	0.6468
695	prednisolone_normalized	0.889
695	thioguanine_normalized	0.6092
695	vincristine_normalized	1
696	immunophenotype	B
696	molecular subtype	ETV6-RUNX1-like
696	Protocol	T16
696	NCI risk	SR
696	Age at diagnosis	1.8
696	WBC at diagnosis	26.2
696	Sex	F
696	Genetically-defined race	White
696	Asparaginase (IU/ml)	0.0016
696	Bortezomib (nM)	0
696	CHZ868 (nM)	0
696	Cytarabine (µM)	1.849559
696	Dasatinib (nM)	0
696	Daunorubicin (µM)	0
696	Dexamethasone  (µM)	0.0352281
696	Ibrutinib (µM)	0
696	Mercaptopurine (µM)	627.8549
696	Nelarabine (µM)	0
696	Panobinostat (nM)	0
696	Prednisolone (µM)	0.0075
696	Ruxolitinib (nM)	0
696	Thioguanine (µM)	18.48309
696	Trametinib (nM)	0
696	Venetoclax (nM)	0
696	Vincristine (µM)	0.2739227
696	Vorinostat (nM)	0
696	asparagise_normalized	0
696	cytarabine_normalized	0.5528
696	dexamethasone_normalized	0.4431
696	mercaptopurine_normalized	0.5548
696	prednisolone_normalized	0
696	thioguanine_normalized	0.1967
696	vincristine_normalized	0.2434
697	immunophenotype	T
697	molecular subtype	T-ALL
697	Protocol	T16
697	NCI risk	HR
697	Age at diagnosis	12.8
697	WBC at diagnosis	27
697	Sex	M
697	Genetically-defined race	Asian/Other
697	Asparaginase (IU/ml)	0.0016
697	Bortezomib (nM)	0
697	CHZ868 (nM)	0
697	Cytarabine (µM)	0.1494948
697	Dasatinib (nM)	0
697	Daunorubicin (µM)	0.0015
697	Dexamethasone  (µM)	0.06324953
697	Ibrutinib (µM)	0
697	Mercaptopurine (µM)	45.9
697	Nelarabine (µM)	0
697	Panobinostat (nM)	0
697	Prednisolone (µM)	0
697	Ruxolitinib (nM)	0
697	Thioguanine (µM)	4.675
697	Trametinib (nM)	0
697	Venetoclax (nM)	0
697	Vincristine (µM)	0.09011675
697	Vorinostat (nM)	0
697	asparagise_normalized	0
697	cytarabine_normalized	0.1901
697	daunorubicin_normalized	0
697	dexamethasone_normalized	0.4993
697	mercaptopurine_normalized	0
697	thioguanine_normalized	0
697	vincristine_normalized	0.0843
698	immunophenotype	B
698	molecular subtype	Hyperdiploid
698	Protocol	T16
698	NCI risk	SR
698	Age at diagnosis	1.7
698	WBC at diagnosis	5.5
698	Sex	M
698	Genetically-defined race	White
698	Asparaginase (IU/ml)	0.0016
698	Bortezomib (nM)	0
698	CHZ868 (nM)	0
698	Cytarabine (µM)	0.3742978
698	Dasatinib (nM)	0
698	Daunorubicin (µM)	0
698	Dexamethasone  (µM)	0.1617148
698	Ibrutinib (µM)	0
698	Mercaptopurine (µM)	217.5485
698	Nelarabine (µM)	0
698	Panobinostat (nM)	0
698	Prednisolone (µM)	0
698	Ruxolitinib (nM)	0
698	Thioguanine (µM)	15.24009
698	Trametinib (nM)	0
698	Venetoclax (nM)	0
698	Vincristine (µM)	0.212613429
698	Vorinostat (nM)	0
698	asparagise_normalized	0
698	cytarabine_normalized	0.3225
698	dexamethasone_normalized	0.5895
698	mercaptopurine_normalized	0.2489
698	thioguanine_normalized	0.141
698	vincristine_normalized	0.2071
699	immunophenotype	B
699	molecular subtype	B-other
699	Protocol	T16
699	NCI risk	HR
699	Age at diagnosis	11.7
699	WBC at diagnosis	15.5
699	Sex	M
699	Genetically-defined race	black
699	Asparaginase (IU/ml)	0.530703
699	Bortezomib (nM)	0
699	CHZ868 (nM)	0
699	Cytarabine (µM)	1.340082
699	Dasatinib (nM)	0
699	Daunorubicin (µM)	0
699	Dexamethasone  (µM)	0.706901
699	Ibrutinib (µM)	0
699	Mercaptopurine (µM)	605.9286
699	Nelarabine (µM)	0
699	Panobinostat (nM)	0
699	Prednisolone (µM)	0
699	Ruxolitinib (nM)	0
699	Thioguanine (µM)	69.1118508
699	Trametinib (nM)	0
699	Venetoclax (nM)	0
699	Vincristine (µM)	0.107756172
699	Vorinostat (nM)	0
699	asparagise_normalized	0.6351
699	cytarabine_normalized	0.5064
699	dexamethasone_normalized	0.7312
699	mercaptopurine_normalized	0.5445
699	thioguanine_normalized	0.5773
699	vincristine_normalized	0.1099
700	immunophenotype	B
700	molecular subtype	Ph-like_non_CRLF2
700	Protocol	T16
700	NCI risk	HR
700	Age at diagnosis	15.5
700	WBC at diagnosis	14.3
700	Sex	M
700	Genetically-defined race	White
700	Asparaginase (IU/ml)	0
700	Bortezomib (nM)	0
700	CHZ868 (nM)	0
700	Cytarabine (µM)	0
700	Dasatinib (nM)	0
700	Daunorubicin (µM)	0
700	Dexamethasone  (µM)	0
700	Ibrutinib (µM)	0
700	Mercaptopurine (µM)	2421.477
700	Nelarabine (µM)	0
700	Panobinostat (nM)	0
700	Prednisolone (µM)	0
700	Ruxolitinib (nM)	0
700	Thioguanine (µM)	598
700	Trametinib (nM)	0
700	Venetoclax (nM)	0
700	Vincristine (µM)	0
700	Vorinostat (nM)	0
700	mercaptopurine_normalized	0.9442
700	thioguanine_normalized	1
701	immunophenotype	T
701	molecular subtype	T-ALL
701	Protocol	T16
701	NCI risk	HR
701	Age at diagnosis	10.1
701	WBC at diagnosis	69.6
701	Sex	M
701	Genetically-defined race	black
701	Asparaginase (IU/ml)	0.0016
701	Bortezomib (nM)	0
701	CHZ868 (nM)	0
701	Cytarabine (µM)	0.1215533
701	Dasatinib (nM)	0
701	Daunorubicin (µM)	0.01648543
701	Dexamethasone  (µM)	0.319327
701	Ibrutinib (µM)	0
701	Mercaptopurine (µM)	45.9
701	Nelarabine (µM)	0
701	Panobinostat (nM)	0
701	Prednisolone (µM)	0.09818806
701	Ruxolitinib (nM)	0
701	Thioguanine (µM)	4.675
701	Trametinib (nM)	0
701	Venetoclax (nM)	0
701	Vincristine (µM)	0.025
701	Vorinostat (nM)	0
701	asparagise_normalized	0
701	cytarabine_normalized	0.1603
701	daunorubicin_normalized	0.2408
701	dexamethasone_normalized	0.6548
701	mercaptopurine_normalized	0
701	prednisolone_normalized	0.1803
701	thioguanine_normalized	0
701	vincristine_normalized	0
702	immunophenotype	B
702	molecular subtype	DUX4
702	Protocol	T16
702	NCI risk	SR
702	Age at diagnosis	6.5
702	WBC at diagnosis	13.9
702	Sex	F
702	Genetically-defined race	Hispanic
702	Asparaginase (IU/ml)	0.1880254
702	Bortezomib (nM)	0
702	CHZ868 (nM)	0
702	Cytarabine (µM)	1.163505
702	Dasatinib (nM)	0
702	Daunorubicin (µM)	0
702	Dexamethasone  (µM)	0.05221664
702	Ibrutinib (µM)	0
702	Mercaptopurine (µM)	653.3625155
702	Nelarabine (µM)	0
702	Panobinostat (nM)	0
702	Prednisolone (µM)	0
702	Ruxolitinib (nM)	0
702	Thioguanine (µM)	20.22002
702	Trametinib (nM)	0
702	Venetoclax (nM)	0
702	Vincristine (µM)	0.025
702	Vorinostat (nM)	0
702	asparagise_normalized	0.5062
702	cytarabine_normalized	0.486
702	dexamethasone_normalized	0.4809
702	mercaptopurine_normalized	0.5662
702	thioguanine_normalized	0.2226
702	vincristine_normalized	0
703	immunophenotype	B
703	molecular subtype	B-other
703	Protocol	T16
703	NCI risk	SR
703	Age at diagnosis	3.7
703	WBC at diagnosis	13.1
703	Sex	F
703	Genetically-defined race	White
703	Asparaginase (IU/ml)	1.487104
703	Bortezomib (nM)	0
703	CHZ868 (nM)	0
703	Cytarabine (µM)	3.560369
703	Dasatinib (nM)	0
703	Daunorubicin (µM)	0
703	Dexamethasone  (µM)	23.2
703	Ibrutinib (µM)	0
703	Mercaptopurine (µM)	5876
703	Nelarabine (µM)	0
703	Panobinostat (nM)	0
703	Prednisolone (µM)	1006
703	Ruxolitinib (nM)	0
703	Thioguanine (µM)	105.66
703	Trametinib (nM)	0
703	Venetoclax (nM)	0
703	Vincristine (µM)	0.1414186
703	Vorinostat (nM)	0
703	asparagise_normalized	0.7632
703	cytarabine_normalized	0.6473
703	dexamethasone_normalized	1
703	mercaptopurine_normalized	1
703	prednisolone_normalized	1
703	thioguanine_normalized	0.6998
703	vincristine_normalized	0.1488
704	immunophenotype	B
704	molecular subtype	Hyperdiploid
704	Protocol	T16
704	NCI risk	SR
704	Age at diagnosis	3.7
704	WBC at diagnosis	43.2
704	Sex	F
704	Genetically-defined race	White
704	Asparaginase (IU/ml)	0.703461889
704	Bortezomib (nM)	0
704	CHZ868 (nM)	0
704	Cytarabine (µM)	7.167371
704	Dasatinib (nM)	0
704	Daunorubicin (µM)	0
704	Dexamethasone  (µM)	0.08152838
704	Ibrutinib (µM)	0
704	Mercaptopurine (µM)	318.6188
704	Nelarabine (µM)	0
704	Panobinostat (nM)	0
704	Prednisolone (µM)	0.07882671
704	Ruxolitinib (nM)	0
704	Thioguanine (µM)	61.18072
704	Trametinib (nM)	0
704	Venetoclax (nM)	0
704	Vincristine (µM)	108.34
704	Vorinostat (nM)	0
704	asparagise_normalized	0.6702
704	cytarabine_normalized	0.7482
704	dexamethasone_normalized	0.5237
704	mercaptopurine_normalized	0.359
704	prednisolone_normalized	0.1592
704	thioguanine_normalized	0.5421
704	vincristine_normalized	1
705	immunophenotype	B
705	molecular subtype	ETV6-RUNX1
705	Protocol	T16
705	NCI risk	SR
705	Age at diagnosis	5.1
705	WBC at diagnosis	15.9
705	Sex	F
705	Genetically-defined race	Asian/Other
705	Asparaginase (IU/ml)	0.0016
705	Bortezomib (nM)	0
705	CHZ868 (nM)	0
705	Cytarabine (µM)	0.7174588
705	Dasatinib (nM)	0
705	Daunorubicin (µM)	0
705	Dexamethasone  (µM)	0.042884372
705	Ibrutinib (µM)	0
705	Mercaptopurine (µM)	152.0846
705	Nelarabine (µM)	0
705	Panobinostat (nM)	0
705	Prednisolone (µM)	0.0075
705	Ruxolitinib (nM)	0
705	Thioguanine (µM)	4.675
705	Trametinib (nM)	0
705	Venetoclax (nM)	0
705	Vincristine (µM)	0.05055862
705	Vorinostat (nM)	0
705	asparagise_normalized	0
705	cytarabine_normalized	0.4163
705	dexamethasone_normalized	0.462
705	mercaptopurine_normalized	0.1457
705	prednisolone_normalized	0
705	thioguanine_normalized	0
705	vincristine_normalized	0.0016
706	immunophenotype	B
706	molecular subtype	ETV6-RUNX1
706	Protocol	T16
706	NCI risk	SR
706	Age at diagnosis	2.2
706	WBC at diagnosis	10.4
706	Sex	M
706	Genetically-defined race	White
706	Asparaginase (IU/ml)	5.281367153
706	Bortezomib (nM)	0
706	CHZ868 (nM)	0
706	Cytarabine (µM)	8.748599
706	Dasatinib (nM)	0
706	Daunorubicin (µM)	0
706	Dexamethasone  (µM)	0.3179269
706	Ibrutinib (µM)	0
706	Mercaptopurine (µM)	761.4129
706	Nelarabine (µM)	0
706	Panobinostat (nM)	0
706	Prednisolone (µM)	0
706	Ruxolitinib (nM)	0
706	Thioguanine (µM)	38.59251
706	Trametinib (nM)	0
706	Venetoclax (nM)	0
706	Vincristine (µM)	1.924373
706	Vorinostat (nM)	0
706	asparagise_normalized	0.9207
706	cytarabine_normalized	0.7769
706	dexamethasone_normalized	0.6544
706	mercaptopurine_normalized	0.6104
706	thioguanine_normalized	0.4091
706	vincristine_normalized	0.5224
707	immunophenotype	B
707	molecular subtype	KMT2A
707	Protocol	T16
707	NCI risk	HR
707	Age at diagnosis	4
707	WBC at diagnosis	432.8
707	Sex	M
707	Genetically-defined race	White
707	Asparaginase (IU/ml)	20
707	Bortezomib (nM)	0
707	CHZ868 (nM)	0
707	Cytarabine (µM)	1.798457
707	Dasatinib (nM)	0
707	Daunorubicin (µM)	0
707	Dexamethasone  (µM)	23.2
707	Ibrutinib (µM)	0
707	Mercaptopurine (µM)	0
707	Nelarabine (µM)	0
707	Panobinostat (nM)	0
707	Prednisolone (µM)	0
707	Ruxolitinib (nM)	0
707	Thioguanine (µM)	254.446
707	Trametinib (nM)	0
707	Venetoclax (nM)	0
707	Vincristine (µM)	0.4507549
707	Vorinostat (nM)	0
707	asparagise_normalized	1
707	cytarabine_normalized	0.5488
707	dexamethasone_normalized	1
707	thioguanine_normalized	0.9534
707	vincristine_normalized	0.3147
708	immunophenotype	B
708	molecular subtype	Near haploid
708	Protocol	T16
708	NCI risk	SR
708	Age at diagnosis	6.7
708	WBC at diagnosis	24.4
708	Sex	F
708	Genetically-defined race	Asian/Other
708	Asparaginase (IU/ml)	0.7398187
708	Bortezomib (nM)	0
708	CHZ868 (nM)	0
708	Cytarabine (µM)	0.90371393
708	Dasatinib (nM)	0
708	Daunorubicin (µM)	0
708	Dexamethasone  (µM)	23.2
708	Ibrutinib (µM)	0
708	Mercaptopurine (µM)	721.1743
708	Nelarabine (µM)	0
708	Panobinostat (nM)	0
708	Prednisolone (µM)	0.7331342
708	Ruxolitinib (nM)	0
708	Thioguanine (µM)	27.41153
708	Trametinib (nM)	0
708	Venetoclax (nM)	0
708	Vincristine (µM)	0.025
708	Vorinostat (nM)	0
708	asparagise_normalized	0.6764
708	cytarabine_normalized	0.4496
708	dexamethasone_normalized	1
708	mercaptopurine_normalized	0.5947
708	prednisolone_normalized	0.3732
708	thioguanine_normalized	0.3104
708	vincristine_normalized	0
709	immunophenotype	B
709	molecular subtype	KMT2A
709	Protocol	T16
709	NCI risk	HR
709	Age at diagnosis	16.8
709	WBC at diagnosis	11.9
709	Sex	M
709	Genetically-defined race	White
709	Asparaginase (IU/ml)	20
709	Bortezomib (nM)	0
709	CHZ868 (nM)	0
709	Cytarabine (µM)	1.700139
709	Dasatinib (nM)	0
709	Daunorubicin (µM)	0
709	Dexamethasone  (µM)	0.5112962
709	Ibrutinib (µM)	0
709	Mercaptopurine (µM)	5876
709	Nelarabine (µM)	0
709	Panobinostat (nM)	0
709	Prednisolone (µM)	0
709	Ruxolitinib (nM)	0
709	Thioguanine (µM)	63.56109
709	Trametinib (nM)	0
709	Venetoclax (nM)	0
709	Vincristine (µM)	0.2206506
709	Vorinostat (nM)	0
709	asparagise_normalized	1
709	cytarabine_normalized	0.5407
709	dexamethasone_normalized	0.7001
709	mercaptopurine_normalized	1
709	thioguanine_normalized	0.5531
709	vincristine_normalized	0.2124
710	immunophenotype	B
710	molecular subtype	Hyperdiploid
710	Protocol	T16
710	NCI risk	HR
710	Age at diagnosis	0.8
710	WBC at diagnosis	10.4
710	Sex	M
710	Genetically-defined race	White
710	Asparaginase (IU/ml)	0
710	Bortezomib (nM)	0
710	CHZ868 (nM)	0
710	Cytarabine (µM)	0
710	Dasatinib (nM)	0
710	Daunorubicin (µM)	0
710	Dexamethasone  (µM)	23.2
710	Ibrutinib (µM)	0
710	Mercaptopurine (µM)	361.0606
710	Nelarabine (µM)	0
710	Panobinostat (nM)	0
710	Prednisolone (µM)	0
710	Ruxolitinib (nM)	0
710	Thioguanine (µM)	16.032
710	Trametinib (nM)	0
710	Venetoclax (nM)	0
710	Vincristine (µM)	0
710	Vorinostat (nM)	0
710	dexamethasone_normalized	1
710	mercaptopurine_normalized	0.3951
710	thioguanine_normalized	0.1556
711	immunophenotype	B
711	molecular subtype	B-other
711	Protocol	T16
711	NCI risk	HR
711	Age at diagnosis	15.2
711	WBC at diagnosis	30.8
711	Sex	M
711	Genetically-defined race	Asian/Other
711	Asparaginase (IU/ml)	0
711	Bortezomib (nM)	0
711	CHZ868 (nM)	0
711	Cytarabine (µM)	0
711	Dasatinib (nM)	0
711	Daunorubicin (µM)	0
711	Dexamethasone  (µM)	0.000175
711	Ibrutinib (µM)	0
711	Mercaptopurine (µM)	0
711	Nelarabine (µM)	0
711	Panobinostat (nM)	0
711	Prednisolone (µM)	0
711	Ruxolitinib (nM)	0
711	Thioguanine (µM)	0
711	Trametinib (nM)	0
711	Venetoclax (nM)	0
711	Vincristine (µM)	0
711	Vorinostat (nM)	0
711	dexamethasone_normalized	0
712	immunophenotype	B
712	molecular subtype	B-other
712	Protocol	T16
712	NCI risk	HR
712	Age at diagnosis	16.3
712	WBC at diagnosis	4.9
712	Sex	M
712	Genetically-defined race	Hispanic
712	Asparaginase (IU/ml)	0
712	Bortezomib (nM)	0
712	CHZ868 (nM)	0
712	Cytarabine (µM)	82.2
712	Dasatinib (nM)	0
712	Daunorubicin (µM)	0
712	Dexamethasone  (µM)	23.2
712	Ibrutinib (µM)	0
712	Mercaptopurine (µM)	0
712	Nelarabine (µM)	0
712	Panobinostat (nM)	0
712	Prednisolone (µM)	0
712	Ruxolitinib (nM)	0
712	Thioguanine (µM)	0
712	Trametinib (nM)	0
712	Venetoclax (nM)	0
712	Vincristine (µM)	0
712	Vorinostat (nM)	0
712	cytarabine_normalized	1
712	dexamethasone_normalized	1
713	immunophenotype	B
713	molecular subtype	ETV6-RUNX1
713	Protocol	T16
713	NCI risk	SR
713	Age at diagnosis	9.8
713	WBC at diagnosis	8.5
713	Sex	F
713	Genetically-defined race	White
713	Asparaginase (IU/ml)	0
713	Bortezomib (nM)	0
713	CHZ868 (nM)	0
713	Cytarabine (µM)	0.02
713	Dasatinib (nM)	0
713	Daunorubicin (µM)	0
713	Dexamethasone  (µM)	0.02864516
713	Ibrutinib (µM)	0
713	Mercaptopurine (µM)	0
713	Nelarabine (µM)	0
713	Panobinostat (nM)	0
713	Prednisolone (µM)	0
713	Ruxolitinib (nM)	0
713	Thioguanine (µM)	33.77011
713	Trametinib (nM)	0
713	Venetoclax (nM)	0
713	Vincristine (µM)	0.025
713	Vorinostat (nM)	0
713	cytarabine_normalized	0
713	dexamethasone_normalized	0.4232
713	thioguanine_normalized	0.3706
713	vincristine_normalized	0
714	immunophenotype	B
714	molecular subtype	DUX4
714	Protocol	T16
714	NCI risk	SR
714	Age at diagnosis	6.3
714	WBC at diagnosis	9.9
714	Sex	M
714	Genetically-defined race	black
714	Asparaginase (IU/ml)	0.931079519
714	Bortezomib (nM)	0
714	CHZ868 (nM)	0
714	Cytarabine (µM)	7.86252
714	Dasatinib (nM)	0
714	Daunorubicin (µM)	0
714	Dexamethasone  (µM)	1.996534
714	Ibrutinib (µM)	0
714	Mercaptopurine (µM)	1218.784
714	Nelarabine (µM)	0
714	Panobinostat (nM)	0
714	Prednisolone (µM)	0.5862256
714	Ruxolitinib (nM)	0
714	Thioguanine (µM)	41.01382424
714	Trametinib (nM)	0
714	Venetoclax (nM)	0
714	Vincristine (µM)	0.025
714	Vorinostat (nM)	0
714	asparagise_normalized	0.705
714	cytarabine_normalized	0.7615
714	dexamethasone_normalized	0.8309
714	mercaptopurine_normalized	0.7461
714	prednisolone_normalized	0.3518
714	thioguanine_normalized	0.4267
714	vincristine_normalized	0
715	immunophenotype	T
715	molecular subtype	T-ALL
715	Protocol	T16
715	NCI risk	HR
715	Age at diagnosis	17.5
715	WBC at diagnosis	62.8
715	Sex	F
715	Genetically-defined race	White
715	Asparaginase (IU/ml)	0.244962
715	Bortezomib (nM)	0
715	CHZ868 (nM)	0
715	Cytarabine (µM)	0
715	Dasatinib (nM)	0
715	Daunorubicin (µM)	0
715	Dexamethasone  (µM)	0
715	Ibrutinib (µM)	0
715	Mercaptopurine (µM)	375.5342
715	Nelarabine (µM)	0
715	Panobinostat (nM)	0
715	Prednisolone (µM)	231.6516
715	Ruxolitinib (nM)	0
715	Thioguanine (µM)	0
715	Trametinib (nM)	0
715	Venetoclax (nM)	0
715	Vincristine (µM)	0.05992202
715	Vorinostat (nM)	0
715	asparagise_normalized	0.5391
715	mercaptopurine_normalized	0.4065
715	prednisolone_normalized	0.9256
715	vincristine_normalized	0.0259
716	immunophenotype	T
716	molecular subtype	T-ALL
716	Protocol	T16
716	NCI risk	SR
716	Age at diagnosis	9
716	WBC at diagnosis	10.2
716	Sex	F
716	Genetically-defined race	Asian/Other
716	Asparaginase (IU/ml)	0.01502384
716	Bortezomib (nM)	0
716	CHZ868 (nM)	0
716	Cytarabine (µM)	0.571724
716	Dasatinib (nM)	1955.425
716	Daunorubicin (µM)	0.0317306
716	Dexamethasone  (µM)	1.857082
716	Ibrutinib (µM)	4.857156
716	Mercaptopurine (µM)	355.4349
716	Nelarabine (µM)	4.150036
716	Panobinostat (nM)	0
716	Prednisolone (µM)	0.1804102
716	Ruxolitinib (nM)	0
716	Thioguanine (µM)	45.19941
716	Trametinib (nM)	0
716	Venetoclax (nM)	11.26329
716	Vincristine (µM)	0
716	Vorinostat (nM)	0
716	asparagise_normalized	0.1922
716	cytarabine_normalized	0.3835
716	dasatinib_normalized	0.8582
716	daunorubicin_normalized	0.3333
716	dexamethasone_normalized	0.824
716	ibrutinib_normalized	0.3273
716	mercaptopurine_normalized	0.3906
716	nelarabine_normalized	0.5731
716	prednisolone_normalized	0.2387
716	thioguanine_normalized	0.4547
716	venetoclax_normalized	0.8103
717	immunophenotype	T
717	molecular subtype	ETP
717	Protocol	T16
717	NCI risk	HR
717	Age at diagnosis	11.9
717	WBC at diagnosis	344
717	Sex	F
717	Genetically-defined race	Unknown
717	Asparaginase (IU/ml)	20
717	Bortezomib (nM)	0
717	CHZ868 (nM)	0
717	Cytarabine (µM)	0
717	Dasatinib (nM)	0
717	Daunorubicin (µM)	7.1
717	Dexamethasone  (µM)	0
717	Ibrutinib (µM)	0
717	Mercaptopurine (µM)	0
717	Nelarabine (µM)	0
717	Panobinostat (nM)	0
717	Prednisolone (µM)	1006
717	Ruxolitinib (nM)	0
717	Thioguanine (µM)	0
717	Trametinib (nM)	0
717	Venetoclax (nM)	0
717	Vincristine (µM)	108.34
717	Vorinostat (nM)	0
717	asparagise_normalized	1
717	daunorubicin_normalized	1
717	prednisolone_normalized	1
717	vincristine_normalized	1
718	immunophenotype	B
718	molecular subtype	DUX4
718	Protocol	T16
718	NCI risk	SR
718	Age at diagnosis	7.8
718	WBC at diagnosis	10.6
718	Sex	M
718	Genetically-defined race	Hispanic
718	Asparaginase (IU/ml)	20
718	Bortezomib (nM)	0
718	CHZ868 (nM)	0
718	Cytarabine (µM)	10.06075
718	Dasatinib (nM)	0
718	Daunorubicin (µM)	0
718	Dexamethasone  (µM)	0.0450217
718	Ibrutinib (µM)	0
718	Mercaptopurine (µM)	0
718	Nelarabine (µM)	0
718	Panobinostat (nM)	0
718	Prednisolone (µM)	0.02278967
718	Ruxolitinib (nM)	0
718	Thioguanine (µM)	42.93659
718	Trametinib (nM)	0
718	Venetoclax (nM)	0
718	Vincristine (µM)	0.077862982
718	Vorinostat (nM)	0
718	asparagise_normalized	1
718	cytarabine_normalized	0.7971
718	dexamethasone_normalized	0.4666
718	prednisolone_normalized	0.0401
718	thioguanine_normalized	0.4399
718	vincristine_normalized	0.0634
719	immunophenotype	B
719	molecular subtype	ETV6-RUNX1
719	Protocol	T16
719	NCI risk	SR
719	Age at diagnosis	8
719	WBC at diagnosis	3.2
719	Sex	F
719	Genetically-defined race	White
719	Asparaginase (IU/ml)	0.0016
719	Bortezomib (nM)	0
719	CHZ868 (nM)	0
719	Cytarabine (µM)	2.889541
719	Dasatinib (nM)	0
719	Daunorubicin (µM)	0
719	Dexamethasone  (µM)	0.0227154
719	Ibrutinib (µM)	0
719	Mercaptopurine (µM)	330.4877
719	Nelarabine (µM)	0
719	Panobinostat (nM)	0
719	Prednisolone (µM)	0.0075
719	Ruxolitinib (nM)	0
719	Thioguanine (µM)	21.68549
719	Trametinib (nM)	0
719	Venetoclax (nM)	0
719	Vincristine (µM)	4.54403
719	Vorinostat (nM)	0
719	asparagise_normalized	0
719	cytarabine_normalized	0.6172
719	dexamethasone_normalized	0.4009
719	mercaptopurine_normalized	0.3696
719	prednisolone_normalized	0
719	thioguanine_normalized	0.2428
719	vincristine_normalized	0.6453
720	immunophenotype	B
720	molecular subtype	Hyperdiploid
720	Protocol	T16
720	NCI risk	SR
720	Age at diagnosis	3.1
720	WBC at diagnosis	27.1
720	Sex	F
720	Genetically-defined race	White
720	Asparaginase (IU/ml)	0.003361079
720	Bortezomib (nM)	0
720	CHZ868 (nM)	0
720	Cytarabine (µM)	4.183643
720	Dasatinib (nM)	0
720	Daunorubicin (µM)	0
720	Dexamethasone  (µM)	0.2112357
720	Ibrutinib (µM)	0
720	Mercaptopurine (µM)	0
720	Nelarabine (µM)	0
720	Panobinostat (nM)	0
720	Prednisolone (µM)	0.1039722
720	Ruxolitinib (nM)	0
720	Thioguanine (µM)	78.34181
720	Trametinib (nM)	0
720	Venetoclax (nM)	0
720	Vincristine (µM)	16.14070442
720	Vorinostat (nM)	0
720	asparagise_normalized	0.0061
720	cytarabine_normalized	0.6705
720	dexamethasone_normalized	0.6151
720	prednisolone_normalized	0.1858
720	thioguanine_normalized	0.6135
720	vincristine_normalized	0.8267
721	immunophenotype	T
721	molecular subtype	T-ALL
721	Protocol	T16
721	NCI risk	HR
721	Age at diagnosis	13.4
721	WBC at diagnosis	335.1
721	Sex	M
721	Genetically-defined race	White
721	Asparaginase (IU/ml)	0
721	Bortezomib (nM)	0
721	CHZ868 (nM)	0
721	Cytarabine (µM)	0
721	Dasatinib (nM)	0
721	Daunorubicin (µM)	0
721	Dexamethasone  (µM)	0
721	Ibrutinib (µM)	0
721	Mercaptopurine (µM)	125.7165
721	Nelarabine (µM)	0
721	Panobinostat (nM)	0
721	Prednisolone (µM)	0.1318169
721	Ruxolitinib (nM)	0
721	Thioguanine (µM)	4.675
721	Trametinib (nM)	0
721	Venetoclax (nM)	0
721	Vincristine (µM)	0.3153302
721	Vorinostat (nM)	0
721	mercaptopurine_normalized	0.0907
721	prednisolone_normalized	0.2086
721	thioguanine_normalized	0
721	vincristine_normalized	0.2635
722	immunophenotype	B
722	molecular subtype	iAMP21
722	Protocol	T16
722	NCI risk	SR
722	Age at diagnosis	9.2
722	WBC at diagnosis	1.8
722	Sex	M
722	Genetically-defined race	White
722	Asparaginase (IU/ml)	0
722	Bortezomib (nM)	0
722	CHZ868 (nM)	0
722	Cytarabine (µM)	0
722	Dasatinib (nM)	0
722	Daunorubicin (µM)	0
722	Dexamethasone  (µM)	0
722	Ibrutinib (µM)	0
722	Mercaptopurine (µM)	2678.154
722	Nelarabine (µM)	0
722	Panobinostat (nM)	0
722	Prednisolone (µM)	0
722	Ruxolitinib (nM)	0
722	Thioguanine (µM)	35.75534
722	Trametinib (nM)	0
722	Venetoclax (nM)	0
722	Vincristine (µM)	0
722	Vorinostat (nM)	0
722	mercaptopurine_normalized	0.9733
722	thioguanine_normalized	0.3871
723	immunophenotype	B
723	molecular subtype	Hyperdiploid
723	Protocol	T16
723	NCI risk	SR
723	Age at diagnosis	9.6
723	WBC at diagnosis	2.8
723	Sex	M
723	Genetically-defined race	black
723	Asparaginase (IU/ml)	0.003762916
723	Bortezomib (nM)	0
723	CHZ868 (nM)	0
723	Cytarabine (µM)	0
723	Dasatinib (nM)	0
723	Daunorubicin (µM)	0
723	Dexamethasone  (µM)	23.2
723	Ibrutinib (µM)	0
723	Mercaptopurine (µM)	1865.829
723	Nelarabine (µM)	0
723	Panobinostat (nM)	0
723	Prednisolone (µM)	1006
723	Ruxolitinib (nM)	0
723	Thioguanine (µM)	39.64245
723	Trametinib (nM)	0
723	Venetoclax (nM)	0
723	Vincristine (µM)	0.08826928
723	Vorinostat (nM)	0
723	asparagise_normalized	0.0201
723	dexamethasone_normalized	1
723	mercaptopurine_normalized	0.869
723	prednisolone_normalized	1
723	thioguanine_normalized	0.4169
723	vincristine_normalized	0.0813
724	immunophenotype	B
724	molecular subtype	Hyperdiploid
724	Protocol	T16
724	NCI risk	SR
724	Age at diagnosis	2
724	WBC at diagnosis	7.1
724	Sex	F
724	Genetically-defined race	Hispanic
724	Asparaginase (IU/ml)	0.0016
724	Bortezomib (nM)	0
724	CHZ868 (nM)	0
724	Cytarabine (µM)	1.771719
724	Dasatinib (nM)	0
724	Daunorubicin (µM)	0
724	Dexamethasone  (µM)	0.05265156
724	Ibrutinib (µM)	0
724	Mercaptopurine (µM)	0
724	Nelarabine (µM)	0
724	Panobinostat (nM)	0
724	Prednisolone (µM)	0.0075
724	Ruxolitinib (nM)	0
724	Thioguanine (µM)	36.5181
724	Trametinib (nM)	0
724	Venetoclax (nM)	0
724	Vincristine (µM)	0
724	Vorinostat (nM)	0
724	asparagise_normalized	0
724	cytarabine_normalized	0.5466
724	dexamethasone_normalized	0.4817
724	prednisolone_normalized	0
724	thioguanine_normalized	0.3932
725	immunophenotype	B
725	molecular subtype	ETV6-RUNX1
725	Protocol	T16
725	NCI risk	SR
725	Age at diagnosis	5
725	WBC at diagnosis	2.8
725	Sex	M
725	Genetically-defined race	White
725	Asparaginase (IU/ml)	0.0016
725	Bortezomib (nM)	0
725	CHZ868 (nM)	0
725	Cytarabine (µM)	2.452575
725	Dasatinib (nM)	0
725	Daunorubicin (µM)	0
725	Dexamethasone  (µM)	0.0592049
725	Ibrutinib (µM)	0
725	Mercaptopurine (µM)	758.1606
725	Nelarabine (µM)	0
725	Panobinostat (nM)	0
725	Prednisolone (µM)	0.09946739
725	Ruxolitinib (nM)	0
725	Thioguanine (µM)	22.07501
725	Trametinib (nM)	0
725	Venetoclax (nM)	0
725	Vincristine (µM)	0.025
725	Vorinostat (nM)	0
725	asparagise_normalized	0
725	cytarabine_normalized	0.5935
725	dexamethasone_normalized	0.4929
725	mercaptopurine_normalized	0.6092
725	prednisolone_normalized	0.1815
725	thioguanine_normalized	0.2479
725	vincristine_normalized	0
726	immunophenotype	B
726	molecular subtype	Hyperdiploid
726	Protocol	T16
726	NCI risk	SR
726	Age at diagnosis	4.3
726	WBC at diagnosis	18
726	Sex	F
726	Genetically-defined race	White
726	Asparaginase (IU/ml)	0
726	Bortezomib (nM)	0
726	CHZ868 (nM)	0
726	Cytarabine (µM)	0
726	Dasatinib (nM)	0
726	Daunorubicin (µM)	0
726	Dexamethasone  (µM)	0.1493511
726	Ibrutinib (µM)	0
726	Mercaptopurine (µM)	383.3921
726	Nelarabine (µM)	0
726	Panobinostat (nM)	0
726	Prednisolone (µM)	0
726	Ruxolitinib (nM)	0
726	Thioguanine (µM)	33.1238
726	Trametinib (nM)	0
726	Venetoclax (nM)	0
726	Vincristine (µM)	0
726	Vorinostat (nM)	0
726	dexamethasone_normalized	0.5818
726	mercaptopurine_normalized	0.4124
726	thioguanine_normalized	0.365
727	immunophenotype	B
727	molecular subtype	KMT2A
727	Protocol	T16
727	NCI risk	HR
727	Age at diagnosis	1.9
727	WBC at diagnosis	475.8
727	Sex	M
727	Genetically-defined race	White
727	Asparaginase (IU/ml)	1.138702
727	Bortezomib (nM)	0
727	CHZ868 (nM)	0
727	Cytarabine (µM)	0.5340955
727	Dasatinib (nM)	0
727	Daunorubicin (µM)	0
727	Dexamethasone  (µM)	0.3894845
727	Ibrutinib (µM)	0
727	Mercaptopurine (µM)	1655.823993
727	Nelarabine (µM)	0
727	Panobinostat (nM)	0
727	Prednisolone (µM)	0.1374409
727	Ruxolitinib (nM)	0
727	Thioguanine (µM)	72.624
727	Trametinib (nM)	0
727	Venetoclax (nM)	0
727	Vincristine (µM)	0.1853354
727	Vorinostat (nM)	0
727	asparagise_normalized	0.73
727	cytarabine_normalized	0.3737
727	dexamethasone_normalized	0.6739
727	mercaptopurine_normalized	0.8345
727	prednisolone_normalized	0.2126
727	thioguanine_normalized	0.5916
727	vincristine_normalized	0.1875
728	immunophenotype	B
728	molecular subtype	Hyperdiploid
728	Protocol	T16
728	NCI risk	HR
728	Age at diagnosis	2.6
728	WBC at diagnosis	71.4
728	Sex	M
728	Genetically-defined race	White
728	Asparaginase (IU/ml)	0.0016
728	Bortezomib (nM)	0
728	CHZ868 (nM)	0
728	Cytarabine (µM)	0.47414
728	Dasatinib (nM)	0
728	Daunorubicin (µM)	0
728	Dexamethasone  (µM)	0.04395677
728	Ibrutinib (µM)	0
728	Mercaptopurine (µM)	284.8234
728	Nelarabine (µM)	0
728	Panobinostat (nM)	0
728	Prednisolone (µM)	0.0075
728	Ruxolitinib (nM)	0
728	Thioguanine (µM)	13.54998
728	Trametinib (nM)	0
728	Venetoclax (nM)	0
728	Vincristine (µM)	0.025
728	Vorinostat (nM)	0
728	asparagise_normalized	0
728	cytarabine_normalized	0.3565
728	dexamethasone_normalized	0.4643
728	mercaptopurine_normalized	0.3267
728	prednisolone_normalized	0
728	thioguanine_normalized	0.1071
728	vincristine_normalized	0
729	immunophenotype	B
729	molecular subtype	ETV6-RUNX1-like
729	Protocol	T16
729	NCI risk	SR
729	Age at diagnosis	6.8
729	WBC at diagnosis	24.7
729	Sex	F
729	Genetically-defined race	White
729	Asparaginase (IU/ml)	1.104924
729	Bortezomib (nM)	0
729	CHZ868 (nM)	0
729	Cytarabine (µM)	4.408643
729	Dasatinib (nM)	0
729	Daunorubicin (µM)	0
729	Dexamethasone  (µM)	0.09906218
729	Ibrutinib (µM)	0
729	Mercaptopurine (µM)	1965.504
729	Nelarabine (µM)	0
729	Panobinostat (nM)	0
729	Prednisolone (µM)	0.0207275
729	Ruxolitinib (nM)	0
729	Thioguanine (µM)	32.48151
729	Trametinib (nM)	0
729	Venetoclax (nM)	0
729	Vincristine (µM)	0.2171909
729	Vorinostat (nM)	0
729	asparagise_normalized	0.7263
729	cytarabine_normalized	0.6781
729	dexamethasone_normalized	0.5424
729	mercaptopurine_normalized	0.884
729	prednisolone_normalized	0.031
729	thioguanine_normalized	0.3594
729	vincristine_normalized	0.2102
730	immunophenotype	B
730	molecular subtype	Hyperdiploid
730	Protocol	T16
730	NCI risk	SR
730	Age at diagnosis	1.3
730	WBC at diagnosis	3.8
730	Sex	M
730	Genetically-defined race	Hispanic
730	Asparaginase (IU/ml)	0.0016
730	Bortezomib (nM)	0
730	CHZ868 (nM)	0
730	Cytarabine (µM)	0.4388429
730	Dasatinib (nM)	0
730	Daunorubicin (µM)	0
730	Dexamethasone  (µM)	0.083110484
730	Ibrutinib (µM)	0
730	Mercaptopurine (µM)	0
730	Nelarabine (µM)	0
730	Panobinostat (nM)	0
730	Prednisolone (µM)	0.0075
730	Ruxolitinib (nM)	0
730	Thioguanine (µM)	10.61444
730	Trametinib (nM)	0
730	Venetoclax (nM)	0
730	Vincristine (µM)	0.025
730	Vorinostat (nM)	0
730	asparagise_normalized	0
730	cytarabine_normalized	0.3454
730	dexamethasone_normalized	0.5255
730	prednisolone_normalized	0
730	thioguanine_normalized	0.0366
730	vincristine_normalized	0
731	immunophenotype	B
731	molecular subtype	Hyperdiploid
731	Protocol	T16
731	NCI risk	HR
731	Age at diagnosis	13.9
731	WBC at diagnosis	2.2
731	Sex	F
731	Genetically-defined race	White
731	Asparaginase (IU/ml)	0.0016
731	Bortezomib (nM)	0
731	CHZ868 (nM)	0
731	Cytarabine (µM)	0
731	Dasatinib (nM)	0
731	Daunorubicin (µM)	0
731	Dexamethasone  (µM)	0.07390647
731	Ibrutinib (µM)	0
731	Mercaptopurine (µM)	179.3401
731	Nelarabine (µM)	0
731	Panobinostat (nM)	0
731	Prednisolone (µM)	0.0075
731	Ruxolitinib (nM)	0
731	Thioguanine (µM)	29.73715
731	Trametinib (nM)	0
731	Venetoclax (nM)	0
731	Vincristine (µM)	108.34
731	Vorinostat (nM)	0
731	asparagise_normalized	0
731	dexamethasone_normalized	0.5143
731	mercaptopurine_normalized	0.1932
731	prednisolone_normalized	0
731	thioguanine_normalized	0.3339
731	vincristine_normalized	1
732	immunophenotype	B
732	molecular subtype	ETV6-RUNX1
732	Protocol	T16
732	NCI risk	SR
732	Age at diagnosis	1.9
732	WBC at diagnosis	13.2
732	Sex	M
732	Genetically-defined race	Hispanic
732	Asparaginase (IU/ml)	0.0016
732	Bortezomib (nM)	0
732	CHZ868 (nM)	0
732	Cytarabine (µM)	4.401990964
732	Dasatinib (nM)	0
732	Daunorubicin (µM)	0
732	Dexamethasone  (µM)	0.02555026
732	Ibrutinib (µM)	0
732	Mercaptopurine (µM)	1101.571
732	Nelarabine (µM)	0
732	Panobinostat (nM)	0
732	Prednisolone (µM)	0.01996128
732	Ruxolitinib (nM)	0
732	Thioguanine (µM)	12.78687
732	Trametinib (nM)	0
732	Venetoclax (nM)	0
732	Vincristine (µM)	0.025
732	Vorinostat (nM)	0
732	asparagise_normalized	0
732	cytarabine_normalized	0.6779
732	dexamethasone_normalized	0.4122
732	mercaptopurine_normalized	0.717
732	prednisolone_normalized	0.0274
732	thioguanine_normalized	0.0903
732	vincristine_normalized	0
733	immunophenotype	B
733	molecular subtype	Hyperdiploid
733	Protocol	T16
733	NCI risk	SR
733	Age at diagnosis	2.7
733	WBC at diagnosis	19.5
733	Sex	F
733	Genetically-defined race	White
733	Asparaginase (IU/ml)	0.0016
733	Bortezomib (nM)	0
733	CHZ868 (nM)	0
733	Cytarabine (µM)	0.6006243
733	Dasatinib (nM)	0
733	Daunorubicin (µM)	0
733	Dexamethasone  (µM)	0.1818126
733	Ibrutinib (µM)	0
733	Mercaptopurine (µM)	369.6408
733	Nelarabine (µM)	0
733	Panobinostat (nM)	0
733	Prednisolone (µM)	0.09068235
733	Ruxolitinib (nM)	0
733	Thioguanine (µM)	21.11922
733	Trametinib (nM)	0
733	Venetoclax (nM)	0
733	Vincristine (µM)	0.025
733	Vorinostat (nM)	0
733	asparagise_normalized	0
733	cytarabine_normalized	0.3906
733	dexamethasone_normalized	0.6007
733	mercaptopurine_normalized	0.4019
733	prednisolone_normalized	0.1727
733	thioguanine_normalized	0.2351
733	vincristine_normalized	0
734	immunophenotype	B
734	molecular subtype	ETV6-RUNX1-like
734	Protocol	T16
734	NCI risk	HR
734	Age at diagnosis	13.1
734	WBC at diagnosis	17.6
734	Sex	F
734	Genetically-defined race	Hispanic
734	Asparaginase (IU/ml)	0
734	Bortezomib (nM)	0
734	CHZ868 (nM)	0
734	Cytarabine (µM)	4.002922
734	Dasatinib (nM)	0
734	Daunorubicin (µM)	0
734	Dexamethasone  (µM)	0.05734343
734	Ibrutinib (µM)	0
734	Mercaptopurine (µM)	355.0641
734	Nelarabine (µM)	0
734	Panobinostat (nM)	0
734	Prednisolone (µM)	0.0075
734	Ruxolitinib (nM)	0
734	Thioguanine (µM)	27.86473
734	Trametinib (nM)	0
734	Venetoclax (nM)	0
734	Vincristine (µM)	0.08120812
734	Vorinostat (nM)	0
734	cytarabine_normalized	0.6642
734	dexamethasone_normalized	0.4899
734	mercaptopurine_normalized	0.3903
734	prednisolone_normalized	0
734	thioguanine_normalized	0.3151
734	vincristine_normalized	0.0694
735	immunophenotype	B
735	molecular subtype	Ph-like_non_CRLF2
735	Protocol	T16
735	NCI risk	SR
735	Age at diagnosis	6.7
735	WBC at diagnosis	16.8
735	Sex	F
735	Genetically-defined race	White
735	Asparaginase (IU/ml)	1.81135
735	Bortezomib (nM)	0
735	CHZ868 (nM)	0
735	Cytarabine (µM)	0.603419227
735	Dasatinib (nM)	0
735	Daunorubicin (µM)	0
735	Dexamethasone  (µM)	23.2
735	Ibrutinib (µM)	0
735	Mercaptopurine (µM)	984.8901
735	Nelarabine (µM)	0
735	Panobinostat (nM)	0
735	Prednisolone (µM)	0
735	Ruxolitinib (nM)	0
735	Thioguanine (µM)	4.675
735	Trametinib (nM)	0
735	Venetoclax (nM)	0
735	Vincristine (µM)	0.025
735	Vorinostat (nM)	0
735	asparagise_normalized	0.7877
735	cytarabine_normalized	0.3913
735	dexamethasone_normalized	1
735	mercaptopurine_normalized	0.6847
735	thioguanine_normalized	0
735	vincristine_normalized	0
736	immunophenotype	B
736	molecular subtype	Low hypodiploid
736	Protocol	T16
736	NCI risk	HR
736	Age at diagnosis	11.9
736	WBC at diagnosis	28.5
736	Sex	F
736	Genetically-defined race	White
736	Asparaginase (IU/ml)	0.9266124
736	Bortezomib (nM)	0
736	CHZ868 (nM)	0
736	Cytarabine (µM)	0.984832263
736	Dasatinib (nM)	0
736	Daunorubicin (µM)	0
736	Dexamethasone  (µM)	0.169300817
736	Ibrutinib (µM)	0
736	Mercaptopurine (µM)	312.9891
736	Nelarabine (µM)	0
736	Panobinostat (nM)	0
736	Prednisolone (µM)	0.04472478
736	Ruxolitinib (nM)	0
736	Thioguanine (µM)	16.54507
736	Trametinib (nM)	0
736	Venetoclax (nM)	0
736	Vincristine (µM)	0.025
736	Vorinostat (nM)	0
736	asparagise_normalized	0.7044
736	cytarabine_normalized	0.462
736	dexamethasone_normalized	0.5939
736	mercaptopurine_normalized	0.3539
736	prednisolone_normalized	0.1048
736	thioguanine_normalized	0.1647
736	vincristine_normalized	0
737	immunophenotype	B
737	molecular subtype	ETV6-RUNX1
737	Protocol	T16
737	NCI risk	SR
737	Age at diagnosis	4.1
737	WBC at diagnosis	28.8
737	Sex	F
737	Genetically-defined race	black
737	Asparaginase (IU/ml)	0.0016
737	Bortezomib (nM)	0
737	CHZ868 (nM)	0
737	Cytarabine (µM)	0.048613946
737	Dasatinib (nM)	0
737	Daunorubicin (µM)	0
737	Dexamethasone  (µM)	0.043874914
737	Ibrutinib (µM)	0
737	Mercaptopurine (µM)	184.0734
737	Nelarabine (µM)	0
737	Panobinostat (nM)	0
737	Prednisolone (µM)	0.0075
737	Ruxolitinib (nM)	0
737	Thioguanine (µM)	4.675
737	Trametinib (nM)	0
737	Venetoclax (nM)	0
737	Vincristine (µM)	0.025
737	Vorinostat (nM)	0
737	asparagise_normalized	0
737	cytarabine_normalized	0.0281
737	dexamethasone_normalized	0.4642
737	mercaptopurine_normalized	0.2007
737	prednisolone_normalized	0
737	thioguanine_normalized	0
737	vincristine_normalized	0
738	immunophenotype	B
738	molecular subtype	PAX5alt
738	Protocol	T16
738	NCI risk	HR
738	Age at diagnosis	11.8
738	WBC at diagnosis	12.3
738	Sex	F
738	Genetically-defined race	White
738	Asparaginase (IU/ml)	0.476189101
738	Bortezomib (nM)	0
738	CHZ868 (nM)	0
738	Cytarabine (µM)	5.405088
738	Dasatinib (nM)	0
738	Daunorubicin (µM)	0
738	Dexamethasone  (µM)	0.6897247
738	Ibrutinib (µM)	0
738	Mercaptopurine (µM)	1273.176844
738	Nelarabine (µM)	0
738	Panobinostat (nM)	0
738	Prednisolone (µM)	0.1294417
738	Ruxolitinib (nM)	0
738	Thioguanine (µM)	24.66861
738	Trametinib (nM)	0
738	Venetoclax (nM)	0
738	Vincristine (µM)	10.19347
738	Vorinostat (nM)	0
738	asparagise_normalized	0.6217
738	cytarabine_normalized	0.7075
738	dexamethasone_normalized	0.7288
738	mercaptopurine_normalized	0.7587
738	prednisolone_normalized	0.2068
738	thioguanine_normalized	0.28
738	vincristine_normalized	0.761
739	immunophenotype	B
739	molecular subtype	ETV6-RUNX1
739	Protocol	T16
739	NCI risk	SR
739	Age at diagnosis	6.8
739	WBC at diagnosis	15.8
739	Sex	M
739	Genetically-defined race	White
739	Asparaginase (IU/ml)	1.799296
739	Bortezomib (nM)	0
739	CHZ868 (nM)	0
739	Cytarabine (µM)	1.095661
739	Dasatinib (nM)	0
739	Daunorubicin (µM)	0
739	Dexamethasone  (µM)	23.2
739	Ibrutinib (µM)	0
739	Mercaptopurine (µM)	1108.81
739	Nelarabine (µM)	0
739	Panobinostat (nM)	0
739	Prednisolone (µM)	1006
739	Ruxolitinib (nM)	0
739	Thioguanine (µM)	193.0469
739	Trametinib (nM)	0
739	Venetoclax (nM)	0
739	Vincristine (µM)	0.2192809
739	Vorinostat (nM)	0
739	asparagise_normalized	0.7869
739	cytarabine_normalized	0.4773
739	dexamethasone_normalized	1
739	mercaptopurine_normalized	0.7188
739	prednisolone_normalized	1
739	thioguanine_normalized	0.8737
739	vincristine_normalized	0.2116
740	immunophenotype	B
740	molecular subtype	DUX4
740	Protocol	T16
740	NCI risk	HR
740	Age at diagnosis	16.9
740	WBC at diagnosis	350.2
740	Sex	M
740	Genetically-defined race	White
740	Asparaginase (IU/ml)	0.8454445
740	Bortezomib (nM)	0
740	CHZ868 (nM)	0
740	Cytarabine (µM)	0
740	Dasatinib (nM)	0
740	Daunorubicin (µM)	0
740	Dexamethasone  (µM)	0.5458408
740	Ibrutinib (µM)	0
740	Mercaptopurine (µM)	5876
740	Nelarabine (µM)	0
740	Panobinostat (nM)	0
740	Prednisolone (µM)	0.1804284
740	Ruxolitinib (nM)	0
740	Thioguanine (µM)	30.1298
740	Trametinib (nM)	0
740	Venetoclax (nM)	0
740	Vincristine (µM)	0.025
740	Vorinostat (nM)	0
740	asparagise_normalized	0.693
740	dexamethasone_normalized	0.7064
740	mercaptopurine_normalized	1
740	prednisolone_normalized	0.2387
740	thioguanine_normalized	0.3377
740	vincristine_normalized	0
741	immunophenotype	T
741	molecular subtype	T-ALL
741	Protocol	T16
741	NCI risk	HR
741	Age at diagnosis	14.9
741	WBC at diagnosis	82.9
741	Sex	M
741	Genetically-defined race	White
741	Asparaginase (IU/ml)	0.0016
741	Bortezomib (nM)	0
741	CHZ868 (nM)	0
741	Cytarabine (µM)	0.6024885
741	Dasatinib (nM)	0
741	Daunorubicin (µM)	0.03571186
741	Dexamethasone  (µM)	0.03326777
741	Ibrutinib (µM)	0
741	Mercaptopurine (µM)	225.6228
741	Nelarabine (µM)	0
741	Panobinostat (nM)	0
741	Prednisolone (µM)	0.0075
741	Ruxolitinib (nM)	0
741	Thioguanine (µM)	4.675
741	Trametinib (nM)	0
741	Venetoclax (nM)	0
741	Vincristine (µM)	1.839332
741	Vorinostat (nM)	0
741	asparagise_normalized	0
741	cytarabine_normalized	0.3911
741	daunorubicin_normalized	0.35
741	dexamethasone_normalized	0.4376
741	mercaptopurine_normalized	0.2595
741	prednisolone_normalized	0
741	thioguanine_normalized	0
741	vincristine_normalized	0.5159
742	immunophenotype	B
742	molecular subtype	ETV6-RUNX1
742	Protocol	T16
742	NCI risk	SR
742	Age at diagnosis	3.7
742	WBC at diagnosis	7
742	Sex	M
742	Genetically-defined race	White
742	Asparaginase (IU/ml)	0.0074685
742	Bortezomib (nM)	0
742	CHZ868 (nM)	0
742	Cytarabine (µM)	6.416677
742	Dasatinib (nM)	0
742	Daunorubicin (µM)	0
742	Dexamethasone  (µM)	0.3457701
742	Ibrutinib (µM)	0
742	Mercaptopurine (µM)	2647.665
742	Nelarabine (µM)	0
742	Panobinostat (nM)	0
742	Prednisolone (µM)	0.04566381
742	Ruxolitinib (nM)	0
742	Thioguanine (µM)	10.96609
742	Trametinib (nM)	0
742	Venetoclax (nM)	0
742	Vincristine (µM)	0.9476786
742	Vorinostat (nM)	0
742	asparagise_normalized	0.1053
742	cytarabine_normalized	0.7322
742	dexamethasone_normalized	0.6625
742	mercaptopurine_normalized	0.97
742	prednisolone_normalized	0.1068
742	thioguanine_normalized	0.046
742	vincristine_normalized	0.421
743	immunophenotype	B
743	molecular subtype	B-other
743	Protocol	T16
743	NCI risk	SR
743	Age at diagnosis	2.6
743	WBC at diagnosis	39.3
743	Sex	F
743	Genetically-defined race	White
743	Asparaginase (IU/ml)	0.0016
743	Bortezomib (nM)	0
743	CHZ868 (nM)	0
743	Cytarabine (µM)	0.1384551
743	Dasatinib (nM)	0
743	Daunorubicin (µM)	0
743	Dexamethasone  (µM)	0.3448859
743	Ibrutinib (µM)	0
743	Mercaptopurine (µM)	250.616357
743	Nelarabine (µM)	0
743	Panobinostat (nM)	0
743	Prednisolone (µM)	0.03702226
743	Ruxolitinib (nM)	0
743	Thioguanine (µM)	4.675
743	Trametinib (nM)	0
743	Venetoclax (nM)	0
743	Vincristine (µM)	0.025
743	Vorinostat (nM)	0
743	asparagise_normalized	0
743	cytarabine_normalized	0.179
743	dexamethasone_normalized	0.6622
743	mercaptopurine_normalized	0.2898
743	prednisolone_normalized	0.0867
743	thioguanine_normalized	0
743	vincristine_normalized	0
744	immunophenotype	T
744	molecular subtype	T-ALL
744	Protocol	T16
744	NCI risk	HR
744	Age at diagnosis	12.3
744	WBC at diagnosis	351
744	Sex	F
744	Genetically-defined race	White
744	Asparaginase (IU/ml)	0
744	Bortezomib (nM)	0
744	CHZ868 (nM)	0
744	Cytarabine (µM)	6.649068
744	Dasatinib (nM)	0
744	Daunorubicin (µM)	0
744	Dexamethasone  (µM)	0
744	Ibrutinib (µM)	0
744	Mercaptopurine (µM)	0
744	Nelarabine (µM)	0
744	Panobinostat (nM)	0
744	Prednisolone (µM)	0
744	Ruxolitinib (nM)	0
744	Thioguanine (µM)	0
744	Trametinib (nM)	0
744	Venetoclax (nM)	0
744	Vincristine (µM)	0
744	Vorinostat (nM)	0
744	cytarabine_normalized	0.7373
745	immunophenotype	B
745	molecular subtype	ETV6-RUNX1
745	Protocol	T16
745	NCI risk	SR
745	Age at diagnosis	4.1
745	WBC at diagnosis	6
745	Sex	M
745	Genetically-defined race	White
745	Asparaginase (IU/ml)	0
745	Bortezomib (nM)	0
745	CHZ868 (nM)	0
745	Cytarabine (µM)	0
745	Dasatinib (nM)	0
745	Daunorubicin (µM)	0
745	Dexamethasone  (µM)	23.2
745	Ibrutinib (µM)	0
745	Mercaptopurine (µM)	749.6921
745	Nelarabine (µM)	0
745	Panobinostat (nM)	0
745	Prednisolone (µM)	2.802430944
745	Ruxolitinib (nM)	0
745	Thioguanine (µM)	30.4696
745	Trametinib (nM)	0
745	Venetoclax (nM)	0
745	Vincristine (µM)	0
745	Vorinostat (nM)	0
745	dexamethasone_normalized	1
745	mercaptopurine_normalized	0.6059
745	prednisolone_normalized	0.5019
745	thioguanine_normalized	0.3409
746	immunophenotype	B
746	molecular subtype	Hyperdiploid
746	Protocol	T16
746	NCI risk	SR
746	Age at diagnosis	5.5
746	WBC at diagnosis	4.6
746	Sex	M
746	Genetically-defined race	Hispanic
746	Asparaginase (IU/ml)	0
746	Bortezomib (nM)	0
746	CHZ868 (nM)	0
746	Cytarabine (µM)	0
746	Dasatinib (nM)	0
746	Daunorubicin (µM)	0
746	Dexamethasone  (µM)	23.2
746	Ibrutinib (µM)	0
746	Mercaptopurine (µM)	543.1928
746	Nelarabine (µM)	0
746	Panobinostat (nM)	0
746	Prednisolone (µM)	0
746	Ruxolitinib (nM)	0
746	Thioguanine (µM)	31.00934
746	Trametinib (nM)	0
746	Venetoclax (nM)	0
746	Vincristine (µM)	0
746	Vorinostat (nM)	0
746	dexamethasone_normalized	1
746	mercaptopurine_normalized	0.513
746	thioguanine_normalized	0.346
747	immunophenotype	T
747	molecular subtype	T-ALL
747	Protocol	T16
747	NCI risk	HR
747	Age at diagnosis	3.7
747	WBC at diagnosis	160.5
747	Sex	M
747	Genetically-defined race	black
747	Asparaginase (IU/ml)	0.1474546
747	Bortezomib (nM)	0
747	CHZ868 (nM)	0
747	Cytarabine (µM)	0.1463915
747	Dasatinib (nM)	0
747	Daunorubicin (µM)	0.028478068
747	Dexamethasone  (µM)	0.09511576
747	Ibrutinib (µM)	0
747	Mercaptopurine (µM)	45.9
747	Nelarabine (µM)	0
747	Panobinostat (nM)	0
747	Prednisolone (µM)	0.06791908
747	Ruxolitinib (nM)	0
747	Thioguanine (µM)	4.675
747	Trametinib (nM)	0
747	Venetoclax (nM)	0
747	Vincristine (µM)	0.1815959
747	Vorinostat (nM)	0
747	asparagise_normalized	0.476
747	cytarabine_normalized	0.1871
747	daunorubicin_normalized	0.318
747	dexamethasone_normalized	0.5385
747	mercaptopurine_normalized	0
747	prednisolone_normalized	0.1449
747	thioguanine_normalized	0
747	vincristine_normalized	0.1846
748	immunophenotype	B
748	molecular subtype	ETV6-RUNX1
748	Protocol	T16
748	NCI risk	SR
748	Age at diagnosis	4.8
748	WBC at diagnosis	1.6
748	Sex	F
748	Genetically-defined race	White
748	Asparaginase (IU/ml)	0.0016
748	Bortezomib (nM)	0
748	CHZ868 (nM)	0
748	Cytarabine (µM)	5.231083
748	Dasatinib (nM)	0
748	Daunorubicin (µM)	0
748	Dexamethasone  (µM)	0.014248263
748	Ibrutinib (µM)	0
748	Mercaptopurine (µM)	1176.489
748	Nelarabine (µM)	0
748	Panobinostat (nM)	0
748	Prednisolone (µM)	0.0075
748	Ruxolitinib (nM)	0
748	Thioguanine (µM)	19.90465
748	Trametinib (nM)	0
748	Venetoclax (nM)	0
748	Vincristine (µM)	0.025
748	Vorinostat (nM)	0
748	asparagise_normalized	0
748	cytarabine_normalized	0.7028
748	dexamethasone_normalized	0.3561
748	mercaptopurine_normalized	0.7359
748	prednisolone_normalized	0
748	thioguanine_normalized	0.2181
748	vincristine_normalized	0
749	immunophenotype	B
749	molecular subtype	NUTM1
749	Protocol	T16
749	NCI risk	HR
749	Age at diagnosis	14.8
749	WBC at diagnosis	21.2
749	Sex	M
749	Genetically-defined race	black
749	Asparaginase (IU/ml)	0.0016
749	Bortezomib (nM)	0
749	CHZ868 (nM)	0
749	Cytarabine (µM)	0.02
749	Dasatinib (nM)	0
749	Daunorubicin (µM)	0
749	Dexamethasone  (µM)	0.01267764
749	Ibrutinib (µM)	0
749	Mercaptopurine (µM)	141.4098
749	Nelarabine (µM)	0
749	Panobinostat (nM)	0
749	Prednisolone (µM)	0.0075
749	Ruxolitinib (nM)	0
749	Thioguanine (µM)	4.675
749	Trametinib (nM)	0
749	Venetoclax (nM)	0
749	Vincristine (µM)	0.025
749	Vorinostat (nM)	0
749	asparagise_normalized	0
749	cytarabine_normalized	0
749	dexamethasone_normalized	0.3449
749	mercaptopurine_normalized	0.1247
749	prednisolone_normalized	0
749	thioguanine_normalized	0
749	vincristine_normalized	0
750	immunophenotype	B
750	molecular subtype	ETV6-RUNX1
750	Protocol	T16
750	NCI risk	SR
750	Age at diagnosis	3.4
750	WBC at diagnosis	10.6
750	Sex	F
750	Genetically-defined race	White
750	Asparaginase (IU/ml)	0.0016
750	Bortezomib (nM)	0
750	CHZ868 (nM)	0
750	Cytarabine (µM)	5.074927
750	Dasatinib (nM)	0
750	Daunorubicin (µM)	0
750	Dexamethasone  (µM)	0.2213847
750	Ibrutinib (µM)	0
750	Mercaptopurine (µM)	417.9588
750	Nelarabine (µM)	0
750	Panobinostat (nM)	0
750	Prednisolone (µM)	0.1567464
750	Ruxolitinib (nM)	0
750	Thioguanine (µM)	18.16148
750	Trametinib (nM)	0
750	Venetoclax (nM)	0
750	Vincristine (µM)	0.4320473
750	Vorinostat (nM)	0
750	asparagise_normalized	0
750	cytarabine_normalized	0.6984
750	dexamethasone_normalized	0.6197
750	mercaptopurine_normalized	0.4373
750	prednisolone_normalized	0.2252
750	thioguanine_normalized	0.1916
750	vincristine_normalized	0.3086
751	immunophenotype	B
751	molecular subtype	ETV6-RUNX1
751	Protocol	T16
751	NCI risk	SR
751	Age at diagnosis	6.6
751	WBC at diagnosis	15.6
751	Sex	F
751	Genetically-defined race	White
751	Asparaginase (IU/ml)	0.507645
751	Bortezomib (nM)	0
751	CHZ868 (nM)	0
751	Cytarabine (µM)	31.90806
751	Dasatinib (nM)	0
751	Daunorubicin (µM)	0
751	Dexamethasone  (µM)	0.09896936
751	Ibrutinib (µM)	0
751	Mercaptopurine (µM)	5876
751	Nelarabine (µM)	0
751	Panobinostat (nM)	0
751	Prednisolone (µM)	0.02387266
751	Ruxolitinib (nM)	0
751	Thioguanine (µM)	56.6704
751	Trametinib (nM)	0
751	Venetoclax (nM)	0
751	Vincristine (µM)	5.506178
751	Vorinostat (nM)	0
751	asparagise_normalized	0.6296
751	cytarabine_normalized	0.9635
751	dexamethasone_normalized	0.5423
751	mercaptopurine_normalized	1
751	prednisolone_normalized	0.0446
751	thioguanine_normalized	0.52
751	vincristine_normalized	0.6728
752	immunophenotype	B
752	molecular subtype	B-other
752	Protocol	T16
752	NCI risk	HR
752	Age at diagnosis	11.5
752	WBC at diagnosis	119.3
752	Sex	M
752	Genetically-defined race	White
752	Asparaginase (IU/ml)	1.44751
752	Bortezomib (nM)	0
752	CHZ868 (nM)	0
752	Cytarabine (µM)	3.196381214
752	Dasatinib (nM)	0
752	Daunorubicin (µM)	0
752	Dexamethasone  (µM)	0
752	Ibrutinib (µM)	0
752	Mercaptopurine (µM)	0
752	Nelarabine (µM)	0
752	Panobinostat (nM)	0
752	Prednisolone (µM)	1.363512
752	Ruxolitinib (nM)	0
752	Thioguanine (µM)	154.109
752	Trametinib (nM)	0
752	Venetoclax (nM)	0
752	Vincristine (µM)	2.351643
752	Vorinostat (nM)	0
752	asparagise_normalized	0.7598
752	cytarabine_normalized	0.6317
752	prednisolone_normalized	0.4328
752	thioguanine_normalized	0.8087
752	vincristine_normalized	0.5511
753	immunophenotype	T
753	molecular subtype	T-ALL
753	Protocol	T16
753	NCI risk	HR
753	Age at diagnosis	1.6
753	WBC at diagnosis	530.7
753	Sex	M
753	Genetically-defined race	White
753	Asparaginase (IU/ml)	0.0016
753	Bortezomib (nM)	0
753	CHZ868 (nM)	0
753	Cytarabine (µM)	0.4276429
753	Dasatinib (nM)	0
753	Daunorubicin (µM)	0.018801057
753	Dexamethasone  (µM)	0.04740745
753	Ibrutinib (µM)	0
753	Mercaptopurine (µM)	173.86
753	Nelarabine (µM)	0
753	Panobinostat (nM)	0
753	Prednisolone (µM)	0.0075
753	Ruxolitinib (nM)	0
753	Thioguanine (µM)	4.675
753	Trametinib (nM)	0
753	Venetoclax (nM)	0
753	Vincristine (µM)	0.435527
753	Vorinostat (nM)	0
753	asparagise_normalized	0
753	cytarabine_normalized	0.3417
753	daunorubicin_normalized	0.2594
753	dexamethasone_normalized	0.4716
753	mercaptopurine_normalized	0.1843
753	prednisolone_normalized	0
753	thioguanine_normalized	0
753	vincristine_normalized	0.3098
754	immunophenotype	B
754	molecular subtype	Hyperdiploid
754	Protocol	T16
754	NCI risk	SR
754	Age at diagnosis	9.5
754	WBC at diagnosis	1.4
754	Sex	F
754	Genetically-defined race	Hispanic
754	Asparaginase (IU/ml)	0.0016
754	Bortezomib (nM)	0
754	CHZ868 (nM)	0
754	Cytarabine (µM)	0
754	Dasatinib (nM)	0
754	Daunorubicin (µM)	0
754	Dexamethasone  (µM)	0.1643279
754	Ibrutinib (µM)	0
754	Mercaptopurine (µM)	1355.388
754	Nelarabine (µM)	0
754	Panobinostat (nM)	0
754	Prednisolone (µM)	0
754	Ruxolitinib (nM)	0
754	Thioguanine (µM)	23.18014
754	Trametinib (nM)	0
754	Venetoclax (nM)	0
754	Vincristine (µM)	13.81331
754	Vorinostat (nM)	0
754	asparagise_normalized	0
754	dexamethasone_normalized	0.591
754	mercaptopurine_normalized	0.7768
754	thioguanine_normalized	0.262
754	vincristine_normalized	0.8044
755	immunophenotype	T
755	molecular subtype	T-ALL
755	Protocol	T16
755	NCI risk	HR
755	Age at diagnosis	2
755	WBC at diagnosis	561
755	Sex	M
755	Genetically-defined race	black
755	Asparaginase (IU/ml)	0.0016
755	Bortezomib (nM)	0
755	CHZ868 (nM)	0
755	Cytarabine (µM)	0.06617378
755	Dasatinib (nM)	0
755	Daunorubicin (µM)	0.02057339
755	Dexamethasone  (µM)	0.1116262
755	Ibrutinib (µM)	0
755	Mercaptopurine (µM)	0
755	Nelarabine (µM)	0
755	Panobinostat (nM)	0
755	Prednisolone (µM)	0
755	Ruxolitinib (nM)	0
755	Thioguanine (µM)	4.675
755	Trametinib (nM)	0
755	Venetoclax (nM)	0
755	Vincristine (µM)	0.1902574
755	Vorinostat (nM)	0
755	asparagise_normalized	0
755	cytarabine_normalized	0.0726
755	daunorubicin_normalized	0.2721
755	dexamethasone_normalized	0.5539
755	thioguanine_normalized	0
755	vincristine_normalized	0.1912
756	immunophenotype	B
756	molecular subtype	Hyperdiploid
756	Protocol	T16
756	NCI risk	SR
756	Age at diagnosis	5.8
756	WBC at diagnosis	2.3
756	Sex	M
756	Genetically-defined race	White
756	Asparaginase (IU/ml)	0.0016
756	Bortezomib (nM)	0
756	CHZ868 (nM)	0
756	Cytarabine (µM)	0
756	Dasatinib (nM)	0
756	Daunorubicin (µM)	0
756	Dexamethasone  (µM)	0.008336014
756	Ibrutinib (µM)	0
756	Mercaptopurine (µM)	1481.716
756	Nelarabine (µM)	0
756	Panobinostat (nM)	0
756	Prednisolone (µM)	0.4837254
756	Ruxolitinib (nM)	0
756	Thioguanine (µM)	53.78998
756	Trametinib (nM)	0
756	Venetoclax (nM)	0
756	Vincristine (µM)	108.34
756	Vorinostat (nM)	0
756	asparagise_normalized	0
756	dexamethasone_normalized	0.3046
756	mercaptopurine_normalized	0.8025
756	prednisolone_normalized	0.3333
756	thioguanine_normalized	0.505
756	vincristine_normalized	1
757	immunophenotype	B
757	molecular subtype	BCR-ABL1
757	Protocol	T16
757	NCI risk	HR
757	Age at diagnosis	14.6
757	WBC at diagnosis	38.4
757	Sex	M
757	Genetically-defined race	White
757	Asparaginase (IU/ml)	0.2385918
757	Bortezomib (nM)	0
757	CHZ868 (nM)	0
757	Cytarabine (µM)	1.096780172
757	Dasatinib (nM)	0
757	Daunorubicin (µM)	0
757	Dexamethasone  (µM)	0.1735316
757	Ibrutinib (µM)	0
757	Mercaptopurine (µM)	205.8231
757	Nelarabine (µM)	0
757	Panobinostat (nM)	0
757	Prednisolone (µM)	0.1086481
757	Ruxolitinib (nM)	0
757	Thioguanine (µM)	52.83306
757	Trametinib (nM)	0
757	Venetoclax (nM)	0
757	Vincristine (µM)	0.025
757	Vorinostat (nM)	0
757	asparagise_normalized	0.5358
757	cytarabine_normalized	0.4775
757	dexamethasone_normalized	0.5963
757	mercaptopurine_normalized	0.233
757	prednisolone_normalized	0.19
757	thioguanine_normalized	0.4998
757	vincristine_normalized	0
758	immunophenotype	B
758	molecular subtype	ETV6-RUNX1
758	Protocol	T16
758	NCI risk	SR
758	Age at diagnosis	5.4
758	WBC at diagnosis	5.4
758	Sex	F
758	Genetically-defined race	White
758	Asparaginase (IU/ml)	0.0016
758	Bortezomib (nM)	0
758	CHZ868 (nM)	0
758	Cytarabine (µM)	0.8736526
758	Dasatinib (nM)	0
758	Daunorubicin (µM)	0
758	Dexamethasone  (µM)	0.02064088
758	Ibrutinib (µM)	0
758	Mercaptopurine (µM)	373.5867317
758	Nelarabine (µM)	0
758	Panobinostat (nM)	0
758	Prednisolone (µM)	0.0075
758	Ruxolitinib (nM)	0
758	Thioguanine (µM)	31.04169
758	Trametinib (nM)	0
758	Venetoclax (nM)	0
758	Vincristine (µM)	0.025
758	Vorinostat (nM)	0
758	asparagise_normalized	0
758	cytarabine_normalized	0.4447
758	dexamethasone_normalized	0.3917
758	mercaptopurine_normalized	0.405
758	prednisolone_normalized	0
758	thioguanine_normalized	0.3463
758	vincristine_normalized	0
759	immunophenotype	B
759	molecular subtype	BCR-ABL1
759	Protocol	T16
759	NCI risk	HR
759	Age at diagnosis	16.1
759	WBC at diagnosis	32.3
759	Sex	M
759	Genetically-defined race	White
759	Asparaginase (IU/ml)	0.7093182
759	Bortezomib (nM)	0
759	CHZ868 (nM)	0
759	Cytarabine (µM)	2.580149
759	Dasatinib (nM)	0
759	Daunorubicin (µM)	0
759	Dexamethasone  (µM)	0.1718357
759	Ibrutinib (µM)	0
759	Mercaptopurine (µM)	0
759	Nelarabine (µM)	0
759	Panobinostat (nM)	0
759	Prednisolone (µM)	0
759	Ruxolitinib (nM)	0
759	Thioguanine (µM)	44.09681
759	Trametinib (nM)	0
759	Venetoclax (nM)	0
759	Vincristine (µM)	0.9944079
759	Vorinostat (nM)	0
759	asparagise_normalized	0.6712
759	cytarabine_normalized	0.6008
759	dexamethasone_normalized	0.5953
759	thioguanine_normalized	0.4476
759	vincristine_normalized	0.4279
760	immunophenotype	B
760	molecular subtype	Ph-like_CRLF2
760	Protocol	T16
760	NCI risk	HR
760	Age at diagnosis	9.9
760	WBC at diagnosis	128.6
760	Sex	M
760	Genetically-defined race	White
760	Asparaginase (IU/ml)	2.734058
760	Bortezomib (nM)	0
760	CHZ868 (nM)	0
760	Cytarabine (µM)	3.482929811
760	Dasatinib (nM)	0
760	Daunorubicin (µM)	0
760	Dexamethasone  (µM)	23.2
760	Ibrutinib (µM)	0
760	Mercaptopurine (µM)	0
760	Nelarabine (µM)	0
760	Panobinostat (nM)	0
760	Prednisolone (µM)	1006
760	Ruxolitinib (nM)	0
760	Thioguanine (µM)	28.87099
760	Trametinib (nM)	0
760	Venetoclax (nM)	0
760	Vincristine (µM)	0.025
760	Vorinostat (nM)	0
760	asparagise_normalized	0.8389
760	cytarabine_normalized	0.6441
760	dexamethasone_normalized	1
760	prednisolone_normalized	1
760	thioguanine_normalized	0.3254
760	vincristine_normalized	0
761	immunophenotype	B
761	molecular subtype	Hyperdiploid
761	Protocol	T16
761	NCI risk	SR
761	Age at diagnosis	2.3
761	WBC at diagnosis	21.4
761	Sex	M
761	Genetically-defined race	White
761	Asparaginase (IU/ml)	0
761	Bortezomib (nM)	0
761	CHZ868 (nM)	0
761	Cytarabine (µM)	0.3333934
761	Dasatinib (nM)	0
761	Daunorubicin (µM)	0
761	Dexamethasone  (µM)	0.05622333
761	Ibrutinib (µM)	0
761	Mercaptopurine (µM)	399.3162116
761	Nelarabine (µM)	0
761	Panobinostat (nM)	0
761	Prednisolone (µM)	0.121362
761	Ruxolitinib (nM)	0
761	Thioguanine (µM)	38.74411848
761	Trametinib (nM)	0
761	Venetoclax (nM)	0
761	Vincristine (µM)	0.025
761	Vorinostat (nM)	0
761	cytarabine_normalized	0.3058
761	dexamethasone_normalized	0.488
761	mercaptopurine_normalized	0.4242
761	prednisolone_normalized	0.2006
761	thioguanine_normalized	0.4103
761	vincristine_normalized	0
762	immunophenotype	B
762	molecular subtype	ETV6-RUNX1
762	Protocol	T16
762	NCI risk	SR
762	Age at diagnosis	9.8
762	WBC at diagnosis	5.1
762	Sex	F
762	Genetically-defined race	black
762	Asparaginase (IU/ml)	0
762	Bortezomib (nM)	0
762	CHZ868 (nM)	0
762	Cytarabine (µM)	26.23236
762	Dasatinib (nM)	0
762	Daunorubicin (µM)	0
762	Dexamethasone  (µM)	2.221629
762	Ibrutinib (µM)	0
762	Mercaptopurine (µM)	5876
762	Nelarabine (µM)	0
762	Panobinostat (nM)	0
762	Prednisolone (µM)	0
762	Ruxolitinib (nM)	0
762	Thioguanine (µM)	12.34384
762	Trametinib (nM)	0
762	Venetoclax (nM)	0
762	Vincristine (µM)	0.1769746
762	Vorinostat (nM)	0
762	cytarabine_normalized	0.9353
762	dexamethasone_normalized	0.8412
762	mercaptopurine_normalized	1
762	thioguanine_normalized	0.0802
762	vincristine_normalized	0.1809
763	immunophenotype	B
763	molecular subtype	DUX4
763	Protocol	T16
763	NCI risk	SR
763	Age at diagnosis	6.6
763	WBC at diagnosis	30
763	Sex	M
763	Genetically-defined race	White
763	Asparaginase (IU/ml)	1.119013
763	Bortezomib (nM)	0
763	CHZ868 (nM)	0
763	Cytarabine (µM)	1.470231
763	Dasatinib (nM)	0
763	Daunorubicin (µM)	0
763	Dexamethasone  (µM)	0.1052254
763	Ibrutinib (µM)	0
763	Mercaptopurine (µM)	718.8523
763	Nelarabine (µM)	0
763	Panobinostat (nM)	0
763	Prednisolone (µM)	0.08024015
763	Ruxolitinib (nM)	0
763	Thioguanine (µM)	19.87413246
763	Trametinib (nM)	0
763	Venetoclax (nM)	0
763	Vincristine (µM)	0.025
763	Vorinostat (nM)	0
763	asparagise_normalized	0.7278
763	cytarabine_normalized	0.5197
763	dexamethasone_normalized	0.5482
763	mercaptopurine_normalized	0.5938
763	prednisolone_normalized	0.1609
763	thioguanine_normalized	0.2176
763	vincristine_normalized	0
764	immunophenotype	B
764	molecular subtype	ETV6-RUNX1
764	Protocol	T16
764	NCI risk	SR
764	Age at diagnosis	4.9
764	WBC at diagnosis	15.5
764	Sex	F
764	Genetically-defined race	White
764	Asparaginase (IU/ml)	2.858167
764	Bortezomib (nM)	0
764	CHZ868 (nM)	0
764	Cytarabine (µM)	1.718258
764	Dasatinib (nM)	0
764	Daunorubicin (µM)	0
764	Dexamethasone  (µM)	0.04736863
764	Ibrutinib (µM)	0
764	Mercaptopurine (µM)	338.4679
764	Nelarabine (µM)	0
764	Panobinostat (nM)	0
764	Prednisolone (µM)	0
764	Ruxolitinib (nM)	0
764	Thioguanine (µM)	4.675
764	Trametinib (nM)	0
764	Venetoclax (nM)	0
764	Vincristine (µM)	0.12972293
764	Vorinostat (nM)	0
764	asparagise_normalized	0.8444
764	cytarabine_normalized	0.5422
764	dexamethasone_normalized	0.4715
764	mercaptopurine_normalized	0.3765
764	thioguanine_normalized	0
764	vincristine_normalized	0.1364
765	immunophenotype	T
765	molecular subtype	T-ALL
765	Protocol	T16
765	NCI risk	SR
765	Age at diagnosis	1.7
765	WBC at diagnosis	23.3
765	Sex	F
765	Genetically-defined race	Asian/Other
765	Asparaginase (IU/ml)	20
765	Bortezomib (nM)	0
765	CHZ868 (nM)	0
765	Cytarabine (µM)	0
765	Dasatinib (nM)	0
765	Daunorubicin (µM)	0
765	Dexamethasone  (µM)	0
765	Ibrutinib (µM)	0
765	Mercaptopurine (µM)	0
765	Nelarabine (µM)	0
765	Panobinostat (nM)	0
765	Prednisolone (µM)	0
765	Ruxolitinib (nM)	0
765	Thioguanine (µM)	0
765	Trametinib (nM)	0
765	Venetoclax (nM)	0
765	Vincristine (µM)	108.34
765	Vorinostat (nM)	0
765	asparagise_normalized	1
765	vincristine_normalized	1
766	immunophenotype	B
766	molecular subtype	Hyperdiploid
766	Protocol	T16
766	NCI risk	SR
766	Age at diagnosis	9.5
766	WBC at diagnosis	7.6
766	Sex	M
766	Genetically-defined race	White
766	Asparaginase (IU/ml)	0.0016
766	Bortezomib (nM)	0
766	CHZ868 (nM)	0
766	Cytarabine (µM)	0.2962056
766	Dasatinib (nM)	0
766	Daunorubicin (µM)	0
766	Dexamethasone  (µM)	0.04096025
766	Ibrutinib (µM)	0
766	Mercaptopurine (µM)	149.0492
766	Nelarabine (µM)	0
766	Panobinostat (nM)	0
766	Prednisolone (µM)	0
766	Ruxolitinib (nM)	0
766	Thioguanine (µM)	4.675
766	Trametinib (nM)	0
766	Venetoclax (nM)	0
766	Vincristine (µM)	0.025
766	Vorinostat (nM)	0
766	asparagise_normalized	0
766	cytarabine_normalized	0.2887
766	dexamethasone_normalized	0.4575
766	mercaptopurine_normalized	0.1398
766	thioguanine_normalized	0
766	vincristine_normalized	0
767	immunophenotype	B
767	molecular subtype	Hyperdiploid
767	Protocol	T16
767	NCI risk	HR
767	Age at diagnosis	14.6
767	WBC at diagnosis	6.4
767	Sex	M
767	Genetically-defined race	White
767	Asparaginase (IU/ml)	2.024743
767	Bortezomib (nM)	0
767	CHZ868 (nM)	0
767	Cytarabine (µM)	0.569345
767	Dasatinib (nM)	0
767	Daunorubicin (µM)	0
767	Dexamethasone  (µM)	0.001385088
767	Ibrutinib (µM)	0
767	Mercaptopurine (µM)	362.4673
767	Nelarabine (µM)	0
767	Panobinostat (nM)	0
767	Prednisolone (µM)	0.06154608
767	Ruxolitinib (nM)	0
767	Thioguanine (µM)	36.50842
767	Trametinib (nM)	0
767	Venetoclax (nM)	0
767	Vincristine (µM)	0.025
767	Vorinostat (nM)	0
767	asparagise_normalized	0.8015
767	cytarabine_normalized	0.3829
767	dexamethasone_normalized	0.1322
767	mercaptopurine_normalized	0.3962
767	prednisolone_normalized	0.1355
767	thioguanine_normalized	0.3931
767	vincristine_normalized	0
768	immunophenotype	B
768	molecular subtype	Hyperdiploid
768	Protocol	T16
768	NCI risk	HR
768	Age at diagnosis	4.4
768	WBC at diagnosis	81.9
768	Sex	M
768	Genetically-defined race	black
768	Asparaginase (IU/ml)	0.0016
768	Bortezomib (nM)	0
768	CHZ868 (nM)	0
768	Cytarabine (µM)	0.7231555
768	Dasatinib (nM)	0
768	Daunorubicin (µM)	0
768	Dexamethasone  (µM)	23.2
768	Ibrutinib (µM)	0
768	Mercaptopurine (µM)	610.3707
768	Nelarabine (µM)	0
768	Panobinostat (nM)	0
768	Prednisolone (µM)	0
768	Ruxolitinib (nM)	0
768	Thioguanine (µM)	31.42255
768	Trametinib (nM)	0
768	Venetoclax (nM)	0
768	Vincristine (µM)	0
768	Vorinostat (nM)	0
768	asparagise_normalized	0
768	cytarabine_normalized	0.4174
768	dexamethasone_normalized	1
768	mercaptopurine_normalized	0.5466
768	thioguanine_normalized	0.3498
769	immunophenotype	B
769	molecular subtype	BCR-ABL1
769	Protocol	T16
769	NCI risk	HR
769	Age at diagnosis	12.9
769	WBC at diagnosis	2.7
769	Sex	F
769	Genetically-defined race	White
769	Asparaginase (IU/ml)	0
769	Bortezomib (nM)	0
769	CHZ868 (nM)	0
769	Cytarabine (µM)	0
769	Dasatinib (nM)	0
769	Daunorubicin (µM)	0
769	Dexamethasone  (µM)	0.06033341
769	Ibrutinib (µM)	0
769	Mercaptopurine (µM)	659.319
769	Nelarabine (µM)	0
769	Panobinostat (nM)	0
769	Prednisolone (µM)	0.0075
769	Ruxolitinib (nM)	0
769	Thioguanine (µM)	22.09596
769	Trametinib (nM)	0
769	Venetoclax (nM)	0
769	Vincristine (µM)	0
769	Vorinostat (nM)	0
769	dexamethasone_normalized	0.4948
769	mercaptopurine_normalized	0.5689
769	prednisolone_normalized	0
769	thioguanine_normalized	0.2482
770	immunophenotype	T
770	molecular subtype	T-ALL
770	Protocol	T16
770	NCI risk	SR
770	Age at diagnosis	8.2
770	WBC at diagnosis	19.1
770	Sex	M
770	Genetically-defined race	White
770	Asparaginase (IU/ml)	0
770	Bortezomib (nM)	0
770	CHZ868 (nM)	0
770	Cytarabine (µM)	0
770	Dasatinib (nM)	0
770	Daunorubicin (µM)	0.03000692
770	Dexamethasone  (µM)	23.2
770	Ibrutinib (µM)	0
770	Mercaptopurine (µM)	0
770	Nelarabine (µM)	0
770	Panobinostat (nM)	0
770	Prednisolone (µM)	0.03367399
770	Ruxolitinib (nM)	0
770	Thioguanine (µM)	20.87071051
770	Trametinib (nM)	0
770	Venetoclax (nM)	0
770	Vincristine (µM)	1.885855
770	Vorinostat (nM)	0
770	daunorubicin_normalized	0.3254
770	dexamethasone_normalized	1
770	prednisolone_normalized	0.0776
770	thioguanine_normalized	0.2317
770	vincristine_normalized	0.5195
771	immunophenotype	B
771	molecular subtype	KMT2A
771	Protocol	T16
771	NCI risk	HR
771	Age at diagnosis	8.6
771	WBC at diagnosis	494.4
771	Sex	F
771	Genetically-defined race	White
771	Asparaginase (IU/ml)	0
771	Bortezomib (nM)	0
771	CHZ868 (nM)	0
771	Cytarabine (µM)	3.530539565
771	Dasatinib (nM)	0
771	Daunorubicin (µM)	0
771	Dexamethasone  (µM)	23.2
771	Ibrutinib (µM)	0
771	Mercaptopurine (µM)	0
771	Nelarabine (µM)	0
771	Panobinostat (nM)	0
771	Prednisolone (µM)	1006
771	Ruxolitinib (nM)	0
771	Thioguanine (µM)	0
771	Trametinib (nM)	0
771	Venetoclax (nM)	0
771	Vincristine (µM)	0
771	Vorinostat (nM)	0
771	cytarabine_normalized	0.6461
771	dexamethasone_normalized	1
771	prednisolone_normalized	1
772	immunophenotype	B
772	molecular subtype	BCR-ABL1
772	Protocol	T16
772	NCI risk	HR
772	Age at diagnosis	11.5
772	WBC at diagnosis	290.9
772	Sex	M
772	Genetically-defined race	black
772	Asparaginase (IU/ml)	1.413019
772	Bortezomib (nM)	0
772	CHZ868 (nM)	0
772	Cytarabine (µM)	11.91128
772	Dasatinib (nM)	0
772	Daunorubicin (µM)	0
772	Dexamethasone  (µM)	23.2
772	Ibrutinib (µM)	0
772	Mercaptopurine (µM)	5876
772	Nelarabine (µM)	0
772	Panobinostat (nM)	0
772	Prednisolone (µM)	0
772	Ruxolitinib (nM)	0
772	Thioguanine (µM)	24.04679
772	Trametinib (nM)	0
772	Venetoclax (nM)	0
772	Vincristine (µM)	0.025
772	Vorinostat (nM)	0
772	asparagise_normalized	0.7568
772	cytarabine_normalized	0.8214
772	dexamethasone_normalized	1
772	mercaptopurine_normalized	1
772	thioguanine_normalized	0.2726
772	vincristine_normalized	0
773	immunophenotype	B
773	molecular subtype	ETV6-RUNX1
773	Protocol	T16
773	NCI risk	SR
773	Age at diagnosis	2.7
773	WBC at diagnosis	23
773	Sex	F
773	Genetically-defined race	White
773	Asparaginase (IU/ml)	1.164632
773	Bortezomib (nM)	0
773	CHZ868 (nM)	0
773	Cytarabine (µM)	0.4918839
773	Dasatinib (nM)	0
773	Daunorubicin (µM)	0
773	Dexamethasone  (µM)	0.0380216
773	Ibrutinib (µM)	0
773	Mercaptopurine (µM)	221.4506
773	Nelarabine (µM)	0
773	Panobinostat (nM)	0
773	Prednisolone (µM)	0
773	Ruxolitinib (nM)	0
773	Thioguanine (µM)	14.72855
773	Trametinib (nM)	0
773	Venetoclax (nM)	0
773	Vincristine (µM)	0.025
773	Vorinostat (nM)	0
773	asparagise_normalized	0.7328
773	cytarabine_normalized	0.3618
773	dexamethasone_normalized	0.4504
773	mercaptopurine_normalized	0.2541
773	thioguanine_normalized	0.1311
773	vincristine_normalized	0
774	immunophenotype	B
774	molecular subtype	Hyperdiploid
774	Protocol	T16
774	NCI risk	SR
774	Age at diagnosis	4.7
774	WBC at diagnosis	9.3
774	Sex	M
774	Genetically-defined race	Hispanic
774	Asparaginase (IU/ml)	0.695175
774	Bortezomib (nM)	0
774	CHZ868 (nM)	0
774	Cytarabine (µM)	2.734006
774	Dasatinib (nM)	0
774	Daunorubicin (µM)	0
774	Dexamethasone  (µM)	0.1901563
774	Ibrutinib (µM)	0
774	Mercaptopurine (µM)	239.8064
774	Nelarabine (µM)	0
774	Panobinostat (nM)	0
774	Prednisolone (µM)	0.1042922
774	Ruxolitinib (nM)	0
774	Thioguanine (µM)	25.87468
774	Trametinib (nM)	0
774	Venetoclax (nM)	0
774	Vincristine (µM)	0.025
774	Vorinostat (nM)	0
774	asparagise_normalized	0.6687
774	cytarabine_normalized	0.6092
774	dexamethasone_normalized	0.605
774	mercaptopurine_normalized	0.277
774	prednisolone_normalized	0.1861
774	thioguanine_normalized	0.2938
774	vincristine_normalized	0
775	immunophenotype	B
775	molecular subtype	ETV6-RUNX1
775	Protocol	T16
775	NCI risk	SR
775	Age at diagnosis	2.8
775	WBC at diagnosis	12.4
775	Sex	M
775	Genetically-defined race	black
775	Asparaginase (IU/ml)	0.0016
775	Bortezomib (nM)	0
775	CHZ868 (nM)	0
775	Cytarabine (µM)	2.659306
775	Dasatinib (nM)	0
775	Daunorubicin (µM)	0
775	Dexamethasone  (µM)	0.07815219
775	Ibrutinib (µM)	0
775	Mercaptopurine (µM)	1761.891
775	Nelarabine (µM)	0
775	Panobinostat (nM)	0
775	Prednisolone (µM)	0.07279366
775	Ruxolitinib (nM)	0
775	Thioguanine (µM)	56.42981
775	Trametinib (nM)	0
775	Venetoclax (nM)	0
775	Vincristine (µM)	0.7085409
775	Vorinostat (nM)	0
775	asparagise_normalized	0
775	cytarabine_normalized	0.6052
775	dexamethasone_normalized	0.5196
775	mercaptopurine_normalized	0.8525
775	prednisolone_normalized	0.1516
775	thioguanine_normalized	0.5188
775	vincristine_normalized	0.3794
776	immunophenotype	B
776	molecular subtype	ETV6-RUNX1
776	Protocol	T16
776	NCI risk	SR
776	Age at diagnosis	6
776	WBC at diagnosis	5.4
776	Sex	F
776	Genetically-defined race	White
776	Asparaginase (IU/ml)	0.0016
776	Bortezomib (nM)	0
776	CHZ868 (nM)	0
776	Cytarabine (µM)	9.419445
776	Dasatinib (nM)	0
776	Daunorubicin (µM)	0
776	Dexamethasone  (µM)	7.389934
776	Ibrutinib (µM)	0
776	Mercaptopurine (µM)	2343.387643
776	Nelarabine (µM)	0
776	Panobinostat (nM)	0
776	Prednisolone (µM)	1.182275
776	Ruxolitinib (nM)	0
776	Thioguanine (µM)	45.27122
776	Trametinib (nM)	0
776	Venetoclax (nM)	0
776	Vincristine (µM)	0.025
776	Vorinostat (nM)	0
776	asparagise_normalized	0
776	cytarabine_normalized	0.7876
776	dexamethasone_normalized	0.9567
776	mercaptopurine_normalized	0.9348
776	prednisolone_normalized	0.4191
776	thioguanine_normalized	0.4552
776	vincristine_normalized	0
777	immunophenotype	B
777	molecular subtype	KMT2A
777	Protocol	T16
777	NCI risk	SR
777	Age at diagnosis	1.1
777	WBC at diagnosis	20.2
777	Sex	M
777	Genetically-defined race	black
777	Asparaginase (IU/ml)	1.601661699
777	Bortezomib (nM)	0
777	CHZ868 (nM)	0
777	Cytarabine (µM)	0.9529989
777	Dasatinib (nM)	0
777	Daunorubicin (µM)	0
777	Dexamethasone  (µM)	0.1191739
777	Ibrutinib (µM)	0
777	Mercaptopurine (µM)	5876
777	Nelarabine (µM)	0
777	Panobinostat (nM)	0
777	Prednisolone (µM)	0.09357286
777	Ruxolitinib (nM)	0
777	Thioguanine (µM)	73.16052
777	Trametinib (nM)	0
777	Venetoclax (nM)	0
777	Vincristine (µM)	0
777	Vorinostat (nM)	0
777	asparagise_normalized	0.7724
777	cytarabine_normalized	0.4572
777	dexamethasone_normalized	0.5602
777	mercaptopurine_normalized	1
777	prednisolone_normalized	0.1757
777	thioguanine_normalized	0.5937
778	immunophenotype	B
778	molecular subtype	Hyperdiploid
778	Protocol	T16
778	NCI risk	SR
778	Age at diagnosis	1.6
778	WBC at diagnosis	9.4
778	Sex	F
778	Genetically-defined race	White
778	Asparaginase (IU/ml)	0
778	Bortezomib (nM)	0
778	CHZ868 (nM)	0
778	Cytarabine (µM)	0.1821019
778	Dasatinib (nM)	0
778	Daunorubicin (µM)	0
778	Dexamethasone  (µM)	0.08102035
778	Ibrutinib (µM)	0
778	Mercaptopurine (µM)	257.0599
778	Nelarabine (µM)	0
778	Panobinostat (nM)	0
778	Prednisolone (µM)	0
778	Ruxolitinib (nM)	0
778	Thioguanine (µM)	53.37119
778	Trametinib (nM)	0
778	Venetoclax (nM)	0
778	Vincristine (µM)	0.025
778	Vorinostat (nM)	0
778	cytarabine_normalized	0.2186
778	dexamethasone_normalized	0.5231
778	mercaptopurine_normalized	0.2971
778	thioguanine_normalized	0.5027
778	vincristine_normalized	0
779	immunophenotype	B
779	molecular subtype	ETV6-RUNX1
779	Protocol	T16
779	NCI risk	SR
779	Age at diagnosis	7.6
779	WBC at diagnosis	3.7
779	Sex	F
779	Genetically-defined race	White
779	Asparaginase (IU/ml)	0
779	Bortezomib (nM)	0
779	CHZ868 (nM)	0
779	Cytarabine (µM)	1.734869
779	Dasatinib (nM)	0
779	Daunorubicin (µM)	0
779	Dexamethasone  (µM)	0.2662154
779	Ibrutinib (µM)	0
779	Mercaptopurine (µM)	2697.536
779	Nelarabine (µM)	0
779	Panobinostat (nM)	0
779	Prednisolone (µM)	0.07627943
779	Ruxolitinib (nM)	0
779	Thioguanine (µM)	31.81798
779	Trametinib (nM)	0
779	Venetoclax (nM)	0
779	Vincristine (µM)	0.025
779	Vorinostat (nM)	0
779	cytarabine_normalized	0.5436
779	dexamethasone_normalized	0.6374
779	mercaptopurine_normalized	0.9754
779	prednisolone_normalized	0.1561
779	thioguanine_normalized	0.3534
779	vincristine_normalized	0
780	immunophenotype	B
780	molecular subtype	B-other
780	Protocol	T16
780	NCI risk	HR
780	Age at diagnosis	11.1
780	WBC at diagnosis	141.1
780	Sex	F
780	Genetically-defined race	White
780	Asparaginase (IU/ml)	0
780	Bortezomib (nM)	0
780	CHZ868 (nM)	0
780	Cytarabine (µM)	0.3310415
780	Dasatinib (nM)	0
780	Daunorubicin (µM)	0
780	Dexamethasone  (µM)	0.07368212
780	Ibrutinib (µM)	0
780	Mercaptopurine (µM)	117.6243865
780	Nelarabine (µM)	0
780	Panobinostat (nM)	0
780	Prednisolone (µM)	0.07426216
780	Ruxolitinib (nM)	0
780	Thioguanine (µM)	18.10913
780	Trametinib (nM)	0
780	Venetoclax (nM)	0
780	Vincristine (µM)	0.025
780	Vorinostat (nM)	0
780	cytarabine_normalized	0.3047
780	dexamethasone_normalized	0.514
780	mercaptopurine_normalized	0.0715
780	prednisolone_normalized	0.1535
780	thioguanine_normalized	0.1908
780	vincristine_normalized	0
781	immunophenotype	B
781	molecular subtype	ETV6-RUNX1
781	Protocol	T16
781	NCI risk	SR
781	Age at diagnosis	6.4
781	WBC at diagnosis	15.5
781	Sex	F
781	Genetically-defined race	White
781	Asparaginase (IU/ml)	0.0016
781	Bortezomib (nM)	0
781	CHZ868 (nM)	0
781	Cytarabine (µM)	21.1899
781	Dasatinib (nM)	0
781	Daunorubicin (µM)	0
781	Dexamethasone  (µM)	23.2
781	Ibrutinib (µM)	0
781	Mercaptopurine (µM)	1386.402
781	Nelarabine (µM)	0
781	Panobinostat (nM)	0
781	Prednisolone (µM)	1006
781	Ruxolitinib (nM)	0
781	Thioguanine (µM)	51.16665
781	Trametinib (nM)	0
781	Venetoclax (nM)	0
781	Vincristine (µM)	108.34
781	Vorinostat (nM)	0
781	asparagise_normalized	0
781	cytarabine_normalized	0.9045
781	dexamethasone_normalized	1
781	mercaptopurine_normalized	0.7833
781	prednisolone_normalized	1
781	thioguanine_normalized	0.4905
781	vincristine_normalized	1
782	immunophenotype	T
782	molecular subtype	T-ALL
782	Protocol	T16
782	NCI risk	SR
782	Age at diagnosis	9.3
782	WBC at diagnosis	14.5
782	Sex	M
782	Genetically-defined race	black
782	Asparaginase (IU/ml)	0.3724052
782	Bortezomib (nM)	0
782	CHZ868 (nM)	0
782	Cytarabine (µM)	0.7078342
782	Dasatinib (nM)	0
782	Daunorubicin (µM)	0.02417196
782	Dexamethasone  (µM)	0.3239786
782	Ibrutinib (µM)	0
782	Mercaptopurine (µM)	269.9771
782	Nelarabine (µM)	0
782	Panobinostat (nM)	0
782	Prednisolone (µM)	0.1376113
782	Ruxolitinib (nM)	0
782	Thioguanine (µM)	9.544196
782	Trametinib (nM)	0
782	Venetoclax (nM)	0
782	Vincristine (µM)	0.025
782	Vorinostat (nM)	0
782	asparagise_normalized	0.5911
782	cytarabine_normalized	0.4143
782	daunorubicin_normalized	0.2949
782	dexamethasone_normalized	0.6562
782	mercaptopurine_normalized	0.3112
782	prednisolone_normalized	0.2127
782	thioguanine_normalized	0.0059
782	vincristine_normalized	0
783	immunophenotype	B
783	molecular subtype	ETV6-RUNX1
783	Protocol	T16
783	NCI risk	SR
783	Age at diagnosis	2.1
783	WBC at diagnosis	14
783	Sex	M
783	Genetically-defined race	White
783	Asparaginase (IU/ml)	2.861844
783	Bortezomib (nM)	0
783	CHZ868 (nM)	0
783	Cytarabine (µM)	1.485448
783	Dasatinib (nM)	0
783	Daunorubicin (µM)	0
783	Dexamethasone  (µM)	0.1601867
783	Ibrutinib (µM)	0
783	Mercaptopurine (µM)	2049.561
783	Nelarabine (µM)	0
783	Panobinostat (nM)	0
783	Prednisolone (µM)	0.02919871
783	Ruxolitinib (nM)	0
783	Thioguanine (µM)	26.26251
783	Trametinib (nM)	0
783	Venetoclax (nM)	0
783	Vincristine (µM)	0.08078405
783	Vorinostat (nM)	0
783	asparagise_normalized	0.8445
783	cytarabine_normalized	0.5212
783	dexamethasone_normalized	0.5886
783	mercaptopurine_normalized	0.8961
783	prednisolone_normalized	0.0639
783	thioguanine_normalized	0.2981
783	vincristine_normalized	0.0687
784	immunophenotype	B
784	molecular subtype	ETV6-RUNX1
784	Protocol	T16
784	NCI risk	SR
784	Age at diagnosis	3.5
784	WBC at diagnosis	5.7
784	Sex	M
784	Genetically-defined race	White
784	Asparaginase (IU/ml)	0
784	Bortezomib (nM)	0
784	CHZ868 (nM)	0
784	Cytarabine (µM)	0
784	Dasatinib (nM)	0
784	Daunorubicin (µM)	0
784	Dexamethasone  (µM)	23.2
784	Ibrutinib (µM)	0
784	Mercaptopurine (µM)	892.0975
784	Nelarabine (µM)	0
784	Panobinostat (nM)	0
784	Prednisolone (µM)	0
784	Ruxolitinib (nM)	0
784	Thioguanine (µM)	34.42474
784	Trametinib (nM)	0
784	Venetoclax (nM)	0
784	Vincristine (µM)	0
784	Vorinostat (nM)	0
784	dexamethasone_normalized	1
784	mercaptopurine_normalized	0.6561
784	thioguanine_normalized	0.3762
785	immunophenotype	B
785	molecular subtype	PAX5alt
785	Protocol	T16
785	NCI risk	HR
785	Age at diagnosis	15.1
785	WBC at diagnosis	185.4
785	Sex	M
785	Genetically-defined race	White
785	Asparaginase (IU/ml)	0.5880946
785	Bortezomib (nM)	0
785	CHZ868 (nM)	0
785	Cytarabine (µM)	0.4460106
785	Dasatinib (nM)	0
785	Daunorubicin (µM)	0
785	Dexamethasone  (µM)	23.2
785	Ibrutinib (µM)	0
785	Mercaptopurine (µM)	213.2977
785	Nelarabine (µM)	0
785	Panobinostat (nM)	0
785	Prednisolone (µM)	124.18
785	Ruxolitinib (nM)	0
785	Thioguanine (µM)	17.03977
785	Trametinib (nM)	0
785	Venetoclax (nM)	0
785	Vincristine (µM)	0.025
785	Vorinostat (nM)	0
785	asparagise_normalized	0.6479
785	cytarabine_normalized	0.3477
785	dexamethasone_normalized	1
785	mercaptopurine_normalized	0.2433
785	prednisolone_normalized	0.8658
785	thioguanine_normalized	0.1732
785	vincristine_normalized	0
786	immunophenotype	B
786	molecular subtype	KMT2A
786	Protocol	T16
786	NCI risk	SR
786	Age at diagnosis	1.4
786	WBC at diagnosis	22.8
786	Sex	M
786	Genetically-defined race	Asian/Other
786	Asparaginase (IU/ml)	2.752524
786	Bortezomib (nM)	0
786	CHZ868 (nM)	0
786	Cytarabine (µM)	0.3196645
786	Dasatinib (nM)	0
786	Daunorubicin (µM)	0
786	Dexamethasone  (µM)	1.928169
786	Ibrutinib (µM)	0
786	Mercaptopurine (µM)	275.5118224
786	Nelarabine (µM)	0
786	Panobinostat (nM)	0
786	Prednisolone (µM)	4.507079
786	Ruxolitinib (nM)	0
786	Thioguanine (µM)	11.86707
786	Trametinib (nM)	0
786	Venetoclax (nM)	0
786	Vincristine (µM)	0
786	Vorinostat (nM)	0
786	asparagise_normalized	0.8397
786	cytarabine_normalized	0.2997
786	dexamethasone_normalized	0.8276
786	mercaptopurine_normalized	0.3171
786	prednisolone_normalized	0.5475
786	thioguanine_normalized	0.0688
787	immunophenotype	B
787	molecular subtype	ETV6-RUNX1
787	Protocol	T16
787	NCI risk	SR
787	Age at diagnosis	2.6
787	WBC at diagnosis	19.2
787	Sex	M
787	Genetically-defined race	White
787	Asparaginase (IU/ml)	0.06639666
787	Bortezomib (nM)	0
787	CHZ868 (nM)	0
787	Cytarabine (µM)	1.203187
787	Dasatinib (nM)	0
787	Daunorubicin (µM)	0
787	Dexamethasone  (µM)	0.0220123
787	Ibrutinib (µM)	0
787	Mercaptopurine (µM)	527.6897
787	Nelarabine (µM)	0
787	Panobinostat (nM)	0
787	Prednisolone (µM)	0.0075
787	Ruxolitinib (nM)	0
787	Thioguanine (µM)	28.80617
787	Trametinib (nM)	0
787	Venetoclax (nM)	0
787	Vincristine (µM)	0.3259126
787	Vorinostat (nM)	0
787	asparagise_normalized	0.3768
787	cytarabine_normalized	0.4908
787	dexamethasone_normalized	0.3979
787	mercaptopurine_normalized	0.5046
787	prednisolone_normalized	0
787	thioguanine_normalized	0.3247
787	vincristine_normalized	0.2683
788	immunophenotype	B
788	molecular subtype	ETV6-RUNX1
788	Protocol	T16
788	NCI risk	SR
788	Age at diagnosis	8.7
788	WBC at diagnosis	10.7
788	Sex	M
788	Genetically-defined race	White
788	Asparaginase (IU/ml)	0.0016
788	Bortezomib (nM)	0
788	CHZ868 (nM)	0
788	Cytarabine (µM)	2.293721
788	Dasatinib (nM)	0
788	Daunorubicin (µM)	0
788	Dexamethasone  (µM)	1.680139
788	Ibrutinib (µM)	0
788	Mercaptopurine (µM)	1077.896
788	Nelarabine (µM)	0
788	Panobinostat (nM)	0
788	Prednisolone (µM)	0.1851812
788	Ruxolitinib (nM)	0
788	Thioguanine (µM)	55.629
788	Trametinib (nM)	0
788	Venetoclax (nM)	0
788	Vincristine (µM)	0.4672884
788	Vorinostat (nM)	0
788	asparagise_normalized	0
788	cytarabine_normalized	0.5839
788	dexamethasone_normalized	0.8144
788	mercaptopurine_normalized	0.7107
788	prednisolone_normalized	0.2412
788	thioguanine_normalized	0.5147
788	vincristine_normalized	0.3198
789	immunophenotype	B
789	molecular subtype	Hyperdiploid
789	Protocol	T16
789	NCI risk	SR
789	Age at diagnosis	4.8
789	WBC at diagnosis	3.1
789	Sex	F
789	Genetically-defined race	White
789	Asparaginase (IU/ml)	0.136854
789	Bortezomib (nM)	0
789	CHZ868 (nM)	0
789	Cytarabine (µM)	0
789	Dasatinib (nM)	0
789	Daunorubicin (µM)	0
789	Dexamethasone  (µM)	1.215113634
789	Ibrutinib (µM)	0
789	Mercaptopurine (µM)	1283.345
789	Nelarabine (µM)	0
789	Panobinostat (nM)	0
789	Prednisolone (µM)	0.7750618
789	Ruxolitinib (nM)	0
789	Thioguanine (µM)	23.91365
789	Trametinib (nM)	0
789	Venetoclax (nM)	0
789	Vincristine (µM)	0
789	Vorinostat (nM)	0
789	asparagise_normalized	0.4667
789	dexamethasone_normalized	0.7832
789	mercaptopurine_normalized	0.761
789	prednisolone_normalized	0.3786
789	thioguanine_normalized	0.271
790	immunophenotype	B
790	molecular subtype	ETV6-RUNX1
790	Protocol	T16
790	NCI risk	SR
790	Age at diagnosis	2.1
790	WBC at diagnosis	36.1
790	Sex	F
790	Genetically-defined race	black
790	Asparaginase (IU/ml)	0.2493965
790	Bortezomib (nM)	0
790	CHZ868 (nM)	0
790	Cytarabine (µM)	0.582422508
790	Dasatinib (nM)	0
790	Daunorubicin (µM)	0
790	Dexamethasone  (µM)	0.3965608
790	Ibrutinib (µM)	0
790	Mercaptopurine (µM)	223.2671
790	Nelarabine (µM)	0
790	Panobinostat (nM)	0
790	Prednisolone (µM)	0.08919235
790	Ruxolitinib (nM)	0
790	Thioguanine (µM)	20.03022
790	Trametinib (nM)	0
790	Venetoclax (nM)	0
790	Vincristine (µM)	0.025
790	Vorinostat (nM)	0
790	asparagise_normalized	0.5413
790	cytarabine_normalized	0.3862
790	dexamethasone_normalized	0.6757
790	mercaptopurine_normalized	0.2564
790	prednisolone_normalized	0.1711
790	thioguanine_normalized	0.2199
790	vincristine_normalized	0
791	immunophenotype	B
791	molecular subtype	Ph-like_CRLF2
791	Protocol	T16
791	NCI risk	SR
791	Age at diagnosis	9.4
791	WBC at diagnosis	22.3
791	Sex	M
791	Genetically-defined race	White
791	Asparaginase (IU/ml)	0
791	Bortezomib (nM)	0
791	CHZ868 (nM)	0
791	Cytarabine (µM)	0.3285002
791	Dasatinib (nM)	0
791	Daunorubicin (µM)	0
791	Dexamethasone  (µM)	23.2
791	Ibrutinib (µM)	0
791	Mercaptopurine (µM)	0
791	Nelarabine (µM)	0
791	Panobinostat (nM)	0
791	Prednisolone (µM)	1006
791	Ruxolitinib (nM)	0
791	Thioguanine (µM)	79.36164
791	Trametinib (nM)	0
791	Venetoclax (nM)	0
791	Vincristine (µM)	108.34
791	Vorinostat (nM)	0
791	cytarabine_normalized	0.3036
791	dexamethasone_normalized	1
791	prednisolone_normalized	1
791	thioguanine_normalized	0.6172
791	vincristine_normalized	1
792	immunophenotype	B
792	molecular subtype	Ph-like_CRLF2
792	Protocol	T16
792	NCI risk	HR
792	Age at diagnosis	16.9
792	WBC at diagnosis	200.1
792	Sex	M
792	Genetically-defined race	Hispanic
792	Asparaginase (IU/ml)	1.446544
792	Bortezomib (nM)	0
792	CHZ868 (nM)	0
792	Cytarabine (µM)	7.277242
792	Dasatinib (nM)	0
792	Daunorubicin (µM)	0
792	Dexamethasone  (µM)	23.2
792	Ibrutinib (µM)	0
792	Mercaptopurine (µM)	0
792	Nelarabine (µM)	0
792	Panobinostat (nM)	0
792	Prednisolone (µM)	1006
792	Ruxolitinib (nM)	0
792	Thioguanine (µM)	103.5863
792	Trametinib (nM)	0
792	Venetoclax (nM)	0
792	Vincristine (µM)	0
792	Vorinostat (nM)	0
792	asparagise_normalized	0.7597
792	cytarabine_normalized	0.7504
792	dexamethasone_normalized	1
792	prednisolone_normalized	1
792	thioguanine_normalized	0.6941
793	immunophenotype	B
793	molecular subtype	Hyperdiploid
793	Protocol	T16
793	NCI risk	SR
793	Age at diagnosis	2.2
793	WBC at diagnosis	32.7
793	Sex	F
793	Genetically-defined race	White
793	Asparaginase (IU/ml)	0.0016
793	Bortezomib (nM)	0
793	CHZ868 (nM)	0
793	Cytarabine (µM)	0.1645378
793	Dasatinib (nM)	0
793	Daunorubicin (µM)	0
793	Dexamethasone  (µM)	0.388784
793	Ibrutinib (µM)	0
793	Mercaptopurine (µM)	299.5702
793	Nelarabine (µM)	0
793	Panobinostat (nM)	0
793	Prednisolone (µM)	0
793	Ruxolitinib (nM)	0
793	Thioguanine (µM)	12.83957
793	Trametinib (nM)	0
793	Venetoclax (nM)	0
793	Vincristine (µM)	0
793	Vorinostat (nM)	0
793	asparagise_normalized	0
793	cytarabine_normalized	0.2039
793	dexamethasone_normalized	0.6738
793	mercaptopurine_normalized	0.3413
793	thioguanine_normalized	0.0915
794	immunophenotype	B
794	molecular subtype	Hyperdiploid
794	Protocol	T16
794	NCI risk	SR
794	Age at diagnosis	5.2
794	WBC at diagnosis	3.4
794	Sex	F
794	Genetically-defined race	White
794	Asparaginase (IU/ml)	0
794	Bortezomib (nM)	0
794	CHZ868 (nM)	0
794	Cytarabine (µM)	0
794	Dasatinib (nM)	0
794	Daunorubicin (µM)	0
794	Dexamethasone  (µM)	0
794	Ibrutinib (µM)	0
794	Mercaptopurine (µM)	5876
794	Nelarabine (µM)	0
794	Panobinostat (nM)	0
794	Prednisolone (µM)	0
794	Ruxolitinib (nM)	0
794	Thioguanine (µM)	49.99251809
794	Trametinib (nM)	0
794	Venetoclax (nM)	0
794	Vincristine (µM)	0
794	Vorinostat (nM)	0
794	mercaptopurine_normalized	1
794	thioguanine_normalized	0.4838
795	immunophenotype	B
795	molecular subtype	Hyperdiploid
795	Protocol	T16
795	NCI risk	SR
795	Age at diagnosis	4.9
795	WBC at diagnosis	16.5
795	Sex	F
795	Genetically-defined race	Asian/Other
795	Asparaginase (IU/ml)	0.0016
795	Bortezomib (nM)	0.49
795	CHZ868 (nM)	0
795	Cytarabine (µM)	0
795	Dasatinib (nM)	20000
795	Daunorubicin (µM)	0
795	Dexamethasone  (µM)	0.268918
795	Ibrutinib (µM)	0
795	Mercaptopurine (µM)	0
795	Nelarabine (µM)	0
795	Panobinostat (nM)	16.71004607
795	Prednisolone (µM)	0
795	Ruxolitinib (nM)	20000
795	Thioguanine (µM)	14.54056
795	Trametinib (nM)	0
795	Venetoclax (nM)	0
795	Vincristine (µM)	0.025
795	Vorinostat (nM)	0
795	asparagise_normalized	0
795	bortezomib_normalized	0
795	dasatinib_normalized	1
795	dexamethasone_normalized	0.6383
795	panobinostat_normalized	0.4094
795	ruxolitinib_normalized	1
795	thioguanine_normalized	0.1274
795	vincristine_normalized	0
796	immunophenotype	B
796	molecular subtype	ETV6-RUNX1-like
796	Protocol	T16
796	NCI risk	SR
796	Age at diagnosis	1.7
796	WBC at diagnosis	3.6
796	Sex	F
796	Genetically-defined race	White
796	Asparaginase (IU/ml)	8.800848
796	Bortezomib (nM)	0
796	CHZ868 (nM)	0
796	Cytarabine (µM)	2.516301
796	Dasatinib (nM)	0
796	Daunorubicin (µM)	0
796	Dexamethasone  (µM)	23.2
796	Ibrutinib (µM)	0
796	Mercaptopurine (µM)	1279.115
796	Nelarabine (µM)	0
796	Panobinostat (nM)	0
796	Prednisolone (µM)	0
796	Ruxolitinib (nM)	0
796	Thioguanine (µM)	31.5109
796	Trametinib (nM)	0
796	Venetoclax (nM)	0
796	Vincristine (µM)	0
796	Vorinostat (nM)	0
796	asparagise_normalized	0.9841
796	cytarabine_normalized	0.5972
796	dexamethasone_normalized	1
796	mercaptopurine_normalized	0.7601
796	thioguanine_normalized	0.3506
797	immunophenotype	B
797	molecular subtype	KMT2A
797	Protocol	T16
797	NCI risk	HR
797	Age at diagnosis	16.3
797	WBC at diagnosis	13.1
797	Sex	F
797	Genetically-defined race	White
797	Asparaginase (IU/ml)	0.8615583
797	Bortezomib (nM)	0
797	CHZ868 (nM)	0
797	Cytarabine (µM)	1.392094
797	Dasatinib (nM)	20000
797	Daunorubicin (µM)	0
797	Dexamethasone  (µM)	0.5857437
797	Ibrutinib (µM)	0
797	Mercaptopurine (µM)	299.6948
797	Nelarabine (µM)	0
797	Panobinostat (nM)	6.975133
797	Prednisolone (µM)	0.2374109
797	Ruxolitinib (nM)	20000
797	Thioguanine (µM)	29.34457
797	Trametinib (nM)	0
797	Venetoclax (nM)	0
797	Vincristine (µM)	0.2071091
797	Vorinostat (nM)	0
797	asparagise_normalized	0.6953
797	cytarabine_normalized	0.5119
797	dasatinib_normalized	1
797	dexamethasone_normalized	0.7131
797	mercaptopurine_normalized	0.3414
797	panobinostat_normalized	0.2833
797	prednisolone_normalized	0.265
797	ruxolitinib_normalized	1
797	thioguanine_normalized	0.3301
797	vincristine_normalized	0.2034
798	immunophenotype	B
798	molecular subtype	Hyperdiploid
798	Protocol	T16
798	NCI risk	SR
798	Age at diagnosis	5.7
798	WBC at diagnosis	7.2
798	Sex	M
798	Genetically-defined race	Hispanic
798	Asparaginase (IU/ml)	0.8652585
798	Bortezomib (nM)	0
798	CHZ868 (nM)	0
798	Cytarabine (µM)	0.709832679
798	Dasatinib (nM)	0
798	Daunorubicin (µM)	0
798	Dexamethasone  (µM)	23.2
798	Ibrutinib (µM)	0
798	Mercaptopurine (µM)	623.1419
798	Nelarabine (µM)	0
798	Panobinostat (nM)	0
798	Prednisolone (µM)	73.91517
798	Ruxolitinib (nM)	0
798	Thioguanine (µM)	24.86269
798	Trametinib (nM)	0
798	Venetoclax (nM)	0
798	Vincristine (µM)	17.55201
798	Vorinostat (nM)	0
798	asparagise_normalized	0.6959
798	cytarabine_normalized	0.4147
798	dexamethasone_normalized	1
798	mercaptopurine_normalized	0.5526
798	prednisolone_normalized	0.816
798	thioguanine_normalized	0.2822
798	vincristine_normalized	0.8387
799	immunophenotype	B
799	molecular subtype	ETV6-RUNX1
799	Protocol	T16
799	NCI risk	SR
799	Age at diagnosis	3.2
799	WBC at diagnosis	6.2
799	Sex	F
799	Genetically-defined race	White
799	Asparaginase (IU/ml)	0.2081457
799	Bortezomib (nM)	0
799	CHZ868 (nM)	0
799	Cytarabine (µM)	3.315806
799	Dasatinib (nM)	0
799	Daunorubicin (µM)	0
799	Dexamethasone  (µM)	0.01645026
799	Ibrutinib (µM)	0
799	Mercaptopurine (µM)	1237.796
799	Nelarabine (µM)	0
799	Panobinostat (nM)	0
799	Prednisolone (µM)	0.0075
799	Ruxolitinib (nM)	0
799	Thioguanine (µM)	21.72221
799	Trametinib (nM)	0
799	Venetoclax (nM)	0
799	Vincristine (µM)	0.7789715
799	Vorinostat (nM)	0
799	asparagise_normalized	0.5188
799	cytarabine_normalized	0.637
799	dexamethasone_normalized	0.3699
799	mercaptopurine_normalized	0.7506
799	prednisolone_normalized	0
799	thioguanine_normalized	0.2433
799	vincristine_normalized	0.393
800	immunophenotype	T
800	molecular subtype	T-ALL
800	Protocol	T16
800	NCI risk	HR
800	Age at diagnosis	3.7
800	WBC at diagnosis	173.9
800	Sex	M
800	Genetically-defined race	White
800	Asparaginase (IU/ml)	0.282578
800	Bortezomib (nM)	0
800	CHZ868 (nM)	0
800	Cytarabine (µM)	0.5772412
800	Dasatinib (nM)	0
800	Daunorubicin (µM)	0.0707412
800	Dexamethasone  (µM)	0
800	Ibrutinib (µM)	0
800	Mercaptopurine (µM)	410.1926518
800	Nelarabine (µM)	0
800	Panobinostat (nM)	0
800	Prednisolone (µM)	1006
800	Ruxolitinib (nM)	0
800	Thioguanine (µM)	23.80646438
800	Trametinib (nM)	0
800	Venetoclax (nM)	0
800	Vincristine (µM)	1.22186
800	Vorinostat (nM)	0
800	asparagise_normalized	0.5568
800	cytarabine_normalized	0.3849
800	daunorubicin_normalized	0.4466
800	mercaptopurine_normalized	0.4319
800	prednisolone_normalized	1
800	thioguanine_normalized	0.2697
800	vincristine_normalized	0.4574
801	immunophenotype	T
801	molecular subtype	T-ALL
801	Protocol	T16
801	NCI risk	HR
801	Age at diagnosis	17.7
801	WBC at diagnosis	75
801	Sex	M
801	Genetically-defined race	White
801	Asparaginase (IU/ml)	0.0016
801	Bortezomib (nM)	0
801	CHZ868 (nM)	0
801	Cytarabine (µM)	0.02
801	Dasatinib (nM)	0
801	Daunorubicin (µM)	0.007959237
801	Dexamethasone  (µM)	0.0108925
801	Ibrutinib (µM)	0
801	Mercaptopurine (µM)	45.9
801	Nelarabine (µM)	0
801	Panobinostat (nM)	0
801	Prednisolone (µM)	0.0075
801	Ruxolitinib (nM)	0
801	Thioguanine (µM)	4.675
801	Trametinib (nM)	0
801	Venetoclax (nM)	0
801	Vincristine (µM)	0.025
801	Vorinostat (nM)	0
801	asparagise_normalized	0
801	cytarabine_normalized	0
801	daunorubicin_normalized	0.1379
801	dexamethasone_normalized	0.3303
801	mercaptopurine_normalized	0
801	prednisolone_normalized	0
801	thioguanine_normalized	0
801	vincristine_normalized	0
802	immunophenotype	B
802	molecular subtype	B-other
802	Protocol	T16
802	NCI risk	SR
802	Age at diagnosis	5.2
802	WBC at diagnosis	3.2
802	Sex	M
802	Genetically-defined race	White
802	Asparaginase (IU/ml)	0
802	Bortezomib (nM)	0
802	CHZ868 (nM)	0
802	Cytarabine (µM)	0
802	Dasatinib (nM)	0
802	Daunorubicin (µM)	0
802	Dexamethasone  (µM)	1.944026
802	Ibrutinib (µM)	0
802	Mercaptopurine (µM)	5876
802	Nelarabine (µM)	0
802	Panobinostat (nM)	0
802	Prednisolone (µM)	1.235586
802	Ruxolitinib (nM)	0
802	Thioguanine (µM)	30.05615
802	Trametinib (nM)	0
802	Venetoclax (nM)	0
802	Vincristine (µM)	0
802	Vorinostat (nM)	0
802	dexamethasone_normalized	0.8284
802	mercaptopurine_normalized	1
802	prednisolone_normalized	0.4233
802	thioguanine_normalized	0.337
803	immunophenotype	B
803	molecular subtype	Ph-like_CRLF2
803	Protocol	T16
803	NCI risk	SR
803	Age at diagnosis	8.6
803	WBC at diagnosis	2.2
803	Sex	F
803	Genetically-defined race	White
803	Asparaginase (IU/ml)	0.0016
803	Bortezomib (nM)	0
803	CHZ868 (nM)	0
803	Cytarabine (µM)	0.5477096
803	Dasatinib (nM)	0
803	Daunorubicin (µM)	0
803	Dexamethasone  (µM)	0.04652848
803	Ibrutinib (µM)	0
803	Mercaptopurine (µM)	488.3276
803	Nelarabine (µM)	0
803	Panobinostat (nM)	0
803	Prednisolone (µM)	0.0075
803	Ruxolitinib (nM)	0
803	Thioguanine (µM)	23.14558
803	Trametinib (nM)	0
803	Venetoclax (nM)	0
803	Vincristine (µM)	0.1565564
803	Vorinostat (nM)	0
803	asparagise_normalized	0
803	cytarabine_normalized	0.3773
803	dexamethasone_normalized	0.4698
803	mercaptopurine_normalized	0.4822
803	prednisolone_normalized	0
803	thioguanine_normalized	0.2616
803	vincristine_normalized	0.1633
804	immunophenotype	B
804	molecular subtype	PAX5alt
804	Protocol	T16
804	NCI risk	SR
804	Age at diagnosis	2.6
804	WBC at diagnosis	15.7
804	Sex	M
804	Genetically-defined race	Hispanic
804	Asparaginase (IU/ml)	0.0016
804	Bortezomib (nM)	0
804	CHZ868 (nM)	0
804	Cytarabine (µM)	0
804	Dasatinib (nM)	20000
804	Daunorubicin (µM)	0
804	Dexamethasone  (µM)	0.01718445
804	Ibrutinib (µM)	0
804	Mercaptopurine (µM)	159.7403
804	Nelarabine (µM)	0
804	Panobinostat (nM)	5.982969
804	Prednisolone (µM)	0.0075
804	Ruxolitinib (nM)	0
804	Thioguanine (µM)	12.86336
804	Trametinib (nM)	0
804	Venetoclax (nM)	0
804	Vincristine (µM)	0.025
804	Vorinostat (nM)	0
804	asparagise_normalized	0
804	dasatinib_normalized	1
804	dexamethasone_normalized	0.3741
804	mercaptopurine_normalized	0.1598
804	panobinostat_normalized	0.2611
804	prednisolone_normalized	0
804	thioguanine_normalized	0.0921
804	vincristine_normalized	0
805	immunophenotype	B
805	molecular subtype	ETV6-RUNX1
805	Protocol	T16
805	NCI risk	SR
805	Age at diagnosis	4.3
805	WBC at diagnosis	19
805	Sex	M
805	Genetically-defined race	White
805	Asparaginase (IU/ml)	0.0016
805	Bortezomib (nM)	0
805	CHZ868 (nM)	0
805	Cytarabine (µM)	0.0520247
805	Dasatinib (nM)	20000
805	Daunorubicin (µM)	0
805	Dexamethasone  (µM)	0.02945945
805	Ibrutinib (µM)	0
805	Mercaptopurine (µM)	45.9
805	Nelarabine (µM)	0
805	Panobinostat (nM)	0
805	Prednisolone (µM)	0.01569774
805	Ruxolitinib (nM)	0
805	Thioguanine (µM)	4.675
805	Trametinib (nM)	0
805	Venetoclax (nM)	0
805	Vincristine (µM)	0.025
805	Vorinostat (nM)	0
805	asparagise_normalized	0
805	cytarabine_normalized	0.0379
805	dasatinib_normalized	1
805	dexamethasone_normalized	0.4259
805	mercaptopurine_normalized	0
805	prednisolone_normalized	0.0044
805	thioguanine_normalized	0
805	vincristine_normalized	0
